<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004185.pub2" GROUP_ID="DEPRESSN" ID="406602072215334158" MERGED_FROM="" MODIFIED="2013-07-16 11:34:21 +0100" MODIFIED_BY="Chris Champion" REVIEW_NO="J06" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-07-16 11:34:21 +0100" MODIFIED_BY="Chris Champion">
<TITLE>Fluoxetine versus other types of pharmacotherapy for depression</TITLE>
<CONTACT MODIFIED="2013-07-16 11:34:21 +0100" MODIFIED_BY="Chris Champion"><PERSON ID="13104" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Corrado</FIRST_NAME><LAST_NAME>Barbui</LAST_NAME><EMAIL_1>corrado.barbui@univr.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Community Medicine, Section of Psychiatry</DEPARTMENT><ORGANISATION>University of Verona</ORGANISATION><ADDRESS_1>Policlinico "GB Rossi"</ADDRESS_1><ADDRESS_2>Piazzale L.A. Scuro, 10</ADDRESS_2><CITY>Verona</CITY><ZIP>37134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39-045-807-6418</PHONE_1><FAX_1>+39-045-585871</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-07-16 11:34:21 +0100" MODIFIED_BY="Chris Champion"><PERSON ID="42841785662847563864120914141825" ROLE="AUTHOR"><FIRST_NAME>Laura</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Magni</LAST_NAME><EMAIL_1>lmagni@fatebenefratelli.it</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatric Unit</DEPARTMENT><ORGANISATION>Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio, Fatebenefratelli</ORGANISATION><CITY>Brescia</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="CCB5692582E26AA2008044A2B7F40EE9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marianna</FIRST_NAME><LAST_NAME>Purgato</LAST_NAME><EMAIL_1>marianna.purgato@univr.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Community Medicine, Section of Psychiatry</DEPARTMENT><ORGANISATION>University of Verona</ORGANISATION><ADDRESS_1>Policlinico "G.B.Rossi"</ADDRESS_1><ADDRESS_2>Pzz.le L.A. Scuro, 10</ADDRESS_2><CITY>Verona</CITY><ZIP>37134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>39 045 812 4441</PHONE_1></ADDRESS></PERSON><PERSON ID="76301156263188977538120914142012" ROLE="AUTHOR"><FIRST_NAME>Chiara</FIRST_NAME><LAST_NAME>Gastaldon</LAST_NAME><EMAIL_1>chiara.gastaldon@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Community Medicine, Section of Psychiatry</DEPARTMENT><ORGANISATION>University of Verona</ORGANISATION><CITY>Verona</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="06510030075421293955120914142216" ROLE="AUTHOR"><FIRST_NAME>Davide</FIRST_NAME><LAST_NAME>Papola</LAST_NAME><EMAIL_1>candido09@hotmail.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Community Medicine, Section of Psychiatry</DEPARTMENT><ORGANISATION>University of Verona</ORGANISATION><CITY>Verona</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="13142" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Toshi</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Furukawa</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>furukawa@kuhp.kyoto-u.ac.jp</EMAIL_1><URL>http://ebmh.med.kyoto-u.ac.jp/</URL><ADDRESS><DEPARTMENT>Department of Health Promotion and Human Behavior</DEPARTMENT><ORGANISATION>Kyoto University Graduate School of Medicine / School of Public Health</ORGANISATION><ADDRESS_1>Yoshida Konoe-cho, Sakyo-ku,</ADDRESS_1><CITY>Kyoto</CITY><ZIP>601-8501</ZIP><COUNTRY CODE="JP">Japan</COUNTRY><PHONE_1>+81 75 753 9491</PHONE_1><FAX_1>+81 75 753 4641</FAX_1></ADDRESS></PERSON><PERSON ID="13121" ROLE="AUTHOR"><FIRST_NAME>Andrea</FIRST_NAME><LAST_NAME>Cipriani</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Lecturer in Psychiatry</POSITION><EMAIL_1>andrea.cipriani@univr.it</EMAIL_1><EMAIL_2>andrea.cipriani@psych.ox.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Public Health and Community Medicine, Section of Psychiatry</DEPARTMENT><ORGANISATION>University of Verona</ORGANISATION><ADDRESS_1>Policlinico "G.B.Rossi"</ADDRESS_1><ADDRESS_2>Piazzale L.A. Scuro, 10</ADDRESS_2><CITY>Verona</CITY><ZIP>37134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 045 8124441</PHONE_1><PHONE_2>+39 045 8124063</PHONE_2><FAX_1>+39 045  8027498</FAX_1></ADDRESS></PERSON><PERSON ID="13104" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Corrado</FIRST_NAME><LAST_NAME>Barbui</LAST_NAME><EMAIL_1>corrado.barbui@univr.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Community Medicine, Section of Psychiatry</DEPARTMENT><ORGANISATION>University of Verona</ORGANISATION><ADDRESS_1>Policlinico "GB Rossi"</ADDRESS_1><ADDRESS_2>Piazzale L.A. Scuro, 10</ADDRESS_2><CITY>Verona</CITY><ZIP>37134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39-045-807-6418</PHONE_1><FAX_1>+39-045-585871</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-21 10:50:02 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="5" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2013-07-16 08:04:40 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-07-16 08:02:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Studies published between 2005 and 2012 added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-07-16 08:04:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Major update of methods and new studies, conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-11-09 09:42:59 +0000" MODIFIED_BY="Chris Champion">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-09 09:42:59 +0000" MODIFIED_BY="Chris Champion">
<DATE DAY="1" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-09-10 09:56:47 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-09-10 09:56:47 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-09-10 09:56:47 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Psychiatry, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-07-15 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-07-02 11:07:34 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-11-09 09:48:49 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared with other antidepressants for depression in adults</TITLE>
<SUMMARY_BODY MODIFIED="2013-07-02 11:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>Depression is a severe mental illness characterised by a persistent low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms such as appetite change, sleep disturbance and poor concentration. The predominant treatment options for depression are drugs and psychological therapies, but antidepressant drugs are the most common treatment for moderate to severe depression. Fluoxetine, one of the first new generation antidepressants, is an extremely popular drug treatment for depression. However, findings from studies comparing fluoxetine with other antidepressants are controversial. In this systematic review, the efficacy and tolerability of fluoxetine was compared with other antidepressants for the acute treatment of depression.</P>
<P>In May 2012 we searched, in a wide-ranging way, for all the useful studies (randomised controlled trials, or RCTs) we could find which compared fluoxetine with any other antidepressant in treating people with depression. One hundred and seventy-one RCTs were included, with 24,868 people in the analyses. Combining the results from all the trials, fluoxetine was similarly effective, but better tolerated, than older generation (tricyclic) antidepressants. In comparison with other new generation antidepressants, important differences in efficacy and in tolerability were found between fluoxetine and some of the antidepressants, for example, fluoxetine was less effective than sertraline and mirtazapine but better tolerated than reboxetine. These differences might have a clinical impact in everyday practice. However, when interpreting these differences it is important to bear in mind that the studies were short in duration (eight weeks or less) and that the average size of each trial was small (each included around 100 people). Moreover, most of the included studies were sponsored by drug companies, which could potentially have led to an overestimation of treatment effect. As a consequence, it is difficult to draw clear, clinically meaningful conclusions. More reliable information is needed about the respective safety profiles of antidepressants.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-07-15 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-07-15 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Depression is common in primary care and is associated with marked personal, social and economic morbidity, thus creating significant demands on service providers. The antidepressant fluoxetine has been studied in many randomised controlled trials (RCTs) in comparison with other conventional and unconventional antidepressants. However, these studies have produced conflicting findings. Other systematic reviews have considered selective serotonin reuptake inhibitor (SSRIs) as a group which limits the applicability of the findings for fluoxetine alone. Therefore, this review intends to provide specific and clinically useful information regarding the effects of fluoxetine for depression compared with tricyclics (TCAs), SSRIs, serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and newer agents, and other conventional and unconventional agents. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-07-05 12:58:04 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of fluoxetine in comparison with all other antidepressive agents for depression in adult individuals with unipolar major depressive disorder.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-07-15 11:32:26 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group Controlled Trials Register (CCDANCTR) to 11 May 2012. This register includes relevant RCTs from the Cochrane Central Register of Controlled Trials (CENTRAL) (all years), MEDLINE (1950 to date), EMBASE (1974 to date) and PsycINFO (1967 to date). No language restriction was applied. Reference lists of relevant papers and previous systematic reviews were handsearched. The pharmaceutical company marketing fluoxetine and experts in this field were contacted for supplemental data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-07-02 11:29:29 +0100" MODIFIED_BY="[Empty name]">
<P>All RCTs comparing fluoxetine with any other AD (including non-conventional agents such as hypericum) for patients with unipolar major depressive disorder (regardless of the diagnostic criteria used) were included. For trials that had a cross-over design only results from the first randomisation period were considered.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-02 10:29:16 +0100" MODIFIED_BY="[Empty name]">
<P>Data were independently extracted by two review authors using a standard form. Responders to treatment were calculated on an intention-to-treat basis: dropouts were always included in this analysis. When data on dropouts were carried forward and included in the efficacy evaluation, they were analysed according to the primary studies; when dropouts were excluded from any assessment in the primary studies, they were considered as treatment failures. Scores from continuous outcomes were analysed by including patients with a final assessment or with the last observation carried forward. Tolerability data were analysed by calculating the proportion of patients who failed to complete the study due to any causes and due to side effects or inefficacy. For dichotomous data, odds ratios (ORs) were calculated with 95% confidence intervals (CI) using the random-effects model. Continuous data were analysed using standardised mean differences (SMD) with 95% CI.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-07-03 12:31:10 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 171 studies were included in the analysis (24,868 participants). The included studies were undertaken between 1984 and 2012. Studies had homogenous characteristics in terms of design, intervention and outcome measures. The assessment of quality with the risk of bias tool revealed that the great majority of them failed to report methodological details, like the method of random sequence generation, the allocation concealment and blinding. Moreover, most of the included studies were sponsored by drug companies, so the potential for overestimation of treatment effect due to sponsorship bias should be considered in interpreting the results. Fluoxetine was as effective as the TCAs when considered as a group both on a dichotomous outcome (reduction of at least 50% on the Hamilton Depression Scale) (OR 0.97, 95% CI 0.77 to 1.22, 24 RCTs, 2124 participants) and a continuous outcome (mean scores at the end of the trial or change score on depression measures) (SMD 0.03, 95% CI -0.07 to 0.14, 50 RCTs, 3393 participants). On a dichotomous outcome, fluoxetine was less effective than dothiepin or dosulepin (OR 2.13, 95% CI 1.08 to 4.20; number needed to treat (NNT) = 6, 95% CI 3 to 50, 2 RCTs, 144 participants), sertraline (OR 1.37, 95% CI 1.08 to 1.74; NNT = 13, 95% CI 7 to 58, 6 RCTs, 1188 participants), mirtazapine (OR 1.46, 95% CI 1.04 to 2.04; NNT = 12, 95% CI 6 to 134, 4 RCTs, 600 participants) and venlafaxine (OR 1.29, 95% CI 1.10 to 1.51; NNT = 11, 95% CI 8 to 16, 12 RCTs, 3387 participants). On a continuous outcome, fluoxetine was more effective than ABT-200 (SMD -1.85, 95% CI -2.25 to -1.45, 1 RCT, 141 participants) and milnacipran (SMD -0.36, 95% CI -0.63 to -0.08, 2 RCTs, 213 participants); conversely, it was less effective than venlafaxine (SMD 0.10, 95% CI 0 to 0.19, 13 RCTs, 3097 participants). Fluoxetine was better tolerated than TCAs considered as a group (total dropout OR 0.79, 95% CI 0.65 to 0.96; NNT = 20, 95% CI 13 to 48, 49 RCTs, 4194 participants) and was better tolerated in comparison with individual ADs, in particular amitriptyline (total dropout OR 0.62, 95% CI 0.46 to 0.85; NNT = 13, 95% CI 8 to 39, 18 RCTs, 1089 participants), and among the newer ADs ABT-200 (total dropout OR 0.18, 95% CI 0.08 to 0.39; NNT = 3, 95% CI 2 to 5, 1 RCT, 144 participants), pramipexole (total dropout OR 0.12, 95% CI 0.03 to 0.42, NNT = 3, 95% CI 2 to 5, 1 RCT, 105 participants), and reboxetine (total dropout OR 0.60, 95% CI 0.44 to 0.82, NNT = 9, 95% CI 6 to 24, 4 RCTs, 764 participants).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-07-05 12:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>The present study detected differences in terms of efficacy and tolerability between fluoxetine and certain ADs, but the clinical meaning of these differences is uncertain. Moreover, the assessment of quality with the risk of bias tool showed that the great majority of included studies failed to report details on methodological procedures. Of consequence, no definitive implications can be drawn from the studies' results. The better efficacy profile of sertraline and venlafaxine (and possibly other ADs) over fluoxetine may be clinically meaningful, as already suggested by other systematic reviews. In addition to efficacy data, treatment decisions should also be based on considerations of drug toxicity, patient acceptability and cost.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-07-15 11:33:45 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-07-02 11:22:05 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-07-02 11:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>Major depression is generally diagnosed when a persistent and unreactive low mood or loss of interest and pleasure, or both, are accompanied by a range of symptoms including appetite loss, insomnia, fatigue, loss of energy, poor concentration, psychomotor symptoms, inappropriate guilt and morbid thoughts of death (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). It was the third leading cause of burden among all diseases in the year 2004 and it is expected to be the greatest cause in 2030 (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>). This condition is associated with marked personal, social and economic morbidity, loss of functioning and productivity, and creates significant demands on service providers in terms of workload (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>; <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). Although pharmacological and psychological interventions are both effective for major depression, in primary and secondary care settings antidepressant (AD) drugs remain the mainstay of treatment in moderate to severe major depression (<LINK REF="REF-APA-2006" TYPE="REFERENCE">APA 2006</LINK>; <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). Amongst ADs many different agents are available, including tricyclics (TCAs); monoamine oxidase inhibitors (MAOIs); selective serotonin reuptake inhibitors (SSRIs); serotonin-noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine, duloxetine and milnacipran; and other agents (mirtazapine, reboxetine, bupropion). Over the last 20 years prescribing ADs has dramatically risen in Western countries, mainly because of the increasing number of prescriptions for SSRIs, which have progressively become the most commonly prescribed ADs (<LINK REF="REF-Ciuna-2004" TYPE="REFERENCE">Ciuna 2004</LINK>). The selective action of SSRIs is purported to be the rationale for potential advantages over other existing therapies. Rather than a breakthrough in pharmacology, the development of SSRIs may be seen as a process of refining the action of existing and commonly used alternatives and this process may be clinically important (<LINK REF="REF-Freemantle-2000" TYPE="REFERENCE">Freemantle 2000</LINK>). SSRIs are generally more acceptable than TCAs, and there is evidence of similar efficacy (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). However, head-to-head comparisons have provided contrasting findings (<LINK REF="REF-Cipriani-2006a" TYPE="REFERENCE">Cipriani 2006a</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-07-02 11:14:39 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine hydrochloride (3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine HCl; Lilly (LY) 110140) was first described in a scientific journal in 1974 as a selective serotonin (5-hydroxytryptamine or 5-HT)-uptake inhibitor (<LINK REF="REF-Wong-2005" TYPE="REFERENCE">Wong 2005</LINK>). It was marketed as an AD in December 1987 and went off patent in August 2001. From its marketing fluoxetine quickly became the most prescribed AD in the United States (<LINK REF="REF-Marshall-2009" TYPE="REFERENCE">Marshall 2009</LINK>) and, despite the availability of newer agents, it remains extremely popular in the pharmacological treatment of major depression and in the treatment of several anxiety disorders.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-07-02 11:18:37 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine&#8217;s presumed mechanism of action is through inhibiting the reuptake of serotonin. It is not clear, however, if reuptake inhibition correlates with clinical effect, either between patients or over time.</P>
<P>The bioavailability of fluoxetine is relatively high, and peak plasma concentrations are reached in six to eight hours. It is highly bound to plasma proteins, mostly albumin. Fluoxetine is metabolised in the liver by isoenzymes of the cytochrome P450 system, including CYP2D6. Only one metabolite of fluoxetine, norfluoxetine (N-demethylated fluoxetine), is biologically active. The extremely slow elimination of fluoxetine and its active metabolite norfluoxetine from the body distinguishes it from other ADs. With time, fluoxetine and norfluoxetine inhibit their own metabolism so the fluoxetine elimination half-life changes from one to three days after a single dose to four to six days after long-term use.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-07-02 11:22:05 +0100" MODIFIED_BY="[Empty name]">
<P>In 2000 Geddes and colleagues (<LINK REF="REF-Geddes-2000" TYPE="REFERENCE">Geddes 2000</LINK>) completed a Cochrane systematic review comparing the group of SSRIs with all other ADs and concluded that there were no large differences between the AD drug classes; however it was suggested that differences may emerge when single, head-to-head drug comparisons were considered. Starting from this consideration, and with the aim to shed light on the field of AD trials and treatment of major depression, a group of researchers agreed to join forces under the rubric of the Meta-Analyses of New Generation Antidepressants Study Group (MANGA Study Group) to systematically review all available evidence for each specific newer AD. We have up to now completed individual reviews on sertraline (<LINK REF="REF-Cipriani-2009a" TYPE="REFERENCE">Cipriani 2009a</LINK>), escitalopram (<LINK REF="REF-Cipriani-2009b" TYPE="REFERENCE">Cipriani 2009b</LINK>), milnacipran (<LINK REF="REF-Nagakawa-2009" TYPE="REFERENCE">Nagakawa 2009</LINK>), fluvoxamine (<LINK REF="REF-Omori-2010" TYPE="REFERENCE">Omori 2010</LINK>), mirtazapine (<LINK REF="REF-Watanabe-2011" TYPE="REFERENCE">Watanabe 2011</LINK>), duloxetine (<LINK REF="REF-Cipriani-2012a" TYPE="REFERENCE">Cipriani 2012a</LINK>) and citalopram (<LINK REF="REF-Cipriani-2012b" TYPE="REFERENCE">Cipriani 2012b</LINK>), and a number of other reviews are now underway. A systematic review comparing fluoxetine with TCAs, heterocyclics, MAOIs, SSRIs, SNRIs and other antidepressants was first published in 2005 (<LINK REF="REF-Cipriani-2005" TYPE="REFERENCE">Cipriani 2005</LINK>) but since then new randomised evidence has been produced. We therefore sought to update that review with the aim of providing the &#8216;best available&#8217; and most up-to-date evidence on the efficacy and acceptability of fluoxetine in individuals with unipolar major depression.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-07-05 12:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of fluoxetine in comparison with all other antidepressive agents for depression in adult individuals with unipolar major depressive disorder. Specifically:</P>
<OL>
<LI>To determine the efficacy of fluoxetine in comparison with other ADs in alleviating the acute symptoms of unipolar major depressive disorder in adults; and</LI>
<LI>Review the acceptability of treatment with fluoxetine in comparison with other ADs.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2013-07-15 09:53:33 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-07-15 09:53:33 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-07-02 11:30:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing fluoxetine with all other active ADs as monotherapy in the acute phase treatment of unipolar depression were included. We included RCTs with a cross-over design but only used the results from the first randomisation period.</P>
<P>We excluded quasi-randomised trials, such as those allocating participants by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-07-15 09:53:33 +0100" MODIFIED_BY="[Empty name]">
<P>The review included participants 18 years or older, of both sexes, with a primary diagnosis of unipolar major depression according to standardised criteria, DSM-III, DSM-III-R, DSM-IV (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>), ICD-10 (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>), Feighner criteria (<LINK REF="REF-Feighner-1972" TYPE="REFERENCE">Feighner 1972</LINK>) or Research Diagnostic Criteria (<LINK REF="REF-Spitzer-1972" TYPE="REFERENCE">Spitzer 1972</LINK>). Studies using ICD-9 were excluded as it only lists disease names and does not have diagnostic criteria.</P>
<P>We included participants with the following subtypes of depression: chronic, with catatonic features, with melancholic features, with atypical features, with postpartum onset, and with a seasonal pattern. We included studies in which up to 20% of participants presented with depressive episodes in bipolar affective disorder. We also included participants with a concurrent secondary diagnosis of another psychiatric disorder.</P>
<P>We excluded participants with a concurrent primary diagnosis of Axis I or II disorders and participants with a serious concomitant medical illness.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-07-05 13:02:41 +0100" MODIFIED_BY="[Empty name]">
<P>We examined fluoxetine in comparison with conventional pharmacological treatments for acute depression. We also examined fluoxetine in comparison with non-conventional ADs (hypericum or other non-conventional ADs). We excluded trials in which fluoxetine was compared to another type of psychopharmacological agent (that is anxiolytics, anticonvulsants, antipsychotics or mood-stabilisers) and trials in which fluoxetine was used as an augmentation strategy.</P>
<SUBSECTION>
<HEADING LEVEL="4">Experimental intervention</HEADING>
<P>Fluoxetine (as monotherapy). No restrictions on dose, frequency, intensity and duration were applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator interventions</HEADING>
<P>Conventional antidepressive agents:</P>
<OL>
<LI>tricyclics (TCAs);</LI>
<LI>heterocyclics;</LI>
<LI>SSRIs;</LI>
<LI>SNRIs;</LI>
<LI>MAOIs or newer ADs; and</LI>
<LI>other conventional psychotropic drugs.</LI>
</OL>
<P>Non-conventional antidepressive agents:</P>
<OL>
<LI>hypericum; and</LI>
<LI>other non-conventional antidepressive agents (e.g. <I>Crocus sativus</I>).</LI>
</OL>
<P>No restrictions on dose, frequency, intensity and duration were applied.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-07-05 13:04:54 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-07-05 13:04:54 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Efficacy</HEADING>
<P>Efficacy was evaluated using the following outcome measures.</P>
<SUBSECTION>
<HEADING LEVEL="6">(1) Dichotomous outcome</HEADING>
<P>Number of participants who responded to treatment at the end of the trial by showing a reduction of at least 50% on the Hamilton Depression Scale (HDRS) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) out of the total number of randomised participants (intention-to-treat analysis).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(2) Continuous outcome</HEADING>
<P>Group mean scores at the end of the trial or change scores on HDRS, or Montgomery-Asberg Depression Scale (MADRS) (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>), or any other depression scale. If both endpoint and change scores were available, we considered endpoint scores.</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-05 13:04:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(3) Failure to complete due to any reason</HEADING>
<P>Number of participants who dropped out during the trial as a proportion of the total number of randomised participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(4) Failure to complete due to inefficacy</HEADING>
<P>Number of participants who dropped out during the trial due to inefficacy as a proportion of the total number of randomised participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(5) Failure to complete due to side effects</HEADING>
<P>Number of participants who dropped out during the trial due to side effects as a proportion of the total number of randomised participants.</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-07-05 13:09:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CCDAN's Specialized Register (CCDANCTR)</B> <BR/>The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) maintains two clinical trials registers at their editorial base in Bristol, UK, a references register and a studies based register. The CCDANCTR-References Register contains over 31,500 reports of randomised controlled trials in depression, anxiety and neurosis. Approximately 65% of these references have been tagged to individual, coded trials. The coded trials are held in the CCDANCTR-Studies Register and records are linked between the two registers through the use of unique Study ID tags. Coding of trials is based on the EU-Psi coding manual. Please contact the CCDAN Trials Search Coordinator for further details. Reports of trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (1950-), EMBASE (1974-) and PsycINFO (1967-); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also sourced from international trials registers c/o the World Health Organization&#8217;s trials portal (<A HREF="http://apps.who.int/trialsearch/">ICTRP</A>), <A HREF="http://www.clinicaltrials.gov/ct2/home">ClinicalTrials.gov</A>, drug companies, the hand-searching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses.</P>
<P>Details of <A HREF="http://ccdan.cochrane.org/search-strategies-identification-studies">CCDAN's generic search strategies</A> can be found on the Group's website.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-07-03 08:14:34 +0100" MODIFIED_BY="[Empty name]">
<P>The CCDANCTR-Studies Register was searched by the Trials Search Co-ordinator (TSC) using the following search strategy:<BR/>Diagnosis = Depress* or Dysthymi* or "Adjustment Disorder*" or "Mood Disorder*" or "Affective Disorder*" or "Affective Symptoms"<BR/>and<BR/>Intervention = Fluoxetine</P>
<P>The CCDANCTR-References Register was searched using similar terms to identify additional untagged/uncoded references:<BR/>Keyword = Depress* or Dysthymi* or "Adjustment Disorder*" or "Mood Disorder*" or "Affective Disorder" or "Affective Symptoms"<BR/>and<BR/>Free-Text = (Fluoxetin* or Prozac)</P>
<P>Searches were conducted to 11 May 2012. No language restrictions were applied.</P>
<SUBSECTION>
<HEADING LEVEL="5">Other trial registers</HEADING>
<P>The CCDAN TSC also searched Clinicalstudyresults.org to December 2011 (before this website was phased out) together with ClinicalTrials.gov and the WHO ICTRP to 16 July 2012 for additional published, unpublished or ongoing studies.</P>
<P>We searched trial databases of the following drug-approving agencies: the Food and Drug Administration (FDA) in the USA, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicines Agency (EMA) in the EU, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the Therapeutic Goods Administration (TGA) in Australia. We also searched ongoing trial registers: ClinicalTrials.gov in the USA, Controlled-Trials.com (ISRCTN) in the UK, the Nederland's Trial Register, the European Union Drug Regulating Authorities Clinical Trials register (EudraCT), UMIN-CTR in Japan and the Australian New Zealand Clinical Trials Registry (ACTRN). These searches were undertaken in November 2010.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-07-03 08:22:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Handsearches</HEADING>
<P>Appropriate journals and conference proceedings relating to fluoxetine treatment for depression have already been handsearched and incorporated into the CCDANCTR databases.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Personal communication</HEADING>
<P>Pharmaceutical companies and experts in this field were asked if they knew of any study that met the inclusion criteria of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reference checking</HEADING>
<P>Reference lists of the included studies, previous systematic reviews and major textbooks of affective disorder that were written in English were checked for published reports and citations of unpublished research (<LINK REF="REF-Trespidi-2011" TYPE="REFERENCE">Trespidi 2011</LINK>).</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-05 13:13:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-07-03 08:25:28 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent review authors (LRM, MP) checked to ensure that studies relating to fluoxetine generated by the search of the CCDANCTR-References Register and the other complementary searches met the rough inclusion criteria, firstly based on the titles and abstracts. All studies that were rated as possible candidates by either of the two review authors were added to a preliminary list, and the full text articles were then retrieved. LRM, CG, MP and AC assessed the full text articles to see if they met the strict inclusion criteria. If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group (CB). Considerable care was taken to group multiple publications to the main study to which they related.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-07-05 13:13:06 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors, working independently and in duplicate (LRM and MP), extracted data from the included studies. Again, any disagreement was discussed with other authors, and decisions were documented. If necessary, we contacted authors of studies for clarification. We extracted the following data from the included studies:</P>
<P>(i) participant characteristics (age, depression diagnosis, comorbidity, depression severity, antidepressant treatment history for the index episode, study setting);<BR/>(ii) intervention details (intended dosage range, mean daily dosage actually prescribed, sponsorship); and<BR/>(iii) outcome measures of interest.</P>
<P>The results were compared with those in the completed reviews of individual antidepressants in <I>The Cochrane Library</I>.</P>
<P>We considered the following comparisons:</P>
<UL>
<LI>fluoxetine versus TCAs;</LI>
<LI>fluoxetine versus the heterocyclics maprotiline, mianserin;</LI>
<LI>fluoxetine versus the SSRIs citalopram, escitalopram, fluvoxamine, paroxetine, sertraline;</LI>
<LI>fluoxetine versus the SNRIs duloxetine, milnacipran, venlafaxine;</LI>
<LI>fluoxetine versus the MAOIs or newer ADs agomelatine, mirtazapine, moclobemide, phenelzine, reboxetine;</LI>
<LI>fluoxetine versus other conventional psychotropic drugs amineptine, bupropion, pramipexole, tianeptine, trazodone; and</LI>
<LI>fluoxetine versus the other non-conventional AD agents <I>Crocus sativus</I>, hypericum.</LI>
</UL>
<P>In the analysis TCAs were pooled as data have shown that drugs belonging to the TCA group are similar in terms of efficacy and tolerability, while drugs belonging to the other classes have rather different efficacy and tolerability profiles (<LINK REF="REF-Cipriani-2011" TYPE="REFERENCE">Cipriani 2011</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-07-05 13:13:22 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent review authors independently assessed trial quality in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This set of criteria is based on evidence of associations between effect overestimation and a high risk of bias in an article, such as sequence generation, allocation concealment, blinding (of participants and personnel, outcome assessment), incomplete outcome data, selective reporting and other source of bias. The categories are defined as:</P>
<UL>
<LI>low risk of bias;</LI>
<LI>high risk of bias; and</LI>
<LI>unclear risk of bias.</LI>
</UL>
<P>If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group.</P>
<P>Non-congruence in quality assessment was reported as percentage disagreement. The ratings were also compared with those in the completed reviews of individual antidepressants in <I>The Cochrane Library</I>. If there were any discrepancies, they were fed back to the authors of the completed reviews.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-07-03 08:37:12 +0100" MODIFIED_BY="[Empty name]">
<P>All comparisons were performed between fluoxetine and comparator ADs as individual ADs. Additionally, fluoxetine was compared with TCAs considered as a class.</P>
<P>Skewed data and non-quantitative data were presented descriptively. An outcome was considered skewed when the mean was smaller than twice the SD. In terms of change score, data were difficult to depict as skewed or not as the possibility existed for negative values; therefore, we entered all of the results of the outcome into the meta-analysis.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous, or event-like, data, odds ratios (ORs) were calculated with their 95% confidence intervals (CI). For statistically significant results, we calculated the number needed to treat to provide benefit (NNT).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data we calculated the standardised mean differences (SMD) with 95% CI.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-07-03 08:42:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (for example pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state, even with a wash-out phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in major depression, we only used data from the first phase of the cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation&#8217; (such as randomisation by clinician or practice) but analysis and pooling of clustered data pose problems (<LINK REF="REF-Barbui-2011b" TYPE="REFERENCE">Barbui 2011b</LINK>). They are commonly analysed as if the randomisation was performed on the individuals rather than the clusters. In this case, approximately correct analyses were performed by dividing the binary data (the number of participants and the number experiencing the event) as presented in a report by a 'design effect&#8217; (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC): design effect = 1 + (m-1) *ICC (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If the ICC was not reported it was assumed to be 0.1. For continuous data only the sample size was reduced; means and standard deviations remained unchanged.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>Studies that compared more than two intervention groups were included in the meta-analysis by combining all relevant experimental intervention groups of the study into a single group, and all relevant control intervention groups into a single control group, as recommended in section 16.5 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-07-03 08:46:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>Responders and remitters to treatment were calculated on a strict intention-to-treat (ITT) basis: dropouts were included in this analysis. Where participants had been excluded from the trial before the endpoint, we assumed that they experienced a negative outcome by the end of the trial (for example failure to respond to treatment). We examined the validity of this decision in the sensitivity analyses by applying worst- and best-case scenarios.</P>
<P>When dichotomous outcomes were not reported but the baseline mean, endpoint mean and their SDs of the HRSD (or other depression scale) were provided, we converted continuous outcome data expressed as mean and SD into the number of responding and remitted patients, according to the validated imputation method (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). We examined the validity of this imputation in the sensitivity analyses (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We applied the loose ITT analyses for continuous variables whereby all the patients with at least one post-baseline measurement were represented by their last observations carried forward (LOCF), with due consideration of the potential bias and uncertainty introduced. Data from trials not using a LOCF approach were extracted and analysed as reported by the authors. Where SDs were not reported, authors were asked to supply the data. When only the standard error (SE) or t-statistics or P values were reported, SDs were calculated according to Altman (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). In the absence of data from the authors, we substituted SDs by those reported in other studies in the review (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-03 08:48:29 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity between studies was investigated by visual inspection of the forest plots and using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). According to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), the following thresholds for the interpretation of I<SUP>2</SUP> were used: 0% to 40%, might not be important; 30% to 60%, may represent moderate heterogeneity; 50% to 90%, may represent substantial heterogeneity; 75% to 100%, considerable heterogeneity. Moreover, we considered the sample size, and the magnitude and the direction of the treatment effects.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-07-03 08:50:12 +0100" MODIFIED_BY="[Empty name]">
<P>Data from included studies were entered into a funnel plot (trial effect against trial variance) to investigate small-study effects (<LINK REF="REF-Sterne-2000" TYPE="REFERENCE">Sterne 2000</LINK>). We used the tests for funnel plot asymmetry only when there were at least 10 studies included in the meta-analysis, and results were interpreted cautiously, with visual inspection of the funnel plots. We followed the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> methodology (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When evidence of small-study effects was identified, possible reasons for funnel plot asymmetry, including publication bias, were investigated.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-07-03 08:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>The primary analysis used a random-effects model (odds ratio (OR)), which had the highest generalisability in our empirical examination of summary effect measures for meta-analyses (<LINK REF="REF-Furukawa-2002" TYPE="REFERENCE">Furukawa 2002</LINK>). The robustness of this summary measure was routinely examined by checking the fixed-effect model OR and the random-effects model risk ratio (RR). Material differences between the models were reported. A P value of less than 0.05 and a 95% confidence interval (CI) not including 1 (for the dichotomous outcomes) were considered statistically significant.</P>
<P>Fixed-effect model analyses were performed routinely for the continuous outcomes as well, to investigate the effect of the choice of method on the estimates. Material differences between the models were reported.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-03 08:52:12 +0100" MODIFIED_BY="[Empty name]">
<P>We undertook a subgroup analysis for the duration of follow up. We considered the following categories: (1) less than 6 weeks, (2) 6 to 16 weeks, and (3) more than 16 weeks. Moreover, with the exception of the TCA group<I>, </I>stratification by each control agent was performed to ascertain whether there were treatment differences between fluoxetine and AD drugs belonging to the same pharmacological class. </P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-07-03 08:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses (worst-case scenario; best-case scenario; excluding ORs imputed based on continuous data; fixed-effect rather than random-effects models; RR rather than OR; excluding trials using LOCF; excluding trials with substituted SD) were not performed in this version of the review. However, we will conduct these analyses in the next update. If cluster-randomised or cross-over trials are included in the next update, we will undertake a sensitivy analysis excluding studies with these study designs.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-07-15 11:33:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-07-15 11:33:45 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>
</P>
<SEARCH_RESULTS MODIFIED="2013-07-03 08:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>The original searches yielded 883 studies; after reading the abstracts, 364 papers were considered potentially relevant for this review. Of these, 219 were excluded because they were not randomised trials or for other reasons. The remaining 145 were retrieved for more detailed evaluation and 132 RCTs meeting the inclusion criteria were included in the 2005 version (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>In July 2012 a new search was conducted to update the review. This new search yielded 524 new records of RCTs published between 2005 and 2012, 12 unpublished RCTs, 10 RCTs defined as 'awaiting assessment' in the previous 2005 version, and five studies still ongoing at the time of inclusion. Of these, 536 were considered potentially relevant for this review. After reading the abstracts, 99 references were considered eligible for possible inclusion and the corresponding full papers were retrieved for a detailed evaluation; 55 trials were excluded or are awaiting assessment for wrong study design (not RCT) or other reasons and five are still ongoing. We included a total of 39 RCTs in the qualitative synthesis and 33 RCTs in the quantitative synthesis (meta-analysis) (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-07-03 11:51:44 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>
</P>
<P>Overall, a total of 171 studies were included in the present systematic review (24,868 participants). Attempts to contact authors for additional information were unsuccessful in 22 cases and successful in two cases with additional data provided by the authors.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>The great majority of included studies were reported to be double-blind (161 out of 171 RCTs, that is 95%). The participants were followed up for six weeks (range four to 24 weeks) in a majority of the trials (80 trials).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>The mean number of participants per study was 135.2, with a minimum sample size of 16 (<LINK REF="STD-O_x0027_Keane-1992" TYPE="STUDY">O'Keane 1992</LINK>) and a maximum of 1096 (<LINK REF="STD-Keller-2007" TYPE="STUDY">Keller 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>A total of 105 trials enrolled only outpatients, 14 trials enrolled only inpatients, and both inpatients and outpatients were enrolled in the remaining trials. Forty-one per cent of the included studies were undertaken in Europe, 20% in USA, 5% in Canada and in Central or South America, 4% of the trials were conducted in Iran and for the remaining 12% the geographic area was unclear. Three per cent of the included studies were multicentric international trials: 2% were conducted in Africa (South Africa and Zimbabwe); 2% in China, Australia and New Zealand; less than 1% in Israel and Turkey.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The majority of included trials (163 RCTs) enrolled patients with a diagnosis of major depression based on DSM-III (34 studies), DSM-III-R (64 studies), DSM-IV or ICD 10 criteria (67 studies). Seventy-eight trials excluded patients over 65 years, while 14 trials included only elderly patients. We also included a minority of studies in which up to 20% of patients presented with depressive episodes in bipolar disorder.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention and comparators</HEADING>
<P>In 74 studies fluoxetine was compared with TCAs (22 studies versus amitriptyline, 15 versus imipramine, 6 versus dothiepin or dosulepin, 5 versus maprotiline, 5 versus clomipramine, 6 versus nortriptyline, 4 versus desipramine, 4 versus doxepine, 3 versus mianserin, 2 versus trimipramine, 1 versus lofepramine, 1 versus nimofensine). Thirty RCTs compared fluoxetine with other SSRIs (13 versus paroxetine, 12 versus sertraline, 3 versus citalopram, 2 versus escitalopram), 20 versus SNRIs (15 versus venlafaxine, 3 versus milnacipran, 2 versus duloxetine), and 20 studies with MAOIs or newer agents (7 versus moclobemide, 4 versus reboxetine, 5 versus mirtazapine, 3 versus agomelatine, 1 versus phenelzine). Moreover, in 19 studies fluoxetine was compared with other conventional agents (4 versus trazodone, 4 versus nefazodone, 4 versus tianeptine, 2 versus amineptine, 2 versus bupropion, 1 versus pramipexole, 1 versus amisulpride, 1 versus ABT-200). Finally, eight studies compared fluoxetine with non-conventional agents (6 versus hypericum and 2 versus <I>Crocus sativus</I>). A fixed dose regimen for fluoxetine was employed in 72 studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>At the end of the reviewing process, 165 RCTs were included in the meta-analysis. For efficacy outcomes, 121 RCTs provided continuous data and 91 dichotomous data. For acceptability outcomes, 139 RCTs provided data on total dropouts, 104 on dropouts due to inefficacy and 125 on dropouts due to side effects. In the majority of trials (130 out of 143, 90%) the 17- or 21- item HDRS was used for reporting outcomes.</P>
<P>Overall, 13,619 patients were included in the efficacy analysis dichotomous outcome (6441 participants randomised to fluoxetine and 7178 randomised to another antidepressant) and 15,870 were included in the efficacy analysis continuous outcome (7625 participants randomised to fluoxetine and 8245 randomised to another antidepressant). A total of 18,756 patients were included in the acceptability analysis (9009 partIcipants randomised to fluoxetine and 9747 randomised to another antidepressant).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-07-15 11:33:45 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>
</P>
<P>Forty-four articles that were initially selected did not meet our inclusion criteria and were excluded because of one of the following reasons: wrong design (24 articles), review or pooled analysis (two articles), wrong comparison (nine articles), wrong intervention (one article) and wrong diagnosis or population (eight articles). A total of 34 records were classified as 'awaiting classification'. Of these, 28 were study reports written in Chinese.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-05 13:16:22 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<P>Our judgement about the overall risk of bias in the individual studies is illustrated in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. The methodological quality of many included studies was judged as poor, although judging articles from some time ago by today&#8217;s standard might be problematic (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). Moreover, many articles failed to report methodologically relevant information on study procedure (in these cases the judgement was defined as 'unclear') and the overall reporting of studies was not good. This type of reporting has been associated with an overestimate of the estimate of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and it should be considered when interpreting the results. However, in general it is not possible to predict the direction or magnitude of bias associated with a lack of adequate sequence generation or adequate allocation concealment (<LINK REF="REF-Odgaard_x002d_Jensen-2011" TYPE="REFERENCE">Odgaard-Jensen 2011)</LINK>.</P>
<ALLOCATION MODIFIED="2013-07-03 12:00:54 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>The majority of studies (161) did not report the methods of generating random sequence, while eight studies (<LINK REF="STD-Akhondzadeh-Basti-2007" TYPE="STUDY">Akhondzadeh Basti 2007</LINK>; <LINK REF="STD-Alves-1999" TYPE="STUDY">Alves 1999</LINK>; <LINK REF="STD-Byerley-1988" TYPE="STUDY">Byerley 1988</LINK>; <LINK REF="STD-Harrer-1999" TYPE="STUDY">Harrer 1999</LINK>; <LINK REF="STD-Hosak-2000" TYPE="STUDY">Hosak 2000</LINK>; <LINK REF="STD-Noorbala-2005" TYPE="STUDY">Noorbala 2005</LINK>; <LINK REF="STD-Rudolph-1999" TYPE="STUDY">Rudolph 1999</LINK>; <LINK REF="STD-Sheehan-2009" TYPE="STUDY">Sheehan 2009</LINK>) specified this information and they were classified as 'low risk'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>All trials failed to report details on allocation concealment and were classified as 'unclear risk'.<BR/>
</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2013-07-03 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<P>One hundred and sixty-three trials were undertaken on a double-blind basis, four trials employed a single-blind design and five an open design. None of the double-blind trials specified if blindness was maintained during the study. Nine studies were classified as 'high risk' of performance and detection bias while the remaining 163 were classified as 'unclear'. For the item on blinding of participants and personnel (performance bias), three RCTs were classified as 'low risk' of bias, nine RCTs as 'high risk' of bias and the remaining 160 as 'unclear'.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-07-03 12:03:07 +0100" MODIFIED_BY="[Empty name]">
<P>Only 11 trials (<LINK REF="STD-Alby-1993" TYPE="STUDY">Alby 1993</LINK>; <LINK REF="STD-Bennie-1995" TYPE="STUDY">Bennie 1995</LINK>; <LINK REF="STD-Berlanga-1997" TYPE="STUDY">Berlanga 1997</LINK>; <LINK REF="STD-Chouinard-1999" TYPE="STUDY">Chouinard 1999</LINK>; <LINK REF="STD-Corrigan-2000" TYPE="STUDY">Corrigan 2000</LINK>; <LINK REF="STD-Dierick-1996" TYPE="STUDY">Dierick 1996</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Guelfi-1999" TYPE="STUDY">Guelfi 1999</LINK>; <LINK REF="STD-O_x0027_Keane-1992" TYPE="STUDY">O'Keane 1992</LINK>; <LINK REF="STD-Sheehan-2009" TYPE="STUDY">Sheehan 2009</LINK>; <LINK REF="STD-Suleman-1997" TYPE="STUDY">Suleman 1997</LINK>) were rated as adequate in terms of addressing incomplete outcome data, while the majority (83 studies) were classified as 'unclear risk' and 77 as 'high risk'.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-07-03 12:04:12 +0100" MODIFIED_BY="[Empty name]">
<P>The study protocol was not available for almost all studies so it was difficult to make a judgement on the possibility of outcome reporting bias. However, in six studies (<LINK REF="STD-Chouinard-1999" TYPE="STUDY">Chouinard 1999</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Guelfi-1999" TYPE="STUDY">Guelfi 1999</LINK>; <LINK REF="STD-Hale-2010" TYPE="STUDY">Hale 2010</LINK>; <LINK REF="STD-O_x0027_Keane-1992" TYPE="STUDY">O'Keane 1992</LINK>; <LINK REF="STD-Wehmeier-2005" TYPE="STUDY">Wehmeier 2005</LINK>) results were consistent with what was stated in the study protocols. Twenty-three studies were classified as 'high risk' of bias, five studies as 'low risk' of bias and the remaining 144 were classified as 'unclear'.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-07-03 12:05:03 +0100" MODIFIED_BY="[Empty name]">
<P>Most of the included studies (115 RCTs) were funded by pharmaceutical industry (and classified as 'high risk' of bias) and five studies were independent of industry (and classified as 'low risk' of bias). The remaining studies did not specify the source of funding and were defined as 'unclear'.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-05 13:23:22 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: fluoxetine versus TCAs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Dichotomous outcome</HEADING>
<P>Twenty-four studies contributed to this comparison including 2124 participants.</P>
<P>We found no difference in terms of efficacy between fluoxetine and TCAs as a class (OR 0.97, 95% CI 0.77 to 1.22, 24 RCTs, 2124 participants). In head-to-head comparisons, only dothiepin/dosulepin was found to be more effective than fluoxetine (OR 2.13, 95% CI 1.08 to 4.20; NNT = 6, 95% CI 3 to 50, 2 RCTs, 144 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Continuous outcome</HEADING>
<P>Fifty studies contributed to this comparison including 3393 participants.</P>
<P>On this outcome (measured with HDRS or MADRS), we found no differences between fluoxetine and TCAs as a class (SMD 0.03, 95% CI -0.07 to 0.14, 50 RCTs, 3393 participants) and between fluoxetine and individual TCAs.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Failure to complete due to any cause</HEADING>
<P>Forty-nine studies contributed to this comparison including 4194 participants.</P>
<P>In terms of participants who dropped out for any cause, fluoxetine was better tolerated than TCAs (OR 0.79, 95% CI 0.65 to 0.96; NNT = 20, 95% CI 13 to 48, 49 RCTs, 4194 participants), in particular amitriptyline (OR 0.62, 95% CI 0.46 to 0.85; NNT = 13, 95% CI 8 to 39, 18 RCTs, 1089 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Failure to complete due to inefficacy</HEADING>
<P>Thirty-three studies contributed to this comparison including 2911 participants.</P>
<P>We found no differences in terms of dropouts due to inefficacy (OR 1.29, 95% CI 0.96 to 1.72, 33 RCTs, 2911 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 Failure to complete due to side effects</HEADING>
<P>Forty studies contributed to this comparison including 3647 participants.</P>
<P>The analysis of dropouts due to side effects revealed that amitriptyline (OR 0.41, 95% CI 0.23 to 0.71; NNT = 12, 95% CI 8 to 22, 16 RCTs, 1038 participants), clomipramine (OR 0.30, 95% CI 0.12 to 0.79; NNT = 11 , 95% CI 6 to 46, 2 RCTs, 163 participants), imipramine (OR 0.47, 95% CI 0.26 to 0.86; NNT= 8, 95% CI 6 to 12, 10 RCTs, 1093 participants) and overall TCAs (OR 0.55, 95% CI 0.40 to 0.75; NNT = 14, 95% CI 10 to 20, 40 RCTs, 3647 participants) were less well tolerated than fluoxetine.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: fluoxetine versus heterocyclics</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Dichotomous outcome</HEADING>
<P>Three studies contributed to this comparison including 216 participants.</P>
<P>In terms of dichotomous outcomes, we found no differences between fluoxetine and individual heterocyclics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Continuous outcome</HEADING>
<P>Eight studies contributed to this comparison including 561 participants.</P>
<P>In terms of continuous outcomes, we found no differences between fluoxetine and individual heterocyclics.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary: acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Failure to complete due to any cause</HEADING>
<P>Six studies contributed to this comparison including 444 participants.</P>
<P>In terms of patients who dropped out during the trial for any reason, we found no differences between fluoxetine and individual heterocyclics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Failure to complete due to inefficacy</HEADING>
<P>Four studies contributed to this comparison including 262 participants overall.</P>
<P>We found no differences in terms of dropouts due to inefficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Failure to complete due to side effects</HEADING>
<P>Four studies contributed to this comparison including 262 participants overall.</P>
<P>Similarly, we found no differences in terms of dropouts due to side effects.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: fluoxetine versus other SSRIs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Dichotomous outcome</HEADING>
<P>Eighteen studies contributed to this comparison including 3238 participants overall.</P>
<P>There was a difference in terms of efficacy in favour of sertraline over fluoxetine (OR 1.37, 95% CI 1.08 to 1.74; NNT = 13, 95% CI 7 to 58, 6 RCTs, 1188 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Continuous outcome</HEADING>
<P>Twenty-two studies contributed to this comparison including 4113 participants overall.</P>
<P>In terms of continuous outcomes (measured with HDRS or MADRS), there were inconclusive results.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Failure to complete due to any cause</HEADING>
<P>Twenty-six studies contributed to this comparison including 5033 participants.</P>
<P>In terms of patients who dropped out for any reason, we found a trend in favour of escitalopram over fluoxetine (OR 1.53, 95%, CI 1 to 2.37, 2 RCTs, 578 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Failure to complete due to inefficacy</HEADING>
<P>Fourteen studies contributed to this comparison including 3371 participants.</P>
<P>No difference was found between fluoxetine and other SSRIs in terms of discontinuation due to inefficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5 Failure to complete due to side effects</HEADING>
<P>Twenty-four studies contributed to this comparison including 4510 participants.</P>
<P>No difference was found between fluoxetine and other SSRIs in terms of discontinuation due to side effects.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: fluoxetine versus SNRIs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Dichotomous outcome</HEADING>
<P>Fifteen studies contributed to this comparison including 3860 participants.</P>
<P>There was a difference in terms of efficacy in favour of venlafaxine over fluoxetine (OR 1.29, 95%, CI 1.10 to 1.51; NNT =11, 95% CI 8 to 16, 12 RCTs, 3387 participants). No difference was found between fluoxetine and other SNRIs (milnacipran and duloxetine).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Continuous outcome</HEADING>
<P>Fifteen studies contributed to this comparison including 3310 participants.</P>
<P>There was a difference in terms of efficacy in favour of fluoxetine over milnacipran (measured with HDRS or Montgomery and Asberg Scale for Depression (MADRS)) (SMD -0.36, 95% CI -0.63 to -0.08, 2 RCTs, 213 participants) and a small difference in favour of venlafaxine over fluoxetine (SMD 0.10 95%, CI 0.00 to 0.19,13 RCTs, 3097 participants).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: Acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Failure to complete due to any cause</HEADING>
<P>Nineteen studies contributed to this comparison including 3775 participants.</P>
<P>There was no evidence that fluoxetine was associated with a smaller or higher rate of dropout for any reason than the SNRIs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Failure to complete due to inefficacy</HEADING>
<P>Eighteen studies contributed to this comparison including 3632 participants.</P>
<P>There was no evidence that fluoxetine was associated with a smaller or higher rate of dropout for inefficacy than the SNRIs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5 Failure to complete due to side effects</HEADING>
<P>Eighteen studies contributed to this comparison including 3732 participants.</P>
<P>The analysis of dropouts due to side effects revealed that fluoxetine had an advantage over venlafaxine (OR 0.72, 95% CI 0.56-0.94; NNT = 36, 95% CI 20 to 202, 13 RCTs, 2640 participants).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 5: fluoxetine versus MAOIs or newer ADs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Dichotomous outcome</HEADING>
<P>Sixteen studies contributed to this comparison including 2567 participants.</P>
<P>There was a difference in terms of efficacy in favour of mirtazapine over fluoxetine (OR 1.46, 95% CI 1.04 to 2.04; NNT = 12, 95% CI 6 to 134, 4 RCTs, 600 participants). No differences were found between fluoxetine and other newer ADs or MAOIs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Continuous outcome</HEADING>
<P>Thirteen studies contributed to this comparison including 2029 participants.</P>
<P>We found no differences in terms of efficacy between fluoxetine and MAOIs or newer ADs (measured with HDRS or MADRS).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.3 Failure to complete due to any reason</HEADING>
<P>Seventeen studies contributed to this comparison including 2611 participants.</P>
<P>In terms of participants who dropped out during the trial for any reason, fluoxetine performed better in comparison with reboxetine only (OR 0.60, 95%, CI 0.44 to 0.82; NNT = 9, 95% CI 6 to 24, 4 RCTs, 764 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.4 Failure to complete due to inefficacy</HEADING>
<P>Sixteen studies contributed to this comparison including 2568 participants.</P>
<P>No differences were found between fluoxetine and MAOIs or newer ADs in terms of dropout due to inefficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.5 Failure to complete due to side effects</HEADING>
<P>Sixteen studies contributed to this comparison including 2157 participants.</P>
<P>No differences were found between fluoxetine and MAOIs or newer ADs in terms of dropout due to side effects. However, we found a trend in favour of fluoxetine over reboxetine (OR 0.41, 95% CI 0.15 to 1.09, 2 RCTs, 211 participants).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 6: fluoxetine versus other conventional psychotropic drugs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Dichotomous outcome</HEADING>
<P>Eight studies contributed to this comparison including 1101 participants.</P>
<P>No differences between fluoxetine and any other conventional AD (amineptine, bupropion, pramipezole, tianeptine, trazodone) were found in terms of dichotomous outcome measures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Continuous outcome</HEADING>
<P>Thirteen studies contributed to this comparison including 1613 participants.</P>
<P>We found an advantage of fluoxetine over ABT-200 (SMD -1.85, 95% CI -2.25 to -1.45, 1 RCT, 141 participants) (measured with HDRS or MADRS). No differences in continuous outcome measures were found between fluoxetine and other conventional ADs.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Failure to complete due to any cause</HEADING>
<P>Seventeen studies contributed to this comparison including 2419 participants.</P>
<P>In terms of participants who dropped out for any reason, fluoxetine was better tolerated than ABT-200 (OR 0.18, 95% CI 0.08 to 0.39; NNT = 3, 95% CI 2 to 5, 1 RCT, 144 participants) and pramipexole (OR 0.12, 95% CI 0.03 to 0.42; NNT = 3, 95% CI 2 to 5, 1 RCT, 105 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Failure to complete due to inefficacy</HEADING>
<P>Fourteen studies contributed to this comparison including 2090 participants.</P>
<P>In terms of dropout due to inefficacy, we found no difference between fluoxetine and other conventional psychotropic drugs. However, due to the large confidence intervals, these results are inconclusive.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.5 Failure to complete due to side effects</HEADING>
<P>Seventeen studies contributed to this comparison including 2424 participants.</P>
<P>In terms of dropout due to side effects fluoxetine was better tolerated than ABT-200 (OR 0.08, 95% CI 0.02 to 0.27; NNT = 3, 95% CI 2 to 5, 1 RCT, 144 participants) and pramipexole (OR 0.06, 95% CI 0.01 to 0.50, NNT = 4, 95% CI 2 to 6, 1 RCT, 105 participants).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 7. fluoxetine versus other non-conventional AD agents</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome: efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.1 Dichotomous outcome</HEADING>
<P>Seven studies contributed to this comparison including 757 participants overall.</P>
<P>No difference between fluoxetine and other non-conventional agents was found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.2 Continuous outcome</HEADING>
<P>Five studies contributed to this outcome including 648 participants overall.</P>
<P>No difference was found on this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome: acceptability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.3 Failure to complete due to any cause</HEADING>
<P>Six studies contributed to this comparison including 719 participants overall.</P>
<P>In terms of patients who dropped out for any reason no differences were found between fluoxetine and other non-conventional ADs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.4 Failure to complete due to inefficacy</HEADING>
<P>Two studies contributed to this comparison including 401 participants overall.</P>
<P>No difference was found on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.5 Failure to complete due to inefficacy</HEADING>
<P>Five studies contributed to this comparison including 679 participants overall.</P>
<P>No difference was found on this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>The great majority of included studies had a follow-up period of between six and 16 weeks.</P>
<P>The subgroup analysis revealed a difference in favour of fluoxetine over nortriptyline, continuous outcome, follow-up &gt; 16 weeks (SMD -0.86, 95% CI -1.27 to -0.44, 1 RCT, 97 participants), and a difference between fluoxetine and TCAs as a class, follow-up six to 16 weeks, dichotomous outcome (failure to complete - inefficacy) (OR 1.38, 95% CI 1.02 to 1.87, 28 RCTs, 1053 participants).</P>
<P>For the other comparisons we found no material difference between fluoxetine and other antidepressants both in terms of efficacy and acceptability.</P>
<P>Moreover, with the exception of the TCA group<I>, </I>stratification by each control agent was performed to ascertain whether there were treatment differences between fluoxetine and AD drugs belonging to the same pharmacological class (see results on efficacy and acceptability).</P>
<P>As reported in the methods, sensitivity analyses were not performed in this version of the review. However, we will conduct these analyses in the next update.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity</HEADING>
<P>For the primary outcomes, I<SUP>2</SUP> indicative of moderate heterogeneity was observed in the comparison between fluoxetine and TCA as a class, (I<SUP>2 </SUP>= 55%) and between fluoxetine and imipramine, continuous outcome analyses (I<SUP>2 </SUP>= 54%). Substantial heterogeneity was found in the comparison between fluoxetine and the following AD drugs: mianserin (I<SUP>2 </SUP>= 78%), paroxetine (I<SUP>2 </SUP>= 86%), agomelatine (I<SUP>2 </SUP>= 67%) and trazodone (I<SUP>2 </SUP>= 62%), desipramine, dothiepin or dosulepin (I<SUP>2 </SUP>= 67%), nortryptiline (I<SUP>2 </SUP>= 87%), and tianeptine (I<SUP>2 </SUP>= 63%). For dichotomous outcomes, moderate heterogeneity was observed in the comparison between fluoxetine and trazodone (I<SUP>2 </SUP>= 58%), while substantial heterogeneity was found in the comparison between fluoxetine versus hypericum (I<SUP>2 </SUP>= 68%) and versus imipramine (I<SUP>2 </SUP>= 68%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of publication bias</HEADING>
<P>Visual inspection of funnel plots did not reveal substantial asymmetry in any of the comparisons between fluoxetine and other conventional and unconventional ADs.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-07-05 13:23:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-07-05 13:23:16 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review detected differences between fluoxetine and some comparator ADs. On a dichotomous outcome, fluoxetine was less effective than dothiepin/dosulepin, sertraline, mirtazapine and venlafaxine. On a continuous outcome, fluoxetine was more effective than ABT-200 and milnacipran, and less effective than sertraline and venlafaxine, although these findings were of borderline statistical significance. However, it is uncertain how these differences translate into clinically meaningful measures. Despite the large number of comparative trials included in this systematic review, the total number of randomised patients was under 25,000. Studies were short, usually eight weeks or less, and the mean size of each trial was around 135 participants, indicating that they were generally underpowered for demonstrating clinically meaningful differences.</P>
<P>In terms of acceptability fluoxetine was better tolerated than TCA, reboxetine, ABT-200 and pramipexole (dropout due to any reasons). By contrast, escitalopram was better tolerated than fluoxetine, although the result was of borderline statistical significance. Moreover, considering dropout due to side effects, fluoxetine was better tolerated than amitriptyline, clomipramine, imipramine, ABT-200 and pramipexole. Fluoxetine was also better tolerated than venlafaxine (dropout due to side effects).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-07-03 12:38:40 +0100" MODIFIED_BY="[Empty name]">
<P>Our review currently includes 171 randomised trials with 24,868 participants in total. All studies in the review involved participants with a formal diagnosis of depression on a standardised and validated scale according to DSM-III or DSM-IV criteria, and therefore there was considerable homogeneity in the study populations. However, studies were short in duration, for some comparisons the confidence intervals were large, and some analyses were unpowered to demonstrate clinically meaningful differences between treatments. Therefore, interpretation of treatment effects, either where there is a statistically different effect or no statistically different effect, should be made with caution There was also considerable variation in the type of control medication used in the trials. The majority used TCAs, SSRIs and SNRIs, with a minority of trials using other non-conventional ADs. Most trials provided useful data that were included in the analyses, but in some cases trials provided only efficacy or tolerability data thus limiting the overall completeness of evidence.</P>
<P>Although it has long been argued that placebo controlled trials are required to adequately demonstrate the efficacy of novel AD drugs (<LINK REF="REF-Cipriani-2009a" TYPE="REFERENCE">Cipriani 2009a</LINK>), in the present review we focused only on the comparison between fluoxetine and other active treatments. The background logic that guided the development of the present review was based on the need to provide real-world evidence for patients in need of pharmacological treatment. We therefore made the choice of including only studies that compared fluoxetine with another active treatment, as we reasoned that clinicians need to know how fluoxetine, a reference AD agent, compares with a selection of possible comparator ADs.</P>
<P>Retrieved randomised evidence compared fluoxetine with a selection of possible comparator ADs but only few studies per comparison were found. This inevitably limited the applicability of the evidence pertaining to each pair wise comparison as often confidence intervals were quite wide around treatment estimates.</P>
<P>Although the search was thorough, it is still possible that some unpublished studies have not been identified. It is very difficult to make a fair judgement on this issue as the small number of trials identified per comparison might have hindered the detection of publication bias. However, although we did our very best to retrieve as much data as possible, through asking pharmaceutical companies and study authors to supply all available information, we can conservatively assume that some trial data are still lacking, most of which are likely to be studies with negative findings. We are also aware that other RCTs comparing fluoxetine with other AD drugs may be currently ongoing, and we aim to include these, as well as other unpublished data, in future updates of this review.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-07-03 12:40:54 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of evidence is a crucial issue in translating the results of research into clinical practice. Using high-quality research evidence is relevant to speedy translation of research in a way that really responds to clinically relevant questions. In the present review only randomised trials were included and the studies were all very similar in design and conduct. However, trial quality is not easy to assess. We note that the majority of included studies failed to report key methodological issues, for example information about randomisation and allocation concealment. Additionally, the reporting of outcome data was often unclear or incomplete and the figures used in the analyses were not immediately understandable. Clearly it is possible that the paucity of information about randomisation and allocation concealment may represent a problem of reporting and not a real defect in study design. However, sometimes discrepancies between published reports and unpublished data posted on drug companies' websites were highlighted, thus confirming that the average quality of clinical trials in the field of ADs is generally low, and that this may represent a potential serious risk of bias (<LINK REF="REF-Horder-2011" TYPE="REFERENCE">Horder 2011</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-07-03 12:50:18 +0100" MODIFIED_BY="[Empty name]">
<P>The first limitation is that we made multiple comparisons. By making multiple comparisons we might have committed a type 1 error, that is, identifying and reporting a spurious association. As stated in the review protocol, we did not carry out a Bonferroni correction. As many statistical tests have been used in the review, the findings from this review are better thought of as hypothesis forming rather than hypothesis testing and it would be very reassuring to see the conclusions replicated in future trials and systematic reviews.</P>
<P>Another limitation is that for many of the comparisons, more trials were found presenting data on dropouts than on efficacy. This is because not all gave a 50% reduction in HDRS as their main outcome and therefore a lot of the data from our primary outcome was lost, which could have led to bias. Although this is a well-known limitation of secondary analyses of data extracted from RCTs, we attempted to control this potential source of bias by extracting continuous efficacy data according to each study&#8217;s definition of efficacy. This secondary analysis included many more participants than the primary analysis and the results did not differ substantially from the analysis of the primary outcomes. It is likely, therefore, that the overall comparison was not hampered by the exclusion of these trials.</P>
<P>Another compelling issue is that most of the included studies were sponsored by the drug industry, and data has shown that drug industry studies are more than four times more likely to demonstrate positive effects of the sponsors' drugs in comparison with independent studies (<LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>). For fluoxetine, it has been shown that the outcome of fluoxetine RCTs varies according to whether this drug was used as a new compound or a reference one, suggesting the presence of bias. This bias may work in favour of fluoxetine in trials where it was the experimental drug and in favour of comparators in trials where fluoxetine was the reference agent (<LINK REF="REF-Barbui-2004" TYPE="REFERENCE">Barbui 2004</LINK>). A possible explanation for this finding is publication bias. Publication bias might have systematically excluded from publication RCTs failing to show a robust effect of the experimental agents in comparison with reference ones. Alternatively, the common belief that newer medicines are better than old ones, and pharmaceutical marketing pressures to show a positive effect of newer drugs, might have favoured fluoxetine when it was the experimental agent and comparators when fluoxetine was the reference drug.</P>
<P>In this review we decided to focus on treatment response because it is one of the main goals for the treatment of major depressive disorder. The term 'treatment response' describes a state of improvement in the patient&#8217;s condition of sufficient quality to result in the treating physician&#8217;s impression of at least a moderate degree of global improvement, conventionally defined as a reduction of at least 50% in depressive symptomatology. However, from a clinical point of view, the ultimate goal of the acute treatment phase of major depressive disorder may well be to achieve remission. Full remission from depression correlates with better longer-term functional recovery, lower risk of relapse and higher level of patients satisfaction than a partial response (without remission). Thus, one important limitation of the present review is that remission was not included as an outcome measure.</P>
<P>Another study limitation is that studies with different duration were lumped together, and this may limit the external validity of study findings. However, the subgroup analysis failed to show material differences, thus suggesting the robustness of the main findings.</P>
<P>From a clinical point of view the analysis of the safety profile of antidepressants remains of crucial importance. In this review, although we included total dropouts as a measure of treatment acceptability. and dropouts due to side effects as a measure of tolerability, individual side effects were not extracted. We acknowledge this limitation and we aim to include data on individual side effects in future updates of this systematic review.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-07-03 12:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Even though there is a heated debate in the scientific literature (<LINK REF="REF-Gartlehner-2010" TYPE="REFERENCE">Gartlehner 2010</LINK>; <LINK REF="REF-Gartlehner-2011" TYPE="REFERENCE">Gartlehner 2011</LINK>), there is now robust evidence that there are statistically and clinically significant differences among antidepressants (<LINK REF="REF-Cipriani-2009a" TYPE="REFERENCE">Cipriani 2009a</LINK>). Results from this review are consistent with this interpretation and might contribute to the development of an evidence-based hierarchy of antidepressants to be used by clinicians (both specialists and general practitioners) (<LINK REF="REF-Barbui-2011a" TYPE="REFERENCE">Barbui 2011a</LINK>). Even though fluoxetine was not among the best treatments in terms of efficacy, it remains an important option for physicians when an AD is to be prescribed for moderate to severe major depression.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-07-05 13:23:38 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-07-03 12:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>The main finding of the present study is that there are differences in terms of efficacy and tolerability between fluoxetine and certain ADs, but the clinical meaning of these differences is uncertain and no definitive implications for clinical practice can be drawn. The better efficacy profile of sertraline and venlafaxine (and possibly other ADs) over fluoxetine may be clinically meaningful, as suggested by other reviews. In addition to efficacy data, treatment decisions should also be based on other considerations, for example, the fluoxetine long half-life, the fact that fluoxetine inhibits CYP-P450 isoenzymes more than some others (and this factor has to be considered particularly for people also taking other medications), the drug toxicity, the patient acceptability and the costs.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-07-05 13:23:38 +0100" MODIFIED_BY="[Empty name]">
<P>Results described in this systematic review come from a set of randomised studies that are in many cases financially supported by pharmaceutical industries. Industry-sponsored trials tend to follow a standard design which involves short-term, double-blind, parallel-group studies of patients with acute episodes or exacerbations of chronic illness. Moreover, it is known that economic support by drug manufacturers can strongly influence the progress of research and its results. Consequently, there is a risk that these studies do not provide adequate information to clinicians in real-world settings. Trials comparing two or more active treatments need to be much larger and of better quality than the studies that we identified for this review. More clinically meaningful outcome measures in trials of antidepressants, such as the ability to work or admission to hospital, are needed. Considering the methodological limitation of standard systematic reviews that rely only on evidence from direct comparisons, and given the wide spectrum of available comparisons for the treatment of major depression, the use of the methodology of multiple treatments meta-analysis (MTM) may provide a more informative and clinically useful summary of the results that can be used to guide treatment decisions. Moreover, an Individual Patient Data (IPD) meta-analysis would provide a more specific approach to those patients or illness characteristics related to clinically meaningful outcomes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-07-03 12:57:33 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank the CCDAN Editorial Team for their support, information and advice. We also would like to thank authors that provided additional data to be used in the present report (Professor Yusuf Moosa, Professor Homayoun Amini).</P>
<SUBSECTION>
<HEADING LEVEL="6">CRG funding acknowledgement</HEADING>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Depression, Anxiety and Neurosis Group. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Disclaimer</HEADING>
<P>The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</SUBSECTION>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-07-03 13:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>LRM, CG, MP, DP, AC, CB: none declared.
<BR/>
TAF has received honoraria for speaking at continuing medical education (CME) meetings sponsored by Asahi Kasei, Eli Lilly, GlaxoSmithKline, Mochida, MSD, Otsuka, Pfizer, Shionogi and Tanabe-Mitsubishi. He is a diplomate of the Academy of Cognitive Therapy. He has received royalties from Igaku-Shoin, Seiwa-Shoten and Nihon Bunka Kagakusha. He is on the advisory board for Sekisui Chemicals and Takeda Science Foundation. The Japanese Ministry of Education, Science, and Technology; the Japanese Ministry of Health, Labor and Welfare; and the Japan Foundation for Neuroscience and Mental Health have funded his research projects.
<BR/>

</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-03 12:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>LRM, CG, MP collected the data; LRM, MP, AC and CB ran the analysis; LRM, CG, MP, DP, TAF, AC and CB drafted and critically revised the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-07-03 13:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>In this update of the review we applied the risk of bias tool to assess the quality of all included studies. However, a formal comparison of intervention effects according to risk of bias was not performed as for most studies the risk of bias was rated as unclear.</P>
<P>A dosage subgroup analysis was not performed as this can be more appropriately examined in a MTM meta-analysis (see discussion).</P>
<P>Summary of findings tables using the GRADE methodology were added.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-08-10 09:07:37 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-07-15 09:53:01 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-07-02 13:32:23 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-07-02 13:19:21 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aguglia-1993" MODIFIED="2013-06-21 11:46:15 +0100" MODIFIED_BY="[Empty name]" NAME="Aguglia 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-06-21 11:46:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, et al</AU>
<TI>Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>3</NO>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akhondzadeh-2003" MODIFIED="2012-07-11 08:29:08 +0100" MODIFIED_BY="[Empty name]" NAME="Akhondzadeh 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-07-11 08:29:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A</AU>
<TI>Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>5</NO>
<PG>379-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akhondzadeh-Basti-2007" MODIFIED="2013-07-02 12:19:26 +0100" MODIFIED_BY="[Empty name]" NAME="Akhondzadeh Basti 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-02 12:19:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S</AU>
<TI>Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomised trial</TI>
<SO>Progress in Neuropsychopharmacology &amp; Biological Psychiatry</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>2</NO>
<PG>439-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alby-1993" MODIFIED="2013-07-02 12:20:01 +0100" MODIFIED_BY="[Empty name]" NAME="Alby 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-09-05 10:45:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alby JM, Cabane J, Ferreri M, Bougerol T</AU>
<TI>Efficacy and acceptability of tianeptine in major depressive disorder and in dysthymia (DSM-IIIR) with somatic complaints: double blind study versus fluoxetine</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>3</NO>
<PG>333</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:20:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alby JM, Ferreri M, Cabane J, De Bodinat C, Dagens V</AU>
<TI>Efficacy of tianeptine (Stablon ®) for the treatment of major depression and dysthymia with somatic complaints. A comparative study versus fluoxetine</TI>
<SO>Annales De Psychiatrie</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>2</NO>
<PG>136-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altamura-1989" MODIFIED="2012-09-05 10:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Altamura 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-09-05 10:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Altamura AC, De Novellis F, Guercetti G, Invernizzi G, Percudani M, Montgomery SA</AU>
<TI>Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>6</NO>
<PG>391-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:46:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altamura AC, Percudani M, Guercetti G, Invernizzi G</AU>
<TI>Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>Suppl 1</VL>
<PG>103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alves-1999" NAME="Alves 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alves C, Cachola I, Brandao J</AU>
<TI>Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression</TI>
<SO>Primary Care Psychiatry</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>2</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amini-2005" MODIFIED="2012-07-18 09:06:37 +0100" MODIFIED_BY="[Empty name]" NAME="Amini 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-18 09:06:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M</AU>
<TI>Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomised trial</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andreoli-2002" MODIFIED="2013-07-02 12:21:53 +0100" MODIFIED_BY="[Empty name]" NAME="Andreoli 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-08-10 13:45:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M</AU>
<TI>Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:21:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosc M, Dubini A, Polin V</AU>
<TI>Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>7 Suppl 1</VL>
<PG>57-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 08:31:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubini A, Bosc M, Polin V</AU>
<TI>Do noradrenaline and serotonin differentially affect social motivation and behaviour?</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>Suppl 1</VL>
<PG>S49-55; discussion S71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:21:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubini A, Bosc M, Polin V</AU>
<TI>Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1997</YR>
<VL>11 Suppl 4</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:50:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Healy DT</AU>
<TI>Reboxetine - the first selective noradrenaline reuptake inhibitor</TI>
<SO>151st Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:51:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Massana J</AU>
<TI>Reboxetine versus fluoxetine: benefits in social function</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:52:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moller H</AU>
<TI>Reboxetine, the first selective noradrenaline reuptake inhibitor, is more effective at improving social functioning than fluoxetine</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:54:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Versiani M, Montgomery SA, Stahl S, Schwartz G</AU>
<TO>The effect of reboxetine on anxiety</TO>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:55:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Versiani MV, Montgomery SA, Stahl SM, Schwartz GE</AU>
<TI>Effect of the novel selective noradrenaline reuptake inhibitor reboxetine on anxiety</TI>
<SO>154th Annual Meeting of the American Psychiatric Association, New Orleans, LA</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ansseau-1994" MODIFIED="2013-07-02 12:22:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ansseau 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-07-02 12:22:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ansseau M, Papart P, Troisfontaines B, Bartholome F, Bataille M, Charles G, et al</AU>
<TI>Controlled comparison of milnacipran and fluoxetine in major depression</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>114</VL>
<NO>1</NO>
<PG>131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armitage-1997" MODIFIED="2012-09-05 10:58:14 +0100" MODIFIED_BY="[Empty name]" NAME="Armitage 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-09-05 10:56:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Armitage R, Yonkers K, Cole D, Rush AJ</AU>
<TI>A multicenter, double blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>3</NO>
<PG>161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:56:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Armitage R, Yonkers K, Rush A, Cole D, Novak K</AU>
<TI>Comparison of the effects of nefazodone and fluoxetine on sleep architecture and sleep efficiency in depressed patients</TI>
<SO>8th ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:58:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, et al</AU>
<TI>Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>1</NO>
<PG>3-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakish-1997" MODIFIED="2012-02-28 11:05:39 +0000" MODIFIED_BY="[Empty name]" NAME="Bakish 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-02-28 11:05:28 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997; 41(2):184-90.&lt;/p&gt;" NOTES_MODIFIED="2012-02-28 11:05:28 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD</AU>
<TI>Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>2</NO>
<PG>184-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basterzi-2009" MODIFIED="2013-06-21 11:48:38 +0100" MODIFIED_BY="[Empty name]" NAME="Basterzi 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-21 11:48:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ba&#351;terzi AD, Yazici K, Aslan E, Delialio&#287;lu N, Ta&#351;delen B, Tot Acar S, et al</AU>
<TI>Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients</TI>
<SO>Progress in Neuropsychopharmacology &amp; Biological Psychiatry</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>2</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-1993a" NAME="Beasley 1993a" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM Jr, Holman SL, Potvin JH</AU>
<TI>Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>3</NO>
<PG>199-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behnke-2002" NAME="Behnke 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Behnke K, Jensen GS, Graubaum HJ, Gruenwald J</AU>
<TI>Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression</TI>
<SO>Advances in Therapy</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>1</NO>
<PG>43-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennie-1995" MODIFIED="2012-09-05 10:59:41 +0100" MODIFIED_BY="[Empty name]" NAME="Bennie 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-08-10 13:46:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bennie EH, Mullin JM, Martindale JJ</AU>
<TI>A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>6</NO>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 10:59:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flament MF, Lane R</AU>
<TI>Acute antidepressant response to fluoxetine and sertraline in psychiatric outpatients with psychomotor agitation</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>2</NO>
<PG>103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-05 09:43:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flament MF, Lane RM, Zhu R, Ying Z</AU>
<TI>Predictors of an acute antidepressant response to fluoxetine and sertraline</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>5</NO>
<PG>259-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlanga-1997" MODIFIED="2012-09-05 11:01:55 +0100" MODIFIED_BY="[Empty name]" NAME="Berlanga 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-09-05 11:01:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berlanga C, Arechavaleta B, Heinze G, Campillo C, Torres M, Caballero A, Apiquian R, Castelli P</AU>
<TI>A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients</TI>
<SO>Salud Mental</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>3</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:00:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berlanga C, Heinze G, Campillo C, Torres M, Caballero A, Apiquián R</AU>
<TI>Nefazodone and fluoxetine in major depression - a comparison study</TI>
<SO>Xth World Congress of Psychiatry, Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:01:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlanga C, Heinze G, Torres M, Apiquian R, Caballero A</AU>
<TI>Personality and clinical predictors of recurrence of depression</TI>
<SO>Psychiatric Services</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>3</NO>
<PG>376-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Besancon-1993" MODIFIED="2013-07-02 12:27:07 +0100" MODIFIED_BY="[Empty name]" NAME="Besancon 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-09-05 11:03:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Besancon G, Cousin R, Guitton B, Lavergne F</AU>
<TI>Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients</TI>
<SO>Encephale</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>4</NO>
<PG>341-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:05:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lavergne F, Berlin I, Payan C, Besancon G</AU>
<TI>Clinical differences in response to mianserin and fluoxetine in depressive patients</TI>
<SO>VIIIth European College of Neuropsychopharmacology Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:27:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lavergne F, Berlin I, Payan C, Besancon G</AU>
<TI>Clinical differences in response to mianserin and fluoxetine in depressive patients</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:05:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lavergne F, Berlin I</AU>
<TI>Symptoms profile during mianserin and fluoxetine treatment in depressed patients</TI>
<SO>VIth World Congress of Biological Psychiatry, Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhurgri-2011" MODIFIED="2012-08-08 16:08:59 +0100" MODIFIED_BY="[Empty name]" NAME="Bhurgri 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-08 16:08:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhurgri GR, Korejo HB, Qureshi MA</AU>
<TI>Role of fluoxetine and nortriptyline in major depressive disorders</TI>
<SO>Rawal Medical Journal</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>1</NO>
<PG>38-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjerkenstedt-2005" MODIFIED="2013-07-02 12:27:44 +0100" MODIFIED_BY="[Empty name]" NAME="Bjerkenstedt 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 12:27:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjerkenstedt L, Edman GV, Alken RG, Mannel M</AU>
<TI>Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomised, placebo-controlled multi-centre study in outpatients</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2005</YR>
<VL>255</VL>
<NO>1</NO>
<PG>40-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bougerol-1997a" MODIFIED="2013-06-21 11:49:02 +0100" MODIFIED_BY="[Empty name]" NAME="Bougerol 1997a" YEAR="1997">
<REFERENCE MODIFIED="2012-08-10 13:47:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bougerol T, Scotto JC, Patris M, Strub N, Lemming O, Hopfner Petersen HE</AU>
<TI>Citalopram and fluoxetine in major depression: Comparison of two clinical trials in a psychiatrist setting and in general practice (first trial)</TI>
<SO>Clinical drug Investigation</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>2</NO>
<PG>77-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 11:49:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, et al</AU>
<TI>Citalopram versus fluoxetine: a double-blind, controlled, multicenter, phase III trial in patients with unipolar major depression treated in general-practice</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>129-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bougerol-1997b" NAME="Bougerol 1997b" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bougerol T, Scotto J-C, Patris M, Strub N, Lemming O, Hopfner Petersen HE</AU>
<TI>Citalopram and fluoxetine in major depression: Comparison of two clinical trials in a psychiatrist setting and in general practice (second trial)</TI>
<SO>Clinical drug Investigation</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>2</NO>
<PG>77-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowden-1993" MODIFIED="2013-07-02 12:28:40 +0100" MODIFIED_BY="[Empty name]" NAME="Bowden 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-06-21 11:49:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, et al</AU>
<TI>Fluoxetine and desipramine in major depressive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>5</NO>
<PG>305-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:06:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenbaum AH, Schatzberg AF, Bowden CL, Samson JA, Schildkraut JJ</AU>
<TI>MHPG as a predictor of clinical response to fluoxetine</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:28:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schatzberg AF</AU>
<TI>Noradrenergic versus serotonergic antidepressants: predictors of treatment response</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59 Suppl 14</VL>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyer-1998" MODIFIED="2013-07-02 12:29:26 +0100" MODIFIED_BY="[Empty name]" NAME="Boyer 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-07-02 12:29:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bisserbe JC, Boyer P, Souetre E, Hotton JM, Troy S</AU>
<TI>A six month sertraline fluoxetine comparative study in depressed outpatients: outcome and costs</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:08:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Danion JM, Bisserbe JC, Hotton JM, Troy S</AU>
<TI>Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression A 6-month double-blind study in a primary-care setting in France</TI>
<SO>PharmacoEconomics</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>157-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:29:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Boyer P</AU>
<TI>Dysthymic patients and measurements of change</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:09:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Danion JM, Boyer P, Troy S, Hotton J</AU>
<TI>Double blind randomized comparative study of sertraline and fluoxetine in depressive outpatient: Medico-economic aspect</TI>
<SO>VIth World Congress of Biological Psychiatry, Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bremner-1984" NAME="Bremner 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bremner JD</AU>
<TI>Fluoxetine in depressed patients: a comparison with imipramine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>10</NO>
<PG>414-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bressa-1989" MODIFIED="2013-07-02 12:30:00 +0100" MODIFIED_BY="[Empty name]" NAME="Bressa 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 12:30:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bressa GM, Brugnoli R, Pancheri P</AU>
<TI>A double-blind study of fluoxetine and imipramine in major depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerley-1988" MODIFIED="2012-09-05 11:11:56 +0100" MODIFIED_BY="[Empty name]" NAME="Byerley 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-09-05 11:11:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Byerley WF, Reimherr FW, Wood DR, Grosser BI</AU>
<TI>Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>2</NO>
<PG>112-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:11:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reimherr FW, Ward MF, Byerley WF</AU>
<TI>The introductory placebo washout: a retrospective evaluation</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>30</VL>
<NO>2</NO>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassano-2002" MODIFIED="2012-09-05 11:13:34 +0100" MODIFIED_BY="[Empty name]" NAME="Cassano 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-10 12:04:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassano GB, Puca F, Scapicchio PL, Trabucchi M</AU>
<TI>Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>5</NO>
<PG>396-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1985" MODIFIED="2012-08-10 13:47:11 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-05-10 09:05:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM Jr, Sayler ME, Potvin JH</AU>
<TI>Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>3</NO>
<PG>143-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:47:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G</AU>
<TI>A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<PG>32-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1999" MODIFIED="2013-07-02 12:30:55 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-06-21 11:49:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Saxena B, Belanger MC, Ravindran A, Bakish D, Beauclair L, et al</AU>
<TI>A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>1-2</NO>
<PG>39-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:30:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect</TI>
<SO>GSK - Clinical Study Register  (www.gsk-clinicalstudyregister.com)</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CL3_x002d_022" MODIFIED="2013-06-20 11:02:35 +0100" MODIFIED_BY="[Empty name]" NAME="CL3-022" YEAR="">
<REFERENCE MODIFIED="2013-06-20 11:02:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Medicines Agency</AU>
<SO>CHMP Assessment Report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf [Accessed 22 October 2012]</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 11:02:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Medicines Agency</AU>
<SO>CHMP Assessment Report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf [Accessed 25 October 2012]</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 11:02:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Medicines Agency</AU>
<SO>CHMP Assessment Report for Valdoxan [Procedure No. EMEA/H/C/656, Doc. Ref. EMEA/CHMP/87018/2006].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000656/WC500070527.pdf [Accessed 22 January 2013]</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-05 11:06:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hickie IB, Rogers NL</AU>
<TI>Novel melatonin-based therapies: potential advances in the treatment of major depression</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<PG>621-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CL3_x002d_024" MODIFIED="2013-06-20 11:01:45 +0100" MODIFIED_BY="[Empty name]" NAME="CL3-024" YEAR="">
<REFERENCE MODIFIED="2013-06-20 11:00:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Medicines Agency</AU>
<SO>CHMP Assessment Report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf [Accessed 22 October 2012]</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 11:00:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>European Medicines Agency</AU>
<SO>CHMP Assessment Report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf [Accessed 25 October 2012]</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 11:00:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Medicines Agency</AU>
<SO>CHMP Assessment Report for Valdoxan [Procedure No. EMEA/H/C/656, Doc. Ref. EMEA/CHMP/87018/2006].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000656/WC500070527.pdf [Accessed 22 January 2013]</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-05 11:06:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hickie IB, Rogers NL</AU>
<TI>Novel melatonin-based therapies: potential advances in the treatment of major depression</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<PG>621-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clayton-2003" MODIFIED="2013-07-02 12:32:16 +0100" MODIFIED_BY="[Empty name]" NAME="Clayton 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-07-02 12:31:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clayton A, Ferguson J, Reisner J, Brown M, Schwartz G, Zajecka J</AU>
<TI>Reboxetine and sexual side effects</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12 Suppl 3</VL>
<PG>205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:32:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE</AU>
<TI>Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>3</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:18:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clayton AH, Zajecka JM, Ferguson JM, Reisner JK, Brown MT, Schwartz GE</AU>
<TI>Reboxetine and sexual side effects</TI>
<SO>155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clerc-1994" MODIFIED="2012-09-05 11:20:27 +0100" MODIFIED_BY="[Empty name]" NAME="Clerc 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-09-05 11:18:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clerc GE, Ruimy P, Verdeau Palles J</AU>
<TI>A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>3</NO>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:20:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Entsuah R, Shaffer M, Zhang J</AU>
<TI>A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>6</NO>
<PG>437-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:19:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thase ME, Entsuah AR, Rudolph RL</AU>
<TI>Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>178</VL>
<PG>234-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-1985" MODIFIED="2012-09-05 11:21:22 +0100" MODIFIED_BY="[Empty name]" NAME="Cohn 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-09-05 11:21:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM Jr, Sayler ME, Bosomworth JC, Wernicke JF</AU>
<TI>High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>3</NO>
<PG>166-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:20:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohn JB, Wilcox C</AU>
<TI>A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corne-1989" NAME="Corne 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corne SJ, Hall JR</AU>
<TI>A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general-practice</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>3</NO>
<PG>245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corrigan-2000" NAME="Corrigan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL</AU>
<TI>Comparison of pramipexole, fluoxetine, and placebo in patients with major depression</TI>
<SO>Depression and Anxiety</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>2</NO>
<PG>58-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-e-Silva-1998" MODIFIED="2012-09-05 11:23:08 +0100" MODIFIED_BY="[Empty name]" NAME="Costa e Silva 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-09-05 11:21:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Costa e Silva J</AU>
<TI>Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>56</VL>
<NO>7</NO>
<PG>352-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:22:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michelson D</AU>
<TI>Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>5</NO>
<PG>338-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:23:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paton C</AU>
<TI>Venlafaxine versus fluoxetine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>10</NO>
<PG>708</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalery-1997" MODIFIED="2013-07-02 12:33:29 +0100" MODIFIED_BY="[Empty name]" NAME="Dalery 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-09-05 11:24:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalery J, Rochat C, Peyron E, Bernard G</AU>
<TI>Comparative study of the efficacy and acceptability of amineptine and fluoxetine in patients with major depression</TI>
<SO>Encephale</SO>
<YR>1992</YR>
<VL>18</VL>
<NO>3</NO>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:33:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dalery J, Rochat C, Peyron E, Bernard G</AU>
<TI>The efficacy and acceptability of amineptine versus fluoxetine in major depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12 Suppl 3</VL>
<PG>S35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalery-2003" MODIFIED="2012-09-05 11:25:31 +0100" MODIFIED_BY="[Empty name]" NAME="Dalery 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-09-05 11:24:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dalery J, Honig A</AU>
<TI>Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison</TI>
<SO>Human Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>379-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:25:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dalery J</AU>
<TI>Fluvoxamine and fluoxetine in the treatment of depression; similarities and differences</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debus-1988" MODIFIED="2012-08-10 13:48:31 +0100" MODIFIED_BY="[Empty name]" NAME="Debus 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-05-10 09:06:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME</AU>
<TI>Fluoxetine versus trazodone: efficacy and activating-sedating effects</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<NO>7</NO>
<PG>294-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:48:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Debus JR, Rush AJ, Himmel C, Tyler D, Polatin P, Weissenburger J</AU>
<TI>Fluoxetine versus trazodone in the treatment of outpatients with major depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>11</NO>
<PG>422-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Jonghe-1991" MODIFIED="2012-07-18 09:20:15 +0100" MODIFIED_BY="[Empty name]" NAME="De Jonghe 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-07-18 09:20:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jonghe F, Ravelli DP, Tuynman Qua H</AU>
<TI>A randomised, double-blind study of fluoxetine and maprotiline in the treatment of major depression</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1991</YR>
<VL>24</VL>
<NO>2</NO>
<PG>62-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demyttenaere-1998" MODIFIED="2013-07-02 12:34:34 +0100" MODIFIED_BY="[Empty name]" NAME="Demyttenaere 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-07-02 12:34:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme MH, Gregoire J, et al</AU>
<TI>Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2001</YR>
<VL>65</VL>
<NO>3</NO>
<PG>243-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:50:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Demyttenaere K, Van Ganse E, Gregoire J, Gaens E, Mesters P</AU>
<TI>Compliance in depressed patients treated with fluoxetine or amitriptyline</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>1</NO>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Demyttenaere K, Van Ganse E, Gregoire P, Mesters P</AU>
<TI>Compliance among patients suffering from major depressive disorder and treated by fluoxetine or amitriptyline</TI>
<SO>VIth World Congress of Biological Psychiatry, Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demyttenaere-2004" MODIFIED="2013-07-02 12:35:25 +0100" MODIFIED_BY="[Empty name]" NAME="Demyttenaere 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-11 08:35:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demyttenaere K, Albert A, Mesters P, Dewé W, De Bruyckere K, Sangeleer M</AU>
<TI>What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>7</NO>
<PG>859-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:35:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Demyttenaere K, Bruffaerts R, Albert A et al. Development of an antidepressant compliance questionnaire. Acta Psychiatr Scand 2004; 110(3):201-7.&lt;/p&gt;" NOTES_MODIFIED="2013-07-02 12:35:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Demyttenaere K, Bruffaerts R, Albert A, et al</AU>
<TI>Development of an antidepressant compliance questionnaire</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>3</NO>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:35:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demyttenaere K, Mesters P, Dewe W, Boulanger B, De Bruyckere K, Sangeleer M, et al</AU>
<TI>Six month compliance with fluoxetine or paroxetine treatment in depressed outpatients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12 Suppl 3</VL>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Nayer-2002" MODIFIED="2013-07-02 12:36:38 +0100" MODIFIED_BY="[Empty name]" NAME="De Nayer 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-07-02 12:35:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Nayer A, De Clercq M, Mignon A</AU>
<TI>Symptom relief obtained with venlafaxine versus fluoxetine in depressed patients with concomitant anxiety</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10 Suppl 3</VL>
<PG>242</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:36:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, et al</AU>
<TI>Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>2</NO>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:36:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preud'homme X, De Nayer A, De Clercq M, Mignon A</AU>
<TI>Symptom relief obtained with venlafaxine versus fluoxetine in major depressed patients with concomitant anxiety</TI>
<SO>International Journal of Neuropsychopharmacology </SO>
<YR>2000</YR>
<VL>3 Suppl 1</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Ronchi-1998" NAME="De Ronchi 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Ronchi D, Rucci P, Lodi M, Ravaglia G, Forti P, Volterra V</AU>
<TI>Fluoxetine and amitriptyline in elderly depressed patients: a 10-week, double-blind study on course of neurocognitive adverse events and depressive symptoms</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>1998</YR>
<VL>Suppl 6</VL>
<PG>125-1,40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Wilde-1993" MODIFIED="2012-09-05 11:31:02 +0100" MODIFIED_BY="[Empty name]" NAME="De Wilde 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-09-05 11:30:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S</AU>
<TI>A double-blind, comparative, multicenter study comparing paroxetine with fluoxetine in depressed patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>2</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:31:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients</TI>
<SO>GSK - Clinical Study Register  (www.gsk-clinicalstudyregister.com), [29060/064]. clinicaltrials.gov.</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-Martinez-1998" MODIFIED="2013-07-02 12:37:17 +0100" MODIFIED_BY="[Empty name]" NAME="Diaz Martinez 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-07-02 12:37:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, et al</AU>
<TI>A randomised, open-label comparison of venlafaxine and fluoxetine in depressed outpatients</TI>
<SO>Clinical Therapeutics</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>3</NO>
<PG>467-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dierick-1996" MODIFIED="2013-07-02 12:38:54 +0100" MODIFIED_BY="[Empty name]" NAME="Dierick 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-02 12:38:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dierick M, Ravizza L, Realini R, Martin A</AU>
<TI>A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>1</NO>
<PG>57-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:33:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Entsuah R, Shaffer M, Zhang J</AU>
<TI>A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effect</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>6</NO>
<PG>437-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:31:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thase ME, Entsuah AR, Rudolph RL</AU>
<TI>Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>178</VL>
<PG>234-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dowling-1990" MODIFIED="2012-08-10 13:49:22 +0100" MODIFIED_BY="[Empty name]" NAME="Dowling 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-08-10 13:49:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dowling B, Webb MG, Halpin CM, Sangiwa MG</AU>
<TI>Fluoxetine: a comparative study with dothiepin</TI>
<SO>Irish Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>1</NO>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duarte-1996" MODIFIED="2012-07-18 09:23:11 +0100" MODIFIED_BY="[Empty name]" NAME="Duarte 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-07-18 09:23:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duarte A, Mikkelsen H, Delini Stula A</AU>
<TI>Moclobemide versus fluoxetine for double depression: A randomised double-blind study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1996</YR>
<VL>30</VL>
<NO>6</NO>
<PG>453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fabre-1991" NAME="Fabre 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fabre LF, Scharf MB, Itil TM</AU>
<TI>Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<NO>1</NO>
<PG>62-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fairweather-1999" MODIFIED="2012-09-05 11:34:16 +0100" MODIFIED_BY="[Empty name]" NAME="Fairweather 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-05 11:34:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fairweather DB, Stanley N, Hindmarch I</AU>
<TI>Fluoxetine and dothiepin in depressed patients: a comparison of efficacy and effects on cognition and subjective sleep</TI>
<SO>Xth European College of Neuropsychopharmacology Congress, Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:33:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fairweather DB, Stanley N, Yoon JS, Hindmarch I</AU>
<TI>The effects of fluoxetine and dothiepin on cognitive function in depressed patients in general practice</TI>
<SO>Human Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>5</NO>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falk-1989" NAME="Falk 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falk WE, Rosenbaum JF, Otto MW, Zusky PM, Weilburg JB, Nixon RA</AU>
<TI>Fluoxetine versus trazodone in depressed geriatric patients</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>4</NO>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-1998" NAME="Fava 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL</AU>
<TI>A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>4</NO>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-2002" MODIFIED="2013-07-02 12:40:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fava 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-05 11:34:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS</AU>
<TI>Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>2</NO>
<PG>137-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:40:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fava M, Rosenbaum JF, Hoog SL, Krebs W, Dillon JA</AU>
<TI>Comparison of symptoms after treatment interruption: Evidence of fluoxetine, sertraline and paroxetine</TI>
<SO>XXIst Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:35:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Sayler M</AU>
<TI>Fluoxetine versus sertraline and paroxetine in major depression: efficacy and tolerability in patients with high or low baseline insomnia</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:36:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Sayler M</AU>
<TI>Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in patients with low and high baseline insomnia</TI>
<SO>IXth Congress of the Association of European Psychiatrists, Copenhagen, Denmark</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:40:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoog SL, Fava M, Rosenbaum JF, Tepner RG, Kopp JB, Sayler M</AU>
<TI>Fluoxetine vs. sertraline and paroxetine in major depression in patients with high or low baseline insomnia</TI>
<SO>XXIst Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-2005" MODIFIED="2013-06-20 11:05:20 +0100" MODIFIED_BY="[Empty name]" NAME="Fava 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-18 09:25:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert J</AU>
<TI>The relationship between early changes in the HAM-17 anxiety/somatization factor items and treatment outcome among depressed outpatients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>2</NO>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:38:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fava M, Alpert J, Nierberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF</AU>
<TI>A double-blind, randomised trial of St. John's Wort, Fluoxetine and placebo in major depressive disorder</TI>
<SO>Journal of Clinical Psychoparmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>5</NO>
<PG>441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:42:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fava M, Alpert JE, Nierenberg AA, Mischoulon D, Otto MW, Murck H, et al</AU>
<TI>A double-blind, randomized trial of St. John&#8217;s Wort, fluoxetine, and placebo in MDD</TI>
<SO>155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-18 09:25:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulom D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF</AU>
<TI>Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomised trial of hypericum extract, fluoxetine and placebo</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>2</NO>
<PG>215-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 08:38:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papakostas GI, Crawford CM, Scalia MJ, Fava M</AU>
<TI>Timing of clinical Improvment and symptom resolution in the treatment of major depressive disorder</TI>
<SO>Neuropsychobiology</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>2-3</NO>
<PG>132-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 11:05:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz V</AU>
<TI>A study on the efficacy of the Hypericum extract LI 160 in 135 depressive patients in the USA</TI>
<TO>US-studie zur Wirksamkeit des Hypericum-Extraktes LI 160 bei 135 Depressiven Patienten</TO>
<SO>Zeitschrift fur Phytotherapie</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>3</NO>
<PG>124-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:44:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tossani E, Mascarini A, Alpert JE, Mischoulon D, Papakostas GI, Ryan JL, et al</AU>
<TI>Relationship between anxious depression and treatment outcome in outpatients with depression</TI>
<SO>157th Annual Meeting of the American Psychiatric Association, New York, NY</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawcett-1989" MODIFIED="2013-07-02 12:41:37 +0100" MODIFIED_BY="[Empty name]" NAME="Fawcett 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 12:41:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawcett J, Zajecka JM, Kravitz HM, Edwards J, et al</AU>
<TI>Fluoxetine versus amitriptyline in adult outpatients with major depression</TI>
<SO>Current Therapeutic Research</SO>
<YR>1989</YR>
<VL>45</VL>
<NO>5</NO>
<PG>821-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feighner-1985a" NAME="Feighner 1985a" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Cohn JB</AU>
<TI>Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feighner-1985b" MODIFIED="2013-07-02 12:41:54 +0100" MODIFIED_BY="[Empty name]" NAME="Feighner 1985b" YEAR="1985">
<REFERENCE MODIFIED="2013-07-02 12:41:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fairweather DB, Kerr JS, Harrison DA, Moon CA, et al</AU>
<TI>A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:48:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP</AU>
<TI>A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<NO>9</NO>
<PG>369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:45:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerr JS, Fairweather DB, Hindmarch I</AU>
<TI>Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>4</NO>
<PG>341-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feighner-1989" NAME="Feighner 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Boyer WF, Merideth CH, Hendrickson GG</AU>
<TI>A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>2</NO>
<PG>127-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feighner-1991" MODIFIED="2013-07-02 12:42:23 +0100" MODIFIED_BY="[Empty name]" NAME="Feighner 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-07-02 12:42:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, et al</AU>
<TI>Double-blind comparison of bupropion and fluoxetine in depressed outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<NO>8</NO>
<PG>329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreri-1989" MODIFIED="2013-07-02 12:42:47 +0100" MODIFIED_BY="[Empty name]" NAME="Ferreri 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 12:42:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferreri M</AU>
<TI>Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finkel-1999" MODIFIED="2013-07-02 12:43:40 +0100" MODIFIED_BY="[Empty name]" NAME="Finkel 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-05 11:48:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Doraiswamy PM, Krishnan KR, Clary C</AU>
<TI>Efficacy and safety of sertraline in depressed geriatric patients with vascular disease</TI>
<SO>151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:49:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doraiswamy PM, Krishnan KR, Oxman T, Jenkyn LR, Coffey DJ, Burt T, et al</AU>
<TI>Does antidepressant therapy improve cognition in elderly depressed patients?</TI>
<SO>Journals of Gerontology Series A-Biological Sciences &amp; Medical Sciences</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>12</NO>
<PG>1137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:45:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Finkel SI, Richter EM, Clary CM, Batzar E</AU>
<TI>Comparative efficacy of sertraline vs Fluoxetine in patients age 70 or over with major depression</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>3</NO>
<PG>221-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:50:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krishnan KR, Doraiswamy PM, Clary CM</AU>
<TI>Clinical and treatment response characteristics of late-life depression associated with vascular disease: A pooled analysis of two multicenter trials with sertraline</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>2</NO>
<PG>347-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:46:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newhouse P, Finkel S, Richter E</AU>
<TI>SSRIs in the treatment of depressed out patients aged 70 years and older</TI>
<SO>VIIIth ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:43:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newhouse P, Ko G, Richter E</AU>
<TI>Comparison of sertraline and fluoxetine in depressed geriatric outpatients: plasma levels and efficacy</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:47:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM</AU>
<TI>A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>8</NO>
<PG>559-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gagiano-1993" MODIFIED="2013-07-02 12:44:49 +0100" MODIFIED_BY="[Empty name]" NAME="Gagiano 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-09-05 11:50:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gagiano CA</AU>
<TI>A double blind comparison of paroxetine and fluoxetine in patients with major depression</TI>
<SO>British Journal of Clinical Research</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>145-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:44:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients</TI>
<SO>[29060/079]. clinicaltrials.gov. GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gattaz-1995" MODIFIED="2013-07-02 12:45:21 +0100" MODIFIED_BY="[Empty name]" NAME="Gattaz 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-09-05 11:52:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gattaz WF, Vogel P, Kick H, Delini-Stula A, Kohler M, Mikkelsen H, et al</AU>
<TI>Comparative efficacy and tolerability of moclobemide and fluoxetine in major depression</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>179</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:45:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gattaz WF, Vogel P, Kick H, Kohnen R</AU>
<TI>Moclobemide versus fluoxetine in the treatment of inpatients with major depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15 Suppl 2</VL>
<PG>35S-40S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:52:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gattaz WF, Vogel P, Kick H, Kohnen R</AU>
<TI>Moclobemide versus fluoxetine in the treatment of major depression</TI>
<SO>Xth World Congress of Psychiatry, Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geerts-1994" MODIFIED="2013-07-02 12:45:55 +0100" MODIFIED_BY="[Empty name]" NAME="Geerts 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-07-02 12:45:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geerts S, Bruynooghe F, De Cuyper H, Demeulemeester F, Haazen L</AU>
<TI>Moclobemide versus fluoxetine for major depressive episodes</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1994</YR>
<VL>7 Suppl 1</VL>
<PG>50-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geretsegger-1994" MODIFIED="2013-07-02 12:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Geretsegger 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-07-18 09:26:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Geretsegger C, Bohmer F, Ludwig M</AU>
<TI>Paroxetine in the elderly depressed patient: randomised comparison with fluoxetine of efficacy, cognitive and behavioural effects</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:53:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression</TI>
<SO>[29060/061]. clinicaltrials.gov. GSK - Clinical Study Register  (www.gsk-clinicalstudyregister.com)</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:46:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schone W, Ludwig M</AU>
<TI>A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13 Suppl 2</VL>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schone W, Ludwig M</AU>
<TI>Paroxetine in the treatment of depression in geriatric patients. A double-blind comparative study with fluoxetine</TI>
<SO>Fortschritte der Neurologie Psychiatrie</SO>
<YR>1994</YR>
<VL>62 Suppl 1</VL>
<PG>16-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghaeli-2004" MODIFIED="2012-09-05 11:56:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ghaeli 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-09-05 11:56:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ghaeli P, Shahsavand E, Mesbahi M, Avarsaji K</AU>
<TI>Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder</TI>
<SO>XII World Congress of Psychiatry, Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:55:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004; 24(4):386-8.&lt;/p&gt;" NOTES_MODIFIED="2012-09-05 11:55:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S</AU>
<TI>Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>386-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillin-1997" NAME="Gillin 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ</AU>
<TI>A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>5</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginestet-1989" MODIFIED="2013-07-02 12:47:24 +0100" MODIFIED_BY="[Empty name]" NAME="Ginestet 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 12:47:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginestet D</AU>
<TI>Fluoxetine in endogenous depression and melancholia versus clomipramine</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstein-2002" MODIFIED="2012-09-06 15:22:32 +0100" MODIFIED_BY="[Empty name]" NAME="Goldstein 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-06 15:22:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Demitrack MA, Goldstein DJ, Mallinckrodt C, Lu Y</AU>
<TI>Efficacy and safety of duloxetine treatment of major depression</TI>
<SO>154th Annual Meeting of the American Psychiatric Association, New Orleans; LA</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:57:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA</AU>
<TI>Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>3</NO>
<PG>225-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GSK-29060_x002f_356" MODIFIED="2013-06-20 11:06:59 +0100" MODIFIED_BY="[Empty name]" NAME="GSK 29060/356" YEAR="">
<REFERENCE MODIFIED="2013-06-20 11:06:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A double-blind, multicenter study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability</TI>
<SO>GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-04 16:43:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>Extension phase for a double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability</TI>
<SO>GSK - Clinical Study Register 1994 (www.gsk-clinicalstudyregister.com)</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guelfi-1998" MODIFIED="2013-07-02 12:47:52 +0100" MODIFIED_BY="[Empty name]" NAME="Guelfi 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-07-02 12:47:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tonelli I, Tournoux A, et al</AU>
<TI>A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>3</NO>
<PG>121-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guelfi-1999" MODIFIED="2012-09-05 11:58:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guelfi 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-05 11:58:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guelfi JD, Bouhassira M, Bonett-Perrin E, Lancrenon S</AU>
<TI>Study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients, followed in general practice</TI>
<SO>Encephale</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>3</NO>
<PG>265-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 11:58:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Guelfi JD</AU>
<TI>Fluoxetine versus tianeptine in elderly depressed</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hale-2010" MODIFIED="2013-07-02 12:48:20 +0100" MODIFIED_BY="[Empty name]" NAME="Hale 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-07-02 12:48:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V</AU>
<TI>Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomised double-blind study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>6</NO>
<PG>305-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:01:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Hale A</AU>
<TI>Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for eight weeks in out-patients with severe major depressive disorder: a randomised double-blind, parallel groups, international study versus selective serotonin reuptake inhibitor (SSRI) with a double-blind extension period of 16 weeks</TI>
<SO>Controlled-Trials.com 2008 (http://www.controlled-trials.com/ISRCTN19313268/servier)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-06-20 11:08:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-20 11:08:59 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN19313268"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrer-1999" NAME="Harrer 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrer G, Schmidt U, Kuhn U, Biller A</AU>
<TI>Comparison of equivalence between the st John's wort extract lohyp-57 and fluoxetine</TI>
<SO>Arzneimittelforschung</SO>
<YR>1999</YR>
<VL>49</VL>
<NO>4</NO>
<PG>289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hashemi-2012" MODIFIED="2013-07-02 12:48:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hashemi 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-07-02 12:48:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hashemi S, Shirazi HG, Mohammadi A, Zadeh-Bagheri G, Noorian Kh, Malekzadeh M</AU>
<TI>Nortriptyline versus fluoxetine in the treatment of major depressive disorder: a six-month, double-blind clinical trial</TI>
<SO>Clinical Pharmacology</SO>
<YR>2012</YR>
<VL>4</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-06-20 11:49:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-20 11:49:03 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="IRCT201101155619N1"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-2003" MODIFIED="2009-08-13 00:12:56 +0100" MODIFIED_BY="[Empty name]" NAME="Hong 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-13 00:12:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJL</AU>
<TI>A double-blind, randomised, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<PG>921-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosak-2000" MODIFIED="2013-07-02 12:49:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hosak 2000" YEAR="1999">
<REFERENCE MODIFIED="2012-07-11 08:41:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosák L, T&#367;ma I, Hanus H, Straka L</AU>
<TI>Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study</TI>
<SO>Acta Medica (Hradec Kralove)</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>4</NO>
<PG>133-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:49:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hosak L, Tuma I, Hanus H</AU>
<TI>A comparative study of three antidepressants with a different mechanism of action in hospitalised patients</TI>
<SO>Ceska a Slovenska Psychiatrie</SO>
<YR>1999</YR>
<VL>95</VL>
<PG>146-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:05:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosak L, Tuma I, Hanus H</AU>
<TI>D-fenfluramine test in depression: Final results</TI>
<SO>Ceska a Slovenska Psychiatrie</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>3</NO>
<PG>126-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:04:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosak L, Tuma I</AU>
<TI>Anxiety in depression</TI>
<SO>Homeostasis in Health and Disease</SO>
<YR>1997</YR>
<VL>38</VL>
<NO>3</NO>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:03:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosak L, Tuma I</AU>
<TI>Comparative study of three antidepressants: Preliminary results</TI>
<SO>Homeostasis in Health and Disease</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>3</NO>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakovijevic-1996" MODIFIED="2013-07-02 12:51:38 +0100" MODIFIED_BY="[Empty name]" NAME="Jakovijevic 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-02 12:50:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jakovljevic M, Vujic D, Aleksandrovsky Y, Szerenberger W, Faltus F, Henigsberg N</AU>
<TI>Efficacy and tolerability of fluoxetine compared with maprotiline in major depressive episode: Results of Central-East European Study</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:51:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jakovljevic M, Vujic D, Henigsberg N, Aleksandrovsky Y, Faltus F, Szerenberger W</AU>
<TI>Central-East European study of fluoxetine (Portal, Lek) and maprotiline (Ladiomil, Pliva) in major depressive episode</TI>
<SO>Psychiatria Danubina</SO>
<YR>1996</YR>
<VL>8 Suppl 1</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:51:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jakovljevic M, VujicD, Henigsberg N</AU>
<TI>Serotonergic (fluoxetine) versus noradrenergic (maprotiline) antidepressants and suicidality</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joyce-2002" MODIFIED="2013-07-02 12:52:21 +0100" MODIFIED_BY="[Empty name]" NAME="Joyce 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-13 09:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harley J, Roberts R, Joyce P, Mulder R, Luty S, Frampton C, Kennedy M</AU>
<TI>Orosomucoid influences the response to antidepressants in major depressive disorder</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>4</NO>
<PG>531-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:07:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joyce PR, Luty SE, Mulder RT, McKenzie JM, Miller AL, Kennedy MA</AU>
<TI>Self mutilation, suicide attempts and borderline personality disorder in depressed patients</TI>
<SO>Australian and New Zealand Journal of Psychiatry, Abstracts of the 40th Congress of the Royal Australian and New Zealand College of Psychiatrists, Sydney, Australia</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>Suppl 1</NO>
<PG>A107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:52:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF</AU>
<TI>Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>3</NO>
<PG>384-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 08:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulder RT, Joyce PR, Frampton CM, Luty SE, Sullivan PF</AU>
<TI>Six months of treatment for depression: outcome and predictors of the course of illness</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>1</NO>
<PG>95-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 08:44:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porter R, Mulder RT, Joyce PR, Luty SE</AU>
<TI>Tryptophan and tyrosine availability and response to antidepressant treatment in major depression</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2005</YR>
<VL>86</VL>
<NO>2-3</NO>
<PG>129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Judd-1993" MODIFIED="2012-09-05 12:08:21 +0100" MODIFIED_BY="[Empty name]" NAME="Judd 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-09-05 12:07:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G</AU>
<TI>A multicenter double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>27</VL>
<NO>1</NO>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:08:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK</AU>
<TI>Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasper-2005" MODIFIED="2012-09-05 12:09:16 +0100" MODIFIED_BY="[Empty name]" NAME="Kasper 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-09-05 12:09:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasper S, Lemming OM, de Swart H</AU>
<TI>Escitalopram in the long-term treatment of major depressive disorder in elderly patients</TI>
<SO>Neuropsychobiology</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>3</NO>
<PG>152-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:08:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kasper S, de Swart H, Friis Andersen H</AU>
<TI>Escitalopram in the treatment of depressed elderly patients</TI>
<SO>The American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>10</NO>
<PG>884-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keegan-1991" MODIFIED="2013-07-02 12:53:06 +0100" MODIFIED_BY="[Empty name]" NAME="Keegan 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-07-02 12:53:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keegan D, Bowen RC, Blackshaw S, Saleh S, Dayal N, Remillard F, et al</AU>
<TI>A comparison of fluoxetine and amitriptyline in the treatment of major depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>2</NO>
<PG>117-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keller-2007" MODIFIED="2013-07-02 12:55:34 +0100" MODIFIED_BY="[Empty name]" NAME="Keller 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-05 12:18:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, et al</AU>
<TI>Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder [NCT00046020]</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2011</YR>
<VL>45</VL>
<NO>1</NO>
<PG>96-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:16:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, et al</AU>
<TI>Correlation between patient and clinician assessments of depression severity in the PREVENT study [NCT00046020]</TI>
<SO>Psychiatry Research</SO>
<YR>2010</YR>
<VL>177</VL>
<NO>1-2</NO>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 11:51:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, et al</AU>
<TI>The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases</TI>
<SO>Journal of Clinical Psychiatry [Comment in: J Clin Psychiatry. 2008 May;69(5):865-6; author reply 866; PMID: 18681767]</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>8</NO>
<PG>1246-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 11:51:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, et al</AU>
<TI>The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases</TI>
<SO>Biological Psychiatry [Erratum appears in Biol Psychiatry. 2008 Apr;63(7):721], [Erratum appears in Biol Psychiatry. 2012 Feb 15;71(4):387]</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>12</NO>
<PG>1371-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:54:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keller MB, Yan B, Ahmed S, Parker-Zavod E, Pedersen R</AU>
<TI>Placebo-controlled trial of venlafaxine ER in prevention of recurrence in patients with recurrent unipolar major depression</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30 Suppl 1</VL>
<PG>175-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:12:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, et al</AU>
<TI>Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study [NCT00046020]</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>7</NO>
<PG>1014-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:14:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornstein SG, Kocsis JH, Ahmed S, Thase M, Friedman ES, Dunlop BW, et al</AU>
<TI>Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: A secondary analysis of data from the PREVENT study  [NCT00046020]</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>6</NO>
<PG>357-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:55:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornstein SG</AU>
<TI>Beyond remission: Rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study  [NCT00046020]</TI>
<SO>CNS Spectrums</SO>
<YR>2006</YR>
<VL>11 Suppl 15</VL>
<PG>28-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:55:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornstein SG</AU>
<TI>Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study. [NCT00046020]</TI>
<SO>Expert Review of Neurotherapeutics</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>5</NO>
<PG>737-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:55:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scapicchio PL</AU>
<TI>Beyond remission. Prevention of recurrences in long-term treatment of depression. First data from the PREVENT study [NCT00046020]</TI>
<SO>Italian Journal of Psychopathology</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>1</NO>
<PG>80-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:19:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, et al</AU>
<TI>Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2011</YR>
<VL>45</VL>
<NO>3</NO>
<PG>412-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:16:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trivedi MH, Dunnerb DL, Kornsteinc SG, Thase ME, Zajeckae JM, Rothschild AJ, et al</AU>
<TI>Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release [NCT00046020]</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>3</NO>
<PG>420-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-06-20 10:18:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-20 10:18:24 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00046020"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerkhofs-1990" NAME="Kerkhofs 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerkhofs M, Rielaert C, De Maertelaer V, Linkowski P, Czarka M, Mendlewicz J</AU>
<TI>Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>5</VL>
<PG>253-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuha-1991" NAME="Kuha 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuha S, Mehtonen O-P, Henttonen A, Naarala M</AU>
<TI>The efficacy of fluoxetine versus maprotiline in depressed patients and by dose</TI>
<SO>Nordic Journal of Psychiatry - Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1991</YR>
<VL>45</VL>
<NO>2</NO>
<PG>109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwon-1996" MODIFIED="2012-03-05 13:45:11 +0000" MODIFIED_BY="[Empty name]" NAME="Kwon 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-05 13:45:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kwon JS, Youn T, Jung HY. Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. J Affect Disord 1996; 40(3):169-73.&lt;/p&gt;" NOTES_MODIFIED="2012-03-05 13:45:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwon JS, Youn T, Jung HY</AU>
<TI>Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>3</NO>
<PG>169-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laakman-1988" NAME="Laakman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laakmann G, Blaschke D, Engel R, Schwarz A</AU>
<TI>Fluoxetine vs amitriptyline in the treatment of depressed out-patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>153</VL>
<PG>64-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Pia-1992" MODIFIED="2013-07-02 12:56:19 +0100" MODIFIED_BY="[Empty name]" NAME="La Pia 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-09-05 12:20:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Pia S, Giorgio D, Ciriello R, Sannino A, De Simone L, Paoletti C, et al</AU>
<TI>Evaluation of the efficacy, tolerability, and therapeutic profile of fluoxetine versus mianserin in the treatment of depressive disorders in the elderly</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1992</YR>
<VL>52</VL>
<NO>6</NO>
<PG>847-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:56:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>La Pia S, Giorgio D, Ciriello R, Sannino A, et al</AU>
<TI>Double blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitive-behavioral parameters</TI>
<SO>New Trends in Experimental and Clinical Psychiatry</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>4</NO>
<PG>139-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapierre-1997" MODIFIED="2013-07-02 12:56:41 +0100" MODIFIED_BY="[Empty name]" NAME="Lapierre 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-07-02 12:56:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD, Joffe R, McKenna K, Bland R, Kennedy S, Ingram P, et al</AU>
<TI>Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults</TI>
<SO>Journal of Psychiatry and Neuroscience</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>2</NO>
<PG>118-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" MODIFIED="2013-07-02 12:57:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 12:57:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee MS, Ham BJ, Kee BS, Kim JB, Yeon BK, Oh KS, et al</AU>
<TI>A comparison of the efficacy and safety between milnacipran and fluoxetine in the treatment of patients with depression</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5 Suppl 1</VL>
<PG>205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 11:52:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee MS, Ham BJ, Kee BS, Kim JB, Yeon BK, Oh KS, et al</AU>
<TI>Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1989" MODIFIED="2013-07-02 12:57:48 +0100" MODIFIED_BY="[Empty name]" NAME="Levine 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-09-05 12:21:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine S, Deo R, Mahadevan K</AU>
<TI>A comparative trial of a new antidepressant, fluoxetine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>150</VL>
<PG>653-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:57:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine S, Deo R, Mahadevan K</AU>
<TI>A comparative trial of a new antidepressant, fluoxetine</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levkovitz-2002" NAME="Levkovitz 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levkovitz Y, Caftori R, Avital A, Richter-Levin G</AU>
<TI>The SSRIs drug fluoxetine, but not the noradrenergic tricyclic drug desipramine, improves memory performance during acute major depression</TI>
<SO>Brain Research Bulletin</SO>
<YR>2002</YR>
<VL>58</VL>
<PG>345-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loeb-1989" MODIFIED="2013-07-02 12:58:15 +0100" MODIFIED_BY="[Empty name]" NAME="Loeb 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 12:58:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loeb C, Albano C, Gandolfo C</AU>
<TI>Fluoxetine versus imipramine</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lonnqvist-1994" MODIFIED="2013-07-02 12:58:37 +0100" MODIFIED_BY="[Empty name]" NAME="Lonnqvist 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-09-05 12:22:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O</AU>
<TI>Moclobemide and fluoxetine in atypical depression: a double-blind trial</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1994</YR>
<VL>32</VL>
<NO>3</NO>
<PG>169-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 12:23:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonnqvist J, Sihvo S, Syvalahti E, Sintonen H, Kiviruusu O, Pitkanen H</AU>
<TI>Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1995</YR>
<VL>91</VL>
<NO>3</NO>
<PG>189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:58:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lonnqvist J, Sintonen H, Syvalahti E, Appelberg B, Koskinen T, Mannikko T, et al</AU>
<TI>Antidepressant efficacy and quality-of-life in depression: a double-blind study with moclobemide and fluoxetine</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>6</NO>
<PG>363-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loo-1999" MODIFIED="2013-07-02 12:59:18 +0100" MODIFIED_BY="[Empty name]" NAME="Loo 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-02 12:59:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loo H, Saiz-Ruiz J, Costa e Silva JA, Ansseau M, Herrington R, Vaz-Serra A, et al</AU>
<TI>Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine</TI>
<SO>Human Psychopharmacology</SO>
<YR>2001</YR>
<VL>16 Suppl 1</VL>
<PG>31-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 12:58:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loo H, Saiz-Ruiz J, Costa e Silva JA, Ansseau M, Herrington R, Vaz-Serra A, et al</AU>
<TI>Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>2-3</NO>
<PG>109-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 11:23:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Loo H</AU>
<TI>Double-blind study comparing tianeptine and fluoxetine in patients with ICD-10 criteria for depressive disorders with or without somatic syndrome [NR537]</TI>
<SO>151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<PG>212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manna-1989" MODIFIED="2013-07-02 12:59:44 +0100" MODIFIED_BY="[Empty name]" NAME="Manna 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 12:59:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manna V, Martucci N, Agnoli A</AU>
<TI>Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>81-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mao-2008" MODIFIED="2013-06-21 11:52:33 +0100" MODIFIED_BY="[Empty name]" NAME="Mao 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-06-21 11:52:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mao PX, Tang YL, Jiang FJ, Shu L, Gu X, Li M, et al</AU>
<TI>Escitalopram in major depressive disorder: a multicenter, randomised, double-blind, fixed-dose, parallel trial in a Chinese population</TI>
<SO>Depression and Anxiety</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>1</NO>
<PG>46-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchesi-1998" NAME="Marchesi 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchesi C, Ceccherininelli A, Rossi A, Maggini C</AU>
<TI>Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>6</NO>
<PG>216-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martenyi-2001" MODIFIED="2013-07-02 13:00:45 +0100" MODIFIED_BY="[Empty name]" NAME="Martenyi 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-07-02 13:00:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Dossenbach M, Mraz K, Metcalfe S</AU>
<TI>Gender differences in the antidepressive effect: A double-blind trial of fluoxetine and maprotiline in the treatment of major depression</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10 Suppl 3</VL>
<PG>221</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:00:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Dossenbach M, Mraz K, Metcalfe S</AU>
<TI>Gender differences in the antidepressive effect? A double blind trial of fluoxetine and maprotiline in the treatment of major depression</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3 Suppl 1</VL>
<PG>241</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:10:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Dossenbach M, Mraz K, Metcalfe S</AU>
<TI>Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>227-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-2012" MODIFIED="2013-06-20 11:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-06-20 11:25:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez JM, Katon W, Greist JH, Kroenke K, Thase ME, Meyers AL, et al</AU>
<TI>A pragmatic 12-week, randomised trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>1</NO>
<PG>17-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-06-20 11:25:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-20 11:25:16 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00666757 "/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masco-1985" MODIFIED="2012-07-18 09:30:25 +0100" MODIFIED_BY="[Empty name]" NAME="Masco 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-07-18 09:30:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masco HL, Sheetz MS</AU>
<TI>Double-blind comparison of fluoxetine and amitriptyline in the treatment of major depressive illness</TI>
<SO>Advances in Therapy</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>6</NO>
<PG>275-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massana-1999" MODIFIED="2012-09-05 14:15:06 +0100" MODIFIED_BY="[Empty name]" NAME="Massana 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-05 14:13:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Massana J, Moller HJ, Burrows GD, Montenegro RM</AU>
<TI>Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:14:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Massana J</AU>
<TI>Reboxetine versus fluoxetine: benefits in social function</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:15:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moller H</AU>
<TI>Reboxetine, the first selective noradrenaline reuptake inhibitor, is more effective at improving social functioning than fluoxetine</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGrath-2000" MODIFIED="2012-09-05 14:16:51 +0100" MODIFIED_BY="[Empty name]" NAME="McGrath 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-05 14:16:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agosti V, McGrath PJ</AU>
<TI>Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2002</YR>
<VL>71</VL>
<NO>1-3</NO>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:15:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF</AU>
<TI>A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>3</NO>
<PG>344-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:16:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McGrath PJ, Stewart JW, Quitkin FM</AU>
<TI>Fluoxetine treatment of atypical depression</TI>
<SO>52nd Annual Meeting of the American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moosa-2003" MODIFIED="2012-03-05 14:10:42 +0000" MODIFIED_BY="[Empty name]" NAME="Moosa 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-03-05 14:10:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Moosa MY, Panz VR, Jeenah FY, Joffe BI. African women with depression: The effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23(6):549-52.&lt;/p&gt;" NOTES_MODIFIED="2012-03-05 14:10:42 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moosa MY, Panz VR, Jeenah FY, Joffe BI</AU>
<TI>African women with depression: The effect of imipramine and fluoxetine on body mass index and leptin secretion</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>549-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno-2006" MODIFIED="2012-07-18 09:32:20 +0100" MODIFIED_BY="[Empty name]" NAME="Moreno 2006" YEAR="2005">
<REFERENCE MODIFIED="2012-07-18 09:32:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno RA, Teng CT, de ALmeida KM, Tavares HJ</AU>
<TI>Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomised double-blind trial in a Brazilian sample</TI>
<SO>Revista Brasileira de Psiquiatria</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mowla-2006" MODIFIED="2012-07-11 08:48:12 +0100" MODIFIED_BY="[Empty name]" NAME="Mowla 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-11 08:48:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mowla A, Ghanizadeh A, Pani A</AU>
<TI>A comparison of effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>2</NO>
<PG>209-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muijen-1988" MODIFIED="2012-05-14 16:32:52 +0100" MODIFIED_BY="[Empty name]" NAME="Muijen 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-05-14 16:32:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muijen M, Roy D, Silverstone T, Mehmet A, Christie M</AU>
<TI>A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1988</YR>
<VL>78</VL>
<NO>3</NO>
<PG>384-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" MODIFIED="2013-07-02 13:02:18 +0100" MODIFIED_BY="[Empty name]" NAME="MY-1043/BRL-029060/115" YEAR="">
<REFERENCE MODIFIED="2013-07-02 13:02:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A multicenter, randomised, double blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder</TI>
<SO>GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1" MODIFIED="2013-07-02 13:01:59 +0100" MODIFIED_BY="[Empty name]" NAME="MY-1045/BRL-029060/1" YEAR="">
<REFERENCE MODIFIED="2013-07-02 13:01:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>GlaxoSmithKline</AU>
<TI>A multicenter, randomised, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of Major Depressive Disorder</TI>
<SO>GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com) </SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-06-20 11:30:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-20 11:30:49 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PAR128"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-2004" MODIFIED="2013-07-02 13:02:47 +0100" MODIFIED_BY="[Empty name]" NAME="Nelson 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-09-05 14:18:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nelson JC, Mazure CM, Jatlow PI, Bowers Jr MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 2004; 55(3):296-300.&lt;/p&gt;" NOTES_MODIFIED="2012-09-05 14:18:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nelson JC, Mazure CM, Jatlow PI, Bowers Jr MB, Price LH</AU>
<TI>Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomised study</TI>
<SO>Biological Psychiatry</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>3</NO>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:02:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nelson JC</AU>
<TI>Synergistic effects of serotonergic and noradrenergic antidepressants</TI>
<SO>XXIst Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemeroff-2007" MODIFIED="2013-07-02 13:03:10 +0100" MODIFIED_BY="[Empty name]" NAME="Nemeroff 2007" YEAR="2005">
<REFERENCE MODIFIED="2012-09-05 14:20:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nemeroff CB, Amchin J</AU>
<TI>Placebo-controlled trial of the efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:03:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemeroff CB, Cantillon M</AU>
<TI>Venlafaxine demonstrates excellent response frequency in trial with fluoxetine and placebo in depressed outpatients</TI>
<SO>International Journal of Neuropsychopharmacology </SO>
<YR>2000</YR>
<VL>3 Suppl 1</VL>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:20:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nemeroff CB, Thase ME; EPIC 014 Study Group</AU>
<TI>A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients</TI>
<SO>Journal of Psychiatric Research.</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>3-4</NO>
<PG>351-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newhouse-2000" MODIFIED="2013-07-02 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Newhouse 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-06 15:24:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newhouse P, Finkel S, Richter E</AU>
<TI>SSRIs in the treatment of depressed out patients aged 70 years and older</TI>
<SO>VIIIth ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:03:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newhouse P, Ko G, Richter E</AU>
<TI>Comparison of sertraline and fluoxetine in depressed geriatric outpatients: plasma levels and efficacy</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:22:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM</AU>
<TI>A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>8</NO>
<PG>559-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-1993" MODIFIED="2013-07-02 13:03:52 +0100" MODIFIED_BY="[Empty name]" NAME="Nielsen 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-07-02 13:03:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen BM, Behnke K, Arup P, Christiansen PE, Geisler A, Ipsen E, et al</AU>
<TI>A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>4</NO>
<PG>269-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noguera-1991" MODIFIED="2012-07-18 09:34:20 +0100" MODIFIED_BY="[Empty name]" NAME="Noguera 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-07-18 09:34:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noguera R, Altuna R, Alvarez E, Ayuso JL, Casais L, Udina C</AU>
<TI>Fluoxetine vs clomipramine in depressed patients: a controlled multicenter trial</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1991</YR>
<VL>22</VL>
<NO>3</NO>
<PG>119-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noorbala-2005" MODIFIED="2013-07-02 13:04:18 +0100" MODIFIED_BY="[Empty name]" NAME="Noorbala 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 13:04:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH</AU>
<TI>Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomised pilot trial</TI>
<SO>Journal of Ethnopharmacology</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>2</NO>
<PG>281-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novotny-2002" NAME="Novotny 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novotny V, Faltus F</AU>
<TI>Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study</TI>
<SO>Human Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>6</NO>
<PG>299-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Keane-1992" MODIFIED="2012-04-04 13:29:38 +0100" MODIFIED_BY="[Empty name]" NAME="O'Keane 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-04-04 13:29:38 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;O'Keane V, McLoughlin D, Dinan TG. D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. J Affect Disord 1992; 26(3):143-50.&lt;/p&gt;" NOTES_MODIFIED="2012-04-04 13:29:38 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Keane V, McLoughlin D, Dinan TG</AU>
<TI>D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment</TI>
<SO>Joournal of Affective Disorders</SO>
<YR>1992</YR>
<VL>26</VL>
<NO>3</NO>
<PG>143-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ontiveros-1997" MODIFIED="2013-07-02 13:04:55 +0100" MODIFIED_BY="[Empty name]" NAME="Ontiveros 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-07-02 13:04:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A Comparative Double-Blind Study of Paroxetine and Fluoxetine in the Treatment of Depression in Out-Patients [Trial MY-0144/BRL 29060/1/CPMS-135 (PAR 135)]</TI>
<SO>GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:23:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ontiveros A, Garcia-Barriga C</AU>
<TI>A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression</TI>
<SO>British Journal of Clinical Research</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>23-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:04:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ontiveros A, et al</AU>
<TI>A double blind study with paroxetine vs. fluoxetine in depressive patients</TI>
<SO>Biological Psychiatry</SO>
<YR>1995</YR>
<VL>35</VL>
<PG>677</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OntiverosSanchez-1998" MODIFIED="2012-07-12 11:28:03 +0100" MODIFIED_BY="[Empty name]" NAME="OntiverosSanchez 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-04-18 11:04:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ontiveros Sanchez de la Barquera JA, Brandi F, Brunner E</AU>
<TI>Double-blind study of fluoxetine vs. amitriptyline in depressive and anxiety symptoms and life quality in adults with major depression</TI>
<TO>Estudio doble-ciego sobre fluoxetina vs amitriptilina en los sintomas depresivos y de ansiedad, y calidad de vida de los adultos con depresion mayor</TO>
<SO>Salud Mental</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>58-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakesch-1991" MODIFIED="2012-09-05 14:26:12 +0100" MODIFIED_BY="[Empty name]" NAME="Pakesch 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-09-05 14:26:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pakesch G, Dossenbach M</AU>
<TI>Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners</TI>
<TO>Wirkung und Sicherheit von Fluoxetin versus Clomipramin bei ambulanten Patienten mit einem depressiven Syndrom in einer klinischen Prufung bei niedergelassenen Arzten</TO>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1991</YR>
<VL>103</VL>
<NO>6</NO>
<PG>176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pande-1996" MODIFIED="2012-09-05 14:52:49 +0100" MODIFIED_BY="[Empty name]" NAME="Pande 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-09-05 14:52:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF</AU>
<TI>Fluoxetine versus phenelzine in atypical depression</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>10</NO>
<PG>1017-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:52:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zubieta JK, Pande AC, Demitrack MA</AU>
<TI>Two year follow-up of atypical depression</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-1989" MODIFIED="2012-08-10 13:54:24 +0100" MODIFIED_BY="[Empty name]" NAME="Perry 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-04-12 11:53:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fudge JL, Perry PJ, Garvey MJ, Kelly MW</AU>
<TI>A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>4</NO>
<PG>275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:54:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G</AU>
<TI>A comparative trial of fluoxetine versus trazodone in outpatients with major depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>8</NO>
<PG>290-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1990" MODIFIED="2012-09-05 14:53:12 +0100" MODIFIED_BY="[Empty name]" NAME="Peters 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-09-05 14:53:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters UH, Lenhard P, Metz M</AU>
<TI>Therapy of depression in the psychiatrist's office - A double-blind multicenter study</TI>
<TO>Ambulante Therapie der Depression mit Fluoxetin - eine multizentrische Doppelblindstudie</TO>
<SO>Nervenheilkunde</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>1</NO>
<PG>28-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poelinger-1989" NAME="Poelinger 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poelinger W, Haber H</AU>
<TI>Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Preskorn-1991" NAME="Preskorn 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preskorn SH, Silkey B, Beber J, Dorey C</AU>
<TI>Antidepressant response and plasma concentrations of fluoxetine</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>3</VL>
<NO>2</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapaport-1996" MODIFIED="2012-09-05 14:54:09 +0100" MODIFIED_BY="[Empty name]" NAME="Rapaport 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-09-05 14:54:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rapaport M, Coccaro E, Sheline Y, Holland P, Perse T, Fabre L</AU>
<TI>Comparison of fluvoxamine and fluoxetine in major depression</TI>
<SO>VIIIth ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L et al</AU>
<TI>A comparison of fluvoxamine and fluoxetine in the treatment of major depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>5</NO>
<PG>373-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remick-1989" NAME="Remick 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remick RA, Keller FD, Gibson RE, Carter D</AU>
<TI>A comparison between fluoxetine and doxepin in depressed patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>5</NO>
<PG>842-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remick-1993" MODIFIED="2013-07-02 13:06:10 +0100" MODIFIED_BY="[Empty name]" NAME="Remick 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-07-02 13:06:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remick RA, Claman J, Reesal R, Gibson RE, et al</AU>
<TI>Comparison of fluoxetine and desipramine in depressed outpatients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>5</NO>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reynaert-1995" MODIFIED="2012-08-10 13:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Reynaert 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-04-16 09:29:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reynaert C, Janne P, Vause M, Zdanowicz N, Lejeune D</AU>
<TI>Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>119</VL>
<NO>4</NO>
<PG>449-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:54:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reynaert C, Parent M, Mirel J, Janne P, Haazen L</AU>
<TI>Moclobemide versus fluoxetine for a major depressive episode</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>118</VL>
<NO>2</NO>
<PG>183-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-1994" MODIFIED="2012-09-05 14:56:09 +0100" MODIFIED_BY="[Empty name]" NAME="Robertson 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-09-05 14:56:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns RA, Lock T, Edwards DR, Katona CL, Harrison DA, Robertson MM, et al</AU>
<TI>Predictors of response to amine-specific antidepressants</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>3</NO>
<PG>97-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:55:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence KM, Katona CL, Abou-Saleh MT, Robertson MM, Nairac BL, Edwards DR, et al</AU>
<TI>Platelet 5-HT uptake sites, labelled with 3H paroxetine, in controls and depressed patients, before and after treatment with fluoxetine or lofepramine</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>115</VL>
<NO>1-2</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:54:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robertson MM, Abou Saleh MT, Harrison DA, Nairac BL</AU>
<TI>A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>2</NO>
<PG>98-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ropert-1989" MODIFIED="2013-07-02 13:06:50 +0100" MODIFIED_BY="[Empty name]" NAME="Ropert 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 13:06:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ropert R</AU>
<TI>Fluoxetine versus clomipramine in major depressive disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudolph-1999" MODIFIED="2012-07-18 09:34:27 +0100" MODIFIED_BY="[Empty name]" NAME="Rudolph 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-07-18 09:34:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudolph RL, Feiger AD</AU>
<TI>A double-blind, randomised, placebo-controlled trial of once-daily venlafaxine extended release (xr) and fluoxetine for the treatment of depression</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>2-3</NO>
<PG>171-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rush-1998" MODIFIED="2013-07-02 13:07:07 +0100" MODIFIED_BY="[Empty name]" NAME="Rush 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-07-02 13:07:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, et al</AU>
<TI>Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>1</NO>
<PG>3-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandor-1998" NAME="Sandor 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandor P, Baker B, Irvine J, Dorian P, McKessok D, Mendlowitz S</AU>
<TI>Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients</TI>
<SO>Depression and Anxiety</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>2</NO>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schatzberg-2006" MODIFIED="2013-06-20 11:32:47 +0100" MODIFIED_BY="[Empty name]" NAME="Schatzberg 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-06-20 11:32:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anonymous</AU>
<TI>Venlafaxine IR, fluoxetine and placebo effective in reducing depression in elderly</TI>
<SO>Brown University Geriatric Psychopharmacology Update</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>6</NO>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 08:53:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schatzberg A, Roose S</AU>
<TI>A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>4</NO>
<PG>361-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schone-1993" MODIFIED="2013-07-02 13:08:02 +0100" MODIFIED_BY="[Empty name]" NAME="Schone 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-09-05 14:58:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geretsegger C, Bohmer F, Ludwig M</AU>
<TI>Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:07:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schone W, Ludwig M</AU>
<TI>A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13 Suppl 2</VL>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:08:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schone W, Ludwig M</AU>
<TI>Paroxetine in the treatment of depression in geriatric patientsa double-blind comparative study with fluoxetine</TI>
<TO>Paroxetin in der Depressionsbehandlung geriatrischer Patienteneine doppelblinde Vergleichsstudie mit Fluoxetin</TO>
<SO>Fortschritte der Neurologie Psychiatrie</SO>
<YR>1994</YR>
<VL>62 Suppl 1</VL>
<PG>16-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schrader-2000" MODIFIED="2013-07-02 13:08:28 +0100" MODIFIED_BY="[Empty name]" NAME="Schrader 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-07-02 13:08:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friede M, Henneicke von Zepelin HH, Freudenstein J</AU>
<TI>Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2001</YR>
<VL>34 Suppl 1</VL>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:55:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schrader E</AU>
<TI>Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomised, controlled study in mild-moderate depression</TI>
<SO>International Journal of Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>2</NO>
<PG>61-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechter-1999" MODIFIED="2013-07-02 13:09:20 +0100" MODIFIED_BY="[Empty name]" NAME="Sechter 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-05 14:58:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sechter D, Troy S, Paternetti S, Boyer P</AU>
<TI>A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients</TI>
<SO>European Psychiatry: the Journal of the Association of European Psychiatrists</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>1</NO>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:09:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sechter D, Troy S, Rioux P</AU>
<TI>A double blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in out patients</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:00:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sechter D, Troy S</AU>
<TI>Comparison of sertraline and fluoxetine on quality-of-life in depressed outpatients</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, CA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 14:59:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sechter D, Troy S</AU>
<TI>Double blind randomized comparative study of sertraline and fluoxetine in depressive outpatients</TI>
<SO>VIth World Congress of Biological Psychiatry, Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheehan-2009" MODIFIED="2012-07-16 14:34:07 +0100" MODIFIED_BY="[Empty name]" NAME="Sheehan 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-16 14:34:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sheehan DV, Nemeroff CB, Thase ME, Entsuah R; EPIC 016 Study Group</AU>
<TI>Placebo controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>2</NO>
<PG>61-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silverstone-1999" MODIFIED="2013-07-02 13:10:16 +0100" MODIFIED_BY="[Empty name]" NAME="Silverstone 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-02 13:10:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silverstone PH, Ravindran A</AU>
<TI>Once-daily venlafaxine extended release (xr) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine xr 360 study group</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>1</NO>
<PG>22-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smeraldi-1998" MODIFIED="2013-07-02 13:11:26 +0100" MODIFIED_BY="[Empty name]" NAME="Smeraldi 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-07-02 13:10:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Biondi F, Casadei G</AU>
<TI>Preliminary results of a randomized double blind study of amisulpride vs fluoxetine in 281 dysthymic patients</TI>
<SO>XXth Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Biondi F, Casadet G</AU>
<TI>Low-dose amisulpride versus fluoxetine in 281 dysthymic patients - a randomized medium-term (3 months), double-blind study</TI>
<SO>149th Annual Meeting of the American Psychiatric Association, New York, NY</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:05:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jori MC, Cesana BM, Casadei G</AU>
<TI>Onset of action in the pharmacologic treatment of dysthymia</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:11:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smeraldi E, Haefele E, Crespi G, Casadei G L, Biondi F, Vigorelli E</AU>
<TI>Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study</TI>
<SO>European Psychiatry</SO>
<YR>1996</YR>
<VL>11 Suppl 3</VL>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:11:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smeraldi E</AU>
<TI>Amisulpride in the treatment of dysthymia: Preliminary results in a comparative double-blind study with fluoxetine</TI>
<SO>Nuova Rivista di Neurologia</SO>
<YR>1995</YR>
<VL>5 Suppl 2</VL>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:01:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smeraldi E</AU>
<TI>Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: A double-blind, comparative study</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>1</NO>
<PG>47-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SouthWalesGroup-1988" NAME="SouthWalesGroup 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>South Wales Antidepressant Drug Trial Group</AU>
<TI>A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>1</NO>
<PG>75-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sramek-1995" MODIFIED="2013-07-02 13:12:19 +0100" MODIFIED_BY="[Empty name]" NAME="Sramek 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-07-02 13:12:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sramek JJ, Kashkin K, Jasinsky O, Kardatzke D, Kennedy S, Cutler NR</AU>
<TI>Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder</TI>
<SO>Depression</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>4</NO>
<PG>199-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stark-1985" NAME="Stark 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stark P, Hardison CD</AU>
<TI>A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stephenson-2000" MODIFIED="2013-07-02 13:12:44 +0100" MODIFIED_BY="[Empty name]" NAME="Stephenson 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-07-02 13:12:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stephenson DA, Harris B, Davies RH, Mullin JM, Richardson E, Boardman H, et al</AU>
<TI>The impact of antidepressants on sleep and anxiety: A comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire</TI>
<SO>Human Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>7</NO>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stratta-1991" MODIFIED="2012-09-05 15:05:58 +0100" MODIFIED_BY="[Empty name]" NAME="Stratta 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stratta P, Bolino F, Cupillari M, Casacchia M</AU>
<TI>A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>3</NO>
<PG>193-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:05:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stratta P, Cupillari M, Casacchia M</AU>
<TI>Double-blind study comparing fluoxetine with imipramine in the treatment of atypical depression</TI>
<SO>Rivista Sperimentale Di Freniatria E Medicina Legale Delle Alienazioni Mentali</SO>
<YR>1992</YR>
<VL>116</VL>
<NO>1</NO>
<PG>148-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suleman-1997" NAME="Suleman 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suleman MI, Sebit MB, Acuda SW, Siziya S</AU>
<TI>Fluoxetine and moclobemide versus amitriptyline in major depression: a single blind randomised clinical trial in Zimbabwe</TI>
<SO>Central-African Journal of Medicine</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>2</NO>
<PG>38-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suri-2000" MODIFIED="2013-07-02 13:13:23 +0100" MODIFIED_BY="[Empty name]" NAME="Suri 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-05 15:07:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Suri RA, Altshuler LL, Rasgon N, Calcagno J, Frye MA, Gitlin MJ, et al</AU>
<TI>A single-blind trial assessing the effectiveness/efficacy of fluoxetine versus sertraline for the treatment of major depression</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association, Chicago, IL</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:13:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Suri RA, Altshuler LL, Rasgon NL, Calcagno JL, Frye MA, Gitlin MJ, et al</AU>
<TI>Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>12</NO>
<PG>942-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamminen-1989" MODIFIED="2013-07-02 13:13:47 +0100" MODIFIED_BY="[Empty name]" NAME="Tamminen 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 13:13:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamminen TT, Lehtinen VV</AU>
<TI>A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 1</VL>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taner-2006" MODIFIED="2013-07-02 13:14:11 +0100" MODIFIED_BY="[Empty name]" NAME="Taner 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-18 09:35:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taner E, Demir EY, Cosar B</AU>
<TI>Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single blind, randomised clinical trial</TI>
<SO>Advances in Therapy</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>6</NO>
<PG>974-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:14:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taner E, Yancar Demir E, Cosar B</AU>
<TI>Efficacy and tolerability of reboxetine compared to fluoxetine in patients with atypical depression</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9 Suppl 1</VL>
<PG>S187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taneri-1989" NAME="Taneri 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taneri Z, Kohler R</AU>
<TI>Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2000" MODIFIED="2012-09-05 15:08:11 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-05 15:08:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McKendrick J, Stephenson DA, Thompson C, Peveler RC</AU>
<TI>Compliance with antidepressant treatment of depression in primary care in the UK</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:07:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thompson C, Peveler RC, Stephenson D, McKendrick J</AU>
<TI>Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomised comparison of fluoxetine and a tricyclic antidepressant</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>3</NO>
<PG>338-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tignol-1993" MODIFIED="2013-07-02 13:15:15 +0100" MODIFIED_BY="[Empty name]" NAME="Tignol 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-07-02 13:14:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>GlaxoSmithKline</AU>
<TI>A double-blind, randomised, multicentre study comparing paroxetine 20mg daily versus fluoxetine 20mg daily in the treatment of adults with major depression with regard to antidepressant efficacy, tolerance and anxiolytic effect. [29060/087]</TI>
<SO>clinicaltrials.gov. GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:15:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tignol J</AU>
<TI>A double-blind, randomised, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13 Suppl 2</VL>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1994" MODIFIED="2013-07-02 13:15:28 +0100" MODIFIED_BY="[Empty name]" NAME="Tollefson 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-07-02 13:15:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Greist JH, Jefferson JW, Heiligenstein JH, Sayler ME, Tollefson SL, et al</AU>
<TI>Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>6</NO>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 10:25:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Heiligenstein JH, Tollefson SL, Birkett MA, Knight DL, Nemeroff CB</AU>
<TI>Is there a relationship between baseline and treatment-associated changes in 3H-IMI platelet binding and clinical response in major depression?</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>1</NO>
<PG>47-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tylee-1997" MODIFIED="2012-07-18 09:35:22 +0100" MODIFIED_BY="[Empty name]" NAME="Tylee 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-07-18 09:35:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tylee A, Beaumont G, Bowden MW, Reynolds A</AU>
<TI>A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general-practice</TI>
<SO>Primary Care Psychiatry</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>1</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tzanakaki-2000" MODIFIED="2012-09-05 15:10:10 +0100" MODIFIED_BY="[Empty name]" NAME="Tzanakaki 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-05 15:09:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP</AU>
<TI>Increased remission rates with venlafaxine compared with fluoxetine in hospitalised patients with major depression and melancholia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1</NO>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:10:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tzanakaki M, Ierodiakonou Ch, Dimitriou E, Alevizos V</AU>
<TI>Randomized, double-blind comparison of venlafaxine and fluoxetine in hospitalized patients with major depression and melancholia</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Upward-1988" NAME="Upward 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upward JW, Edwards JG, Goldie A, Waller DG</AU>
<TI>Comparative effects of fluoxetine and amitriptyline on cardiac function</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1988</YR>
<VL>26</VL>
<NO>4</NO>
<PG>399-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Moffaert-1995" NAME="Van Moffaert 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Moffaert M, Bartholome F, Cosyns P, De Nayer AR, Mertens C</AU>
<TI>A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression</TI>
<SO>Human Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>5</NO>
<PG>393-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Versiani-1999" MODIFIED="2013-07-02 13:17:06 +0100" MODIFIED_BY="[Empty name]" NAME="Versiani 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-02 13:16:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Versiani M, Ontiveros A, Mazzotti G, Ospina J, Davila J, Mata S, et al</AU>
<TI>A double-blind comparison of fluoxetine and amitriptyline in the treatment of major depression with associated anxiety ('anxious depression')</TI>
<SO>Cross Cultural Psychiatry</SO>
<YR>1999</YR>
<PG>249-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 11:53:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Versiani M, Ontiveros A, Mazzotti G, Ospina J, Davila J, Mata S, et al</AU>
<TI>Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>6</NO>
<PG>321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:17:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Versiani M, Plewes J, Ontiveiros A, Mazzotti G, Ospina J, Davila J, et al</AU>
<TI>Fluoxetine and amitriptyline in the treatment of major depression with associated anxiety</TI>
<SO>XXIst Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:12:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Versiani M, Plewes J, Ontiveiros A, Mazzotti G, Ospina J, Davila J, et al</AU>
<TI>Fluoxetine and ammitriptyline in the treatment of major depression with associated anxiety</TI>
<SO>XIth European College of Neuropsychopharmacology Congress, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:11:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Versiani MV, Ontiveiros A, Mazzotti G, Ospina J, Davila J, Mata S, et al</AU>
<TI>A double-blind comparison of fluoxetine and amitriptyline in the treatment of major depression with associated anxiety</TI>
<SO>151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Versiani-2005" MODIFIED="2013-07-02 13:17:38 +0100" MODIFIED_BY="[Empty name]" NAME="Versiani 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 13:17:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ, Comparative Efficacy Antidepressants Study Group</AU>
<TI>Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients</TI>
<SO>CNS Drugs</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>2</NO>
<PG>137-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wehmeier-2005" MODIFIED="2012-07-11 11:44:27 +0100" MODIFIED_BY="[Empty name]" NAME="Wehmeier 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-11 11:44:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, Dittmann RW, Gattaz WF</AU>
<TI>Fluoxetine versus trimipramine in the treatment of depression in geriatric patients</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2005</YR>
<VL>38</VL>
<NO>1</NO>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-WELL-AK1A4006" MODIFIED="2013-07-02 13:18:33 +0100" MODIFIED_BY="[Empty name]" NAME="WELL AK1A4006" YEAR="4006">
<REFERENCE MODIFIED="2013-07-02 13:18:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A multicenter, double blind, placebo-controlled comparison of the safety and efficacy and effects on sexual functioning of Wellbutrin (bupropion HCI) Sustained Release (SR) and Fluoxetine in outpatients with moderate to severe recurrent Major Depression</TI>
<SO>GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheatley-1998" MODIFIED="2013-07-02 13:19:21 +0100" MODIFIED_BY="[Empty name]" NAME="Wheatley 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-09-05 15:23:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kremer CM</AU>
<TI>Mirtazapine versus fluoxetine - efficacy on symptoms associated with depression</TI>
<SO>151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:18:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kremer CM</AU>
<TI>Mirtazapine vs fluoxetine: Efficacy on symptoms associated with depression</TI>
<SO>XXIst Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:21:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wheatley D, Kremer CM</AU>
<TI>A randomized, double-blind comparison of mirtazapine and fluoxetine in patients with major depression</TI>
<SO>150th Annual Meeting of the American Psychiatric Association, San Diego, CA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:19:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley DP, van Moffaert M, Timmerman L, Kremer CM (Mirtazapine-Fluoxetine Study Group)</AU>
<TI>Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>6</NO>
<PG>306-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1993" NAME="Williams 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C</AU>
<TI>A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>3-4</NO>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winokur-2003" MODIFIED="2012-09-05 15:24:34 +0100" MODIFIED_BY="[Empty name]" NAME="Winokur 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-09-05 15:23:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Winokur A, DeMartinis NA 3rd, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64(10):1224-9.&lt;/p&gt;" NOTES_MODIFIED="2012-09-05 15:23:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winokur A, DeMartinis NA 3rd, McNally DP, Gary EM, Cormier JL, Gary KA</AU>
<TI>Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>10</NO>
<PG>1224-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:24:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Winokur A, Gary KA, DeMartinis NA, McNally DP, Rodner SA, Cormier JL</AU>
<TI>Comparative effects of mirtazapine and fluoxetine on sleep continuity measures and daytime sleepiness in patients with major depression and insomnia: An interim report</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2001" MODIFIED="2012-09-05 15:26:13 +0100" MODIFIED_BY="[Empty name]" NAME="Wolf 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-09-05 15:26:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gattaz WF, Maras Schmidt AA, Löw Bahro HM, Kohnen Dittmann RW, Wolff Berger RM, Riemann D</AU>
<TI>Efficacy and safety of fluoxetine versus trimipramine in geriatric depression</TI>
<SO>Xth World Congress of Psychiatry, Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-05 15:24:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolf R, Dykierek P, Gattaz WF, Maras A, Kohnen R, Dittmann RW et al</AU>
<TI>Differential effects of trimipramine and fluoxetine on sleep in geriatric depression</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>2</NO>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1987" NAME="Young 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young JP, Coleman A, Lader MH</AU>
<TI>A controlled comparison of fluoxetine and amitriptyline in depressed out-patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>151</VL>
<PG>337-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1997" MODIFIED="2012-08-10 13:56:09 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-08-10 13:56:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu BR, Zhou DP, Zhang F</AU>
<TI>Fluoxetine and amitriptyline in the treatment of 22 depressive-disorder cases: a double blind randomised study</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>4</NO>
<PG>259-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006-a" MODIFIED="2013-06-20 11:38:06 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2006 a" YEAR="2006">
<REFERENCE MODIFIED="2013-06-20 11:38:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly</AU>
<TI>Depression with lack of motivation; comparison between fluoxetine and trazodone (ID#6706)</TI>
<SO>[Trial B1Y-GH-S013; Summary ID#6706] www.lillytrials.com/results/Prozac.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-09 18:27:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao J, Ang Q, Wang J, Sun X, Wei J, Li M, Liu P</AU>
<TI>A comparative efficacy of fluoxetine and trazodone in depression with remarkable retardation and loss of energy: a randomised open-label trial</TI>
<SO>Internal Medicine Journal - Tokyo</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-07-02 13:24:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baca-Baldomero-2005" MODIFIED="2012-07-11 11:58:09 +0100" MODIFIED_BY="[Empty name]" NAME="Baca Baldomero 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-11 11:58:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baca Baldomero E, Giner Ubago J, Leal Cercos C, Vallejo Ruiloba J, Garcia Calvo C, Prieto Lopez R</AU>
<TI>Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study</TI>
<SO>Depression and Anxiety</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>2</NO>
<PG>68-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitrain-2011" MODIFIED="2013-07-02 13:21:25 +0100" MODIFIED_BY="[Empty name]" NAME="Bitrain 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-07-02 13:21:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bitran S, Farabaugh AH, Ameral VE, LaRocca RA, Clain AJ, Fava M, Mischoulon D</AU>
<TI>Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>4</NO>
<PG>206-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brasseur-1989" MODIFIED="2013-07-02 13:21:45 +0100" MODIFIED_BY="[Empty name]" NAME="Brasseur 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-02 13:21:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brasseur R</AU>
<TI>A multicenter open trial of fluoxetine in depressed out patients in Belgium</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4 Suppl 11</VL>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-1989" MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" NAME="Cohn 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohn JB, Collins G, Ashbrook E, Wernicke JF</AU>
<TI>A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>4</NO>
<PG>313-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ducher-2008" MODIFIED="2012-07-11 11:58:49 +0100" MODIFIED_BY="[Empty name]" NAME="Ducher 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-07-11 11:58:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ducher JL, Dalery J</AU>
<TI>Correlations between Beck's suicidal ideation scale, suicidal risk assessment scale RSD and Hamilton's depression rating scale</TI>
<SO>Encephale</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>2</NO>
<PG>132-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodnick-1987" MODIFIED="2012-08-10 13:56:38 +0100" MODIFIED_BY="[Empty name]" NAME="Goodnick 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-08-10 13:56:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodnick PJ, Fieve RR, Peselow ED, Barouche F, Schlegel A</AU>
<TI>Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>23</YR>
<VL>1</VL>
<PG>162-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gu-2001" MODIFIED="2013-07-02 13:22:11 +0100" MODIFIED_BY="[Empty name]" NAME="Gu 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-07-02 13:22:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gu NF, Li HF, Shu L, Zhang HY, et al</AU>
<TI>Multicenter study of St.John's wort extract in treatment of mild to moderate depression</TI>
<SO>Chinese Journal of Clinical Pharmacy</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>5</NO>
<PG>271-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunter-2006" MODIFIED="2012-08-10 13:57:06 +0100" MODIFIED_BY="[Empty name]" NAME="Hunter 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-11 12:01:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunter AM, Leuchter AF, Cook LA, Abrams M</AU>
<TI>Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2010</YR>
<VL>122</VL>
<NO>6</NO>
<PG>461-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-10 13:57:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hunter AM, Leuchter AF, Morgan ML, Cook LA</AU>
<TI>Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression</TI>
<SO>American Journal of Psychiatry.</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>8</NO>
<PG>1426-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 12:02:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunter AM, Ravikumar S, Cook LA, Leuchter AF</AU>
<TI>Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2009</YR>
<VL>119</VL>
<NO>4</NO>
<PG>266-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iovieno-2011" MODIFIED="2012-07-11 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Iovieno 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-11 12:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iovieno N, Van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA</AU>
<TI>Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse</TI>
<SO>Depression and Anxiety</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>2</NO>
<PG>137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kroenke-2001" MODIFIED="2013-07-02 13:23:03 +0100" MODIFIED_BY="[Empty name]" NAME="Kroenke 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-07-11 12:06:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aikens JE, Kroenke K, Nease DE Jr, Klinkman MS, Sen A</AU>
<TI>Trajectories of improvement for six depression-related outcomes</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>1</NO>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:23:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al</AU>
<TI>Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomised trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>23</NO>
<PG>2947-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musgnung-2005" MODIFIED="2012-07-18 10:52:01 +0100" MODIFIED_BY="[Empty name]" NAME="Musgnung 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-18 10:52:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musgnung J, Trivedi M, Benattia I, Graepel J</AU>
<TI>Depression remission rates with venlafaxine XR versus SSRIs using treatment algorithms</TI>
<SO>Psychiatriki</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemetz-2005" MODIFIED="2012-07-11 12:09:22 +0100" MODIFIED_BY="[Empty name]" NAME="Nemetz 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-11 12:09:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemets B, Bersudsky Y, Belmaker RH</AU>
<TI>Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>5</NO>
<PG>586-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peveler-2005" MODIFIED="2013-07-02 13:23:31 +0100" MODIFIED_BY="[Empty name]" NAME="Peveler 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 13:23:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, et al</AU>
<TI>A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine</TI>
<SO>Health Technology Assessment</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>16</NO>
<PG>1-134</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roose-1994" NAME="Roose 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;. .&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roose SP, Glassman AH, Attia E, Woodring S</AU>
<TI>Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>12</NO>
<PG>1735-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1999" MODIFIED="2013-07-02 13:24:06 +0100" MODIFIED_BY="[Empty name]" NAME="Schmidt 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-02 13:24:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt U, Harrer G, Kuhn U, Biller A</AU>
<TI>Equivalence comparison of the st john's wort extract lohyp-57 versus fluoxetine HCl</TI>
<SO>Zeitschrift fur Phytotherapie</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>2</NO>
<PG>89-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serrano_x002d_Blanco-2006" MODIFIED="2013-06-21 11:54:35 +0100" MODIFIED_BY="[Empty name]" NAME="Serrano-Blanco 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-06-21 11:54:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serrano-Blanco A, Gabarron E, Garcia-Bayo I, Soler-Vila M, Caramés E, Peñarrubia-Maria MT, et al</AU>
<TI>Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>2-3</NO>
<PG>153-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1996" MODIFIED="2013-07-02 13:24:35 +0100" MODIFIED_BY="[Empty name]" NAME="Simon 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-02 13:24:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon GE, Von Korff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, Wagner EH</AU>
<TI>Initial antidepressant choice in primary-care: effectiveness and cost of fluoxetine vs tricyclic antidepressants</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<NO>24</NO>
<PG>1897-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1998" MODIFIED="2012-08-10 13:57:46 +0100" MODIFIED_BY="[Empty name]" NAME="Simon 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-08-10 13:57:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon GE, Heiligenstein JH, Grothaus L, Katon W, Revicki D</AU>
<TI>Should anxiety and insomnia influence antidepressant selection: a randomised comparison of fluoxetine and imipramine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>2</NO>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1999" MODIFIED="2013-07-02 13:24:59 +0100" MODIFIED_BY="[Empty name]" NAME="Simon 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-02 13:24:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon GE, Heiligenstein J, Revicki D, VonKorff M, Katon WJ, Ludman E, et al</AU>
<TI>Long-term outcomes of initial antidepressant drug choice in a "real world" randomised trial</TI>
<SO>Archives of Family Medicine</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>4</NO>
<PG>319-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strik-1998" MODIFIED="2012-08-10 13:58:05 +0100" MODIFIED_BY="[Empty name]" NAME="Strik 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-08-10 13:58:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strik JJ, Honig A, Lousberg R, Cheriex EC, Van Praag HM</AU>
<TI>Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>6</NO>
<PG>263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-07-02 13:32:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2012-07-18 10:53:23 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2006" YEAR="2005">
<REFERENCE MODIFIED="2012-07-18 10:53:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JD, Guo XF, Luo Q, Xun GL, Chen YG</AU>
<TI>A randomised and double-blinded clinical trial of reboxetine mesylate for treatment of depression</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>1678-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GSK-29060_x002f_134" MODIFIED="2013-07-02 13:25:28 +0100" MODIFIED_BY="[Empty name]" NAME="GSK 29060/134" YEAR="">
<REFERENCE MODIFIED="2013-07-02 13:25:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A randomized, double-blind, controlled study of paroxetine and fluoxetine in the treatment of patients with major depression with associated anxiety</TI>
<SO>GSK - Clinical Study Register (www.gsk-clinicalstudyregister.com)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-20 10:03:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silva JAC, Ruschel S, Caetano D</AU>
<TI>Double-blind, randomised, controlled study of Paroxetine and Fluoxetine in the treatment of patients with major depression and associated anxiety</TI>
<TO>Estudo Randomizado, Duplo-cego, Controlado de Paroxetina e Fluoxetina no Tratamento de Pacientes com Depressão Maior Associada à Ansiedade</TO>
<SO>Revista da Associacao Medica Brasileira (Sao Paulo)</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>12</NO>
<PG>92-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2006a" MODIFIED="2012-07-02 13:56:15 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2006a" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 13:56:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang J, Sun Z</AU>
<TI>A control study of citalopram and fluoxetine in first-episode senile depression</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>175-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2006b" MODIFIED="2012-07-02 13:57:02 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2006b" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 13:57:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang K</AU>
<TI>Contrast study of citalopram and fluoxetine in treatment of depression</TI>
<SO>Modern Medicine and Health</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>1456-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2006" MODIFIED="2012-07-02 14:00:24 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:00:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang R-H, Du B, Zhang H-Y</AU>
<TI>Randomized, double blind, double-dummy, multicenter, parallel controlled clinical trial of Kaiyuanshen in the treatment of depressive disorder</TI>
<SO>Chinese Journal of Clinical Pharmacology</SO>
<YR>2006</YR>
<VL>22</VL>
<PG>15-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" MODIFIED="2013-06-21 11:54:54 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-06-21 11:54:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li HF, Zhao JP, Kuang WH, Yao PF, Chen JD, Sun XL, et al</AU>
<TI>Bupropion-sustained release in treatment of depression (72 patients): a randomised, double-blind, double-dummy, multicenter clinical trial</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>614-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006a" MODIFIED="2012-07-02 14:02:34 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2006a" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:02:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li HF, Ma C, Chen YG, Fan JX, Gu NF</AU>
<TI>Clinical effect of reboxetine in the treatment of anxiety in depressive patients</TI>
<SO>Chinese Journal of Clinical Pharmacy</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>339-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006b" MODIFIED="2012-07-02 14:03:19 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2006b" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:03:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L, Zhang H, Chen J</AU>
<TI>A control study on the curative effect and reliability of reboxetine with fluoxetine for treatment of depression</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>721-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006c" MODIFIED="2012-07-02 14:04:04 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2006c" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:04:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li N, Ji WD, Zhang DH, Li Y</AU>
<TI>Efficacy and safety of reboxetine versus fluoxetine for the elders with depression</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>1682-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2005" MODIFIED="2012-07-11 12:19:51 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-11 12:19:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang C, Liu L, Zhang X</AU>
<TI>A comparative study of citalopram and fluoxetine in the treatment of depression</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<PG>82-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Licinio-2004" MODIFIED="2013-07-02 13:26:31 +0100" MODIFIED_BY="[Empty name]" NAME="Licinio 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-07-02 13:26:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, et al</AU>
<TI>Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans</TI>
<SO>Molecular Psychiatry</SO>
<YR>2004</YR>
<VL>9</VL>
<PG>1075-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-01 15:37:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>National Institute of General Medical Sciences (NIGMS)</AU>
<TI>Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2007" MODIFIED="2013-07-02 13:26:58 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-02 13:26:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma X, Gao C, Tan Q</AU>
<TI>Bupropion SR and fluoxetine in treatment of depression in multicenter clinical trial</TI>
<SO>Journal of Xi'an Jiaotong University (Medical Sciences)</SO>
<YR>2007</YR>
<VL>28</VL>
<PG>533-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00909155" MODIFIED="2013-07-02 13:28:23 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00909155" YEAR="9155">
<REFERENCE MODIFIED="2013-06-20 10:41:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kolden G</AU>
<TI>Brain Imaging Techniques That Predict Antidepressant Responsiveness</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00909155</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-02 13:28:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Light SN, Heller AS, Johnstone T, Kolden GG, Peterson MJ, Kalin NH, et al</AU>
<TI>Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 Weeks of antidepressant treatment in major depressive disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2011</YR>
<VL>70</VL>
<NO>10</NO>
<PG>962-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2006" MODIFIED="2012-07-02 14:12:43 +0100" MODIFIED_BY="[Empty name]" NAME="Qin 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:12:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin S</AU>
<TI>The efficacy and tolerability of venlafaxine and fluoxetine in treatment of patients with first-episode depression</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2006</YR>
<VL>18</VL>
<PG>519-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sackeim-2006" MODIFIED="2012-07-02 14:13:53 +0100" MODIFIED_BY="[Empty name]" NAME="Sackeim 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:13:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sackeim HA, Roose SP, Lavori PW</AU>
<TI>Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD)</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>483-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salehi-2009" MODIFIED="2012-07-02 14:14:58 +0100" MODIFIED_BY="[Empty name]" NAME="Salehi 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-02 14:14:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salehi B, Sanjani FG</AU>
<TI>Comparison of the effect of fluoxetine and imipramine on fasting blood sugar of  patients with major depressive disorders, four and eight weeks after treatment [Arabic]</TI>
<SO>Scientific Journal of Kurdistan University of Medical Sciences</SO>
<YR>2009</YR>
<VL>14</VL>
<PG>45-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2005" MODIFIED="2013-07-02 13:30:10 +0100" MODIFIED_BY="[Empty name]" NAME="Shen 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 13:30:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen YF, Li HF, Ma C, et al</AU>
<TI>Comparison of reboxetine with fluoxetine in treatment of depression: a randomised double-blind multicenter study</TI>
<SO>Chinese Journal of New Medicines and Clinical Practice</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>619-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stassen-1999" MODIFIED="2012-07-02 14:17:01 +0100" MODIFIED_BY="[Empty name]" NAME="Stassen 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-07-02 14:16:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stassen HH, Angst J, Delini-Stula A</AU>
<TI>Fluoxetine versus moclobemide: Cross-comparison between the time courses of improvement</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1999</YR>
<VL>32</VL>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2006" MODIFIED="2013-07-02 13:30:30 +0100" MODIFIED_BY="[Empty name]" NAME="Su 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-07-02 13:30:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su H, Jiang K, Lou F, et al</AU>
<TI>The cognition function comparison study between venlafaxine and fluoxetine hydrochloride in first-episode major depression treatment</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2006</YR>
<VL>32</VL>
<PG>32-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2005" MODIFIED="2013-07-02 13:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-02 13:30:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun CY, Wang GH, Zhou T, Tian YL</AU>
<TI>A comparative clinical study for venlafaxine versus fluoxetine in the treatment of depression</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2005</YR>
<VL>14</VL>
<PG>617-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2006" MODIFIED="2012-07-02 14:19:57 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:19:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun P, Song L, Sun F</AU>
<TI>Comparative study of fluoxetine vs venlafaxine in treatment of depressive patients who cured by fluoxetine but had no obvious effect</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2006</YR>
<VL>28</VL>
<PG>545-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-1997" MODIFIED="2012-08-10 09:09:09 +0100" MODIFIED_BY="[Empty name]" NAME="Tan 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-08-10 09:09:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan MG, He Qi, Gao CL, Ren YP, Zhang TL</AU>
<TI>Fluoxetine and amitriptyline in the treatment of 18 depressive-disorder cases: a double blind randomised study</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>262-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2012-07-11 12:20:03 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-11 12:20:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Hu Y, Qi F</AU>
<TI>Comparison of event-related potential P300 in the geriatric depression treated with venlafaxine or fluoxetine</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2006</YR>
<VL>18</VL>
<PG>94-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007a" MODIFIED="2012-07-02 14:22:56 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-07-02 14:22:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang D, Wang X, Li X</AU>
<TI>Comparison between the effects of fluoxetine and paroxetine on the life quality of the depressive disorder</TI>
<SO>Nervous Diseases and Mental Health</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>23-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007b" MODIFIED="2013-07-02 13:31:24 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-07-02 13:31:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Zhang B, Li J, Sun X-L</AU>
<TI>Double-blind, double-dummy, randomised controlled trials of bupropion hydrochloride sustained-release tablets for depression</TI>
<SO>Chinese Journal of Evidence-Based Medicine</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>409-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2009" MODIFIED="2013-07-02 13:31:41 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-07-02 13:31:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X-Q, Zhang H-Y, Shu L, et al</AU>
<TI>Efficacy and safety of morinda officinalis oligose capsule in the treatment of mild or moderate depression</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2009</YR>
<VL>18</VL>
<PG>802-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2011" MODIFIED="2013-07-02 13:32:23 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-07-02 13:32:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang HC, Chen PS</AU>
<TI>Genetic polymorphisms of CYP2C19 influence treatment response to antidepresants in a Taiwanese population with major depressive disorder [conference abstract]</TI>
<SO>Biological Psychiatry [abstracts from the 66th Annual Meeting of the Society of Biological Psychiatry San Francisco, CA United States May 12-14, 2011]</SO>
<YR>2011</YR>
<VL>69</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2005" MODIFIED="2013-06-21 11:55:23 +0100" MODIFIED_BY="[Empty name]" NAME="Xiao 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-06-21 11:55:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao B, Xie W, Shi Z</AU>
<TI>A clinical control study of venlafaxine and fluoxetine in the treatment of senile depression</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<PG>703-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2010" MODIFIED="2012-07-02 14:27:13 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-02 14:27:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu S-Q, Cao J, Huang W-W</AU>
<TI>Comparison of escitalopram with fluoxetine in old depressive patients</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2010</YR>
<VL>19</VL>
<PG>207-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2005" MODIFIED="2012-07-02 14:28:17 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-02 14:28:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao HD, Wang JL, Xia JM</AU>
<TI>A comparative study of citalopram and fluoxetine in the treatment of senile depressive disorders</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>355-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006" MODIFIED="2012-07-02 14:31:51 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-02 14:31:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao H, Guan T</AU>
<TI>A control study in the treatment of depressive disorder with citalopram and fluoxetine</TI>
<SO>Evaluation and Analysis of Drug-Use in Hospitals of China</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2005" MODIFIED="2012-07-02 14:32:57 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-02 14:32:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou M, Yao L</AU>
<TI>The efficacy and tolerability of venlafaxine and fluoxetine in treatment of elderly patients with first-episode depression</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>38</VL>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2005" MODIFIED="2012-07-02 14:33:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-02 14:33:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu J, Jiang X, Zhou D, Zhang F</AU>
<TI>Comparative study of mirtazapine vs. fluoxetine in treatment of elderly depressive patients</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<PG>277-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2006" MODIFIED="2012-07-11 12:20:39 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-11 12:20:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu J</AU>
<TI>Comparative study of mirtazapine and fluoxetine in the treatment of senile depression</TI>
<SO>China Journal of Health Psychology</SO>
<YR>2006</YR>
<VL>14</VL>
<PG>546-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-06-20 10:34:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ChiCTR_x002d_TRC_x002d_11001668" MODIFIED="2013-06-20 10:23:05 +0100" MODIFIED_BY="[Empty name]" NAME="ChiCTR-TRC-11001668" YEAR="1668">
<REFERENCE MODIFIED="2013-06-20 10:23:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>ChiCTR-TRC-11001668</AU>
<TI>Efficacy and safety of agomelatine with flexible dose (25 mg/day with potential adjustment at 50 mg) given orally for 8 weeks in out-patients with Major Depressive Disorder</TI>
<SO>www.chictr.org</SO>
<YR>(accessed 16 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CTRI_x002f_2011_x002f_05_x002f_001719" MODIFIED="2013-06-20 10:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="CTRI/2011/05/001719" YEAR="1719">
<REFERENCE MODIFIED="2013-06-20 10:25:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>CTRI/2011/05/001719</AU>
<TI>An Open-Label, Randomized, Parallel Group, Prospective, Multicentre Clinical Trial for Evaluation of Efficacy and Safety of IN-ASTR-001 in Patients with Major Depressive Disorder</TI>
<SO>[Clinical Trials Registry - India] www.ctri.nic.in</SO>
<YR>(accessed 16 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EUCTR2007_x002d_002130_x002d_11_x002d_ES" MODIFIED="2013-06-20 10:34:45 +0100" MODIFIED_BY="[Empty name]" NAME="EUCTR2007-002130-11-ES" YEAR="">
<REFERENCE MODIFIED="2013-06-20 10:34:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>EUCTR2007-002130-11-ES</AU>
<TI>Therapeutic strategies in major depressive disorder resistant to treatment with SSRIs. Pragmatic, parallel group, randomised trial with blinded evaluation</TI>
<TO>Estrategias terapéuticas en Trastorno Depresivo Mayor resistente a tratamiento con Inhibidores Selectivos de la Recaptación de la Serotonina. Ensayo clínico pragmático, paralelo, aleatorizado con evaluación enmascarada</TO>
<SO>[EU Clinical Trials Register] www.clinicaltrialsregister.eu</SO>
<YR>(accessed 16 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01204086" MODIFIED="2013-06-20 10:22:17 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01204086" YEAR="2012">
<REFERENCE MODIFIED="2013-06-20 10:22:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01204086</AU>
<TI>Pharmacogenomics Studies of Antidepressants</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01204086</SO>
<YR>(accessed 16 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-08-02 11:33:06 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01254305" MODIFIED="2013-06-20 10:20:59 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01254305" YEAR="">
<REFERENCE MODIFIED="2013-06-20 10:20:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01254305</AU>
<TI>Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01204086</SO>
<YR>(accessed 16 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-08-02 11:33:10 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-07-15 09:53:01 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-07-15 09:53:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2013-07-02 13:33:43 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skew ness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1980" MODIFIED="2012-06-25 11:34:03 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1980" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistic manual of mental disorders :DSM III</SO>
<YR>1980</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1987" MODIFIED="2013-07-02 13:34:36 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1987" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>DSM-III-R: diagnostic and statistical manual of mental disorders</SO>
<YR>1987</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" MODIFIED="2012-08-02 16:16:50 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000" MODIFIED="2013-07-02 13:35:01 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2000" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with major depressive disorder (revision)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157 Suppl 4</VL>
<PG>1-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2006" MODIFIED="2012-08-02 16:16:56 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2006" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006</SO>
<YR>2006</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbui-2004" MODIFIED="2012-07-12 11:55:06 +0100" MODIFIED_BY="[Empty name]" NAME="Barbui 2004" TYPE="JOURNAL_ARTICLE">
<AU>Barbui C, Cipriani A, Brambilla P, Hotopf M</AU>
<TI>"Wish bias" in antidepressant drug trials?</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>126-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbui-2011a" MODIFIED="2013-05-17 13:19:19 +0100" MODIFIED_BY="[Empty name]" NAME="Barbui 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Barbui C, Tansella M</AU>
<TI>Cochrane reviews impact on mental health policy and practice</TI>
<SO>Epidemiology and Psychiatric Sciences</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>3</NO>
<PG>211-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbui-2011b" MODIFIED="2013-06-20 10:35:45 +0100" MODIFIED_BY="[Empty name]" NAME="Barbui 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Barbui C, Cipriani A</AU>
<TI>Cluster randomised trials</TI>
<SO>Epidemiology and Psychiatric Sciences</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>4</NO>
<PG>307-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2013-06-21 11:55:44 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of randomised controlled trials. The CONSORT statement</TI>
<SO>Journal of American Medical Association JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2005" MODIFIED="2013-06-21 11:55:59 +0100" MODIFIED_BY="[Empty name]" NAME="Cipriani 2005" TYPE="COCHRANE_REVIEW">
<AU>Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al</AU>
<TI>Fluoxetine versus other types of pharmacotherapy for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-08-02 16:08:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-02 16:08:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004185.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2006a" MODIFIED="2012-07-11 12:24:17 +0100" MODIFIED_BY="[Empty name]" NAME="Cipriani 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR</AU>
<TI>Are all antidepressants really the same? The case of fluoxetine: a systematic review</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>6</NO>
<PG>850-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2009a" MODIFIED="2013-06-21 11:56:15 +0100" MODIFIED_BY="[Empty name]" NAME="Cipriani 2009a" TYPE="COCHRANE_REVIEW">
<AU>Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al</AU>
<TI>Sertraline versus other antidepressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-08-02 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-02 16:04:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006117.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2009b" MODIFIED="2013-06-21 11:56:22 +0100" MODIFIED_BY="[Empty name]" NAME="Cipriani 2009b" TYPE="COCHRANE_REVIEW">
<AU>Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C</AU>
<TI>Escitalopram versus other antidepressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-08-02 16:05:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-02 16:05:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006532.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2011" MODIFIED="2013-06-20 10:36:45 +0100" MODIFIED_BY="[Empty name]" NAME="Cipriani 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al</AU>
<TI>Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<PG>1306-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2012a" MODIFIED="2012-11-15 11:26:55 +0000" MODIFIED_BY="[Empty name]" NAME="Cipriani 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C</AU>
<TI>Duloxetine versus other anti-depressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<VL>10</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cipriani-2012b" MODIFIED="2013-07-02 13:36:03 +0100" MODIFIED_BY="[Empty name]" NAME="Cipriani 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C</AU>
<TI>Citalopram versus other anti-depressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<VL>7</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciuna-2004" MODIFIED="2012-07-11 12:24:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ciuna 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, Barbui C</AU>
<TI>Are we going to increase the use of antidepressants up to that of benzodiazepines?</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2004</YR>
<VL>60</VL>
<NO>9</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1992" MODIFIED="2012-11-27 15:41:01 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A power primer</TI>
<SO>Psychological Bulletin</SO>
<YR>1992</YR>
<VL>112</VL>
<NO>1</NO>
<PG>155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-07-11 12:24:53 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feighner-1972" MODIFIED="2013-07-15 09:51:53 +0100" MODIFIED_BY="[Empty name]" NAME="Feighner 1972" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R</AU>
<TI>Diagnostic criteria for use in psychiatric research</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freemantle-2000" MODIFIED="2012-07-18 10:58:26 +0100" MODIFIED_BY="[Empty name]" NAME="Freemantle 2000" TYPE="JOURNAL_ARTICLE">
<AU>Freemantle N, Mason J</AU>
<TI>The importance of achieving additional drug benefits at a reasonable cost</TI>
<SO>Pharmacoeconomics</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>4</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2002" MODIFIED="2012-07-12 11:41:47 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2002" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Guyatt GH, Griffith LE</AU>
<TI>Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>72-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2012-07-11 12:25:16 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gartlehner-2010" MODIFIED="2013-07-02 13:37:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gartlehner 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gartlehner G, Chapman A, Strobelberger M, Thaler K</AU>
<TI>Differences in efficacy and safety of pharmaceutical treatments between men and women: An umbrella review</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5</VL>
<PG>e11895</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gartlehner-2011" MODIFIED="2013-07-02 13:37:42 +0100" MODIFIED_BY="[Empty name]" NAME="Gartlehner 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, et al</AU>
<TI>Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>155</VL>
<NO>11</NO>
<PG>772-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geddes-2000" MODIFIED="2013-06-21 10:51:52 +0100" MODIFIED_BY="[Empty name]" NAME="Geddes 2000" TYPE="COCHRANE_REVIEW">
<AU>Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J</AU>
<TI>SSRIs versus other antidepressants for depressive disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2012-08-02 16:08:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-02 16:08:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001851"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" MODIFIED="2012-07-03 12:13:46 +0100" MODIFIED_BY="[Empty name]" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-07-11 15:44:25 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-08-03 08:57:26 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JP, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0</SO>
<YR>2011</YR>
<EN>The Cochrane Collaboration, 2011</EN>
<PB>Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horder-2011" MODIFIED="2012-07-13 15:51:37 +0100" MODIFIED_BY="[Empty name]" NAME="Horder 2011" TYPE="JOURNAL_ARTICLE">
<AU>Horder J, Matthews P, Waldmann R</AU>
<TI>Placebo, Prozac and PLoS: significant lessons for psychopharmacology</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1277-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" MODIFIED="2013-07-02 13:42:42 +0100" MODIFIED_BY="[Empty name]" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7400</NO>
<PG>1167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2009" MODIFIED="2012-07-13 15:53:50 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2009" TYPE="JOURNAL_ARTICLE">
<AU>Marshall KP, Georgievskava Z, Georgievsky I</AU>
<TI>Social reactions to Valium and Prozac: a cultural lag perspective of drug diffusion and adoption</TI>
<SO>Research in Social and Administrative Pharmacy</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>2</NO>
<PG>94-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" MODIFIED="2013-07-02 13:43:05 +0100" MODIFIED_BY="[Empty name]" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagakawa-2009" MODIFIED="2013-06-21 11:56:50 +0100" MODIFIED_BY="[Empty name]" NAME="Nagakawa 2009" TYPE="COCHRANE_REVIEW">
<AU>Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, et al</AU>
<TI>Milnacipran versus other antidepressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-08-03 08:54:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-03 08:54:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006529.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2012-08-02 11:20:12 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2010" TYPE="BOOK">
<AU>National Institute for Clinical Excellence</AU>
<SO>Depression: management of depression in primary and secondary care - NICE guidance</SO>
<YR>2010</YR>
<PB>National Institute for Clinical Excellence</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Odgaard_x002d_Jensen-2011" MODIFIED="2013-06-20 10:40:30 +0100" MODIFIED_BY="[Empty name]" NAME="Odgaard-Jensen 2011" TYPE="COCHRANE_REVIEW">
<AU>Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Schünemann H, et al</AU>
<TI>Randomisation to protect against selection bias in healthcare trials</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4. Art. No.: MR000012</NO>
<IDENTIFIERS MODIFIED="2013-06-20 10:39:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-20 10:39:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000012.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Omori-2010" MODIFIED="2013-06-21 11:57:04 +0100" MODIFIED_BY="[Empty name]" NAME="Omori 2010" TYPE="COCHRANE_REVIEW">
<AU>Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al</AU>
<TI>Fluvoxamine versus other anti-depressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-08-02 16:27:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-02 16:27:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006114.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2013-07-02 13:43:50 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1972" MODIFIED="2013-07-15 09:53:01 +0100" MODIFIED_BY="[Empty name]" NAME="Spitzer 1972" TYPE="JOURNAL_ARTICLE">
<AU>Spitzer RL, Endicott J, Robins E</AU>
<TI>Research diagnostic criteria: rationale and reliability</TI>
<SO>Archives General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<NO>6</NO>
<PG>773-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2000" MODIFIED="2013-07-02 13:44:11 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Gavaghan D, Egger M</AU>
<TI>Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>11</NO>
<PG>1119-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trespidi-2011" MODIFIED="2012-07-11 12:27:11 +0100" MODIFIED_BY="[Empty name]" NAME="Trespidi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Trespidi C, Barbui C, Cipriani A</AU>
<TI>Why it is important to include unpublished data in systematic reviews</TI>
<SO>Epidemiology and Psychiatric Sciences</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>2</NO>
<PG>133-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-2011" MODIFIED="2012-11-15 11:30:33 +0000" MODIFIED_BY="[Empty name]" NAME="Watanabe 2011" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA</AU>
<TI>Mirtazapine versus other antidepressive agents for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<VL>12</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1977" MODIFIED="2012-06-25 11:35:47 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1977" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Manual of the international statistical classification of diseases, injuries, and causes of death</SO>
<YR>1977</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" MODIFIED="2012-06-25 09:32:14 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)</SO>
<YR>1992</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2012-06-25 09:11:33 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2006" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO Collaborative Centre for Drug Statistics Methodology</TI>
<SO>http://www.whocc.no/atcddd/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2005" MODIFIED="2012-08-09 16:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Wong 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wong DT, Perry KW, Bymaster FP</AU>
<TI>Case history: the discovery of fluoxetine hydrochloride (Prozac)</TI>
<SO>Nature Reviews Drug Discovery</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>9</NO>
<PG>764-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-08-09 16:38:20 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cochrane-2005" MODIFIED="2012-08-09 16:38:20 +0100" MODIFIED_BY="[Empty name]" NAME="Cochrane 2005" TYPE="COCHRANE_REVIEW">
<AU>Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C</AU>
<TI>Fluoxetine versus other types of pharmacotherapy for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-08-09 16:38:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-09 16:38:20 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004185.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-07-04 15:49:15 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-07-04 15:49:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-07-04 12:51:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aguglia-1993">
<CHAR_METHODS MODIFIED="2013-07-04 04:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients suffering from a major depressive episode according to DSM-III-R, with a baseline score on Hamilton Rating Scale for Depression-17 Item (HDRS-17) of at least 18, recruited from nine separated psychiatric clinics.<BR/>Age: 18 years or more<BR/>Exclusion criteria: depression secondary to other conditions, concomitant illness of renal, cardiac or hepatic origin; hypersensitivity to other antidepressants, likelihood of poor compliance, risk of suicide, peptic ulcer history, an improvement of greater than 25% in the HDRS score during a pre-treatment placebo washout period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 56 participants<BR/>Sertraline: 52 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Sertraline dose range: 50-150 mg/day<BR/>Benzodiazepines were allowed for hypnotic use and as maintenance treatment for pre-existing anxiety</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:51:39 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 and Hamilton Rating Scale for Anxiety (HAM-A), Montgomery and Asberg Scale for Depression (MADRS), Zung Self-Rating Scale for Anxiety, Leeds Sleep Evaluation Questionnaire, Clinical Global Impression Scale, including severity (CGI-S) and improvement (CGI-I)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:51:46 +0100" MODIFIED_BY="[Empty name]">
<P>Seventy-five per cent of the patients were women. Higher percentage of patients with a family history of psychiatric illness in the fluoxetine group. Higher percentage of patients with severe depression in the fluoxetine group (30.4%) than in the sertraline group (13.7%).<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:52:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akhondzadeh-2003">
<CHAR_METHODS MODIFIED="2013-07-04 12:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:52:24 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients meeting DSM-IV diagnostic criteria for major depression, with a minimum baseline score of 20 on the Hamilton Rating Scale for Depression-17 Item (HDRS-17).<BR/>Age range: 19-54 years<BR/>Exclusion criteria: any other psychiatric primary disease, current or past history of bipolar disorder, use of anxiolytic or MAOI or tryptophan, organic mental disorder, epilepsy, suicidal tendencies, any severe general disease, pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 24 participants<BR/>Nortriptyline: 24 participants<BR/>Fluoxetine dose: 60 mg/day<BR/>Nortriptyline dose: 150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:52:32 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:53:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<CHAR_METHODS MODIFIED="2013-07-04 12:53:08 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:53:10 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients meeting DSM-IV diagnostic criteria for major depression, with a minimum baseline score of 18 and not superior to 25 on the Hamilton Rating Scale for Depression-17 Item (HDRS-17).<BR/>Age range: 19-55 years<BR/>Exclusion criteria: patients posed a significant risk of suicide at any time during participation, persons who scored greater than 2 on the suicide item of the HDRS, any clinical significant deterioration during the trial, pregnancy and women not using medically accepted means of birth control.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Petal of <I>Crocus sativus</I>: 20 participants<BR/>Fluoxetine dose: 10 mg/day<BR/>Petal of <I>Crocus sativus</I> dose: 15 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:53:51 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17, remission was defined as an endpoint score of 7 or less</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:53:52 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: independent study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:55:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alby-1993">
<CHAR_METHODS MODIFIED="2013-07-04 12:55:01 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:55:06 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients suffering from a major depressive episode, recurrent depression or disthymia according to DSM-III-R, with a score of at least 25 on the HARD Humeur, Agoisse, Ralentissement, Danger (HARD), Ferreri anxiety rating diagram (FARD), Hopkins Symptom check-list (HSCL).<BR/>Age range: 25-65 years<BR/>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 104 participants<BR/>Tianeptine: 102 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Tianeptine dose: 37.5 mg/day<BR/>Benzodiazepines allowed for severe anxiety or sleep disorders</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:55:15 +0100" MODIFIED_BY="[Empty name]">
<P>HARD and on the FARD scales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:55:16 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:56:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altamura-1989">
<CHAR_METHODS MODIFIED="2013-07-04 12:56:04 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week double-blind randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III criteria for major depressive episode and scoring at least 18 on Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: over 65 years<BR/>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 13 participants<BR/>Amitriptyline: 15 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose: 75 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>Elderly patients only<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:57:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alves-1999">
<CHAR_METHODS MODIFIED="2013-07-04 12:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week double-blind randomised multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:57:28 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients meeting DSM-IV diagnostic criteria for major depression, with a minimum baseline score of 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21), recruited from three clinical sites.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: known sensitivity to venlafaxine or fluoxetine, a history of any clinically significant cardiac, hepatic or renal disease or abnormalities on a screening physical examination, ECG or laboratory tests, with any mental or neurologic disorder and breast-feeding women; used of any investigational drug, antipsychotic drug, electroconvulsive therapy or sumatriptan within 30 days of baseline, fluoxetine within 21 days and MAOIs within 14 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:57:36 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 47 participants<BR/>Venlafaxine: 40 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Venlafaxine dose range: 75-150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:57:44 +0100" MODIFIED_BY="[Empty name]">
<P>Patients in the fluoxetine group had more chronic histories of depression at baseline. Predominance of females in the whole study.<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 12:59:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amini-2005">
<CHAR_METHODS MODIFIED="2012-01-30 11:30:32 +0000" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 12:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>In and outpatients meeting DSM-IV diagnostic criteria for major depression, with a minimum baseline score of 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-60 years<BR/>Exclusion criteria: history of recent suicidal attempt (1 month or less before the study) or actual ideation; pregnancy or lactation; history or current diagnosis (DSM-IV) of dysthymic disorder, bipolar disorder, any psychotic disorder, eating disorders, personality disorders and mental retardation; current diagnosis (DSM-IV) of anxiety disorders (except for specific phobia), mental disorder due to general medical condition, substance or alcohol abuse or dependency (except for nicotine and caffeine) and postpartum depression; current diagnosis of any serious systemic medical illnesses; treatment with any antidepressant drugs within 1 week, or with MAOIs within 5 weeks, or electroconvulsive therapy within 3 months ago; BMI more than 30 and white blood count more than 4000/mm or neutrophil more than 1500/mm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 12:58:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 18 participants<BR/>Mirtazapine: 18 participants<BR/>Fluoxetine dose: 20 mg/day</P>
<P>Mirtazapine dose: 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 12:59:02 +0100" MODIFIED_BY="[Empty name]">
<P>Mean decrease in HDRS-17 score from baseline</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 12:59:04 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:00:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andreoli-2002">
<CHAR_METHODS MODIFIED="2013-07-04 13:00:00 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>In and outpatients meeting DSM-III-R diagnostic criteria for major depression, with a minimum baseline score of 22 on the Hamilton Rating Scale for Depression-21 item (HDRS-21), recruited from 33 clinical sites.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: history of unresponsiveness to antidepressant treatment, association with endocrine disorders, substance abuse, drug hypersensitivity, chronic respiratory insufficiency, or gastro-intestinal, hepatic or renal disease, ECT within 6 months of baseline, high risk of suicide, pregnancy or absence of adequate contraception measures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:00:16 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 127 participants<BR/>Reboxetine: 126 participants<BR/>Placebo: 128 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Reboxetine dose range: 8-10 mg/day<BR/>Chloral hydrate (0.5-1 g) was allowed as hypnotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:00:25 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: absolute change in the HDRS-21 total score<BR/>Secondary outcomes: Clinical Global Impression Scale (CGI) Severity and Improvement, Montgomery and Asberg Scale for Depression (MADRS), Quality of Sleep Questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:00:39 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS total score<BR/>Remission: total score less than 10<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:02:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ansseau-1994">
<CHAR_METHODS MODIFIED="2013-07-04 13:02:11 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 25 on Montgomery and Asberg Scale for Depression (MADRS) and of at least 4 on Clinical Global Impression Scale (CGI).<BR/>Age range: 19-68 years<BR/>Exclusion criteria: serious or uncontrolled medical illness, major anxiety, agitation, suicide risk, resistance during the current episode to at least two antidepressants, substance abuse or dependence, concomitant therapy with lithium, MAOIs, long-acting neuroleptic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:02:23 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 93 participants<BR/>Milnacipram: 97 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Milnacipram dose: 100 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:02:26 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression-24 item (HDRS-24), MADRS, CGI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:03:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Armitage-1997">
<CHAR_METHODS MODIFIED="2013-07-04 13:03:01 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:03:05 +0100" MODIFIED_BY="[Empty name]">
<P>Patients meeting DSM-III-R diagnostic criteria for non psychotic, moderate to severe major depression disorder and a minimum score of 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17). All patients were required to have subjective sleep disturbance (score of 1 or 2 on at least one of the sleep items of the HDRS-17).</P>
<P>Age range: 18-55 years<BR/>Exclusion criteria: patients with current general medical condition, history of head trauma or current DSM-III-R axis I disorder in the categories of organic mental syndromes or disorders, bipolar disorder, schizophrenia, delusional disorder, or psychotic disorder NOS. Shift workers, or those with any evidence of independence sleep disorder (such as narcolepsy, bruxism, sleep apnoea) were ineligible. Patients with a history of psychoactive substance abuse, to be pregnant, lactating, or sexual active without an adequate method of contraception, previous participation in a nefazodone trial, significant suicide risk, or known hypersensitivity to trazodone, etoperidone, fluoxetine or metachlorophenylpiperazine were other exclusion criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:03:13 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 22 participants<BR/>Nefazodone: 12 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Nefazodone dose range: 400-500 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:03:15 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 total score and sleep parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:03:17 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:04:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bakish-1997">
<CHAR_METHODS MODIFIED="2013-07-04 13:03:54 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:03:58 +0100" MODIFIED_BY="[Empty name]">
<P>Patients meeting DSM-III-R diagnostic criteria for major affective disorder, unipolar and had met the diagnostic criteria for major depressive disorder episode for at least one month before entering the study, with a minimum baseline score of 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17), with a score of two or more on item one.</P>
<P>Age range: 23-54 years<BR/>Exclusion criteria: concurrent DSM-III-R Axis I diagnosis or unstable medical condition, suicidal patients or having receiving fluoxetine within 36 days preceding enrolment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 9 participants<BR/>Paroxetine: 12 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Paroxetine dose range: 20-50 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:04:05 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-17 total score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:04:06 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:05:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basterzi-2009">
<CHAR_METHODS MODIFIED="2013-07-04 13:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:05:21 +0100" MODIFIED_BY="[Empty name]">
<P>Patients diagnosed with major depression (MD) or MD-recurrent according to DSM-IV diagnostic criteria.<BR/>Exclusion criteria: any additional axis I or axis II DSM-IV diagnosis, current pregnancy, acute or chronic infections within the past month, autoimmune, allergic, neoplastic, or endocrine disease and other acute physical disorders, including surgery or infarction of the hearth or brain within the past 6 months, patients exposed to any drug including antidepressants, non-steroidal anti-inflammatory drugs and oral contraceptives in the past 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:05:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 21 participants<BR/>Venlafaxine: 22 participants</P>
<P>Placebo: 21 participants<BR/>Fluoxetine dose range: 20-40 mg/day</P>
<P>Venlafaxine dose range: 75-150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:05:48 +0100" MODIFIED_BY="[Empty name]">
<P>Response was defined as a 50% reduction in the index total Hamilton Rating Scale for Depression (HDRS) score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by academy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:07:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-1993a">
<CHAR_METHODS MODIFIED="2013-07-04 13:06:24 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:06:37 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: psychosis, organic mental disorder, substance abuse active within 1 year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 56 participants<BR/>Imipramine: 62 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Imipramine dose range: 150-300 mg/day<BR/>Chloral hydrate (max 1g) and flurazepam (max 30 mg) were allowed as hypnotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:06:50 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Raskin, Covi, Clinical Global Impression Severity and Improvement Scales (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:07:01 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score<BR/>Remission: total score less than 7<BR/>One patient on fluoxetine committed suicide<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:07:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Behnke-2002">
<CHAR_METHODS MODIFIED="2013-07-04 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with ICD-10 depression, with a score between 16 and 24 points on Hamilton Rating Scale for Depression (HDRS-17).<BR/>Age range: 18-73 years<BR/>Exclusion criteria: participation in a clinical study less than 4 weeks, pregnancy and lactation, insufficient contraception, suicide risk, dementia, or other severe intellectual impairment, chronic alcohol or drug abuse or dependence, severe cardiac, liver, kidney or respiratory insufficiency, neoplasia, Parkinson's or Alzheimer's disease, hypersensitivity to an ingredient of the Hypericum perforatum, febrile illness, anaemia, thyroid or parathyroid disease, pituitary insufficiency.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 35 participants<BR/>Hypericum: 35 participants<BR/>Fluoxetine dose: 40 mg/day<BR/>Hypericum dose: 300 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:07:49 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, von Zerssen Depression Scale (VZD), Clinical Global Impression (CGI) Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:10:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennie-1995">
<CHAR_METHODS MODIFIED="2013-07-04 13:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:10:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with a diagnosis of major depression or bipolar disorder, depressed, according to DSM-III-R, scoring at least 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17), and with a higher on the Raskin Depression Scale than on the Covi Anxiety Scale.<BR/>Age: over 18 years<BR/>Exclusion criteria: pregnant or lactating women, women of childbearing potential not practicing a reliable method of contraception, patients with previous treatment with sertraline or fluoxetine, treated with MAOI within two weeks or other antidepressants medication within one week of double-blind therapy, treated with reserpine or methyl-dopa, likely to require additional treatments with psychoactive medication, ECT or intensive psychotherapy during the study; failure to respond to previous antidepressant therapy at clinically appropriate dosages, use of ECT to treat a previous episode of depression, a history of severe allergies or multiple adverse events associated with pharmacotherapy, the presence of significant medical disease; psychiatric history including another Axis I disorder and significant suicide risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:10:24 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 144 participants<BR/>Sertraline: 142 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Sertraline dose range: 50-100 mg/day<BR/>Chloral hydrate (max 1 g) and temazepam (max 20 mg) were allowed as hypnotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:10:27 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17, Clinical Global Impression Severity and Improvement Scales (CGI S-I)<BR/>Secondary outcomes: Hamilton Rating Scale for Anxiety, the Raskin Depression Scale and Covi Anxiety Scale, self-rated Leeds Sleep Questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-10 11:13:55 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with concomitant medical conditions were allowed to participate in the study provided that the conditions were clearly not associated with the illness of the study and that any required medications were not psychoactive agents.</P>
<P>One patient attempted suicide in the fluoxetine group.<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:11:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berlanga-1997">
<CHAR_METHODS MODIFIED="2013-07-04 13:11:17 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised two-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:11:19 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with a diagnosis of moderate to severe major depressive episode without psychotic features or bipolar disorder of the depressed type according to DSM-III-R, with a total score of least 18 points on Hamilton Rating Scale for Depression-17 item (HDRS-17) at baseline.<BR/>Age: over 18 years<BR/>Exclusion criteria: concomitant organic mental disorder, psychoactive substance abuse disorder, schizophrenia or other psychotic disorder or any medical condition that contraindicated treatment with antidepressants; pregnancy or lactating; women of childbearing potential not practicing a reliable method of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:11:32 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 37 participants<BR/>Nefazodone: 37 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Nefazodone: 400-500 mg/day<BR/>Concomitant psychotropic medication was prohibited, but occasionally use of benzodiazepines for severe anxiety or insomnia was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:11:34 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Hamilton Rating Scale for Anxiety, Clinical Global Impression, Patient Global Assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-10 11:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>One patient attempted suicide in the fluoxetine group.<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:14:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Besancon-1993">
<CHAR_METHODS MODIFIED="2013-07-04 13:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:14:11 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with a diagnosis of depressive episode less than 2 months duration, according to DSM-III criteria, with a minimum score of 25 on the Montgomery and Asberg Scale for Depression (MADRS).</P>
<P>Age range: 18-65 years<BR/>Exclusion criteria: absence of resistance to mianserin or fluoxetine, absence of associated psychotropic treatment, with the exception of prazepam (40 mg/day).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:14:18 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 33 participants<BR/>Mianserin: 32 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Mianserin dose range: 60-90 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:14:26 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), Hamilton Rating Scale for Anxiety (HAM-A), MADRS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:15:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bhurgri-2011">
<CHAR_METHODS MODIFIED="2013-07-04 13:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with a diagnosis of major depressive episode, single episode or recurrent, according to DSM-IV criteria, with a minimum score of 18 on the Hamilton Rating Scale for Depression-24 item (HDRS-24).</P>
<P>Age range: 30-50 years</P>
<P>Exclusion criteria: DSM-IV diagnosis of acute or chronic mental disorder, a Mini Mental State Examination score less than 23, concomitant use of any psychotropic drugs (except intermittent use of chloral Hydate or diazepam specifically for sleep), presence of another axis I psychiatric disorder, or any unstable medical condition that might interfere with safety or the interpretation of results.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 96 participants<BR/>Nortriptyline: 96 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Nortriptyline dose range: 25-100 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-24 and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:16:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjerkenstedt-2005">
<CHAR_METHODS MODIFIED="2012-02-13 15:21:55 +0000" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-17 11:42:58 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients meeting the DSM-IV criteria for an acute, recurrent episode of Major Depressive Disorder (MDD) with mild or moderate intensity, aged 18-70 years, a minimum total score of 21 on the Hamilton Rating Scale for Depression-21 item (HDRS-21), history of at least two episodes of non-psychotic MDD, capacity and willingness to give informed consent and to comply with study procedures.<BR/>Exclusion criteria: a diagnosis of psychotic mental disorder, other disorders requiring concomitant psychoactive medication; MAOI treatment within 14 days prior to entry; history of treatment resistant MDD (at least two different antidepressants over 6 weeks at sufficient doses) from at least two previous depressive episodes, risk of suicide; history of seizure disorder, alcohol or substance abuse; other serious unstable acute or chronic medical illness; severely impaired hepatic or renal function, pregnancy, breast feeding, or use of inadequate contraceptives in fertile women; known intolerance or hypersensibility to study medications, substantial placebo response at the end of placebo run-in phase; treatment with any investigation drug during 3 months prior to inclusion; participation in another clinical trial within 30 days before the start of the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 57 participants</P>
<P>Hypericum: 59 participants</P>
<P>Placebo: 58 participants<BR/>Fluoxetine dose: 20 mg/day</P>
<P>Hypericum dose: 900 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in HDRS-21 total score</P>
<P>Secondary endpoint: change in total Montgomery and Asberg Scale for Depression (MADRS) score and Clinical Global Impression (CGI) score</P>
<P>Response was defined as a 50% reduction in the HDRS-21 total score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:16:36 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:18:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bougerol-1997a">
<CHAR_METHODS MODIFIED="2013-07-04 13:17:46 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:17:48 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for a major depressive disorder or bipolar disorder. The severity of depression should be 25 or more on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy, lactation, failure to use a safe contraceptive method, alcohol or drug abuse within the last year, patients with severe somatic, neurological or psychiatric disease, treatment with MAOI within 2 weeks prior to entry the trial, hypersensitivity to study drugs, suicide risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 158 participants<BR/>Citalopram: 158 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Citalopram dose range: 20-40 mg/day<BR/>Concomitant psychotropic medication was prohibited, but use of benzodiazepines for insomnia was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:18:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: MADRS score<BR/>Secondary outcomes: Hamilton Rating Scale for Depression -17 item (HDRS-17), Clinical Global Impression (CGI) scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:19:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bougerol-1997b">
<CHAR_METHODS MODIFIED="2013-07-04 13:18:43 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (primary care) fulfilling DSM-III-R criteria for a major depressive disorder. The severity of depression should be 22 or more on the Montgomery and Asberg Scale for Depression (MADRS) score.<BR/>Age range: 18-70 years<BR/>Exclusion criteria: pregnancy, lactation, failure to use a safe contraceptive method, alcohol or drug abuse within the last year, patients with severe somatic, neurological or psychiatric disease, treatment with MAOI within 2 weeks prior to entry the trial, hypersensitivity to study drugs, suicide risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:19:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 184 participants<BR/>Citalopram: 173 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Citalopram dose: 20 mg/day<BR/>Concomitant psychotropic medication was prohibited, but use of benzodiazepines for insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:19:50 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: MADRS score<BR/>Secondary outcomes: Hamilton Rating Scale for Depression-17 item (HDRS-17), Clinical Global Impression (CGI) scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:20:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bowden-1993">
<CHAR_METHODS MODIFIED="2013-07-04 13:20:31 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a total score of at least 20 on Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-60 years<BR/>Exclusion criteria: use of heterocyclics antidepressant drugs within 7 days or MAOI within 14 days of starting active treatment; patients with other significant medical disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:20:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 28 participants<BR/>Desipramine: 30 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Desipramine dose range: 150-250 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:20:57 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI), Patient self-rated Global Improvement (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:20:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:21:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boyer-1998">
<CHAR_METHODS MODIFIED="2013-07-04 13:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-six-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (primary care) fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 20 at Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy, lactation, failure to use a safe contraceptive method; concurrent major psychiatric disorders, such as anxiety disorder, dementia, somatoform disorders, agoraphobia, social phobia, any history of schizophrenia, psychosis or personality disorder; severe concurrent medical illness; alcohol or drug dependence; serious adverse reactions related to medicines; previous treatment with antidepressant for less than 3 week; major suicide risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:21:49 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 120 participants<BR/>Sertraline: 122 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Sertraline dose range: 50-150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>MADRS and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:21:59 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the MADRS total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:22:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bremner-1984">
<CHAR_METHODS MODIFIED="2013-07-04 13:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:22:35 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling Research Diagnostic Criteria (RDC) criteria for major depressive disorder, with a score of at least 20 on Hamilton Rating Scale for Depression (HDRS), of 8 on Raskin Depression Scale (RDS).<BR/>Age range: 23-69 years<BR/>Exclusion criteria: suicide risk, history of schizophrenia or other psychotic state likely to be aggravated by imipramine, organic brain disease, history of seizures; glaucoma, chronic urinary retention or serious cardiovascular disease; history of multiple adverse reaction to drugs, drug or alcohol abuse, pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:22:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Imipramine: 20 participants<BR/>Fluoxetine dose range: 60-80 mg/day<BR/>Imipramine dose range: 125-300 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, RDS, Covi Anxiety scale (CAS), Clinical Global Impressions (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>Patients over 65 years in the imipramine group only<BR/>Funding: by academy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:25:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bressa-1989">
<CHAR_METHODS MODIFIED="2013-07-04 13:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week, double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:25:13 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depression, with a score of at least 20 on Hamilton Rating Scale for Depression (HDRS).</P>
<P>Age: not stated<BR/>Exclusion criteria: suicidal ideas, psychosis, seizure disorders, serious cardiac, renal or hepatic disease, alcoholism or drug abuse, use of antidepressant drug with the preceding 14 days, concurrent medication potentially interacting.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:25:20 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 18 participants</P>
<P>Imipramine: 12 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>imipramine dose range: 75-175 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:25:21 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI) scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:25:22 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:26:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byerley-1988">
<CHAR_METHODS MODIFIED="2013-07-04 13:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depression (duration of at least 1 month) with a score of at least 20 on Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age: not stated<BR/>Exclusion criteria: psychotic symptoms bipolar illness, schizophrenia, active drug or alcohol abuse, significant medical illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 32 participants<BR/>Imipramine: 34 participants<BR/>Placebo: 29 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Imipramine dose range: 150-300 mg/day<BR/>Intermittent administration of flurazepam for insomnia (15-30 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:26:16 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI) scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:26:17 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:27:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cassano-2002">
<CHAR_METHODS MODIFIED="2013-07-04 13:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty-two week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:27:42 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling ICD-10 criteria for major depression, with a Mini Mental State Examination (MMSE) score of at least 22 and a Hamilton Rating Scale for Depression (HDRS-21) score of at least 18.<BR/>Age: over 65 years<BR/>Exclusion criteria: concurrent major medical disorders, dementia, any history of schizophrenia, psychosis; alcohol or drug dependence; major suicide risk; use of long-acting neuroleptic drugs within 6 months or oral neuroleptics within 2 weeks before the study entry; ECT; daily use of benzodiazepines within 8 weeks or SSRI within 4 weeks, MAOI within 3 weeks, TCA within 1 week before the study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 119 participants<BR/>Paroxetine: 123 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Paroxetine dose range: 20-40 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:27:52 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Anxiety Scale, Buschke Selective Reminding Test (BSRT), Blessed Information and Memory Test (BIMT), Clifton Assessment Scale (CLAS), Cancellation Task Test (CTT), Wechsler Paried Word Test (WPW), Mini Mental Sate Evaluation (MMSE) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Depression response: total score less than 10 on the HDRS-21<BR/>Anxiety response: total score less than 8 on the Covi Anxiety scale (CAS)<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:29:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1985">
<CHAR_METHODS MODIFIED="2013-07-04 13:28:36 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling Research Diagnostic Criteria (RDC) criteria for major depressive disorder, with a score of at least 21 on Hamilton Rating Scale for Depression (HDRS-17) and of at least 8 on the Raskin Depression Scale (RAS).</P>
<P>Age range: 21-70 years<BR/>Exclusion criteria: physical illness, schizophrenia, schizoaffective illness, chronic or acute organic brain syndrome, mental deficiency, alcoholism, epilepsy, drug addiction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:28:48 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 23 participants<BR/>Amitriptyline: 28 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Amitriptyline dose range: 100-300 mg/day<BR/>Benzodiazepines were allowed for agitation and insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17, Clinical Global Impression (CGI), Efficacy Index-Side Effects rating (EISE)</P>
<P>Secondary outcomes: Hamilton Rating Scale for Anxiety (HAM-A) and Zung Depression Scale (SDS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:29:02 +0100" MODIFIED_BY="[Empty name]">
<P>One patient attempted suicide in the fluoxetine group<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:30:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1999">
<CHAR_METHODS MODIFIED="2013-07-04 13:29:41 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:29:45 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III criteria for major depressive disorder, with a score of at least 20 on Hamilton Rating Scale for Depression (HDRS-21).</P>
<P>Age: not stated<BR/>Exclusion criteria: significant concurrent illness including renal, hepatic, cardiovascular or neurological disease, non-stabilised diabetes, other current Axis I psychiatric diagnosis; organic brain syndrome, past or present abuse of alcohol or drugs; pregnancy or lactating; ECT; continuous lithium therapy in preceding 2 months, use of important psychotropic drug, current therapy with an anticoagulant or type 1 antiarrhythmic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:29:57 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 101 participants<BR/>Paroxetine: 102 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Paroxetine dose range: 20-50 mg/day<BR/>Chloral hydrate was allowed just during the first two weeks of the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:30:00 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS-21, Clinical Global Impression<BR/>Secondary outcomes: HDRS-21 anxiety and somatization scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-21 total score and/or a total score less than 10<BR/>Two participants dropped out (1 in the fluoxetine and 1 in the paroxetine group) due to attempted suicide<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:31:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CL3_x002d_022">
<CHAR_METHODS MODIFIED="2013-07-04 13:30:46 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-IV criteria for single or recurrent episode of Major Depressive Disorder (MDD), with or without melancholic features, without atypical features, without psychotic features and a score of at least 22 on Hamilton Rating Scale for Depression (HDRS). Morover decrease in HDRS total score should not be more than 20% between start of run-in and inclusion visit and a severity of illness of at least 4 on CGI.</P>
<P>Age range: 18-59 years<BR/>Exclusion criteria: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:31:02 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 137 participants<BR/>Agomelatine: 133 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Agomelatine dose: 25 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:31:03 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS score<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:31:05 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:31:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CL3_x002d_024">
<CHAR_METHODS MODIFIED="2013-07-04 13:31:39 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:31:45 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-IV criteria for single or recurrent episode of Major Depressive Disorder (MDD), with or without melancholic features, without atypical features, without psychotic features and a score of at least 22 on Hamilton Rating Scale for Depression (HDRS).</P>
<P>Age range: 18-59 years<BR/>Exclusion criteria: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 148 participants<BR/>Agomelatine 25mg: 150 participants</P>
<P>Agomelatine 50mg: 151 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Agomelatine dose range: 25-50 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS score<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:32:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clayton-2003">
<CHAR_METHODS MODIFIED="2013-07-04 13:32:22 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 22 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: other psychiatric diagnoses, have received Tricyclics (TCAs) within the previous 14 days and fluoxetine within 14 days or 28 days when resistant to treatment, uncontrolled medical or metabolic illness, use of illicit drugs, history of DSM-IV substance abuse in the previous 12 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:32:34 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 150 participants<BR/>Reboxetine: 150 participants<BR/>Fluoxetine dose: 20-40 mg/day<BR/>Reboxetine dose: 8-10 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS score</P>
<P>Response: decrease of at least 50% in the HDRS score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:32:39 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:33:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clerc-1994">
<CHAR_METHODS MODIFIED="2013-07-04 13:33:23 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:33:29 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depressive disorder, with melancholia, with a score of at least 25 on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age: over 18 years<BR/>Exclusion criteria: medical illness, psychotherapy or ECT during the study duration<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 34 participants<BR/>Venlafaxine: 34 participants<BR/>Fluoxetine dose: 40 mg/day<BR/>Venlafaxine dose: 200 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Hamilton Rating Scale for Depression (HDRS-21), MADRS, Clinical Global Impression Scale (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:33:40 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS or in the MADRS total scores, or a CGI score of 1 or 2<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:34:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohn-1985">
<CHAR_METHODS MODIFIED="2013-07-04 13:34:13 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:34:17 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depressive illness, with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 20-64 years<BR/>Exclusion criteria: concomitant physical condition or history of conditions that could interfere with therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 54 participants<BR/>Imipramine: 54 participants<BR/>Placebo: 57 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Imipramine dose range: 75-300 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS), Clinical Global Impression (CGI) Severity and Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>One patient attempted suicide in the fluoxetine group<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:35:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corne-1989">
<CHAR_METHODS MODIFIED="2013-07-04 13:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (general practice) fulfilling Research Diagnostic Criteria (RDC) criteria for primary unipolar major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS-17).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: physical illness, use of other antidepressant medication, pregnancy, potential childbearing, lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:35:48 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 49 participants<BR/>Dothiepin: 51 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Dothiepine dose range: 50-100 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:35:50 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:35:51 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:36:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corrigan-2000">
<CHAR_METHODS MODIFIED="2013-07-04 13:36:32 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III-R criteria for major depression (single or recurrent episode, with or without melancholia and without psychotic features).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: clinically relevant disease, clinically significant changes on the ECG, lifetime history of hypomania/mania, psychotic disorder, dementia, borderline or antisocial personality disorders, history of a serious suicidal attempting the past 12 months, pregnancy or lactation, non-responders to at least two trials of antidepressant treatment in the past, use of fluoxetine in the past 6 months or use of another investigational drug within one month prior to the baseline visit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 35 participants<BR/>Pramipexole 1 mg: 35 participants<BR/>Pramipexole 5 mg: 33 participants<BR/>Placebo: 35 participants<BR/>Fluoxetine dose: 20 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Hamilton Rating Scale for Depression (HDRS-17), Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) Severity<BR/>Secondary outcomes: Beck Depression Inventory, CGI Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:36:47 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:38:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costa-e-Silva-1998">
<CHAR_METHODS MODIFIED="2013-07-04 13:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) and depressive symptoms for at least 1 month before study entry.<BR/>Age range: 18-60 years<BR/>Exclusion criteria: pregnancy, absence of methods of contraception, known sensitivity to fluoxetine or venlafaxine, history of significant cardiac, renal or hepatic disease, clinically significant abnormalities on a screening examination, ECG, laboratory tests, acute suicide tendency, seizures, history or presence of any psychotic disorder not associated with depression, drug or alcohol dependence within the past year, psychotherapy, use of fluoxetine, antipsychotic drugs, ECT, MAOI within the past 14 days, any other antidepressant, anxiolitics, sedative-hypnotic drugs (but zopiclone) within 7 days before baseline.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:37:59 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 186 participants<BR/>Venlafaxine: 196 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Venlafaxine dose range: 75-125 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:38:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) Severity and Improvement<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:38:06 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS or in the MADRS; or a CGI-I score of 1 or 2<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:38:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalery-1997">
<CHAR_METHODS MODIFIED="2013-07-04 13:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:38:48 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III-R criteria for major depression (single or recurrent), with a score of at least 20 on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 82 participants<BR/>Amineptine: 87 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amineptine dose: 200 mg/day<BR/>Anxiolitics and non-barbiturate hypnotics were allowed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:38:57 +0100" MODIFIED_BY="[Empty name]">
<P>MADRS, Clinical Global Impression (CGI), Mood Anxiety Retardation and Danger (MARD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:38:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:40:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalery-2003">
<CHAR_METHODS MODIFIED="2013-07-04 13:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: acute suicidal ideation, dementia, history of epilepsy, alcoholism in the previous 6 months, other psychoactive substance, pregnancy, lactation, absence of contraception, hepatic, renal, pulmonary, endocrine, cardiac disease, previous failure with SSRI therapy, concomitant use of lithium, warfarin, carbamazepine, theophyline, insulin, hypoglycaemic agents, MAOI or ECT in the previous 2 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:39:55 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 94 participants<BR/>Fluvoxamine: 90 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Fluvoxamine dose: 100 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:40:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: area under the curve of the change in HDRS-17 total score from baseline<BR/>Secondary outcomes: numbers of HDRS-17 responders, Clinical Global Impression (CGI) Severity and Improvement, Clinical Anxiety Scale (CAS), Irritability Depression and Anxiety Scale (IDAS) total score and sub-scores, Beck Scale for Suicide Ideation (SSI), Sleep Evaluation and the HDRS-17 total and subtotal scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:40:05 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:40:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Jonghe-1991">
<CHAR_METHODS MODIFIED="2013-07-04 13:40:41 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised, two-site study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:40:47 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depressive disorder without psychotic features, with a score of at least 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: high suicide risk, other psychiatric diagnosis, somatic disease which could contraindicate treatment with fluoxetine or maprotiline, history of hypersensitivity, severe allergies, multiple severe reactions to drugs, lactation, pregnancy or pregnancy wish, MAOI use within 2 weeks before starting the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:40:55 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 30 participants<BR/>Maprotiline: 35 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Maprotiline dose range: 50-150 mg/day<BR/>Only oxazepam was allowed as hypnotic or anxiolytic, if absolutely required</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:40:57 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS), Clinical Global Impression (CGI) Severity and Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:40:58 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:42:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Nayer-2002">
<CHAR_METHODS MODIFIED="2013-07-04 13:41:37 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with a score between 18 and 25 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) and minimum baseline of 8 on the Covi Anxiety Scale (CAS), and considered by the investigator to be moderately depressed.<BR/>Age range: 18-70 years<BR/>Exclusion criteria: pregnancy, childbearing potential, absence of contraceptive method, psychiatric disease or personality disorder, known clinically significant laboratory abnormalities, use of antipsychotic drug or ECT within 30 days of baseline, use of fluoxetine within 21 and MAOI within 14 days before baseline; patients who previously failed to respond to venlafaxine or fluoxetine, high suicide risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:41:57 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 73 participants<BR/>Venlafaxine: 73 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Venlafaxine dose range: 75-150 mg/day<BR/>Lormetazepam was allowed (2 mg) as hypnotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) Severity<BR/>Secondary outcome: CAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-21 or in the MADRS total score<BR/>Remission: total score less than 8 on the HDRS-21<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:43:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Ronchi-1998">
<CHAR_METHODS MODIFIED="2013-07-04 13:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>Ten-week double-blind, randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:42:43 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 16 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: over 60 years<BR/>Exclusion criteria: mental organic disorder, Mini Mental State Examination (MMSE) less than 24, high suicide risk, history of alcohol or drug abuse, severe physical illness, epilepsy, schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:42:55 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 32 participants<BR/>Amitriptyline: 33 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose range: 50-100 mg/day<BR/>Patients taking lorazepam 5 mg/day for at least 6 months before enrolment were allowed to continue; triazolam was allowed (0.25 mg/day) during the first 2 weeks for insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:42:57 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Montgomery and Asberg Scale for Depression (MADRS), Covi Anxiety Scale (CAS), Clinical Global Impression (CGI) Severity and Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:43:02 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-17 total score or a total score less than 10<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:43:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Wilde-1993">
<CHAR_METHODS MODIFIED="2013-07-04 13:43:37 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:43:39 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III criteria for major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy, lactation, severe concomitant disease, schizophrenia, abuse of alcohol or drugs, severe risk of suicide, ECT in the previous 3 months, MAOI or oral neuroleptics in the previous 14 days, depot neuroleptics in the previous 4 weeks, patients receiving lithium.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:43:48 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 41 participants<BR/>Paroxetine: 37 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Paroxetine dose range: 20-40 mg/day<BR/>Temazepam or other short-acting benzodiazepines were permitted as hypnotic<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:43:52 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Hopkins Symptoms Check List (HSLC), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:43:54 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:44:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Debus-1988">
<CHAR_METHODS MODIFIED="2013-07-04 13:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age: over 18 years<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception, history of glaucoma, suicidal risk, history serious medical conditions, seizures, history of severe allergies, multiple adverse medication reactions or known allergy, other DSM-III diagnosis including substance abuse, bipolar disorder, schizophrenia, schizoaffective disorder, paranoid disorder, organic mental disorder, other psychotropic medications, with the exception of some hypnotics, use of fluoxetine or MAOI within the past 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:44:38 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 22 participants<BR/>Trazodone: 21 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Trazodone dose range: 50-400 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Inventory for Depressive Symptomatology - Clinician Version (IDS-C)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:44:42 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:45:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demyttenaere-1998">
<CHAR_METHODS MODIFIED="2013-07-04 13:45:09 +0100" MODIFIED_BY="[Empty name]">
<P>Nine-week double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 15 on the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age range: 18-60 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:45:27 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 35 participants<BR/>Amitriptyline: 31 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose: 150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:45:32 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-21 total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:46:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demyttenaere-2004">
<CHAR_METHODS MODIFIED="2013-07-04 13:46:11 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-two-week double-blind randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:46:26 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depression disorder.<BR/>Age range: 22-63 years<BR/>Exclusion criteria: other DSM-IV Axis I disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 42 participants<BR/>Paroxetine: 43 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Paroxetine dose: 20 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS-17)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:46:34 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:47:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diaz-Martinez-1998">
<CHAR_METHODS MODIFIED="2013-07-04 13:47:11 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:47:13 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-55 years<BR/>Exclusion criteria: lactation, childbearing potential, previous treatment with venlafaxine or fluoxetine, history of clinically significant medical disease, abnormalities on ECG or laboratory tests, acute suicidal tendencies, history of seizure disorder, organic mental disorder, bipolar disorder, history of any psychotic disorder not associated with depression, current use of investigational drugs, antipsychotic drugs, ECT within the previous 30 days or MAOI or paroxetine within the previous 14 days, use of antidepressant or hypnotic drugs, but zopiclone (7.5 mg), history of drug or alcohol abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:47:27 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 75 participants<BR/>Venlafaxine: 70 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Venlafaxine dose range: 75-150 mg/day<BR/>Only zopiclone was allowed for insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression, Symptom Checklist 61 Item (SCL-61)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:47:31 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:48:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dierick-1996">
<CHAR_METHODS MODIFIED="2013-07-04 13:48:11 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:48:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age range: 18-83 years<BR/>Exclusion criteria: history of clinically significant disease, abnormalities on ECG or laboratory tests, acute suicidal tendencies, history of seizure disorder, organic mental disorder, bipolar disorder or personality disorder, history of any psychotic disorder not associated with depression, venlafaxine or fluoxetine hypersensitivity or use within 2 months of baseline, current use of investigational drugs, antipsychotic drugs, ECT or MAOI within the previous 14 days, use of antidepressant drug within 7 days, use of any anxiolytic that could not be withdrawn at baseline, drug or alcohol abuse within 2 years of the start of the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 161 participants<BR/>Venlafaxine: 153 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Venlafaxine dose range: 75-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:48:28 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) scales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS or MADRS total score, or a score of 1 or 2 on the CGI<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:49:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dowling-1990">
<CHAR_METHODS MODIFIED="2013-07-04 13:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:49:17 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depression (unipolar), with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS-17).<BR/>Age range: 18-75 years<BR/>Exclusion criteria: significant physical illness, lactation, pregnancy, history of schizophrenia or drug or alcohol abuse, current use of antidepressant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:49:26 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 30 participants<BR/>Dothiepin: 30 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Dothiepine dose range: 100-200 mg/day<BR/>Benzodiazepines were allowed for sedation at the discretion of the doctor</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:49:27 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) Severity and Improvement, Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:49:28 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:50:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duarte-1996">
<CHAR_METHODS MODIFIED="2013-07-04 13:50:14 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:50:23 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for double depression (dysthymia and major depression), with a score of at least 16 on the Hamilton Rating Scale for Depression (HDRS).</P>
<P>Age range: 18-65 years<BR/>Exclusion criteria: suicidal tendencies, delusional depression, severe organic disease, alcoholism, drug abuse, ongoing ECT or structured psychotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:50:31 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 21 participants<BR/>Moclobemide: 21 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Moclobemide dose: 300 mg/day<BR/>Use of single benzodiazepines was allowed at discretion of the doctor</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:50:35 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: percentage of responders defined as decrease of at least 50% in the HDRS<BR/>Secondary outcomes: endpoint score at HDRS, percentage of end of treatment Clinical Global Impression (CGI) very good and good responses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:50:37 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:51:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fabre-1991">
<CHAR_METHODS MODIFIED="2013-07-04 13:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:51:21 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression (single episode or recurrent).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: concurrent diagnosis of bipolar disorder or schizophrenia, hyperactivity or agitation, presence of hyper thyroidism or a clinically unstable medical condition, history of narrow angle glaucoma, urinary retention, seizures or substance abuse, MAOI use within 14 days of baseline, pregnancy, lactation, potential childbearing, history of allergy to the study drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 103 participants<BR/>Nortriptyline: 102 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Nortriptyline dose range: 50-100 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:51:40 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), Zung Depression Scale, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:52:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fairweather-1999">
<CHAR_METHODS MODIFIED="2013-07-04 13:52:12 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:52:24 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (general practice) fulfilling DSM-III-R criteria for major depression.</P>
<P>Age range: 18-70 years<BR/>Exclusion criteria: concurrent illness, concomitant use of psychotropic medication, long-term treatment with benzodiazepines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 42 participants<BR/>Dothiepin: 42 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Dothiepine dose range: 75-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), Leeds Sleep Evaluation Questionnaire (LSEQ)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:53:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Falk-1989">
<CHAR_METHODS MODIFIED="2013-07-04 13:53:17 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:53:18 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for unipolar major depression (single or recurrent), with the present episode lasting 4 weeks or more and with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).</P>
<P>Age: over 62 years<BR/>Exclusion criteria: serious medical illness, unstable cardiac arrhythmia, seizure disorders, history of allergy to either drug, severe psychosis, suicidal symptoms or DSM-II diagnosis of schizophrenia, bipolar disorder, organic mental disorder, substance abuse disorder within the past year or paranoid disorders, use of either drugs within 1 month preceding study entry, MAOI in the prior 14 days or other antidepressants at the time of entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:53:33 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 14 participants<BR/>Trazodone: 13 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Trazodone dose range: 50-400 mg/day<BR/>Only use of benzodiazepines and chloral hydrate for sleep were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:53:35 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI), Treatment Emergent Symptom Scale (TESS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:53:37 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:54:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fava-1998">
<CHAR_METHODS MODIFIED="2013-07-04 13:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:54:38 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for moderate to moderately severe major depression without a history of mania or hypomania, with a score of at least 18 on the Hamilton Rating Scale for Depression-21 item (HDRS-21), of at least 8 on the Raskin Depression Scale (and grater than Covi Anxiety Scale (CAS) score).<BR/>Mean age: 41.3 years<BR/>Exclusion criteria: schizophrenia, adjustment disorder, bipolar disorder, panic disorder, social phobia, obsessive compulsive disorder, psychotic depression, atypical depression, serious concomitant medical illness, significant abnormal laboratory values, history of seizure disorder, high suicidal risk, recent history of alcohol or drug abuse, use other psychotropic drug within 14 days of baseline, ECT within 3 months of baseline, any investigational drug within 30 days of baseline, previous treatment with paroxetine, pregnancy, childbearing potential without contraceptive.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 54 participants<BR/>Paroxetine: 55 participants<BR/>Placebo: 19 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Paroxetine dose range: 20-50 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Covy Anxiety Scale (CAS), Raskin Depression Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:54:55 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-21 total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:56:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fava-2002">
<CHAR_METHODS MODIFIED="2013-07-04 13:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>Ten-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:55:46 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depression or atypical major depression, with a baseline score of at least 16 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: over 18 years<BR/>Exclusion criteria: pregnancy, lactation, suicide risk, serious medical illness, seizure disorders, presence of any of the following diagnosis: organic mental disorder, substance use disorder, schizophrenia, delusional disorder, psychotic disorders not elsewhere classified, bipolar disorder, antisocial personality disorder, mood congruent or mood incongruent features, history of multiple adverse drug reactions, concomitant use of any antidepressants, anxiolytic or other psychotropic medication within 7 days prior study entry, with the exception of chloral hydrate, hyper- or hypothyroidism, use of MAOI within 2 weeks of active therapy, lack of response to the treatment of a current major depressive episode by any SSRI.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:55:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 92 participants<BR/>Sertraline: 96 participants<BR/>Paroxetine: 96 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Sertraline dose range: 50-200 mg/day<BR/>Paroxetine dose range: 20-60 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: total score on the HDRS-17</P>
<P>Secondary outcomes: improvement on the Clinical Global Impression (CGI) Severity scale and HDRS sleep disturbance, cognitive disturbance (COG) factors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:56:12 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-17 total<BR/>Remission: total score of maximum 7 on the HDRS-17 at the endpoint<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:58:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fava-2005">
<CHAR_METHODS MODIFIED="2013-07-04 13:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for current major depression episode of at lest 2 weeks duration, Hamilton Rating Scale for Depression (HDRS) score at least 16.</P>
<P>Age range: 18-65 years</P>
<P>Inclusion criteria: negative pregnancy test within 5 days before study start in women of childbearing potential, use of adequate contraception.<BR/>
</P>
<P>Exclusion criteria: pregnancy, lactation, or non use of medically accepted contraception, current serious suicide or homicidal risk, serious or instable medical illness, history of seizure disorders, presence of any of the following diagnosis: organic mental disorder, substance use disorder, including alcohol, active within the last 6 months, schizophrenia, delusional disorder, psychotic disorders not elsewhere classified, bipolar disorder, antisocial personality disorder; history of multiple adverse drug reactions or allergy to the study drugs; mood congruent or mood incongruent psychotic features, concomitant use of other psychotropic drugs within 14 days before baseline, other investigational psychotropic drug within 40 days, fluoxetine within 40 days or any other investigational drug within 1 month, hypothyroidism; failure to respond during the course of current MDE to at least 2 adequate antidepressant trials; any other condition which, in the investigator judgement, may pose significant risk to the patient's health or may decrease the chances of obtaining reliable data to achieve the objectives of the study; mental condition rendering the patients unable to understand nature, scope and risk of the study; history or suspicion of unreality, poor cooperation, or non compliance with medical treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:58:06 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 47 participants<BR/>St John's wort: 45 participants<BR/>Fluoxetine dose: 20 mg/day</P>
<P>St John's wort dose: 900 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:57:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: total score on the HDRS</P>
<P>Secondary outcome: improvement on the Clinical Global Impression (CGI) scale and Beck Depression Inventory (BDI) score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:57:07 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS total<BR/>Remission: total score of maximum 8 on the HDRS at the endpoint<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:58:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fawcett-1989">
<CHAR_METHODS MODIFIED="2013-07-04 13:58:24 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:58:27 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for unipolar major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Mean age: 39.9 in the fluoxetine group, 44.5 in the amitriptyline one<BR/>Exclusion criteria: significant medical illness, concomitant medication with any potential psychiatric side effect, psychotic features, any other DSM-III Axis I diagnosis other than unipolar major depression.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:58:35 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Amitriptyline: 20 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Amitriptyline dose range: 50-200 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression for Severity and Improvement (CGI S-I), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement: a decrease of at least 50% on the total HDRS-21 score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 13:59:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feighner-1985a">
<CHAR_METHODS MODIFIED="2013-07-04 13:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 13:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for unipolar major depression (single or recurrent episode), with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS) and Raskin Depression Scale (RDS) score of at least 8 and equal or greater to the Covi Anxiety Scale (CAS) score.<BR/>Age: over 64 years<BR/>Exclusion criteria: history of, or current conditions that might put them at risk or that precluded evaluation of the results</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 13:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 78 participants<BR/>Doxepine: 79 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Doxepine dose range: 50-250 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 13:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI) Severity, RDS, CAS scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 13:59:30 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:00:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feighner-1985b">
<CHAR_METHODS MODIFIED="2013-07-04 13:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:00:02 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling Research Diagnostic Criteria criteria for unipolar major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS) and Raskin Depression Scale (RDS) score of at least 8.<BR/>Age range: 19-69 years<BR/>Exclusion criteria: serious illness or condition that contraindicated the use of amitriptyline or that could make patients unsuitable for study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:00:12 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 22 participants<BR/>Amitriptyline: 22 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Amitriptyline dose range: 75-300 mg/day<BR/>Only chloral hydrate (max 1 g) was allowed for sleep and one benzodiazepine for agitation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:00:13 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, RAS, Covi Anxiety Scale (CAS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:00:16 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:01:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feighner-1989">
<CHAR_METHODS MODIFIED="2013-07-04 14:00:44 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for unipolar major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS) and Raskin Depression Scale (RDS) score of at least 8 and equal or greater to the Covi Anxiety score (CAS).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: pregnancy, non-contraception, serious suicide risk, organic brain syndrome, schizophrenia, seizures, drug or alcohol abuse within the past year, contraindication to imipramine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:01:00 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 61 participants<BR/>Imipramine: 58 participants<BR/>Placebo: 59 participants<BR/>Fluoxetine dose range: not stated<BR/>Imipramine dose range: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:01:02 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, RDS, CAS, Clinical Global Impression (CGI), Patient Global Improvement Scale (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement: a moderately or markedly improved on the CGI or a decrease of at least 50% on the total HDRS score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:01:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feighner-1991">
<CHAR_METHODS MODIFIED="2013-07-04 14:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind two-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for non-psychotic major depressive episode, lasting between 4 weeks to 2 years, single or recurrent, which was not secondary to another pre-existing psychiatric or medical condition, with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age: over 18 years<BR/>Exclusion criteria: seizures, current diagnosis or history of hepatic or renal dysfunction, anorexia or bulimia, other unstable medical disorder, pregnancy, lactation, childbearing potential, alcohol or substance abuse within the past year, use of psychoactive drug within 1 week of baseline, previous treatment with bupropion or fluoxetine, high suicidal risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:01:51 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 62 participants<BR/>Bupropion: 61 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Bupropion dose range: 225-450 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:01:53 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI) Severity and Improvement, Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:02:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferreri-1989">
<CHAR_METHODS MODIFIED="2013-07-04 14:02:24 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depression, with a score between 18 and 25 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) .<BR/>Age range: 18-65 years<BR/>Exclusion criteria: organic brain disease, seizures, other serious illness, hyperthyroidism, allergy, drug or alcohol abuse, use of MAOI within 2 week, serious suicidal risk, pregnancy and lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 31 participants<BR/>Amineptine: 32 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amineptine dose: 200 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) Severity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:02:41 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:03:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finkel-1999">
<CHAR_METHODS MODIFIED="2013-07-04 14:03:16 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 18 on the Hamilton Rating Scale for Depression (HDRS-24) .<BR/>Age: over 70 years<BR/>Exclusion criteria: any significant medical problem, criteria for any other Axis I psychiatric or neurological disorder, any cognitive impairment, suicidal risk, drug abuse or dependence, any medical contraindication to study medications, history of failure to respond to either ECT or adequate trials with two or more antidepressants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:03:29 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 33 participants<BR/>Sertraline: 42 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Sertraline dose range: 50-100 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-10 13:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-24, Hamilton Rating Scale for Anxiety (HAM-A), Clinical Global Impression (CGI) Severity and Improvement, Profile Of Mood States (POMS), Quality of Life Enjoyment and satisfaction Questionnaire (Q-LES-Q).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:03:36 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-24 total<BR/>Remission: total score of maximum 7 on the HDRS-24 at the week 10 and 12<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:04:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gagiano-1993">
<CHAR_METHODS MODIFIED="2013-07-04 14:04:00 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:04:10 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 18 on the Hamilton Rating Scale for Depression- 21 item (HDRS-21).<BR/>Age: 18-65 years<BR/>Exclusion criteria: pregnancy, lactation, hepatic, renal, neurological, gastrointestinal, or severe cardiovascular disease, schizophrenia, organic brain syndrome, unstable diabetes, recent treatment with MAOI, neuroleptics, lithium therapy, ECTin the previous 3 months, alcohol or drug abuse, severe risk of suicide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 45 participants<BR/>Paroxetine: 45 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Paroxetine dose range: 20-40 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:05:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gattaz-1995">
<CHAR_METHODS MODIFIED="2013-07-04 14:04:44 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week randomised, double-blind, two-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: serious allergies, drug and alcohol abuse, resistance to a previous treatment with an antidepressant prescribed at an effective dosage during at least 3 weeks, and therapy with MAOI in the last 14 days, or with fluoxetine in the last 5 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:05:00 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 34 participants<BR/>Moclobemide: 36 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 300-600 mg/day<BR/>Chloral hydrate and low dose of diazepam as hypnotic or/and anxiolytic were allowed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:05:02 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:05:05 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-17 total<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:06:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geerts-1994">
<CHAR_METHODS MODIFIED="2013-07-04 14:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:06:10 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depression without psychotic features, with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: suicidal intent, any other psychiatric illness, severe organic disease, alcoholism and drug abuse, use of MAOI in the preceding 2 week, use of an antidepressant drug in the previous 4 days, or any investigational drug in the preceding 4 weeks, patients who ever received fluoxetine or moclobemide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:06:19 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 25 participants<BR/>Moclobemide: 24 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 300-600 mg/day<BR/>Only lithium and bromazepam were allowed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>Final score of less than 10 or a decrease of at least 50% from baseline on the HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:06:25 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:07:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geretsegger-1994">
<CHAR_METHODS MODIFIED="2013-07-04 14:06:55 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:06:57 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression-17 item (HDRS).<BR/>Age range: 61-85 years<BR/>Exclusion criteria: improvement of more than 20% on the HDRS during the placebo run-in period (3-7 days), severe renal, hepatic or gastrointestinal disease, cardiovascular disease, glaucoma, neurological disease, senile dementia, schizophrenia, organic brain syndrome, prostatic hypertrophy or diabetes, or were considered at serious risk of suicide, lithium therapy, electroconvulsive therapy during the previous 3 months, monoamine oxidase inhibitors or oral neuroleptics in the previous 2 weeks, depot neuroleptics in the previous 4 weeks and know alcohol abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 52 participants<BR/>Paroxetine: 54 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Paroxetine dose range: 20-40 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:07:19 +0100" MODIFIED_BY="[Empty name]">
<P>Endpoint score on HDRS-17, on Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) and on Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:08:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghaeli-2004">
<CHAR_METHODS MODIFIED="2013-07-04 14:07:53 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:07:55 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for major depression disorder.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: diabetes mellitus, history of myocardial infarction and other heart disease, pregnancy, electroconvulsive therapy within 6 months before the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:08:07 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 19 participants<BR/>Imiprimamine: 24 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Imipramine dose range: 75-200 mg/day</P>
<P>Benzodiazepines allowed when needed for anxiety, agitation or sleep<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:08:22 +0100" MODIFIED_BY="[Empty name]">
<P>Priamry outcome: fasting blood glucose (FBG) levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:08:11 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:09:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gillin-1997">
<CHAR_METHODS MODIFIED="2013-07-04 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:09:06 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for non-psychotic, moderate to severe major depressive disorder, with a score of at least 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 21-55 years<BR/>Exclusion criteria: patients engaged in shift work and with a primary sleep disorder independent of affective disturbance, current general medical condition, history of psychoactive substance use disorder within 12 months prior to study entry, current DSM-III Axis I disorder (organic mental syndrome, bipolar disorder-depressive, and schizophrenia, delusional disorder, psychotic disorder NOS), pregnancy, lactation, not use of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Nefazodone: 24 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Nefazodone dose range: 200-500 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Inventory of Depressive Symptomatology (IDS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:10:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ginestet-1989">
<CHAR_METHODS MODIFIED="2013-07-04 14:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:09:58 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depression with melancholia, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: known hypersensitivity to clomipramine, narrow angle glaucoma, risk of chronic urinary retention, no improvement or lack of efficacy with previous treatment with clomipramine at least 200 mg/day during 6 weeks, organic brain disease, history of seizures, serious illness including cardiovascular, hepatic, renal, respiratory, hematologic disease, hyperthyroidism, history of severe allergy or multiple adverse drug reaction, recent history of drug or alcohol abuse, concurrent administration of other psychotropic drug except some benzodiazepines, use of MAOIs, pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:10:11 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 28 participants<BR/>Clomipramine: 26 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Clomipramine dose range: 50-200 mg/day<BR/>Only oxazepam (50-300 mg/day) as hypnotic or anxiolytic was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:10:13 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Covi Anxiety Scale (CAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:11:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldstein-2002">
<CHAR_METHODS MODIFIED="2013-07-04 14:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for non-psychotic major depressive disorder, with a score of at least 15 on the Hamilton Rating Scale for Depression-17 item (HDRS-17) and at least 4 on the Clinical Global Impression-Severity of Illness (CGI).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: any primary DSM-IV Axis I diagnosis other than major depressive disorder or any anxiety disorder as a primary diagnosis within the past year with the exception of specific phobias, history of substance abuse or dependence within the past year or a positive urine drug screen at study entry, failure of 2 or more adequate courses of antidepressant therapy during the present episode.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:11:10 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 33 participants<BR/>Duloxetine: 70 participants<BR/>Placebo: 70 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Duloxetine dose range: 40-120 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:11:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17<BR/>Secondary outcomes: Montgomery and Asberg Scale for Depression (MADRS), CGI, Patient Global Impresion (PGI), Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:12:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-29060_x002f_356">
<CHAR_METHODS MODIFIED="2013-07-04 14:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week, multicentre, randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:11:59 +0100" MODIFIED_BY="[Empty name]">
<P>Patients suffering from a major depressive episode according to DSM-III-R, with a baseline score on Hamilton Rating Scale for Depression-17 Item (HDRS-17) of at least 18, and an HDRS item 10 score of 1 or more.<BR/>Age: 18 years or more<BR/>Exclusion criteria: severe co-existing disease not stabilised with medication, neurological disorders, DSM-III diagnosis of schizophrenia, bipolar disorder or psychotic depression, or who met criteria for substance dependence and abuse within the past 6 months, ECT or fluoxetine within 3 months preceding baseline, any investigational drug within 30 days from baseline, MAOIs within 2 weeks preceding baseline, lithium treatment in the past 8 weeks, currently receiving Type 1C antiarrhythmics or oral anticoagulants, patients posing a suicidal risk, pregnant or lactating, hypersensitive to fluoxetine or patients with clinically significant abnormal laboratory values at retest oral screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 70 participants<BR/>Paroxetine: 68 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Paroxetine dose: 20 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:12:16 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS and Hamilton Rating Scale for Anxiety (HAM-A)</P>
<P>Secondary outcomes: Clinical Global Impression Scale (CGI), including severity and improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:12:18 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:13:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guelfi-1998">
<CHAR_METHODS MODIFIED="2013-07-04 14:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depression for less than 3 months, with a score of at least 22 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: serious or uncontrolled medical illness, no remission between episodes, depression with psychotic features, dysthymia, personality disorder, lack of response to antidepressants, ECT or neuroleptics, major risk of suicide, schizophrenia and dependence of psychoactive substances (DSM-III-R) during the previous six months, use of MAOI in the previous 2 weeks, fluoxetine in the previous 4 weeks, long-acting neuroleptics or ECT in the previous 3 months, pregnancy, lactation, not use of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:13:31 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 100 participants<BR/>Milnacipram 100 mg group: 100 participants<BR/>Milnacipram 200 mg group: 100 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Only oxazepam (max 50 mg/day) or chloral hydrate (max 2 g/day) as hypnotic or anxiolytic were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the total score on the HDRS-17<BR/>Secondary outcomes: change in the total score Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:13:48 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the MADRS and HDRS-17 total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:14:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guelfi-1999">
<CHAR_METHODS MODIFIED="2013-07-04 14:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:14:26 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (general practice) fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 25 on the Montgomery and Asberg Scale for Depression (MADRS) and a Mini Mental State Examination (MMSE) of at least 24.<BR/>Age: over 65 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:14:36 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 122 participants<BR/>Tianeptine: 115 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Tianeptine dose range: 20-37.5 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:14:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the total score on the MADRS</P>
<P>Secondary outcomes: total number of responders at endpoint, total number of remissions at endpoint, mean variation on the Geriatric Depression Scale (GDS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:14:50 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the MADRS total score<BR/>Remission: total score less than 10 on the MADRS<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:16:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hale-2010">
<CHAR_METHODS MODIFIED="2013-07-04 14:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-17 12:08:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients, aged 18 to 65 years and presented with MDD of severe intensity according to DSM-IV-TR criteria, with a score of at least 25 on the Hamilton Rating Scale for Depression-17 item (HDRS-17) and a Clinical Global Impression (CGI) score of at least 4.</P>
<P>Exclusion criteria: seasonal pattern, psychotic features, post-partum onset, suicidal intent and/or known suicidal tendencies for the current episode, bipolar disorder, anxiety symptoms (such as panic attacks, obsessive compulsive disorder, PTSD) drug abuse or dependency, resistant to fluoxetine for current episode, treatment with electroconvulsive therapy or formal psychotherapy within 3 months, or light therapy started within the earlier two weeks, not responders to the administration of an appropriate dose of two different early antidepressant treatments for at least four weeks each, patients with neurologic disorders or severe uncontrolled organic disorders.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:15:51 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 263 participants</P>
<P>Agomelatine: 252 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Agomelatine dose range: 25-50 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:16:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: responders to treatment were defined by a decrease of at least 50% in total score from baseline</P>
<P>Secondary outcomes: patients with a score of 1 or 2 at CGI scale were considered responders</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS total score<BR/>Remission: total score less than 6 on the HDRS<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:17:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrer-1999">
<CHAR_METHODS MODIFIED="2013-07-04 14:16:52 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:16:57 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (general practice) fulfilling ICD-10 criteria for mild depressive episode, with a Mini Mental State Examination (MMSE) of at least 25.<BR/>Age range: 60-80 years old<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:17:02 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 79 participants<BR/>Hypericum: 70 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Hypericum dose: 800 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: change in the total score on the Hamilton Rating Scale for Depression-17 item (HDRS-17)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-17 total score or a total score of less than 10<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:19:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hashemi-2012">
<CHAR_METHODS MODIFIED="2013-07-04 14:19:19 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty four-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with a diagnosis of Major Depressive Disorder (MDD), who responded to the drugs in 8 weeks.<BR/>Age range: 15-60 years<BR/>Exclusion criteria: patients received any antidepressant drug previously, had criteria for grief, adjustment disorder, MDD with psychotic features, concomitant axis II or III disorder, bipolar disorder or schizophrenia, pregnancy or breastfeeding.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 49 participants<BR/>Nortriptyline: 48 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Nortriptyline dose range: 50-150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:19:28 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the total score of Beck Depression Inventory (BDI)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:19:30 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:20:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-2003">
<CHAR_METHODS MODIFIED="2013-07-04 14:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:20:07 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive episode (lasting between 1 week and 1 year), with a score of at least 15 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-75 years<BR/>Exclusion criteria: pregnancy, lactation, actual suicide risk, history of current diagnosis of bipolar disorder, schizophrenia, psychotic symptoms, organic mental disorder, current diagnosis on DSM-IV of anxiety or eating disorder, epilepsy, alcohol or substance abuse in the previous 6 months, serious medical diseases.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 66 participants<BR/>Mirtazapine: 66 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Mirtazapine dose range: 30-45 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:20:14 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:20:16 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:21:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hosak-2000">
<CHAR_METHODS MODIFIED="2013-07-04 14:20:47 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week, randomised and open study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>Hospitalized patients. Diagnoses for inclusion (according to the ICD-10) were: bipolar affective disorder, most recent episode depressed (8 participants); major depressive episode, single (44 participants), major depressive episode, recurrent (38 participants).</P>
<P>Average age: 44.5 years (SD: 14.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:20:56 +0100" MODIFIED_BY="[Empty name]">
<P>Citalopram: 29 participants<BR/>Amitriptyline: 31 participants<BR/>Fluoxetine: 30 participants<BR/>Citalopram dose range: 20-60 mg/day<BR/>Amitriptyline dose range: 150-300 mg/day<BR/>Fluoxetine: 20-60 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:21:01 +0100" MODIFIED_BY="[Empty name]">
<P>Mean change on Hamilton Depression Rating Scale-21 item (HDRS-21)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:21:04 +0100" MODIFIED_BY="[Empty name]">
<P>Study report published only in Czech</P>
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:21:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jakovijevic-1996">
<CHAR_METHODS MODIFIED="2013-07-04 14:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-IV criteria for major depressive episode without psychotic features, with a score between 18 and 26 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 40-65 years<BR/>Exclusion criteria: past history of hypersensitivity, to fluoxetine or maprotiline, history or presence of gastrointestinal, liver or kidney disease, pregnancy, lactation, history of seizures or serious brain damage, current evidence of clinically important cardiovascular or hematopoietic disease, urinary retention or glaucoma with closed angle, abnormal findings in physical examination, laboratory tests and ECG at admission, evidence of substance use disorder within the past 6 months or currently, use of MAOIs within 2 weeks before the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 50 participants<BR/>Maprotiline: 48 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Maprotiline dose range: 75-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:21:53 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI) scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:22:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joyce-2002">
<CHAR_METHODS MODIFIED="2013-07-04 14:22:22 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, open study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder.<BR/>Mean age: 31.6 years<BR/>Exclusion criteria: current moderate to severe alcohol or drug dependence, history of mania (hypomanic patients were included), schizophrenia or severe antisocial personality disorder, major physical illness, use of drugs within 2 weeks of study entry (with the exception of oral contraceptive or occasional hypnotic drugs for sleep).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:22:35 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 100 participants<BR/>Nortriptyline: 95 participants<BR/>Fluoxetine dose range: 10-80 mg/day<BR/>Nortriptyline dose range: 50-175 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: improvement greater than 60% from baseline on the Montgomery and Asberg Scale for Depression (MADRS) (response) and 2 months sustained improvement (recovery)<BR/>Secondary outcomes: Hamilton Rating Scale for Depression (HDRS), Symptom Checklist-90 (SCL-90)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:22:46 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:24:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Judd-1993">
<CHAR_METHODS MODIFIED="2013-07-04 14:23:42 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder (1 month minimum duration of episode), with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 21-63 years<BR/>Exclusion criteria: organic mental disorder, substance use disorder, schizophrenia or schizoaffective disorder, paranoid or other psychotic disorder, bipolar disorder, significant physical illness, history of seizures, drug allergy, glaucoma or urinary retention, use of other psychotropic medication (including lithium), pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 30 participants<BR/>Amitriptyline: 28 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose range: 50-200 mg/day<BR/>Only temazepam or chloral hydrate were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:25:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasper-2005">
<CHAR_METHODS MODIFIED="2013-07-04 14:24:35 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:24:46 +0100" MODIFIED_BY="[Empty name]">
<P>Patients from general practice and specialist settings fulfilling DSM-IV-R criteria for major depressive disorder, with a score of at least 22, and maximum 40 on the Montgomery and Asberg Scale for Depression (MADRS), and at least 22 on the Mini Mental State Exams (MMSE) at the screening visit.<BR/>Age: over 65 years<BR/>Exclusion criteria: subjects met the DSM-IV criteria for mania or any bipolar disorder, schizophrenia, or any psychotic disorder, obsessive-compulsive disorder, eating disorders, or mental retardation or any pervasive developmental or cognitive disorder; had a MADRS score over 5 on item 10 (suicidal thoughts); receiving treatment with antipsychotic, antidepressant, hypnotics, anxiolytics (except oxazepam: 30 mg/day maximum; temazepam: 10mg/day maximum; zolpidem: 5mg/day maximum), antiepileptics, barbiturates, chloral hydrate, antiparkinsonian drugs, diuretics, lithium, sodium valproate or carbamazepine; were receiving electroconvulsive treatment, receiving treatment with behavior therapy or psychotherapy, had received treatment with any investigational drug within 30 days before entry; had a history of schizophrenia, psychotic disorder or drug abuse; had a history of severe drug allergy or hypersensitivity (including to citalopram); or had a lack of response to more than one antidepressant treatment (including citalopram) during the present depressive episode.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 164 participants</P>
<P>Escitalopram: 174 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Escitalopram dose: 10 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:24:59 +0100" MODIFIED_BY="[Empty name]">
<P>Changes from baseline in MADRS total score at final assessment</P>
<P>Response: at least 50% reduction on the MADRS total score from baseline</P>
<P>Secondary outcome: changes in Clinical Global Impression (CGI) score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:25:02 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:25:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keegan-1991">
<CHAR_METHODS MODIFIED="2013-07-04 14:25:31 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:25:33 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R or DIS criteria for unipolar major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: any serious psychiatric disorder other than depression, such as schizophrenia, bipolar disorder, panic or obsessive disorder, alcohol or drug abuse within the past six months, serious medical disorders, use of psychoactive drugs that could affect mood.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:25:41 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Amitriptyline : 22 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Amitriptyline dose range: 100-250 mg/day<BR/>Only small amounts of benzodiazepines or chloral hydrate for sleep and anxiety were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnostic Interview Schedule, HDRS-21, Beck Depression Inventory (BDI), Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:26:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keller-2007">
<CHAR_METHODS MODIFIED="2013-07-04 14:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>Ten-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:26:29 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for Major Depressive Episode (MDD), had experienced depressive symptoms for at least 1 month prior to the start of the study, and had a recurrent depression (at least 3 episode of MMD, with at least 2 episode in the past 5 years and a interval of at least 2 months between the end of the previous episode and the beginning of the current episode) and a total score on Hamilton Rating Scale for Depression-17 item (HDRS-17) of at least 20 at screening and 18 at the randomisation.<BR/>Age: 18 years or older<BR/>Exclusion criteria: patients who failed a trial of fluoxetine, venlafaxine, or venlafaxine ER during the current episode or were treatment resistant, hypersensitivity to venlafaxine or fluoxetine, serious medical disease, cancer, seizure disorder, bipolar disorder, eating disorder, other axis I disorder, substance dependence/abuse within 6 months, axis II disorder, any psychotic disorder, post-partum depression; pregnancy, breastfeeding or not using a medically acceptable method of birth control; use of the following drugs: any investigational drug, antipsychotic drug, fluoxetine, monoamine oxidase inhibitor within 30 days or other antidepressant within 14 days; ECT within 3 months, any anxiolytic, sedative-hypnotic drug, sumatriptan or any other psychotropic drug or substance within 7 days, or any non-psychopharmacologic drug with psychotropic effects within 7 days of randomisation, unless a stable dose of the drug had been maintained for at least 1 month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:26:35 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 275 participants</P>
<P>Venlafaxine : 821 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Venlafaxine dose range: 75-300 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:26:51 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17</P>
<P>Secondary outcomes: Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology (IDS), Clinical Global Impression (CGI)</P>
<P>Response: at least 50% reduction from baseline HDRS-17 total score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:26:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:27:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kerkhofs-1990">
<CHAR_METHODS MODIFIED="2013-07-04 14:27:33 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:27:44 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling Research Diagnostic Criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-64 years<BR/>Exclusion criteria: concurrent medical disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 16 participants<BR/>Amitriptyline: 18 participants<BR/>Fluoxetine dose range: 40-60 mg/day<BR/>Amitriptyline dose range: 100-150 mg/day<BR/>Only oxazepam (max 100 mg/day) was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:27:52 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI) Severity and Improvement, Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:28:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuha-1991">
<CHAR_METHODS MODIFIED="2013-07-04 14:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:28:33 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling Research Diagnostic Criteria for unipolar major depressive episode, with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17) and 8 on the Raskin Depression Scale (RDS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: serious non-stabilised somatic illness, drug or alcohol abuse, evidence of dementia, depressive schizophrenic, serious suicide risk, concurrent administration of other psychotropic drug (with the exclusion of benzodiazepines or chloral hydrate for insomnia or anxiety).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:28:39 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 24 participants<BR/>Maprotiline: 22 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Maprotiline dose range: 50-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, RDS, Covi Anxiety Scale (CAS), Patient Global Impression (PGI), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:28:43 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:29:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kwon-1996">
<CHAR_METHODS MODIFIED="2013-07-04 14:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:29:19 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for unipolar major depression, drug free for a minimum of 2 weeks.</P>
<P>Mean age: 44,31 years (SD=9,31)<BR/>Exclusion criteria: previously received ECT; neurological disorders and major illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:29:25 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty participants were randomly assigned to a 6-weeks of treatment with fluoxetine or amitriptyline</P>
<P>No other information about the interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:29:33 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS) was assessed at baseline and at the end of the 6th week</P>
<P>Response: a reduction of at least 50% of the HDRS score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:29:35 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by academy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:30:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Pia-1992">
<CHAR_METHODS MODIFIED="2013-07-04 14:30:10 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 18 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) and 20 on the Mini Mental State Examination (MMSE).<BR/>Age range: 60-80 years<BR/>Exclusion criteria: history of serious allergies or alcohol and drug abuse in the last year, diagnosis of schizophrenia, dementia, glaucoma, prostatic hypertrophia, recent stroke, serious internal disease, and/or surgical conditions that could interfere with study drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:30:21 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Mianserin: 20 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Mianserin dose: 40 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Geriatric Depression Scale (GDS), Geriatric Rating Scale (GRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:31:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laakman-1988">
<CHAR_METHODS MODIFIED="2013-07-04 14:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:31:03 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with depressive syndrome with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS) and 8 on the Raskin Depression Scale (RDS).<BR/>Age range: 19-74 years<BR/>Exclusion criteria: severe organic illness, evidence of psychosis, psychopathic disorder, addictive illness, suicide tendencies, a period of less than 4 weeks since the last treatment with amitriptyline or neuroleptics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:31:11 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 63 participants<BR/>Amitriptyline : 65 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Amitriptyline dose range: 50-150 mg/day<BR/>Chloral derivative was allowed (eventually changed in flurazepam or nitrazepam only if its effects was inadequate)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI), RDS , Covi Anxiety Scale (CAS), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:32:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapierre-1997">
<CHAR_METHODS MODIFIED="2013-07-04 14:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:31:47 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 18 on the first 17 items of the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-64 years<BR/>Exclusion criteria: marked suicide risk, major depressive episode associated with moo-incongruent psychotic features, bipolar disorder, acute confusional state, epileptic or seizure disorder, mental retardation, history of unstable diabetes or clinically significant physical disease, known sensitivity to moclobemide, MAOI, fluoxetine or other SSRIs, history of alcohol or substance abuse within the last 6 months, treatment with MAOI within the past 2 weeks, fluoxetine within the past 5 weeks, try- or heterocyclics antidepressants or lithium or daytime benzodiazepines within the past week, ECT within the past 3 months, concomitant use of medication known to affect the action of moclobemide or fluoxetine, use of any investigational drug within the past 3 months, pregnancy, lactation, absence of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:32:00 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 62 participants<BR/>Moclobemide: 66 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 200-600 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:32:04 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Hamilton Rating Scale for Depression (HDRS-21)<BR/>Secondary outcomes: Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the MADRS total score and a total score of less than 10<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:32:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2005">
<CHAR_METHODS MODIFIED="2013-07-04 14:32:43 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:32:45 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS) total score and over 21 on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-64 years<BR/>Exclusion criteria: previous treatment with either study drugs, hypersensitivity reaction to study drugs, non-responder to more than two antidepressant drugs, history of severe renal or liver disease, diagnosis of non-depressive axis I disorders according to DSM-IV criteria; participation in another study in the past 3 months, pregnancy, high suicidal risk, history of psychotic episodes or patients requiring electroconvulsive therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 62 participants<BR/>Moclobemide: 66 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 200-600 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS score and MADRS score</P>
<P>Response: a decrease of 50% or more of the initial score on the HDRS or MADRS, or a Clinical Global Impression (CGI) rating of "remarkably improved" or "moderately improved"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>Remission: a score of 7 or less on HDRS or a score of 8 or less on MADRS<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:34:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-1989">
<CHAR_METHODS MODIFIED="2013-07-04 14:33:49 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, two-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:33:51 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling Research Diagnostic Criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Mean age: 46.1 (fluoxetine) and 45.4 (imipramine) years<BR/>Exclusion criteria: significant physical illness, history of drug abuse, schizophrenia, duration of illness more than 1 year.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 30 participants<BR/>Imipramine: 30 participants<BR/>Fluoxetine dose range: 40-60 mg/day<BR/>Imipramine dose range: 75-150 mg/day<BR/>Only temazepam was allowed for night sedation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:34:05 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Montgomery and Asberg Scale for Depression (MADRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:34:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levkovitz-2002">
<CHAR_METHODS MODIFIED="2013-07-04 14:34:38 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for non-psychotic depressive episode (no longer than 5 months), with a score of at least 21 on the Hamilton Rating Scale for Depression (HDRS-17) and no more than 2 previous antidepressive drugs given for the current episode and no medication for 3-5 days before first assessment.<BR/>Age range: 25-50 years<BR/>Exclusion criteria: psychotic state, significant past head injury, severe neurological disease of physical illness, history of drug addiction or alcoholism, ECT in the last year, suicide risk, or suicide attempt in the last year.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:34:47 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 8 participants<BR/>Desipramine: 9 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Desipramine dose range: 125-200 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:34:48 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 and Clinical Global Impression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:35:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loeb-1989">
<CHAR_METHODS MODIFIED="2013-07-04 14:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:35:23 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III criteria for major depressive episode, with a score of at least 18 on the first 17 items of the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy, serious vascular disease, hyperthyroidism, glaucoma, urinary retention, hepatic, respiratory or renal marked failure, hematological disease, organic brain disease, seizures, alcohol and/or drug abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:35:28 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 15 participants<BR/>Imipramine: 15 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Imipramine dose range: 100-150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:35:29 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:35:30 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:36:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lonnqvist-1994">
<CHAR_METHODS MODIFIED="2013-07-04 14:36:02 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:36:05 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for predominantly major depressive disorder, with a score of at least 16 on Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: over 18 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:36:15 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 107 participants<BR/>Moclobemide: 102 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 300-450 mg/day<BR/>Benzodiazepines were permitted only if strongly indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI), Montgomery and Asberg Scale for Depression (MADRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:36:19 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:37:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loo-1999">
<CHAR_METHODS MODIFIED="2013-07-04 14:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:37:05 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling ICD-10 criteria for depressive episode, recurrent depressive disorder, or bipolar affective disorder (depressive), with a score of at least 25 on the Montgomery and Asberg Scale for Depression (MADRS), requiring an antidepressant treatment.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: severe risk of suicide, acute or chronic psychosis, failure to respond to 2 antidepressants for the current depressive episode, previous history of drug abuse or dependence, severe somatic diseases in evolution, current treatment with barbiturate, buspirone, anti-epileptic drugs, use of diazepam, lorazepam and alprazolam.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:37:10 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 196 participants<BR/>Tianeptine: 191 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Tianeptine dose: 37.5 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: MADRS global score<BR/>Secondary outcomes: decrease of at least 50% in MADRS global score (responder patients) and Clinical Global Impression (CGI) scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:37:15 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:37:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manna-1989">
<CHAR_METHODS MODIFIED="2013-07-04 14:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 18 on the first 17 items of Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Mean age: 48 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 15 participants<BR/>Clomipramine: 15 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Clomipramine dose: 75 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:37:56 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI), Zung Self-Rating for Depression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:37:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:39:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mao-2008">
<CHAR_METHODS MODIFIED="2013-07-04 14:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, parallel group, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:38:45 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 18 on the first 17 items of Hamilton Rating Scale for Depression (HDRS) and a score of at least 4 on Clinical Global Impression-Severity (CGI).</P>
<P>Age range: 18-65 years<BR/>Exclusion criteria: any current primary DSM-IV axis I diagnosis or any anxiety disorder as a primary diagnosis within the year preceding enrolment, or schizoaffective disorder, a history of substance abuse or dependence within the past year; serious suicidal risk or serious medical illness; currently take St. John's wort or other Chinese herbal medicine for depression were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:38:53 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 117 participants<BR/>Escitalopram: 123 participants<BR/>Fluoxetine dose: 10 mg/day<BR/>Escitalopram dose: 20 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:38:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in HDRS total score</P>
<P>Secondary outcome: change in Montgomery and Asberg Scale for Depression (MADRS) total score</P>
<P>Response: at least 50% decrease from HDRS baseline score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:39:00 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:39:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marchesi-1998">
<CHAR_METHODS MODIFIED="2013-07-04 14:39:38 +0100" MODIFIED_BY="[Empty name]">
<P>Ten-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 16 on the Hamilton Rating Scale for Depression-17 item (HDRS-17) and a summary score of the HDRS items (agitation, psychic anxiety and somatic anxiety) higher than 5 or the score of at least one of the above items higher than 3.<BR/>Mean age: 44.1 (females) and 42.1 (males) years old<BR/>Exclusion criteria: serious suicide risk, schizophrenia, epilepsy, organic brain disease, chronic disease such as cardiovascular, renal, hepatic, respiratory, endocrine-metabolic, urinary disease, glaucoma, use of antidepressants the week before enrolment, use of fluoxetine during the previous month, use of lithium during the previous 6 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 67 participants<BR/>Amitriptyline : 75 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose range: 75-225 mg/day<BR/>Bromazepam (max 6 mg) was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>Change in HDRS-17 total score, in agitation/anxiety score and in the response rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-17 total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:40:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martenyi-2001">
<CHAR_METHODS MODIFIED="2013-07-04 14:40:28 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, four-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:40:30 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for non-psychotic major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: history of any psychoactive disorder, bipolar mood disorder, substance abuse disorder, somatic disorder, glaucoma, urinary retention and/or prostatic disease and known allergy to maprotiline, pregnancy, absence of contraception, use of MAOI within 2 weeks and depot neuroleptics within 4 weeks of study entry, concomitant psychotropic active medication, with the exception of midazolam, max 15 mg, or medazepam, max 5 mg, for insomnia.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:40:36 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 59 participants<BR/>Maprotiline : 46 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Maprotiline dose range: 100-200 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:40:37 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression-Severity (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:40:38 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:41:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez-2012">
<CHAR_METHODS MODIFIED="2013-07-04 14:41:09 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, open study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-11 11:50:38 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for Major Depressive Disorder (MDD), with a score of at least 16 on the Patient Health Questionnaire (PHQ-9) at baseline and a score of at least 20 on Quick Inventory of Depression Syntomatology Self-Report scale (QIDS-SR) at visit 1 and 2.<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception. Patients taking an investigational drug (bupriopion, sertraline, venlafaxine, paroxetine, fluoxetine or escitalopram) were allowed to participated only if they had not adequately responded to treatment. Patients with a history of bipolar disorder, primary psychotic disorder, cognitive disorder or obsessive-compulsive disorder, or current (within last 6 months) primary axis I diagnosis of panic disorder, post-traumatic stress disorder, generalized anxiety disorder, social anxiety disorder, dysthymia, alcohol or eating disorders were excluded. To be at serious risk of suicide, the presence of a serious, unstable medical illness or clinically significant laboratories abnormality, dementia, mental retardation diagnosis, history of substance abuse or dependence within previous 6 months or positive urine drug screen for any substance of abuse, treatment with electroconvulsive therapy, initiation of psychotherapy within 6 weeks before study entry or during study participation were exclusion criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:41:16 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 57 participants<BR/>Duloxetine: 372 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Duloxetine dose range: 30-120 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in QIDS-SR total score</P>
<P>Secondary measures: Hamilton Rating Scale for Depression (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 17:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:42:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masco-1985">
<CHAR_METHODS MODIFIED="2013-07-04 14:41:50 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive illness, with a score of at least 20 on the Hamilton Rating Scale for Depression-17 item (HDRS-17), a score of at least 8 on the Raskin Depression Scale (RDS) and greater than the Covi Anxiety Scale (CAS) score.<BR/>Mean age: 51 years in both groups<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:42:00 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Amitriptyline: 21 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Amitriptyline dose range: 150-300 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, RDS , CAS, Clinical Global Impression (CGI) Improvement and Severity, Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:42:10 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:43:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massana-1999">
<CHAR_METHODS MODIFIED="2013-07-04 14:42:54 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:42:58 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for depressive episode (lasting between 1 to 8 months), without psychotic features, with a score of at least 22 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy, absence of contraception, dysthymia/cyclothymia, substance abuse disorder, high risk of suicide, resistance to antidepressant treatment, history of major depressive disorder associated with endocrine disorder and/or drug hypersensitivity, chronic respiratory insufficiency, a history of seizures or brain injury, a history or current evidence of any other important clinical condition or use of electroconvulsive therapy in the previous 6 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:43:12 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 89 participants<BR/>Reboxetine: 79 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Reboxetine dose range: 8-10 mg/day</P>
<P>Chloral hydrate (0.5-1 mg) for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the HDRS total score, number of patients showing response (decrease of at least 50% in HDRS total score) and remission (a final score of 10 or less)</P>
<P>Seconday outcomes: Clinical Global Impression-Severity (CGI-S), Montgomery and Asberg Scale for Depression (MADRS), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:44:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGrath-2000">
<CHAR_METHODS MODIFIED="2013-07-04 14:43:54 +0100" MODIFIED_BY="[Empty name]">
<P>Ten-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:44:04 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for major depressive episode, lasting for at least 1 month and having Columbia criteria for atypical depression.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: significant suicidal risk, pregnancy, lactation, absence of contraception, unstable and serious physical illness, history of seizures, psychosis or organic mental syndrome, substance use disorder within 6 months, history of mania, antisocial personality disorder, history of non-response to an adequate trial of fluoxetine or imipramine, history of no response to any other SSRIs, hypothyroidism.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 49 participants<BR/>Imipramine: 53 participants<BR/>Placebo: 52 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Imipramine dose range: 50-300 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:45:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moosa-2003">
<CHAR_METHODS MODIFIED="2013-07-04 14:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:45:07 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for depressive episode, with a score of at least 17 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age: under 50 years<BR/>Exclusion criteria: history of a serious medical illness, psychotic symptoms, psychoactive substance abuse or dependency, comorbid illness that required pharmacotherapy, or presence of an eating disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:45:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 14 participants<BR/>Reboxetine: 14 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Reboxetine dose: 150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:45:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the HDRS-21 total score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:45:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by academy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:47:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moreno-2006">
<CHAR_METHODS MODIFIED="2013-07-04 14:46:35 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for mild to moderate, non psychotic major depressive disorder, with a baseline score of at least 10 and a maximum score of 24 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: patients with other types of depression, psychosis, personality disorders, bipolar disorders, suicidal ideation, uncontrolled organic disease, history of alcohol or drug abuse 1 year prior, abnormal laboratory tests or a history of seizures, treated with electroconvulsive therapy or have taken any investigational drug up to 30 days before screening. Patients who used MAO-inhibitors 2 weeks before the enrolment, benzodiazepines in doses equivalent to diazepam 10mg/day 1 week before the enrolment and patients already treated with fluoxetine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:47:02 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Hypericum: 20 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Hypericum dose: 900 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the HDRS total score</P>
<P>Seconday outcomes: Clinical Global Impression (CGI) Severity, Montgomery and Asberg Scale for Depression (MADRS), UKU side effects rating scale (UKU)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:47:07 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:47:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mowla-2006">
<CHAR_METHODS MODIFIED="2013-07-04 14:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:47:46 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depression disorder, based on a structured clinical interview.<BR/>Mean age: 30.8 (SD: 9.9) (fluoxetine) and 35 (SD: 9.4) (nortriptyline) years<BR/>Exclusion criteria: patients with another DSM-IV diagnosis, psychotic symptoms, alcohol or other drugs addiction, major physical illness, potentially pregnant women, breast-feeding or planning to be pregnant in the next two months, patients in whom tricyclics were contraindicated (i.e. narrow-angle glaucoma, prostatism).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:47:54 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 36 participants</P>
<P>Nortriptyline : 20 participants<BR/>Fluoxetine dose: 40 mg/day<BR/>Nortriptyline dose: 150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:47:56 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: change in Hamilton Rating Scale for Depression (HDRS) and in Clinical Global Impression (CGI) total scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:47:58 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:49:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muijen-1988">
<CHAR_METHODS MODIFIED="2013-07-04 14:48:41 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:48:48 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling Research Diagnostic Criteria for major depressive disorder or bipolar illness, with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: serious somatic illness, alcohol or drug abuse, pregnancy, severe depression with indication for hospital admission or ECT, or TCA, neuroleptics in the previous 4 weeks, MAOI in the previous 2 weeks.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 26 participants<BR/>Mianserin: 27 participants<BR/>Placebo: 28 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Mianserin dose range: 20-80 mg/day<BR/>Only temazepam (max 20 mg) nightly for the shortest possible period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:48:59 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, CGI, Montgomery and Asberg Scale for Depression (MADRS), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:49:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<CHAR_METHODS MODIFIED="2013-07-04 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with moderate to severe depression (DSM: single episode or recurrent), with a score of at least 18 in the first 17 items of Hamilton Rating Scale for Depression-21 item (HDRS-21) both at the screening and baseline visit, the HDRS score could not decrease by more than 25% between screen and baseline visit. The Raskin Depression Scale (RDS) score had to be at least 8 at baseline and must have exceeded the Covi Anxiety Score (CAS).<BR/>Age: over 18 years<BR/>Exclusion criteria: patients with a primary psychiatric diagnosis other than depression, or those with a serious concomitant diseases. Patients were also excluded if they had a serious suicidal threat, recent ECT or with substance abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:49:46 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 289 participants</P>
<P>Paroxetine: 284 participants<BR/>Fluoxetine dose range: 20-50 mg/day<BR/>Paroxetine dose range:20-80 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:49:51 +0100" MODIFIED_BY="[Empty name]">
<P>Changes in HDRS total score, RDS and Clinical Global Impression (CGI) Severity of illness and Improvement; CAS, Symptom Checklist-90 (SCL-90), Global Assessment of Functioning (GAF) Scale</P>
<P>Response: at least 50% reduction on the HDRS-21 total score from baseline or a score under 10 at HDRS-21 at the endpoint</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:50:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<CHAR_METHODS MODIFIED="2013-07-04 14:50:29 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:50:31 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for Major Depressive Disorder (MDD), with a total score of at least 18 on the first 17 items of the Hamilton Rating Scale for Depression-21 item (HDRS-21). Total score could not have decreased by more than 25% between the screen and the baseline visits.<BR/>Age: over 18 years<BR/>Exclusion criteria: primary psychiatric diagnosis other than MDD, serious suicidal or homicidal risk, substance abuse or dependence, prior ECT (within 3 months of the study), serious concomitant medical conditions, and subjects with a history of hypersensitivity to fluoxetine or who had previously taken paroxetine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:50:37 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 351 participants<BR/>Paroxetine: 357 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Paroxetine dose: 20 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:50:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-21<BR/>Secondary outcomes: HDRS-21 subscale, Raskin Depression rating scale (RDS), Clinical Global Impression (CGI), Symptom Checklist-90 (SCL-90), Global Assessment of Functioning (GAF) Scale, Covi Anxiety Scale (CAS)</P>
<P>Response: a decrease of 50% from baseline in the HDRS-21 total score at any time during the 12-week study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:50:45 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:51:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nelson-2004">
<CHAR_METHODS MODIFIED="2013-07-04 14:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients with unipolar non-psychotic major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression (HDRS) after at least one week in the hospital without medication.<BR/>Age: 21 years and older<BR/>Exclusion criteria: patients who had more than 30% improvement in the first week remained medication free for two-weeks and were excluded if the HDRS score drop below 18. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression, active medical illness, substance abuse in the past 6 months, and cluster B personality disorder were excluded.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 14 participants<BR/>Desipramine: 12 participants<BR/>Fluoxetine + desipramine: 13 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Desipramine mean dose: 293 mg/day (SD: 116.8)</P>
<P>Fluoxetine + desipramine dose: 20 mg/day fluoxetine + 98,1 (SD: 45.0) desipramine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Montgomery and Asberg Scale for Depression (MADRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:51:44 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:52:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nemeroff-2007">
<CHAR_METHODS MODIFIED="2013-07-04 14:52:09 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive episode, the symptoms is present for at least 1 month, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age: over 18 years<BR/>Exclusion criteria: bipolar or psychotic disorder, history of alcohol or substance abuse within the past year, any clinically significant medical disorders or abnormalities, history of non response to venlafaxine or fluoxetine, patients receiving any study drug within 6 months; electroconvulsive therapy within 3 months, astemizole, cisapride, sumatriptan, terfenadine, any other antidepressant, anxiolytic, sedative-hypnotic drug within 7 days, pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:52:25 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 104 participants<BR/>Venlafaxine: 102 participants</P>
<P>Placebo: 102 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Venlafaxine dose range: 75-225 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: reduction in total score and item 1 of the HDRS-21, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI), Patient Global Impression (PGI)<BR/>Response: 1) decrease of 50% HDRS-21 score; 2) decrease of 50% MADRS score; 3) CGI score of 1 or 2; 4) PGI score of 1 or 2</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:53:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newhouse-2000">
<CHAR_METHODS MODIFIED="2013-07-04 14:53:07 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:53:09 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive episode (single or recurrent), without psychotic features, with a score of at least 18 on the Hamilton Rating Scale for Depression- 24 item (HDRS-24).<BR/>Age: over 60 years<BR/>Exclusion criteria: DSM-III-R criteria for any other psychiatric disorder, significant cognitive impairment (Mini Mental State Examination less than 24), any medical contraindication to any antidepressant therapy, endocrine, cardiovascular, gastrointestinal, renal disease, failure to respond to ECT in a prior depressive episode or to adequate trials (6 weeks) of 2 or more antidepressants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:53:17 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 119 participants<BR/>Sertraline: 117 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Sertraline dose range: 50-100 mg/day<BR/>Temazepam and chloral hydrate were allowed for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:53:22 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-24 (total and factor scores), Clinical Global Impression (CGI) Severity, Efficacy<BR/>Secondary outcomes: Montgomery and Asberg Scale for Depression (MADRS), Hamilton Rating Scale for Anxiety (HAM-A), Profile Of Mood State (POMS), Beck Depression Inventory (BDI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:54:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nielsen-1993">
<CHAR_METHODS MODIFIED="2013-07-04 14:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III and Bech-Rafaelsen Melancholia Scale criteria for major depressive disorder, with a score of at least 18 on the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: suicide risk, history of schizophrenia or organic brain dysfunction, history of severe allergies or serious physical illness, recent period of alcohol or alcohol abuse, pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:54:15 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 29 participants<BR/>Imipramine: 30 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Imipramine dose range: 75-150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:54:17 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Bech-Rafaelsen Melancholia Scale (MES), Clinical Global Impression (CGI), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:55:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noguera-1991">
<CHAR_METHODS MODIFIED="2013-07-04 14:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III criteria for major depressive disorder, with a score of at least 17 on the first 17 items of the Hamilton Rating Scale for Depression-21 item (HDRS-21), a score of at least 8 on the Raskin Depression Scale (RDS), greater than Covi Anxiety Scale (CAS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: history of manic episode, pregnancy, lactation, absence of contraception, glaucoma, chronic urinary retention, brain or other significant organic illness, schizophrenia, other mental illness or severe suicidal risk, recent history (less than 1 year) of alcohol or drug abuse, concurrent treatment with other psychotropic drug including lithium, use of MAOI less of 2 weeks prior the study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:55:07 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 60 participants<BR/>Clomipramine: 60 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Clomipramine dose: 100 mg/day<BR/>Chloralzepate (10 mg) for insomnia was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:55:08 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, CAS, RDS, Patient Global Impression (PGI), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:55:10 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:55:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noorbala-2005">
<CHAR_METHODS MODIFIED="2013-07-04 14:55:40 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for depressive episode, with a score of at least 18 on the Hamilton Rating Scale for Depression (HDRS) and to be free of psychotropic medication for at least 4 weeks before study entry.<BR/>Age range: 18-55 years<BR/>Exclusion criteria: pregnancy, absence of contraception, current cognitive disorder in the last year, bipolar disorder, schizophrenia or schizotypal personality disorder, significant risk o suicide (two or more at the suicide item of the HDRS or to be judged to have significant suicidal ideation in the view of an investigator).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:55:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Crocus Sativus: 20 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Crocus sativus dose: 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:55:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the HDRS total score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:55:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:56:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Novotny-2002">
<CHAR_METHODS MODIFIED="2013-07-04 14:56:36 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:56:45 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-IV criteria for major depressive disorder, (single or recurrent), without psychotic features, with or without melancholia, or bipolar II disorder, current episode depressed, moderate or severe without psychotic features with or without melancholia, with a score of at least 25 on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: dysthymia, cyclothymia, double-depression, psychotic disorder, drug or alcohol abuse or dependence, serious risk of suicide, treatment resistant depression, recurrent ECT, non-response to previous treatment with fluoxetine or tianeptine, severe hepatic, cardiovascular, neurological, metabolic disease, cancer or allergy, pregnancy, previous treatment with neuroleptics in the previous 2 months, MAOI, fluoxetine lithium, valproates or carbamazepine within 1 month of baseline, other antidepressants, diazepam, lorazepam, alprazolam, bromazepam, barbiturates, buspirone the week before recruitment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:56:54 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 91 participants<BR/>Tianeptine: 87 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Tianeptine dose: 37.5 mg/day<BR/>Chloralzepate (max 30 mg), oxazepam (max 60 mg) for anxiety and nitrazepam (1 mg) or lorazepam (1 mg) for insomnia. For patients who were usually taking benzodiazepines for at least 1 month before baseline continuation during the trial was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:56:55 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: MADRS total score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:56:58 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the MADRS total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:57:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Keane-1992">
<CHAR_METHODS MODIFIED="2013-07-04 14:57:29 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:57:32 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-64 years<BR/>Exclusion criteria: not specified. Patients were physical healthy, non obese and did not have DSM-III-R axis 2 disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:57:37 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 7 participants<BR/>Amitryptyline: 9 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitryptyline dose: 250 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:57:39 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:58:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ontiveros-1997">
<CHAR_METHODS MODIFIED="2013-07-04 14:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind two-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:58:04 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 18 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-75 years<BR/>Exclusion criteria: pregnancy, lactation, severe coexisting disease, unstable diabetes, organic brain syndrome, history of alcohol or drug abuse, schizophrenia or psychosis, severe risk of suicide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:58:14 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 61 participants<BR/>Paroxetine: 60 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Paroxetine dose: 20 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change from baseline on the HDRS-21 total score at endpoint<BR/>Secondary outcomes: change from baseline in the Hamilton sub-factor scores (anxiety, retardation, sleep disturbance, melancholia, recognition), proportion of patients responding to treatment, change from baseline on the Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the HDRS-21 total score<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:59:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-OntiverosSanchez-1998">
<CHAR_METHODS MODIFIED="2013-07-04 14:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 18 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception, severe suicide risk, severe medical illness, history of psychosis or of substance abuse in the previous 1 years, hypersensitivity to fluoxetine or amitriptyline, psychotherapy or use of psychotropic drugs (benzodiazepines, too).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 21 participants<BR/>Amitriptyline : 21 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Amitriptyline dose range: 150-250 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Hamilton Rating Scale for Anxiety (HAM-A), Clinical Global Impression (CGI), Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS), Symptom Checklist-90 (SCL-90)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 14:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pakesch-1991">
<CHAR_METHODS MODIFIED="2013-07-04 14:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 14:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling Kielholz/Poeldinger scheme for depression, with a score of at least 11 on the Hamilton Rating Scale for Depression (HDRS-14).<BR/>Age range: 19-79 years<BR/>Exclusion criteria: organic disease, endogenous depression, organic psychosis, schizophrenia, alcohol or substance abuse, previous treatment with clomipramine, use of neuroleptics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 14:59:54 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 46 participants<BR/>Clomipramine: 48 participants<BR/>Fluoxetine dose: 40 mg/day<BR/>Clomipramine dose: 50 mg/day. Oxazepam (maw 15 mg) or chloral hydrate (max o.25g) were allowed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 14:59:57 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-14, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 14:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:00:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pande-1996">
<CHAR_METHODS MODIFIED="2013-07-04 15:00:31 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:00:34 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder or dysthymic disorder or depressive disorder NOS and Columbia criteria for atypical depression, with a score of at least 10 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Mean age: 32.8 (fluoxetine) and 34.3 (phenelzine) years<BR/>Exclusion criteria: pregnancy, serious medical illness, comorbid psychiatric illness, alcohol or drug abuse, participation to a clinical trial in the previous month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Phenelzine: 20 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Phenelzine dose range: 45-90 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:00:51 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:01:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perry-1989">
<CHAR_METHODS MODIFIED="2013-07-04 15:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depression (lasting more than 1 month), with a score of at least 20 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: over 18 years<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception, serious suicide risk, glaucoma, presence of cardiovascular arrythmias, hypertension, serious medical illness, including hepatic, renal, respiratory, hematologic disease, histiory of seizure, severe allergies or multiple drug reaction, psychotic patients and patients with DSM-III diagnosis of organic mental disorder, substance abuse disorder within the past year, schizophrenia, paraniod disorder, bipolar disorder, use of MAOI in the past 14 days, lithium or any other psychotropic drug, use of trazodone or fluoxetine within 4 weeks of study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:01:32 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 21 participants<BR/>Trazodone: 19 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Trazodone dose range: 50-400 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:02:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peters-1990">
<CHAR_METHODS MODIFIED="2013-07-04 15:02:03 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:02:05 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling ICD 9 criteria for major unipolar or bipolar depression, with a score of at least 17 on the HDRS, a score of at least 8 on the Raskin Depression Scale (RDS), greater than Covi Anxiety Scale (CAS) score.<BR/>Age range: 25-63 years<BR/>Exclusion criteria: history of psychosis, suicide risk, severe mental diseases, contraindication to amitriptyline, severe organic disease, known drug allergy, use of amitriptyline within 4 weeks of baseline, use of neuroleptics within 2 weeks of study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:02:20 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 51 participants<BR/>Amitriptyline: 51 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose: 100 mg/day<BR/>Chloral hydrate or benzodiazepines for insomnia were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS-17), Clinical Global Impression (CGI), RDS, CAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:02:23 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:03:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poelinger-1989">
<CHAR_METHODS MODIFIED="2013-07-04 15:03:04 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling Kielholz/Poeldinger scheme for depression, with a score of at least 14 on the Hamilton Rating Scale for Depression (HDRS-14).<BR/>Age range: 21-67 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 73 participants<BR/>Maprotiline: 69 participants<BR/>Fluoxetine dose: 40 mg/day<BR/>Maprotiline dose: 75 mg/day<BR/>Only chloral hydrate and oxazepam were allowed for insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:03:24 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-14, Clinical Global Impresison (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:03:26 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:04:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Preskorn-1991">
<CHAR_METHODS MODIFIED="2013-07-04 15:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:03:55 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depression (lasting more than 1 month), with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age: over 18 years<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception, contraindication to amitriptyline, medical illness, history of seizures, glaucoma, severe allergies, multiple adverse drug reaction, known allergy to study medication, use of MAOI within 2 weeks, use of other investigational drugs in past 2 weeks, suicidal risk, DSM-III diagnosis such as substance abuse in the past year, schizophrenia, schizoaffective disorder, bipolar or paranoid disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:04:07 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 30 participants<BR/>Amitriptyline: 31 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Amitriptyline dose range: 50-200 mg/day<BR/>Only chloral hydrate was allowed for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:04:08 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:05:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rapaport-1996">
<CHAR_METHODS MODIFIED="2013-07-04 15:04:44 +0100" MODIFIED_BY="[Empty name]">
<P>Seven-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:04:47 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for current major depressive episode, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) and with a minimum score of 2 on the depressive mood item.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: unstable medical condition other Axis 1 diagnosis, acute suicidally, history of substance dependence within 6 months of the baseline, history of seizure disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:04:59 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 49 participants<BR/>Fluvoxamine: 51 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Fluvoxamine dose range: 100-150 mg/day<BR/>Only chloral hydrate (max 1 g) was allowed for sleep<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:05:01 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI), Hamilton Rating Scale for Anxiety (HAM-A), Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS), Symptom Checklist-90 (SCL-90)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:05:02 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:05:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Remick-1989">
<CHAR_METHODS MODIFIED="2013-07-04 15:05:35 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:05:48 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III criteria for current major depressive episode, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Measn age: 43 years<BR/>Exclusion criteria: psychosis, bipolar disorder, concurrent use of any psychoactive medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:05:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 38 participants<BR/>Doxepine: 37 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Doxepine dose range: 100-200 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:05:54 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI), Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:06:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Remick-1993">
<CHAR_METHODS MODIFIED="2013-07-04 15:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder (lasting 1 month or more), with a score of at least 20 on the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: any abnormalities on laboratory examination, presence of psychosis, bipolar disorder, concurrent use of any psychoactive medication, pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:06:43 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 26 participants<BR/>Desipramine: 20 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Desipramine dose range: 150-300 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:06:44 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Clinical Global Impression (CGI), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:06:46 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reynaert-1995">
<CHAR_METHODS MODIFIED="2013-07-04 15:07:17 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:07:19 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 16 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Mean age: 47 years<BR/>Exclusion criteria: suicide risk, any other psychiatric illness, severe organic disease, alcoholism and drug abuse, use of MAOI in the previous 2 weeks and antidepressants in the previous 4 days or any investigational drugs in the previous 4 weeks, use in the past of fluoxetine or moclobemide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:07:31 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 50 participants<BR/>Moclobemide: 51 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 300-600 mg/day<BR/>Lithium and one benzodiazepine were permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score or a score of maximum 10 on the HDRS-17<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:08:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robertson-1994">
<CHAR_METHODS MODIFIED="2013-07-04 15:08:03 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:08:05 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder or bipolar disorder (currently depressive), with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: previous use of fluoxetine or lofepramine prior entry to study or during present episode, use of psychoactive drugs (a part from short acting benzodiazepines within 7 days prior entry), use of MAOI within 14 days and depot neuroleptics within 6 months, ECT, serious suicide risk, pregnancy, lactation, absence of contraception, history of glaucoma, cardiovascular disease or urinary retention, significant other medical illness, history of severe allergies or multiple adverse drug reaction, concurrent use of diuretics.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:08:18 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 90 participants<BR/>Lofepramine: 93 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Lofepramine dose range: 140-210 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:08:20 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Montgomery and Asberg Scale for Depression (MADRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:08:21 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:09:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ropert-1989">
<CHAR_METHODS MODIFIED="2013-07-04 15:08:56 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:08:58 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for current major depressive disorder, with a score between 18 and 25 on the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: organic brain disease, history of seizures, serious illness, including cardiovascular, hepatic, renal, respiratory, hematologic, hyperthyroidism, history of severe allergy or multiple drug reaction, history (less than 1 year) of drug and alcohol abuse, concurrent administration of psychotropic drugs (except benzodiazepines), MAOI within 2 weeks, serious suicidal risk, pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 71 participants<BR/>Clomipramine: 72 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Clomipramine dose: 75 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:09:13 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:09:15 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:10:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rudolph-1999">
<CHAR_METHODS MODIFIED="2013-07-04 15:09:47 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:09:51 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for current major depressive disorder, with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age: over 18 years<BR/>Exclusion criteria: recent treatment within 6 months or known hypersensitivity to either study drugs, serious medical conditions, bipolar mood disorder, psychotic disorder not associated with depression, history of drug or alcohol dependence within 1 years of study entry, suicidal patients, pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:10:08 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 103 participants<BR/>Venlafaxine: 100 participants<BR/>Venlafaxine: 100 participants<BR/>Placebo: 98 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Venlafaxine dose range: 75-250 mg/day<BR/>Chloral hydrate was allowed as hypnotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:10:11 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS-21 total score and depressed mood items, Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) total score, Clinical Global Impression (CGI)<BR/>Secondary outcome: Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score from baseline on HDRS and MDRS or a CGi score of 1 or 2.<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:11:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rush-1998">
<CHAR_METHODS MODIFIED="2013-07-04 15:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:11:06 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for moderate to severe major depressive disorder, non psychotic, with a score of at least 18 on the first 17 items of the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 19-55 years<BR/>Exclusion criteria: engaged in a shift work, independent sleep/wake disorders, significant concurrent general medical conditions, DSM-III criteria for psychoactive use disorder within 1 year prior to study, other major lifetime Axis I disorders (organic mental syndrome, bipolar, any psychotic, any eating,panic or obsessive-compulsive disorder), pregnancy, lactation, absence of contraception.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 61 participants<BR/>Nefazodone: 64 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Nefazodone dose range: 200-500 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:11:17 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 total score, Inventory of Depressive Symptomatology (IDS), Clinical Global Impression (CGI) Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:11:19 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:12:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sandor-1998">
<CHAR_METHODS MODIFIED="2013-07-04 15:11:51 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depressive disorder, with a score of at least 18 on the Hamilton Rating Scale for Depression (HDRS-17).<BR/>Age range: 18-75 years<BR/>Exclusion criteria: serious medical disease, suicidal patients, history of alcohol or substance abuse, treatment resistant depression, bipolar mood disorder, use of antidepressants in the previous 2 weeks and fluoxetine in the previous 6 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Doxepine: 20 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Doxepine dose range: 75-225 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:12:01 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:12:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schatzberg-2006">
<CHAR_METHODS MODIFIED="2013-07-04 15:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for unipolar depression (single or recurrent, nonpsychotic) with a current episode of at least 4 weeks in duration; had a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age: 65 years<BR/>Exclusion criteria: bipolar disorder, psychotic disorder not related to depression, current substance abuse or substance dependence within the past year, current suicidal intent, at least 18 at the MMSE score, have received treatment with fluoxetine or venlafaxine in the past six months, electroconvulsive therapy within 3 months serious medical disease, suicidal patients, history of alcohol or substance abuse, any investigational drug or antipsychotic drug within the prior 30 days, use of astemizole, cisapride, sumatriptan, terfenadine, paroxetine, sertraline, or any monoamine oxidase inhibitor within 14 days, use of other antidepressant, anxiolytic, sedative-hypnotic drug, or any other psychotropic drug or substance within 7 days, patients with a known hypersensitivity to venlafaxine or fluoxetine, renal or hepatic disease, seizure disorder or myocardiac infarction within the prior 6 months, and patients with a severe, acute or unstable medical illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 100 participants</P>
<P>Venlafaxine: 104 participants</P>
<P>Placebo: 96 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Venlafaxine dose range: 75-225 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:12:51 +0100" MODIFIED_BY="[Empty name]">
<P>Decrease in HDRS-21 score, Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) score and Clinical Global Impression (CGI) score.</P>
<P>Response: decrease of at least 50% HDRS score from baseline to endpoint</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:12:52 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:13:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schone-1993">
<CHAR_METHODS MODIFIED="2013-07-04 15:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 18 on the first 17 items of the Hamilton Rating Scale for Depression (HDRS-21).<BR/>Age range: 65-85 years old<BR/>Exclusion criteria: severe physical illness, senile dementia, schizophrenia, organic brain syndrome, alcohol abuse, ECT during the previous 3 months, MAOI in the previous 2 weeks, depot neuroleptics in the previous 4 weeks, oral neuroleptics in the previous 2 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 52 participants<BR/>Paroxetine: 54 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Paroxetine dose range: 20-40 mg/day<BR/>Temazepam (15-30 mg) was allowed for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:13:45 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery&#8211;Åsberg Depression Rating Scale (MADRS), Clinical Global Impression (CGI), Mini Mental State Examination (MMSE), Sandoz Clinical Assessment-Geriatric (SCAG)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:13:47 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:14:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schrader-2000">
<CHAR_METHODS MODIFIED="2013-07-04 15:14:24 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:14:29 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling ICD 10 criteria for mild to moderate depression, with a score between 16 and 24 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Mean age: 46.5 years<BR/>Exclusion criteria: history of alcohol and substance abuse, dementia, history of seizures, glaucoma, pituitary deficiency, suicidal ideation, thyroid or parathyroid pathology, Parkinson's disease, pregnancy, any serious concomitant medical conditions, MAOI in the previous 2 weeks, SSRI in the previous 5 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:14:42 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 114 participants<BR/>Hypericum: 126 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Hypericum dose: 500 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change from baseline to endpoint on the HDRS-21<BR/>Secondary outcomes: change in depression and anxiety/somatization subscores of the HDRS-21, Clinical Global Impression (CGI) items 1-3, responder rates</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:14:51 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score or a score of maximum 10 on the HDRS-21<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:16:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sechter-1999">
<CHAR_METHODS MODIFIED="2013-07-04 15:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-four-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:15:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 20 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: 18-65 years<BR/>Exclusion criteria: pregnancy, absence of contraception, use of anticoagulants, serotoninergic drugs, MAOI or lithium, antihypertensive, epilepsy, organic brain disease, malignancy, severe disease or surgical intervention in the pervious 4 weeks, dermatological, haematological, endocrine, respiratory, cardiovascular, renal, hepatic, neurologic diseases, severe allergies or known fluoxetine allergy, previous treatment with sertraline, failure to respond to three or more previous antidepressant treatment, history of alcohol or drug dependence, psychosis, personality disorders, significant suicide risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 120 participants<BR/>Sertraline: 118 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Sertraline dose range: 50-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:16:02 +0100" MODIFIED_BY="[Empty name]">
<P>Change from baseline to endpoint on the HDRS-17 and Clinacal Global Impression (CGI), Covi Anxiety Scale (CAS), Hamilton Rating Scale for Anxiety (HAM-A)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:16:06 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS-17<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:17:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheehan-2009">
<CHAR_METHODS MODIFIED="2013-07-04 15:16:38 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:16:55 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-IV criteria for the melancholic subtype of MDD of at least 1 month duration, with a score of at least 24 on the first 21 items of the Hamilton Rating Scale for Depression (HDRS-21). (In patients at the moment of randomisation, then patients could complete the protocol as outpatients if, in the opinion of the investigator, the response to treatment was sufficient to allow discharge from hospital).<BR/>Age range: adults, over 18 years old<BR/>Exclusion criteria: severe or poorly controlled medical illnesses, known hypersensibility to either study drug, treatment with either study drug within 3 months, or myocardial infarction within 6 months before the start of the study, patients with clinically significant abnormalities on the physical examination, electrocardiogram, laboratory tests, or urine test, pregnancy, lactation, absence of contraception. Patients with active suicidal ideation, history of seizures, the presence or history of an organic mental disorder, mania or hypomania or psychotic disorder; electroconvulsive therapy within 3 months, any investigational or antipsychotic drug within 30 days, or astemizole, cisapride, sumatriptan, terfenadine, or any monoamine oxidase inhibitor within 14 days; patients could not have taken any other antidepressant, anxiolytic, sedative-hypnotic, or other psychotropic drug within 2 days before the start of double blind treatment; any non psychopharmacological drug with psychotropic effects in the last 2 days, and history of alcohol or drug dependence or abuse within 1 year before double-blind treatment.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 99 participants</P>
<P>Venlafaxine: 95 participants<BR/>Fluoxetine dose range: 60-80 mg/day</P>
<P>Venlafaxine dose range: 225-375 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS-21) total score, Clinical Global Impression (CGI) Improvement , Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) total score</P>
<P>Response: decrease of at least 50% in the total score on the HDRS and MADRS, or a score of 1-2 on the CGI-I</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:18:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silverstone-1999">
<CHAR_METHODS MODIFIED="2013-07-04 15:17:53 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 20 on the first 17 items on the Hamilton Depression (HDRS-21) and a score of at least 8 on the Covi Anxiety Scale (CAS) and symptoms of depression for at least 1 month before study entry.<BR/>Age: over 18<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception, history of clinically significant medical disease, clinically significant abnormalities on a physical examination, ECG or laboratory tests, suicide risk, history of seizure disorder, organic mental disorder, bipolar disorder, history of mania or any psychotic disorder not associated with depression, use of any investigational drug, ECT within 30 days, fluoxetine within 28 days, MAOI or paroxetine within 14 days, any other antidepressant, antipsychotic, anxiolytic, sedative-hypnotic drug or psychotropic or substance within 7 days of the start of the study, history of drug abuse within 6 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:18:06 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 119 participants<BR/>Venlafaxine: 122 participants<BR/>Placebo: 118 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Venlafaxine dose range: 75-225 mg/day<BR/>Chloral hydrate (max 1 g) or zopiclone (max 7.5 mg) for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:18:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: HDRS-21, Hamilton Rating Scale for Anxiety (HAM-A) and Clinical Global Impression (CGI) Improvement<BR/>Secondary outcomes: CAS, HDRS mood items, Hospital Anxiety and Depression Scale (HADS), Clinical Global Impression (CGI) Severity, HDRS and HAM-A response rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:18:24 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS and HAM-A, or a score of 1 on the CGI-I<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:19:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smeraldi-1998">
<CHAR_METHODS MODIFIED="2013-07-04 15:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:18:58 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for dysthymia or a single episode of major depression partial remission, with a score between 14 and 26 on the Montgomery&#8211;Åsberg Depression Rating Scale (MADRS).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: experience of inefficacy or intolerance to the study drug, suicidal risk, abuse or dependence on psychoactive substances, use of antidepressants or psychoactive drug in the previous 2 weeks, discontinuation of continuous or occasional use of benzodiazepines in the previous 2 weeks, need for psychoactive agents other than the study drug, severe debilitation, clinically relevant concomitant disease, cancer, pheochromocytoma, Parkinson's syndrome, pregnancy, absence of contraception, previous evidence of poor compliance, participation in a clinical trial in the previous 6 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 139 participants<BR/>Amisulpride: 142 participants</P>
<P>Fluoxetine dose: 20 mg/day<BR/>Amisulpride dose: 50 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: a reduction of at least 50% on the MADRS total score<BR/>Secondary outcomes: change at endpoint on MADRS, Hamilton Rating Scale for Anxiety (HAM-A), Sheean Disability Scale (SDS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:19:17 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:20:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SouthWalesGroup-1988">
<CHAR_METHODS MODIFIED="2013-07-04 15:19:58 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 16-70 years<BR/>Exclusion criteria: pregnancy, absence of contraception, ECT, use of adequate doses of tricyclics in the previous 4 weeks, use of MAOI in the previous 10 days, history of sensitivity to drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:20:16 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 31 participants<BR/>Dothiepin: 28 participants<BR/>Fluoxetine dose range: 60-80 mg/day<BR/>Dothiepine dose range: 150-225 mg/day<BR/>Temazepam for night sedation was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:20:20 +0100" MODIFIED_BY="[Empty name]">
<P>Global Assessment of Severity (GAS), Clinical Global Impression (CGI), HDRS-17, Beck and Rafaelsen Mania Scale (MAS), Montgomery&#8211;Åsberg Depression Rating Scale (MADRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:20:21 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:21:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sramek-1995">
<CHAR_METHODS MODIFIED="2013-07-04 15:20:53 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive disorder, without melancholia, with a score of at least 21 on the Hamilton Rating Scale for Depression (HDRS-24) and a score of at least 2 on the item 1 of HDRS-21 and a score of maximum 18 on the Hamilton Rating Scale for Anxiety (HAM-A), a score of at least 8 on the Raskin Depression Scale (RDS) and a total Covi Anxiety Scale (CAS) less than RDS.<BR/>Age range: 18-65 years<BR/>Exclusion criteria: any clinically significant hematological, endocrine, cardiological, renal, gastrointestinal, neurological disorder, seizure disorder, significant suicidal risk, other Axis I disorders besides dysthymia, Axis 2 diagnosis of antisocial or borderline disorder, history of substance or alcohol abuse within 6 months, ECT in the previous 6 months, use of MAOI or fluoxetine within 3 weeks, any other antidepressant within the last week, use of benzopines within the last 2 weeks, being in any type of psychotherapy since less than 3 months, or having ended such therapy within 1 month prior the study.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:21:05 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 72 participants<BR/>ABT-200: 72 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>ABT-200 dose: 20 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:21:09 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, Montgomery&#8211;Åsberg Depression Rating Scale (MADRS), Clinical Global Impression (CGI), HAM-A</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:21:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:22:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stark-1985">
<CHAR_METHODS MODIFIED="2013-07-04 15:21:53 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III criteria for major depressive disorder (with a duration of illness of at least 4 weeks), with a score of at least 20 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) and a score of at least 8 on the Raskin Depression Scale (RDS).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:22:47 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 185 participants<BR/>Imipramine: 186 participants<BR/>Placebo: 169 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Imipramine dose range: 75-300 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, RDS, Covi Anxiety Scale (CAS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:22:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:23:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stephenson-2000">
<CHAR_METHODS MODIFIED="2013-07-04 15:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:23:32 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III-R criteria for major depression, with a score of at least 22 on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: concurrent treatment for depressive illness, use of other drugs with psychopharmacological effect, serious risk of suicide, significant cardiac, renal or hepatic disease, pregnancy, lactation, absence of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 51 participants<BR/>Dothiepin: 56 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Dothiepine dose range: 75-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:23:40 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), MADRS, Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:23:42 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:24:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stratta-1991">
<CHAR_METHODS MODIFIED="2013-07-04 15:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:24:43 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with atypical depression according to Quitkin et al (1988) criteria<BR/>Mean age: 35 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 14 participants<BR/>Imipramine: 14 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Imipramine dose range: 75-125 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:24:52 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), Clinical Global Impression (CGI), Covi Anxiety Scale (CAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:24:53 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:25:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suleman-1997">
<CHAR_METHODS MODIFIED="2013-07-04 15:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, single-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:25:33 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: any physical illness or psychiatric diagnosis beside depressive disorder, drug or alcohol abuse, organic mental disorder, pregnancy or lactation, use of any medication except incidental analgesics and current psychotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:25:41 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 15 participants<BR/>Moclobemide: 15 participants<BR/>Amitriptyline: 15 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Moclobemide dose: 240 mg/day<BR/>Amitriptyline dose: 100 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:25:43 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:25:45 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:26:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suri-2000">
<CHAR_METHODS MODIFIED="2013-07-04 15:26:29 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for unipolar major depressive disorder, with a score of at least 14 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 18-62 years<BR/>Exclusion criteria: diagnosis of a mood disorder to a secondary general medical condition, bipolar disorder, substance abuse, history of prior treatment with sertraline or fluoxetine. For patients with a history of substance abuse a period of 30 days of sobriety was required prior to study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 18 participants<BR/>Sertraline (50 mg): 17 participants<BR/>Sertraline (100 mg): 17 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Lorazepam (0.5 mg) was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: a HDRS-21 score of maximum 7 or a Clinical Global Impression (CGI) score of maximum 2 at endpoint (remission)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:26:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:28:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tamminen-1989">
<CHAR_METHODS MODIFIED="2013-07-04 15:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 14:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling RDC (Research Diagnostic Criteria) for unipolar major depressive disorder with a score of at least 17 on the first 17 items of the Hamilton Rating Scale for Depression (HDRS) and a score of at least 8 and equal to or higher than the Covi Anxiety Scale (CAS) score. Age mean: 40.7 (fluoxetine); 42.7 (doxepin). Exclusion criteria: history of drug abuse, concurrent administration of other psychotropic drugs including lithium.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 26 participants<BR/>Doxepine: 25 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Doxepine dose range: 50-150 mg/day<BR/>Chloral hydrate and oxazepam were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:27:59 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI), Raskin Depression Scale (RDS), CAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:28:01 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:28:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taner-2006">
<CHAR_METHODS MODIFIED="2013-07-04 15:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week single-blind randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 14:24:59 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-IV criteria for major depressive disorder lasting at least 1 month and for atypical depression.</P>
<P>Exclusion criteria: significant suicide risk, pregnancy, lactation or unwillingness to use effective birth control in women, unstable and serious physical illness, a history of seizures, psychosis or organic mental syndrome, substance abuse disorders within the past 6 months, except for nicotine dependence, history of mania, antisocial personality disorder and use of an antidepressant over the previous month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:28:50 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 21 participants<BR/>Reboxetine: 22 participants<BR/>Fluoxetine dose range: 40-80 mg/day</P>
<P>Reboxetine dose range: 4-10 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:28:53 +0100" MODIFIED_BY="[Empty name]">
<P>Change in the Hamilton Rating Scale for Depression-17 item (HDRS-17) score and in Clinical Global Impression (CGI) score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:28:55 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:29:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taneri-1989">
<CHAR_METHODS MODIFIED="2013-07-04 15:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:29:26 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients with diagnosis of neurotic or reaction depressive disorder on the ICD, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: suicidality, severe organic disease, diabetes mellitus, glaucoma, hyperthyroidism, pregnancy, hypersensitivity to drug, abnormal liver values, organic psychosis, schizophrenia, psychopathy, addiction to alcohol or drugs, seizures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Nomifensine: 20 participants<BR/>Fluoxetine dose: 40 mg/day<BR/>Nomifensine dose: 150 mg/day<BR/>Chloral hydrate or benzodiazepines for sleep were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:29:41 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Clinical Global Impression (CGI), Symptom Check List of Taneri, Patient Global Impression (PGI), Zung Depression Scale (SDS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:30:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-2000">
<CHAR_METHODS MODIFIED="2013-07-04 15:30:35 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:30:38 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (general practice) DSM-III-R criteria for major unipolar depression, with a score of at least 12 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-70 years<BR/>Exclusion criteria: suicidal ideation, history of treatment resistant depression, bipolar disorder, organic brain disease, substance use disorder, use of antidepressants within the last 6 months, participation to another study within 3 months, medical contraindication to either drug, pregnancy, lactation, absence of contraception, administration of any other psychotropic medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:30:46 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 76 participants<BR/>Dothiepin: 76 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Dothiepine dose range: 75-150 mg/day<BR/>Concomitant use of benzodiazepines was allowed for insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes (all were dichotomised as above or below 80% of full compliance): pill count, patient completed questionnaire, Medication Event Monitoring System<BR/>Secondary outcomes: HDRS, Short-Form Health Survey Questionnaire 36 (SF-36)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:30:58 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:31:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tignol-1993">
<CHAR_METHODS MODIFIED="2013-07-04 15:31:39 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:31:43 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 24 on the Montgomery and Asberg Scale for Depression (MADRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: pregnancy or nursing, severe concomitant physical disease, severe risk of suicide, abuse of alcohol or illicit drugs, schizophrenia or psychosis, organic brain syndrome, history of serious allergic drug reaction, treatment with any investigational compound during the previous 6 months, lithium or ECT in the previous 3 months, depot neuroleptics in th previous month, MAOI or oral neuroleptics in the previous 2 weeks, present use of oral anticoagulant or psychotropic drug (except chloral hydrate: 500 mg for sleep).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 87 participants<BR/>Paroxetine: 89 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Paroxetine dose: 20 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>MADRS, Hamilton Rating Scale for Anxiety (HAM-A), Hospital Anxiety and Depression (14 items), Clinical Global Impression (CGI) Severity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:31:54 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:33:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tollefson-1994">
<CHAR_METHODS MODIFIED="2013-07-04 15:32:39 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling DSM-III-R criteria for major depressive unipolar disorder for at least 1 month, non-psychotic, and subtype as agitated according Research Diagnostic Criteria, with a score of at least 14 on the Hamilton Rating Scale for Depression-17 item (HDRS-17) and a score of 2 or more on at least 2 items of the Agitation Rating Scale (ARS).<BR/>Age range: 18-65 years old<BR/>Exclusion criteria: pregnancy, breast feeding, absence of contraception, serious suicidal risk, contraindication to use study drug, concurrent DSM diagnosis such as organic mental disorder, substance use disorder, schizophrenia and related psychotic disorders, bipolar disorder, severe allergies, drug reactions, use of other psychotropic drugs within 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 62 participants<BR/>Imipramine: 62 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Imipramine dose range: 150-300 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change on Hamilton Rating Scale for Depression (HDRS) from baseline to endpoint<BR/>Secondary outcomes: percentages of responders, remitters and weekly change from baseline, Clinical Global Impression (CGI), Hamilton Rating Scale for Anxiety (HAM-A), ARS, HDRS-17 item 3, HDRS-17 item 9, Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:33:04 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS-17 during at least 4 weeks of treatment<BR/>Remission: endpoint score of maximum 7 on the HDRS-17<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:34:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tylee-1997">
<CHAR_METHODS MODIFIED="2013-07-04 15:33:39 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:33:45 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients (general practice) fulfilling DSM-IV criteria for major depressive disorder, with a score of at least 19 on the Montgomery&#8211;Åsberg Depression Rating Scale (MADRS).<BR/>Age: over 18 years<BR/>Exclusion criteria: use of study drugs within 1 month of entry, psychosis, organic mental disorder, bipolar depression, acute suicidal risk, use of psychoactive drug or ECT within 1 month of entry, drug or alcohol dependence, history of clinically significant physical disorder, clinically significant abnormalities (ECG, laboratory test), pregnancy, lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:33:54 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 170 participants<BR/>Venlafaxine: 171 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Venlafaxine dose: 75 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:33:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: endpoint score on MADRS and Clinical Global Impression (CGI), and Hamilton Rating Scale for Depression (HDRS)<BR/>Secondary outcomes: Hospital Anxiety and Depression Scale (HADS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS or MADRS and a CGI Improvement of 1 or 2<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:35:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tzanakaki-2000">
<CHAR_METHODS MODIFIED="2013-07-04 15:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-IV criteria for major depression, with melancholia and symptoms lasting at least 1 month before study entry, with a score of at least 25 on the Montgomery&#8211;Åsberg Depression Rating Scale (MADRS).<BR/>Age range: 18-64 years<BR/>Exclusion criteria: pregnancy, absence of contraception, known sensitivity to venlafaxine or fluoxetine, history of uncontrolled heart failure within the last 6 months, hepatic or renal disease, clinically significant abnormality (ECG, laboratory tests), acute suicide tendencies, history of seizure disorders, any psychotic disorder not associated with depression, history of alcohol or drug dependence within the past year, use of any investigational drug, antipsychotic drug or ECT within 30 days, fluoxetine within 14 days, MAOI or benzodiazepines within 7 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 54 participants<BR/>Venlafaxine: 55 participants<BR/>Fluoxetine dose: 60 mg/day<BR/>Venlafaxine dose: 225 mg/day</P>
<P>Temazepam and oxazepam were allowed for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Hamilton Rating Scale for Depression (HDRS), MADRS, Clinical Global Impression (CGI), Severity and improvement scores at each assessment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS or MADRS and a CGI improvement of 1 or 2<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:36:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Upward-1988">
<CHAR_METHODS MODIFIED="2013-07-04 15:36:02 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:36:11 +0100" MODIFIED_BY="[Empty name]">
<P>Depressed outpatients<BR/>Age range: 24-63 years<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:36:18 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 11 participants<BR/>Amitriptyline: 12 participants<BR/>Fluoxetine dose range: 60-80 mg/day<BR/>Amitriptyline dose range: 150-200 mg/day<BR/>Temazepam (10-20 mg) was allowed for sleep</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy data not reported. Only dropout rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:37:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Moffaert-1995">
<CHAR_METHODS MODIFIED="2013-07-04 15:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:36:58 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for moderate to severe major depression, with a score of at least 18 on the first 17 items of Hamilton Rating Scale for Depression (HDRS) and a score of at least 3 on the Clinical Global Impression.<BR/>Age range: 18-80 years old<BR/>Exclusion criteria: Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) score more than 40, suicidal ideation, history of mania, hypomania or psychosis, comorbid severe psychiatric disorder, organic mood disorder, psychotropic drug dependence, pregnancy, lactation, clinically significant renal, hepatic, cardiovascular, respiratory, cerebrovascular disease, use of concomitant serotonergic drug (including lithium and carbamazepine).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:37:13 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 82 participants<BR/>Sertraline: 83 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Sertraline dose range: 50-100 mg/day<BR/>Chloral hydrate and short acting benzodiazepines as hypnotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, MADRS, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:37:19 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS or MADRS, or a score less than 10 on the HDRS</P>
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:38:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Versiani-1999">
<CHAR_METHODS MODIFIED="2013-07-04 15:38:06 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:38:08 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatients fulfilling DSM-IV criteria for major depression, with a score of at least 18 on the first 17 items on the HDRS-21 and a score of at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A).<BR/>Age: over 18 years<BR/>Exclusion criteria: pregnancy, lactation, absence of contraception, suicidal risk, medical disease, history of allergy to study drugs, previous participation to any antidepressant trial, history of unresponsiveness to fluoxetine or amitriptyline, organic mental disorder, substance abuse, bipolar disorder, melancholic disorder, panic or obsessive compulsive disorder, concomitant medication with psychotropic effect.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:38:21 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 77 participants<BR/>Amitriptyline : 80 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose range: 50-250 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:38:23 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21, HAM-A, Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS), Clinical Global Impression (CGI), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:38:27 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS and a decrease of at least 25% in the total score on the HAM-A<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:39:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Versiani-2005">
<CHAR_METHODS MODIFIED="2013-07-04 15:39:01 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:39:10 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-IV criteria for major depressive episode, with a score of at least 25 on the first 17 items of the Hamilton Rating Scale for Depression (HDRS).<BR/>Age range: 18-65 years<BR/>Exclusion criteria: bipolar disorder, depressive disorder NOS, anxiety disorder, schizophrenia, adjustment disorder or psychotic symptoms or borderline personality disorder, eating disorder, post-partum depression, organic mental illness, epilepsy (treatment with anticonvulsive medication for epilepsy or seizures), alcohol or substance abuse in the past 6 months, a decrease of 25% in the HDRS score from the washout period to the screening measurement, duration of the present episode exceeding 12 months, lack of response to two adequate antidepressant drugs for a duration of at least 6 weeks, actual risk of suicide Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) item of 5-6), unstable medical conditions, participation in another clinical trial within 30 days, MAOI within 3 weeks, fluoxetine for the current episode of depression, ECT within 3 months, depot antipsychotic (2 months) or other psychotropic drugs (1 week), use of benzodiazepines within 2 weeks of treatment start (patients receiving a stable dosage could participate if the dosage was kept the same throughout the trial), pregnancy, lactation, absence of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:39:17 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 152 participants<BR/>Mirtazapine: 147 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Mirtazapine dose range: 30-60 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:39:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in the HDRS score</P>
<P>Secondary outcomes: MADRS score and Clinical Global Impression (CGI) score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:39:22 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:40:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wehmeier-2005">
<CHAR_METHODS MODIFIED="2013-07-04 15:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind, parallel group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:40:01 +0100" MODIFIED_BY="[Empty name]">
<P>In and out-patients fulfilling DSM-III-R criteria for major depression, with a score of at least 16 on Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age range: 61-85 years<BR/>Exclusion criteria: a reduction of HDRS-17 total score of more than 25% between the screening visit and the baseline visit, serious suicidal risk, severe organic brain disorder, significant organic illness, a history of seizures, a history of schizophrenia and a recent history (in the last year) of drug or alcohol abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:40:09 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 20 participants<BR/>Trimipramine: 21 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Trimipramine dose: 150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:40:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-17</P>
<P>Secondary outcomes: Montgomery&#8211;Åsberg Depression Rating Scale (MADRS), the Adjective Mood Scale (AMS), Clinical Global Impression (CGI), Patient Global Impression (PGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:40:27 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS or a total score on HDRS lower than 10<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:41:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WELL-AK1A4006">
<CHAR_METHODS MODIFIED="2013-07-04 15:41:15 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, double-blind, multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:41:22 +0100" MODIFIED_BY="[Empty name]">
<P>Out-patients fulfilling DSM-IV criteria for recurrent major depression, with a score of at least 20 on Hamilton Rating Scale for Depression-21 item (HDRS-21) on day -1 and -7, were currently experiencing a recurrent major depressive episode and had a normal sexual functioning.</P>
<P>Mean age Fluoxetine: 37.1 years (SD: 10.7)</P>
<P>Mean age Bupropion: 38.6 years (SD: 12.0)<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:41:27 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 155 participants<BR/>Bupropion: 158 participants<BR/>Fluoxetine dose range: 20-60 mg/day<BR/>Bupropion dose range: 150-400 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:41:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: change in HDRS-21; incidence of the orgasm dysfunction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS-21 between baseline and endpoint</P>
<P>Remission: HDRS-21 total score dropped to less than 8 between baseline and endpoint<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:43:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wheatley-1998">
<CHAR_METHODS MODIFIED="2013-07-04 15:42:49 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:42:54 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depressive episode, with a score of at least 21 on the Hamilton Rating Scale for Depression-17 item (HDRS-17) and a score of at least 2 on the HDRS-17 item 1.<BR/>Age range: 18-75 years<BR/>Exclusion criteria: bipolar disorder, depressive disorder NOS, anxiety disorder within the last 2 years, schizophrenia, adjustment disorder, schizotypal or borderline personality disorder, eating disorder within the last 2 years, epilepsy, treatment with anticonvulsive medication for seizures, alcohol or substance abuse in the previous year, post-partum depression within 1 year after delivery, high risk of suicide, unstable medical conditions, non-responders to antidepressant treatments, use of MAOI within 2 weeks, previous use of fluoxetine for the current episode of depression, ECT within 3 months, continuous use of benzodiazepines, pregnancy, lactation, absence of contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 67 participants<BR/>Mirtazapine: 66 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Mirtazapine dose range: 15-60 mg/day<BR/>Temazepam (20 mg) oxazepam (15 mg) and nitrazepam (5 mg) were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:43:12 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:44:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Williams-1993">
<CHAR_METHODS MODIFIED="2013-07-04 15:43:57 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:44:00 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III criteria for major depressive episode, with a score of at least 17 on the Hamilton Rating Scale for Depression-21 item (HDRS-21).<BR/>Age range: 20-86 years<BR/>Exclusion criteria: suicide risk, other psychiatric disorder, alcohol abuse, use of MAOI in the previous 2 weeks, use of other antidepressants in the previous week, pregnancy, lactation, known allergy to trial medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 60 participants<BR/>Moclobemide: 62 participants<BR/>Fluoxetine dose range: 20-40 mg/day<BR/>Moclobemide dose range: 300-600 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:44:15 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: HDRS-21</P>
<P>Secondary outcome: Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:44:16 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:45:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winokur-2003">
<CHAR_METHODS MODIFIED="2013-07-04 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week double-blind randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:44:48 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for major depressive disorder (based on a semi structured clinical interview), a score of at least 18 on the Hamilton Rating Scale for Depression-21 item (HDRS-21) and a score of at least 4 on the 3 HDRS-21 sleep item.</P>
<P>Age range: 18-75 years</P>
<P>Exclusion criteria: patients with an history of primary sleep disorder, significant medical problems, current alcohol or substance abuse or dependence, psychosis, or suicidal ideation. Psychotropic drugs were discontinued at least 1 week before study initiation and no subject received any prolonged-acting central nervous system agent during the previous month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:45:02 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 8 participants<BR/>Mirtazapine: 8 participants<BR/>Fluoxetine dose range: 20-40 mg/day</P>
<P>Mirazapine dose range: 15-45 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Change in the HDRS-21 score and in Clinical Global Impression (CGI) score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:45:05 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:45:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2001">
<CHAR_METHODS MODIFIED="2013-07-04 15:45:36 +0100" MODIFIED_BY="[Empty name]">
<P>Five-week randomised, double-blind two-centre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:45:38 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients fulfilling DSM-III-R criteria for major depression, with a score of at least 16 on the Hamilton Rating Scale for Depression-17 item (HDRS-17).<BR/>Age: over 60 years<BR/>Exclusion criteria: serious suicidal risk, glaucoma, chronic urinary retention, prostatic hypertrophy, significant organic illness, severe organic brain disease, history of seizures, schizophrenia, hypo- or hyperthyroidism, history of severe allergy, known allergy to imipramine, history of less than 1 year of alcohol or drug abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 10 participants<BR/>Trimipramine: 9 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Trimipramine dose: 150 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:45:54 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Montgomery and Asberg Scale for Depression (MADRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:45:57 +0100" MODIFIED_BY="[Empty name]">
<P>This study focuses on sleep related problems<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:46:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Young-1987">
<CHAR_METHODS MODIFIED="2013-07-04 15:46:35 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:46:38 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients fulfilling RDC criteria for moderate-severe major depression, with a score of at least 18 on the Hamilton Rating Scale for Depression (HDRS).<BR/>Age: 20-65 years<BR/>Exclusion criteria: schizophrenia, organic features, use of antidepressant drugs or ECT during the 4 weeks before.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 25 participants<BR/>Amitriptyline: 25 participants<BR/>Fluoxetine dose range: 40-80 mg/day<BR/>Amitriptyline dose range: 50-150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:46:51 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS, Hamilton Rating Scale for Anxiety (HAM-A), Beck Depression Inventory Scale (BDI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>Most patients taking sedatives during study<BR/>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:47:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-1997">
<CHAR_METHODS MODIFIED="2013-07-04 15:47:26 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:47:29 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with serious depressive disorder<BR/>Mean age: 51 years<BR/>Exclusion criteria: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:47:35 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 8 participants<BR/>Amitriptyline: 8 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Amitriptyline dose: 150 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Rating Scale for Depression (HDRS), Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-04 15:48:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2006-a">
<CHAR_METHODS MODIFIED="2013-07-04 15:48:07 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, open label trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-04 15:48:09 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for major depression, with a score of at least 18 on Hamilton Rating Scale for Depression-17 item (HDRS-17) and a HDRS retardation score of at least 8 (assessed using the score of the first item of depressed mood, the 7th item of interest and activity, the 8th item of retardation and 14 item of decreased sexuality in the HDRS scale.<BR/>Age: over 18 years<BR/>Exclusion criteria: past history of any manic or hypomanic episode, any medical record listed as follows: disease in heart, liver, kidney, immune system, neural system, blood system, narrow-angle glaucoma, past history of allergic reaction to the studied drugs, being medicated with MAOIs in the past 2 weeks, being treated with ECT in the past 6 months, recurrent suicidal ideation or a suicide attempt, lack of therapeutic reaction to fluoxetine or trazodone in past 6 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-04 15:48:23 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 61 participants<BR/>Trimipramine: 59 participants<BR/>Fluoxetine dose range: 20-80 mg/day<BR/>Trimipramine dose range: 100-300 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-04 15:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>Reduction in HDRS-17 and reduction in HDRS-17 retardation factor score; total score of Symptom Checklist-90-R (SCL-90-R) energy related 5 items; medical outcomes study-Short Form (SF-36); 4) cognitive function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-04 15:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>Response: decrease of at least 50% in the total score on the HDRS-17 from baseline<BR/>Funding: by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-11-15 12:15:17 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-04-12 11:07:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baca-Baldomero-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-12 11:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-18 14:31:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bitrain-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-18 14:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brasseur-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-23 11:56:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohn-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-23 11:56:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not meeting inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-12 11:06:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ducher-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-12 11:06:13 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:44:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodnick-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial: randomisation to different doses of fluoxetine, without any drug comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:44:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:44:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not fulfilled inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-15 12:05:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hunter-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-15 12:05:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation to fluoxetine or placebo, no drug comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-15 12:05:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iovieno-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-15 12:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation to fluoxetine or placebo, no drug comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-16 09:23:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kroenke-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-16 09:23:52 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong diagnosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-12 11:41:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musgnung-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-12 11:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial: not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-12 11:44:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nemetz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-12 11:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong drug comparison: neither antidepressant nor herbal product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-12 11:44:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peveler-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-12 11:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-18 14:34:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roose-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-18 14:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial: not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmidt-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term treatment of depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:48:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serrano_x002d_Blanco-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:48:04 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong inclusion criteria: diagnosis of dysthymia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simon-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not meeting inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simon-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not meeting inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simon-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not meeting inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-23 11:55:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strik-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-23 11:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-07-02 11:59:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-07-02 11:47:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, double dummy clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:47:01 +0100" MODIFIED_BY="[Empty name]">
<P>48 participants randomised to fluoxetine or reboxetine<BR/>Fluoxetine dose: 20 mg/day<BR/>Reboxetine dose: 8 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:48:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GSK-29060_x002f_134">
<CHAR_METHODS MODIFIED="2013-07-02 11:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:47:11 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with major depression with associated anxiety</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:48:06 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine and paroxetine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>Montgomery and Asberg Scale for Depression (MADRS), Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:48:10 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Portuguese to English</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:48:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2006a">
<CHAR_METHODS MODIFIED="2013-07-02 11:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>Citalopram: 30 participants<BR/>Fluoxetine: 30 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:48:22 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI) and Treatment Emergent Symptom Scale (TESS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:48:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2006b">
<CHAR_METHODS MODIFIED="2013-07-02 11:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:48:36 +0100" MODIFIED_BY="[Empty name]">
<P>Citalopram: 26 participants<BR/>Fluoxetine: 25 participants<BR/>Citalopram dose-range: 20-60 mg/day<BR/>Fluoxetine dose-range: 20-60 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:48:51 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale 17-Item (HDRS-17)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:48:53 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:49:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, double dummy multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:49:18 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:49:25 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 145 participants</P>
<P>Kaiyuanshen: 144 participants<BR/>Fluoxetine dose: 20 mg/day<BR/>Kaiyuanshen dose: 1440 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:49:44 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:49:45 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:50:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:49:52 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, double dummy multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:50:10 +0100" MODIFIED_BY="[Empty name]">
<P>144 participants randomised to fluoxetine or bupropion</P>
<P>61 patients in Bupropion group and 64 in fluoxetine group completed the study<BR/>Fluoxetine dose: 20 mg/day<BR/>Bupropion dose: 300 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:50:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006a">
<CHAR_METHODS MODIFIED="2013-07-02 11:50:16 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, double dummy trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:50:33 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder, with a score of at least 18 at Hamilton Depression Rating Scale (HDRS) and a score of 14 or greater at the Hamilton Anxiety Scale (HAM-A)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:50:45 +0100" MODIFIED_BY="[Empty name]">
<P>137 participants randomised to fluoxetine or reboxetine</P>
<P>64 patients in Reboxetine group and 68 in fluoxetine group completed the study<BR/>Fluoxetine dose: 20 mg/day<BR/>Reboxetine dose: 8 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:50:47 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS), Hamilton Rating Scale for Anxiety (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:50:49 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:51:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006b">
<CHAR_METHODS MODIFIED="2013-07-02 11:50:51 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised, double-blind, double dummy trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:50:52 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>228 participants randomised to fluoxetine or reboxetine<BR/>Fluoxetine dose: unclear<BR/>Reboxetine dose: unclear<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:51:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006c">
<CHAR_METHODS MODIFIED="2013-07-02 11:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>Four-week, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:51:10 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty patients randomised to fluoxetine or reboxetine</P>
<P>Fluoxetine dose range: 4-8 mg</P>
<P>Reboxetine dose range: 20-40 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:51:31 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:51:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:51:34 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week, (likely) randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>In- and outpatients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>Citalopram: 30 participants<BR/>Fluoxetine: 30 participants<BR/>Citalopram dose range: 10-60 mg/day<BR/>Fluoxetine: dose range: 10-40 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>Change in Hamilton Depression Rating Scale 24 Item (HDRS-24) from baseline to endpoint, number of patients who responded to treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:51:45 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:52:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Licinio-2004">
<CHAR_METHODS MODIFIED="2013-07-02 11:51:53 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:51:59 +0100" MODIFIED_BY="[Empty name]">
<P>Out-patients fulfilling DSM-IV criteria for unipolar major depressive disorder, with a score of at least 18 on the Hamilton Depression Rating Scale-21 item (HDRS-21)<BR/>Age range: 18-70 years</P>
<P>Exclusion criteria: active suicidal risk or history of life-threatening suicide attempts<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:52:11 +0100" MODIFIED_BY="[Empty name]">
<P>272 participants randomised to fluoxetine or desipramine<BR/>Fluoxetine dose range: 10-40 mg/day<BR/>Desipramine dose range: 50-200 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-18 17:03:29 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-21.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-18 17:06:11 +0100" MODIFIED_BY="[Empty name]">
<P>Funding:unclear.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:52:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2007">
<CHAR_METHODS MODIFIED="2013-07-02 11:52:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, double dummy multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:52:21 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>228 participants randomised to fluoxetine or bupropion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-17 item (HDRS-17)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:53:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00909155">
<CHAR_METHODS MODIFIED="2013-07-02 11:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:52:39 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:52:54 +0100" MODIFIED_BY="[Empty name]">
<P>Participants randomised to fluoxetine or venlafaxine</P>
<P>Fluoxetine: 10 participants</P>
<P>Venlafaxine: 17 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:53:04 +0100" MODIFIED_BY="[Empty name]">
<P>Mood and Anxiety Symptoms Questionnaire (MASQ-AD), Hamilton Depression Rating Scale (HDRS); fMRI response to an emotional regulation task</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:53:07 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by National Grants and industry</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:53:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:53:08 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised single-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:53:12 +0100" MODIFIED_BY="[Empty name]">
<P>First episode depressive patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:53:28 +0100" MODIFIED_BY="[Empty name]">
<P>Eighty participants randomised to fluoxetine or venlafaxine</P>
<P>Fluoxetine dose range: 20-40 mg/day</P>
<P>Venlafaxine dose range: 75-225 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:53:29 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:53:31 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:53:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sackeim-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:53:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised (unpublished) multi-site trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Out-patients with depression according to DSM-IV criteria</P>
<P>Age range: 18-60 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:53:49 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 173 participants</P>
<P>Sertraline: 177 participants</P>
<P>Fluoxetine range dose: 20- 80 mg/day</P>
<P>Sertraline range dose: 50-150mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:53:50 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-24 item (HDRS-24)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:53:57 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:54:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salehi-2009">
<CHAR_METHODS MODIFIED="2013-07-02 11:53:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:54:00 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to DSM-IV criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:54:06 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 40 participants</P>
<P>Imipramine: 40 participants</P>
<P>Fluoxetine dose: 20 mg/day</P>
<P>Imipramine dose: 100 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:54:07 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:54:09 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Arabic to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:54:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shen-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:54:23 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:54:29 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 113 participants</P>
<P>Reboxetine: 109 participants</P>
<P>Fluoxetine dose: 20 mg/day</P>
<P>Reboxetine dose: 8 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:54:31 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-17 item (HDRS-17), Hamilton Rating Scale for Anxiety (HAM-A), Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:54:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stassen-1999">
<CHAR_METHODS MODIFIED="2013-07-02 11:54:35 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:54:37 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-III criteria for major depressive disorder, with a score of at least 15 on the Hamilton Depression Rating Scale-17 item (HDRS-17).<BR/>Age range: 18-86 years old<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:54:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 440 participants<BR/>Moclobemide: 437 participants<BR/>Fluoxetine dose: 20-40 mg/day<BR/>Moclobemide dose: 300-600 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:54:57 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17, Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:54:59 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: probably by industry</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:55:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve-week, (likely) randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with first episode major depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:55:14 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 40 participants</P>
<P>Venlafaxine: 40 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:55:16 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression rating scale-17 item (HDRS-17), Hamilton Rating Scale for Anxiety (HAM-A), Wechsler Adult Intelligence Scale (WAIS), Wisconsin Card Sorting Test (WCST)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:55:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:55:19 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:55:32 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 51 participants</P>
<P>Venlafaxine: 51 participants</P>
<P>Fluoxetine dose-rage: 20-40 mg/day</P>
<P>Venlafaxine dose-rage: 50-200 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:55:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:55:36 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week, (likely) randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:55:38 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:55:47 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty participants randomised to fluoxetine or venlafaxine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:55:55 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:55:56 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:56:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tan-1997">
<CHAR_METHODS MODIFIED="2013-07-02 11:55:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:56:01 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:56:02 +0100" MODIFIED_BY="[Empty name]">
<P>Eighteen participants randomised to fluoxetine or amitriptyline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:56:04 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:56:05 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:56:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:56:06 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week, randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:56:08 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:56:09 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty patients randomised to fluoxetine or venlafaxine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:56:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2007a">
<CHAR_METHODS MODIFIED="2013-07-02 11:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Participants assigned to fluoxetine or paroxetine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:56:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2007b">
<CHAR_METHODS MODIFIED="2013-07-02 11:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week, randomised, double-blind, double dummy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:56:40 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>48 participants randomised to fluoxetine or bupropion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression rating scale (HDRS), Hamilton Rating Scale for Anxiety (HAM-A) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:56:44 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:57:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2009">
<CHAR_METHODS MODIFIED="2013-07-02 11:56:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, double dummy multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:56:57 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with mild or moderate depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:57:04 +0100" MODIFIED_BY="[Empty name]">
<P>High-dose of Morinda Officinalis Oligose capsule: 119 participants</P>
<P>Low-dose of Morinda Officinalis Oligose capsule: 119 participants</P>
<P>Fluoxetine: 118 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:57:06 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-17 item (HDRS-17)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:57:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2011">
<CHAR_METHODS MODIFIED="2013-07-02 11:57:16 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>Out-patients with major depressive disorder (MDD)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:57:39 +0100" MODIFIED_BY="[Empty name]">
<P>117 participants randomised to fluoxetine or venlafaxine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:57:41 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-21 item (HDRS-21)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:57:50 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract from conference</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:58:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:57:53 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week, (likely) randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:57:55 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-II-R criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:57:56 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty participants randomised to fluoxetine or venlafaxine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression rating scale (HDRS) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:58:05 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:58:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2010">
<CHAR_METHODS MODIFIED="2013-07-02 11:58:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, open trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:58:15 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty patients randomised to fluoxetine or escitalopram</P>
<P>Fluoxetine dose range: 20-40 mg/day</P>
<P>Escitalopram dose range: 10-20bmg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:58:17 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:58:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:58:26 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:58:27 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with senile depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:58:29 +0100" MODIFIED_BY="[Empty name]">
<P>50 participants randomised to fluoxetine or citalopram</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:58:30 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-17 item (HDRS-17) and Clinical Global Impression (CGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:58:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, single-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>Citalopram: 30 participants<BR/>Fluoxetine: 30 participants<BR/>Citalopram dose range: 20-60 mg/day<BR/>Fluoxetine dose range: 20-60 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:58:48 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale-24 item (HDRS-24)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:59:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:58:59 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week randomised, single-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:59:01 +0100" MODIFIED_BY="[Empty name]">
<P>First episode depressive patients aged 60 years or over</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:59:02 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty-four patients randomised to fluoxetine or venlafaxine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:59:03 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:59:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2005">
<CHAR_METHODS MODIFIED="2013-07-02 11:59:06 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>Elderly patients with depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty patients randomised to fluoxetine or mirtazapine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-07-02 11:59:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2006">
<CHAR_METHODS MODIFIED="2013-07-02 11:59:18 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with depression according to CCMD-III criteria, aged 60 years or over</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine: 23 participants</P>
<P>Mirtazapine: 23 participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>Hamilton Depression Rating Scale (HDRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Waiting for translation from Chinese to English (only abstract available in English)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-07-02 12:02:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-07-02 12:00:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ChiCTR_x002d_TRC_x002d_11001668">
<CHAR_STUDY_NAME MODIFIED="2013-06-21 10:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-ChiCTR_x002d_TRC_x002d_11001668" TYPE="STUDY">ChiCTR-TRC-11001668</LINK>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-02 11:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Eight-week, randomised, double-blind, multicentre study with parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatients suffering from moderate to severe Major Depressive Disorder, according DSM-IV-TR criteria</P>
<P>Age range: 18 to 65 years</P>
<P>Exclusion criteria: all types of depression other than major depressive disorder and all other psychiatric disorders. Pregnancy, breastfeeding or possibility of becoming pregnant during the study without an effective contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 12:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>Agomelatine: 314 participants</P>
<P>Fluoxetine: 314 participants</P>
<P>Agomelatine dosage range: 25-50 mg</P>
<P>Fluoxetine dosage range: 20-40 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 12:00:05 +0100" MODIFIED_BY="[Empty name]">
<P>Change from baseline to end-point on Depression-Hamilton Depression Rating Scale-17 items (HDRS-17), Clinical Global (CGI) Improvement, Leeds Sleep Evaluation Questionnaire (LSEQ) and Hamilton Anxiety Rating Scale (HAM-A)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-02 12:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>August 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-02 12:00:09 +0100" MODIFIED_BY="[Empty name]">
<P>Shu Liang, Prof, +86 10 65610341-308,  shu-liang@126.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-07-02 12:00:10 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-02 12:01:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTRI_x002f_2011_x002f_05_x002f_001719">
<CHAR_STUDY_NAME MODIFIED="2013-06-21 10:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-CTRI_x002f_2011_x002f_05_x002f_001719" TYPE="STUDY">CTRI/2011/05/001719</LINK>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-02 12:01:52 +0100" MODIFIED_BY="[Empty name]">
<P>Eight week, randomised, open-label study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 12:00:39 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for Major Depression Disorder, with a score of at least 20 on the Hamilton Depression Rating Scale-17 item (HDRS-17), a score of 2 in the first item of the HDRS-17 at screening and baseline and a score of at least 4 on Clinical Global Impression of Severity (CGI-S) at the enrolment visit.</P>
<P>Exclusion criteria: history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder or obsessive-compulsive disorder. Patients recording more than 20% reduction on HDRS-17 score at baseline (at the time of study allocation) as against the same recorded at the time of screening. Patients not responding to the administration of an appropriate dose of two different earlier antidepressant treatments (including fluoxetine) for at least 4 weeks each, for the current and earlier episodes, or not responding to fluoxetine monotherapy for at least 4 weeks. Substance or alcohol abuse in the last 30 days or dependence in the last 6 months,or with a risk of suicidal behavior (scoring 3 on item N°3 of HDRS-17). Concomitant psychotropic medication, neurologic disorders or serious or uncontrolled diseases, hepatic insufficiency or renal insufficiency, clinically significant abnormalities on physical examination or laboratory test. Patients having participated in any type of clinical study within in the last one month of the screening date, pregnancy, breastfeeding, absence of adequate contraception measures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 12:00:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine dose range: 20-40 mg</P>
<P>IN-ASTR-001 dose range: 25-50 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 12:00:54 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17 and CGI-S</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-02 12:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>April 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-02 12:00:57 +0100" MODIFIED_BY="[Empty name]">
<P>Kanhei Charan Sahoo, MD, 07966523302, kanheicharan_sahoo@intaspharma.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-07-02 12:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-02 12:01:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2007_x002d_002130_x002d_11_x002d_ES">
<CHAR_STUDY_NAME MODIFIED="2013-06-21 10:51:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-EUCTR2007_x002d_002130_x002d_11_x002d_ES" TYPE="STUDY">EUCTR2007-002130-11-ES</LINK>.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-02 12:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, single-blind study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-06 10:03:30 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for Major Depression Disorder, with a score of at least 14 on the Hamilton Depression Rating Scale-17 item (HDRS-17) and resistant to a SSRI (administered at correct dose for at least 6 weeks).</P>
<P>Exclusion criteria: treatment with any antidepressant drugs or psychotherapy, and to be resistant to any investigational drug.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 12:01:31 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine dose: 20 mg</P>
<P>Venlafaxine range dose: 75-150 mg</P>
<P>Nortriptyline dose: 25 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 12:01:33 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS-17</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-02 12:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>February 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-08-02 16:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<A HREF="https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002130-11%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20">https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002130-11 </A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-07-02 12:01:37 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by academy</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-02 12:02:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01204086">
<CHAR_STUDY_NAME MODIFIED="2013-06-21 10:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-NCT01204086" TYPE="STUDY">NCT01204086</LINK>.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-02 12:01:41 +0100" MODIFIED_BY="[Empty name]">
<P>Six-week open-label, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 11:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for Major Depression Disorder, with a score of at least 16 on the Hamilton Depression Rating Scale (HDRS).<BR/>Age range: 16-65 years old.<BR/>Exclusion criteria: monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study, diagnosis of substance abuse within the past three months, an organic mental disease, mental retardation or dementia, a serious surgical condition or physical illness, pregnancy, breastfeeding. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 12:02:10 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine range dose: 20-80 mg</P>
<P>Venlafaxine range dose 75- 225 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 12:02:13 +0100" MODIFIED_BY="[Empty name]">
<P>HDRS</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-02 12:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>March 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-02 12:02:16 +0100" MODIFIED_BY="[Empty name]">
<P>Po See Chen, MD, +886-6-2353535 ext 5213, <A HREF="mailto:chenps%40mail.ncku.edu.tw?subject=NCT01204086,%20HR-95-06,%20Pharmacogenomics%20Studies%20of%20Antidepressants">chenps@mail.ncku.edu.tw</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-07-02 12:02:18 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by academy</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-02 12:02:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01254305">
<CHAR_STUDY_NAME MODIFIED="2013-06-21 10:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-NCT01254305" TYPE="STUDY">NCT01254305</LINK>.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-02 12:02:26 +0100" MODIFIED_BY="[Empty name]">
<P>Eight week, randomised, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 12:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>Patients fulfilling DSM-IV criteria for major depression disorder, with a minimum duration of 4 weeks. Age range: 18-65 years old.<BR/>Exclusion criteria: patients with a suicide risk, history or current diagnosis (DSM-IV) of any manic or hypomanic episode, schizophrenia or any other psychotic disorder, obsessive-compulsive disorder, pregnancy, breastfeeding, absence of adequate contraception measures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 12:02:48 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine dose range: 20-60 mg</P>
<P>F2695 SR dose range: 40-120 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 12:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical Global Impression (CGI) Severity, Patient Global Impression (PGI) Severity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-02 12:02:54 +0100" MODIFIED_BY="[Empty name]">
<P>April 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-02 12:02:55 +0100" MODIFIED_BY="[Empty name]">
<P>Carl Gommoll, MS, Forest Laboratories</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-07-02 12:02:57 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: by industry</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-07-04 15:49:15 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-07-04 15:48:58 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:51:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>No information about randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:54:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Quote: "patients were randomised to receive capsule of petal of Crocus or fluoxetine in a 1:1 ratio using computer code", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:55:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Quote: "randomised". No other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:57:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>Quote: "Patients were allocated to treatments groups using a balanced randomisation from randomly permuted blocks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:59:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>Randomised trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:00:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>Randomised trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Quote: "randomly assigned". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:03:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>Randomised trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:04:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>Randomised trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-11 15:24:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>Quote: "consequently randomised", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:07:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Quote: "randomly assigned", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-11 15:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Randomised, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:10:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Quote: "randomly assigned, in equal proportion", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:11:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Quote: "randomised". No other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:14:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>Quote: "the patients were allocated at random", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:15:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned". No other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:16:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>Quote: "randomly assigned", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:19:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:21:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>Randomised, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:24:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Quote: "randomly assigned", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:25:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>Quote: "randomised schedule". No other information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:26:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>Quote: "randomisation was carried out by using a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:31:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:32:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:28:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:29:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Quote: "randomly assigned. Assigment was stratified to ensure balanced distribution of male and female patients to each of the two study drug regimen". No other information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:30:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:32:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-10 11:47:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Quote: "randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:34:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Quote: "randomly assigned", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:35:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Randomly assigned, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Quote: &#8220;randomised clinical trial&#8221;, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:39:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Quote: "random allocation". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:40:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:42:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:43:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Quote: "randomised trial", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:44:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:44:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:45:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:46:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>Randomised trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:47:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:48:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:49:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:50:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:51:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:52:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:53:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:55:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:57:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:58:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Quote: "(patients) were randomly assigned to fluoxetine treatment", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:00:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:01:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:02:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:02:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>Quote: "randomly assigned", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:03:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:12:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>No information about randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:04:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:05:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:06:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:07:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:08:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Randomised, no information about randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:10:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>Randomised, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:11:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:14:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Quote: "deux groupes de traitment ont été constitués par tirage au sorte", randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:16:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:17:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>Quote: "...randomised in blocks of four for a total of 32 patients at each centre, it was ensured that equal numbers of patients from each sample and with each degree of severity were randomly allocated to each trial centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:20:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:21:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>Quote: "the subjects were randomised to the study antidepressant using computer randomisation program (Excel) at the beginning of the initial hospitalisation at the Dpt. of Psychiatry in Hradec Kralovc"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:22:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:24:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:25:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:25:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:26:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:27:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Quote: "randomly allocated, according to predetermined schedule", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:28:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:29:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>Quote: "randomly assigned", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:30:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:31:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:32:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:33:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:34:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Quote: "randomly allocated", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:34:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Randomised, no information about randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:35:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:36:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:37:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:50:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:38:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:41:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:42:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:43:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:44:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:48:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:49:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:51:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:53:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:54:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:55:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>Quote: "were randomly allocated", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Quote: "randomised in a 1:1 ratio using a computer-generated code", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:58:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:00:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:00:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:01:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:02:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:03:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:04:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:05:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:05:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:06:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:07:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:08:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:09:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:10:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Quote: "randomised in blocks of six using a table of random numbers..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:11:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:12:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>Randomised, no other information about the randomisation procedures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:13:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Quote: "randomisation was by number in six-patients unit with equal numbers of each treatment", no other information about the randomisation procedures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:14:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-13 10:24:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Quote: "patients were enrolled by investigators and assigned to blinded treatment by a computerized randomisation process generated by the sponsor. Medication was randomised in blocks of six patients, lots containing equal numbers of each treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:18:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:19:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:20:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:21:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:22:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:23:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:25:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:25:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Randomised, quote "the secret codes were only known to the dispenser", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:26:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:28:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:29:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:31:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:32:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:33:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:34:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Quote: "eligible patients were randomised by the permuted blocks method", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:35:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:36:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:37:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:38:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:39:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Randomised trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:41:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:40:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:43:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Quote: "patients were allocated to treatment with either mirtazepine or fluoxetine, according to the centrally prepared randomisation list", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:44:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:45:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:46:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:46:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:47:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:48:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Randomised, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-07-04 15:48:59 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:52:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:54:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:55:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:56:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:59:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:00:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:02:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:03:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:04:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:05:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:07:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:07:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:10:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:11:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:14:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:15:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:16:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:18:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:20:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:21:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:22:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:24:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:25:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:26:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:32:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:28:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:29:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:30:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:32:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:33:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:34:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:35:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:36:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:38:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:40:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:41:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:42:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:44:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:44:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:45:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:46:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:47:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:48:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:49:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:50:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:51:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:52:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:53:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:55:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:56:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:58:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:59:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:00:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:01:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:02:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:02:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:03:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:04:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:05:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:06:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:08:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:09:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:10:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:11:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:13:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:14:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:16:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:17:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:19:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:20:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:21:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:22:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:22:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:25:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:25:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:26:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:27:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:28:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:29:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:31:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:32:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:33:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:34:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:34:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:35:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:36:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:50:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:50:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:38:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:39:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:41:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:42:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:43:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:44:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:46:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:47:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:48:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:51:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:52:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:53:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:54:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:55:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:58:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:00:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:00:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:01:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:02:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:03:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:04:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:05:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:05:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:06:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:07:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:08:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:09:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:10:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:11:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:12:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:13:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:14:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:16:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:18:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:19:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:20:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:21:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:22:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:23:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:25:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:25:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:26:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:28:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:28:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:29:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:31:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:32:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:33:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:34:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:35:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:36:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:37:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:39:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:41:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:40:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:43:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:44:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:46:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:47:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-07-04 15:49:00 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:51:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>Quote: "double-blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:52:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Quote: "double blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:54:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:55:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:56:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Quote: "double blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:58:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 12:59:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>"Double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:00:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>"Double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:02:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Quote: "double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:03:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:04:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:06:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:07:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:08:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:10:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:11:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Quote: "this was a double-blind trial", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:15:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Quote: "a double dummy-procedure was used to preserve the blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:16:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:18:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:20:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:21:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:22:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:24:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:25:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:26:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>Quote: "double blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:31:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:32:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:28:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:29:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:30:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:32:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:33:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Double blind medication, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:34:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:38:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:39:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:40:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:41:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:42:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:43:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:44:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:44:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:45:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>Quote: "double blind design", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>Quote: "double blind trial", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:47:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Quote: "Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:48:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:49:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>Quote: "double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:50:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>Quote: "double blinding was achieved by appropriate drug packaging and formulation", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:51:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:52:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:53:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:55:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:56:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:57:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:58:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 13:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:00:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:02:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:02:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:03:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:12:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>Quote: "double-blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:04:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:05:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:07:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:09:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:10:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:11:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>Quote: " this study used double-blind placebo lead in such that investigators and patients did not know when randomisation occurred and when active study drug was first administered", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:13:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:14:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:16:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:17:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>Quote: "patients were asked to take coated tablets twice daily...", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:19:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Quote: "both patients and the evaluating team were unaware of treatment allocation", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:20:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:21:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:22:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:23:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Not double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:24:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:25:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:25:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:26:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:28:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:28:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:29:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>Quote: "randomly assigned by an another psychiatrist who was blind to the rating of HDRS", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:30:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:31:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:32:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:33:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:34:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:34:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Quote: "Both the psychiatrist and the patient knew the name of the medication, but this information was withheld from examiner", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:35:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:36:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:37:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:50:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:50:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:38:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:40:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:40:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Quote: "non-blinded study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:42:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:43:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:44:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:46:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:48:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:49:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:52:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:53:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:54:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:55:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:56:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Quote: "throughout the study the person who administered the medications, rater and patients were blind to assignments", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:57:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:57:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:58:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 14:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:00:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:00:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:01:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:02:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:03:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:04:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:05:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:06:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:06:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:07:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:08:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:09:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:10:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>Quote: "in a double blind manner", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:13:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:13:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:15:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:16:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:17:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:18:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:19:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:20:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:21:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:22:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:25:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:25:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Single blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:27:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Sinlge blind, with a blinder rater, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:28:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:29:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Single blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:29:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:31:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Open label, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:32:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:33:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:34:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:35:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:36:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:37:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:38:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:39:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:41:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:40:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:43:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:44:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Double blind, double dummy, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:46:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:46:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-04 15:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Open label trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-07-04 15:49:01 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:51:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>Quote: "double-blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Quote: "were put in capsules to provide similar appearance with fluoxetine". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:54:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Quote: "capsules (...) did not have any different taste compared to fluoxetine", "the person who administered the medication, raters and patients were blind to assignment", not clear if blindness was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:55:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Quote: "double blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:58:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 12:59:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>"Double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:00:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>"Double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:02:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Quote: "double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:03:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>Quote: "double dummy capsule-dosing scheme"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:04:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:06:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:07:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:08:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:11:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Quote: "double-dummy", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:14:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:15:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Quote: "a double dummy-procedure was used to preserve the blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:16:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>Quote: "a double dummy technique with matching placebos for each active treatment was applied. Thus, both placebos were identical in shape, weight, colour, smell and taste to their corresponding verum formulations", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-10 11:22:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>Double dummy" no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:21:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>Quote: "all medication were prepared in identical capsules and administered by use of the double dummy technique", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:22:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:24:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Quote: "the study drugs and placebo were supplied as identical capsules". No other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>Unclear if raters were independent and unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:26:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>Quote: "capsules looked identical", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:31:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:28:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>Unclear if raters were independent and unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:29:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Quote: "double blind conditions in identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:30:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:32:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:33:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Double blind medication, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:34:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Quote: "double blind study. Placebo and the study drugs were supplied as identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Quote: "a double dummy technique was employed", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:36:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:38:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:41:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:42:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:43:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:44:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:44:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:45:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>Quote: "double blind design", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:46:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>Quote: "double blind trial", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:47:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Quote: "Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:48:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:49:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>Quote: "all patients took identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:50:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>Quote: "double blinding was achieved by appropriate drug packaging and formulation", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:51:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Quote: "patients received two bottles of identical capsules". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:52:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Quote: "drugs and placebos were packaged in identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:53:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Quote: "all capsules were identical", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:55:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:56:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:57:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:58:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 13:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Quote: "the study drugs and placebo were supplied in identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:00:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Quote: "to ensure the double blind, study drugs were divided into daytime and bedtime doses", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:01:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:02:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Quote: "a double dummy technique was used to maintain the double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>Quote: "(treatments) were administered in identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:03:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:12:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>Quote: "double-blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:04:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Quote: " double dummy technique", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:05:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Double dummy, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:06:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>Quote:"patients received capsules of identical appearance and taste", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:07:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:08:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:09:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Quote: "double-dummy dosing scheme", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:10:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:11:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>Quote: " this study used double-blind placebo lead in such that investigators and patients did not know when randomisation occurred and when active study drug was first administered", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:13:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Quote: "both investigator and patients were blind (...) during the entire duration of the study, all patients two capsules orally in the morning and one in the evening, irrespective the treatment and daily dosage allocated...the appearance and taste of the study treatment were the same from the inclusion to the end of the study for all patients. The packaging and labelling were identical"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:17:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>Double-blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:19:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Quote: "both patients and the evaluating team were unaware of treatment allocation", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:20:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:21:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Not double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:24:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Quote: "medication was given in matching capsules". Unclear if raters were independent and unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:25:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Quote: "study drugs were packaged as identical capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:27:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:28:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:28:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>Quote: "Randomly assigned by an another psychiatrist who was blind to the rating of HDRS", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Quote: "four identical capsules were given"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:32:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:33:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:34:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:35:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Quote: "Both the psychiatrist and the patient knew the name of the medication, but this information was withheld from examiner", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:35:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Quote: "the study drugs were supplied in identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:37:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:50:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:50:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:38:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:39:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Quote: " we administered treatments in a double blind fashion using a double-dummy design", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:40:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Quote: "to maintain the blind, all patients took three capsules of study medication every day", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:41:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Quote: "non-blinded study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:42:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Quote: "capsules that looked identical were supplied to all patients in two bottles marked 'morning dose' and 'bedtime dose'", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:43:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:44:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Quote: "all patients received identical capsules", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:46:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:47:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:48:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Quote: "the investigator was blind as to medications and he did not personally manage any patients in the study", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:49:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:53:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Quote: "double dummy procedure was used to ensured patients and physician blindness to treatment assignment", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:54:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>Quote: " apparently identical capsules in seven doubles enveloped marked 'morning' and 'midday' dose", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:56:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Quote: " throughout the study the person who administered the medications, rater and patients were blind to assignments", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:57:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:57:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:58:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Quote: "all active and placebo medication was supplied as identical coloured capsules", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 14:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:00:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:01:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Quote: "double dummy", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:01:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:02:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:03:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:04:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Quote: "fluoxetine, amitriptyline and placebo were identical in appearance", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:05:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Quote: "Study medication was provided in identical-appearing green capsules", no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:06:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Quote: " medication was dispensed in opaque gelatine capsules containing either placebo, fluoxetine or doxepine (...) in a dose-dispensing system administered by a pharmacist", not clear if blindness was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:07:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>Quote: "medication was dispensed in opaque gelatine capsules containing either placebo, fluoxetine or doxepine...in a dose-dispensing system administered by a pharmacist", not clear if blindness was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:07:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:08:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>Quote: "blindness was maintained by having each subject on lofepramine taking placebo-fluoxetine in addiction and vice versa", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:09:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:10:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:11:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Quote: "double dummy dosing regimen was employed", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:12:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>Quote: "in a double blind manner", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:13:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Quote: "medication for each patient was packaged individually and code-labelled with the study number and a unique patient randomisation number. Units were distributed to study sites according to the lowest available randomisation number", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:14:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:15:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Quote: " treatment blindness was assured by 'double dummies', whereby hypericum active and placebo tablets were dispensed together with capsules containing fluoxetine or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:16:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:17:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:18:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:19:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:20:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>Quote: "placebo tablets resembled the opposite active medication", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:21:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>Quote: "patients in the ABT-200 group received one placebo capsule which resembled fluoxetine", not clear if blindness was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:23:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:24:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:26:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Single blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:27:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Sinlge blind, with a blinder rater, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:28:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Quote: "the study drugs and placebo were supplied in identical capsules" , no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:29:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Quote: "both psychiatrists, one rated the tests and the other who performed the drug follow-up, were blinded to each other until the end of the study", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:29:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:31:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Open label, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:32:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:33:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:34:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Quote: "identical capsules" and "In order to maintain blinding, a matched placebo was taken in the evening by patients randomised to received fluoxetine", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:35:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:36:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:37:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:38:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:39:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:40:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:43:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Quote: "active medication was prepared as indistinguishable looking tablets and packaging was performed using a double dummy technique", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:44:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Double blind, double dummy, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:46:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:46:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Quote: "both drugs and placebo were identically formulated", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:47:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-04 15:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Open label trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-07-04 15:49:04 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:51:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:52:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Unclear if raters were independent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:54:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Quote: "the person who administered the medication, raters and patients were blind to assignment", not clear if blindness was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:55:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:56:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Quote: "double blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:58:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>Quote: "the investigators were provided individual sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 12:59:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>"Double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>"Double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:02:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Quote: "double blind", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:03:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:04:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:06:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>Unclear if raters were independent and unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:07:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:08:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:10:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:11:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Quote: "this was a double-blind trial", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:14:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:15:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Quote: "a double dummy-procedure was used to preserve the blind". No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:16:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>Quote: "all investigators and personnel, actively involved in the trial, were blinded to group assignment until the database was closed", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:18:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:20:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:21:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:22:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:24:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Unclear if raters were independent and unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:25:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:26:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:31:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:32:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:28:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:30:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:32:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:33:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Double blind medication, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:36:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:36:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:38:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Unclear if raters were independent and unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:40:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:41:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:42:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:43:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Quote: "all ratings were conducted under double blind condition", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:44:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:44:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:45:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>Quote: "double blind design", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:46:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>Quote: "double blind trial", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:47:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Quote: "Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:48:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:49:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:50:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>Quote: "double blinding was achieved by appropriate drug packaging and formulation", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:52:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Unclear if blinding was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:52:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:55:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:56:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:57:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:58:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 13:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:00:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:01:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:02:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:02:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:03:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:12:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:05:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:06:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:07:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:10:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>Quote: " this study used double-blind placebo lead in such that investigators and patients did not know when randomisation occurred and when active study drug was first administered", further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:13:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:15:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:16:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:17:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>Double-blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:19:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Quote: "both patients and the evaluating team were unaware of treatment allocation", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:20:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:22:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:23:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Not double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:24:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:25:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:25:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:28:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:29:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Double-blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:29:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:30:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:32:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:33:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:34:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:35:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Quote: "Both the psychiatrist and the patient knew the name of the medication, but this information was withheld from examination", not clear if blinding of the examinator was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:35:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:36:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:50:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:38:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:40:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:40:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:41:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Quote: "non-blinded study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:42:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:43:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:44:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:46:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-20 09:41:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>Double blind, no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:48:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:49:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:51:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:52:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:53:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:54:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:55:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:56:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Quote: " throughout the study the person who administered the medications, rater and patients were blind to assignments", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:57:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:57:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:58:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 14:59:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:00:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:01:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:01:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:02:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:03:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:04:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:05:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Double blind, no other information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:06:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:07:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:07:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:08:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:10:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:12:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>Quote: "in a double blind manner", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:13:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Quote: "medication for each patient was packaged individually and code-labelled with the study number and a unique patient randomisation number. Units were distributed to study sites according to the lowest available randomisation number", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:14:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:16:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:17:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:18:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:19:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:20:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:21:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:23:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:24:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>Quote: "double dummy", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:25:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Single blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:27:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Sinlge blind, with a blinder rater, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:28:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:29:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Single blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:29:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:31:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Open label, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:32:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:33:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:34:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:38:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:41:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:40:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:43:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:44:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:45:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Double blind, double dummy, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:46:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Quote: "since investigators were blind with regard to treatment", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:47:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Quote: " an independent assessor scored the patients", no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:47:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>Double blind, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-04 15:49:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Open label trial, no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-07-04 15:49:08 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:52:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>Incoherence between denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:54:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Number of responders reported with denominator. Reasons for dropout not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:55:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Dropout rate reported with reasons. Scores at endpoint are reported with denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:56:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Number of dropouts reported, but reasons not specified</P>
<P>Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>Quote: "Efficacy analysis were performed on ITT basis using a last observation carried forward method (LOCF)", but scores reported without denominator. Reasons and number of dropouts reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 12:59:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>Quote: "A observed cases analysis over the 6 weeks was the primary efficacy analysis (...) an intention to treat analysis with LOCF was also performed...all discussion of result is based on observed cases (OC) analysis". Number of randomised, and number of lost during the follow-up reported. Number of responders reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:01:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>Number of randomised and number of lost during follow-up reported, but the reasons for dropout were not clear. Only most common side effects were reported</P>
<P>Quote: "Statistical analysis was carried out on the intent to treat population"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:02:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Number and reasons for drop-out reported. Rating scale scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:03:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>Mean baseline and endpoint scores reported without standard deviations. Number and reasons for dropout specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:04:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>Baseline and endpoint scores for each arm not reported. Number and reasons for dropout not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:06:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>Number and reason for dropout not clearly reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:07:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Quote: "efficacy data were analysed in accordance with ITT principle", but scores reported without denominator.</P>
<P>Study completion rates and reasons for study discontinuations reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:08:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Number of dropouts reported, but reasons not specified. Endpoint scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:10:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Scores reported with denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:11:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Number of dropouts reported. Scores at rating scales were reported with denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:14:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>Number of dropouts reported. Mean endpoint scores not clearly reported. No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:15:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Mean endpoint score not reported. Number and reasons for drop-out not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>Reasons for and number of dropouts reported. Number of responders in the text is different from number reported in the table. The so called "ITT population" in this study was different from the randomised sample</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:18:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>Quote: "all efficacy analyses were made on the basis of the efficacy group, whereas the tolerability analyses were made on the basis of the ITT population"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:20:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>Quote: "all efficacy analyses were made on the basis of the efficacy group, whereas the tolerability analyses were made on the basis of the ITT population"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:21:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>Rating scale reported without denominator. Number and reasons for dropout reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Criteria and number of drop-out reported. Rating scale reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:24:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Criteria and number of dropouts reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:25:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>Number of drop-out reported, but unclear reasons for dropout. Rating scale scores reported without denominators. Vital signs and side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:27:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>Number and reason for dropout during the study were reported. Withdrawals were not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:31:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:32:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:28:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>Rating scale scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:29:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Scores reported without standard deviations. Reasons for withdrawal reported, but withdrawals not included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:30:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Quote: "the efficacy analysis included all randomised patients who underwent at least one on-therapy efficacy evaluation". Number of patients responding to treatment reported with denominator. Reason for withdrawal reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:33:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Number of withdrawals reported, but reasons not clearly described. Mean scores reported only at the baseline and not at the endpoint</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:33:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Quote: "analysis are on the ITT patients and use the last observation carried forward (LOCF) method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Scores reported without standard deviations. Reasons for dropout not clear. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:36:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Scores reported without denominator. Effect side reported. Number of patients randomised and number lost during follow-up not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:37:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Quote: "results are reported for the observed-case analysis, for which no missing data were replaced". Number randomised, and number lost during follow-up reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:38:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Rating scale scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:39:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Number and reasons of attrition not clear. Ratings scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:40:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Reasons and number of dropouts were not clear. Rating scale scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:41:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Rating scale scores reported without denominator. Number and reasons of dropouts reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:42:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Rating scale scores reported without denominator. Number and reason for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:43:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Number and reasons for discontinuation not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:44:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>Quote: "the Last Observation Carried Forward (LOCF) data set was used". Scores in follow-up were reported without denominator. Reasons for withdrawal not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>Rating scale scores reported with denominator, but withdrawal not included in analysis. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:45:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>Rating scale scores reported without denominator. Reasons for dropouts not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>Mean scores at rating scales only referred to the whole sample (not to each arm). Number and reasons for dropouts not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:47:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Rating scale scores reported without denominator. Number and reasons for withdrawal reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>Scores reported with denominator. Number and reasons for withdrawals reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:49:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>Number and reasons for dropouts were reported. Scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:50:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>Scores reported without denominators. Mean scores and standard deviations reported only in figure and they were not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:52:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Number and reasons for withdrawal reported. No endpoint scores (CGI, Zung Depression Scale) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:53:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Scores reported without denominators. Number and reasons for dropouts not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:54:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Scores reported without denominators. Reasons and number of dropouts described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:55:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Quote: "we chose to conduct all analyses with an ITT approach". Number and reasons for dropout reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:56:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Scores reported without denominators. Mean scores and standard deviations reported at each follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:57:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Primary and secondary endpoint scores reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:59:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Mean endpoint scores reported without denominators. Adverse events not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 13:59:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Scores reported without denominators. Reasons and number of early termination not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:00:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Mean endpoint score and standard deviation at CGI not reported. Number and reasons for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:01:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Categorical endpoint not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:02:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Responders denominator was different from the number of randomised. Reasons for discontinuation were unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:03:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>Scores reported without denominators. Number and reasons for early termination reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:03:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Responders at endpoint reported without denominators. Number and reasons for withdrawal were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:13:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>All ITT analyses used last observation carried forward (LOCF) data set. Number and reasons for dropout reported. Mean endpoint scores (HDRS) reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:04:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Reasons for withdrawal were not clear. Denominator of responders was different from number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:05:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Scores reported without denominators. Response rate was based on patients completed the trials and not on randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:06:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>End-point scores reported without denominators. Analysis of HDRS scores were based on completers, instead of on randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:07:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Number of drop-out was reported, but reasons for withdrawn were reported only partially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:08:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Initial number of randomised patients was different from the sum of the number of the patients in the different groups. Result on primary outcome (FBG) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:09:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Endpoint scores reported without denominators. Number and reasons for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>End-point scores and standard deviations reported. Dropouts not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:11:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Number and reasons for dropout not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:14:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Number and reasons for withdrawal were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Mean endpoint scores reported with denominators. Dropouts reported with reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:16:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Number and reasons for discontinuation clearly reported. Mean endpoint scores reported with standard deviation, but without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:17:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>Rating scale scores reported without denominator. Number and reasons for withdrawal reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:19:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Rating scale scores reported with standard deviations, but without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:20:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Rating scale scores reported without denominator. Mean scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:21:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:22:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Denominator of the responders was different from the number of randomised patients. Number and reasons for withdrawal were not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:23:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Number of drop-out reported, but reasons for withdrawal not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:24:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Number and reasons for withdrawal reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:25:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Rating scale scores reported without denominators and only in percentage. Number and reasons for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:26:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Number and reasons for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Number and reasons for dropout not clearly reported. Denominatosr of the responders was different from the number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:28:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Denominator reported for responders was different from the number of randomised patients. Reasons for withdrawal were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:29:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Number and reasons for withdrawal reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:29:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>Only the total number of randomised patients was reported, the number of participants in each group was not reported. Number and reason for dropout not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:30:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Quote: "the statistical evaluation was conducted on the patients who completed the trial". The analysis was not conducted on ITT basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:31:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Rating scale scores reported without denominators. Reasons for withdrawals not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:32:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Denominator reported for responders was different from the number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:33:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Number and reasons for dropout reported. ITT number was different from the number of randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:34:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Denominator reported for responders was different from the number of randomised number. Number and reasons for withdrawals not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:35:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Number and reasons for withdrawals was not clearly reported. Rating scale scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>Number and reasons for discontinuation not reported. Scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:36:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported. Scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:37:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported, but withdrawal was not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:50:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Mean rating scale scores not reported, both at baseline and at endpoint. Number and reasons for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:51:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Mean score at endpoint (HDRS) not reported. Responders were reported in percentage, and without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:38:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Number and reasons for dropout not reported. Scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:39:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Number and reasons for discontinuation clearly reported. Denominator reported for responders was different from the number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:40:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported. Scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:40:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Number and reasons for discontinuation were not reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:41:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Number and reasons for discontinuation clearly reported. Endpoint mean score reported as a class</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:42:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Number and reasons for early termination reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:43:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>Number of withdrawals reported, but reasons for dropout not clearly described. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:44:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Number of drop out was reported; reasons for dropout were not clearly stated</P>
<P>Quote: "in the analyses to follow-up, we will focus on the ITT group to estimate treatment effects without bias related to attrition", unclear how this analysis was carried out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>Only the total number of randomised patients reported, not the number of the single group. Number and reasons for dropout not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:47:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>Number and reasons of withdrawals not clearly reported. Endpoint scores and responders reported only in figures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:48:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Number of dropouts was reported, but the reasons were not clearly described. Endpoint scores not reported (HDRS, CGI)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:49:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported. Score reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:52:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Number and reasons for dropout reported without distinguish the study arms. Score reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Number and reasons of dropout reported. Denominator reported for responders was different from the number of randomised patients. Mean endpoint scores (HDRS-21, MADRS, CGI) reported only in figures and without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:53:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Scores reported without denominator. Number and reasons for dropout not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:54:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>Reasons and numbers of dropouts reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:56:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Number of withdrawals reported, but reasons for drop-out not clearly described. Baseline and end-point scores reported only in figures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Number and reasons for drop out reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:57:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>End point scores reported for each patient. All patients complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:58:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Only principal reasons for withdrawals reported. Endpoint scores reported with standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 14:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported. Scores reported without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:00:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>Only completers were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:01:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Number and reasons for drop-out were reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:01:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Number and reasons for dropout were reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:02:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>It was unclear which was the last observation carried forward (LOCF) population</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:03:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>Reasons for dropout not clearly reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:04:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Number and reasons for dropout reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:05:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Quote: "the ITT-LOCF patients sample was the patients sample analysed for efficacy with at least one valid efficacy assessment after baseline determination". Rating scale scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:06:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:07:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>Number and reasons for dropout reported but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:07:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Number and reasons for dropout were reported. Denominator reported for responders was different from the number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:08:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>Reasons and number of dropouts reported. Scores reported with denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:09:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Reasons for discontinuation not clearly reported. Analysis not based on the ITT number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:10:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:11:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Scores reported with denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:12:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>Denominator reported for responders was different from the number of randomised. Number and reasons for dropout not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:13:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Number and reasons for dropout described. Number of responders is reported only in figures and in percentage. Endpoint scores not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:14:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Scores reported without denominator. Number and reasons for dropout not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:15:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Number and reasons for dropout clearly reported. Primary outcome scores (HDRS-21) and secondary reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>End point scores reported without denominators. Number and reasons for discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Number and reasons for withdrawal reported. Scores reported with denominators. Mean scores (HDRS, MADRS, CGI) and standard deviations reported clearly at baseline and at the endpoint</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:18:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Number and reasons for withdrawal reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Quote: "a total of 281 patients were included. The intention to treat analysis consisted of 268 patients". Scores at rating scales were reported without denominators. Number and reasons for dropout were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:20:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>End point scores (MADRS, CGI, MAS) not reported</P>
<P>Quote: "there was no significant differences between numbers remaining in the trial in the two groups at any time point". No ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:22:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>Number and reasons for dropout reported, but included in the analysis only by estimation of outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:23:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Responders reported without denominators. Number and reasons for dropout reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:24:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>Reasons and number of dropouts not clearly reported. Statistical analysis was not on an ITT basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:25:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Withdrawals were reported, but not included in the analysis. Scores reported without denominators. Side effects not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:26:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Endpoint mean scores and standard deviation reported. Scores reported with denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Scores reported with denominators, but withdrawals not included in the analysis. Reasons and number of discontinuation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:28:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Number and reasons for dropout reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:29:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Number and reasons for dropout reported, mean endpoint scores (HDRS-17, CGI, Global Assessment of Functioning [GAF]) reported, but data in the text was different from tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:30:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>Scores reported without denominators. Reasons and number of dropouts reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:31:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Only main reason for dropout reported. Score reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:32:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Denominators of responders were different from number of randomised patients. Reasons and number of dropouts not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:33:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Number and reason for withdrawals reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:34:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported. Denominator reported for responders was different from the number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:35:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Number and reasons for discontinuation reported. Scores reported without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:36:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Number and reason for dropouts reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Responders denominator is different from number of randomised patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:38:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Number and reason for dropout reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:39:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Reasons and number of dropouts not clearly reported. Only baseline scores at rating scales (HDRS, MADRS, CGI) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:42:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Mean score at baseline and endpoint not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Number of dropouts reported, but the reasons were unclear. Last observation carried forward analysis (LOCF) was used to report responders</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:43:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Scores reported without denominators. Reason and numbers of dropouts reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:44:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Number and reasons for dropout reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:45:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Number and reasons for dropout not clearly reported</P>
<P>Only HDRS baseline scores reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:46:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Number and reasons for dropout reported. Scores reported without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:47:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Number and reasons for dropout reported, but not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:47:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>No information provided, impossible to evaluate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-04 15:49:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Number and reasons for dropout not clearly reported. Number of the responders not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-07-04 15:49:13 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:52:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>No follow-up scores reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:52:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Mean endpoint scores and standard deviation reported only in figure. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Mean endpoint scores and standard deviation reported only in figures. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:55:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Full side effects reported. Other outcomes not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:56:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Endpoint scores reported only in figure. Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:58:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>Only most common side effects reported (at last 7% incidence). Mean endpoint scores and standard deviation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:59:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>Side-effects are reported. Vital signs and body weight not reported</P>
<P>Mean endpoint scores (HDRS) reported in figures and without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:01:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>Only most common side effects were reported</P>
<P>Mean endpoint scores and standard deviation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:02:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Endpoint scores reported only in figures. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:03:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:04:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>Side effects not reported. Mean baseline and endpoint score reported only in the whole sample</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:06:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>Adverse effects not reported. Number of responders only reported for the whole sample (not for each study arm)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:07:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Only side-effect over 5% reported. Vital signs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:08:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Side effects not reported. Mean endpoint scores and standard deviation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:11:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Scores reported without standard deviations. Only adverse events occurring at least in 3% of the sample reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:12:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Scores reported without standard deviations. Only adverse effect occurred in at least 10% of the sample were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:14:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>SIde effects not clearly reported. No further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:15:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Mean score reported at sixth week and without number of patients. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:17:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>The duration of the study was not clearly reported. Adverse experiences reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:18:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>Side effects reported only when recorded in at least 5 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:20:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>Side effects reported only when recorder in at least 5 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>No standard deviations reported. No endpoint scores. Vital signs measures not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:22:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Scores at rating scales were reported without standard deviations. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:24:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Scores at rating scales were reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:25:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>No secondary endpoint scores. No standard deviations reported for HDRS score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:27:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>No detailed endpoint scores at CGI. Side effects reported only with percentage, without denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-05 11:22:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-05 11:23:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:28:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>Standard deviations not reported (HDRS). No endpoint scores (CGI, CAS)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:29:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Side effects reported only with an incidence over 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Effect side reported only with an incidence over 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:33:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Side effects reported partially. Baseline mean scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:33:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Treatment-emergent study events reported only if it was reported by three or more patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:34:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Side effects reported only over 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:36:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Means and standard deviations reported only in figures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:37:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Scores reported without standard deviations. Adverse events were reported with a frequency of at least 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Mean scores reported without standard deviations. Side effects reported only if they occurred at least in 5% of the patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:39:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Data at follow-up not reported. Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:40:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:41:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Vital signs not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:42:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Mean scores reported without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:43:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Incidence of adverse effects not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:44:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>No follow-up scores (MADRS, HDRS, HSLC)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:45:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>No endpoint scores (IDS-C). Scores without standard deviation (HDRS)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:46:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>No endpoint scores (CGI). Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:46:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>The type of adverse events was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:47:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Mean scores reported without standard deviations. Adverse events reported over 5%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>No CGI endpoint scores reported. Only most common (over 5%) side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:50:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>Only most common side effects were reported. Mean scores were reported without standard deviations. No endpoint scores (MADRS, CGI)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:50:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>No vital signs and side effects reported. Quote: "no clinically significant changes in vitals signs were recorded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:52:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Scores reported without standard deviations. Only most common adverse events were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:53:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Only most common adverse events were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:54:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Side effects reported. Scores reported for each follow-up with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:55:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Adverse events reported. Primary and secondary endpoint reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:56:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Only adverse events reported by at least 10% of the patients described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:57:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Only most frequent (at least 10%) adverse events reported. Scores reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Mean endpoint scores and standard deviations reported (HDRS, CGI)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:59:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Adverse effects were described only when reported by more than 10% of the sample. Mean scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:00:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Mean endpoint scores (HDRS, RDS, CAS) reported without standard deviations. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:01:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Number and reasons of early termination were reported. Side effects reported by more than 10% of the sample described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:02:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Scores reported without standard deviations. Most frequent (reported at least 5%) adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:03:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>End-point scores reported without standard deviations. Side effects not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:03:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Only most common side effects reported. Primary endpoint scores reported in figures and without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:13:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>Most frequent side effects reported. Number of responders not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:04:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Scores were reported without standard deviations. Only adverse events occurred over 10% were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:05:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Number and reasons for dropouts reported. Endpoint scores at CGI not reported. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:06:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>Number and reasons of withdrawals reported. Adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:07:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Mean end point score not reported. Side effects reported partially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:08:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Number and reasons for withdrawals not clearly reported. Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:09:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Only the most frequently occurring adverse events (at least in 10% of patients) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:10:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>Number but not reasons for dropouts reported. Side effects occurred on at least 3 occasion reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:11:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>Mean scores reported without standard deviations. Only common treatment emergent adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:14:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Scores reported without standard deviations. Endpoint scores at MADRS not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:15:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:16:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Adverse events reported for more than 2% of the subjects. Secondary outcome scores (CGI) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:17:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>Mean scores reported without standard deviation. Adverse drug reactions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:19:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Adverse drug reactions reported. Number of withdrawal reported only in the total sample and without specify reasons for discontinuation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:20:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Only main reasons for premature discontinuation reported. Adverse events reported for more than 5% of the subjects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Endpoint score at CGI and vital signs not reported. Side effects not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:23:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Endpoint scores at SCL-90 and Simpson-Angus Scale (SAS) not reported. Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:24:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Only most common side effects reported. Endpoint scores reported with maximum, minimum, mean and standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:25:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Endpoint scores reported only in figure and without standard deviations. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Endpoint scores reported with standard deviations. Only 12 most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:27:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Adverse events reported. Mean endpoint score (HDRS) reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:28:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Adverse events were reported. Mean scores were reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:29:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Mean scores reported without standard deviations. Only most predominant (4%) adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:30:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>Side effects not reported. Baseline and endpoint score reported for the whole group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:30:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Number and reasons of adverse events reported. Endpoint scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:31:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Endpoint scores reported without standard deviations. Side effects partially reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:32:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Number and reasons for premature termination reported. Only most frequently reported adverse events were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:33:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Mean baseline and end-point scores reported with standard deviations. Adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:34:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Mean scores reported without standard deviations. Side effects not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:35:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Endpoint scores reported with standard errors. Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:35:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>End point scores reported without standard deviations. Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Only most common side effects reported. Mean cores reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Only serious adverse events reported. End point mean scores reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:50:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Only most frequent side effects reported; baseline and endpoint scores at rating scales were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:51:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Adverse events reported. Secondary outcome measures reported only at endpoint, and not at the baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:38:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Endpoint scores were reported only in figures and they were not clear. Side effects reported only in percentage without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Side effects reported. Secondary endpoint scores (MADRS, CGI) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Side effects reported. Secondary end point scores not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Endpoint scores reported with standard deviation. Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:41:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Side effects reported only when occurred in more than 5% of the sample. Mean endpoint scores reported with standard deviation and denominator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Adverse events reported. End point scores reported without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>SIde effects not clearly reported. Mean endpoint scores reported with standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:44:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Side effects reported. Only endpoint adjusted scores reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:46:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>Side effects not reported. Mean baseline and endpoint score (HDRS) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:47:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>SIde effects not reported. Secondary endpoint not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:48:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Side effects not reported. Item in which there was significant improvement reported without mean and standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:49:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Only severe and moderate side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:52:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Side effects not reported. End point score on HDRS and MADRS reported with standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:52:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Adverse events reported, but not clear the number of patients reporting at least one side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:53:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Adverse events reported. End point scores reported without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:54:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>Only most frequent side effects reported. End point scores and standard deviation not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:55:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>Only most common side effects reported. Baseline and mean changes in efficacy measures reported with standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:56:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Side effects not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Endpoint scores (MADRS, Clinical Global Impression [CGI]) reported only in figures and without standard deviation. Only most frequent adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:58:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Only adverse events reported for more than 5% of the sample reported. Secondary outcome not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Only most common side effects reported. Vital signs reported. Scores reported without standard deviation (HDRS, RDS, CAS, SCL-90)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:00:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>No figures for percentages</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Only most frequent (at least 20%) treatment emergent adverse events reported. Vital signs described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:01:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Only most frequent (at least 10%) adverse events reported</P>
<P>Vital signs described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:02:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>Three rating scales for depression were listed in methods, but only one was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:03:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>End point scores not reported (CGI). Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Adverse events not reported. Endpoint scores reported with mean and standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-11 12:48:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Mean scores reported without standard deviation. Only adverse events reported for more than 20% of the sample.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:06:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:07:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>End point scores not clearly reported. Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:07:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Secondary outcomes not reported. Side effects and vital signs not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:08:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>Adverse events experienced by more than five subjects in either group were reported. Scores reported only in figures and without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:09:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Endpoint scores reported only in figures and without standard deviation. Only side effects reported by more than 3 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:10:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Only most common adverse events reported. End point scores reported without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:11:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:12:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>End-point scores not reported. Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:13:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Baseline scores reported without standard deviation. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:14:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Only those adverse events occurred in at least 5% of participants were reported. Endpoint score at HDRS-21 was reported only in figures and without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:15:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Only those adverse events occurred in at least 2% of participants were reported. Endpoint scores reported with standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:16:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>Mean scores reported without standard deviations. Treatment-related adverse events were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:17:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Only most common (10%) side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:18:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Only most common side effects reported. Endpoint scores reported without standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:19:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Treatment emergent adverse events reported. Endpoint scores not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:20:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>Number and reasons for attrition reported. Only main side effects reported. Vital signs not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>End point scores (MADRS, CGI) not reported. Only side effects reported by at least 20% of the sample reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:23:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Adverse events reported only if they occurred at least in 5% of the sample. Endpoint mean scores and standard deviations reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:24:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>End-point mean scores and standard deviations reported. Side effects not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Endpoint mean scores and standard deviations reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:26:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Effects side not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:27:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Endpoint scores reported without standard deviations. Side effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:28:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Endpoint mean scores reported without standard deviations. Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:29:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Side effects were described, but the whole number of patients reporting side effects was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:30:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>End point mean scores and standard deviations reported. Only most common side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:31:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Adverse events not clearly described. End point scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:32:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Only most common adverse events are reported. Endpoint scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:33:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Adverse events reported. Mean endpoint scores reported with standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:34:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Adverse events reported only if they occurred in at least 5% of the sample. Endpoint scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:35:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Only most common adverse events were reported. Mean endpoint scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:36:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Endpoint scores reported with standard deviation. Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:37:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Side effects reported only when occurred at least at 4% of the sample. Endpoint scores reported without standard deviations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:38:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Only most frequent side effects reported. Mean endpoint scores reported with standard deviation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Adverse events occurring in more 5% reported. Number of responders reported only in figure and without denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:42:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Most frequent side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:41:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Primary and secondary endpoint scores reported with standard deviations. Side effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:43:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Adverse events occurred in more than 5% of the sample reported. Endpoint scores not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:44:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Only most common side effects were reported. Mean endpoint scores not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:45:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Side effects not reported. Number of responders not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:46:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Side effects not clearly reported. Mean endpoint scores and standard deviation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:47:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Only most common side effects were reported. Endpoint scores (HRSD, HAM-A) not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:47:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>No information provided, impossible to evaluate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:49:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Endpoint scores reported with standard deviations. Side effects reported only with percentage</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-07-04 15:49:15 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:52:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aguglia-1993">
<DESCRIPTION>
<P>Funding: unclear information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:53:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2003">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akhondzadeh-Basti-2007">
<DESCRIPTION>
<P>Funding: independent study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:55:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alby-1993">
<DESCRIPTION>
<P>Last author's affiliation was IRIS and this company produces tianeptine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:56:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altamura-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 12:58:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alves-1999">
<DESCRIPTION>
<P>First author's affiliation was Wyeth-Lederle, Portugal, and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-10 14:28:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amini-2005">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:01:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andreoli-2002">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:02:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ansseau-1994">
<DESCRIPTION>
<P>Last author's affiliation was Laboratories Pierre Fabre Medicament, and this company produces milnacipran</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:03:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Armitage-1997">
<DESCRIPTION>
<P>This study was supported in part by Bristol-Myers Squibbs. This company produces nefazodone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:04:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bakish-1997">
<DESCRIPTION>
<P>Quote: "this study was supported by grants from SmithKline Beecham", and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:06:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basterzi-2009">
<DESCRIPTION>
<P>Funding: by academy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beasley-1993a">
<DESCRIPTION>
<P>Authors' affiliation was Psychopharmacology Division, Lilly Reasearch Laboratories, Eli Lilly and Company, Indianapolis. This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:09:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Behnke-2002">
<DESCRIPTION>
<P>Last author's affiliation was PhytoPharm Consulting, Istitute for Phytopharmaceuticals, Berlin; probably this company produces <I>Hypericum perforatum</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:11:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennie-1995">
<DESCRIPTION>
<P>Quote: "supported by a research grant from international Pharmaceuticals group, Pfizer, Inc, New York". This company produces sertraline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:12:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berlanga-1997">
<DESCRIPTION>
<P>Quote: "supported by Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT". This company produces nefazodone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:14:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Besancon-1993">
<DESCRIPTION>
<P>Last author's affiliation was Organon, and this company produces mianserin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:15:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bhurgri-2011">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bjerkenstedt-2005">
<DESCRIPTION>
<P>Quote: "the study was funded by a grant from Lichtwer Pharma GmbH, Berlin, Germany", and this company produces hypericum extract LI 160</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:18:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bougerol-1997a">
<DESCRIPTION>
<P>Quote: "sponsored by Lundbeck, Copenaghen. This company also delivered the citalopram tablets and bought (in bulk) the fluoxetine capsules (active and placebo) from Eli LIlly, England, and packed them"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:20:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bougerol-1997b">
<DESCRIPTION>
<P>Quote: "sponsored by Lundbeck, Copenaghen. This company also delivered the citalopram tablets and bought (in bulk) the fluoxetine capsules (active and placebo) from Eli LIlly, England, and packed them"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:21:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bowden-1993">
<DESCRIPTION>
<P>Quote: "this research was supported in part by a grant from Eli Lilly and Company", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:22:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyer-1998">
<DESCRIPTION>
<P>Last author's affiliation was Pfizer France, Orsay. This company produces sertraline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bremner-1984">
<DESCRIPTION>
<P>Funding: by academy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:25:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bressa-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:27:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Byerley-1988">
<DESCRIPTION>
<P>The study was supported, in part, by Eli Lilly. This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:31:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CL3_x002d_022">
<DESCRIPTION>
<P>Funding: by industry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:32:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CL3_x002d_024">
<DESCRIPTION>
<P>Funding: by industry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:28:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cassano-2002">
<DESCRIPTION>
<P>The study was supported by SmithKline. This company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:29:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1985">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chouinard-1999">
<DESCRIPTION>
<P>Funding by SmithKline, and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:33:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Clayton-2003">
<DESCRIPTION>
<P>Funding by Pharmacia Corporation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:33:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Clerc-1994">
<DESCRIPTION>
<P>Quote: "this work was supported by a grant from Wyeth-Ayerst Research, Paris, France", this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:34:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1985">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:36:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corne-1989">
<DESCRIPTION>
<P>Second author had affiliation in Eli Lilly, this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:37:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corrigan-2000">
<DESCRIPTION>
<P>Authors' affiliation was in Pharmacia&amp;Upjohn Inc, and this company produces pramipexole</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:38:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Costa-e-Silva-1998">
<DESCRIPTION>
<P>Quote: "supported by a grant from Wyeth-AYerst International". This company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:39:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalery-1997">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dalery-2003">
<DESCRIPTION>
<P>Quote: "the study was supported by a grant from Solvay Pharmaceuticals". This company produces maprotiline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:41:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Jonghe-1991">
<DESCRIPTION>
<P>Quote: "the study was supported by Eli Lilly Nederlands". This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:42:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Nayer-2002">
<DESCRIPTION>
<P>Funding by Wyeth, and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:43:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Ronchi-1998">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:44:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Wilde-1993">
<DESCRIPTION>
<P>Funding by Smithkline, and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:45:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Debus-1988">
<DESCRIPTION>
<P>Quote: "supported in part by Ely Lilly". This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:46:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demyttenaere-1998">
<DESCRIPTION>
<P>Quote: "we are indebted to Eli Lilly Belgium for financial support for the present study", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:47:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demyttenaere-2004">
<DESCRIPTION>
<P>Quote: "Eli Lilly Benelux provided logistic and material support for this study", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:48:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-Martinez-1998">
<DESCRIPTION>
<P>Quote: "this study was supported by Wyeth-Ayerst International, Saint David's, Pennsylvania": Tihs company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:49:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dierick-1996">
<DESCRIPTION>
<P>Quote: "this study was supported by Wyeth-Ayerst Research" and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:50:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dowling-1990">
<DESCRIPTION>
<P>In the aknowledgements authors thank Eli Lilly Company. This company produces fluoxetine and probably the study was supported by this industry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:51:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duarte-1996">
<DESCRIPTION>
<P>The last author's affiliation was Hoffmann&#8211;La Roche Ltd, and this company produces moclobemide</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fabre-1991">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:53:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fairweather-1999">
<DESCRIPTION>
<P>Quote: "the research grant provided by Lilly Industries", and Eli LIlly produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Falk-1989">
<DESCRIPTION>
<P>Quote: "this research was supported by a grant from Eli Lilly and Company", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:55:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fava-1998">
<DESCRIPTION>
<P>Quote: "this study was supported by SmithKline Beecham Pharmaceuticals" and this industry produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fava-2002">
<DESCRIPTION>
<P>Quote: "supported by a grant from Ely Lilly ", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:57:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>Quote: "the study was supported by a grant of Lichtwer Pharma AG (Berlin, Germany)", and this company produces St. John's wort</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:59:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fawcett-1989">
<DESCRIPTION>
<P>Supported by Eli Lilly, and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 13:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985a">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:00:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feighner-1985b">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:01:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feighner-1989">
<DESCRIPTION>
<P>Quote: "(study) performed at the Feighner Research Institute". This institute usually receives founds by pharmacological industries</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feighner-1991">
<DESCRIPTION>
<P>Quote: "supported by a grant from Burroghs Wellcome, Co.", and this industry produces bupropion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:03:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferreri-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:03:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finkel-1999">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:13:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GSK-29060_x002f_356">
<DESCRIPTION>
<P>Funding: unclear information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:04:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gagiano-1993">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:05:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gattaz-1995">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:06:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Geerts-1994">
<DESCRIPTION>
<P>Last author's affiliation was Roche Industry and this company produces moclobemide</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:07:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Geretsegger-1994">
<DESCRIPTION>
<P>Funding: by industry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:08:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghaeli-2004">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:09:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gillin-1997">
<DESCRIPTION>
<P>Quote: "this study was supported by Bristol-Myers-Squibb Pharmaceutical Research Institute", that produces nefazodone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:10:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginestet-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldstein-2002">
<DESCRIPTION>
<P>First author's affiliation was Lilly Corporate Center and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:14:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guelfi-1998">
<DESCRIPTION>
<P>Quote: "this study was sponsored by Pierre Fabbre Medicament, Boulogne, France" and this company produces milnacipram</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:15:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guelfi-1999">
<DESCRIPTION>
<P>Author's affiliation was Eli Lilly and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:16:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hale-2010">
<DESCRIPTION>
<P>Quote: "this study was supported by Servier. Authors have received honoraria, research grants or both, from Servier". This company produces agomelatine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harrer-1999">
<DESCRIPTION>
<P>The last author's affiliation was Dr Loges co.gmbh and this company produces St John's wort extract LoHyp-57</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:19:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashemi-2012">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:20:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2003">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:21:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hosak-2000">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:22:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jakovijevic-1996">
<DESCRIPTION>
<P>Funding: unclear, probably funded by a pharmaceutical company that produces maprotiline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:23:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joyce-2002">
<DESCRIPTION>
<P>Quote: "this project also received a grant from Lottery Health and an unrestricted grant from Eli Lilly (New Zealand)". Eli Lilly produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:24:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Judd-1993">
<DESCRIPTION>
<P>Quote: "the authors are grateful to Eli Lilly, Australia for financial support for this study". Eli Lilly company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:25:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasper-2005">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:26:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keegan-1991">
<DESCRIPTION>
<P>Quote: "the study was supported by Eli Lilly, Canada Inc.". Eli Lilly Company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:27:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keller-2007">
<DESCRIPTION>
<P>Quote: "this clinical trial and analysis were sponsored by Wyeth Research, Collegeville", and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:28:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kerkhofs-1990">
<DESCRIPTION>
<P>Last author's affiliation was Eli Lilly Benelux and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:29:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuha-1991">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:30:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kwon-1996">
<DESCRIPTION>
<P>Quote: "this work was supported by grant N°. 02-94-158 from the Seoul National University Hospital research found"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:30:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Pia-1992">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:31:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laakman-1988">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:32:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lapierre-1997">
<DESCRIPTION>
<P>Quote: "this study was supported by Hoffmann-La Roche", and this company produces moclobemide</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:33:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Quote: "funding for this study was provided by Bukwang Pharm, Seoul, Korea", and this company produces milnacipran</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:34:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-22 15:28:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levkovitz-2002">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:35:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loeb-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lonnqvist-1994">
<DESCRIPTION>
<P>Last author's affiliation was Roche OY, Espoo, Finland. This company produces moclobemide</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loo-1999">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:50:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115">
<DESCRIPTION>
<P>Funding: by Glasko Smith Kline, and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:51:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1">
<DESCRIPTION>
<P>Funding by Glasko Smithkline, and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manna-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mao-2008">
<DESCRIPTION>
<P>Quote: "contract grant sponsor: Xian-Janssen Pharmaceutical Company (honoraria to authors for conducting this trial)". This company produces escitalopram</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marchesi-1998">
<DESCRIPTION>
<P>Two author's affiliation was Eli LIlly Italia, Sesto Fiorentino, Italy. This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:40:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martenyi-2001">
<DESCRIPTION>
<P>Quote: "this work was sponsored by Eli Lilly and Company". This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:41:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinez-2012">
<DESCRIPTION>
<P>Quote: "funded by Lilly USA, Indianapolis", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:42:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Masco-1985">
<DESCRIPTION>
<P>Quote: "supported by a grant from Eli Lilly &amp; Company", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:43:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massana-1999">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:44:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McGrath-2000">
<DESCRIPTION>
<P>Quote: "supported by Eli Lilly and Company", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:46:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moosa-2003">
<DESCRIPTION>
<P>Funding: by academy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:47:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moreno-2006">
<DESCRIPTION>
<P>Quote: "the authors are grateful to Marjan, for the financial support and donation of hypericum perforatum, and to Eli Lilly Brazil, for the donation of fluoxetine", this two pharmaceutical companies produce the two study drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mowla-2006">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:49:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muijen-1988">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:52:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nelson-2004">
<DESCRIPTION>
<P>Quote: "this research was supported in part by National Institute of Mental Health Grants R01-MH-47894 and MH-30020"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:52:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nemeroff-2007">
<DESCRIPTION>
<P>Quote: "this study was funded by a series of grants to the participating research sites from Wyeth Research, Collegeville", and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:53:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Newhouse-2000">
<DESCRIPTION>
<P>Quote: "supported by a grant from Pfizer", this company produces sertraline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nielsen-1993">
<DESCRIPTION>
<P>One of the authors' affiliation was Eli Lilly, Denmark. This company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:55:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Noguera-1991">
<DESCRIPTION>
<P>One of the authors' affiliation was Eli Lilly Spain, Madrid; this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:56:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noorbala-2005">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Novotny-2002">
<DESCRIPTION>
<P>Quote: "this work was supported by Servier", and this company produces tianeptine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keane-1992">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:58:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ontiveros-1997">
<DESCRIPTION>
<P>Quote: "paroxetine was supplied by SmithKline Beecham, Mexico"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 14:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-OntiverosSanchez-1998">
<DESCRIPTION>
<P>Last author affiliation was Laboratories Eli Lilly y Cia; this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:00:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakesch-1991">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:01:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pande-1996">
<DESCRIPTION>
<P>Quote: "supported by a research grant from Eli Lilly &amp; Company, Indianapolis" and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:01:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perry-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1990">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:03:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poelinger-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:04:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Preskorn-1991">
<DESCRIPTION>
<P>Quote: "this work was supported in part by Eli Lilly and Company" and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:05:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rapaport-1996">
<DESCRIPTION>
<P>Quote: "this study was supported by grants from Solvay Pharmaceuticals", and this company produces fluvoxamine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:06:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remick-1989">
<DESCRIPTION>
<P>Quote: "the authors gratefully acknowledge (...) Eli Lilly of Canada for financial support", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:07:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remick-1993">
<DESCRIPTION>
<P>Quote: "the authors wish to aknowledge (...) Eli Lilly for financial support", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:07:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reynaert-1995">
<DESCRIPTION>
<P>Last author's affiliation is Roche S. A., Brussels, Belgium and this company produces moclobemide</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:08:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robertson-1994">
<DESCRIPTION>
<P>One author's affiliation was Lilly Industries Ltd, and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ropert-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:10:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rudolph-1999">
<DESCRIPTION>
<P>Quote: "Wyeth-Ayerst Research provided financial support and the study drugs to the investigators". This company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:11:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rush-1998">
<DESCRIPTION>
<P>Quote: "this study was sponsored by Bristol-Myers Squibb Pharmaceutical research Institute", this company produces nefazodone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:12:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sandor-1998">
<DESCRIPTION>
<P>Quote: "the original study of cardiac effects of fluoxetine and doxepin was supported by Eli Lilly, Canada". Eli Lilly Company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:13:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schatzberg-2006">
<DESCRIPTION>
<P>Quote: "funding for this study provided by Wyeth Research", and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:14:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schone-1993">
<DESCRIPTION>
<P>Quote: "this research was supported by SmithKline Beecham Pharmaceuticals" and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:15:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrader-2000">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:16:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-1999">
<DESCRIPTION>
<P>Second author's affiliation was Pfizer, and this company produces sertraline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:17:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sheehan-2009">
<DESCRIPTION>
<P>Quote: "this study was funded by Wyeth Pharmaceuticals and administered by Quitiles", and this company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:18:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silverstone-1999">
<DESCRIPTION>
<P>Quote: "This study was supported by Wyeth-Ayerst Research, Philadelphia". This company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:19:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smeraldi-1998">
<DESCRIPTION>
<P>Synthelabo Clinical Research (Limito di Pioltello, Milano) participated at the study, and this company produces amisulpride</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:20:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SouthWalesGroup-1988">
<DESCRIPTION>
<P>Quote: "we would like to thank (...) Eli Lilly", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:21:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sramek-1995">
<DESCRIPTION>
<P>Funding: by industry. (Abbott Laboratories, Abbott Park)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:23:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stark-1985">
<DESCRIPTION>
<P>Both authors' affiliation was Lilly Research laboratories, and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:24:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stephenson-2000">
<DESCRIPTION>
<P>First author's affiliation was Eli Lilly, and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:25:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stratta-1991">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:26:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suleman-1997">
<DESCRIPTION>
<P>Quote: "the drugs used in this study were provided by Mess Eli Lilly Company and Hoffman La Roche Company", and these companies produce study drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:27:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suri-2000">
<DESCRIPTION>
<P>Quote: "supported in part from Eli Lilly and Company", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:28:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tamminen-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taner-2006">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taneri-1989">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:31:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2000">
<DESCRIPTION>
<P>Quote: "this study was carried out by Eli Lilly and Company", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:32:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tignol-1993">
<DESCRIPTION>
<P>Quote: "this research was supported by SmithKline Beecham Pharmaceuticals" and this company produces paroxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:33:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-1994">
<DESCRIPTION>
<P>Quote: "study funding was provided through a research grant from Lilly Research Laboratories, a division of Eli Lilly and Company" and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:34:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tylee-1997">
<DESCRIPTION>
<P>Quote: "this study was funded by Wyeth Laboratories Ltd." This company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:35:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tzanakaki-2000">
<DESCRIPTION>
<P>Quote: "this study was supported by a grant from Wyeth-Ayerst International". This company produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:36:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Upward-1988">
<DESCRIPTION>
<P>Quote: "we thank Lilly Industries Ltd for financial support and drug assays", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Moffaert-1995">
<DESCRIPTION>
<P>Quote: "we would like to acknowledge the financial and logistic support of Pfizer Belgium", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:38:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Versiani-1999">
<DESCRIPTION>
<P>Authors' affiliation was Eli lilly Venezuela, and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:39:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Versiani-2005">
<DESCRIPTION>
<P>Quote: "this study was supported by Organon NV, The Netherlands", and this company produces mirtazepine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:42:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-WELL-AK1A4006">
<DESCRIPTION>
<P>Funding probably by SmithKline, and this company produces bupropion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:41:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wehmeier-2005">
<DESCRIPTION>
<P>Quote: "this work was supported by Lilly Deutschland, Bad Homburg, Germany", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:43:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wheatley-1998">
<DESCRIPTION>
<P>Quote: "supported by a clinical research grant from NV Organon, Oss, The Netherlands" and this company produces mirtazapine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:44:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1993">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:45:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Winokur-2003">
<DESCRIPTION>
<P>Quote: "funds for this study were provided through on unrestricted educational grant from Organon, Inc" and this industry produces venlafaxine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:46:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Quote: "this work was supported by Lilly Deutschland", this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:47:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-13 11:45:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-1997">
<DESCRIPTION>
<P>Funding: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-04 15:49:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhao-2006-a">
<DESCRIPTION>
<P>Quote: "this study was financially supported by Eli Lilly Asia, Inc", and this company produces fluoxetine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-07-04 16:02:20 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-07-04 15:53:34 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:04 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to TCAs</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to TCAs </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>TCAs</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TCAs</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>471 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>463 per 1000</B>
<BR/>(406 to 520)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.97 </B>
<BR/>(0.77 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2124<BR/>(24 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.03 higher</B>
<BR/>(0.07 lower to 0.14 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3393<BR/>(50 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>335 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>284 per 1000</B>
<BR/>(246 to 326)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.79 </B>
<BR/>(0.65 to 0.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4194<BR/>(49 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>193 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
<BR/>(87 to 152)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.55 </B>
<BR/>(0.40 to 0.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3647<BR/>(40 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(66 to 112)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.29 </B>
<BR/>(0.96 to 1.72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2911<BR/>(33 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in study design: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-07-04 15:53:47 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:10:23 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to ABT-200</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to ABT 200 </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>ABT 200</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ABT 200</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>1.85 standard deviations lower</B>
<BR/>(2.25 to 1.45 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>141<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a large effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>. However, only one study contributed to this analysis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>528 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<BR/>(82 to 304)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.18 </B>
<BR/>(0.08 to 0.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>144<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>14 per 1000</B>
<BR/>(2 to 115)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.24 </B>
<BR/>(0.03 to 2.20)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>144<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>361 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
<BR/>(11 to 132)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.08 </B>
<BR/>(0.02 to 0.27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>144<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in study design: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-07-04 15:54:02 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:10:32 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to agomelatine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to agomelatine </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>agomelatine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Agomelatine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>282 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>361 per 1000</B>
<BR/>(280 to 450)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.44 </B>
<BR/>(0.99 to 2.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>515<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.02 standard deviations higher</B>
<BR/>(0.18 lower to 0.23 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1213<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>135 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>170 per 1000</B>
<BR/>(122 to 233)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.31 </B>
<BR/>(0.89 to 1.94)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>785<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>55 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
<BR/>(23 to 142)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.08 </B>
<BR/>(0.41 to 2.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>785<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(25 to 97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.51 </B>
<BR/>(0.74 to 3.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>785<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in this analysis. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-07-04 15:54:39 +0100" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:12:51 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to amineptine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to amineptine</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>amineptine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Amineptine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>719 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>486 per 1000</B>
<BR/>(249 to 727)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.37 </B>
<BR/>(0.13 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>63<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0 standard deviations higher</B>
<BR/>(0 to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P>No data available on this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>210 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>140 per 1000</B>
<BR/>(43 to 370)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.61 </B>
<BR/>(0.17 to 2.21)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>232<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>94 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
<BR/>(19 to 366)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.04 </B>
<BR/>(0.19 to 5.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>63<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - (Copy)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>84 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
<BR/>(3 to 418)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.52 </B>
<BR/>(0.03 to 7.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>232<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-07-04 15:55:11 +0100" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:14:24 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to amisulpride</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to amisulpride </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>amisulpride</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Amisulpride</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score</B>
</P>
<P>(HDRS or MADRS)<B> </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.17 standard deviations higher</B>
<BR/>(0.07 lower to 0.41 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>268<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a very small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>225 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
<BR/>(191 to 409)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.39 </B>
<BR/>(0.81 to 2.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>281<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
<BR/>(25 to 156)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.16 </B>
<BR/>(0.43 to 3.10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>281<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
<BR/>(32 to 155)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.77 </B>
<BR/>(0.33 to 1.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>281<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2013-07-04 15:55:23 +0100" MODIFIED_BY="[Empty name]" NO="6" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:15:00 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to bupropion</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to bupropion </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>bupropion</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Bupropion</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>493 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>447 per 1000</B>
<BR/>(318 to 582)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.83 </B>
<BR/>(0.48 to 1.43)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>436<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0 standard deviations higher</B>
<BR/>(0 to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P>No data available on this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>356 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>356 per 1000</B>
<BR/>(270 to 450)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.00 </B>
<BR/>(0.67 to 1.48)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>436<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.16 </B>
<BR/>(0.33 to 4.10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>436<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
<BR/>(28 to 124)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.01 </B>
<BR/>(0.45 to 2.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>436<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2013-07-04 15:55:37 +0100" MODIFIED_BY="[Empty name]" NO="7" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:26 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to citalopram</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to citalopram </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>citalopram</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Citalopram</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>379 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>268 per 1000</B>
<BR/>(109 to 522)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.60 </B>
<BR/>(0.20 to 1.79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.06 standard deviations higher</B>
<BR/>(0.10 lower to 0.21 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>661<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>211 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>189 per 1000</B>
<BR/>(138 to 254)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.87 </B>
<BR/>(0.60 to 1.27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>732<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>66 per 1000</B>
<BR/>(37 to 112)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.87 </B>
<BR/>(0.48 to 1.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>732<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>49 per 1000</B>
<BR/>(27 to 89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.64 </B>
<BR/>(0.34 to 1.20)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>732<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in the analysis and less than 100 patients. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2013-07-04 15:56:47 +0100" MODIFIED_BY="[Empty name]" NO="8" READONLY="YES">
<TITLE MODIFIED="2013-07-04 15:56:07 +0100" MODIFIED_BY="[Empty name]">Fluoxetine compared to Crocus sativus</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to <I>Crocus sativus </I>
</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>
<I>Crocus sativus</I>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Crocus sativus</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(35 to 464)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.53 </B>
<BR/>(0.11 to 2.60)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0 standard deviations higher</B>
<BR/>(0 to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P>No data available on this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(3 to 475)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.00 </B>
<BR/>(0.06 to 17.18)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis and less than 50 patients. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-09" MODIFIED="2013-07-04 15:57:03 +0100" MODIFIED_BY="[Empty name]" NO="9" READONLY="YES">
<TITLE MODIFIED="2012-11-20 15:03:04 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to duloxetine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to for duloxetine</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>duloxetine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>485 per 1000</B>
<BR/>(289 to 684)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.41 </B>
<BR/>(0.61 to 3.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>103<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0 standard deviations higher</B>
<BR/>(0 to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P>No data available on this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>281 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>260 per 1000</B>
<BR/>(171 to 372)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.90 </B>
<BR/>(0.53 to 1.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>532<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
<BR/>(14 to 152)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 3.33 </B>
<BR/>(0.93 to 12.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>432<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>66 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(5 to 80)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.28 </B>
<BR/>(0.07 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>532<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in the analysis. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-10" MODIFIED="2013-07-04 15:57:21 +0100" MODIFIED_BY="[Empty name]" NO="10" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:33 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to escitalopram</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to escitalopram </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>escitalopram</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Escitalopram</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>236 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>239 per 1000</B>
<BR/>(147 to 363)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.02 </B>
<BR/>(0.56 to 1.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>240<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.07 standard deviations higher</B>
<BR/>(0.19 lower to 0.33 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>231<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>148 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>210 per 1000</B>
<BR/>(148 to 292)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.53 </B>
<BR/>(1.00 to 2.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>578<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
<BR/>(6 to 82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.74 </B>
<BR/>(0.46 to 6.53)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>578<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>89 per 1000</B>
<BR/>(51 to 151)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.17 </B>
<BR/>(0.64 to 2.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>578<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in the analysis. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-11" MODIFIED="2013-07-04 15:57:37 +0100" MODIFIED_BY="[Empty name]" NO="11" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:40 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to fluvoxamine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to fluvoxamine </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>fluvoxamine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluvoxamine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)<B> </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>605 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>592 per 1000</B>
<BR/>(443 to 727)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.95 </B>
<BR/>(0.52 to 1.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>177<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0 standard deviations higher</B>
<BR/>(0 to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P>No data available on this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>170 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>936 per 1000</B>
<BR/>(69 to 219)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 071 </B>
<BR/>(0.36 to 1.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>284<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(6 to 239)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.04 </B>
<BR/>(0.14 to 7.71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>100<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in the analysis.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-12" MODIFIED="2013-07-04 15:57:56 +0100" MODIFIED_BY="[Empty name]" NO="12" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:22:34 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to hypericum</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to hypericum </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>hypericum</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hypericum</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>490 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>485 per 1000</B>
<BR/>(346 to 625)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.98 </B>
<BR/>(0.55 to 1.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>717<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.13 standard deviations higher</B>
<BR/>(0.02 lower to 0.29 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>648<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a very small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>129 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
<BR/>(88 to 189)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.04 </B>
<BR/>(0.65 to 1. 68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>679<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 4.70 </B>
<BR/>(0.22 to 99.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>401<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>35 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
<BR/>(20 to 88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.21 </B>
<BR/>(0.56 to 2.64)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>679<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-13" MODIFIED="2013-07-04 15:58:10 +0100" MODIFIED_BY="[Empty name]" NO="13" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:11 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to maprotiline</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to maprotiline</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>maprotiline</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Maprotiline</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>398 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>563 per 1000</B>
<BR/>(984 to 734)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.95 </B>
<BR/>(0.91 to 4.18)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>163<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score</B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.04 standard deviations higher</B>
<BR/>(0.15 lower to 0.23 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>433<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
<BR/>(84 to 257)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.75 </B>
<BR/>(0.90 to 3.41)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>351<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
<BR/>(11 to 121)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.53 </B>
<BR/>(0.15 to 1.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>209<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
<BR/>(6 to 279)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 2.54 </B>
<BR/>(0.33 to 19.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>209<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-14" MODIFIED="2013-07-04 15:58:25 +0100" MODIFIED_BY="[Empty name]" NO="14" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:20 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to mianserin</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to mianserin </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>mianserin</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Mianserin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>593 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>538 per 1000</B>
<BR/>(282 to 776)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.80 </B>
<BR/>(0.27 to 2.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>53<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.43 standard deviations higher</B>
<BR/>(0.38 lower to 1.23 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>128<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>362 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>263 per 1000</B>
<BR/>(93 to 560)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.63 </B>
<BR/>(0.18 to 2.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>74 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
<BR/>(30 to 522)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 2.27 </B>
<BR/>(0.38 to 13.63)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>53<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects -</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>148 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
<BR/>(38 to 450)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.05 </B>
<BR/>(0.23 to 4.70)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>53<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in the analysis and less than 100 patients. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-15" MODIFIED="2013-07-04 15:58:41 +0100" MODIFIED_BY="[Empty name]" NO="15" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:51:02 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to milnacipran</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to milnacipran </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>milnacipran</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Milnacipran</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)<B> </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>473 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>518 per 1000</B>
<BR/>(412 to 623)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.20 </B>
<BR/>(0.78 to 1.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>370<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.36 standard deviations lower</B>
<BR/>(0.63 to 0.08 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>213<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>411 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>406 per 1000</B>
<BR/>(322 to 497)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.98 </B>
<BR/>(0.68 to 1.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>560<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>137 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>165 per 1000</B>
<BR/>(97 to 267)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.25 </B>
<BR/>(0.68 to 2.30)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>560<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
<BR/>(59 to 175)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.50 </B>
<BR/>(0.81 to 2.76)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>560<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-16" MODIFIED="2013-07-04 15:59:07 +0100" MODIFIED_BY="[Empty name]" NO="16" READONLY="YES">
<TITLE MODIFIED="2012-11-20 15:36:46 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to mirtazapine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to mirtazapine</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> Fluoxetine<BR/>
<B>Comparison: </B>mirtazapine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Mirtazapine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>354 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>444 per 1000</B>
<BR/>(363 to 527)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.46 </B>
<BR/>(1.04 to 2.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>600<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.57 standard deviations higher</B>
<BR/>(0.15 lower to 1.29 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a medium effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>327 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>304 per 1000</B>
<BR/>(211 to 416)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.90 </B>
<BR/>(0.55 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>301<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
<BR/>(31 to 119)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.45 </B>
<BR/>(0.71 to 2.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>600<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>98 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>93 per 1000</B>
<BR/>(56 to 151)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.95 </B>
<BR/>(0.55 to 1.64)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>600<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
<P>
<SUP>2 </SUP>Only one study included in the analysis and less than 100 patients. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-17" MODIFIED="2013-07-04 15:59:30 +0100" MODIFIED_BY="[Empty name]" NO="17" READONLY="YES">
<TITLE MODIFIED="2012-11-20 15:36:53 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to moclobemide</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to moclobemide</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>moclobemide</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Moclobemide</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)<B> </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>436 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>496 per 1000</B>
<BR/>(416 to 575)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.27 </B>
<BR/>(0.92 to 1.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>721<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.13 standard deviations higher</B>
<BR/>(0.04 lower to 0.30 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>540<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a very small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>209 per 1000</B>
<BR/>(155 to 275)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.01 </B>
<BR/>(0.70 to 1.45)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>721<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
<BR/>(21 to 93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.70 </B>
<BR/>(0.32 to 1.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>679<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>86 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
<BR/>(57 to 144)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.07 </B>
<BR/>(0.64 to 1.80)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>721<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-18" MODIFIED="2013-07-04 15:59:50 +0100" MODIFIED_BY="[Empty name]" NO="18" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:25:45 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to nefazodone</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to nefazodone</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>nefazodone</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nefazodone</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.06 standard deviations lower</B>
<BR/>(0.30 lower to 0.18 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>271<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effects approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>220 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(58 to 269)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.54 </B>
<BR/>(0.22 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>161<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>24 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(1 to 211)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.71 </B>
<BR/>(0.05 to 10.71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>161<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>96 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
<BR/>(33 to 161)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.76 </B>
<BR/>(0.32 to 1.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>286<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-19" MODIFIED="2013-07-04 16:00:05 +0100" MODIFIED_BY="[Empty name]" NO="19" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:45 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to paroxetine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to paroxetine </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>paroxetine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Paroxetine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)<B> </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>426 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>477 per 1000</B>
<BR/>(408 to 550)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.23 </B>
<BR/>(0.93 to 1.65)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1574<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.01 standard deviations lower</B>
<BR/>(0.25 lower to 0.24 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2061<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>317 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>313 per 1000</B>
<BR/>(273 to 358)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.98</B>
<BR/>(0.81 to 1.20)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1848<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>52 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 1000</B>
<BR/>(22 to 71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.75 </B>
<BR/>(0.41 to 1.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1005<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<BR/>(87 to 151)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.85 </B>
<BR/>(0.62 to 1.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1509<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-20" MODIFIED="2013-07-04 16:00:33 +0100" MODIFIED_BY="[Empty name]" NO="20" READONLY="YES">
<TITLE MODIFIED="2012-11-20 15:36:59 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to phenelzine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to phenelzine</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>phenelzine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Phenelzine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
<BR/>(45 to 564)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.42 </B>
<BR/>(0.27 to 7.34)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.05 standard deviations lower</B>
<BR/>(0.67 lower to 0.57 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
<BR/>(1 to 308)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.18 </B>
<BR/>(0.01 to 4.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(1 to 303)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.32 </B>
<BR/>(0.01 to 8.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis and less than 50 patients. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-21" MODIFIED="2013-07-04 16:01:00 +0100" MODIFIED_BY="[Empty name]" NO="21" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:29:52 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to pramipexole</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to pramipexole </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>pramipexole</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pramipexole</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>657 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>513 per 1000</B>
<BR/>(315 to 707)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.55 </B>
<BR/>(0.24 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0 standard deviations higher</B>
<BR/>(0 to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD>
<P>No data available on this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>443 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(23 to 250)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.12 </B>
<BR/>(0.03 to 0.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(3 to 215)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.49 </B>
<BR/>(0.05 to 4.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>314 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
<BR/>(5 to 186)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.06 </B>
<BR/>(0.01 to 0.50)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-22" MODIFIED="2013-07-04 16:01:20 +0100" MODIFIED_BY="[Empty name]" NO="22" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:31:01 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to reboxetine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to reboxetine </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>reboxetine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Reboxetine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>566 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>501 per 1000</B>
<BR/>(418 to 589)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.77 </B>
<BR/>(0.55 to 1.10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>721<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.04 standard deviations higher</B>
<BR/>(0.31 lower to 0.40 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>205<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This effect approaches zero</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>361 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>253 per 1000</B>
<BR/>(199 to 316)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.60 </B>
<BR/>(0.44 to 0.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>764<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>88 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>82 per 1000</B>
<BR/>(43 to 146)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.92 </B>
<BR/>(0.47 to 1.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>464<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>129 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 1000</B>
<BR/>(22 to 139)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.41 </B>
<BR/>(0.15 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>211<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-23" MODIFIED="2013-07-04 16:01:34 +0100" MODIFIED_BY="[Empty name]" NO="23" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:50:55 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to sertraline</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to sertraline</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>sertraline</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Sertraline</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond</B>
</P>
<P>(reduction &#8805; 50% on HDRS)<B> </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>416 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>494 per 1000</B>
<BR/>(435 to 554)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.37 </B>
<BR/>(1.08 to 1.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1188</P>
<P>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.09 standard deviations higher</B>
<BR/>(0.03 lower to 0.20 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1160<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a very small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>229 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>258 per 1000</B>
<BR/>(217 to 307)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.17 </B>
<BR/>(0.93 to 1.49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1591<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>70 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>76 per 1000</B>
<BR/>(49 to 118)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.09 </B>
<BR/>(0.68 to 1.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1056<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>134 per 1000</B>
<BR/>(102 to 174)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.25 </B>
<BR/>(0.92 to 1.70)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1591<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-24" MODIFIED="2013-07-04 16:01:49 +0100" MODIFIED_BY="[Empty name]" NO="24" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:31:38 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to tianeptine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to tianeptine </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>tianeptine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Tianeptine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>534 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>562 per 1000</B>
<BR/>(462 to 657)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.12 </B>
<BR/>(0.75 to 1.67)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>387<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.15 standard deviations lower</B>
<BR/>(0.40 lower to 0.10 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>730<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a very small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>225 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>218 per 1000</B>
<BR/>(167 to 279)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.96 </B>
<BR/>(0.69 to 1.33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>830<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 1000</B>
<BR/>(13 to 110)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.82 </B>
<BR/>(0.27 to 2.53)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>830<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
<BR/>(66 to 152)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.13 </B>
<BR/>(0.71 to 1.80)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>830<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-25" MODIFIED="2013-07-04 16:02:04 +0100" MODIFIED_BY="[Empty name]" NO="25" READONLY="YES">
<TITLE MODIFIED="2012-11-22 14:32:18 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to trazodone</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to trazodone</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings:</B> in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>trazodone</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trazodone</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>642 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>467 per 1000</B>
<BR/>(189 to 769)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.49 </B>
<BR/>(0.13 to 1.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>110<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.25 standard deviations lower</B>
<BR/>(0.76 lower to 0.26 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>203<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>145 per 1000</B>
<BR/>(71 to 274)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.51 </B>
<BR/>(0.23 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>230<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>147 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>38 per 1000</B>
<BR/>(7 to 207)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.23 </B>
<BR/>(0.04 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>70<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
<BR/>(34 to 280)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.66 </B>
<BR/>(0.20 to 2.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>110<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-26" MODIFIED="2013-07-04 16:02:20 +0100" MODIFIED_BY="[Empty name]" NO="26" READONLY="YES">
<TITLE MODIFIED="2012-11-20 14:51:11 +0000" MODIFIED_BY="[Empty name]">Fluoxetine compared to venlafaxine</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine compared to venlafaxine </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with depression<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> fluoxetine<BR/>
<B>Comparison: </B>venlafaxine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Venlafaxine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to respond </B>
</P>
<P>(reduction &#8805; 50% on HDRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>341 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
<BR/>(363 to 439)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.29 </B>
<BR/>(1.10 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3387<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Endpoint score </B>
</P>
<P>(HDRS or MADRS)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean endpoint score in the intervention groups was<BR/>
<B>0.10 standard deviations higher</B>
<BR/>(0.0 to 0.19 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3097<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>This corresponds to a very small effect according<BR/>to conventions proposed<BR/>by <LINK REF="REF-Cohen-1992" TYPE="REFERENCE">Cohen 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - total - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>256 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>234 per 1000</B>
<BR/>(203 to 267)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.89 </B>
<BR/>(0.74 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2683<BR/>(14 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - inefficacy - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
<BR/>(40 to 79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.31 </B>
<BR/>(0.91 to 1.89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2640<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Failure to complete - side effects - </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(69 to 110)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.72 </B>
<BR/>(0.56 to 0.94)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2640<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-07-02 12:18:24 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-07-02 12:04:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Fluoxetine versus TCAs</NAME>
<DICH_OUTCOME CHI2="34.47212565160214" CI_END="1.220952954570382" CI_START="0.7656546451248843" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="OR" EFFECT_SIZE="0.966865192850464" ESTIMABLE="YES" EVENTS_1="489" EVENTS_2="506" I2="33.27942630386925" I2_Q="23.409991450862165" ID="CMP-001.01" LOG_CI_END="0.0866989301495437" LOG_CI_START="-0.11596707832774442" LOG_EFFECT_SIZE="-0.014634074089100354" METHOD="MH" MODIFIED="2013-05-06 15:36:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0586327107346738" P_Q="0.24279021152541325" P_Z="0.7771388776824315" Q="9.13957333678715" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10218378373474718" TOTALS="YES" TOTAL_1="1049" TOTAL_2="1075" WEIGHT="100.0" Z="0.2830495195245511">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.803513533294984" CI_END="1.2762649999478035" CI_START="0.6799124889263325" DF="10" EFFECT_SIZE="0.9315301995341196" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="153" I2="7.437520495704129" ID="CMP-001.01.01" LOG_CI_END="0.10594085938979754" LOG_CI_START="-0.16754698144395522" LOG_EFFECT_SIZE="-0.03080306102707882" MODIFIED="2012-04-18 11:12:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3730297861321281" P_Z="0.6588486843202683" STUDIES="11" TAU2="0.021289540195999438" TOTAL_1="382" TOTAL_2="395" WEIGHT="40.63306698698273" Z="0.44150328616154594">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="3.1798817064731453" CI_START="0.4528470342367313" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.5024109642669728" LOG_CI_START="-0.34404847217172324" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="4540" O_E="0.0" SE="0.4972144630058766" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="0.2472222222222222" WEIGHT="4.056081440487806"/>
<DICH_DATA CI_END="2.2007178503122966" CI_START="0.30418324071316566" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.3425643660848531" LOG_CI_START="-0.5168647175226534" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="4541" O_E="0.0" SE="0.5048328979536247" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.25485625485625485" WEIGHT="3.96935655045818"/>
<DICH_DATA CI_END="2.3503233413368143" CI_START="0.18428165894705595" EFFECT_SIZE="0.6581196581196581" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.3711276136328123" LOG_CI_START="-0.7345178867801717" LOG_EFFECT_SIZE="-0.18169513657367978" ORDER="4542" O_E="0.0" SE="0.6494616399760819" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.4218004218004218" WEIGHT="2.7046983496564834"/>
<DICH_DATA CI_END="0.9022881496892555" CI_START="0.06657856345344113" EFFECT_SIZE="0.24509803921568626" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="-0.04465474645408598" LOG_CI_START="-1.176665579725674" LOG_EFFECT_SIZE="-0.6106601630898799" ORDER="4543" O_E="0.0" SE="0.6649487670077282" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="0.4421568627450981" WEIGHT="2.603552068216734"/>
<DICH_DATA CI_END="1.1340282950884841" CI_START="0.13266860689272184" EFFECT_SIZE="0.3878787878787879" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.054623890753967744" LOG_CI_START="-0.8772318312140062" LOG_EFFECT_SIZE="-0.41130397023001913" MODIFIED="2012-04-16 09:43:48 +0100" MODIFIED_BY="[Empty name]" ORDER="1003" O_E="0.0" SE="0.5473766638442052" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.2996212121212121" WEIGHT="3.5271318937634257"/>
<DICH_DATA CI_END="6.499715881043865" CI_START="0.4862510738935428" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.8128943729518269" LOG_CI_START="-0.3131394265186271" LOG_EFFECT_SIZE="0.2498774732165999" ORDER="4544" O_E="0.0" SE="0.6614378277661477" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.4375" WEIGHT="2.6260177879526463"/>
<DICH_DATA CI_END="2.854752494093967" CI_START="0.7207040347215746" EFFECT_SIZE="1.434375" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.4555684610551476" LOG_CI_START="-0.14224304662043702" LOG_EFFECT_SIZE="0.15666270721735526" ORDER="4545" O_E="0.0" SE="0.35115743882332695" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="0.1233115468409586" WEIGHT="6.284916021714386"/>
<DICH_DATA CI_END="8.145930452819718" CI_START="0.04177273299209062" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.9109406979074103" LOG_CI_START="-1.379107109974146" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2012-04-04 13:51:42 +0100" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="1.3451854182690985" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="1.8095238095238095" WEIGHT="0.7413368137233515"/>
<DICH_DATA CI_END="2.8771971772722402" CI_START="0.22944421578567958" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.45896962555628534" LOG_CI_START="-0.6393228862544613" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2012-04-18 11:12:12 +0100" MODIFIED_BY="[Empty name]" ORDER="4546" O_E="0.0" SE="0.645142458073247" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.41620879120879123" WEIGHT="2.7338725214407127"/>
<DICH_DATA CI_END="3.0892902579021215" CI_START="0.6261429867390408" EFFECT_SIZE="1.3908045977011494" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.4898587148676853" LOG_CI_START="-0.20332647947202218" LOG_EFFECT_SIZE="0.14326611769783154" ORDER="4547" O_E="0.0" SE="0.40718041447719583" STUDY_ID="STD-Peters-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.16579588993382097" WEIGHT="5.288532509035829"/>
<DICH_DATA CI_END="1.876499468915076" CI_START="0.45600799772135603" EFFECT_SIZE="0.9250398724082934" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.27334844583554696" LOG_CI_START="-0.3410275403711053" LOG_EFFECT_SIZE="-0.033839547267779164" ORDER="4548" O_E="0.0" SE="0.3608874955079673" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="0.1302397844140131" WEIGHT="6.09757103053318"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4468788399936612" CI_START="0.2745785611260464" DF="0" EFFECT_SIZE="0.6303030303030303" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.16043216531029394" LOG_CI_START="-0.5613333751405459" LOG_EFFECT_SIZE="-0.20045060491512595" NO="2" P_CHI2="1.0" P_Z="0.2763071283122035" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="48" WEIGHT="5.026790782390462" Z="1.088652600586918">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="1.4468788399936612" CI_START="0.2745785611260465" EFFECT_SIZE="0.6303030303030303" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.16043216531029394" LOG_CI_START="-0.5613333751405458" LOG_EFFECT_SIZE="-0.20045060491512595" ORDER="4549" O_E="0.0" SE="0.42396865125786987" STUDY_ID="STD-Pakesch-1991" TOTAL_1="46" TOTAL_2="48" VAR="0.17974941724941726" WEIGHT="5.026790782390462"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3937472208700155" CI_END="5.149406376273741" CI_START="0.5619914083861046" DF="1" EFFECT_SIZE="1.70115317997953" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="28.25097800907022" ID="CMP-001.01.03" LOG_CI_END="0.7117571664454436" LOG_CI_START="-0.250270323788638" LOG_EFFECT_SIZE="0.23074342132840286" MODIFIED="2012-04-23 09:42:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23777351081548048" P_Z="0.34711534249193277" STUDIES="2" TAU2="0.195232997014716" TOTAL_1="42" TOTAL_2="42" WEIGHT="5.273625845082584" Z="0.9401993187599644">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="3.28304508802456" CI_START="0.37604354132626894" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.5162768471965359" LOG_CI_START="-0.42476186607518557" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="4550" O_E="0.0" SE="0.5527707983925666" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.3055555555555555" WEIGHT="3.4757971071022946"/>
<DICH_DATA CI_END="18.25442960754227" CI_START="0.7099646649405716" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.2613682671862079" LOG_CI_START="-0.1487632656516334" LOG_EFFECT_SIZE="0.5563025007672873" MODIFIED="2012-04-23 09:42:04 +0100" MODIFIED_BY="[Empty name]" ORDER="1097" O_E="0.0" SE="0.8283182426526118" STUDY_ID="STD-Nelson-2004" TOTAL_1="14" TOTAL_2="12" VAR="0.6861111111111111" WEIGHT="1.7978287379802902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3572921570051042" CI_END="4.199904438147432" CI_START="1.0788954875116046" DF="1" EFFECT_SIZE="2.128675162230542" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.623239408860424" LOG_CI_START="0.03297937666126803" LOG_EFFECT_SIZE="0.32810939276084594" MODIFIED="2013-04-29 16:07:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5500141914503672" P_Z="0.02933310609205466" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="8.197337269731294" Z="2.1789806448680125">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="8.100075556648452" CI_START="0.9336332663950007" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.9084890699505573" LOG_CI_START="-0.02982368229003217" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="4551" O_E="0.0" SE="0.551169555389155" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.3037878787878788" WEIGHT="3.4909313796700023"/>
<DICH_DATA CI_END="4.314525215819166" CI_START="0.750951689451384" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.6349330115240771" LOG_CI_START="-0.12438800131746502" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="4552" O_E="0.0" SE="0.44602892164275504" STUDY_ID="STD-Fairweather-1999" TOTAL_1="42" TOTAL_2="42" VAR="0.19894179894179892" WEIGHT="4.706405890061292"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.543628888699885" CI_START="0.2821965932123575" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.7314599319718997" Z="0.0">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="3.543628888699885" CI_START="0.2821965932123575" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" ORDER="4553" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Sandor-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.41666666666666663" WEIGHT="2.7314599319718997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.513485977868253" CI_END="1.3496383302569677" CI_START="0.4067400386462863" DF="4" EFFECT_SIZE="0.7409129143207239" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="220" I2="68.03448689618124" ID="CMP-001.01.06" LOG_CI_END="0.13021740388953315" LOG_CI_START="-0.39068307444254824" LOG_EFFECT_SIZE="-0.1302328352765075" MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0139146791785012" P_Z="0.327066359760798" STUDIES="5" TAU2="0.2935305809177737" TOTAL_1="377" TOTAL_2="384" WEIGHT="28.11562955471754" Z="0.9800400551130447">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="2.332666527149271" CI_START="0.5012338603070389" EFFECT_SIZE="1.08130081300813" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="41" LOG_CI_END="0.36785265745195933" LOG_CI_START="-0.29995959839658354" LOG_EFFECT_SIZE="0.03394652952768786" ORDER="4554" O_E="0.0" SE="0.3922762248094146" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.1538806365507264" WEIGHT="5.534619820969454"/>
<DICH_DATA CI_END="7.341739229291792" CI_START="0.2733609001579917" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" ORDER="4555" O_E="0.0" SE="0.8394384210560641" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.704656862745098" WEIGHT="1.7565044871502233"/>
<DICH_DATA CI_END="0.6425597904356273" CI_START="0.130408119365213" EFFECT_SIZE="0.2894736842105263" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.19208645484783926" LOG_CI_START="-0.8846953680693309" LOG_EFFECT_SIZE="-0.5383909114585851" ORDER="4556" O_E="0.0" SE="0.4068419040957183" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="0.16552033492822965" WEIGHT="5.293976136920134"/>
<DICH_DATA CI_END="1.8207727460103473" CI_START="0.8001385062288291" EFFECT_SIZE="1.207008858780615" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="101" LOG_CI_END="0.26025574408563823" LOG_CI_START="-0.09683482890267331" LOG_EFFECT_SIZE="0.08171045759148245" ORDER="4558" O_E="0.0" SE="0.2097567702001784" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.043997902644810453" WEIGHT="9.694916313095852"/>
<DICH_DATA CI_END="1.048712258712155" CI_START="0.2410714777427824" EFFECT_SIZE="0.5028067361668003" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="43" LOG_CI_END="0.020656344632479246" LOG_CI_START="-0.6178541699281317" LOG_EFFECT_SIZE="-0.29859891264782623" ORDER="4559" O_E="0.0" SE="0.3750642369309246" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="0.14067318182457675" WEIGHT="5.835612796581878"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.777598902327279" CI_START="0.54947433871781" DF="0" EFFECT_SIZE="0.9883040935672515" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="0.24983377341871357" LOG_CI_START="-0.2600525849756742" LOG_EFFECT_SIZE="-0.005109405778480298" NO="7" P_CHI2="1.0" P_Z="0.9686668917160041" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="7.385585770450424" Z="0.03928032646237765">
<NAME>Fluoxetine vs Lofepramine</NAME>
<DICH_DATA CI_END="1.777598902327279" CI_START="0.54947433871781" EFFECT_SIZE="0.9883040935672515" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" LOG_CI_END="0.24983377341871357" LOG_CI_START="-0.2600525849756742" LOG_EFFECT_SIZE="-0.005109405778480298" ORDER="4560" O_E="0.0" SE="0.2995097708990436" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" VAR="0.0897061028639976" WEIGHT="7.385585770450424"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.454592299285608" CI_START="0.5612492447000237" DF="0" EFFECT_SIZE="2.0454545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.8724238963453764" LOG_CI_START="-0.2508442304391017" LOG_EFFECT_SIZE="0.31078983295313745" MODIFIED="2012-03-21 11:18:33 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.2781078860883528" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="2.636503858673072" Z="1.0845796561380476">
<NAME>Fluoxetine vs Trimipramine</NAME>
<DICH_DATA CI_END="7.454592299285608" CI_START="0.5612492447000238" EFFECT_SIZE="2.0454545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.8724238963453764" LOG_CI_START="-0.2508442304391016" LOG_EFFECT_SIZE="0.31078983295313745" MODIFIED="2012-03-21 11:18:33 +0000" MODIFIED_BY="[Empty name]" ORDER="969" O_E="0.0" SE="0.6598132579401048" STUDY_ID="STD-Wehmeier-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.4353535353535353" WEIGHT="2.636503858673072"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="106.06164422387904" CI_END="0.14378068608695346" CI_START="-0.0742644465448477" CI_STUDY="95" CI_TOTAL="95" DF="48" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.03475811977105287" ESTIMABLE="YES" I2="54.74330013338306" I2_Q="9.91652448610633" ID="CMP-001.02" MODIFIED="2013-05-06 15:36:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.869065028998641E-6" P_Q="0.35246397485423175" P_Z="0.5320580010356379" Q="8.880652033419993" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="50" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.07360344888346916" TOTALS="YES" TOTAL_1="1700" TOTAL_2="1693" UNITS="" WEIGHT="100.0" Z="0.6248675409474146">
<NAME>End-point score on rating scale</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="33.14247318972187" CI_END="0.2910003138987729" CI_START="-0.08643962927754092" DF="17" EFFECT_SIZE="0.10228034231061597" ESTIMABLE="YES" I2="48.70630232486079" ID="CMP-001.02.01" MODIFIED="2012-06-19 10:36:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01081204496383048" P_Z="0.2881270383250095" STUDIES="19" TAU2="0.07414334210431496" TOTAL_1="502" TOTAL_2="521" WEIGHT="33.49415800604665" Z="1.0622393886997372">
<NAME>Fluoxetine vs Amiptriptyline</NAME>
<CONT_DATA CI_END="2.851370316464487" CI_START="0.7992590836286297" EFFECT_SIZE="1.8253147000465582" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="10.0" ORDER="4561" SD_1="2.0" SD_2="1.0" SE="0.5235073830495479" STUDY_ID="STD-Altamura-1989" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.8899745964925053"/>
<CONT_DATA CI_END="1.4493101310713077" CI_START="0.20823583060213002" EFFECT_SIZE="0.8287729808367189" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="10.6" ORDER="4562" SD_1="6.21" SD_2="5.45" SE="0.3166064045713629" STUDY_ID="STD-Chouinard-1985" TOTAL_1="20" TOTAL_2="24" WEIGHT="1.779832984300335"/>
<CONT_DATA CI_END="0.5174494719170113" CI_START="-0.4551428590349775" EFFECT_SIZE="0.031153306441016927" ESTIMABLE="YES" MEAN_1="14.22" MEAN_2="13.94" ORDER="4563" SD_1="8.31" SD_2="9.4" SE="0.24811484767671063" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" WEIGHT="2.2891497999514043"/>
<CONT_DATA CI_END="0.973324060503538" CI_START="-0.008266688219621676" EFFECT_SIZE="0.48252868614195815" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="7.2" ORDER="4564" SD_1="6.3" SD_2="4.5" SE="0.2504104045956513" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" WEIGHT="2.2699310346115924"/>
<CONT_DATA CI_END="0.3949155956580206" CI_START="-0.8821288916277359" EFFECT_SIZE="-0.24360664798485765" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="14.6" ORDER="4565" SD_1="6.5" SD_2="7.9" SE="0.32578264125231904" STUDY_ID="STD-Fawcett-1989" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.7214612475310653"/>
<CONT_DATA CI_END="-0.06334027783245466" CI_START="-1.2813684540758503" EFFECT_SIZE="-0.6723543659541525" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="19.0" ORDER="4566" SD_1="6.21" SD_2="5.45" SE="0.31072718321638726" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.8184121932735633"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="11.7" MEAN_2="11.4" MODIFIED="2012-06-19 10:36:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1004" SD_1="0.0" SD_2="5.43" SE="0.0" STUDY_ID="STD-Hosak-2000" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.2598438471108258" CI_START="-0.904253749090205" EFFECT_SIZE="-0.32220495098968954" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="11.6" ORDER="4567" SD_1="6.2" SD_2="6.0" SE="0.29696912937770387" STUDY_ID="STD-Judd-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="1.912378731173333"/>
<CONT_DATA CI_END="0.8237093964189098" CI_START="-0.46846611945657035" EFFECT_SIZE="0.17762163848116977" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.0" ORDER="4568" SD_1="2.5" SD_2="3.0" SE="0.3296426684541134" STUDY_ID="STD-Keegan-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.6975665784440488"/>
<CONT_DATA CI_END="0.6645788119773868" CI_START="-1.144645207830558" EFFECT_SIZE="-0.24003319792658562" ESTIMABLE="YES" MEAN_1="8.44" MEAN_2="9.8" ORDER="4569" SD_1="6.2" SD_2="4.6" SE="0.461545220748665" STUDY_ID="STD-Kerkhofs-1990" TOTAL_1="9" TOTAL_2="10" WEIGHT="1.079490575910731"/>
<CONT_DATA CI_END="0.7848842847162738" CI_START="-0.3356699529425175" EFFECT_SIZE="0.22460716588687818" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="7.0" ORDER="4570" SD_1="8.0" SD_2="5.2" SE="0.28586092563373106" STUDY_ID="STD-Laakman-1988" TOTAL_1="22" TOTAL_2="28" WEIGHT="1.9920923506641421"/>
<CONT_DATA CI_END="0.44895143046490743" CI_START="-0.21060069066351855" EFFECT_SIZE="0.11917536990069444" ESTIMABLE="YES" MEAN_1="8.96" MEAN_2="8.15" ORDER="4571" SD_1="6.6" SD_2="6.9" SE="0.16825618387146113" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" WEIGHT="3.0360191704101918"/>
<CONT_DATA CI_END="0.585426686970647" CI_START="-1.417763338062632" EFFECT_SIZE="-0.41616832554599253" ESTIMABLE="YES" MEAN_1="7.28" MEAN_2="10.77" MODIFIED="2012-04-04 13:52:37 +0100" MODIFIED_BY="[Empty name]" ORDER="990" SD_1="5.6" SD_2="9.3" SE="0.5110272537746067" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.9243001980070974"/>
<CONT_DATA CI_END="0.9454136072487161" CI_START="-0.27367806721812926" EFFECT_SIZE="0.33586777001529344" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="5.8" ORDER="4572" SD_1="6.21" SD_2="5.45" SE="0.310998488768897" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" WEIGHT="1.8166113528872032"/>
<CONT_DATA CI_END="0.5658779404354558" CI_START="-0.3062473405771292" EFFECT_SIZE="0.12981529992916327" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.0" ORDER="4573" SD_1="9.0" SD_2="6.0" SE="0.2224850272484081" STUDY_ID="STD-Peters-1990" TOTAL_1="40" TOTAL_2="41" WEIGHT="2.5134361377181533"/>
<CONT_DATA CI_END="0.23982829060373528" CI_START="-0.7777384753457015" EFFECT_SIZE="-0.2689550923709831" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="15.6" ORDER="4574" SD_1="7.8" SD_2="6.1" SE="0.2595881286533512" STUDY_ID="STD-Preskorn-1991" TOTAL_1="29" TOTAL_2="31" WEIGHT="2.1945729271219108"/>
<CONT_DATA CI_END="0.7922742845926187" CI_START="-0.6396804040217989" EFFECT_SIZE="0.0762969402854099" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="7.0" ORDER="4575" SD_1="2.5" SD_2="2.6" SE="0.3653012759187142" STUDY_ID="STD-Suleman-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.494392198746411"/>
<CONT_DATA CI_END="0.5302530622141995" CI_START="-0.09935464144599115" EFFECT_SIZE="0.2154492103841042" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="8.7" ORDER="4576" SD_1="8.9" SD_2="7.7" SE="0.16061716149542948" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="79" WEIGHT="3.1127515752995776"/>
<CONT_DATA CI_END="0.7937922300659574" CI_START="-1.1719740482477756" EFFECT_SIZE="-0.1890909090909091" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="11.0" ORDER="4577" SD_1="10.0" SD_2="10.0" SE="0.5014802041821805" STUDY_ID="STD-Yu-1997" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.9517843535033936"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.272849189667875" CI_END="0.10056747138210584" CI_START="-0.3072415430758466" DF="4" EFFECT_SIZE="-0.10333703584687037" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.6857165971537982" P_Z="0.3205673232694045" STUDIES="5" TAU2="0.0" TOTAL_1="191" TOTAL_2="181" WEIGHT="11.603804128236114" Z="0.9932927490491913">
<NAME>Fluoxetine vs Clomipramine</NAME>
<CONT_DATA CI_END="0.523753942257844" CI_START="-0.5438550682244169" EFFECT_SIZE="-0.010050562983286392" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="10.5" ORDER="4578" SD_1="7.2" SD_2="12.0" SE="0.2723542419410317" STUDY_ID="STD-Ginestet-1989" TOTAL_1="28" TOTAL_2="26" WEIGHT="2.093727361807939"/>
<CONT_DATA CI_END="0.3967492994278131" CI_START="-1.0453979480764617" EFFECT_SIZE="-0.32432432432432434" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="10.0" ORDER="4579" SD_1="4.5" SD_2="4.5" SE="0.3679014662717653" STUDY_ID="STD-Manna-1989" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.4807576372007263"/>
<CONT_DATA CI_END="0.3173916975896487" CI_START="-0.5053693695561126" EFFECT_SIZE="-0.09398883598323195" ESTIMABLE="YES" MEAN_1="6.21" MEAN_2="6.66" ORDER="4580" SD_1="4.57" SD_2="4.93" SE="0.20989188414572807" STUDY_ID="STD-Noguera-1991" TOTAL_1="47" TOTAL_2="44" WEIGHT="2.629753041961386"/>
<CONT_DATA CI_END="0.5038826170584483" CI_START="-0.30543890727577566" EFFECT_SIZE="0.09922185489133634" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="7.7" ORDER="4581" SD_1="5.19" SD_2="6.68" SE="0.2064633663470474" STUDY_ID="STD-Pakesch-1991" TOTAL_1="46" TOTAL_2="48" WEIGHT="2.662050255185916"/>
<CONT_DATA CI_END="0.10490589919086529" CI_START="-0.673404394163899" EFFECT_SIZE="-0.2842492474865168" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="9.6" ORDER="4582" SD_1="4.5" SD_2="5.3" SE="0.19855219266628787" STUDY_ID="STD-Ropert-1989" TOTAL_1="55" TOTAL_2="48" WEIGHT="2.737515832080146"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.694150390180594" CI_END="0.8568516496330205" CI_START="-0.32456091390233066" DF="3" EFFECT_SIZE="0.26614536786534493" ESTIMABLE="YES" I2="65.49404064383012" ID="CMP-001.02.03" MODIFIED="2012-08-10 12:02:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.033646309594100754" P_Z="0.377198150947339" STUDIES="4" TAU2="0.2325934245767021" TOTAL_1="76" TOTAL_2="71" WEIGHT="6.27660773341184" Z="0.8830705746132539">
<NAME>Fluoxetine vs Desipramine</NAME>
<CONT_DATA CI_END="0.5150180436046915" CI_START="-0.5150180436046915" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="13.0" MODIFIED="2012-08-10 12:02:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4583" SD_1="5.0" SD_2="6.2" SE="0.2627691364061218" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" WEIGHT="2.1690101898207135"/>
<CONT_DATA CI_END="0.7601360463994616" CI_START="-1.1504798731999841" EFFECT_SIZE="-0.1951719134002613" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="10.4" MODIFIED="2012-08-10 10:46:20 +0100" MODIFIED_BY="[Empty name]" ORDER="4584" SD_1="1.3" SD_2="4.5" SE="0.48741097659705496" STUDY_ID="STD-Levkovitz-2002" TOTAL_1="8" TOTAL_2="9" WEIGHT="0.9943398380497219"/>
<CONT_DATA CI_END="0.8175985442394041" CI_START="-0.7247362969010612" EFFECT_SIZE="0.046431123669171466" ESTIMABLE="YES" MEAN_1="17.1" MEAN_2="16.7" MODIFIED="2012-04-23 09:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="1129" SD_1="8.7" SD_2="7.9" SE="0.3934599955168069" STUDY_ID="STD-Nelson-2004" TOTAL_1="14" TOTAL_2="12" WEIGHT="1.3546075373738355"/>
<CONT_DATA CI_END="1.7072223948661351" CI_START="0.4532525539722374" EFFECT_SIZE="1.0802374744191863" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="6.9" MODIFIED="2012-08-10 12:02:20 +0100" MODIFIED_BY="[Empty name]" ORDER="4585" SD_1="5.0" SD_2="6.2" SE="0.3198961437008669" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" WEIGHT="1.758650168167569"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.165934344972056" CI_END="0.5861846678389241" CI_START="-0.2705982821825479" DF="3" EFFECT_SIZE="0.15779319282818813" ESTIMABLE="YES" I2="67.27011249381641" ID="CMP-001.02.04" MODIFIED="2013-04-29 16:08:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.02716418745310689" P_Z="0.4703370655323855" STUDIES="4" TAU2="0.128140812918721" TOTAL_1="128" TOTAL_2="138" WEIGHT="9.078850104911794" Z="0.7219307408978717">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<CONT_DATA CI_END="0.7646441439861308" CI_START="-0.136135897709597" EFFECT_SIZE="0.3142541231382669" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="9.7" ORDER="4586" SD_1="6.9" SD_2="5.8" SE="0.22979504950115556" STUDY_ID="STD-Corne-1989" TOTAL_1="34" TOTAL_2="44" WEIGHT="2.447698320208824"/>
<CONT_DATA CI_END="1.2178207536294277" CI_START="0.1734511405714465" EFFECT_SIZE="0.6956359471004371" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="8.9" ORDER="4587" SD_1="7.26" SD_2="5.7" SE="0.2664257152926879" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.1399816243385588"/>
<CONT_DATA CI_END="0.499342319872143" CI_START="-0.5888020940924469" EFFECT_SIZE="-0.044729887110151946" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="10.0" ORDER="4588" SD_1="7.8" SD_2="5.0" SE="0.27759296154106256" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="27" TOTAL_2="25" WEIGHT="2.0536900817046995"/>
<CONT_DATA CI_END="0.14245119467638595" CI_START="-0.7628373851357335" EFFECT_SIZE="-0.3101930952296738" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="11.3" ORDER="4589" SD_1="7.1" SD_2="6.3" SE="0.23094520791017598" STUDY_ID="STD-Stephenson-2000" TOTAL_1="37" TOTAL_2="39" WEIGHT="2.4374800786597115"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="24.175273420698375" CI_END="0.18855687941362678" CI_START="-0.21453782748113667" DF="11" EFFECT_SIZE="-0.012990474033754949" ESTIMABLE="YES" I2="54.498963430204576" ID="CMP-001.02.05" MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.012014172536867096" P_Z="0.8994731288394688" STUDIES="12" TAU2="0.06106152857653361" TOTAL_1="534" TOTAL_2="529" WEIGHT="26.355865419013746" Z="0.1263269440792214">
<NAME>Fluoxetine vs Imipramine</NAME>
<CONT_DATA CI_END="0.5909513763026629" CI_START="-0.5909513763026629" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="10.5" ORDER="4590" SD_1="7.61" SD_2="8.7" SE="0.30151134457776363" STUDY_ID="STD-Beasley-1993a" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.8807783304633532"/>
<CONT_DATA CI_END="1.3525029460270193" CI_START="-0.14471444075013407" EFFECT_SIZE="0.6038942526384427" ESTIMABLE="YES" MEAN_1="15.3" MEAN_2="10.3" ORDER="4591" SD_1="7.61" SD_2="8.7" SE="0.381950229337634" STUDY_ID="STD-Bressa-1989" TOTAL_1="18" TOTAL_2="12" WEIGHT="1.409688041743817"/>
<CONT_DATA CI_END="0.4854091799337703" CI_START="-0.7023582999897018" EFFECT_SIZE="-0.10847456002796577" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="13.7" ORDER="4592" SD_1="7.7" SD_2="8.5" SE="0.30300747597721955" STUDY_ID="STD-Byerley-1988" TOTAL_1="20" TOTAL_2="24" WEIGHT="1.8704949219127107"/>
<CONT_DATA CI_END="-0.29312899102416495" CI_START="-1.0699158253166123" EFFECT_SIZE="-0.6815224081703887" ESTIMABLE="YES" MEAN_1="11.49" MEAN_2="17.1" ORDER="4593" SD_1="7.61" SD_2="8.7" SE="0.19816354800895394" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" WEIGHT="2.7412552295303327"/>
<CONT_DATA CI_END="0.570455451825097" CI_START="-0.22914706515307948" EFFECT_SIZE="0.17065419333600879" ESTIMABLE="YES" MEAN_1="17.69" MEAN_2="16.04" ORDER="4595" SD_1="9.91" SD_2="9.21" SE="0.20398398217654484" STUDY_ID="STD-Feighner-1989" TOTAL_1="52" TOTAL_2="45" WEIGHT="2.6855637058675836"/>
<CONT_DATA CI_END="0.9706176539575503" CI_START="-0.1584239943214426" EFFECT_SIZE="0.40609682981805384" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="6.4" ORDER="4596" SD_1="7.61" SD_2="8.7" SE="0.2880261211901671" STUDY_ID="STD-Levine-1989" TOTAL_1="22" TOTAL_2="28" WEIGHT="1.9762818623802607"/>
<CONT_DATA CI_END="0.050469485619338394" CI_START="-1.4290041511727176" EFFECT_SIZE="-0.6892673327766896" ESTIMABLE="YES" MEAN_1="7.44" MEAN_2="13.23" ORDER="4597" SD_1="7.61" SD_2="8.7" SE="0.37742367932828236" STUDY_ID="STD-Loeb-1989" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.4321158870868735"/>
<CONT_DATA CI_END="0.7544122436813692" CI_START="-0.029051671838872417" EFFECT_SIZE="0.36268028592124835" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="5.8" ORDER="4598" SD_1="5.6" SD_2="4.8" SE="0.1998669163566537" STUDY_ID="STD-McGrath-2000" TOTAL_1="49" TOTAL_2="53" WEIGHT="2.724887579552335"/>
<CONT_DATA CI_END="0.47863105893962266" CI_START="-0.7184409636446375" EFFECT_SIZE="-0.11990495235250741" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="8.2" ORDER="4599" SD_1="7.61" SD_2="8.7" SE="0.30538112741525136" STUDY_ID="STD-Nielsen-1993" TOTAL_1="21" TOTAL_2="22" WEIGHT="1.8543066871752196"/>
<CONT_DATA CI_END="0.2334410560198807" CI_START="-0.17415626962145825" EFFECT_SIZE="0.029642393199211223" ESTIMABLE="YES" MEAN_1="16.5" MEAN_2="16.2" ORDER="4600" SD_1="10.1" SD_2="10.1" SE="0.1039808202743557" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="185" WEIGHT="3.6653430593603025"/>
<CONT_DATA CI_END="0.8019814600379018" CI_START="-0.8729460558924156" EFFECT_SIZE="-0.035482297927256864" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="7.4" ORDER="4601" SD_1="4.8" SD_2="11.7" SE="0.4272852790005153" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="9" WEIGHT="1.2078080243765181"/>
<CONT_DATA CI_END="0.2781320779671402" CI_START="-0.4320218443334945" EFFECT_SIZE="-0.07694488318317715" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="12.2" ORDER="4602" SD_1="7.6" SD_2="7.9" SE="0.18116504382280443" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="60" WEIGHT="2.907342089564437"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4181579425649102" CI_START="-0.16206532016794667" DF="0" EFFECT_SIZE="0.12804631119848175" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.06" NO="6" P_CHI2="1.0" P_Z="0.38700172281990697" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="3.23947021365724" Z="0.8650675504466304">
<NAME>Fluoxetine vs Lofepramine</NAME>
<CONT_DATA CI_END="0.4181579425649102" CI_START="-0.16206532016794667" EFFECT_SIZE="0.12804631119848175" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="13.2" ORDER="4603" SD_1="7.2" SD_2="6.8" SE="0.1480188583335163" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" WEIGHT="3.23947021365724"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.103781850039163E-32" CI_END="0.37758628528271343" CI_START="-1.1226441398077696" DF="0" EFFECT_SIZE="-0.37252892726252806" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.07" NO="7" P_CHI2="0.0" P_Z="0.3303670475516609" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="1.405923188072446" Z="0.9733748475203197">
<NAME>Fluoxetine vs Nomifensine</NAME>
<CONT_DATA CI_END="0.3775862852827135" CI_START="-1.1226441398077696" EFFECT_SIZE="-0.372528927262528" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="13.2" ORDER="4604" SD_1="7.4" SD_2="5.3" SE="0.38271887568447915" STUDY_ID="STD-Taneri-1989" TOTAL_1="15" TOTAL_2="13" WEIGHT="1.405923188072446"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.552348178372872" CI_END="0.2448850770360455" CI_START="-1.1950634935679822" DF="1" EFFECT_SIZE="-0.4750892082659684" ESTIMABLE="YES" I2="86.75908503710635" ID="CMP-001.02.08" MODIFIED="2012-08-02 17:06:39 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.005993241071027722" P_Z="0.19590012050297492" STUDIES="2" TAU2="0.2344272913058868" TOTAL_1="134" TOTAL_2="117" WEIGHT="5.699553300105395" Z="1.2933208263880511">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<CONT_DATA CI_END="-0.438862543922505" CI_START="-1.272003406942508" EFFECT_SIZE="-0.8554329754325065" ESTIMABLE="YES" MEAN_1="16.16" MEAN_2="19.71" MODIFIED="2012-08-02 17:06:39 +0100" MODIFIED_BY="[Empty name]" ORDER="2927" SD_1="4.02" SD_2="4.21" SE="0.21253983991331263" STUDY_ID="STD-Hashemi-2012" TOTAL_1="48" TOTAL_2="49" WEIGHT="2.6049873076143"/>
<CONT_DATA CI_END="0.198040684150591" CI_START="-0.43865525196172056" EFFECT_SIZE="-0.12030728390556479" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="13.4" ORDER="4605" SD_1="10.3" SD_2="11.3" SE="0.16242541728687054" STUDY_ID="STD-Joyce-2002" TOTAL_1="86" TOTAL_2="68" WEIGHT="3.0945659924910944"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.026408557917301265" CI_END="0.9224108430043992" CI_START="-0.10283763835511561" DF="1" EFFECT_SIZE="0.4097866023246418" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.09" MODIFIED="2012-03-21 11:19:03 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8709065592249096" P_Z="0.11716723032302126" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.845767906544755" Z="1.5667752676664464">
<NAME>Fluoxetine vs Trimipramine</NAME>
<CONT_DATA CI_END="0.999582752263249" CI_START="-0.23739203887868027" EFFECT_SIZE="0.3810953566922844" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="12.1" MODIFIED="2012-03-21 11:19:03 +0000" MODIFIED_BY="[Empty name]" ORDER="970" SD_1="11.1" SD_2="10.0" SE="0.3155605921585877" STUDY_ID="STD-Wehmeier-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="1.7866275589019787"/>
<CONT_DATA CI_END="1.388982040343848" CI_START="-0.44347936598721294" EFFECT_SIZE="0.4727513371783175" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="9.3" ORDER="4606" SD_1="8.7" SD_2="9.1" SE="0.46747323440259175" STUDY_ID="STD-Wolf-2001" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.0591403476427765"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="75.99311337997335" CI_END="0.95696298057328" CI_START="0.6493774635359639" CI_STUDY="95" CI_TOTAL="95" DF="47" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7883084377466046" ESTIMABLE="YES" EVENTS_1="598" EVENTS_2="706" I2="38.152290504278746" I2_Q="43.80544383823011" ID="CMP-001.03" LOG_CI_END="-0.019104862268834337" LOG_CI_START="-0.18750278751754135" LOG_EFFECT_SIZE="-0.10330382489318786" METHOD="MH" MODIFIED="2013-05-06 15:37:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.004693777061127169" P_Q="0.06655271693294651" P_Z="0.016186519604288036" Q="16.015786251770155" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="49" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.15527943335505776" TOTALS="YES" TOTAL_1="2085" TOTAL_2="2109" WEIGHT="99.99999999999997" Z="2.4046825512469923">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.60558787370565" CI_END="0.850007307373012" CI_START="0.45853722474310576" DF="16" EFFECT_SIZE="0.6243076098640645" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="149" I2="3.6468921083160097" ID="CMP-001.03.01" LOG_CI_END="-0.07057734071143076" LOG_CI_START="-0.338625401882089" LOG_EFFECT_SIZE="-0.20460137129675987" MODIFIED="2012-04-16 09:45:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41155208449050973" P_Z="0.002770789184989253" STUDIES="18" TAU2="0.015477360062106486" TOTAL_1="534" TOTAL_2="555" WEIGHT="28.270329302710184" Z="2.9920852042562966">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="3.316202688540135" CI_START="0.07538743058858548" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.520641067060489" LOG_CI_START="-1.1227010583884514" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4607" O_E="0.0" SE="0.9653072991634228" STUDY_ID="STD-Altamura-1989" TOTAL_1="13" TOTAL_2="15" VAR="0.9318181818181819" WEIGHT="0.9000779736340738"/>
<DICH_DATA CI_END="1.9275942292628039" CI_START="0.06326283430131652" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2850156174615675" LOG_CI_START="-1.1988513547243185" LOG_EFFECT_SIZE="-0.4569178686313755" ORDER="4608" O_E="0.0" SE="0.8716308047219646" STUDY_ID="STD-Chouinard-1985" TOTAL_1="23" TOTAL_2="28" VAR="0.7597402597402597" WEIGHT="1.0693459670770566"/>
<DICH_DATA CI_END="2.2525959194364544" CI_START="0.27189802006905167" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.3526832930562181" LOG_CI_START="-0.5655939548847917" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="4609" O_E="0.0" SE="0.5394006009862361" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="0.2909530083443127" WEIGHT="2.192742004326899"/>
<DICH_DATA CI_END="0.7764070207128679" CI_START="0.08129406164801084" EFFECT_SIZE="0.2512315270935961" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.10991054612876511" LOG_CI_START="-1.0899411775017878" LOG_EFFECT_SIZE="-0.5999258618152765" ORDER="4610" O_E="0.0" SE="0.5756748440983785" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.33140152612769247" WEIGHT="2.0105011292151125"/>
<DICH_DATA CI_END="1.9143812170476135" CI_START="0.15541348740135755" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.28202842454573146" LOG_CI_START="-0.8085112940948942" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="4611" O_E="0.0" SE="0.6405884289881728" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.4103535353535353" WEIGHT="1.7298719712917945"/>
<DICH_DATA CI_END="0.7547906056049147" CI_START="0.05493055588904852" EFFECT_SIZE="0.20361990950226244" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.12217351385863832" LOG_CI_START="-1.2601860059608958" LOG_EFFECT_SIZE="-0.691179759909767" ORDER="4612" O_E="0.0" SE="0.6684741711135538" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="0.44685771744595276" WEIGHT="1.6249995824139434"/>
<DICH_DATA CI_END="1.6638491289033994" CI_START="0.11758042918440263" EFFECT_SIZE="0.4423076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.22111394367628012" LOG_CI_START="-0.9296649589106928" LOG_EFFECT_SIZE="-0.3542755076172063" MODIFIED="2012-04-16 09:45:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1005" O_E="0.0" SE="0.6759732238270267" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.4569397993311036" WEIGHT="1.5982389418157217"/>
<DICH_DATA CI_END="10.989588690168986" CI_START="0.5853241964793986" EFFECT_SIZE="2.536231884057971" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0409814382894846" LOG_CI_START="-0.23260352239140616" LOG_EFFECT_SIZE="0.40418895794903914" ORDER="4613" O_E="0.0" SE="0.7481101102511858" STUDY_ID="STD-Judd-1993" TOTAL_1="30" TOTAL_2="28" VAR="0.5596687370600414" WEIGHT="1.3685923806748985"/>
<DICH_DATA CI_END="4.713326527047947" CI_START="0.10506356811151449" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6733275275981517" LOG_CI_START="-0.9785478540104684" LOG_EFFECT_SIZE="-0.15261016320615833" ORDER="4614" O_E="0.0" SE="0.9703197760719181" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.9415204678362572" WEIGHT="0.8921158887275361"/>
<DICH_DATA CI_END="2.1191401204849263" CI_START="0.27136924023355763" EFFECT_SIZE="0.7583333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.32615967381390926" LOG_CI_START="-0.5664393812669719" LOG_EFFECT_SIZE="-0.12013985372653124" ORDER="4615" O_E="0.0" SE="0.5243171033910918" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="0.2749084249084249" WEIGHT="2.274524024358368"/>
<DICH_DATA CI_END="1.594216800562836" CI_START="0.017792844084640585" EFFECT_SIZE="0.16842105263157894" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20254738160566757" LOG_CI_START="-1.7497546268715134" LOG_EFFECT_SIZE="-0.773603622632923" ORDER="4616" O_E="0.0" SE="1.1467918638302979" STUDY_ID="STD-Masco-1985" TOTAL_1="20" TOTAL_2="21" VAR="1.3151315789473683" WEIGHT="0.6654415741048033"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-04 13:53:55 +0100" MODIFIED_BY="[Empty name]" ORDER="991" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9151125318571494" CI_START="0.15795416455588412" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.28219429816297775" LOG_CI_START="-0.80146891917449" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="4617" O_E="0.0" SE="0.6365491380834674" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.4051948051948052" WEIGHT="1.7457940995454213"/>
<DICH_DATA CI_END="3.409541412887333" CI_START="0.5552534500861718" EFFECT_SIZE="1.375921375921376" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.532695969829551" LOG_CI_START="-0.2555087342675903" LOG_EFFECT_SIZE="0.1385936177809804" ORDER="4618" O_E="0.0" SE="0.4629953448628715" STUDY_ID="STD-Peters-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.21436468936468936" WEIGHT="2.6470666202081397"/>
<DICH_DATA CI_END="0.996704556230113" CI_START="0.11660326777680632" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0014335564465193368" LOG_CI_START="-0.9332892784144932" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="4619" O_E="0.0" SE="0.5473766638442052" STUDY_ID="STD-Preskorn-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.2996212121212121" WEIGHT="2.150958958484499"/>
<DICH_DATA CI_END="9.605256995687844" CI_START="0.1285304392988976" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9825089892201968" LOG_CI_START="-0.8909940080988465" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="4620" O_E="0.0" SE="1.1005049346146119" STUDY_ID="STD-Upward-1988" TOTAL_1="11" TOTAL_2="12" VAR="1.2111111111111112" WEIGHT="0.7161002559409837"/>
<DICH_DATA CI_END="1.840751015282016" CI_START="0.34768417601657425" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.264995048687653" LOG_CI_START="-0.4588150747037657" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="4621" O_E="0.0" SE="0.4251696493980147" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="0.18076923076923077" WEIGHT="2.911699176538529"/>
<DICH_DATA CI_END="3.437213993211045" CI_START="0.2909332971339966" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5362065711764066" LOG_CI_START="-0.5362065711764066" LOG_EFFECT_SIZE="0.0" ORDER="4622" O_E="0.0" SE="0.629940788348712" STUDY_ID="STD-Young-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.39682539682539686" WEIGHT="1.7722587543524142"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.21990975969753984" CI_END="1.1407428905220256" CI_START="0.375349532013147" DF="1" EFFECT_SIZE="0.6543525885214843" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="40" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.057187770789712745" LOG_CI_START="-0.42556412127684046" LOG_EFFECT_SIZE="-0.18418817524356387" NO="2" P_CHI2="0.6391087024208089" P_Z="0.13475757211077416" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="132" WEIGHT="6.16724284725717" Z="1.4956013463154638">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="1.7608969943800044" CI_START="0.3285658514022512" EFFECT_SIZE="0.7606382978723404" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.2457339521735525" LOG_CI_START="-0.4833775757707886" LOG_EFFECT_SIZE="-0.11882181179861807" ORDER="4623" O_E="0.0" SE="0.4282837206747771" STUDY_ID="STD-Noguera-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.18342694539503052" WEIGHT="2.888852055926357"/>
<DICH_DATA CI_END="1.2214526031994524" CI_START="0.27713919951336724" EFFECT_SIZE="0.5818181818181818" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.08687661943200746" LOG_CI_START="-0.5573020417806833" LOG_EFFECT_SIZE="-0.2352127111743379" ORDER="4624" O_E="0.0" SE="0.37839373433213475" STUDY_ID="STD-Ropert-1989" TOTAL_1="71" TOTAL_2="72" VAR="0.1431818181818182" WEIGHT="3.2783907913308132"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6221955042220303" CI_END="1.2408085211039226" CI_START="0.15958346910056256" DF="1" EFFECT_SIZE="0.44498598661901995" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.0937047672811339" LOG_CI_START="-0.7970120982624607" LOG_EFFECT_SIZE="-0.35165366549066335" NO="3" P_CHI2="0.43023279761470323" P_Z="0.12172306240345908" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="50" WEIGHT="2.7344153192657847" Z="1.5475816077032907">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="2.1096848858011246" CI_START="0.16940730468855322" EFFECT_SIZE="0.5978260869565217" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.3242175915167711" LOG_CI_START="-0.7710678672193939" LOG_EFFECT_SIZE="-0.22342513785131143" ORDER="4625" O_E="0.0" SE="0.6433761002120849" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.4139328063241107" WEIGHT="1.7189943405979313"/>
<DICH_DATA CI_END="1.4562396179587855" CI_START="0.042918760916288205" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.16323284214397715" LOG_CI_START="-1.367352824799902" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="4626" O_E="0.0" SE="0.8990735972840785" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" VAR="0.8083333333333333" WEIGHT="1.0154209786678532"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.929996733663086" CI_END="2.685347561317259" CI_START="0.915498626725855" DF="4" EFFECT_SIZE="1.5679387758033074" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="68" I2="42.27991507456795" ID="CMP-001.03.04" LOG_CI_END="0.4290005038879167" LOG_CI_START="-0.03834230281595006" LOG_EFFECT_SIZE="0.19532910053598332" MODIFIED="2013-04-29 16:08:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.13963430863448145" P_Z="0.10134650950365404" STUDIES="5" TAU2="0.15709930323590537" TOTAL_1="237" TOTAL_2="241" WEIGHT="13.050146292161456" Z="1.6383605211911059">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="6.903675130153286" CI_START="0.9156909231505022" EFFECT_SIZE="2.5142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.8390803463657038" LOG_CI_START="-0.03825109076591778" LOG_EFFECT_SIZE="0.400414627799893" ORDER="4627" O_E="0.0" SE="0.515348829031769" STUDY_ID="STD-Corne-1989" TOTAL_1="49" TOTAL_2="51" VAR="0.26558441558441553" WEIGHT="2.3249148651593576"/>
<DICH_DATA CI_END="8.100075556648452" CI_START="0.9336332663950007" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.9084890699505573" LOG_CI_START="-0.02982368229003217" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="4628" O_E="0.0" SE="0.551169555389155" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.3037878787878788" WEIGHT="2.131436050282107"/>
<DICH_DATA CI_END="8.517969128422692" CI_START="0.9286434513604249" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.9303360617320986" LOG_CI_START="-0.03215099949326086" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="4629" O_E="0.0" SE="0.5653696641515683" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="31" TOTAL_2="28" VAR="0.3196428571428571" WEIGHT="2.0602794145158354"/>
<DICH_DATA CI_END="2.2025526356465464" CI_START="0.40626213338547673" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.34292629578905837" LOG_CI_START="-0.39119365522249705" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="4630" O_E="0.0" SE="0.4312256931765528" STUDY_ID="STD-Stephenson-2000" TOTAL_1="51" TOTAL_2="56" VAR="0.18595559845559845" WEIGHT="2.8674448031188566"/>
<DICH_DATA CI_END="1.7216161674821535" CI_START="0.46469757853608457" EFFECT_SIZE="0.8944444444444445" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="30" LOG_CI_END="0.23593633241061943" LOG_CI_START="-0.3328295905535321" LOG_EFFECT_SIZE="-0.04844662907145634" ORDER="4631" O_E="0.0" SE="0.33409591858586807" STUDY_ID="STD-Thompson-2000" TOTAL_1="76" TOTAL_2="76" VAR="0.11162008281573498" WEIGHT="3.6660711590852997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5938752101102716" CI_END="1.3186042817601489" CI_START="0.49207957182321055" DF="3" EFFECT_SIZE="0.8055173681385064" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="63" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.12011448164716995" LOG_CI_START="-0.3079646638799716" LOG_EFFECT_SIZE="-0.09392509111640088" NO="5" P_CHI2="0.45856435784822414" P_Z="0.3897484560160681" STUDIES="4" TAU2="0.0" TOTAL_1="162" TOTAL_2="161" WEIGHT="7.987012976166224" Z="0.8600736464566542">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="1.0982799642183618" CI_START="0.3092883678229756" EFFECT_SIZE="0.5828252032520326" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="48" LOG_CI_END="0.04071306089448757" LOG_CI_START="-0.5096364132825975" LOG_EFFECT_SIZE="-0.234461676194055" ORDER="4632" O_E="0.0" SE="0.3232780054054535" STUDY_ID="STD-Feighner-1985a" TOTAL_1="78" TOTAL_2="79" VAR="0.10450866877892842" WEIGHT="3.766425831552958"/>
<DICH_DATA CI_END="3.769862326152959" CI_START="0.5228880604803338" EFFECT_SIZE="1.404" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.5763254902366071" LOG_CI_START="-0.2815912746490341" LOG_EFFECT_SIZE="0.14736710779378645" ORDER="4633" O_E="0.0" SE="0.5039445544503026" STUDY_ID="STD-Remick-1989" TOTAL_1="38" TOTAL_2="37" VAR="0.253960113960114" WEIGHT="2.390953232713853"/>
<DICH_DATA CI_END="17.18118077307193" CI_START="0.058203217416075405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2350530073187374" LOG_CI_START="-1.2350530073187374" LOG_EFFECT_SIZE="0.0" ORDER="4634" O_E="0.0" SE="1.4509525002200232" STUDY_ID="STD-Sandor-1998" TOTAL_1="20" TOTAL_2="20" VAR="2.1052631578947367" WEIGHT="0.43284856582445186"/>
<DICH_DATA CI_END="5.314216826324215" CI_START="0.2940226285574358" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7254392701636566" LOG_CI_START="-0.5316192441475438" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="4635" O_E="0.0" SE="0.7384023938464008" STUDY_ID="STD-Tamminen-1989" TOTAL_1="26" TOTAL_2="25" VAR="0.5452380952380953" WEIGHT="1.396785346074961"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.36656116257729" CI_END="1.2083863328853957" CI_START="0.5127176525658927" DF="11" EFFECT_SIZE="0.7871219752933515" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="268" I2="56.635824897589785" ID="CMP-001.03.06" LOG_CI_END="0.08220580466312442" LOG_CI_START="-0.29012172979973705" LOG_EFFECT_SIZE="-0.10395796256830632" MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.008054059416109038" P_Z="0.2737413701062006" STUDIES="12" TAU2="0.2726014722330804" TOTAL_1="610" TOTAL_2="615" WEIGHT="27.59574173859115" Z="1.0944872118254112">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="1.8954141847193027" CI_START="0.4332348369130427" EFFECT_SIZE="0.9061784897025171" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" LOG_CI_END="0.27770412643244" LOG_CI_START="-0.3632766285222591" LOG_EFFECT_SIZE="-0.04278625104490955" ORDER="4636" O_E="0.0" SE="0.3765152683662993" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.1417637473129464" WEIGHT="3.294041682448761"/>
<DICH_DATA CI_END="5.67331316667771" CI_START="0.17626384629593778" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.753836757265777" LOG_CI_START="-0.753836757265777" LOG_EFFECT_SIZE="0.0" ORDER="4637" O_E="0.0" SE="0.8856148855400953" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.7843137254901961" WEIGHT="1.041379036656772"/>
<DICH_DATA CI_END="17.093060428104796" CI_START="0.1106077526579963" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2328198279661584" LOG_CI_START="-0.9562144316335955" LOG_EFFECT_SIZE="0.13830269816628146" ORDER="4638" O_E="0.0" SE="1.2858495599832396" STUDY_ID="STD-Bressa-1989" TOTAL_1="18" TOTAL_2="12" VAR="1.6534090909090908" WEIGHT="0.5409845893756903"/>
<DICH_DATA CI_END="4.024726258020917" CI_START="0.5152151642282508" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.6047363471451639" LOG_CI_START="-0.2880113629546646" LOG_EFFECT_SIZE="0.15836249209524964" ORDER="4639" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Byerley-1988" TOTAL_1="32" TOTAL_2="34" VAR="0.275" WEIGHT="2.2740399441777366"/>
<DICH_DATA CI_END="1.4720761005994296" CI_START="0.3162917570243721" EFFECT_SIZE="0.6823529411764706" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.1679302619145963" LOG_CI_START="-0.4999121262173072" LOG_EFFECT_SIZE="-0.16599093215135544" ORDER="4640" O_E="0.0" SE="0.39229392466181784" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="0.153894523326572" WEIGHT="3.164796379066109"/>
<DICH_DATA CI_END="2.2726714660670098" CI_START="0.5393499783951208" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.3565366593120562" LOG_CI_START="-0.26812933432794916" LOG_EFFECT_SIZE="0.044203662492053486" ORDER="4642" O_E="0.0" SE="0.3669318968106771" STUDY_ID="STD-Feighner-1989" TOTAL_1="61" TOTAL_2="58" VAR="0.1346390168970814" WEIGHT="3.374992580695006"/>
<DICH_DATA CI_END="26.429733766912282" CI_START="0.9806135620006545" EFFECT_SIZE="5.090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.4220927884006" LOG_CI_START="-0.008502104704649216" LOG_EFFECT_SIZE="0.7067953418479753" ORDER="4643" O_E="0.0" SE="0.8403385217689542" STUDY_ID="STD-Levine-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.7061688311688311" WEIGHT="1.135846061688165"/>
<DICH_DATA CI_END="0.8648087636462993" CI_START="0.1214418839191164" EFFECT_SIZE="0.32407407407407407" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="18" LOG_CI_END="-0.06307991805573498" LOG_CI_START="-0.9156315042176132" LOG_EFFECT_SIZE="-0.4893557111366741" ORDER="4644" O_E="0.0" SE="0.5007930219099012" STUDY_ID="STD-McGrath-2000" TOTAL_1="49" TOTAL_2="53" VAR="0.2507936507936508" WEIGHT="2.4095973281726693"/>
<DICH_DATA CI_END="3.3019711721904006" CI_START="0.3323789372171282" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5187732773418912" LOG_CI_START="-0.4783665051653172" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="4645" O_E="0.0" SE="0.585724844166263" STUDY_ID="STD-Nielsen-1993" TOTAL_1="29" TOTAL_2="30" VAR="0.3430735930735931" WEIGHT="1.9634126145868835"/>
<DICH_DATA CI_END="1.5188664552390403" CI_START="0.6718907268161788" EFFECT_SIZE="1.010204081632653" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" LOG_CI_END="0.18151959064857084" LOG_CI_START="-0.17270135283846075" LOG_EFFECT_SIZE="0.004409118905055016" ORDER="4646" O_E="0.0" SE="0.20807113562623145" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.0432935974807896" WEIGHT="4.927520189871248"/>
<DICH_DATA CI_END="1.2064460145415323" CI_START="0.002940478055883613" EFFECT_SIZE="0.05956112852664577" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.08150789308171011" LOG_CI_START="-2.5315820572904144" LOG_EFFECT_SIZE="-1.2250370821043521" ORDER="4647" O_E="0.0" SE="1.5349419718524533" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="14" VAR="2.356046856954298" WEIGHT="0.389623850307015"/>
<DICH_DATA CI_END="0.4814061160735749" CI_START="0.09916106206725049" EFFECT_SIZE="0.2184873949579832" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="34" LOG_CI_END="-0.3174883964869722" LOG_CI_START="-1.0036588303564533" LOG_EFFECT_SIZE="-0.6605736134217128" ORDER="4648" O_E="0.0" SE="0.40305990945336045" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="0.16245729060855113" WEIGHT="3.0795074815451002"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0412807804728923" CI_START="0.2411009060382097" DF="0" EFFECT_SIZE="0.5010526315789474" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" I2="0.0" ID="CMP-001.03.07" LOG_CI_END="0.01756785243832372" LOG_CI_START="-0.6178011575750328" LOG_EFFECT_SIZE="-0.30011665256835457" NO="7" P_CHI2="1.0" P_Z="0.06408635874762932" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="3.321678038489263" Z="1.8515785973959604">
<NAME>Fluoxetine vs Lofepramine</NAME>
<DICH_DATA CI_END="1.0412807804728923" CI_START="0.2411009060382097" EFFECT_SIZE="0.5010526315789474" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.01756785243832372" LOG_CI_START="-0.6178011575750328" LOG_EFFECT_SIZE="-0.30011665256835457" ORDER="4649" O_E="0.0" SE="0.37321890160916915" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" VAR="0.1392923485183547" WEIGHT="3.321678038489263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.16285997165224" CI_START="0.6667088487816369" DF="0" EFFECT_SIZE="6.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.03.08" LOG_CI_END="1.7793284732016752" LOG_CI_START="-0.17606378073534243" LOG_EFFECT_SIZE="0.8016323462331665" NO="8" P_CHI2="1.0" P_Z="0.10805148466285457" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.6635612572758011" Z="1.607013144596364">
<NAME>Fluoxetine vs Nomifensine</NAME>
<DICH_DATA CI_END="60.16285997165224" CI_START="0.6667088487816369" EFFECT_SIZE="6.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.7793284732016752" LOG_CI_START="-0.17606378073534243" LOG_EFFECT_SIZE="0.8016323462331665" ORDER="4650" O_E="0.0" SE="1.1486070893103677" STUDY_ID="STD-Taneri-1989" TOTAL_1="20" TOTAL_2="20" VAR="1.319298245614035" WEIGHT="0.6635612572758011"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.543459438342298" CI_END="1.4742752942717283" CI_START="0.3594193525171824" DF="2" EFFECT_SIZE="0.7279306778115777" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="76" I2="55.980678882659745" ID="CMP-001.03.09" LOG_CI_END="0.16857858774263587" LOG_CI_START="-0.44439854251600225" LOG_EFFECT_SIZE="-0.13790997738668323" NO="9" P_CHI2="0.10313376915564532" P_Z="0.3778197389066653" STUDIES="3" TAU2="0.2112747196948181" TOTAL_1="227" TOTAL_2="221" WEIGHT="9.003125316578576" Z="0.8819206311092985">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<DICH_DATA CI_END="8.251259355410493" CI_START="0.5137099856738948" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.9165202381699855" LOG_CI_START="-0.2892819922259821" LOG_EFFECT_SIZE="0.3136191229720017" ORDER="4651" O_E="0.0" SE="0.7082941989518957" STUDY_ID="STD-Akhondzadeh-2003" TOTAL_1="24" TOTAL_2="24" VAR="0.5016806722689076" WEIGHT="1.489394272546022"/>
<DICH_DATA CI_END="1.3485007434802019" CI_START="0.4418173430793864" EFFECT_SIZE="0.771875" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" LOG_CI_END="0.12985119023218777" LOG_CI_START="-0.35475724035266826" LOG_EFFECT_SIZE="-0.11245302506024026" ORDER="4652" O_E="0.0" SE="0.28466139097596405" STUDY_ID="STD-Fabre-1991" TOTAL_1="103" TOTAL_2="102" VAR="0.08103210751237067" WEIGHT="4.140604453831945"/>
<DICH_DATA CI_END="0.8419643412164277" CI_START="0.19964377227010083" EFFECT_SIZE="0.4099913867355728" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" LOG_CI_END="-0.07470630130423607" LOG_CI_START="-0.6997442327319254" LOG_EFFECT_SIZE="-0.3872252670180807" ORDER="4653" O_E="0.0" SE="0.36715037490828445" STUDY_ID="STD-Joyce-2002" TOTAL_1="100" TOTAL_2="95" VAR="0.13479939779529382" WEIGHT="3.3731265902006093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.777258940904222" CI_START="0.4091126177773166" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.03.10" LOG_CI_END="0.9902171171912175" LOG_CI_START="-0.38815712586325507" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-03-21 11:20:03 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.3919466063210234" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="1.2067469115043712" Z="0.8560925347243811">
<NAME>Fluoxetine vs Trimipramine</NAME>
<DICH_DATA CI_END="9.777258940904222" CI_START="0.4091126177773166" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9902171171912175" LOG_CI_START="-0.38815712586325507" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-03-21 11:20:03 +0000" MODIFIED_BY="[Empty name]" ORDER="971" O_E="0.0" SE="0.8096638534327413" STUDY_ID="STD-Wehmeier-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.6555555555555556" WEIGHT="1.2067469115043712"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.754494479985638" CI_END="1.7208332806671343" CI_START="0.9609902431983505" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2859642269099574" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.23573879665318823" LOG_CI_START="-0.01728102164116102" LOG_EFFECT_SIZE="0.10922888750601356" METHOD="MH" MODIFIED="2013-05-06 15:37:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.949122453352534" P_Q="0.5683944133836514" P_Z="0.09060089017546206" Q="4.810065758250375" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="33" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1450" TOTAL_2="1461" WEIGHT="100.0" Z="1.692236497728486">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.477475927833803" CI_END="1.8835735308819055" CI_START="0.44286554976759945" DF="10" EFFECT_SIZE="0.9133289808616135" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.27498257884400246" LOG_CI_START="-0.35372810189573656" LOG_EFFECT_SIZE="-0.03937276152586705" MODIFIED="2012-04-16 09:45:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8570897818800336" P_Z="0.8060817246940439" STUDIES="13" TAU2="0.0" TOTAL_1="411" TOTAL_2="424" WEIGHT="16.195986359483683" Z="0.24548396242222809">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="5.803074751685154" CI_START="0.043080609969293006" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7636581649183615" LOG_CI_START="-1.3657181562463239" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4654" O_E="0.0" SE="1.2508061916349222" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="1.564516129032258" WEIGHT="1.4119009754934904"/>
<DICH_DATA CI_END="5.857126622998092" CI_START="0.24761989508624313" EFFECT_SIZE="1.2043010752688172" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7676846129770684" LOG_CI_START="-0.6062144647445754" LOG_EFFECT_SIZE="0.0807350741162465" ORDER="4655" O_E="0.0" SE="0.8070351191638119" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.651305683563748" WEIGHT="3.3915593008021703"/>
<DICH_DATA CI_END="123.07864795221792" CI_START="0.24941441908990408" EFFECT_SIZE="5.54054054054054" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0901827167749967" LOG_CI_START="-0.6030784427974784" LOG_EFFECT_SIZE="0.7435521369887593" ORDER="4656" O_E="0.0" SE="1.5820349369906253" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="2.502834541858932" WEIGHT="0.8825760599880867"/>
<DICH_DATA CI_END="3.151931737693131" CI_START="0.028856875100118452" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4985768032768393" LOG_CI_START="-1.5397507002783448" LOG_EFFECT_SIZE="-0.5205869485007528" ORDER="4657" O_E="0.0" SE="1.1973236654721853" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="1.4335839598997493" WEIGHT="1.5408527931007376"/>
<DICH_DATA CI_END="5.823325204961337" CI_START="0.04293079833271303" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7651710440624268" LOG_CI_START="-1.3672310353903891" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-04-16 09:45:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1006" O_E="0.0" SE="1.2525835370311154" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="1.5689655172413794" WEIGHT="1.4078970025037887"/>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.03103423373996879" ORDER="4658" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Judd-1993" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="1.066338759294639"/>
<DICH_DATA CI_END="89.9506535045962" CI_START="0.13320913249504976" EFFECT_SIZE="3.4615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9540043229056843" LOG_CI_START="-0.87546599996867" LOG_EFFECT_SIZE="0.5392691614685069" ORDER="4659" O_E="0.0" SE="1.6620448737603815" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.7623931623931623" WEIGHT="0.7996478846053388"/>
<DICH_DATA CI_END="6.240672274566779" CI_START="0.049007943794167605" EFFECT_SIZE="0.553030303030303" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7952313764465558" LOG_CI_START="-1.3097335186173438" LOG_EFFECT_SIZE="-0.257251071085394" ORDER="4660" O_E="0.0" SE="1.2364667991048128" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="1.5288501452885015" WEIGHT="1.4448386949913306"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4661" O_E="0.0" SE="0.0" STUDY_ID="STD-Masco-1985" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-04 13:54:23 +0100" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.120175997580382" CI_START="0.058410614478573784" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2335082249664329" LOG_CI_START="-1.2335082249664326" LOG_EFFECT_SIZE="0.0" ORDER="4662" O_E="0.0" SE="1.4491376746189437" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.0999999999999996" WEIGHT="1.0518770708361642"/>
<DICH_DATA CI_END="33.9911086347409" CI_START="0.3268828690028341" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5313653295168224" LOG_CI_START="-0.4856078389561472" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="4663" O_E="0.0" SE="1.184780023339229" STUDY_ID="STD-Preskorn-1991" TOTAL_1="30" TOTAL_2="31" VAR="1.4037037037037037" WEIGHT="1.5736525043907785"/>
<DICH_DATA CI_END="3.3191623413844646" CI_START="0.034362382033997316" EFFECT_SIZE="0.33771929824561403" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5210284944222353" LOG_CI_START="-1.4639167380781792" LOG_EFFECT_SIZE="-0.4714441218279719" ORDER="4664" O_E="0.0" SE="1.1659666552081103" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="1.3594782410571882" WEIGHT="1.6248453134771594"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="145.74545024217892" CI_START="0.37219979855997615" DF="0" EFFECT_SIZE="7.365217391304348" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="2.1635950062059615" LOG_CI_START="-0.42922386625177106" LOG_EFFECT_SIZE="0.8671855699770953" NO="2" P_CHI2="1.0" P_Z="0.18984220228619145" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.9522801259518855" Z="1.3110460611981316">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="145.74545024217892" CI_START="0.37219979855997615" EFFECT_SIZE="7.3652173913043475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1635950062059615" LOG_CI_START="-0.42922386625177106" LOG_EFFECT_SIZE="0.8671855699770952" ORDER="4665" O_E="0.0" SE="1.5230346403420856" STUDY_ID="STD-Noguera-1991" TOTAL_1="60" TOTAL_2="60" VAR="2.3196345156819462" WEIGHT="0.9522801259518855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0163801780758825" CI_END="5.345326399717987" CI_START="0.20012041131976557" DF="1" EFFECT_SIZE="1.0342673337923638" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="1.6116191981323358" ID="CMP-001.04.03" LOG_CI_END="0.7279742295201764" LOG_CI_START="-0.6987086131556037" LOG_EFFECT_SIZE="0.014632808182286312" NO="3" P_CHI2="0.3133794669413672" P_Z="0.9679298197477364" STUDIES="2" TAU2="0.03001448290398275" TOTAL_1="54" TOTAL_2="50" WEIGHT="3.231546338558073" Z="0.04020483904632173">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="10.886262075961533" CI_START="0.2592625439573307" EFFECT_SIZE="1.68" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.036878785315787" LOG_CI_START="-0.5862602218640613" LOG_EFFECT_SIZE="0.22530928172586284" ORDER="4666" O_E="0.0" SE="0.9534398874851099" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.909047619047619" WEIGHT="2.4299517456194253"/>
<DICH_DATA CI_END="6.348684220381443" CI_START="0.009476571405428616" EFFECT_SIZE="0.24528301886792453" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8026837260731798" LOG_CI_START="-2.0233487606610843" LOG_EFFECT_SIZE="-0.6103325172939523" ORDER="4667" O_E="0.0" SE="1.6600254717941292" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" VAR="2.7556845670053214" WEIGHT="0.8015945929386478"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.396437076218286" CI_END="3.660573716646513" CI_START="0.49397953273514955" DF="2" EFFECT_SIZE="1.3447113051103625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.5635491571013317" LOG_CI_START="-0.30629104501224136" LOG_EFFECT_SIZE="0.12862905604454522" MODIFIED="2013-04-29 16:08:43 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4974707981326564" P_Z="0.5621399997763366" STUDIES="3" TAU2="0.0" TOTAL_1="137" TOTAL_2="134" WEIGHT="8.461164277241815" Z="0.5796658204578491">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="15.734420680350373" CI_START="0.49827064874341565" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1968507574202762" LOG_CI_START="-0.30253469473583805" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="4668" O_E="0.0" SE="0.8807464366741915" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.7757142857142857" WEIGHT="2.847623009445969"/>
<DICH_DATA CI_END="4.807363139264934" CI_START="0.2769420383227244" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6819069291646853" LOG_CI_START="-0.5576111156669964" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="4669" O_E="0.0" SE="0.7280990352474073" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="31" TOTAL_2="28" VAR="0.5301282051282051" WEIGHT="4.166806873106739"/>
<DICH_DATA CI_END="5.558186722457528" CI_START="0.04378726191303077" EFFECT_SIZE="0.49333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7449331324325046" LOG_CI_START="-1.3586522110819146" LOG_EFFECT_SIZE="-0.30685953932470506" ORDER="4670" O_E="0.0" SE="1.2356564436957576" STUDY_ID="STD-Thompson-2000" TOTAL_1="76" TOTAL_2="76" VAR="1.526846846846847" WEIGHT="1.4467343946891067"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.060797849928977826" CI_END="4.919327682674528" CI_START="0.6035191341560805" DF="1" EFFECT_SIZE="1.7230520548369306" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.6919057524307496" LOG_CI_START="-0.21930895634265338" LOG_EFFECT_SIZE="0.23629839804404812" NO="5" P_CHI2="0.8052393241176158" P_Z="0.3093793751402085" STUDIES="3" TAU2="0.0" TOTAL_1="142" TOTAL_2="141" WEIGHT="7.710235372032972" Z="1.0165251840464202">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="5.766774153314231" CI_START="0.42335735457871115" EFFECT_SIZE="1.5625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7609329432801512" LOG_CI_START="-0.3732928912479256" LOG_EFFECT_SIZE="0.19382002601611284" ORDER="4671" O_E="0.0" SE="0.6662498697102228" STUDY_ID="STD-Feighner-1985a" TOTAL_1="78" TOTAL_2="79" VAR="0.4438888888888889" WEIGHT="4.976339584181101"/>
<DICH_DATA CI_END="11.98798498278542" CI_START="0.35358355314477835" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0787461902381124" LOG_CI_START="-0.45150794429410923" LOG_EFFECT_SIZE="0.3136191229720017" ORDER="4672" O_E="0.0" SE="0.898878853504359" STUDY_ID="STD-Remick-1989" TOTAL_1="38" TOTAL_2="37" VAR="0.8079831932773109" WEIGHT="2.7338957878518713"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4673" O_E="0.0" SE="0.0" STUDY_ID="STD-Tamminen-1989" TOTAL_1="26" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.041860904288007" CI_END="2.0536690663895905" CI_START="0.9703253609395984" DF="9" EFFECT_SIZE="1.4116398896655507" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="60" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.31253046154939157" LOG_CI_START="-0.013082617519426392" LOG_EFFECT_SIZE="0.14972392201498264" MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8306440017021659" P_Z="0.07147188502904546" STUDIES="10" TAU2="0.0" TOTAL_1="543" TOTAL_2="550" WEIGHT="60.3817084450748" Z="1.8024674906343585">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="4.673555277366459" CI_START="0.774415627231515" EFFECT_SIZE="1.9024390243902438" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.6696473837569364" LOG_CI_START="-0.11102589181544657" LOG_EFFECT_SIZE="0.2793107459707449" ORDER="4674" O_E="0.0" SE="0.45857134646625597" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.21028767979987495" WEIGHT="10.504380717206706"/>
<DICH_DATA CI_END="82.16475480197155" CI_START="0.12105854372842961" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9146855635554856" LOG_CI_START="-0.9170045547296883" LOG_EFFECT_SIZE="0.49884050441289873" ORDER="4675" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="2.766729205753596" WEIGHT="0.7983946691140947"/>
<DICH_DATA CI_END="4.410468947564418" CI_START="0.3871193285967105" EFFECT_SIZE="1.3066666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6444847687222367" LOG_CI_START="-0.41215514412064713" LOG_EFFECT_SIZE="0.1161648123007948" ORDER="4676" O_E="0.0" SE="0.6206755152558342" STUDY_ID="STD-Byerley-1988" TOTAL_1="32" TOTAL_2="34" VAR="0.3852380952380952" WEIGHT="5.733965243989473"/>
<DICH_DATA CI_END="1.960624471059898" CI_START="0.005406426634017478" EFFECT_SIZE="0.10295616717635066" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2923944188772434" LOG_CI_START="-2.2670896860718552" LOG_EFFECT_SIZE="-0.9873476335973059" ORDER="4677" O_E="0.0" SE="1.5034536328977535" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="2.260372826273453" WEIGHT="0.977246683856884"/>
<DICH_DATA CI_END="4.446024257991747" CI_START="0.6444547612590713" EFFECT_SIZE="1.6927083333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.6479718279273481" LOG_CI_START="-0.19080756337669866" LOG_EFFECT_SIZE="0.22858213227532476" ORDER="4679" O_E="0.0" SE="0.49270316647694706" STUDY_ID="STD-Feighner-1989" TOTAL_1="61" TOTAL_2="58" VAR="0.24275641025641023" WEIGHT="9.099417174701012"/>
<DICH_DATA CI_END="24.14845588814672" CI_START="0.17768491477903403" EFFECT_SIZE="2.0714285714285716" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3828893661145807" LOG_CI_START="-0.7503494416731445" LOG_EFFECT_SIZE="0.3162699622207181" ORDER="4680" O_E="0.0" SE="1.2530750353969131" STUDY_ID="STD-Levine-1989" TOTAL_1="30" TOTAL_2="30" VAR="1.5701970443349753" WEIGHT="1.4067927695606486"/>
<DICH_DATA CI_END="25.068757237020414" CI_START="0.18407535813453782" EFFECT_SIZE="2.1481481481481484" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3991328047008436" LOG_CI_START="-0.7350043458929435" LOG_EFFECT_SIZE="0.33206422940395003" ORDER="4681" O_E="0.0" SE="1.2536027264080623" STUDY_ID="STD-Nielsen-1993" TOTAL_1="29" TOTAL_2="30" VAR="1.5715197956577267" WEIGHT="1.4056086693018321"/>
<DICH_DATA CI_END="2.270419115947087" CI_START="0.7635643564373132" EFFECT_SIZE="1.3166666666666667" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="28" LOG_CI_END="0.35610603470051416" LOG_CI_START="-0.11715435288691854" LOG_EFFECT_SIZE="0.11947584090679779" ORDER="4682" O_E="0.0" SE="0.27799549434555876" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.07728149487643159" WEIGHT="28.583063154871788"/>
<DICH_DATA CI_END="8.2917027849037" CI_START="0.011615697584441467" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9186437264669701" LOG_CI_START="-1.9349547033862324" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="4683" O_E="0.0" SE="1.6762178432358128" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="14" VAR="2.80970625798212" WEIGHT="0.7861824852617749"/>
<DICH_DATA CI_END="16.35338689370616" CI_START="0.06114941244280502" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213607711547949" LOG_CI_START="-1.213607711547949" LOG_EFFECT_SIZE="0.0" ORDER="4684" O_E="0.0" SE="1.425758354436649" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="2.0327868852459012" WEIGHT="1.0866568772105858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.027142456519722" CI_START="0.07280084731454084" DF="0" EFFECT_SIZE="0.38415841584158417" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="0.30688426961382753" LOG_CI_START="-1.1378635659906982" LOG_EFFECT_SIZE="-0.4154896481884353" NO="7" P_CHI2="1.0" P_Z="0.2596082919046119" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="3.067079081656768" Z="1.1273174824419165">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<DICH_DATA CI_END="2.027142456519722" CI_START="0.07280084731454084" EFFECT_SIZE="0.38415841584158417" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30688426961382753" LOG_CI_START="-1.1378635659906982" LOG_EFFECT_SIZE="-0.4154896481884353" ORDER="4685" O_E="0.0" SE="0.8486520302512245" STUDY_ID="STD-Fabre-1991" TOTAL_1="103" TOTAL_2="102" VAR="0.7202102684495253" WEIGHT="3.067079081656768"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="72.17660092462353" CI_END="0.7481371877150591" CI_START="0.3997465919867178" CI_STUDY="95" CI_TOTAL="95" DF="38" EFFECT_MEASURE="OR" EFFECT_SIZE="0.546868623279506" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="355" I2="47.35135831668675" I2_Q="41.87966468776011" ID="CMP-001.05" LOG_CI_END="-0.1260187572095368" LOG_CI_START="-0.39821523011499066" LOG_EFFECT_SIZE="-0.2621169936622637" METHOD="MH" MODIFIED="2013-05-06 15:41:59 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="6.817625133443972E-4" P_Q="0.09912194777282335" P_Z="1.6015381581975933E-4" Q="12.043977314297825" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="40" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3819596982999992" TOTALS="YES" TOTAL_1="1810" TOTAL_2="1837" WEIGHT="100.0" Z="3.774772404875325">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.141135254933506" CI_END="0.7125715464186122" CI_START="0.23315709829036063" DF="14" EFFECT_SIZE="0.4076041144140214" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="81" I2="30.490511965700914" ID="CMP-001.05.01" LOG_CI_END="-0.14717152338284378" LOG_CI_START="-0.632351358243338" LOG_EFFECT_SIZE="-0.3897614408130909" MODIFIED="2012-04-16 10:25:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12575426963715786" P_Z="0.0016382387129832488" STUDIES="16" TAU2="0.35418514932561324" TOTAL_1="510" TOTAL_2="528" WEIGHT="30.665912838510668" Z="3.1490112806347397">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="2.6303079649357346" CI_START="0.02827812038772938" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.420006600064705" LOG_CI_START="-1.5485494609418304" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-04-16 10:25:10 +0100" MODIFIED_BY="[Empty name]" ORDER="4686" O_E="0.0" SE="1.1563395747448983" STUDY_ID="STD-Chouinard-1985" TOTAL_1="23" TOTAL_2="28" VAR="1.3371212121212122" WEIGHT="1.4871126674872706"/>
<DICH_DATA CI_END="2.08238500019606" CI_START="0.06693180068270524" EFFECT_SIZE="0.37333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31856102680904397" LOG_CI_START="-1.1743674909080055" LOG_EFFECT_SIZE="-0.42790323204948083" ORDER="4687" O_E="0.0" SE="0.8769536014223438" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="0.7690476190476191" WEIGHT="2.221069284089398"/>
<DICH_DATA CI_END="0.5489361347962343" CI_START="0.022119989301159163" EFFECT_SIZE="0.11019283746556474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.2604781799925115" LOG_CI_START="-1.6552150874237888" LOG_EFFECT_SIZE="-0.9578466337081502" ORDER="4688" O_E="0.0" SE="0.8192753634841714" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.6712121212121213" WEIGHT="2.4273978385665607"/>
<DICH_DATA CI_END="1.0169686798002837" CI_START="0.06145715324514617" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.007307577898787688" LOG_CI_START="-1.2114275605547122" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="4689" O_E="0.0" SE="0.7158910531638176" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.5125" WEIGHT="2.858113119217923"/>
<DICH_DATA CI_END="1.5042772627918581" CI_START="0.04727260915925346" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17732789117766895" LOG_CI_START="-1.3253904266331067" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="4690" O_E="0.0" SE="0.8827041784576907" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="0.7791666666666667" WEIGHT="2.2017129878851085"/>
<DICH_DATA CI_END="2.051842801672525" CI_START="0.10445961303699022" EFFECT_SIZE="0.46296296296296297" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3121440850063834" LOG_CI_START="-0.9810515873082452" LOG_EFFECT_SIZE="-0.3344537511509309" MODIFIED="2012-04-16 09:46:14 +0100" MODIFIED_BY="[Empty name]" ORDER="1007" O_E="0.0" SE="0.7596295393394316" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.577037037037037" WEIGHT="2.665772368270338"/>
<DICH_DATA CI_END="74.1336120044427" CI_START="0.11331125163252181" EFFECT_SIZE="2.8983050847457625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8700151607231488" LOG_CI_START="-0.9457269632231292" LOG_EFFECT_SIZE="0.4621440987500096" ORDER="4691" O_E="0.0" SE="1.6539808617543488" STUDY_ID="STD-Judd-1993" TOTAL_1="30" TOTAL_2="28" VAR="2.7356526910496584" WEIGHT="0.8200079673330459"/>
<DICH_DATA CI_END="2.8050797634266047" CI_START="0.00658294468003717" EFFECT_SIZE="0.13588850174216027" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4479452150836296" LOG_CI_START="-2.181579794498616" LOG_EFFECT_SIZE="-0.8668172897074932" ORDER="4692" O_E="0.0" SE="1.5445960069873335" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.385776824801215" WEIGHT="0.9236670387463196"/>
<DICH_DATA CI_END="10.563903405339099" CI_START="0.2771046853217874" EFFECT_SIZE="1.7109375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0238244214330305" LOG_CI_START="-0.5573561310485308" LOG_EFFECT_SIZE="0.23323414519224997" ORDER="4693" O_E="0.0" SE="0.9287932834976358" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="0.8626569634703196" WEIGHT="2.0540195843808355"/>
<DICH_DATA CI_END="2.6659126353172984" CI_START="0.0062343867701999" EFFECT_SIZE="0.1289198606271777" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4258459130368416" LOG_CI_START="-2.2052062583708363" LOG_EFFECT_SIZE="-0.8896801726669974" ORDER="4694" O_E="0.0" SE="1.5454930694031654" STUDY_ID="STD-Masco-1985" TOTAL_1="20" TOTAL_2="21" VAR="2.3885488275732176" WEIGHT="0.9227428735369722"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-04 13:54:47 +0100" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.171483155193931" CI_START="0.037833518513163855" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.06873604823906786" LOG_CI_START="-1.422123267488801" LOG_EFFECT_SIZE="-0.6766936096248666" ORDER="4695" O_E="0.0" SE="0.875738141931184" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.7669172932330826" WEIGHT="2.2251877417368573"/>
<DICH_DATA CI_END="7.780255992088858" CI_START="0.6142213515673176" EFFECT_SIZE="2.186046511627907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8909938867226687" LOG_CI_START="-0.21167509068244453" LOG_EFFECT_SIZE="0.33965939802011214" ORDER="4696" O_E="0.0" SE="0.647713215627232" STUDY_ID="STD-Peters-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.4195324096981692" WEIGHT="3.189634648690484"/>
<DICH_DATA CI_END="0.6175745325954108" CI_START="0.03832515397580421" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.20931062164468192" LOG_CI_START="-1.4165160916410293" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="4697" O_E="0.0" SE="0.7091184688393067" STUDY_ID="STD-Preskorn-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.5028490028490028" WEIGHT="2.8892878144203777"/>
<DICH_DATA CI_END="1.698436326888109" CI_START="0.10523966090226755" EFFECT_SIZE="0.42277992277992277" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.23004927013482138" LOG_CI_START="-0.9778205599450508" LOG_EFFECT_SIZE="-0.3738856449051147" ORDER="4698" O_E="0.0" SE="0.7095087172410047" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="0.503402619840976" WEIGHT="2.8874811429639697"/>
<DICH_DATA CI_END="118.95804526560195" CI_START="0.24745191881562512" EFFECT_SIZE="5.425531914893617" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.075393819187927" LOG_CI_START="-0.6065091741914517" LOG_EFFECT_SIZE="0.7344423224982377" ORDER="4699" O_E="0.0" SE="1.575363093944971" STUDY_ID="STD-Young-1987" TOTAL_1="25" TOTAL_2="25" VAR="2.4817688777638716" WEIGHT="0.8927057611852092"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0014169768468637548" CI_END="0.7904399528904086" CI_START="0.11576848421918749" DF="1" EFFECT_SIZE="0.30250295074992006" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.10213111639446576" LOG_CI_START="-0.9364096529795829" LOG_EFFECT_SIZE="-0.5192703846870244" NO="2" P_CHI2="0.9699725241842567" P_Z="0.01469394572379105" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="132" WEIGHT="5.78036285838467" Z="2.4398356366464933">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="1.604146835915282" CI_START="0.06004058347598737" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.20524411900366946" LOG_CI_START="-1.2215550959229318" LOG_EFFECT_SIZE="-0.5081554884596312" ORDER="4700" O_E="0.0" SE="0.8381089216179064" STUDY_ID="STD-Noguera-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.70242656449553" WEIGHT="2.3575243306129727"/>
<DICH_DATA CI_END="0.9753443839784554" CI_START="0.09135922320699043" EFFECT_SIZE="0.29850746268656714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.01084201234902022" LOG_CI_START="-1.0392476017246703" LOG_EFFECT_SIZE="-0.5250448070368453" ORDER="4701" O_E="0.0" SE="0.6040905338890259" STUDY_ID="STD-Ropert-1989" TOTAL_1="71" TOTAL_2="72" VAR="0.3649253731343283" WEIGHT="3.422838527771698"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2927621393119262" CI_END="1.6815625163744157" CI_START="0.04251743012135387" DF="1" EFFECT_SIZE="0.26738682986384577" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="22.646249484669244" ID="CMP-001.05.03" LOG_CI_END="0.22571301795558227" LOG_CI_START="-1.3714329933924896" LOG_EFFECT_SIZE="-0.5728599877184537" NO="3" P_CHI2="0.2555396623024382" P_Z="0.15972736053724584" STUDIES="2" TAU2="0.4607325443537712" TOTAL_1="54" TOTAL_2="50" WEIGHT="3.060690629206601" Z="1.4059891032311316">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="2.971753439838066" CI_START="0.0841254178925499" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4730127740791998" LOG_CI_START="-1.0750727654071621" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4702" O_E="0.0" SE="0.9093531090412992" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.8269230769230769" WEIGHT="2.1147352338204892"/>
<DICH_DATA CI_END="1.3698239193313095" CI_START="0.003494027962182422" EFFECT_SIZE="0.06918238993710692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.13666474542104062" LOG_CI_START="-2.4566736237454934" LOG_EFFECT_SIZE="-1.1600044391622264" ORDER="4703" O_E="0.0" SE="1.5233397952803855" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" VAR="2.3205641318848866" WEIGHT="0.9459553953861118"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.830219249644456" CI_END="7.159464138949874" CI_START="0.5863014879159935" DF="4" EFFECT_SIZE="2.04880562214855" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="63.06630634341668" ID="CMP-001.05.04" LOG_CI_END="0.854880518089124" LOG_CI_START="-0.23187900366121064" LOG_EFFECT_SIZE="0.3115007572139567" MODIFIED="2013-04-29 16:11:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.028539932067401796" P_Z="0.26119154919000853" STUDIES="5" TAU2="1.196784987775247" TOTAL_1="237" TOTAL_2="241" WEIGHT="11.562580479013228" Z="1.1235793256506106">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="17.83409334303401" CI_START="0.6553098907894159" EFFECT_SIZE="3.4186046511627906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.2512510353942434" LOG_CI_START="-0.1835532770570643" LOG_EFFECT_SIZE="0.5338488791685896" ORDER="4704" O_E="0.0" SE="0.8428111555297908" STUDY_ID="STD-Corne-1989" TOTAL_1="49" TOTAL_2="51" VAR="0.7103306438854612" WEIGHT="2.340464709417773"/>
<DICH_DATA CI_END="64.45722913614652" CI_START="0.8154632258389126" EFFECT_SIZE="7.25" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.809271632284812" LOG_CI_START="-0.08859561914282459" LOG_EFFECT_SIZE="0.8603380065709937" ORDER="4705" O_E="0.0" SE="1.1148166180830024" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.242816091954023" WEIGHT="1.573427554532461"/>
<DICH_DATA CI_END="376.1915566102111" CI_START="1.1299072476526284" EFFECT_SIZE="20.617021276595743" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.5754090438492767" LOG_CI_START="0.053042794380819144" LOG_EFFECT_SIZE="1.3142259191150478" ORDER="4706" O_E="0.0" SE="1.4816504208520769" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="31" TOTAL_2="28" VAR="2.1952879696111367" WEIGHT="0.9919368751994853"/>
<DICH_DATA CI_END="3.0280903952619536" CI_START="0.09297917752924137" EFFECT_SIZE="0.5306122448979592" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4811688356818921" LOG_CI_START="-1.0316142997972835" LOG_EFFECT_SIZE="-0.27522273205769565" ORDER="4707" O_E="0.0" SE="0.8886163021777597" STUDY_ID="STD-Stephenson-2000" TOTAL_1="51" TOTAL_2="56" VAR="0.7896389324960754" WEIGHT="2.1820331051307833"/>
<DICH_DATA CI_END="1.6147919902402612" CI_START="0.2933048351431117" EFFECT_SIZE="0.6882051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.20811658653770504" LOG_CI_START="-0.5326807775967944" LOG_EFFECT_SIZE="-0.16228209552954473" ORDER="4708" O_E="0.0" SE="0.4351480386986982" STUDY_ID="STD-Thompson-2000" TOTAL_1="76" TOTAL_2="76" VAR="0.1893538155833238" WEIGHT="4.474718234732725"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2508957195743586" CI_END="1.5266533991421771" CI_START="0.4444507570988575" DF="2" EFFECT_SIZE="0.8237246257556495" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" I2="11.146483481775988" ID="CMP-001.05.05" LOG_CI_END="0.18374044902369677" LOG_CI_START="-0.3521763496654691" LOG_EFFECT_SIZE="-0.08421795032088618" NO="5" P_CHI2="0.3245074255694731" P_Z="0.5378901500941147" STUDIES="3" TAU2="0.042626373875008935" TOTAL_1="142" TOTAL_2="141" WEIGHT="10.332121577315199" Z="0.6160066259705299">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="1.1977127890014279" CI_START="0.32541890897590214" EFFECT_SIZE="0.6243063263041065" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="34" LOG_CI_END="0.07835268691287205" LOG_CI_START="-0.4875572153041978" LOG_EFFECT_SIZE="-0.20460226419566288" ORDER="4709" O_E="0.0" SE="0.3324182778615016" STUDY_ID="STD-Feighner-1985a" TOTAL_1="78" TOTAL_2="79" VAR="0.11050191145640648" WEIGHT="5.191200588381864"/>
<DICH_DATA CI_END="3.3212608707415727" CI_START="0.3810676274030262" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5213029888998102" LOG_CI_START="-0.4189979440050476" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="4710" O_E="0.0" SE="0.5523374225529992" STUDY_ID="STD-Remick-1989" TOTAL_1="38" TOTAL_2="37" VAR="0.30507662835249044" WEIGHT="3.7210070256096097"/>
<DICH_DATA CI_END="32.31355348821109" CI_START="0.3032666132414541" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5093847195609154" LOG_CI_START="-0.5181753987335642" LOG_EFFECT_SIZE="0.4956046604136756" ORDER="4711" O_E="0.0" SE="1.190998850070631" STUDY_ID="STD-Tamminen-1989" TOTAL_1="26" TOTAL_2="25" VAR="1.4184782608695652" WEIGHT="1.419913963323724"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.706404808843878" CI_END="0.8553384818949847" CI_START="0.26376570670374616" DF="9" EFFECT_SIZE="0.4749831145924453" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="158" I2="62.03557615517275" ID="CMP-001.05.06" LOG_CI_END="-0.06786198851257033" LOG_CI_START="-0.578781669583678" LOG_EFFECT_SIZE="-0.3233218290481242" MODIFIED="2012-05-23 11:05:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.004790433152589202" P_Z="0.01311536041215341" STUDIES="10" TAU2="0.4658022021420182" TOTAL_1="543" TOTAL_2="550" WEIGHT="32.027473314908995" Z="2.4806213728992916">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="2.238261849740891" CI_START="0.39063634707851924" EFFECT_SIZE="0.935064935064935" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.34991089240026985" LOG_CI_START="-0.40822734988269666" LOG_EFFECT_SIZE="-0.029158228741213422" ORDER="4712" O_E="0.0" SE="0.44533415636183893" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.19832251082251082" WEIGHT="4.405558120054665"/>
<DICH_DATA CI_END="4.2435986733527225" CI_START="0.09341917109101555" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6277343049678096" LOG_CI_START="-1.0295639905292362" LOG_EFFECT_SIZE="-0.20091484278071337" ORDER="4713" O_E="0.0" SE="0.973505222533836" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.9477124183006536" WEIGHT="1.9226296215480694"/>
<DICH_DATA CI_END="4.699689794797371" CI_START="0.24426275643645198" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6720691930732062" LOG_CI_START="-0.6121427463183198" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="4714" O_E="0.0" SE="0.754352450150206" STUDY_ID="STD-Byerley-1988" TOTAL_1="32" TOTAL_2="34" VAR="0.569047619047619" WEIGHT="2.6881675373991647"/>
<DICH_DATA CI_END="0.5470991425779476" CI_START="0.08638101493517869" EFFECT_SIZE="0.21739130434782608" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.26193396585487916" LOG_CI_START="-1.063581697508269" LOG_EFFECT_SIZE="-0.6627578316815741" ORDER="4715" O_E="0.0" SE="0.47089184579347154" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="0.22173913043478258" WEIGHT="4.234672781593296"/>
<DICH_DATA CI_END="1.3769763774124133" CI_START="0.26305872600239566" EFFECT_SIZE="0.6018518518518519" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.13892648982305533" LOG_CI_START="-0.5799472875112437" LOG_EFFECT_SIZE="-0.22051039884409412" ORDER="4717" O_E="0.0" SE="0.4222700152887555" STUDY_ID="STD-Feighner-1989" TOTAL_1="61" TOTAL_2="58" VAR="0.17831196581196582" WEIGHT="4.562906108012714"/>
<DICH_DATA CI_END="116.31012674614621" CI_START="0.24616847677305534" EFFECT_SIZE="5.350877192982456" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.065617528989033" LOG_CI_START="-0.6087675616404442" LOG_EFFECT_SIZE="0.7284249836742944" ORDER="4718" O_E="0.0" SE="1.57094704065546" STUDY_ID="STD-Levine-1989" TOTAL_1="30" TOTAL_2="30" VAR="2.4678746045441473" WEIGHT="0.897058118702399"/>
<DICH_DATA CI_END="4.61773275154273" CI_START="0.23422750041969193" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6644287947810695" LOG_CI_START="-0.6303621161835088" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="4719" O_E="0.0" SE="0.7605665904189708" STUDY_ID="STD-Nielsen-1993" TOTAL_1="29" TOTAL_2="30" VAR="0.5784615384615385" WEIGHT="2.66181848179777"/>
<DICH_DATA CI_END="0.9170546240748768" CI_START="0.34130952489779337" EFFECT_SIZE="0.5594635627530364" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="52" LOG_CI_END="-0.03760479494310931" LOG_CI_START="-0.46685159173064394" LOG_EFFECT_SIZE="-0.2522281933368766" ORDER="4720" O_E="0.0" SE="0.25214169323891034" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.06357543346938477" WEIGHT="5.737969502360592"/>
<DICH_DATA CI_END="0.15762174073350835" CI_START="3.0175041502760597E-4" EFFECT_SIZE="0.006896551724137931" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.8023838805685005" LOG_CI_START="-3.5203521239014495" LOG_EFFECT_SIZE="-2.161368002234975" ORDER="4721" O_E="0.0" SE="1.5965480002935644" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="14" VAR="2.5489655172413794" WEIGHT="0.8722389042092026"/>
<DICH_DATA CI_END="0.37015264160433503" CI_START="0.05211396945104013" EFFECT_SIZE="0.1388888888888889" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="27" LOG_CI_END="-0.43161914691640735" LOG_CI_START="-1.2830458459461296" LOG_EFFECT_SIZE="-0.8573324964312684" ORDER="4722" O_E="0.0" SE="0.5001322576401918" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="0.2501322751322751" WEIGHT="4.044454139231127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3813187803234241" CI_START="0.019215959498092478" DF="0" EFFECT_SIZE="0.16292134831460675" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.05.07" LOG_CI_END="0.14029391649251957" LOG_CI_START="-1.7163379253123952" LOG_EFFECT_SIZE="-0.7880220044099379" NO="7" P_CHI2="1.0" P_Z="0.0961604325785357" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="1.6269171761637242" Z="1.6637598396104953">
<NAME>Fluoxetine vs Lofepramine</NAME>
<DICH_DATA CI_END="1.3813187803234241" CI_START="0.019215959498092478" EFFECT_SIZE="0.16292134831460675" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14029391649251957" LOG_CI_START="-1.7163379253123952" LOG_EFFECT_SIZE="-0.7880220044099379" ORDER="4723" O_E="0.0" SE="1.0905947343520461" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" VAR="1.1893968745964099" WEIGHT="1.6269171761637242"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.774918129496993" CI_START="0.420118298289202" DF="0" EFFECT_SIZE="0.8635250917992656" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" ID="CMP-001.05.08" LOG_CI_END="0.2491783254318418" LOG_CI_START="-0.37662840231593947" LOG_EFFECT_SIZE="-0.06372503844204884" NO="8" P_CHI2="1.0" P_Z="0.6897746713697015" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="4.9439411264969" Z="0.3991608741866518">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<DICH_DATA CI_END="1.774918129496993" CI_START="0.420118298289202" EFFECT_SIZE="0.8635250917992656" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.2491783254318418" LOG_CI_START="-0.37662840231593947" LOG_EFFECT_SIZE="-0.06372503844204884" ORDER="4724" O_E="0.0" SE="0.3676019696723096" STUDY_ID="STD-Fabre-1991" TOTAL_1="103" TOTAL_2="102" VAR="0.13513120810696166" WEIGHT="4.9439411264969"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-07-02 12:05:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Fluoxetine versus heterocyclics</NAME>
<DICH_OUTCOME CHI2="2.291431324326494" CI_END="2.718862890218789" CI_START="0.7796886723202728" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4559761663899402" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" I2="12.718309348073195" I2_Q="41.871170384867185" ID="CMP-002.01" LOG_CI_END="0.4343873070642212" LOG_CI_START="-0.10807877536574903" LOG_EFFECT_SIZE="0.163154265849236" METHOD="MH" MODIFIED="2013-05-06 15:42:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3179966392696548" P_Q="0.18965237286477665" P_Z="0.2384088707692792" Q="1.7203167629916767" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04474461102272703" TOTALS="SUB" TOTAL_1="106" TOTAL_2="110" WEIGHT="200.0" Z="1.1789731942544357">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5706279500274842" CI_END="4.18431818916457" CI_START="0.9102361834287913" DF="1" EFFECT_SIZE="1.9515936612821916" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.6216247022798957" LOG_CI_START="-0.04084590454581794" LOG_EFFECT_SIZE="0.29038939886703885" NO="1" P_CHI2="0.45000961394878614" P_Z="0.08574678510036975" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="83" WEIGHT="100.0" Z="1.7182732559223368">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="4.472625686337195" CI_START="0.42864301592911647" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.6505625536252654" LOG_CI_START="-0.3679042480323268" LOG_EFFECT_SIZE="0.1413291527964693" ORDER="4725" O_E="0.0" SE="0.598252440785646" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="0.35790598290598286" WEIGHT="42.309653959929676"/>
<DICH_DATA CI_END="6.851852204253763" CI_START="0.9196235329672421" EFFECT_SIZE="2.510204081632653" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.8358079865804992" LOG_CI_START="-0.036389923758730625" LOG_EFFECT_SIZE="0.39970903141088426" ORDER="4726" O_E="0.0" SE="0.5123333699825506" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="0.26248548199767713" WEIGHT="57.69034604007032"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3809391261857584" CI_START="0.27020332713912426" DF="0" EFFECT_SIZE="0.8020833333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.3767482918771285" LOG_CI_START="-0.5683093076113016" LOG_EFFECT_SIZE="-0.09578050786708653" NO="2" P_CHI2="1.0" P_Z="0.6911608323444818" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.3972802206808627">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="2.3809391261857584" CI_START="0.27020332713912426" EFFECT_SIZE="0.8020833333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.3767482918771285" LOG_CI_START="-0.5683093076113016" LOG_EFFECT_SIZE="-0.09578050786708653" ORDER="4727" O_E="0.0" SE="0.5551315120500688" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.3081709956709957" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.365786928333797" CI_END="0.24332895148283126" CI_START="-0.12537636962401547" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.05897629092940789" ESTIMABLE="YES" I2="57.22784348437884" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-05-06 15:42:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0219767251769708" P_Q="0.35642533179910674" P_Z="0.530651103379283" Q="0.8504493445587087" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.08164553519490804" TOTALS="SUB" TOTAL_1="287" TOTAL_2="274" UNITS="" WEIGHT="200.0" Z="0.6270124109757486">
<NAME>End-point score on rating scale</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.065005674261505" CI_END="0.22796177916719154" CI_START="-0.1507971130297788" DF="4" EFFECT_SIZE="0.03858233306870638" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2012-08-01 16:33:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5470064948354053" P_Z="0.6896691708830649" STUDIES="5" TAU2="0.0" TOTAL_1="221" TOTAL_2="212" WEIGHT="100.0" Z="0.3993040681662345">
<NAME>Fluoxetine vs Maprotiline</NAME>
<CONT_DATA CI_END="0.8294461431675726" CI_START="-0.17790658249712266" EFFECT_SIZE="0.32576978033522497" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="16.38" ORDER="4728" SD_1="8.34" SD_2="7.6" SE="0.25698245825192834" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="28" TOTAL_2="34" WEIGHT="14.137172054327255"/>
<CONT_DATA CI_END="0.42794310057450474" CI_START="-0.42388392340191366" EFFECT_SIZE="0.0020295885862955643" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="6.49" ORDER="4729" SD_1="4.77" SD_2="4.98" SE="0.21730680530242424" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="40" TOTAL_2="45" WEIGHT="19.7707364850911"/>
<CONT_DATA CI_END="1.005757267026473" CI_START="-0.26522917902406035" EFFECT_SIZE="0.3702640440012063" ESTIMABLE="YES" MEAN_1="12.56" MEAN_2="10.15" ORDER="4730" SD_1="6.57" SD_2="6.14" SE="0.3242371941719114" STUDY_ID="STD-Kuha-1991" TOTAL_1="21" TOTAL_2="18" WEIGHT="8.880631242307347"/>
<CONT_DATA CI_END="0.3216125142494729" CI_START="-0.4496132495409232" EFFECT_SIZE="-0.06400036764572511" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.6" ORDER="4731" SD_1="6.7" SD_2="5.5" SE="0.19674488150642727" STUDY_ID="STD-Martenyi-2001" TOTAL_1="59" TOTAL_2="46" WEIGHT="24.119184334120842"/>
<CONT_DATA CI_END="0.25269709891239955" CI_START="-0.40571760255902123" EFFECT_SIZE="-0.07651025182331087" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.5" ORDER="4732" SD_1="6.5" SD_2="6.5" SE="0.1679660204638738" STUDY_ID="STD-Poelinger-1989" TOTAL_1="73" TOTAL_2="69" WEIGHT="33.092275884153466"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.160162821037343" CI_END="1.2333949548146836" CI_START="-0.37757286093570547" DF="2" EFFECT_SIZE="0.42791104693948906" ESTIMABLE="YES" I2="78.16632696302324" ID="CMP-002.02.02" MODIFIED="2012-08-01 16:33:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.010254080573455115" P_Z="0.2977710015001649" STUDIES="3" TAU2="0.3936404378339012" TOTAL_1="66" TOTAL_2="62" WEIGHT="100.0" Z="1.041225321062749">
<NAME>Fluoxetine vs Mianserin</NAME>
<CONT_DATA CI_END="1.013770712652853" CI_START="0.023977882171884846" EFFECT_SIZE="0.5188742974123689" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="10.5" ORDER="4733" SD_1="5.0" SD_2="4.5" SE="0.25250281083946635" STUDY_ID="STD-Besancon-1993" TOTAL_1="33" TOTAL_2="32" WEIGHT="36.92522850987227"/>
<CONT_DATA CI_END="1.8944422288239111" CI_START="0.44291356574843854" EFFECT_SIZE="1.1686778972861749" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="6.4" ORDER="4734" SD_1="6.25" SD_2="7.35" SE="0.3702947285064791" STUDY_ID="STD-La-Pia-1992" TOTAL_1="19" TOTAL_2="16" WEIGHT="31.821488856646123"/>
<CONT_DATA CI_END="0.31707265229669956" CI_START="-1.1846626683853607" EFFECT_SIZE="-0.4337950080443306" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="14.5" ORDER="4735" SD_1="7.5" SD_2="10.2" SE="0.38310278467552383" STUDY_ID="STD-Muijen-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="31.253282633481597"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.732633506173904" CI_END="2.534962137579834" CI_START="0.7768790276014139" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.403338491045344" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="33" I2="0.0" I2_Q="48.36438652765974" ID="CMP-002.03" LOG_CI_END="0.40397147705675146" LOG_CI_START="-0.1096466024802041" LOG_EFFECT_SIZE="0.14716243728827366" METHOD="MH" MODIFIED="2013-05-06 15:31:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4493733234502095" P_Q="0.16403323924676239" P_Z="0.26137711259882146" Q="1.9366478535897937" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="221" WEIGHT="200.0" Z="1.1231422274783749">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.162157261542367" CI_END="3.408301537848571" CI_START="0.8969298498533771" DF="3" EFFECT_SIZE="1.7484299776077832" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.5325380105167857" LOG_CI_START="-0.04724152241068983" LOG_EFFECT_SIZE="0.24264824405304797" NO="1" P_CHI2="0.7620941736178878" P_Z="0.10088859480673451" STUDIES="4" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="1.6405609106430799">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="5.24127499084663" CI_START="0.2712312625494321" EFFECT_SIZE="1.1923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.719436946169729" LOG_CI_START="-0.5666602544428196" LOG_EFFECT_SIZE="0.0763883458634547" ORDER="4736" O_E="0.0" SE="0.7554598619236282" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="0.5707196029776674" WEIGHT="20.32254876143225"/>
<DICH_DATA CI_END="13.002691200938191" CI_START="0.8338089930068234" EFFECT_SIZE="3.292682926829268" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.1140332486727391" LOG_CI_START="-0.07893342512219785" LOG_EFFECT_SIZE="0.5175499117752705" ORDER="4737" O_E="0.0" SE="0.7007545294674203" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="0.49105691056910566" WEIGHT="23.61941500258485"/>
<DICH_DATA CI_END="9.466538495432681" CI_START="0.2155821082347306" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9761912052812676" LOG_CI_START="-0.6663872853097813" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="4738" O_E="0.0" SE="0.964858736267844" STUDY_ID="STD-Kuha-1991" TOTAL_1="24" TOTAL_2="22" VAR="0.930952380952381" WEIGHT="12.458722054884754"/>
<DICH_DATA CI_END="4.31840619753233" CI_START="0.5718285038848651" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6353234904877658" LOG_CI_START="-0.24273420019982933" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="4739" O_E="0.0" SE="0.515775433965561" STUDY_ID="STD-Poelinger-1989" TOTAL_1="73" TOTAL_2="69" VAR="0.2660242982823628" WEIGHT="43.59931418109814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3209443906854637" CI_END="2.2518423007625605" CI_START="0.17594416622334175" DF="1" EFFECT_SIZE="0.629443020514264" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="24.296586059835523" ID="CMP-002.03.02" LOG_CI_END="0.35253797307686197" LOG_CI_START="-0.7546251284821782" LOG_EFFECT_SIZE="-0.20104357770265815" NO="2" P_CHI2="0.2504227693043296" P_Z="0.4765899538098024" STUDIES="2" TAU2="0.26770695871164146" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="0.7117978752460756">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="2.0789327713338395" CI_START="0.021319270277053118" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3178404453147198" LOG_CI_START="-1.671227664564453" LOG_EFFECT_SIZE="-0.6766936096248666" ORDER="4740" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-La-Pia-1992" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="25.903304413575352"/>
<DICH_DATA CI_END="2.7156467809759937" CI_START="0.31376356155233437" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.43387328142256937" LOG_CI_START="-0.5033974939409932" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="4741" O_E="0.0" SE="0.5505574930137207" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.30311355311355315" WEIGHT="74.09669558642464"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.348368288261792" CI_END="9.120401185340345" CI_START="0.6234523972392813" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3845620106812953" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.9600139423577398" LOG_CI_START="-0.20519670081500507" LOG_EFFECT_SIZE="0.37740862077136744" METHOD="MH" MODIFIED="2013-05-06 15:42:41 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5095720316675418" P_Q="0.9367996126964098" P_Z="0.2042078525581832" Q="0.006287372155966286" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="132" WEIGHT="200.0" Z="1.2696542183182795">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3750980727071762" CI_END="19.190616434719097" CI_START="0.3349573170993223" DF="1" EFFECT_SIZE="2.535357449050463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="27.27791421950836" ID="CMP-002.04.01" LOG_CI_END="1.283088925225164" LOG_CI_START="-0.4750105306624019" LOG_EFFECT_SIZE="0.40403919728138105" NO="1" P_CHI2="0.24093807986851934" P_Z="0.3676618414216217" STUDIES="3" TAU2="0.6246064597466279" TOTAL_1="104" TOTAL_2="105" WEIGHT="100.0" Z="0.9008617485911156">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="8.916726646681083" CI_START="0.15577808620632244" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9502054530097351" LOG_CI_START="-0.8074936359383985" LOG_EFFECT_SIZE="0.07135590853566827" ORDER="4742" O_E="0.0" SE="1.032481145598948" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="1.0660173160173159" WEIGHT="63.08340266649061"/>
<DICH_DATA CI_END="179.22460503285396" CI_START="0.49166009227316687" EFFECT_SIZE="9.387096774193548" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.253397631980428" LOG_CI_START="-0.30833504167715897" LOG_EFFECT_SIZE="0.9725312951516346" ORDER="4743" O_E="0.0" SE="1.5047744532877143" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="2.264346155267339" WEIGHT="36.916597333509394"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4744" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuha-1991" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.63241489112055" CI_START="0.378897597927624" DF="0" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="1.134572795012291" LOG_CI_START="-0.4214781479846658" LOG_EFFECT_SIZE="0.35654732351381263" NO="2" P_CHI2="1.0" P_Z="0.36908070111313473" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.8981967023846862">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="13.63241489112055" CI_START="0.378897597927624" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.134572795012291" LOG_CI_START="-0.4214781479846658" LOG_EFFECT_SIZE="0.35654732351381263" ORDER="4745" O_E="0.0" SE="0.9140320264928059" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.8354545454545454" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8447597402484746" CI_END="1.8827226699645156" CI_START="0.26559841535515394" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7071408329999052" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.2747863520005093" LOG_CI_START="-0.5757745204356671" LOG_EFFECT_SIZE="-0.1504940842175789" METHOD="MH" MODIFIED="2013-05-06 15:42:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8387338918625747" P_Q="0.5020913907017462" P_Z="0.4879500992645426" Q="0.45051316026934374" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="132" WEIGHT="200.0" Z="0.6935728988049014">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3937986303367321" CI_END="1.9269683674428668" CI_START="0.14598239064878982" DF="2" EFFECT_SIZE="0.5303804756812842" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.2848745854609698" LOG_CI_START="-0.8356995284984148" LOG_EFFECT_SIZE="-0.2754124715187225" NO="1" P_CHI2="0.8212733873017568" P_Z="0.3353307455427582" STUDIES="3" TAU2="0.0" TOTAL_1="104" TOTAL_2="105" WEIGHT="100.0" Z="0.9634320806547289">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="19.585707496377132" CI_START="0.07018148833854859" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.291939264228172" LOG_CI_START="-1.1537774259415738" LOG_EFFECT_SIZE="0.069080919143299" ORDER="4746" O_E="0.0" SE="1.436626090298576" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="2.0638945233265718" WEIGHT="20.992727912164447"/>
<DICH_DATA CI_END="5.352803104047256" CI_START="0.04116065178507048" EFFECT_SIZE="0.46938775510204084" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7285812687153074" LOG_CI_START="-1.3855177567371488" LOG_EFFECT_SIZE="-0.3284682440109208" ORDER="4747" O_E="0.0" SE="1.2418322325097255" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="1.5421472937000889" WEIGHT="28.095095938369617"/>
<DICH_DATA CI_END="2.4949108339828974" CI_START="0.06707869861371313" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3970550289168517" LOG_CI_START="-1.1734153716826143" LOG_EFFECT_SIZE="-0.38818017138288136" ORDER="4748" O_E="0.0" SE="0.922502087265986" STUDY_ID="STD-Kuha-1991" TOTAL_1="24" TOTAL_2="22" VAR="0.851010101010101" WEIGHT="50.912176149465935"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.704721097811667" CI_START="0.23231455890551125" DF="0" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.6725338829659199" LOG_CI_START="-0.6339235725751466" LOG_EFFECT_SIZE="0.019305155195386624" NO="2" P_CHI2="1.0" P_Z="0.9538094244028412" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.057923675567749466">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="4.704721097811667" CI_START="0.23231455890551125" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6725338829659199" LOG_CI_START="-0.6339235725751466" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="4749" O_E="0.0" SE="0.7674195764535269" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.5889328063241106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-07-02 12:05:23 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Fluoxetine versus other SSRIs</NAME>
<DICH_OUTCOME CHI2="19.29598392514054" CI_END="1.4587427940787945" CI_START="1.0457196262885027" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2350854097895916" ESTIMABLE="YES" EVENTS_1="734" EVENTS_2="676" I2="11.898765743420453" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.163978723723832" LOG_CI_START="0.01941525902663911" LOG_EFFECT_SIZE="0.09169699137523557" METHOD="MH" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31180993512263155" P_Q="0.4718454865889309" P_Z="0.012903529867785292" Q="3.539847060288234" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013848459096863129" TOTALS="SUB" TOTAL_1="1615" TOTAL_2="1623" WEIGHT="500.0" Z="2.4864207697649547">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7936427274467222" CI_START="0.1974050739554374" DF="0" EFFECT_SIZE="0.5950413223140496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.2537359409652797" LOG_CI_START="-0.7046416887356429" LOG_EFFECT_SIZE="-0.22545287388518162" MODIFIED="2012-11-20 11:36:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3564551962881749" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.9221407080712068">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="1.7936427274467222" CI_START="0.1974050739554374" EFFECT_SIZE="0.5950413223140496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2537359409652797" LOG_CI_START="-0.7046416887356429" LOG_EFFECT_SIZE="-0.22545287388518162" MODIFIED="2012-04-16 09:34:21 +0100" MODIFIED_BY="[Empty name]" ORDER="998" O_E="0.0" SE="0.5629557637321" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="0.31691919191919193" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.848332559705193" CI_START="0.5626206223683673" DF="0" EFFECT_SIZE="1.0197597830298335" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.2667801139895907" LOG_CI_START="-0.2497843531934926" LOG_EFFECT_SIZE="0.008497880398049051" MODIFIED="2012-11-20 11:36:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9485834040827176" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="123" WEIGHT="100.0" Z="0.06448581187138412">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="1.848332559705193" CI_START="0.5626206223683673" EFFECT_SIZE="1.0197597830298335" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.2667801139895907" LOG_CI_START="-0.2497843531934926" LOG_EFFECT_SIZE="0.008497880398049051" MODIFIED="2012-03-21 10:39:56 +0000" MODIFIED_BY="[Empty name]" ORDER="944" O_E="0.0" SE="0.303432525058695" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="0.09207129726349557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7414139286949246" CI_START="0.5229175340490649" DF="0" EFFECT_SIZE="0.9542619542619543" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.24090201384070334" LOG_CI_START="-0.28156679551384434" LOG_EFFECT_SIZE="-0.020332390836570527" MODIFIED="2012-11-20 11:36:24 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.878754832150396" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="86" WEIGHT="100.0" Z="0.15254787671823564">
<NAME>Fluoxetine vs Fluvoxamine</NAME>
<DICH_DATA CI_END="1.7414139286949246" CI_START="0.5229175340490649" EFFECT_SIZE="0.9542619542619543" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" LOG_CI_END="0.24090201384070334" LOG_CI_START="-0.28156679551384434" LOG_EFFECT_SIZE="-0.020332390836570527" ORDER="4750" O_E="0.0" SE="0.3069007648771784" STUDY_ID="STD-Dalery-2003" TOTAL_1="91" TOTAL_2="86" VAR="0.09418807948219712" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.654532328252682" CI_END="1.6463638378864087" CI_START="0.9263257626879222" DF="8" EFFECT_SIZE="1.2349369367671947" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="335" I2="36.78154362023248" ID="CMP-003.01.04" LOG_CI_END="0.21652581831554896" LOG_CI_START="-0.03323625731576521" LOG_EFFECT_SIZE="0.09164478049989187" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12430189097972788" P_Z="0.15033970329300167" STUDIES="9" TAU2="0.06638942988340746" TOTAL_1="787" TOTAL_2="787" WEIGHT="100.0" Z="1.4383326107203975">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="1.736519630467192" CI_START="0.5434280458631325" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.2396796971517571" LOG_CI_START="-0.2648579517677981" LOG_EFFECT_SIZE="-0.012589127308020516" ORDER="4751" O_E="0.0" SE="0.29636791247698807" STUDY_ID="STD-Chouinard-1999" TOTAL_1="101" TOTAL_2="102" VAR="0.08783393954596765" WEIGHT="13.95654777656929"/>
<DICH_DATA CI_END="3.067121720912139" CI_START="0.4710015494300689" EFFECT_SIZE="1.2019230769230769" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.486731011610628" LOG_CI_START="-0.3269776641920758" LOG_EFFECT_SIZE="0.07987667370927604" ORDER="4752" O_E="0.0" SE="0.4779765040894149" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" VAR="0.22846153846153847" WEIGHT="7.300046649961982"/>
<DICH_DATA CI_END="2.2078388042654606" CI_START="0.4826243246110041" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.3439673620944976" LOG_CI_START="-0.31639079312323104" LOG_EFFECT_SIZE="0.013788284485633285" ORDER="4753" O_E="0.0" SE="0.38789764920048103" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" VAR="0.15046458625525946" WEIGHT="9.925690388543249"/>
<DICH_DATA CI_END="2.232498692745576" CI_START="0.6755463556160122" EFFECT_SIZE="1.2280701754385965" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.34879121325664275" LOG_CI_START="-0.17034484457311183" LOG_EFFECT_SIZE="0.08922318434176545" ORDER="4755" O_E="0.0" SE="0.30494309013412874" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.09299028822055137" WEIGHT="13.50501713336325"/>
<DICH_DATA CI_END="3.1513141911627143" CI_START="0.5641385371104002" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.49849170520058983" LOG_CI_START="-0.24861423198398994" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="4756" O_E="0.0" SE="0.43885372573625553" STUDY_ID="STD-Gagiano-1993" TOTAL_1="45" TOTAL_2="45" VAR="0.1925925925925926" WEIGHT="8.311101300106786"/>
<DICH_DATA CI_END="7.626402951753082" CI_START="1.1688983459586533" EFFECT_SIZE="2.9857142857142858" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.8823197481051809" LOG_CI_START="0.06777674408841351" LOG_EFFECT_SIZE="0.4750482460967972" MODIFIED="2012-04-02 15:06:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1017" O_E="0.0" SE="0.4784665926123471" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="0.22893028024606973" WEIGHT="7.288459760308174"/>
<DICH_DATA CI_END="1.1700570869341544" CI_START="0.6048100248843087" EFFECT_SIZE="0.8412266376338232" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="132" LOG_CI_END="0.0682070514347683" LOG_CI_START="-0.21838101890259312" LOG_EFFECT_SIZE="-0.0750869837339124" MODIFIED="2012-03-21 13:13:58 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="0.16834325114999368" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.028339450207749847" WEIGHT="22.721959993966955"/>
<DICH_DATA CI_END="2.678976916662604" CI_START="0.5682800038800113" EFFECT_SIZE="1.2338593974175036" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.42796897153682223" LOG_CI_START="-0.24543762524570553" LOG_EFFECT_SIZE="0.09126567314555831" ORDER="4757" O_E="0.0" SE="0.3955623683664715" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="61" TOTAL_2="60" VAR="0.1564695872676921" WEIGHT="9.658239775172358"/>
<DICH_DATA CI_END="8.23358195928647" CI_START="1.2712727072420802" EFFECT_SIZE="3.235294117647059" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="34" LOG_CI_END="0.915588812942743" LOG_CI_START="0.10423872328919694" LOG_EFFECT_SIZE="0.5099137681159699" ORDER="4758" O_E="0.0" SE="0.47659105891020986" STUDY_ID="STD-Schone-1993" TOTAL_1="52" TOTAL_2="54" VAR="0.2271390374331551" WEIGHT="7.332937222007962"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6227917849909264" CI_END="1.7420016002777685" CI_START="1.0813576886001375" DF="5" EFFECT_SIZE="1.3724892801089954" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="249" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="0.24104854963346137" LOG_CI_START="0.03396937248301448" LOG_EFFECT_SIZE="0.13750896105823793" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7578994113575916" P_Z="0.009241439522115234" STUDIES="6" TAU2="0.0" TOTAL_1="590" TOTAL_2="598" WEIGHT="100.0" Z="2.602990942250666">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="2.166633561485716" CI_START="0.8539865120776342" EFFECT_SIZE="1.360248447204969" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.33578546615061683" LOG_CI_START="-0.06854898853407955" LOG_EFFECT_SIZE="0.13361823880826865" ORDER="4759" O_E="0.0" SE="0.2375080601696209" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.05641007864553626" WEIGHT="26.22958141930693"/>
<DICH_DATA CI_END="3.0616546084618483" CI_START="0.892646622256381" EFFECT_SIZE="1.6531713900134952" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="26" LOG_CI_END="0.4859561954740014" LOG_CI_START="-0.04932043403155522" LOG_EFFECT_SIZE="0.2183178807212231" ORDER="4761" O_E="0.0" SE="0.3144241418336132" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.09886254096780413" WEIGHT="14.966363763444594"/>
<DICH_DATA CI_END="4.549620045146434" CI_START="0.7197032685678197" EFFECT_SIZE="1.8095238095238095" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.6579751287040433" LOG_CI_START="-0.14284652493826153" LOG_EFFECT_SIZE="0.25756430188289087" ORDER="4762" O_E="0.0" SE="0.4704066034806081" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="42" VAR="0.22128237259816205" WEIGHT="6.6865369045437015"/>
<DICH_DATA CI_END="1.9498922584891152" CI_START="0.6282099291303991" EFFECT_SIZE="1.1067708333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.29001061503617886" LOG_CI_START="-0.2018952036706175" LOG_EFFECT_SIZE="0.0440577056827807" ORDER="4763" O_E="0.0" SE="0.2889479128814455" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.08349089635854341" WEIGHT="17.721845317704453"/>
<DICH_DATA CI_END="2.8530641619800026" CI_START="0.9720231736889672" EFFECT_SIZE="1.6653061224489796" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" LOG_CI_END="0.4553115385272248" LOG_CI_START="-0.012323381076529838" LOG_EFFECT_SIZE="0.2214940787253475" ORDER="4764" O_E="0.0" SE="0.27469106660543063" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.07545518207282913" WEIGHT="19.609160167084116"/>
<DICH_DATA CI_END="1.8976490933092347" CI_START="0.5491535279724274" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.2782159072857199" LOG_CI_START="-0.260306221979867" LOG_EFFECT_SIZE="0.008954842652926412" ORDER="4765" O_E="0.0" SE="0.3163305644581379" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="83" VAR="0.10006502601040415" WEIGHT="14.786512427916216"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="83.4283398267919" CI_END="0.14799343484560387" CI_START="-0.01597639777805676" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06600851853377356" ESTIMABLE="YES" I2="74.8286972465247" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.141334332073086E-9" P_Q="0.9258365701037811" P_Z="0.11455966639706446" Q="0.46812382560425964" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.06612902544141676" TOTALS="SUB" TOTAL_1="2048" TOTAL_2="2065" UNITS="" WEIGHT="400.0" Z="1.5780258713318014">
<NAME>End-point score on rating scales</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other SSRIs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8206742988147528" CI_END="0.20822745338634488" CI_START="-0.09691838196815969" DF="2" EFFECT_SIZE="0.05565453570909259" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2012-05-31 11:30:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6634268102545198" P_Z="0.4746444887810751" STUDIES="3" TAU2="0.0" TOTAL_1="336" TOTAL_2="325" WEIGHT="100.00000000000001" Z="0.714942646616131">
<NAME>Fluoxetine vs Citalopram</NAME>
<CONT_DATA CI_END="0.3476206029589819" CI_START="-0.0953967266408394" EFFECT_SIZE="0.12611193815907124" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="9.0" ORDER="4766" SD_1="8.75" SD_2="8.65" SE="0.1130167016063268" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="161" TOTAL_2="153" WEIGHT="47.44314430100191"/>
<CONT_DATA CI_END="0.20721185137868134" CI_START="-0.2484932180965598" EFFECT_SIZE="-0.020640683358939232" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="11.5" ORDER="4767" SD_1="9.64" SD_2="9.69" SE="0.11625342941752619" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="149" TOTAL_2="147" WEIGHT="44.838097221708445"/>
<CONT_DATA CI_END="0.6149533258195222" CI_START="-0.4833788868954179" EFFECT_SIZE="0.06578721946205217" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="11.4" MODIFIED="2012-05-31 11:30:47 +0100" MODIFIED_BY="[Empty name]" ORDER="999" SD_1="4.49" SD_2="4.49" SE="0.280191937550497" STUDY_ID="STD-Hosak-2000" TOTAL_1="26" TOTAL_2="25" WEIGHT="7.718758477289658"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.32971462008807373" CI_START="-0.18639925376746166" DF="0" EFFECT_SIZE="0.07165768316030605" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" MODIFIED="2012-11-20 11:40:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5862721434784897" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="118" WEIGHT="100.0" Z="0.5442460872466076">
<NAME>Fluoxetine vs Escitalopram</NAME>
<CONT_DATA CI_END="0.32971462008807373" CI_START="-0.18639925376746166" EFFECT_SIZE="0.07165768316030605" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="8.9" MODIFIED="2012-03-21 10:41:10 +0000" MODIFIED_BY="[Empty name]" ORDER="945" SD_1="7.4" SD_2="6.5" SE="0.13166412187330373" STUDY_ID="STD-Mao-2008" TOTAL_1="113" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="72.8982047894339" CI_END="0.24435343226049538" CI_START="-0.2602635675211655" DF="10" EFFECT_SIZE="-0.00795506763033503" ESTIMABLE="YES" I2="86.28224106631302" ID="CMP-003.02.03" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.2186029962890643E-11" P_Z="0.9507253205300273" STUDIES="11" TAU2="0.151040256544059" TOTAL_1="1035" TOTAL_2="1026" WEIGHT="100.0" Z="0.06179596032945102">
<NAME>Fluoxetine vs Paroxetine</NAME>
<CONT_DATA CI_END="0.49420814323773815" CI_START="-0.011685789513713074" EFFECT_SIZE="0.24126117686201254" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="7.8" ORDER="4768" SD_1="7.2" SD_2="6.85" SE="0.12905694613316315" STUDY_ID="STD-Cassano-2002" TOTAL_1="119" TOTAL_2="123" WEIGHT="9.882003466269778"/>
<CONT_DATA CI_END="-0.8924886239704934" CI_START="-1.4983159737306562" EFFECT_SIZE="-1.1954022988505748" ESTIMABLE="YES" MEAN_1="10.67" MEAN_2="11.99" ORDER="4769" SD_1="1.1" SD_2="1.1" SE="0.15455063321031703" STUDY_ID="STD-Chouinard-1999" TOTAL_1="98" TOTAL_2="100" WEIGHT="9.473551739763288"/>
<CONT_DATA CI_END="0.7969786299527299" CI_START="-0.09895971970798961" EFFECT_SIZE="0.34900945512237014" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="9.7" ORDER="4770" SD_1="10.3" SD_2="9.5" SE="0.2285599012858825" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" WEIGHT="8.152169004263516"/>
<CONT_DATA CI_END="0.4735425527850616" CI_START="-0.27787694634022225" EFFECT_SIZE="0.09783280322241965" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="12.1" ORDER="4771" SD_1="10.3" SD_2="10.0" SE="0.1916921701246515" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" WEIGHT="8.824783005712181"/>
<CONT_DATA CI_END="0.3531815792547939" CI_START="-0.2299141523381427" EFFECT_SIZE="0.0616337134583256" ESTIMABLE="YES" MEAN_1="8.73" MEAN_2="8.3" ORDER="4773" SD_1="7.1" SD_2="6.8" SE="0.14875164446702116" STUDY_ID="STD-Fava-2002" TOTAL_1="88" TOTAL_2="93" WEIGHT="9.569773846751955"/>
<CONT_DATA CI_END="0.3888589498719161" CI_START="-0.5298033686924962" EFFECT_SIZE="-0.07047220941029005" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.3" ORDER="4774" SD_1="7.2" SD_2="6.85" SE="0.2343569386505832" STUDY_ID="STD-Gagiano-1993" TOTAL_1="35" TOTAL_2="38" WEIGHT="8.045952467826508"/>
<CONT_DATA CI_END="0.43414561161450693" CI_START="-0.33138954244531793" EFFECT_SIZE="0.0513780345845945" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="22.4" MODIFIED="2012-04-04 15:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1018" SD_1="9.6" SD_2="13.2" SE="0.19529316867510538" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="51" TOTAL_2="54" WEIGHT="8.759777968531914"/>
<CONT_DATA CI_END="0.4053652832320161" CI_START="-0.27749968482971793" EFFECT_SIZE="0.06393279920114908" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="12.0" MODIFIED="2012-03-21 11:44:27 +0000" MODIFIED_BY="[Empty name]" ORDER="973" SD_1="9.07" SD_2="9.6" SE="0.17420344798376033" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="68" TOTAL_2="64" WEIGHT="9.1361072404968"/>
<CONT_DATA CI_END="0.008630923263865359" CI_START="-0.2826765910950967" EFFECT_SIZE="-0.13702283391561568" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-11.8" MODIFIED="2012-03-29 15:21:41 +0100" MODIFIED_BY="[Empty name]" ORDER="983" SD_1="8.71" SD_2="8.79" SE="0.07431450696460715" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1" TOTAL_1="377" TOTAL_2="350" WEIGHT="10.584703984782717"/>
<CONT_DATA CI_END="0.5020588345120145" CI_START="-0.24734093534106597" EFFECT_SIZE="0.12735894958547425" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="9.8" ORDER="4775" SD_1="7.2" SD_2="6.85" SE="0.1911769235976401" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="52" TOTAL_2="58" WEIGHT="8.83406331275325"/>
<CONT_DATA CI_END="0.8092529501979902" CI_START="0.0388085603218728" EFFECT_SIZE="0.4240307552599315" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="20.0" ORDER="4776" SD_1="7.2" SD_2="6.85" SE="0.19654554776344985" STUDY_ID="STD-Schone-1993" TOTAL_1="52" TOTAL_2="54" WEIGHT="8.737113962848083"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.819600691479232" CI_END="0.20167327573067767" CI_START="-0.029124453766976685" DF="6" EFFECT_SIZE="0.0862744109818505" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.04" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5671503803496631" P_Z="0.14283723899888737" STUDIES="7" TAU2="0.0" TOTAL_1="564" TOTAL_2="596" WEIGHT="99.99999999999999" Z="1.4653067747232968">
<NAME>Fluoxetine vs Sertraline</NAME>
<CONT_DATA CI_END="0.675768011881347" CI_START="-0.1669555265288981" EFFECT_SIZE="0.25440624267622447" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.2" ORDER="4777" SD_1="5.4" SD_2="5.5" SE="0.21498444488203378" STUDY_ID="STD-Aguglia-1993" TOTAL_1="40" TOTAL_2="48" WEIGHT="7.500544898593342"/>
<CONT_DATA CI_END="0.3555409373006632" CI_START="-0.1426485267893371" EFFECT_SIZE="0.10644620525566305" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="11.93" ORDER="4778" SD_1="6.25" SD_2="6.3" SE="0.1270914843383999" STUDY_ID="STD-Bennie-1995" TOTAL_1="124" TOTAL_2="124" WEIGHT="21.46218760632054"/>
<CONT_DATA CI_END="0.3763574627818866" CI_START="-0.20243026825295202" EFFECT_SIZE="0.08696359726446728" ESTIMABLE="YES" MEAN_1="8.73" MEAN_2="8.11" ORDER="4780" SD_1="7.1" SD_2="7.1" SE="0.14765264453843088" STUDY_ID="STD-Fava-2002" TOTAL_1="88" TOTAL_2="96" WEIGHT="15.900999764492132"/>
<CONT_DATA CI_END="0.7765827974616382" CI_START="-0.14607988777500086" EFFECT_SIZE="0.3152514548433186" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="9.0" ORDER="4781" SD_1="6.25" SD_2="6.3" SE="0.2353774591049847" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="41" WEIGHT="6.25715841189112"/>
<CONT_DATA CI_END="0.24038207768430597" CI_START="-0.2721522793932233" EFFECT_SIZE="-0.01588510085445866" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="13.8" ORDER="4782" SD_1="6.25" SD_2="6.3" SE="0.13075096305859057" STUDY_ID="STD-Newhouse-2000" TOTAL_1="118" TOTAL_2="116" WEIGHT="20.277625501929194"/>
<CONT_DATA CI_END="0.5259603021564327" CI_START="-0.0818743288715999" EFFECT_SIZE="0.2220429866424164" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="8.9" ORDER="4783" SD_1="6.25" SD_2="6.3" SE="0.155062704167667" STUDY_ID="STD-Sechter-1999" TOTAL_1="79" TOTAL_2="89" WEIGHT="14.417573825407004"/>
<CONT_DATA CI_END="0.1795125473947724" CI_START="-0.4333083250136631" EFFECT_SIZE="-0.12689788880944536" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="13.7" ORDER="4784" SD_1="6.25" SD_2="6.3" SE="0.15633472789354508" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="82" WEIGHT="14.183909991366654"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="17.23814388021956" CI_END="1.2020995607967306" CI_START="0.9238891549503102" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0538532855149385" ESTIMABLE="YES" EVENTS_1="640" EVENTS_2="622" I2="0.0" I2_Q="38.616768890590386" ID="CMP-003.03" LOG_CI_END="0.07994043847705137" LOG_CI_START="-0.03438013081572737" LOG_EFFECT_SIZE="0.022780153830662002" METHOD="MH" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8729753396150407" P_Q="0.1637576879300936" P_Z="0.4347397508499866" Q="6.516437678020551" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2504" TOTAL_2="2529" WEIGHT="500.0" Z="0.7811066957868973">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.12335289915850291" CI_END="1.2667978549815213" CI_START="0.6032410831153275" DF="2" EFFECT_SIZE="0.8741764753911114" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="76" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.102707319326905" LOG_CI_START="-0.21950908895076413" LOG_EFFECT_SIZE="-0.0584008848119296" MODIFIED="2012-04-16 09:41:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.940187042560606" P_Z="0.4774085580383145" STUDIES="3" TAU2="0.0" TOTAL_1="372" TOTAL_2="360" WEIGHT="100.0" Z="0.7104767352382345">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="1.4963550737335654" CI_START="0.4275419891846881" EFFECT_SIZE="0.7998466257668712" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.17503466055095843" LOG_CI_START="-0.36902122648969954" LOG_EFFECT_SIZE="-0.09699328296937053" ORDER="4785" O_E="0.0" SE="0.3195811211677574" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="184" TOTAL_2="173" VAR="0.10213209300684081" WEIGHT="35.07585584670662"/>
<DICH_DATA CI_END="1.4808461351364763" CI_START="0.5624204453158014" EFFECT_SIZE="0.9126106194690266" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="48" LOG_CI_END="0.1705099362169439" LOG_CI_START="-0.24993890006782032" LOG_EFFECT_SIZE="-0.03971448192543822" ORDER="4786" O_E="0.0" SE="0.24697372768897616" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="158" TOTAL_2="158" VAR="0.06099602216858854" WEIGHT="58.73121630340042"/>
<DICH_DATA CI_END="4.269353505494388" CI_START="0.21655649077264413" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6303621161835088" LOG_CI_START="-0.6644287947810695" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2012-04-16 09:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1000" O_E="0.0" SE="0.7605665904189708" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="0.5784615384615385" WEIGHT="6.192927849892946"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5329544217834215" CI_END="2.365269689508595" CI_START="0.9958745827589547" DF="1" EFFECT_SIZE="1.5347677235177233" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.37388066642175555" LOG_CI_START="-0.0017953517824668055" LOG_EFFECT_SIZE="0.18604265731964437" MODIFIED="2012-11-20 11:42:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.46536747929746036" P_Z="0.052230302207998756" STUDIES="2" TAU2="0.0" TOTAL_1="281" TOTAL_2="297" WEIGHT="100.0" Z="1.941230689558729">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="2.9271703077190034" CI_START="1.0122107304670072" EFFECT_SIZE="1.721311475409836" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" LOG_CI_END="0.4664479911563339" LOG_CI_START="0.005270936962008148" LOG_EFFECT_SIZE="0.23585946405917102" MODIFIED="2012-03-21 09:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="0.27089768449698276" STUDY_ID="STD-Kasper-2005" TOTAL_1="164" TOTAL_2="174" VAR="0.0733855554658268" WEIGHT="66.3577363415871"/>
<DICH_DATA CI_END="2.5800561544662477" CI_START="0.5806757335132254" EFFECT_SIZE="1.224" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.4116291584087449" LOG_CI_START="-0.2360663227896601" LOG_EFFECT_SIZE="0.08778141780954238" MODIFIED="2012-03-21 10:42:16 +0000" MODIFIED_BY="[Empty name]" ORDER="946" O_E="0.0" SE="0.3804595318002831" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="0.14474945533769062" WEIGHT="33.6422636584129"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8551917908217699" CI_END="1.374154026695488" CI_START="0.3632793174912131" DF="1" EFFECT_SIZE="0.7065420984950147" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.1380354148158281" LOG_CI_START="-0.4397593270344142" LOG_EFFECT_SIZE="-0.1508619561092931" MODIFIED="2012-11-20 11:42:19 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3550878258458121" P_Z="0.30607553579186175" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="141" WEIGHT="100.0" Z="1.0234914899523773">
<NAME>Fluoxetine vs Fluvoxamine</NAME>
<DICH_DATA CI_END="1.2877288268001506" CI_START="0.2354184436225254" EFFECT_SIZE="0.5505952380952381" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.10982441781920156" LOG_CI_START="-0.6281595157928619" LOG_EFFECT_SIZE="-0.2591675489868302" ORDER="4787" O_E="0.0" SE="0.43349541568311356" STUDY_ID="STD-Dalery-2003" TOTAL_1="94" TOTAL_2="90" VAR="0.1879182754182754" WEIGHT="61.29899530488041"/>
<DICH_DATA CI_END="3.0554429730669526" CI_START="0.3599937951046601" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4850741824386101" LOG_CI_START="-0.443704984718908" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="4788" O_E="0.0" SE="0.5455694803193516" STUDY_ID="STD-Rapaport-1996" TOTAL_1="49" TOTAL_2="51" VAR="0.2976460578559274" WEIGHT="38.7010046951196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1278524837966515" CI_END="1.203017208309104" CI_START="0.8063873352892704" DF="9" EFFECT_SIZE="0.9849354501263092" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="293" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="0.08027183965924217" LOG_CI_START="-0.0934563016539769" LOG_EFFECT_SIZE="-0.006592230997367394" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9590093970692675" P_Z="0.8817554042163421" STUDIES="10" TAU2="0.0" TOTAL_1="924" TOTAL_2="924" WEIGHT="100.00000000000003" Z="0.1487442993972274">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="1.488088203631381" CI_START="0.5297105536976814" EFFECT_SIZE="0.8878378378378379" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" LOG_CI_END="0.17262867396194437" LOG_CI_START="-0.2759613743043352" LOG_EFFECT_SIZE="-0.0516663501711954" ORDER="4789" O_E="0.0" SE="0.2635040149081642" STUDY_ID="STD-Cassano-2002" TOTAL_1="119" TOTAL_2="123" VAR="0.06943436587272205" WEIGHT="14.998266871814572"/>
<DICH_DATA CI_END="1.3370822867469812" CI_START="0.42317043240693003" EFFECT_SIZE="0.7522058823529412" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.12615813544483503" LOG_CI_START="-0.3734846847609497" LOG_EFFECT_SIZE="-0.12366327465805736" ORDER="4790" O_E="0.0" SE="0.2934926658607264" STUDY_ID="STD-Chouinard-1999" TOTAL_1="101" TOTAL_2="102" VAR="0.086137944914036" WEIGHT="12.089853669873264"/>
<DICH_DATA CI_END="4.566381052582725" CI_START="0.46241700841647987" EFFECT_SIZE="1.453125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6595721494076081" LOG_CI_START="-0.3349662002675122" LOG_EFFECT_SIZE="0.16230297457004794" ORDER="4791" O_E="0.0" SE="0.5841967496433944" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" VAR="0.3412858422939068" WEIGHT="3.0513869032324985"/>
<DICH_DATA CI_END="2.34071993753399" CI_START="0.450000054612555" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.3693494543375237" LOG_CI_START="-0.34678743351814556" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="4792" O_E="0.0" SE="0.420662352861187" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" VAR="0.17695681511470984" WEIGHT="5.8850242572416835"/>
<DICH_DATA CI_END="1.7170957865486596" CI_START="0.4737844346325153" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.2347945225396036" LOG_CI_START="-0.32441921137232815" LOG_EFFECT_SIZE="-0.04481234441636228" ORDER="4794" O_E="0.0" SE="0.32848491545249575" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.10790233967983327" WEIGHT="9.651274963307714"/>
<DICH_DATA CI_END="3.7319713351904125" CI_START="0.467895734600722" EFFECT_SIZE="1.3214285714285714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5719382993251488" LOG_CI_START="-0.32985091387559723" LOG_EFFECT_SIZE="0.12104369272477576" ORDER="4795" O_E="0.0" SE="0.5297154477627168" STUDY_ID="STD-Gagiano-1993" TOTAL_1="45" TOTAL_2="45" VAR="0.2805984555984556" WEIGHT="3.711335998671944"/>
<DICH_DATA CI_END="2.885052223429204" CI_START="0.37960719686479727" EFFECT_SIZE="1.0465116279069768" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.46015367889273995" LOG_CI_START="-0.4206655625012255" LOG_EFFECT_SIZE="0.019744058195757187" MODIFIED="2012-04-02 15:09:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1019" O_E="0.0" SE="0.5173975825203794" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="0.26770025839793277" WEIGHT="3.890153695280636"/>
<DICH_DATA CI_END="2.842624851708605" CI_START="0.6947494234077165" EFFECT_SIZE="1.4053156146179402" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.4537195485461672" LOG_CI_START="-0.15817180498376926" LOG_EFFECT_SIZE="0.14777387178119897" MODIFIED="2012-03-21 11:45:15 +0000" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.3594280099745342" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="70" TOTAL_2="68" VAR="0.12918849435425386" WEIGHT="8.061051834683052"/>
<DICH_DATA CI_END="1.3427116598183348" CI_START="0.6834876984812581" EFFECT_SIZE="0.9579806376400223" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="109" LOG_CI_END="0.12798276025285643" LOG_CI_START="-0.16526929752598446" LOG_EFFECT_SIZE="-0.01864326863656401" MODIFIED="2012-03-21 13:14:50 +0000" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.17225771036038856" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.029672718778603516" WEIGHT="35.096047558177624"/>
<DICH_DATA CI_END="3.7794943997725357" CI_START="0.45436020269493693" EFFECT_SIZE="1.3104395604395604" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5774337061665241" LOG_CI_START="-0.34259971538440825" LOG_EFFECT_SIZE="0.11741699539105793" ORDER="4796" O_E="0.0" SE="0.5404321860579041" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="61" TOTAL_2="60" VAR="0.29206694772732505" WEIGHT="3.5656042477170344"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.082441951686428" CI_END="1.4886792854329498" CI_START="0.9273849502781935" DF="8" EFFECT_SIZE="1.1749803254103504" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="185" I2="0.0" ID="CMP-003.03.05" LOG_CI_END="0.17280114532162671" LOG_CI_START="-0.032739956169530834" LOG_EFFECT_SIZE="0.07003059457604795" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.637997681167018" P_Z="0.18168929248315166" STUDIES="9" TAU2="0.0" TOTAL_1="784" TOTAL_2="807" WEIGHT="100.00000000000001" Z="1.3355717390751152">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="5.094993185570374" CI_START="1.0767443131835042" EFFECT_SIZE="2.3422222222222224" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="18" LOG_CI_END="0.7071436074845133" LOG_CI_START="0.03211258671785505" LOG_EFFECT_SIZE="0.36962809710118416" ORDER="4797" O_E="0.0" SE="0.3965165630557782" STUDY_ID="STD-Aguglia-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.15722538477756695" WEIGHT="9.271497743080602"/>
<DICH_DATA CI_END="1.7470709106978453" CI_START="0.499937748450796" EFFECT_SIZE="0.9345730027548209" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.24231053263020738" LOG_CI_START="-0.3010840700388831" LOG_EFFECT_SIZE="-0.02938676870433785" ORDER="4798" O_E="0.0" SE="0.31919267945448826" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.10188396661733568" WEIGHT="14.307597637960036"/>
<DICH_DATA CI_END="2.189149369465039" CI_START="0.47436600917752286" EFFECT_SIZE="1.019047619047619" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.3402753952459916" LOG_CI_START="-0.32388643801544853" LOG_EFFECT_SIZE="0.008194478615271538" ORDER="4799" O_E="0.0" SE="0.3901319485118672" STUDY_ID="STD-Boyer-1998" TOTAL_1="120" TOTAL_2="122" VAR="0.15220293724966621" WEIGHT="9.577441976228274"/>
<DICH_DATA CI_END="1.8155443638066315" CI_START="0.4973328845276651" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.25900686559868535" LOG_CI_START="-0.3033528235010683" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="4801" O_E="0.0" SE="0.33033286510255166" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.10911980176686059" WEIGHT="13.358847583270588"/>
<DICH_DATA CI_END="2.998911379912667" CI_START="0.4564656392213444" EFFECT_SIZE="1.17" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.47696363222049015" LOG_CI_START="-0.34059190872816697" LOG_EFFECT_SIZE="0.06818586174616162" ORDER="4802" O_E="0.0" SE="0.4802361717184375" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="42" VAR="0.2306267806267806" WEIGHT="6.320665779397"/>
<DICH_DATA CI_END="1.8200534581833416" CI_START="0.6104380856904852" EFFECT_SIZE="1.054054054054054" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" LOG_CI_END="0.26008414416808484" LOG_CI_START="-0.2143583782490765" LOG_EFFECT_SIZE="0.022862882959504165" ORDER="4803" O_E="0.0" SE="0.27868988619620316" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.07766805266805267" WEIGHT="18.768525153454704"/>
<DICH_DATA CI_END="2.7009322371339817" CI_START="0.8717868979203711" EFFECT_SIZE="1.5344827586206897" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.4315136884421881" LOG_CI_START="-0.05958966227823707" LOG_EFFECT_SIZE="0.18596201308197552" ORDER="4804" O_E="0.0" SE="0.2884765392139705" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.08321871367686944" WEIGHT="17.51667065872182"/>
<DICH_DATA CI_END="2.7022850405251164" CI_START="0.0925142966973681" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.43173115704652326" LOG_CI_START="-1.0337911483744857" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4805" O_E="0.0" SE="0.8608550566567107" STUDY_ID="STD-Suri-2000" TOTAL_1="18" TOTAL_2="35" VAR="0.7410714285714285" WEIGHT="1.9670368387164028"/>
<DICH_DATA CI_END="2.6397222912698473" CI_START="0.5407991053660222" EFFECT_SIZE="1.1948051948051948" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.42155823985731816" LOG_CI_START="-0.26696403551117137" LOG_EFFECT_SIZE="0.07729710217307338" ORDER="4806" O_E="0.0" SE="0.40444139279168123" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="83" VAR="0.163572840203275" WEIGHT="8.9117166291706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.6282277208621805" CI_END="1.302981068958929" CI_START="0.7026068951737353" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9568090108957942" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.11493810588418885" LOG_CI_START="-0.15328759248704588" LOG_EFFECT_SIZE="-0.019174743301428467" METHOD="MH" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8669492380541869" P_Q="0.6195469420947559" P_Z="0.7793046983714662" Q="1.7788563137702407" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1687" TOTAL_2="1684" WEIGHT="400.0" Z="0.280225246960385">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.535253329077381" CI_END="1.5641125320102287" CI_START="0.4814555689958471" DF="2" EFFECT_SIZE="0.86778493249913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.194267995701424" LOG_CI_START="-0.31744378544551377" LOG_EFFECT_SIZE="-0.06158789487204492" MODIFIED="2012-04-16 09:42:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7651934170592358" P_Z="0.6370772344090322" STUDIES="3" TAU2="0.0" TOTAL_1="372" TOTAL_2="360" WEIGHT="99.99999999999999" Z="0.4717892387089101">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="8.584800951925201" CI_START="0.2339307747425228" EFFECT_SIZE="1.4171270718232045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.933730230017299" LOG_CI_START="-0.6309126408599979" LOG_EFFECT_SIZE="0.15140879457865059" ORDER="4807" O_E="0.0" SE="0.9190789674604466" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="184" TOTAL_2="173" VAR="0.8447061484281606" WEIGHT="10.695975030697607"/>
<DICH_DATA CI_END="1.6205452708033294" CI_START="0.4465319263157458" EFFECT_SIZE="0.8506616257088847" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.2096611677875169" LOG_CI_START="-0.35014748430720105" LOG_EFFECT_SIZE="-0.07024315825984206" ORDER="4808" O_E="0.0" SE="0.3288343733379569" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="158" TOTAL_2="158" VAR="0.10813204508856682" WEIGHT="83.55484134665322"/>
<DICH_DATA CI_END="5.432557677106979" CI_START="0.03989029015460108" EFFECT_SIZE="0.46551724137931033" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7350043458929435" LOG_CI_START="-1.3991328047008436" LOG_EFFECT_SIZE="-0.33206422940395" MODIFIED="2012-04-16 09:42:07 +0100" MODIFIED_BY="[Empty name]" ORDER="1001" O_E="0.0" SE="1.2536027264080623" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="1.5715197956577267" WEIGHT="5.7491836226491575"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.02420759124142" CI_END="6.529476617247789" CI_START="0.4642999207391033" DF="1" EFFECT_SIZE="1.741159233343113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="2.3635434308857652" ID="CMP-003.04.02" LOG_CI_END="0.814878370961002" LOG_CI_START="-0.3332013904724712" LOG_EFFECT_SIZE="0.24083849024426543" MODIFIED="2012-11-20 11:43:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.31152333176920755" P_Z="0.410904427048147" STUDIES="2" TAU2="0.023551227566773747" TOTAL_1="281" TOTAL_2="297" WEIGHT="100.0" Z="0.8223030887338119">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="5.338645263845943" CI_START="0.21130482034038733" EFFECT_SIZE="1.062111801242236" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7274310643168853" LOG_CI_START="-0.6750905955962773" LOG_EFFECT_SIZE="0.026170234360304082" MODIFIED="2012-03-21 10:00:54 +0000" MODIFIED_BY="[Empty name]" ORDER="930" O_E="0.0" SE="0.823848165627177" STUDY_ID="STD-Kasper-2005" TOTAL_1="164" TOTAL_2="174" VAR="0.6787258000072645" WEIGHT="64.7606000477371"/>
<DICH_DATA CI_END="39.21756728338028" CI_START="0.4755564831896274" EFFECT_SIZE="4.31858407079646" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5934806503166756" LOG_CI_START="-0.3227978932780941" LOG_EFFECT_SIZE="0.6353413785192908" MODIFIED="2012-03-21 10:42:49 +0000" MODIFIED_BY="[Empty name]" ORDER="947" O_E="0.0" SE="1.1256315022393426" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="1.2670462788335992" WEIGHT="35.2393999522629"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8423369727125827" CI_END="1.3867185526678938" CI_START="0.41001686662841313" DF="3" EFFECT_SIZE="0.7540411101925265" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.1419883259425002" LOG_CI_START="-0.38719827759006403" LOG_EFFECT_SIZE="-0.12260497582378192" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.839316130971269" P_Z="0.3637771656275064" STUDIES="4" TAU2="0.0" TOTAL_1="503" TOTAL_2="502" WEIGHT="100.0" Z="0.9081913084567695">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="3.7393161423988075" CI_START="0.2925850254192717" EFFECT_SIZE="1.0459770114942528" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.572792184355913" LOG_CI_START="-0.5337479049509629" LOG_EFFECT_SIZE="0.01952213970247505" ORDER="4810" O_E="0.0" SE="0.6499871259206402" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.42248326386257423" WEIGHT="22.870906436759164"/>
<DICH_DATA CI_END="17.061232349926986" CI_START="0.06329960347815218" EFFECT_SIZE="1.0392156862745099" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2320103974905594" LOG_CI_START="-1.1985990104848538" LOG_EFFECT_SIZE="0.016705693502852715" MODIFIED="2012-04-02 15:10:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1020" O_E="0.0" SE="1.427751997955372" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="2.038475767665557" WEIGHT="4.740098142036321"/>
<DICH_DATA CI_END="2.338517229206193" CI_START="0.30596730798741106" EFFECT_SIZE="0.8458781362007168" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.36894057395442803" LOG_CI_START="-0.51432497456141" LOG_EFFECT_SIZE="-0.07269220030349098" MODIFIED="2012-03-21 11:45:48 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="0.5188345554331829" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="70" TOTAL_2="68" VAR="0.2691892959115485" WEIGHT="35.895094439685835"/>
<DICH_DATA CI_END="1.4425448385077853" CI_START="0.19192883727288684" EFFECT_SIZE="0.5261805332476711" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.15912932117880135" LOG_CI_START="-0.7168597676950325" LOG_EFFECT_SIZE="-0.2788652232581156" MODIFIED="2012-03-21 13:15:45 +0000" MODIFIED_BY="[Empty name]" ORDER="979" O_E="0.0" SE="0.5145603270204135" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.2647723301433549" WEIGHT="36.493900981518685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4471705796829633" CI_END="1.7677084681925366" CI_START="0.6767280603669235" DF="4" EFFECT_SIZE="1.0937357646955321" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="0.24741064241061259" LOG_CI_START="-0.16958581522651006" LOG_EFFECT_SIZE="0.03891241359205123" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.48595679909667744" P_Z="0.7145204872062977" STUDIES="5" TAU2="0.0" TOTAL_1="531" TOTAL_2="525" WEIGHT="100.0" Z="0.3657917365730532">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="7.137415244873104" CI_START="0.7397331575799682" EFFECT_SIZE="2.2977777777777777" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.853540964139723" LOG_CI_START="-0.13092491417456292" LOG_EFFECT_SIZE="0.36130802498258" ORDER="4811" O_E="0.0" SE="0.5782801301065029" STUDY_ID="STD-Aguglia-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.334407908875994" WEIGHT="17.94169192893498"/>
<DICH_DATA CI_END="4.0201360029514355" CI_START="0.2416914881356969" EFFECT_SIZE="0.9857142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6042407457044245" LOG_CI_START="-0.6167386442584274" LOG_EFFECT_SIZE="-0.006248949277001492" ORDER="4812" O_E="0.0" SE="0.717209337609635" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.5143892339544514" WEIGHT="11.664014881352912"/>
<DICH_DATA CI_END="1.7247791197729314" CI_START="0.17894579762148038" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.23673348595661783" LOG_CI_START="-0.7472784961632298" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="4814" O_E="0.0" SE="0.5780135092350676" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.3340996168582375" WEIGHT="17.958247710886333"/>
<DICH_DATA CI_END="7.138712835737957" CI_START="0.38911465437741316" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8536199122341563" LOG_CI_START="-0.40992241300144355" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="4815" O_E="0.0" SE="0.7422110164787749" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.5508771929824562" WEIGHT="10.891435978986921"/>
<DICH_DATA CI_END="2.0655943696186707" CI_START="0.46568111250286115" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.3150450411273824" LOG_CI_START="-0.33191137620110794" LOG_EFFECT_SIZE="-0.008433167536862813" ORDER="4816" O_E="0.0" SE="0.38002540202467" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.14441930618401205" WEIGHT="41.54460949983886"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.269744377475103" CI_END="1.210741327560215" CI_START="0.8198479914348378" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9963050966181952" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="241" I2="0.0" I2_Q="23.785484196088383" ID="CMP-003.05" LOG_CI_END="0.08305136691433795" LOG_CI_START="-0.08626666298305619" LOG_EFFECT_SIZE="-0.0016076480343591131" METHOD="MH" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8847058334820705" P_Q="0.2627517308596542" P_Z="0.9703103104678916" Q="5.248344042874185" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2242" TOTAL_2="2268" WEIGHT="500.0" Z="0.0372190988646624">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.765487548090106" CI_END="1.2005453007471663" CI_START="0.34105887652211325" DF="2" EFFECT_SIZE="0.6398879835461291" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.07937855214259555" LOG_CI_START="-0.4671706428799209" LOG_EFFECT_SIZE="-0.19389604536866262" MODIFIED="2012-04-16 09:42:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4136464365571072" P_Z="0.164331645714541" STUDIES="3" TAU2="0.0" TOTAL_1="372" TOTAL_2="360" WEIGHT="100.0" Z="1.3906498047322782">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="1.1773179347046523" CI_START="0.11144393065286957" EFFECT_SIZE="0.3622222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07089375990568784" LOG_CI_START="-0.9529435786484597" LOG_EFFECT_SIZE="-0.4410249093713859" ORDER="4817" O_E="0.0" SE="0.601407120743269" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="184" TOTAL_2="173" VAR="0.3616905248807089" WEIGHT="28.496832534863902"/>
<DICH_DATA CI_END="1.6058033719893634" CI_START="0.316918719199639" EFFECT_SIZE="0.7133786848072562" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.20569236554540182" LOG_CI_START="-0.4990521079065429" LOG_EFFECT_SIZE="-0.14667987118057052" ORDER="4818" O_E="0.0" SE="0.4139703922470784" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="158" TOTAL_2="158" VAR="0.17137148565719995" WEIGHT="60.144394952554066"/>
<DICH_DATA CI_END="9.703496801820677" CI_START="0.23187517303842783" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9869282670569043" LOG_CI_START="-0.6347457489455417" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-04-16 09:42:45 +0100" MODIFIED_BY="[Empty name]" ORDER="1002" O_E="0.0" SE="0.9525793444156804" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="0.9074074074074074" WEIGHT="11.358772512582036"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29673881922475936" CI_END="2.121451071312649" CI_START="0.6432579133296676" DF="1" EFFECT_SIZE="1.1681781496687749" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.3266330197444127" LOG_CI_START="-0.1916148624137388" LOG_EFFECT_SIZE="0.06750907866533698" MODIFIED="2012-11-20 11:44:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5859342331850869" P_Z="0.6096131270936562" STUDIES="2" TAU2="0.0" TOTAL_1="281" TOTAL_2="297" WEIGHT="100.00000000000001" Z="0.5106257733752351">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="2.5444711220362453" CI_START="0.646604827804479" EFFECT_SIZE="1.2826797385620916" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.405597526299321" LOG_CI_START="-0.18936105709993817" LOG_EFFECT_SIZE="0.10811823459969139" MODIFIED="2012-03-21 10:02:08 +0000" MODIFIED_BY="[Empty name]" ORDER="931" O_E="0.0" SE="0.3494816169812105" STUDY_ID="STD-Kasper-2005" TOTAL_1="164" TOTAL_2="174" VAR="0.12213740060780151" WEIGHT="75.87550649700943"/>
<DICH_DATA CI_END="2.9332871832045333" CI_START="0.2583560294355592" EFFECT_SIZE="0.8705357142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.46735458462234314" LOG_CI_START="-0.5877813985656327" LOG_EFFECT_SIZE="-0.06021340697164479" MODIFIED="2012-03-21 10:44:23 +0000" MODIFIED_BY="[Empty name]" ORDER="948" O_E="0.0" SE="0.6197920995319695" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="0.38414224664224667" WEIGHT="24.124493502990585"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.70654473495209" CI_START="0.14103819473791854" DF="0" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.8868597037455603" LOG_CI_START="-0.8506632595599679" LOG_EFFECT_SIZE="0.018098222092796223" MODIFIED="2012-11-20 11:44:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9674311179157203" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="51" WEIGHT="100.0" Z="0.040830382372161265">
<NAME>Fluoxetine vs Fluvoxamine</NAME>
<DICH_DATA CI_END="7.70654473495209" CI_START="0.14103819473791854" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8868597037455603" LOG_CI_START="-0.8506632595599679" LOG_EFFECT_SIZE="0.018098222092796223" ORDER="4819" O_E="0.0" SE="1.0206295895230488" STUDY_ID="STD-Rapaport-1996" TOTAL_1="49" TOTAL_2="51" VAR="1.0416847590099871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8718296376901686" CI_END="1.1558257049080278" CI_START="0.6203537581754522" DF="8" EFFECT_SIZE="0.8467708189560421" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="100" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="0.0628923487006865" LOG_CI_START="-0.20736058242146232" LOG_EFFECT_SIZE="-0.07223411686038793" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.868498267429265" P_Z="0.29476230095803324" STUDIES="9" TAU2="0.0" TOTAL_1="756" TOTAL_2="753" WEIGHT="100.00000000000001" Z="1.0477315965718665">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="10.987361768334925" CI_START="0.32576108861014585" EFFECT_SIZE="1.8918918918918919" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.040893424270497" LOG_CI_START="-0.48710079237597326" LOG_EFFECT_SIZE="0.27689631594726183" ORDER="4820" O_E="0.0" SE="0.8975513665514947" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" VAR="0.8055984555984556" WEIGHT="3.128220840068189"/>
<DICH_DATA CI_END="1.9373187362654363" CI_START="0.210692750090532" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.28720107865068367" LOG_CI_START="-0.6763504081500726" LOG_EFFECT_SIZE="-0.19457466474969443" ORDER="4821" O_E="0.0" SE="0.5659949130035479" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" VAR="0.3203502415458937" WEIGHT="7.866670758132721"/>
<DICH_DATA CI_END="1.9207575176636413" CI_START="0.281968985208677" EFFECT_SIZE="0.7359307359307359" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2834725416510692" LOG_CI_START="-0.5497986586788101" LOG_EFFECT_SIZE="-0.13316305851387042" ORDER="4823" O_E="0.0" SE="0.489467627832736" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.23957855869620576" WEIGHT="10.518845639794506"/>
<DICH_DATA CI_END="5.240788167404054" CI_START="0.19081099408284896" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7193966058795148" LOG_CI_START="-0.7193966058795148" LOG_EFFECT_SIZE="0.0" ORDER="4824" O_E="0.0" SE="0.8451542547285166" STUDY_ID="STD-Gagiano-1993" TOTAL_1="45" TOTAL_2="45" VAR="0.7142857142857143" WEIGHT="3.52812582854177"/>
<DICH_DATA CI_END="3.9847888878150517" CI_START="0.3886383994003248" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6004053176303363" LOG_CI_START="-0.4104542911686228" LOG_EFFECT_SIZE="0.09497551323085675" MODIFIED="2012-04-02 15:10:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1021" O_E="0.0" SE="0.593783938044273" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="0.35257936507936505" WEIGHT="7.147581869865152"/>
<DICH_DATA CI_END="4.068130414488871" CI_START="0.4370011766206225" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6093948669117255" LOG_CI_START="-0.35951739369512575" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-03-21 11:46:29 +0000" MODIFIED_BY="[Empty name]" ORDER="976" O_E="0.0" SE="0.5691438580735064" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="70" TOTAL_2="68" VAR="0.32392473118279563" WEIGHT="7.779862526482151"/>
<DICH_DATA CI_END="1.066896323438988" CI_START="0.4333104857802805" EFFECT_SIZE="0.6799245283018868" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="53" LOG_CI_END="0.028122218537865395" LOG_CI_START="-0.3632008012462318" LOG_EFFECT_SIZE="-0.16753929135418316" MODIFIED="2012-03-21 13:18:22 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="0.2298650789013674" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.052837954498331854" WEIGHT="47.694690331159535"/>
<DICH_DATA CI_END="4.899363377725196" CI_START="0.3189189859041397" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6901396515584721" LOG_CI_START="-0.4963196255423593" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="4825" O_E="0.0" SE="0.6969320524371696" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="61" TOTAL_2="60" VAR="0.4857142857142857" WEIGHT="5.188420336090839"/>
<DICH_DATA CI_END="3.9847888878150517" CI_START="0.3886383994003248" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6004053176303363" LOG_CI_START="-0.4104542911686228" LOG_EFFECT_SIZE="0.09497551323085675" ORDER="4826" O_E="0.0" SE="0.593783938044273" STUDY_ID="STD-Schone-1993" TOTAL_1="52" TOTAL_2="54" VAR="0.35257936507936505" WEIGHT="7.147581869865152"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.08805198912242" CI_END="1.7011229854987573" CI_START="0.9150024045047452" DF="8" EFFECT_SIZE="1.2476103646931016" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="89" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="0.2307357127852123" LOG_CI_START="-0.03857776466385722" LOG_EFFECT_SIZE="0.09607897406067757" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8490929884976741" P_Z="0.16197661221069895" STUDIES="9" TAU2="0.0" TOTAL_1="784" TOTAL_2="807" WEIGHT="99.99999999999999" Z="1.3984545490568558">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.2484182378588838" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="4827" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Aguglia-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.4166666666666667" WEIGHT="6.0062391582780625"/>
<DICH_DATA CI_END="1.8221964710504777" CI_START="0.47179316481959366" EFFECT_SIZE="0.9272" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.2605952012280484" LOG_CI_START="-0.3262483553169693" LOG_EFFECT_SIZE="-0.03282657704446041" ORDER="4828" O_E="0.0" SE="0.3447148100369983" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.11882830025884382" WEIGHT="21.06063659777267"/>
<DICH_DATA CI_END="2.916235765169951" CI_START="0.44674928473907405" EFFECT_SIZE="1.1414141414141414" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4648226319138607" LOG_CI_START="-0.349936134142121" LOG_EFFECT_SIZE="0.05744324888586982" ORDER="4829" O_E="0.0" SE="0.47859333230222095" STUDY_ID="STD-Boyer-1998" TOTAL_1="120" TOTAL_2="122" VAR="0.22905157772414408" WEIGHT="10.925921899985802"/>
<DICH_DATA CI_END="4.289402959033075" CI_START="0.47578097605235414" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6323968470467438" LOG_CI_START="-0.32259292707525744" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="4831" O_E="0.0" SE="0.560965720594886" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.31468253968253973" WEIGHT="7.9527756824614935"/>
<DICH_DATA CI_END="5.38568512540602" CI_START="0.6339882796953598" EFFECT_SIZE="1.8478260869565217" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.7312409587494463" LOG_CI_START="-0.197918770684009" LOG_EFFECT_SIZE="0.26666109403271865" ORDER="4832" O_E="0.0" SE="0.5457930244840508" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="42" VAR="0.2978900255754476" WEIGHT="8.401085751186672"/>
<DICH_DATA CI_END="2.5986098273749496" CI_START="0.7450265494004478" EFFECT_SIZE="1.3914141414141414" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.41474107652349207" LOG_CI_START="-0.1278282506709467" LOG_EFFECT_SIZE="0.14345641292627276" ORDER="4833" O_E="0.0" SE="0.31870790855549835" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.10157473097581991" WEIGHT="24.638014053694864"/>
<DICH_DATA CI_END="4.643442214870202" CI_START="0.6685360227120756" EFFECT_SIZE="1.7619047619047619" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6668400453574753" LOG_CI_START="-0.1748751866913239" LOG_EFFECT_SIZE="0.2459824293330757" ORDER="4834" O_E="0.0" SE="0.4944276938630607" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.24445874445874444" WEIGHT="10.237308772993686"/>
<DICH_DATA CI_END="4.411511204754002" CI_START="0.04711055012151384" EFFECT_SIZE="0.45588235294117646" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.6445873866244426" LOG_CI_START="-1.32688182436837" LOG_EFFECT_SIZE="-0.34114721887196364" ORDER="4835" O_E="0.0" SE="1.1580507734671626" STUDY_ID="STD-Suri-2000" TOTAL_1="18" TOTAL_2="35" VAR="1.3410815939278937" WEIGHT="1.8661054335647558"/>
<DICH_DATA CI_END="2.168176454713898" CI_START="0.2716172512912326" EFFECT_SIZE="0.7674074074074074" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3360946238949966" LOG_CI_START="-0.5660426500665804" LOG_EFFECT_SIZE="-0.11497401308579189" ORDER="4836" O_E="0.0" SE="0.5299199003765576" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="83" VAR="0.28081510081510075" WEIGHT="8.911912650061979"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-07-02 12:05:40 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Fluoxetine versus SNRIs</NAME>
<DICH_OUTCOME CHI2="11.751859242006141" CI_END="1.4858732827348755" CI_START="1.107658890921429" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="OR" EFFECT_SIZE="1.282903251380982" ESTIMABLE="YES" EVENTS_1="706" EVENTS_2="810" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.17198177378824017" LOG_CI_START="0.04440603783039758" LOG_EFFECT_SIZE="0.10819390580931883" METHOD="MH" MODIFIED="2013-05-06 15:43:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6262228190822037" P_Q="0.92519163953058" P_Z="8.861014848872454E-4" Q="0.15550881810186706" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1589" TOTAL_2="2271" WEIGHT="300.0" Z="3.324396400943482">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>SNRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SNRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.248968950654988" CI_START="0.6134498713425022" DF="0" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.5117455609529733" LOG_CI_START="-0.21222092028630904" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2012-08-01 16:31:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4174285906260252" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="70" WEIGHT="100.0" Z="0.8108904533591681">
<NAME>Fluoxetine vs Duloxetine</NAME>
<DICH_DATA CI_END="3.248968950654988" CI_START="0.6134498713425022" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" LOG_CI_END="0.5117455609529733" LOG_CI_START="-0.21222092028630904" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2012-05-28 12:01:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4839" O_E="0.0" SE="0.42526149477183356" STUDY_ID="STD-Goldstein-2002" TOTAL_1="33" TOTAL_2="70" VAR="0.18084733893557423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13036949434294567" CI_END="1.8416057191402821" CI_START="0.7779989749860003" DF="1" EFFECT_SIZE="1.1969826071499516" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="113" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.2651966549972767" LOG_CI_START="-0.10902097519310949" LOG_EFFECT_SIZE="0.07808783990208357" MODIFIED="2012-08-01 16:31:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7180493252793165" P_Z="0.41337445857956656" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="239" WEIGHT="100.00000000000001" Z="0.8179697667410725">
<NAME>Fluoxetine vs Milnacipran</NAME>
<DICH_DATA CI_END="1.8613297040555716" CI_START="0.7115390031412585" EFFECT_SIZE="1.1508295625942684" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="91" LOG_CI_END="0.26982330809556304" LOG_CI_START="-0.14780128899534842" LOG_EFFECT_SIZE="0.0610110095501073" MODIFIED="2012-05-28 13:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="4843" O_E="0.0" SE="0.2453147556062976" STUDY_ID="STD-Guelfi-1998" TOTAL_1="100" TOTAL_2="200" VAR="0.060179329318177516" WEIGHT="80.29275304098582"/>
<DICH_DATA CI_END="3.708068274436345" CI_START="0.5323280856540062" EFFECT_SIZE="1.4049586776859504" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.5691477219498012" LOG_CI_START="-0.2738206198261536" LOG_EFFECT_SIZE="0.14766355106182386" MODIFIED="2012-05-28 13:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="939" O_E="0.0" SE="0.495163776719785" STUDY_ID="STD-Lee-2005" TOTAL_1="31" TOTAL_2="39" VAR="0.24518716577540112" WEIGHT="19.707246959014196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.477525832089464" CI_END="1.5130749798862673" CI_START="1.1007950067322045" DF="11" EFFECT_SIZE="1.2905756012997587" ESTIMABLE="YES" EVENTS_1="621" EVENTS_2="669" I2="4.160529360381593" ID="CMP-004.01.03" LOG_CI_END="0.17986044986324864" LOG_CI_START="0.04170645091181349" LOG_EFFECT_SIZE="0.11078345038753105" MODIFIED="2012-08-01 16:31:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4041670461806539" P_Z="0.001670393257545703" STUDIES="12" TAU2="0.00335837429305617" TOTAL_1="1425" TOTAL_2="1962" WEIGHT="99.99999999999996" Z="3.1433266425964015">
<NAME>Fluoxetine vs Venlafaxine</NAME>
<DICH_DATA CI_END="10.488527207978645" CI_START="0.9078140776350466" EFFECT_SIZE="3.085714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.020714509132199" LOG_CI_START="-0.042003086858850916" LOG_EFFECT_SIZE="0.4893557111366741" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4861" O_E="0.0" SE="0.6242455764220838" STUDY_ID="STD-Alves-1999" TOTAL_1="47" TOTAL_2="40" VAR="0.3896825396825397" WEIGHT="1.6755768972319913"/>
<DICH_DATA CI_END="6.511295078708866" CI_START="0.8846166439046037" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.8136673771394278" LOG_CI_START="-0.05324489371621586" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4862" O_E="0.0" SE="0.5092285591855548" STUDY_ID="STD-Clerc-1994" TOTAL_1="34" TOTAL_2="34" VAR="0.2593137254901961" WEIGHT="2.5071953803539992"/>
<DICH_DATA CI_END="2.4650605929172213" CI_START="0.806804972009093" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.39182759900723113" LOG_CI_START="-0.09323143407174175" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4863" O_E="0.0" SE="0.2849260771115265" STUDY_ID="STD-Costa-e-Silva-1998" TOTAL_1="186" TOTAL_2="196" VAR="0.08118286941816355" WEIGHT="7.789928870387011"/>
<DICH_DATA CI_END="3.389716133407083" CI_START="0.9045305744839598" EFFECT_SIZE="1.7510288065843622" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="36" LOG_CI_END="0.5301633303987238" LOG_CI_START="-0.04357674875413476" LOG_EFFECT_SIZE="0.2432932908222945" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4864" O_E="0.0" SE="0.3370177625535848" STUDY_ID="STD-De-Nayer-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.11358097227662445" WEIGHT="5.631725287023327"/>
<DICH_DATA CI_END="2.401484836949991" CI_START="0.9843748441396328" EFFECT_SIZE="1.5375178900020445" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="73" LOG_CI_END="0.3804798488347614" LOG_CI_START="-0.006839493294041611" LOG_EFFECT_SIZE="0.1868201777703599" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4865" O_E="0.0" SE="0.22751329882812363" STUDY_ID="STD-Dierick-1996" TOTAL_1="161" TOTAL_2="153" VAR="0.051762301143655085" WEIGHT="11.947790369162213"/>
<DICH_DATA CI_END="1.2474843812840462" CI_START="0.6585113715356844" EFFECT_SIZE="0.9063568010936432" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="209" LOG_CI_END="0.09603511688892179" LOG_CI_START="-0.18143672100203478" LOG_EFFECT_SIZE="-0.04270080205655648" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="932" O_E="0.0" SE="0.1629883310848971" STUDY_ID="STD-Keller-2007" TOTAL_1="275" TOTAL_2="821" VAR="0.026565196069840036" WEIGHT="22.0084123364186"/>
<DICH_DATA CI_END="2.2696362637190997" CI_START="0.7573955233082956" EFFECT_SIZE="1.3111111111111111" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="51" LOG_CI_END="0.3559562618992162" LOG_CI_START="-0.1206772661656152" LOG_EFFECT_SIZE="0.11763949786680052" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="950" O_E="0.0" SE="0.2799768937592974" STUDY_ID="STD-Nemeroff-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.07838706103910491" WEIGHT="8.056355348142036"/>
<DICH_DATA CI_END="2.077119617993901" CI_START="0.6897261369925668" EFFECT_SIZE="1.19693094629156" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="46" LOG_CI_END="0.3174615075793054" LOG_CI_START="-0.16132331622279097" LOG_EFFECT_SIZE="0.0780690956782572" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4866" O_E="0.0" SE="0.2812405755244525" STUDY_ID="STD-Rudolph-1999" TOTAL_1="103" TOTAL_2="100" VAR="0.07909626132132526" WEIGHT="7.98706185792166"/>
<DICH_DATA CI_END="3.184447258470895" CI_START="1.0067068877132204" EFFECT_SIZE="1.7904761904761906" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="48" LOG_CI_END="0.5030340603987131" LOG_CI_START="0.002903039988770484" LOG_EFFECT_SIZE="0.2529685501937418" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="957" O_E="0.0" SE="0.2937794370772787" STUDY_ID="STD-Sheehan-2009" TOTAL_1="99" TOTAL_2="95" VAR="0.08630635764944275" WEIGHT="7.344808386275991"/>
<DICH_DATA CI_END="1.823522705600693" CI_START="0.6370725933898501" EFFECT_SIZE="1.077829457364341" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="43" LOG_CI_END="0.2609111753030479" LOG_CI_START="-0.19581107769236347" LOG_EFFECT_SIZE="0.03255004880534225" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4867" O_E="0.0" SE="0.2682809122211189" STUDY_ID="STD-Silverstone-1999" TOTAL_1="119" TOTAL_2="122" VAR="0.0719746478621957" WEIGHT="8.742119409031863"/>
<DICH_DATA CI_END="1.9342557378252172" CI_START="0.8001088813556678" EFFECT_SIZE="1.2440318302387268" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="104" LOG_CI_END="0.2865138938337006" LOG_CI_START="-0.09685090881511975" LOG_EFFECT_SIZE="0.0948314925092904" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4868" O_E="0.0" SE="0.22519038276229567" STUDY_ID="STD-Tylee-1997" TOTAL_1="170" TOTAL_2="171" VAR="0.05071070848862923" WEIGHT="12.180163621113428"/>
<DICH_DATA CI_END="3.049788046017822" CI_START="0.6479782463581567" EFFECT_SIZE="1.4057724957555178" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" LOG_CI_END="0.4842696578243395" LOG_CI_START="-0.18843957382878246" LOG_EFFECT_SIZE="0.1479150419977785" MODIFIED="2012-05-28 12:07:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4869" O_E="0.0" SE="0.39515273263744544" STUDY_ID="STD-Tzanakaki-2000" TOTAL_1="54" TOTAL_2="55" VAR="0.15614568211084046" WEIGHT="4.1288622369378585"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="26.096813511937242" CI_END="0.13896625613243682" CI_START="-0.0405997025997642" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.04918327676633631" ESTIMABLE="YES" I2="46.35360369343138" I2_Q="89.53769607790097" ID="CMP-004.02" MODIFIED="2013-05-06 15:43:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.025162908700317232" P_Q="0.0019906822615739506" P_Z="0.28296983074752513" Q="9.558124170793272" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.018159291280741004" TOTALS="SUB" TOTAL_1="1399" TOTAL_2="1911" UNITS="" WEIGHT="200.0" Z="1.0736717781508787">
<NAME>End-point score on rating scale</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>SNRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SNRIs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.09769909204433704" CI_END="-0.08398403733726978" CI_START="-0.6284778908423487" DF="1" EFFECT_SIZE="-0.35623096408980925" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2012-08-01 16:31:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7546085060194989" P_Z="0.010329984812092474" STUDIES="2" TAU2="0.0" TOTAL_1="101" TOTAL_2="112" WEIGHT="100.0" Z="2.564583072148471">
<NAME>Fluoxetine vs Milnacipran</NAME>
<CONT_DATA CI_END="-0.06012478796218207" CI_START="-0.708465794812621" EFFECT_SIZE="-0.3842952913874015" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.61" MODIFIED="2012-05-28 13:20:50 +0100" MODIFIED_BY="[Empty name]" ORDER="4875" SD_1="1.68" SD_2="1.47" SE="0.16539615318558656" STUDY_ID="STD-Ansseau-1994" TOTAL_1="75" TOTAL_2="74" WEIGHT="70.53082778602561"/>
<CONT_DATA CI_END="0.21244687140832685" CI_START="-0.7905717899709265" EFFECT_SIZE="-0.2890624592812998" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="14.5" MODIFIED="2012-05-28 13:20:50 +0100" MODIFIED_BY="[Empty name]" ORDER="940" SD_1="5.9" SD_2="7.4" SE="0.25587680929112383" STUDY_ID="STD-Lee-2005" TOTAL_1="26" TOTAL_2="38" WEIGHT="29.469172213974392"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.0574644941523" CI_END="0.19375940877238956" CI_START="0.003552521812046558" DF="12" EFFECT_SIZE="0.09865596529221807" ESTIMABLE="YES" I2="29.64956776481122" ID="CMP-004.02.02" MODIFIED="2012-08-01 16:31:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.147448550537702" P_Z="0.04203463864313271" STUDIES="13" TAU2="0.00829491208496021" TOTAL_1="1298" TOTAL_2="1799" WEIGHT="100.00000000000001" Z="2.033177051818275">
<NAME>Fluoxetine vs Venlafaxine</NAME>
<CONT_DATA CI_END="0.6879614680102137" CI_START="-0.27211331879492723" EFFECT_SIZE="0.20792407460764328" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="8.5" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4893" SD_1="9.7" SD_2="9.26" SE="0.24492153794102556" STUDY_ID="STD-Alves-1999" TOTAL_1="38" TOTAL_2="30" WEIGHT="3.4482077857748847"/>
<CONT_DATA CI_END="0.8369547557523722" CI_START="-0.6209630631251655" EFFECT_SIZE="0.10799584631360337" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="11.2" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="985" SD_1="8.1" SD_2="8.1" SE="0.37192464514077994" STUDY_ID="STD-Basterzi-2009" TOTAL_1="15" TOTAL_2="14" WEIGHT="1.6058117597484436"/>
<CONT_DATA CI_END="1.0655563349251918" CI_START="0.08677499989443999" EFFECT_SIZE="0.5761656674098159" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="11.0" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4894" SD_1="11.6" SD_2="10.3" SE="0.24969370425968387" STUDY_ID="STD-Clerc-1994" TOTAL_1="34" TOTAL_2="33" WEIGHT="3.3329913645566718"/>
<CONT_DATA CI_END="0.24277733089960146" CI_START="-0.15852704025946152" EFFECT_SIZE="0.04212514532006998" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="9.8" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4895" SD_1="9.7" SD_2="9.26" SE="0.10237544524401995" STUDY_ID="STD-Costa-e-Silva-1998" TOTAL_1="186" TOTAL_2="196" WEIGHT="12.540113371246736"/>
<CONT_DATA CI_END="0.916444927410111" CI_START="0.08902998187373862" EFFECT_SIZE="0.5027374546419248" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="8.6" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4896" SD_1="8.6" SD_2="7.6" SE="0.21107911983661837" STUDY_ID="STD-De-Nayer-2002" TOTAL_1="44" TOTAL_2="49" WEIGHT="4.455095374683001"/>
<CONT_DATA CI_END="0.3214554849980963" CI_START="-0.4261782855026276" EFFECT_SIZE="-0.05236140025226563" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="8.7" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4897" SD_1="9.7" SD_2="9.26" SE="0.19072640528039383" STUDY_ID="STD-Diaz-Martinez-1998" TOTAL_1="55" TOTAL_2="55" WEIGHT="5.270672377674463"/>
<CONT_DATA CI_END="0.3925502525200948" CI_START="-0.05083851922516841" EFFECT_SIZE="0.1708558666474632" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="10.79" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4898" SD_1="8.9" SD_2="9.9" SE="0.11311145899686352" STUDY_ID="STD-Dierick-1996" TOTAL_1="161" TOTAL_2="153" WEIGHT="11.164466183921007"/>
<CONT_DATA CI_END="0.10140249834798032" CI_START="-0.17689834350314815" EFFECT_SIZE="-0.03774792257758391" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.2" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="933" SD_1="6.52" SD_2="8.37" SE="0.07099641729295282" STUDY_ID="STD-Keller-2007" TOTAL_1="266" TOTAL_2="781" WEIGHT="17.65591160289548"/>
<CONT_DATA CI_END="0.4577902106707761" CI_START="-0.10094838990326613" EFFECT_SIZE="0.178420910383755" ESTIMABLE="YES" MEAN_1="14.2" MEAN_2="12.5" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4899" SD_1="9.7" SD_2="9.26" SE="0.14253797645806274" STUDY_ID="STD-Rudolph-1999" TOTAL_1="103" TOTAL_2="95" WEIGHT="8.229023181664878"/>
<CONT_DATA CI_END="0.5524664951467446" CI_START="-0.019372229729687884" EFFECT_SIZE="0.26654713270852837" ESTIMABLE="YES" MEAN_1="18.09" MEAN_2="15.59" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="958" SD_1="8.89" SD_2="9.81" SE="0.14587990631129535" STUDY_ID="STD-Sheehan-2009" TOTAL_1="99" TOTAL_2="91" WEIGHT="7.960840684274661"/>
<CONT_DATA CI_END="0.32622055904562514" CI_START="-0.17900190625194984" EFFECT_SIZE="0.07360932639683765" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="11.3" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4900" SD_1="9.7" SD_2="9.26" SE="0.12888565026773585" STUDY_ID="STD-Silverstone-1999" TOTAL_1="119" TOTAL_2="122" WEIGHT="9.453332719002132"/>
<CONT_DATA CI_END="0.12039846557402129" CI_START="-0.37695513359842714" EFFECT_SIZE="-0.12827833401220293" ESTIMABLE="YES" MEAN_1="7.77" MEAN_2="8.99" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4901" SD_1="9.7" SD_2="9.26" SE="0.1268782495738468" STUDY_ID="STD-Tylee-1997" TOTAL_1="124" TOTAL_2="125" WEIGHT="9.652305194003414"/>
<CONT_DATA CI_END="0.42791288402565464" CI_START="-0.32317425323156457" EFFECT_SIZE="0.05236931539704501" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="12.5" MODIFIED="2012-05-28 12:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4902" SD_1="9.7" SD_2="9.26" SE="0.19160738237582392" STUDY_ID="STD-Tzanakaki-2000" TOTAL_1="54" TOTAL_2="55" WEIGHT="5.231228400554245"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="14.834980451250306" CI_END="1.0568420734499913" CI_START="0.7741405603710065" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9045133028121989" ESTIMABLE="YES" EVENTS_1="424" EVENTS_2="604" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.024010094446976684" LOG_CI_START="-0.11118017749379142" LOG_EFFECT_SIZE="-0.043585041523407385" METHOD="MH" MODIFIED="2013-05-06 15:44:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6732652193259615" P_Q="0.8796165541728647" P_Z="0.20631045689036598" Q="0.25653841333007515" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1661" TOTAL_2="2114" WEIGHT="300.0" Z="1.2637760161913005">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>SRNIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SNRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.311630120909372" CI_END="1.521682251251241" CI_START="0.5331334275826399" DF="1" EFFECT_SIZE="0.9006995471860979" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="124" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.18232397507908282" LOG_CI_START="-0.2731640862622207" LOG_EFFECT_SIZE="-0.045420055591569" MODIFIED="2012-08-02 17:47:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5766817069495072" P_Z="0.6958824125742071" STUDIES="2" TAU2="0.0" TOTAL_1="90" TOTAL_2="442" WEIGHT="100.00000000000001" Z="0.3908847703851325">
<NAME>Fluoxetine vs Duloxetine</NAME>
<DICH_DATA CI_END="2.5987821193180474" CI_START="0.46158024420129035" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="0.4147698699802714" LOG_CI_START="-0.33575278741292414" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2012-05-28 12:06:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4908" O_E="0.0" SE="0.4408607240998343" STUDY_ID="STD-Goldstein-2002" TOTAL_1="33" TOTAL_2="70" VAR="0.1943581780538302" WEIGHT="36.83209154411953"/>
<DICH_DATA CI_END="1.5545635672931744" CI_START="0.41544226208980783" EFFECT_SIZE="0.8036363636363636" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="100" LOG_CI_END="0.19160848537580974" LOG_CI_START="-0.3814893256661137" LOG_EFFECT_SIZE="-0.09494042014515197" MODIFIED="2012-08-02 17:47:45 +0100" MODIFIED_BY="[Empty name]" ORDER="2928" O_E="0.0" SE="0.3366404910859431" STUDY_ID="STD-Martinez-2012" TOTAL_1="57" TOTAL_2="372" VAR="0.11332682023858495" WEIGHT="63.167908455880486"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.909213272610109" CI_END="1.4178904870246662" CI_START="0.6835402882448773" DF="2" EFFECT_SIZE="0.9844720779181652" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="138" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.15164268873311526" LOG_CI_START="-0.16523588278337864" LOG_EFFECT_SIZE="-0.006796597025131698" MODIFIED="2012-08-01 16:31:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.634697616073106" P_Z="0.9329952836998078" STUDIES="3" TAU2="0.0" TOTAL_1="224" TOTAL_2="336" WEIGHT="99.99999999999999" Z="0.08407690884832712">
<NAME>Fluoxetine vs Milnacipran</NAME>
<DICH_DATA CI_END="1.5478133278199624" CI_START="0.3852225208738038" EFFECT_SIZE="0.7721739130434783" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.18971858193716057" LOG_CI_START="-0.4142883310871818" LOG_EFFECT_SIZE="-0.11228487457501066" MODIFIED="2012-05-28 13:21:07 +0100" MODIFIED_BY="[Empty name]" ORDER="4912" O_E="0.0" SE="0.3547966505929384" STUDY_ID="STD-Ansseau-1994" TOTAL_1="93" TOTAL_2="97" VAR="0.12588066327196762" WEIGHT="27.52339004133784"/>
<DICH_DATA CI_END="1.6488858816351921" CI_START="0.6312214651217188" EFFECT_SIZE="1.02020202020202" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="99" LOG_CI_END="0.21719059943401395" LOG_CI_START="-0.19981824106382873" LOG_EFFECT_SIZE="0.00868617918509262" MODIFIED="2012-05-28 13:21:07 +0100" MODIFIED_BY="[Empty name]" ORDER="4913" O_E="0.0" SE="0.24495305713548465" STUDY_ID="STD-Guelfi-1998" TOTAL_1="100" TOTAL_2="200" VAR="0.06000200020002001" WEIGHT="57.74245162406304"/>
<DICH_DATA CI_END="3.4861141727324267" CI_START="0.5209747237683088" EFFECT_SIZE="1.34765625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.5423416064617834" LOG_CI_START="-0.2831833469389344" LOG_EFFECT_SIZE="0.12957912976142455" MODIFIED="2012-05-28 13:21:07 +0100" MODIFIED_BY="[Empty name]" ORDER="941" O_E="0.0" SE="0.4849174440420058" STUDY_ID="STD-Lee-2005" TOTAL_1="31" TOTAL_2="39" VAR="0.23514492753623187" WEIGHT="14.734158334599115"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.353071069606614" CI_END="1.0631201446774772" CI_START="0.7384865473705118" DF="13" EFFECT_SIZE="0.8860586465256739" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="342" I2="2.6441188530049162" ID="CMP-004.03.03" LOG_CI_END="0.026582347516696303" LOG_CI_START="-0.13165741159911026" LOG_EFFECT_SIZE="-0.05253753204120697" MODIFIED="2012-08-01 16:31:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.42092428209615484" P_Z="0.19309969784795164" STUDIES="14" TAU2="0.003236687266547734" TOTAL_1="1347" TOTAL_2="1336" WEIGHT="99.99999999999999" Z="1.3014639457587374">
<NAME>Fluoxetine vs Venlafaxine</NAME>
<DICH_DATA CI_END="1.9701518917517862" CI_START="0.25624808297418683" EFFECT_SIZE="0.7105263157894737" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.29449971002287156" LOG_CI_START="-0.5913393749385173" LOG_EFFECT_SIZE="-0.14841983245782286" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4935" O_E="0.0" SE="0.5203462634805103" STUDY_ID="STD-Alves-1999" TOTAL_1="47" TOTAL_2="40" VAR="0.27076023391812865" WEIGHT="3.1532670123038327"/>
<DICH_DATA CI_END="3.343293883515944" CI_START="0.26055475272637874" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5241745537925548" LOG_CI_START="-0.5841010005474412" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="986" O_E="0.0" SE="0.6510065466717856" STUDY_ID="STD-Basterzi-2009" TOTAL_1="22" TOTAL_2="21" VAR="0.42380952380952375" WEIGHT="2.0231661835082946"/>
<DICH_DATA CI_END="7.863367958413255" CI_START="0.8239902898150359" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.8956085985162557" LOG_CI_START="-0.08407790614826752" LOG_EFFECT_SIZE="0.4057653461839942" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4936" O_E="0.0" SE="0.5754727023663513" STUDY_ID="STD-Clerc-1994" TOTAL_1="34" TOTAL_2="34" VAR="0.3311688311688311" WEIGHT="2.5836459191429624"/>
<DICH_DATA CI_END="1.1537329827225835" CI_START="0.3299575611578648" EFFECT_SIZE="0.6169950738916257" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" LOG_CI_END="0.0621053083445359" LOG_CI_START="-0.481541915092395" LOG_EFFECT_SIZE="-0.20971830337392955" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4937" O_E="0.0" SE="0.3193410701440107" STUDY_ID="STD-Costa-e-Silva-1998" TOTAL_1="186" TOTAL_2="196" VAR="0.10197871908072197" WEIGHT="8.211586905750456"/>
<DICH_DATA CI_END="1.5658669810597876" CI_START="0.3790731833690584" EFFECT_SIZE="0.7704402515723271" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.19475486637749204" LOG_CI_START="-0.42127693761729235" LOG_EFFECT_SIZE="-0.11326103561990018" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4938" O_E="0.0" SE="0.36186013107314635" STUDY_ID="STD-De-Nayer-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.13094275446027467" WEIGHT="6.439030017753777"/>
<DICH_DATA CI_END="2.870258525861611" CI_START="0.6193789729251353" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.457921015653357" LOG_CI_START="-0.20804354243675716" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4939" O_E="0.0" SE="0.39119087799986213" STUDY_ID="STD-Diaz-Martinez-1998" TOTAL_1="75" TOTAL_2="70" VAR="0.15303030303030302" WEIGHT="5.528905697890472"/>
<DICH_DATA CI_END="1.6695711044399562" CI_START="0.5994773927222538" EFFECT_SIZE="1.0004349717268377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.22260491971164212" LOG_CI_START="-0.2222271902150145" LOG_EFFECT_SIZE="1.888647483138149E-4" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4940" O_E="0.0" SE="0.2612965833253749" STUDY_ID="STD-Dierick-1996" TOTAL_1="161" TOTAL_2="153" VAR="0.06827590445751461" WEIGHT="12.081584965878703"/>
<DICH_DATA CI_END="1.3476209102994117" CI_START="0.3433579351705446" EFFECT_SIZE="0.6802325581395349" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.12956774107221325" LOG_CI_START="-0.4642529113949878" LOG_EFFECT_SIZE="-0.16734258516138728" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="951" O_E="0.0" SE="0.3488131907188706" STUDY_ID="STD-Nemeroff-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.1216706420194792" WEIGHT="6.917011659628088"/>
<DICH_DATA CI_END="3.228491168404628" CI_START="0.8645612959708808" EFFECT_SIZE="1.670697012802276" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.5089996027231554" LOG_CI_START="-0.06320421053555396" LOG_EFFECT_SIZE="0.2228976960938007" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4941" O_E="0.0" SE="0.3361153523627227" STUDY_ID="STD-Rudolph-1999" TOTAL_1="103" TOTAL_2="100" VAR="0.11297353009391727" WEIGHT="7.434677196795118"/>
<DICH_DATA CI_END="1.4579269243356079" CI_START="0.44949358383279814" EFFECT_SIZE="0.8095238095238095" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" LOG_CI_END="0.1637357563871998" LOG_CI_START="-0.34727650309849045" LOG_EFFECT_SIZE="-0.09177037335564533" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="954" O_E="0.0" SE="0.300171130773375" STUDY_ID="STD-Schatzberg-2006" TOTAL_1="100" TOTAL_2="104" VAR="0.09010270774976657" WEIGHT="9.256385826085992"/>
<DICH_DATA CI_END="1.3760206271612803" CI_START="0.3810983653707712" EFFECT_SIZE="0.7241541353383458" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.13862494421575475" LOG_CI_START="-0.4189629140249373" LOG_EFFECT_SIZE="-0.1401689849045913" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="959" O_E="0.0" SE="0.32752986803499523" STUDY_ID="STD-Sheehan-2009" TOTAL_1="99" TOTAL_2="95" VAR="0.10727581445502139" WEIGHT="7.8179883686030625"/>
<DICH_DATA CI_END="1.0123614053140904" CI_START="0.3402927389021698" EFFECT_SIZE="0.586940572267058" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="47" LOG_CI_END="0.0053355800079279885" LOG_CI_START="-0.46814731769338797" LOG_EFFECT_SIZE="-0.23140586884272996" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4942" O_E="0.0" SE="0.27812619788789655" STUDY_ID="STD-Silverstone-1999" TOTAL_1="119" TOTAL_2="122" VAR="0.07735418195157741" WEIGHT="10.720636983155162"/>
<DICH_DATA CI_END="1.576411506880548" CI_START="0.6076455911772949" EFFECT_SIZE="0.9787234042553191" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.19766959630044625" LOG_CI_START="-0.21634964880873306" LOG_EFFECT_SIZE="-0.009340026254143404" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4943" O_E="0.0" SE="0.24319695400544797" STUDY_ID="STD-Tylee-1997" TOTAL_1="170" TOTAL_2="171" VAR="0.05914475843752797" WEIGHT="13.850038954579801"/>
<DICH_DATA CI_END="2.5336084707213598" CI_START="0.41371267627024" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.40373950236156414" LOG_CI_START="-0.3833011719981921" LOG_EFFECT_SIZE="0.010219165181686028" MODIFIED="2012-05-28 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="4944" O_E="0.0" SE="0.4623115880330914" STUDY_ID="STD-Tzanakaki-2000" TOTAL_1="54" TOTAL_2="55" VAR="0.21373200442967882" WEIGHT="3.9820743089242647"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.356358578345816" CI_END="1.8494478889759982" CI_START="1.0042136790017133" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3628062476781282" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.2670420989122908" LOG_CI_START="0.001826132866351232" LOG_EFFECT_SIZE="0.13443411588932105" METHOD="MH" MODIFIED="2013-05-06 15:44:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7191061462953496" P_Q="0.3752303605352918" P_Z="0.04692744189190241" Q="1.96043078879139" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1639" TOTAL_2="1993" WEIGHT="300.0" Z="1.9869544761186293">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>SRNIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SNRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.001019255817874903" CI_END="12.10727189935988" CI_START="0.9150762692917713" DF="1" EFFECT_SIZE="3.328524778481803" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="1.083046295700614" LOG_CI_START="-0.038542707078749947" LOG_EFFECT_SIZE="0.5222517943109319" MODIFIED="2012-08-02 17:48:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9745312365504234" P_Z="0.06796208946251511" STUDIES="2" TAU2="0.0" TOTAL_1="90" TOTAL_2="342" WEIGHT="100.0" Z="1.8252581028778259">
<NAME>Fluoxetine vs Duloxetine</NAME>
<DICH_DATA CI_END="21.40913967121033" CI_START="0.5399563073309837" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.3305992154703759" LOG_CI_START="-0.2676413813858655" LOG_EFFECT_SIZE="0.5314789170422551" MODIFIED="2012-05-28 12:06:31 +0100" MODIFIED_BY="[Empty name]" ORDER="4949" O_E="0.0" SE="0.9388144380119043" STUDY_ID="STD-Goldstein-2002" TOTAL_1="33" TOTAL_2="70" VAR="0.8813725490196078" WEIGHT="49.24738432785063"/>
<DICH_DATA CI_END="19.974651108218982" CI_START="0.532252194286708" EFFECT_SIZE="3.2606060606060607" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="1.3004792023490546" LOG_CI_START="-0.27388253944408864" LOG_EFFECT_SIZE="0.5132983314524829" MODIFIED="2012-08-02 17:48:30 +0100" MODIFIED_BY="[Empty name]" ORDER="2929" O_E="0.0" SE="0.9247878803456016" STUDY_ID="STD-Martinez-2012" TOTAL_1="57" TOTAL_2="272" VAR="0.8552326236341107" WEIGHT="50.752615672149375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3146822143930086" CI_END="2.301171880551673" CI_START="0.6810537423135699" DF="2" EFFECT_SIZE="1.2518872636769143" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="46" I2="13.595050432248186" ID="CMP-004.04.02" LOG_CI_END="0.36194905847189723" LOG_CI_START="-0.16681861632610126" LOG_EFFECT_SIZE="0.09756522107289797" MODIFIED="2012-08-01 16:31:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.31432085959201606" P_Z="0.4695060766248257" STUDIES="3" TAU2="0.05329235256599554" TOTAL_1="224" TOTAL_2="336" WEIGHT="100.00000000000001" Z="0.7232829409234235">
<NAME>Fluoxetine vs Milnacipran</NAME>
<DICH_DATA CI_END="2.0431374593000764" CI_START="0.1634298273471374" EFFECT_SIZE="0.5778491171749599" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3102975863129535" LOG_CI_START="-0.7866686780967183" LOG_EFFECT_SIZE="-0.23818554589188232" MODIFIED="2012-05-28 13:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4952" O_E="0.0" SE="0.6443634137848251" STUDY_ID="STD-Ansseau-1994" TOTAL_1="93" TOTAL_2="97" VAR="0.4152042090244338" WEIGHT="20.592002924440422"/>
<DICH_DATA CI_END="2.4881206023118234" CI_START="0.777849599094024" EFFECT_SIZE="1.391180654338549" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="37" LOG_CI_END="0.3958714273246982" LOG_CI_START="-0.10910436778914334" LOG_EFFECT_SIZE="0.14338352976777746" MODIFIED="2012-05-28 13:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4953" O_E="0.0" SE="0.29662528172037056" STUDY_ID="STD-Guelfi-1998" TOTAL_1="100" TOTAL_2="200" VAR="0.08798655775568918" WEIGHT="68.28536930525613"/>
<DICH_DATA CI_END="16.064558487439612" CI_START="0.4675920482862473" EFFECT_SIZE="2.740740740740741" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.2058687940578705" LOG_CI_START="-0.3301328829138927" LOG_EFFECT_SIZE="0.43786795557198893" MODIFIED="2012-05-28 13:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="942" O_E="0.0" SE="0.9022549883841396" STUDY_ID="STD-Lee-2005" TOTAL_1="31" TOTAL_2="39" VAR="0.814064064064064" WEIGHT="11.122627770303467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.095018077311554" CI_END="1.8874093697898182" CI_START="0.9060712909692406" DF="11" EFFECT_SIZE="1.3077184116899558" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="57" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.2758661067143831" LOG_CI_START="-0.042837630075416126" LOG_EFFECT_SIZE="0.11651423831948342" MODIFIED="2012-08-01 16:31:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7047679345902398" P_Z="0.15183545107462995" STUDIES="13" TAU2="0.0" TOTAL_1="1325" TOTAL_2="1315" WEIGHT="99.99999999999997" Z="1.4330783384753434">
<NAME>Fluoxetine vs Venlafaxine</NAME>
<DICH_DATA CI_END="95.46603060956487" CI_START="0.20748103053319458" EFFECT_SIZE="4.450549450549451" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9798488653720594" LOG_CI_START="-0.6830216035849094" LOG_EFFECT_SIZE="0.648413630893575" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4973" O_E="0.0" SE="1.564183294886732" STUDY_ID="STD-Alves-1999" TOTAL_1="47" TOTAL_2="40" VAR="2.4466693800027133" WEIGHT="1.4324327057050972"/>
<DICH_DATA CI_END="9.69912778796005" CI_START="0.5055156846759127" EFFECT_SIZE="2.2142857142857144" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9867326812860907" LOG_CI_START="-0.2962653649740215" LOG_EFFECT_SIZE="0.3452336581560347" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4974" O_E="0.0" SE="0.7536394033159457" STUDY_ID="STD-Clerc-1994" TOTAL_1="34" TOTAL_2="34" VAR="0.5679723502304147" WEIGHT="6.1705279113346245"/>
<DICH_DATA CI_END="2.1669517075713296" CI_START="0.0795612940700077" EFFECT_SIZE="0.4152173913043478" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3358492327923653" LOG_CI_START="-1.0992981616600583" LOG_EFFECT_SIZE="-0.38172446443384656" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4975" O_E="0.0" SE="0.8430126835955296" STUDY_ID="STD-Costa-e-Silva-1998" TOTAL_1="186" TOTAL_2="196" VAR="0.7106703847029365" WEIGHT="4.9315256628121285"/>
<DICH_DATA CI_END="6.662007567568773" CI_START="0.699506245068976" EFFECT_SIZE="2.1587301587301586" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.8236051216832115" LOG_CI_START="-0.1552084038499401" LOG_EFFECT_SIZE="0.3341983589166358" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4976" O_E="0.0" SE="0.5749599101032672" STUDY_ID="STD-De-Nayer-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.33057889822595704" WEIGHT="10.601672577320942"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4977" O_E="0.0" SE="0.0" STUDY_ID="STD-Diaz-Martinez-1998" TOTAL_1="75" TOTAL_2="70" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.631192954046894" CI_START="0.6394580222636719" EFFECT_SIZE="1.5238095238095237" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5600493270322364" LOG_CI_START="-0.1941879598602631" LOG_EFFECT_SIZE="0.1829306835859867" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4978" O_E="0.0" SE="0.443042715855438" STUDY_ID="STD-Dierick-1996" TOTAL_1="161" TOTAL_2="153" VAR="0.19628684807256233" WEIGHT="17.854936662223558"/>
<DICH_DATA CI_END="4.028623439589861" CI_START="0.2383940853250297" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6051566752436662" LOG_CI_START="-0.6227045238586765" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="952" O_E="0.0" SE="0.7212517463636765" STUDY_ID="STD-Nemeroff-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.5202040816326531" WEIGHT="6.73714290930529"/>
<DICH_DATA CI_END="9.386611062183395" CI_START="0.5921691112562509" EFFECT_SIZE="2.357638888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9725088230808333" LOG_CI_START="-0.22755425003829166" LOG_EFFECT_SIZE="0.3724772865212708" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4979" O_E="0.0" SE="0.7049229895581915" STUDY_ID="STD-Rudolph-1999" TOTAL_1="103" TOTAL_2="100" VAR="0.4969164212076583" WEIGHT="7.052874669437641"/>
<DICH_DATA CI_END="16.526155045793853" CI_START="0.6412322002344779" EFFECT_SIZE="3.25531914893617" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.2181718229222316" LOG_CI_START="-0.1929846771584688" LOG_EFFECT_SIZE="0.5125935728818813" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="955" O_E="0.0" SE="0.8289203134847368" STUDY_ID="STD-Schatzberg-2006" TOTAL_1="100" TOTAL_2="104" VAR="0.6871088861076344" WEIGHT="5.100631516813327"/>
<DICH_DATA CI_END="2.7707688062579585" CI_START="0.41603664039901583" EFFECT_SIZE="1.0736579275905118" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.44260028963814574" LOG_CI_START="-0.3808684193194857" LOG_EFFECT_SIZE="0.030865935159330046" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="960" O_E="0.0" SE="0.48370959587756274" STUDY_ID="STD-Sheehan-2009" TOTAL_1="99" TOTAL_2="95" VAR="0.23397497314403506" WEIGHT="14.978906473922796"/>
<DICH_DATA CI_END="3.2774413711826753" CI_START="0.32153196893572866" EFFECT_SIZE="1.0265486725663717" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5155349315140412" LOG_CI_START="-0.4927758400270436" LOG_EFFECT_SIZE="0.011379545743498773" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4980" O_E="0.0" SE="0.5922867384220497" STUDY_ID="STD-Silverstone-1999" TOTAL_1="119" TOTAL_2="122" VAR="0.3508035805106296" WEIGHT="9.990460287952803"/>
<DICH_DATA CI_END="1.9651010081157414" CI_START="0.16218494736157543" EFFECT_SIZE="0.5645438898450946" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.29338487844674543" LOG_CI_START="-0.7899894558040488" LOG_EFFECT_SIZE="-0.24830228867865167" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4981" O_E="0.0" SE="0.636379446728361" STUDY_ID="STD-Tylee-1997" TOTAL_1="170" TOTAL_2="171" VAR="0.4049788002182948" WEIGHT="8.65400667411226"/>
<DICH_DATA CI_END="4.304035453194155" CI_START="0.24172663336866515" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6338758400428989" LOG_CI_START="-0.6166754965190637" LOG_EFFECT_SIZE="0.00860017176191757" MODIFIED="2012-05-28 12:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4982" O_E="0.0" SE="0.7345800454254492" STUDY_ID="STD-Tzanakaki-2000" TOTAL_1="54" TOTAL_2="55" VAR="0.539607843137255" WEIGHT="6.494881949059522"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.839153907204643" CI_END="1.0013483141058879" CI_START="0.6221771226635305" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7893136340228633" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="206" I2="0.0" I2_Q="69.30248790621806" ID="CMP-004.05" LOG_CI_END="5.851709675157854E-4" LOG_CI_START="-0.20608596186063324" LOG_EFFECT_SIZE="-0.10275039544655871" METHOD="MH" MODIFIED="2013-05-06 15:44:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.46531420778336396" P_Q="0.038480979863736886" P_Z="0.051311542070892564" Q="6.515185966504165" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1639" TOTAL_2="2093" WEIGHT="300.0" Z="1.9488650564465684">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>SRNIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SNRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.51005178958731E-5" CI_END="1.229431347827321" CI_START="0.06502571164143363" DF="1" EFFECT_SIZE="0.2827448466493394" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="29" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.08970428249140902" LOG_CI_START="-1.186914886186968" LOG_EFFECT_SIZE="-0.5486053018477796" MODIFIED="2012-08-02 17:49:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9946416933838156" P_Z="0.09208080244302431" STUDIES="2" TAU2="0.0" TOTAL_1="90" TOTAL_2="442" WEIGHT="100.0" Z="1.6845221499572574">
<NAME>Fluoxetine vs Duloxetine</NAME>
<DICH_DATA CI_END="2.3858110664902514" CI_START="0.03315499857093281" EFFECT_SIZE="0.28125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.3776360487100381" LOG_CI_START="-1.4794509864712004" LOG_EFFECT_SIZE="-0.5509074688805811" MODIFIED="2012-05-28 12:06:46 +0100" MODIFIED_BY="[Empty name]" ORDER="4988" O_E="0.0" SE="1.090862117194542" STUDY_ID="STD-Goldstein-2002" TOTAL_1="33" TOTAL_2="70" VAR="1.1899801587301586" WEIGHT="47.25613582889154"/>
<DICH_DATA CI_END="2.1496578207756105" CI_START="0.037544414672926574" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="22" LOG_CI_END="0.33236933508963895" LOG_CI_START="-1.425454662045901" LOG_EFFECT_SIZE="-0.546542663478131" MODIFIED="2012-08-02 17:49:06 +0100" MODIFIED_BY="[Empty name]" ORDER="2930" O_E="0.0" SE="1.0325545172865358" STUDY_ID="STD-Martinez-2012" TOTAL_1="57" TOTAL_2="372" VAR="1.066168831168831" WEIGHT="52.743864171108456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.21310351763878402" CI_END="2.7640124958401735" CI_START="0.8136950803857592" DF="2" EFFECT_SIZE="1.4996877574981775" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.44154000211104893" LOG_CI_START="-0.08953830974824367" LOG_EFFECT_SIZE="0.1760008461814026" MODIFIED="2012-08-01 16:31:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8989285213334821" P_Z="0.19391813902132318" STUDIES="3" TAU2="0.0" TOTAL_1="224" TOTAL_2="336" WEIGHT="99.99999999999999" Z="1.299075153554822">
<NAME>Fluoxetine vs Milnacipran</NAME>
<DICH_DATA CI_END="3.819893362429215" CI_START="0.3989589592308473" EFFECT_SIZE="1.2344961240310077" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5820512391538599" LOG_CI_START="-0.39907177773758173" LOG_EFFECT_SIZE="0.09148973070813907" MODIFIED="2012-05-28 14:40:24 +0100" MODIFIED_BY="[Empty name]" ORDER="4992" O_E="0.0" SE="0.5763165167592932" STUDY_ID="STD-Ansseau-1994" TOTAL_1="93" TOTAL_2="97" VAR="0.3321407274895647" WEIGHT="29.30017428431831"/>
<DICH_DATA CI_END="3.4567327168059188" CI_START="0.7114215695416484" EFFECT_SIZE="1.5681818181818181" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.5386658001082263" LOG_CI_START="-0.14787297160609053" LOG_EFFECT_SIZE="0.19539641425106788" MODIFIED="2012-05-28 14:40:24 +0100" MODIFIED_BY="[Empty name]" ORDER="4993" O_E="0.0" SE="0.40327627292671875" STUDY_ID="STD-Guelfi-1998" TOTAL_1="100" TOTAL_2="200" VAR="0.16263175230566534" WEIGHT="59.83936755519733"/>
<DICH_DATA CI_END="12.673387448648722" CI_START="0.31001106231794084" EFFECT_SIZE="1.9821428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1028927122494792" LOG_CI_START="-0.5086228086885651" LOG_EFFECT_SIZE="0.297134951780457" MODIFIED="2012-05-28 14:40:24 +0100" MODIFIED_BY="[Empty name]" ORDER="943" O_E="0.0" SE="0.9466121941294894" STUDY_ID="STD-Lee-2005" TOTAL_1="31" TOTAL_2="39" VAR="0.896074646074646" WEIGHT="10.860458160484354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.116150891525427" CI_END="0.9420567834176926" CI_START="0.5574083761338466" DF="12" EFFECT_SIZE="0.7246449764337919" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="153" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="-0.02592291888257103" LOG_CI_START="-0.2538265094630853" LOG_EFFECT_SIZE="-0.13987471417282824" MODIFIED="2012-08-01 16:31:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6057715458882356" P_Z="0.016135478979623172" STUDIES="13" TAU2="0.0" TOTAL_1="1325" TOTAL_2="1315" WEIGHT="100.0" Z="2.4058366208997954">
<NAME>Fluoxetine vs Venlafaxine</NAME>
<DICH_DATA CI_END="5.460451156287437" CI_START="0.24105463332335147" EFFECT_SIZE="1.1472868217054264" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7372285266958686" LOG_CI_START="-0.6178845165044518" LOG_EFFECT_SIZE="0.05967200509570844" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5015" O_E="0.0" SE="0.796000109493616" STUDY_ID="STD-Alves-1999" TOTAL_1="47" TOTAL_2="40" VAR="0.6336161743138486" WEIGHT="2.828468093236028"/>
<DICH_DATA CI_END="51.56679577569641" CI_START="0.6277717180991133" EFFECT_SIZE="5.689655172413793" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.7123701463346306" LOG_CI_START="-0.2021982537047301" LOG_EFFECT_SIZE="0.7550859463149502" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5016" O_E="0.0" SE="1.124626955449548" STUDY_ID="STD-Clerc-1994" TOTAL_1="34" TOTAL_2="34" VAR="1.26478578892372" WEIGHT="1.4169696940776466"/>
<DICH_DATA CI_END="1.2890735318052502" CI_START="0.20049291558535326" EFFECT_SIZE="0.5083798882681564" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.11027769124513205" LOG_CI_START="-0.6979009685627312" LOG_EFFECT_SIZE="-0.2938116386587996" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5017" O_E="0.0" SE="0.47472814532002494" STUDY_ID="STD-Costa-e-Silva-1998" TOTAL_1="186" TOTAL_2="196" VAR="0.22536681195899072" WEIGHT="7.952205193065927"/>
<DICH_DATA CI_END="3.1464334925214414" CI_START="0.4149093806786127" EFFECT_SIZE="1.142578125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.497818556316714" LOG_CI_START="-0.3820467461040146" LOG_EFFECT_SIZE="0.057885905106349694" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5018" O_E="0.0" SE="0.516837234045426" STUDY_ID="STD-De-Nayer-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.2671207264957265" WEIGHT="6.709187848939419"/>
<DICH_DATA CI_END="2.0503823208553555" CI_START="0.22149956403285384" EFFECT_SIZE="0.6739130434782609" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.31183484854681537" LOG_CI_START="-0.6546271242414182" LOG_EFFECT_SIZE="-0.1713961378473014" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5019" O_E="0.0" SE="0.56770454687973" STUDY_ID="STD-Diaz-Martinez-1998" TOTAL_1="75" TOTAL_2="70" VAR="0.3222884525479196" WEIGHT="5.560742614998064"/>
<DICH_DATA CI_END="1.1504919872489947" CI_START="0.1770290623934742" EFFECT_SIZE="0.4512987012987013" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.06088359831481907" LOG_CI_START="-0.7519554308075175" LOG_EFFECT_SIZE="-0.34553591624634916" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5020" O_E="0.0" SE="0.47746566932454665" STUDY_ID="STD-Dierick-1996" TOTAL_1="161" TOTAL_2="153" VAR="0.22797346538353733" WEIGHT="7.861279510709301"/>
<DICH_DATA CI_END="1.435323594104998" CI_START="0.20409168645099773" EFFECT_SIZE="0.5412371134020618" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.15694982392098242" LOG_CI_START="-0.6901746856415584" LOG_EFFECT_SIZE="-0.266612430860288" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="953" O_E="0.0" SE="0.497605130250988" STUDY_ID="STD-Nemeroff-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.24761086565210275" WEIGHT="7.237821036993652"/>
<DICH_DATA CI_END="4.3810496842547" CI_START="0.5135755497332982" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6415781784179153" LOG_CI_START="-0.2893956603065528" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5021" O_E="0.0" SE="0.5468586412615775" STUDY_ID="STD-Rudolph-1999" TOTAL_1="103" TOTAL_2="100" VAR="0.2990543735224586" WEIGHT="5.992766838002485"/>
<DICH_DATA CI_END="1.300330268723501" CI_START="0.34414179066077705" EFFECT_SIZE="0.6689529035208047" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" LOG_CI_END="0.11405367205095404" LOG_CI_START="-0.4632625858756066" LOG_EFFECT_SIZE="-0.17460445691232626" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="956" O_E="0.0" SE="0.33911842766762784" STUDY_ID="STD-Schatzberg-2006" TOTAL_1="100" TOTAL_2="104" VAR="0.11500130798376412" WEIGHT="15.583849991149803"/>
<DICH_DATA CI_END="2.3784834535785997" CI_START="0.2878583436312675" EFFECT_SIZE="0.8274456521739131" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3763001345053404" LOG_CI_START="-0.5408211779145873" LOG_EFFECT_SIZE="-0.08226052170462347" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="961" O_E="0.0" SE="0.5387215987391794" STUDY_ID="STD-Sheehan-2009" TOTAL_1="99" TOTAL_2="95" VAR="0.29022096094809735" WEIGHT="6.1751677981850035"/>
<DICH_DATA CI_END="1.5156383972592575" CI_START="0.24093767129729285" EFFECT_SIZE="0.6042966042966043" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.1805955991805369" LOG_CI_START="-0.6180952915023908" LOG_EFFECT_SIZE="-0.21874984616092702" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5022" O_E="0.0" SE="0.46915498277082324" STUDY_ID="STD-Silverstone-1999" TOTAL_1="119" TOTAL_2="122" VAR="0.22010639785869143" WEIGHT="8.142258243468094"/>
<DICH_DATA CI_END="1.0868061381482572" CI_START="0.3496449215847271" EFFECT_SIZE="0.6164383561643836" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="36" LOG_CI_END="0.036152082594941536" LOG_CI_START="-0.4563727752851659" LOG_EFFECT_SIZE="-0.21011034634511222" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5023" O_E="0.0" SE="0.2893115395561418" STUDY_ID="STD-Tylee-1997" TOTAL_1="170" TOTAL_2="171" VAR="0.083701166920345" WEIGHT="21.411447394879538"/>
<DICH_DATA CI_END="7.797806219396762" CI_START="0.4011802899916304" EFFECT_SIZE="1.7687074829931972" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8919724384831074" LOG_CI_START="-0.3966604120378236" LOG_EFFECT_SIZE="0.24765601322264186" MODIFIED="2012-05-28 12:08:40 +0100" MODIFIED_BY="[Empty name]" ORDER="5024" O_E="0.0" SE="0.7569493152314815" STUDY_ID="STD-Tzanakaki-2000" TOTAL_1="54" TOTAL_2="55" VAR="0.5729722658294087" WEIGHT="3.1278357422950376"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-07-02 12:05:56 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Fluoxetine versus MAOIs or newer ADs</NAME>
<DICH_OUTCOME CHI2="22.664634908213564" CI_END="1.4253439905287664" CI_START="1.0127018875810614" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2014360364417258" ESTIMABLE="YES" EVENTS_1="591" EVENTS_2="538" I2="33.8175970592667" I2_Q="52.4139423333806" ID="CMP-005.01" LOG_CI_END="0.1539196890181066" LOG_CI_START="0.00548161946421916" LOG_EFFECT_SIZE="0.07970065424116284" METHOD="MH" MODIFIED="2013-05-06 15:44:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0915245766809728" P_Q="0.07779392696025966" P_Z="0.035315541815892804" Q="8.405823462038786" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.056817532629332736" TOTALS="SUB" TOTAL_1="1311" TOTAL_2="1286" WEIGHT="500.0" Z="2.1047216839511615">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0918768209519865" CI_START="0.9934202116055545" DF="0" EFFECT_SIZE="1.4415660630449363" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="71" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.32053610774980235" LOG_CI_START="-0.0028670083236140877" LOG_EFFECT_SIZE="0.15883454971309413" MODIFIED="2012-11-20 15:03:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.054202673639201046" STUDIES="1" TAU2="0.0" TOTAL_1="263" TOTAL_2="252" WEIGHT="100.0" Z="1.9252133419000836">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="2.0918768209519865" CI_START="0.9934202116055545" EFFECT_SIZE="1.4415660630449363" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="71" LOG_CI_END="0.32053610774980235" LOG_CI_START="-0.0028670083236140877" LOG_EFFECT_SIZE="0.15883454971309413" MODIFIED="2012-05-28 14:14:27 +0100" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="0.18996859125276788" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.036088065662561196" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.117087380282814" CI_END="2.041954549664885" CI_START="1.0417711031208654" DF="3" EFFECT_SIZE="1.4585092539051843" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="105" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.310046071223264" LOG_CI_START="0.01777230670657977" LOG_EFFECT_SIZE="0.16390918896492185" MODIFIED="2012-11-20 15:03:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5484636708841168" P_Z="0.027926078145720533" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="297" WEIGHT="100.0" Z="2.198323257906225">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="9.651397153685426" CI_START="0.6475746361358066" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.9845901871484379" LOG_CI_START="-0.18871016980436273" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2012-05-28 14:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="913" O_E="0.0" SE="0.689202437604511" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.475" WEIGHT="6.205278260332484"/>
<DICH_DATA CI_END="2.686130646529386" CI_START="0.6833576511299049" EFFECT_SIZE="1.3548387096774193" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" LOG_CI_END="0.42912713182001905" LOG_CI_START="-0.1653519386927636" LOG_EFFECT_SIZE="0.13188759656362775" MODIFIED="2012-05-28 14:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="4844" O_E="0.0" SE="0.34919994873806715" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="0.12194060419866871" WEIGHT="24.171662860188693"/>
<DICH_DATA CI_END="1.961224987441794" CI_START="0.7259929367062165" EFFECT_SIZE="1.1932457786116322" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.29252741783895664" LOG_CI_START="-0.1390676045952734" LOG_EFFECT_SIZE="0.07672990662184158" MODIFIED="2012-05-28 14:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="966" O_E="0.0" SE="0.25352105260768365" STUDY_ID="STD-Versiani-2005" TOTAL_1="152" TOTAL_2="147" VAR="0.06427292411530791" WEIGHT="45.859235661504954"/>
<DICH_DATA CI_END="4.012238548647704" CI_START="1.008853467184628" EFFECT_SIZE="2.011904761904762" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="27" LOG_CI_END="0.6033867462031934" LOG_CI_START="0.0038280909003902534" LOG_EFFECT_SIZE="0.30360741855179185" MODIFIED="2012-05-28 14:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="4845" O_E="0.0" SE="0.35218372198807546" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.12403337403337403" WEIGHT="23.76382321797386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.685326464754936" CI_END="1.7490697786122742" CI_START="0.9178991156331471" DF="6" EFFECT_SIZE="1.267071269885349" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="158" I2="10.251204161352168" ID="CMP-005.01.03" LOG_CI_END="0.24280713587190908" LOG_CI_START="-0.03720504857160352" LOG_EFFECT_SIZE="0.1028010436501528" MODIFIED="2012-11-20 15:03:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3509306241543585" P_Z="0.1501149569198283" STUDIES="7" TAU2="0.01972005880417767" TOTAL_1="359" TOTAL_2="362" WEIGHT="100.00000000000001" Z="1.4391255403964447">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="14.803512852064111" CI_START="1.1148641822335295" EFFECT_SIZE="4.0625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="1.1703647850733412" LOG_CI_START="0.04722196290052035" LOG_EFFECT_SIZE="0.6087933739869308" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4846" O_E="0.0" SE="0.6597396533909495" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" VAR="0.43525641025641026" WEIGHT="5.946208417191406"/>
<DICH_DATA CI_END="2.603556305658109" CI_START="0.39440070576268416" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.4155669743574751" LOG_CI_START="-0.40406231657929237" LOG_EFFECT_SIZE="0.0057523288890913415" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4847" O_E="0.0" SE="0.4814543027266815" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.2317982456140351" WEIGHT="10.756214805955858"/>
<DICH_DATA CI_END="3.3489025601908144" CI_START="0.3427866780358222" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.5249025114732565" LOG_CI_START="-0.4649760647183701" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4848" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="0.3380952380952381" WEIGHT="7.560841957834448"/>
<DICH_DATA CI_END="1.759140719638204" CI_START="0.43900304693266895" EFFECT_SIZE="0.8787878787878788" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" LOG_CI_END="0.24530058153702555" LOG_CI_START="-0.3575324654948884" LOG_EFFECT_SIZE="-0.05611594197893139" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4849" O_E="0.0" SE="0.3541071158982555" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="0.12539184952978055" WEIGHT="18.643438302292626"/>
<DICH_DATA CI_END="2.645919515276093" CI_START="0.8596850119748752" EFFECT_SIZE="1.5081967213114753" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" LOG_CI_END="0.42257662949506153" LOG_CI_START="-0.0656606448254851" LOG_EFFECT_SIZE="0.1784579923347882" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4850" O_E="0.0" SE="0.28679299174937484" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.08225022011655697" WEIGHT="26.53111218863186"/>
<DICH_DATA CI_END="1.832205108698046" CI_START="0.3653638364096653" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.26297408974100756" LOG_CI_START="-0.4372744411788078" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4851" O_E="0.0" SE="0.41132945334843113" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="0.1691919191919192" WEIGHT="14.320875460887871"/>
<DICH_DATA CI_END="3.7003764921985014" CI_START="0.8238693723674019" EFFECT_SIZE="1.746031746031746" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.5682459133010433" LOG_CI_START="-0.0841416418917567" LOG_EFFECT_SIZE="0.24205213570464335" MODIFIED="2012-05-28 13:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="4852" O_E="0.0" SE="0.3832156792907316" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.14685425685425685" WEIGHT="16.241308867205937"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.341739229291792" CI_START="0.2733609001579917" DF="0" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2012-11-20 15:03:41 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6781944478191994" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.4149282252652017">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="7.341739229291792" CI_START="0.2733609001579917" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2012-05-28 13:36:14 +0100" MODIFIED_BY="[Empty name]" ORDER="4853" O_E="0.0" SE="0.8394384210560641" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.704656862745098" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7311268074899138" CI_END="1.0984274137731926" CI_START="0.546401332749874" DF="2" EFFECT_SIZE="0.7747142717251759" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="201" I2="26.770152359269897" ID="CMP-005.01.05" LOG_CI_END="0.04077136317795041" LOG_CI_START="-0.2624882500197703" LOG_EFFECT_SIZE="-0.11085844342090996" MODIFIED="2012-11-20 15:03:40 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2552370559818148" P_Z="0.15187094853730868" STUDIES="3" TAU2="0.025703482416435965" TOTAL_1="366" TOTAL_2="355" WEIGHT="100.0" Z="1.4329541226809683">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="1.3755176153121687" CI_START="0.5045267147338989" EFFECT_SIZE="0.8330578512396695" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="77" LOG_CI_END="0.13846615647334753" LOG_CI_START="-0.29711583288723464" LOG_EFFECT_SIZE="-0.07932483820694357" MODIFIED="2012-05-28 14:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4855" O_E="0.0" SE="0.2558630167160275" STUDY_ID="STD-Andreoli-2002" TOTAL_1="127" TOTAL_2="126" VAR="0.06546588332302618" WEIGHT="34.80610483936877"/>
<DICH_DATA CI_END="0.9214810229154664" CI_START="0.3684659474023264" EFFECT_SIZE="0.5826957852274308" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="91" LOG_CI_END="-0.03551360426255213" LOG_CI_START="-0.43360264223807893" LOG_EFFECT_SIZE="-0.23455812325031553" MODIFIED="2012-06-25 10:15:40 +0100" MODIFIED_BY="[Empty name]" ORDER="3217" O_E="0.0" SE="0.23383947147934342" STUDY_ID="STD-Clayton-2003" TOTAL_1="150" TOTAL_2="150" VAR="0.05468089842173866" WEIGHT="39.47595874943276"/>
<DICH_DATA CI_END="2.0062066215410352" CI_START="0.5892523585447124" EFFECT_SIZE="1.0872727272727272" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.30237565947902567" LOG_CI_START="-0.22969867049069173" LOG_EFFECT_SIZE="0.036338494494166956" MODIFIED="2012-05-28 14:11:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4856" O_E="0.0" SE="0.31254309523462287" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.09768318637883855" WEIGHT="25.71793641119846"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.433308409673026" CI_END="0.20647183534540461" CI_START="-0.03011234255880832" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08817974639329815" ESTIMABLE="YES" I2="3.485061219392865" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2013-05-06 15:44:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.41153706311316873" P_Q="0.6261456031769163" P_Z="0.14400526839402286" Q="2.6038262845187052" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.001036682147053305" TOTALS="SUB" TOTAL_1="951" TOTAL_2="1078" UNITS="" WEIGHT="500.0" Z="1.461037070422472">
<NAME>End-point score on rating scales</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAOIs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.066010657902545" CI_END="0.2252595495957109" CI_START="-0.18398565801737268" DF="2" EFFECT_SIZE="0.02063694578916912" ESTIMABLE="YES" I2="67.02940181296115" ID="CMP-005.02.01" MODIFIED="2012-11-20 15:03:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04817079506463695" P_Z="0.8433035675573599" STUDIES="3" TAU2="0.021818817357774547" TOTAL_1="536" TOTAL_2="677" WEIGHT="100.0" Z="0.19766961100699224">
<NAME>Fluoxetine vs Agomelatine</NAME>
<CONT_DATA CI_END="0.09111488908222917" CI_START="-0.39399374039444135" EFFECT_SIZE="-0.15143942565610607" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="14.5" MODIFIED="2012-05-28 14:14:48 +0100" MODIFIED_BY="[Empty name]" ORDER="994" SD_1="7.6" SD_2="8.2" SE="0.12375447541463655" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="133" TOTAL_2="129" WEIGHT="29.352117955911886"/>
<CONT_DATA CI_END="0.17255698725838758" CI_START="-0.22279813975293428" EFFECT_SIZE="-0.025120576247273357" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="12.7" MODIFIED="2012-05-28 14:14:48 +0100" MODIFIED_BY="[Empty name]" ORDER="1098" SD_1="7.4" SD_2="8.2" SE="0.10085775303266607" STUDY_ID="STD-CL3_x002d_024" TOTAL_1="146" TOTAL_2="301" WEIGHT="34.070758939696724"/>
<CONT_DATA CI_END="0.3764326028861018" CI_START="0.026258420171062585" EFFECT_SIZE="0.20134551152858218" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="11.1" MODIFIED="2012-05-28 14:14:48 +0100" MODIFIED_BY="[Empty name]" ORDER="935" SD_1="8.5" SD_2="7.3" SE="0.08933179014440276" STUDY_ID="STD-Hale-2010" TOTAL_1="257" TOTAL_2="247" WEIGHT="36.5771231043914"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2896075290361066" CI_START="-0.15146810416203038" DF="0" EFFECT_SIZE="0.5690697124370382" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" MODIFIED="2012-11-20 15:03:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12163445946522651" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.5479494835311078">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<CONT_DATA CI_END="1.2896075290361066" CI_START="-0.15146810416203038" EFFECT_SIZE="0.5690697124370382" ESTIMABLE="YES" MEAN_1="10.13" MEAN_2="7.16" MODIFIED="2012-05-28 14:09:04 +0100" MODIFIED_BY="[Empty name]" ORDER="914" SD_1="5.01" SD_2="5.15" SE="0.36762809025195303" STUDY_ID="STD-Amini-2005" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4679100521250388" CI_END="0.29758558550408987" CI_START="-0.04076454523421083" DF="5" EFFECT_SIZE="0.1284105201349395" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.03" MODIFIED="2012-11-20 15:03:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7813199619086547" P_Z="0.13683275693411762" STUDIES="6" TAU2="0.0" TOTAL_1="271" TOTAL_2="269" WEIGHT="99.99999999999999" Z="1.487689655395467">
<NAME>Fluoxetine vs Moclobemide</NAME>
<CONT_DATA CI_END="1.1152522460768686" CI_START="-0.11514974440434744" EFFECT_SIZE="0.5000512508362606" ESTIMABLE="YES" MEAN_1="13.44" MEAN_2="9.84" MODIFIED="2012-05-28 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4876" SD_1="6.84" SD_2="7.28" SE="0.31388382648519814" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" WEIGHT="7.562034374450378"/>
<CONT_DATA CI_END="0.41717144791185307" CI_START="-0.6609871801669961" EFFECT_SIZE="-0.1219078661275715" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="13.0" MODIFIED="2012-05-28 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4877" SD_1="7.0" SD_2="9.0" SE="0.2750455203726259" STUDY_ID="STD-Gattaz-1995" TOTAL_1="26" TOTAL_2="27" WEIGHT="9.848438376457183"/>
<CONT_DATA CI_END="0.8429597506752106" CI_START="-0.6434965928766357" EFFECT_SIZE="0.09973157889928737" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="9.1" MODIFIED="2012-05-28 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4878" SD_1="6.2" SD_2="7.3" SE="0.3792050148055842" STUDY_ID="STD-Geerts-1994" TOTAL_1="13" TOTAL_2="15" WEIGHT="5.181176413617256"/>
<CONT_DATA CI_END="0.42282906137380577" CI_START="-0.2707197515391227" EFFECT_SIZE="0.07605465491734152" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.5" MODIFIED="2012-05-28 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4879" SD_1="6.0" SD_2="7.0" SE="0.17692896869114763" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" WEIGHT="23.800091779411602"/>
<CONT_DATA CI_END="0.4446780737162884" CI_START="-0.09880321436078687" EFFECT_SIZE="0.17293742967775078" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.6" MODIFIED="2012-05-28 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4880" SD_1="6.0" SD_2="5.5" SE="0.13864573338183414" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" WEIGHT="38.758191589966096"/>
<CONT_DATA CI_END="0.5218809058652704" CI_START="-0.3561344981052954" EFFECT_SIZE="0.08287320387998745" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="12.2" MODIFIED="2012-05-28 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4881" SD_1="9.0" SD_2="7.6" SE="0.22398763724645943" STUDY_ID="STD-Reynaert-1995" TOTAL_1="42" TOTAL_2="38" WEIGHT="14.850067466097475"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5673132739545028" CI_START="-0.6725145473345209" DF="0" EFFECT_SIZE="-0.052600636690009" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.04" MODIFIED="2012-11-20 15:03:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8679162071891943" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.1663059203964429">
<NAME>Fluoxetine vs Phenelzine</NAME>
<CONT_DATA CI_END="0.5673132739545028" CI_START="-0.6725145473345209" EFFECT_SIZE="-0.052600636690009" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.9" MODIFIED="2012-05-28 13:36:27 +0100" MODIFIED_BY="[Empty name]" ORDER="4885" SD_1="4.18" SD_2="3.21" SE="0.3162884193456174" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.280729211890643" CI_END="0.3958292885432224" CI_START="-0.30636489892625607" DF="1" EFFECT_SIZE="0.044732194808483144" ESTIMABLE="YES" I2="21.919482220306655" ID="CMP-005.02.05" MODIFIED="2012-11-20 15:03:52 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2577636018645222" P_Z="0.8028093435232704" STUDIES="2" TAU2="0.01878851431044828" TOTAL_1="109" TOTAL_2="96" WEIGHT="100.0" Z="0.24971294931964202">
<NAME>Fluoxetine vs Reboxetine</NAME>
<CONT_DATA CI_END="0.45136984356919996" CI_START="-0.1554081847913773" EFFECT_SIZE="0.14798082938891133" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.4" MODIFIED="2012-05-28 14:11:38 +0100" MODIFIED_BY="[Empty name]" ORDER="4886" SD_1="8.7" SD_2="7.3" SE="0.1547931577178879" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" WEIGHT="75.06334224846012"/>
<CONT_DATA CI_END="0.3836709089458695" CI_START="-0.9157964430000726" EFFECT_SIZE="-0.2660627670271015" ESTIMABLE="YES" MEAN_1="6.65" MEAN_2="8.07" MODIFIED="2012-05-28 14:11:38 +0100" MODIFIED_BY="[Empty name]" ORDER="962" SD_1="3.11" SD_2="6.94" SE="0.3315028648985325" STUDY_ID="STD-Taner-2006" TOTAL_1="20" TOTAL_2="17" WEIGHT="24.936657751539883"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="23.21323028997182" CI_END="0.9875248688657255" CI_START="0.645329194135247" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7982973304562869" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="314" I2="35.381677549289456" I2_Q="42.6279183448773" ID="CMP-005.03" LOG_CI_END="-0.005451958713997214" LOG_CI_START="-0.19021868734127537" LOG_EFFECT_SIZE="-0.09783532302763628" METHOD="MH" MODIFIED="2013-05-06 15:33:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07971637717741631" P_Q="0.13737377474480106" P_Z="0.037928157467141004" Q="6.9720321881380505" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08511575892149499" TOTALS="SUB" TOTAL_1="1317" TOTAL_2="1294" WEIGHT="500.0" Z="2.0756302931230195">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0274475380910295" CI_END="2.490658491297182" CI_START="0.5937140189795458" DF="1" EFFECT_SIZE="1.2160340713868103" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="52" I2="66.96887435973359" ID="CMP-005.03.01" LOG_CI_END="0.39631418297091764" LOG_CI_START="-0.2264226962422455" LOG_EFFECT_SIZE="0.0849457433643361" MODIFIED="2012-11-20 15:04:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0818669261688465" P_Z="0.5928531191446198" STUDIES="2" TAU2="0.18093814441470865" TOTAL_1="400" TOTAL_2="385" WEIGHT="100.0" Z="0.5347060795385822">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="1.5817669514700943" CI_START="0.4172547466019974" EFFECT_SIZE="0.8124036979969184" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.19914249740049184" LOG_CI_START="-0.37959871417818225" LOG_EFFECT_SIZE="-0.09022810838884521" MODIFIED="2012-05-28 14:14:58 +0100" MODIFIED_BY="[Empty name]" ORDER="995" O_E="0.0" SE="0.3399554524965136" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="137" TOTAL_2="133" VAR="0.11556970968210932" WEIGHT="45.128216905517675"/>
<DICH_DATA CI_END="2.770297148759592" CI_START="1.0363386557716212" EFFECT_SIZE="1.694392523364486" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="30" LOG_CI_END="0.44252635503745824" LOG_CI_START="0.015501697783139824" LOG_EFFECT_SIZE="0.22901402641029905" MODIFIED="2012-05-28 14:14:58 +0100" MODIFIED_BY="[Empty name]" ORDER="936" O_E="0.0" SE="0.2508363974773311" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.06291889829940564" WEIGHT="54.87178309448232"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5865027310117" CI_END="1.6800133273163476" CI_START="0.5058990064516279" DF="2" EFFECT_SIZE="0.9219094712144104" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="49" I2="22.6755117626453" ID="CMP-005.03.02" LOG_CI_END="0.22531272693835727" LOG_CI_START="-0.2959361735129571" LOG_EFFECT_SIZE="-0.035311723287299916" MODIFIED="2012-11-20 15:04:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2743773608250242" P_Z="0.790583187812871" STUDIES="3" TAU2="0.0677754380389755" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="0.2655533884684577">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="10.944829454668549" CI_START="0.23390040115316965" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0392089986610609" LOG_CI_START="-0.6309690333492113" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2012-05-28 14:09:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1062" O_E="0.0" SE="0.9810708435174291" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.9624999999999999" WEIGHT="9.099387531140644"/>
<DICH_DATA CI_END="1.2140052480871342" CI_START="0.29653908050829225" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="0.08422056417775314" LOG_CI_START="-0.5279180634104659" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-05-28 14:09:24 +0100" MODIFIED_BY="[Empty name]" ORDER="4914" O_E="0.0" SE="0.3595732599803958" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="0.1292929292929293" WEIGHT="47.57169098956935"/>
<DICH_DATA CI_END="2.8010722863556294" CI_START="0.618148652325078" EFFECT_SIZE="1.315856777493606" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.44732431666372585" LOG_CI_START="-0.2089070732585561" LOG_EFFECT_SIZE="0.11920862170258491" MODIFIED="2012-05-28 14:09:24 +0100" MODIFIED_BY="[Empty name]" ORDER="4915" O_E="0.0" SE="0.385473566838118" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.14858987073090105" WEIGHT="43.32892147929001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.161794881545732" CI_END="1.4661790887603185" CI_START="0.6981247958729551" DF="5" EFFECT_SIZE="1.0117193173276828" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="75" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="0.16618702113053252" LOG_CI_START="-0.15606693652511383" LOG_EFFECT_SIZE="0.005060042302709327" MODIFIED="2012-11-20 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5263646856858946" P_Z="0.9509205277459907" STUDIES="7" TAU2="0.0" TOTAL_1="359" TOTAL_2="362" WEIGHT="100.0" Z="0.06155083863489459">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4916" O_E="0.0" SE="0.0" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7567393745204902" CI_START="0.3090865294675779" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.440395709320173" LOG_CI_START="-0.5099199218385969" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4917" O_E="0.0" SE="0.5582201058809031" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.31160968660968663" WEIGHT="11.499018531492993"/>
<DICH_DATA CI_END="4.808185824114187" CI_START="0.49225716141315984" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.6819812436926667" LOG_CI_START="-0.30780795697837776" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4918" O_E="0.0" SE="0.5814070760097335" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="0.338034188034188" WEIGHT="10.600127702334989"/>
<DICH_DATA CI_END="1.5755433064214213" CI_START="0.23154059444845657" EFFECT_SIZE="0.603988603988604" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.19743034497835923" LOG_CI_START="-0.6353728560525046" LOG_EFFECT_SIZE="-0.21897125553707264" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4919" O_E="0.0" SE="0.4891927227278604" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="0.23930951996989733" WEIGHT="14.973100783321284"/>
<DICH_DATA CI_END="2.413069060470331" CI_START="0.604576581794726" EFFECT_SIZE="1.2078431372549019" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.38256975131284476" LOG_CI_START="-0.21854867917986667" LOG_EFFECT_SIZE="0.08201053606648906" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4920" O_E="0.0" SE="0.35309994165563924" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.12467956879721585" WEIGHT="28.739316276794224"/>
<DICH_DATA CI_END="1.489435663170907" CI_START="0.20813261145902012" EFFECT_SIZE="0.5567765567765568" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.17302174841489976" LOG_CI_START="-0.6816598666068667" LOG_EFFECT_SIZE="-0.25431905909598346" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4921" O_E="0.0" SE="0.5020442114060125" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="0.25204839020628494" WEIGHT="14.216339798817575"/>
<DICH_DATA CI_END="3.418028386786818" CI_START="0.6496668722344996" EFFECT_SIZE="1.4901610017889089" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.5337756652231267" LOG_CI_START="-0.18730927818239804" LOG_EFFECT_SIZE="0.17323319352036431" MODIFIED="2012-05-28 13:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4922" O_E="0.0" SE="0.42356886518444214" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.17941058355363612" WEIGHT="19.972096907238946"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.009391292006816" CI_START="0.008124886132875167" DF="0" EFFECT_SIZE="0.1804878048780488" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-005.03.04" LOG_CI_END="0.6030784427974784" LOG_CI_START="-2.0901827167749967" LOG_EFFECT_SIZE="-0.7435521369887592" MODIFIED="2012-11-20 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2791597937567736" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.082208759403857">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="4.009391292006816" CI_START="0.008124886132875167" EFFECT_SIZE="0.18048780487804877" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6030784427974784" LOG_CI_START="-2.0901827167749967" LOG_EFFECT_SIZE="-0.7435521369887593" MODIFIED="2012-05-28 13:36:43 +0100" MODIFIED_BY="[Empty name]" ORDER="4925" O_E="0.0" SE="1.5820349369906253" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.502834541858932" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.618193371521924" CI_END="0.8290612955812889" CI_START="0.44058351160099024" DF="3" EFFECT_SIZE="0.60437632063117" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="136" I2="0.0" ID="CMP-005.03.05" LOG_CI_END="-0.081413359258382" LOG_CI_START="-0.3559717599194704" LOG_EFFECT_SIZE="-0.21869255958892622" MODIFIED="2012-11-20 15:03:59 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.45430898634221584" P_Z="0.0017943202280884614" STUDIES="4" TAU2="0.0" TOTAL_1="387" TOTAL_2="377" WEIGHT="99.99999999999999" Z="3.1223196190618134">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="0.8666744353500004" CI_START="0.2914404208333217" EFFECT_SIZE="0.5025773195876289" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="48" LOG_CI_END="-0.06214401380901906" LOG_CI_START="-0.5354502146543595" LOG_EFFECT_SIZE="-0.29879711423168925" MODIFIED="2012-05-28 14:12:04 +0100" MODIFIED_BY="[Empty name]" ORDER="4927" O_E="0.0" SE="0.278022405280033" STUDY_ID="STD-Andreoli-2002" TOTAL_1="127" TOTAL_2="126" VAR="0.07729645783769494" WEIGHT="33.650001211857905"/>
<DICH_DATA CI_END="1.011714542760396" CI_START="0.3924828459827537" EFFECT_SIZE="0.6301433194637078" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="63" LOG_CI_END="0.00505799274896105" LOG_CI_START="-0.4061793199577969" LOG_EFFECT_SIZE="-0.2005606636044179" MODIFIED="2012-06-25 10:16:26 +0100" MODIFIED_BY="[Empty name]" ORDER="3218" O_E="0.0" SE="0.24156283314147814" STUDY_ID="STD-Clayton-2003" TOTAL_1="150" TOTAL_2="150" VAR="0.05835260235533761" WEIGHT="44.57429137559001"/>
<DICH_DATA CI_END="1.7402247472895396" CI_START="0.4201462595180684" EFFECT_SIZE="0.855072463768116" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.2406053403541715" LOG_CI_START="-0.3765994985443938" LOG_EFFECT_SIZE="-0.06799707909511112" MODIFIED="2012-05-28 14:12:04 +0100" MODIFIED_BY="[Empty name]" ORDER="4928" O_E="0.0" SE="0.3625491775822437" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.13144190616556128" WEIGHT="19.78840672497981"/>
<DICH_DATA CI_END="1.6005013681269036" CI_START="0.01805684179690657" EFFECT_SIZE="0.17" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2042560497202079" LOG_CI_START="-1.7433582069636597" LOG_EFFECT_SIZE="-0.769551078621726" MODIFIED="2012-05-28 14:12:04 +0100" MODIFIED_BY="[Empty name]" ORDER="963" O_E="0.0" SE="1.1440382552221602" STUDY_ID="STD-Taner-2006" TOTAL_1="21" TOTAL_2="22" VAR="1.3088235294117647" WEIGHT="1.9873006875722647"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.858480015364364" CI_END="1.4780758035825166" CI_START="0.6899840902267547" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0098756302738778" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.1696967075590756" LOG_CI_START="-0.16116092318504716" LOG_EFFECT_SIZE="0.004267892187014223" METHOD="MH" MODIFIED="2013-05-06 15:44:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6176669665114713" P_Q="0.5950187377014522" P_Z="0.9596721197138914" Q="1.892486420041561" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1298" TOTAL_2="1270" WEIGHT="400.0" Z="0.05056504187395954">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4089013643439214" CI_END="2.8814659955341555" CI_START="0.40611180924584733" DF="1" EFFECT_SIZE="1.081756612518159" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="58.48729986201174" ID="CMP-005.04.01" LOG_CI_END="0.4596134987953846" LOG_CI_START="-0.3913543815620731" LOG_EFFECT_SIZE="0.034129558616655745" MODIFIED="2012-11-20 15:04:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12064720893556702" P_Z="0.8750749476430556" STUDIES="2" TAU2="0.292747020871044" TOTAL_1="400" TOTAL_2="385" WEIGHT="100.0" Z="0.15721558296370725">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="1.564583163770976" CI_START="0.286306861964522" EFFECT_SIZE="0.6692913385826772" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.19439865256173688" LOG_CI_START="-0.5431682430450651" LOG_EFFECT_SIZE="-0.17438479524166411" MODIFIED="2012-05-28 14:15:14 +0100" MODIFIED_BY="[Empty name]" ORDER="996" O_E="0.0" SE="0.4332504454944515" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="137" TOTAL_2="133" VAR="0.18770594852114073" WEIGHT="52.0056654943502"/>
<DICH_DATA CI_END="4.638647826204977" CI_START="0.7140874073878505" EFFECT_SIZE="1.82" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6663914014168623" LOG_CI_START="-0.14624862544671258" LOG_EFFECT_SIZE="0.2600713879850748" MODIFIED="2012-05-28 14:15:14 +0100" MODIFIED_BY="[Empty name]" ORDER="937" O_E="0.0" SE="0.47734877441267304" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.227861852433281" WEIGHT="47.994334505649796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1584125919587105" CI_END="2.9571939967914993" CI_START="0.7132009246727556" DF="3" EFFECT_SIZE="1.4522649527370752" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.470879815893202" LOG_CI_START="-0.1467881024287988" LOG_EFFECT_SIZE="0.1620458567322016" MODIFIED="2012-11-20 15:04:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7629950237030916" P_Z="0.3037629418524066" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="297" WEIGHT="100.0" Z="1.0283974077911562">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="83.16605151283552" CI_START="0.12093827951085495" EFFECT_SIZE="3.1714285714285713" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9199460829082542" LOG_CI_START="-0.9174362140354908" LOG_EFFECT_SIZE="0.5012549344363818" MODIFIED="2012-05-28 14:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1063" O_E="0.0" SE="1.666692406493645" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="2.777863577863578" WEIGHT="4.738865469905533"/>
<DICH_DATA CI_END="109.46408440569732" CI_START="0.24276843640709503" EFFECT_SIZE="5.155038759689923" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.039271648828983" LOG_CI_START="-0.6148077788212715" LOG_EFFECT_SIZE="0.7122319350038556" MODIFIED="2012-05-28 14:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="4954" O_E="0.0" SE="1.5590193937068118" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="2.4305414699539547" WEIGHT="5.416044923313048"/>
<DICH_DATA CI_END="2.8074997608381795" CI_START="0.49116546972165215" EFFECT_SIZE="1.1742857142857144" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4483197279373553" LOG_CI_START="-0.3087721728857681" LOG_EFFECT_SIZE="0.0697737775257936" MODIFIED="2012-05-28 14:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="967" O_E="0.0" SE="0.4447195302088533" STUDY_ID="STD-Versiani-2005" TOTAL_1="152" TOTAL_2="147" VAR="0.19777546054918316" WEIGHT="66.55993495195185"/>
<DICH_DATA CI_END="7.392745096167514" CI_START="0.38796226599574557" EFFECT_SIZE="1.6935483870967742" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8688057318655299" LOG_CI_START="-0.41121051272216164" LOG_EFFECT_SIZE="0.2287976095716842" MODIFIED="2012-05-28 14:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="4955" O_E="0.0" SE="0.7518878782534094" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.5653353814644138" WEIGHT="23.28515465482958"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.643869259996967" CI_END="1.5609462253190496" CI_START="0.3173661083210346" DF="5" EFFECT_SIZE="0.7038404853572403" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="11.408295095717946" ID="CMP-005.04.03" LOG_CI_END="0.1933879418519932" LOG_CI_START="-0.49843945362103204" LOG_EFFECT_SIZE="-0.15252575588451942" MODIFIED="2012-11-20 15:04:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3424279524814072" P_Z="0.387467925881104" STUDIES="6" TAU2="0.11429115721906485" TOTAL_1="338" TOTAL_2="341" WEIGHT="100.0" Z="0.8642184169188839">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="5.6758954602083325" CI_START="0.19965036299809322" EFFECT_SIZE="1.064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.754034387935408" LOG_CI_START="-0.6997298958481786" LOG_EFFECT_SIZE="0.027152246043614776" MODIFIED="2012-05-28 13:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="4956" O_E="0.0" SE="0.8539483365437431" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.729227761485826" WEIGHT="19.57834095994865"/>
<DICH_DATA CI_END="12.101088580677217" CI_START="0.612382413181689" EFFECT_SIZE="2.7222222222222223" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0828244400120106" LOG_CI_START="-0.21297729016159547" LOG_EFFECT_SIZE="0.4349235749252076" MODIFIED="2012-05-28 13:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="4957" O_E="0.0" SE="0.7611603506259895" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="0.5793650793650793" WEIGHT="23.80819219314875"/>
<DICH_DATA CI_END="8.737186854248607" CI_START="0.01396717041921071" EFFECT_SIZE="0.34933333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9413716236711689" LOG_CI_START="-1.854891567815078" LOG_EFFECT_SIZE="-0.4567599720719546" MODIFIED="2012-05-28 13:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="4958" O_E="0.0" SE="1.6425388404050558" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="2.6979338422391854" WEIGHT="5.872467885660987"/>
<DICH_DATA CI_END="1.5462555349544165" CI_START="0.06006757388703051" EFFECT_SIZE="0.3047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1892812672343369" LOG_CI_START="-1.2213599087344011" LOG_EFFECT_SIZE="-0.516039320750032" MODIFIED="2012-05-28 13:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="4959" O_E="0.0" SE="0.8286176095504746" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.6866071428571427" WEIGHT="20.620222311622022"/>
<DICH_DATA CI_END="2.224600364340955" CI_START="0.025848275217141982" EFFECT_SIZE="0.23979591836734693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34725200401357464" LOG_CI_START="-1.5875684308550917" LOG_EFFECT_SIZE="-0.6201582134207586" MODIFIED="2012-05-28 13:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="4960" O_E="0.0" SE="1.1365231009574714" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="1.291684759009987" WEIGHT="11.746076732854295"/>
<DICH_DATA CI_END="2.837187185483553" CI_START="0.08811544098292953" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4528879896347094" LOG_CI_START="-1.0549479809626718" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-05-28 13:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="4961" O_E="0.0" SE="0.8857103130373326" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.7844827586206897" WEIGHT="18.3746999167653"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-11-20 15:04:06 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-28 13:37:04 +0100" MODIFIED_BY="[Empty name]" ORDER="4964" O_E="0.0" SE="0.0" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.759596698911098" CI_END="1.7744656357983815" CI_START="0.474117932769375" DF="2" EFFECT_SIZE="0.9172273322437701" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-005.04.05" LOG_CI_END="0.24906759324255923" LOG_CI_START="-0.3241136178607596" LOG_EFFECT_SIZE="-0.03752301230910015" MODIFIED="2012-11-20 15:04:05 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6839994865115351" P_Z="0.7974751743968365" STUDIES="3" TAU2="0.0" TOTAL_1="237" TOTAL_2="227" WEIGHT="100.0" Z="0.25661606239927093">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="1.8544116054771973" CI_START="0.3840027237288681" EFFECT_SIZE="0.843859649122807" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.26820613657623726" LOG_CI_START="-0.4156656951735565" LOG_EFFECT_SIZE="-0.07372977929865965" MODIFIED="2012-05-28 14:12:14 +0100" MODIFIED_BY="[Empty name]" ORDER="4966" O_E="0.0" SE="0.40170969918999216" STUDY_ID="STD-Andreoli-2002" TOTAL_1="127" TOTAL_2="126" VAR="0.161370682423314" WEIGHT="70.24808020157812"/>
<DICH_DATA CI_END="4.988963058617443" CI_START="0.36824645268333" EFFECT_SIZE="1.355421686746988" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6980102881648791" LOG_CI_START="-0.4338614280222643" LOG_EFFECT_SIZE="0.13207443007130737" MODIFIED="2012-05-28 14:12:14 +0100" MODIFIED_BY="[Empty name]" ORDER="4967" O_E="0.0" SE="0.6648670489436849" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.4420481927710843" WEIGHT="25.64421894815147"/>
<DICH_DATA CI_END="8.648116214920153" CI_START="0.012848013179958985" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9369215171107735" LOG_CI_START="-1.8911640265500982" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-05-28 14:12:14 +0100" MODIFIED_BY="[Empty name]" ORDER="964" O_E="0.0" SE="1.6612314475956143" STUDY_ID="STD-Taner-2006" TOTAL_1="21" TOTAL_2="22" VAR="2.75968992248062" WEIGHT="4.107700850270421"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.144843992204406" CI_END="1.4443825156868895" CI_START="0.7134919617247413" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="1.015162703510307" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" I2="1.1019072747482268" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.15968222263303433" LOG_CI_START="-0.14661091532894696" LOG_EFFECT_SIZE="0.006535653652043657" METHOD="MH" MODIFIED="2013-06-21 10:51:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4366868896510726" P_Q="0.49108362837193587" P_Z="0.9333402397276915" Q="3.4139441668402366" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004378283624202691" TOTALS="SUB" TOTAL_1="1192" TOTAL_2="1165" WEIGHT="500.0" Z="0.08364304769389429">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34935773156808214" CI_END="3.0801389729304924" CI_START="0.7328630601476664" DF="1" EFFECT_SIZE="1.5024380431092428" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.48857031189500344" LOG_CI_START="-0.1349771683032725" LOG_EFFECT_SIZE="0.17679657179586547" MODIFIED="2012-11-20 15:04:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5544771317030361" P_Z="0.26638301199355086" STUDIES="2" TAU2="0.0" TOTAL_1="400" TOTAL_2="385" WEIGHT="100.0" Z="1.1114307228051383">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="4.894371030613178" CI_START="0.19230041380773044" EFFECT_SIZE="0.9701492537313433" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6896968890942495" LOG_CI_START="-0.7160197812101913" LOG_EFFECT_SIZE="-0.013161446057970849" MODIFIED="2012-05-28 14:15:28 +0100" MODIFIED_BY="[Empty name]" ORDER="997" O_E="0.0" SE="0.8257249305465704" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="137" TOTAL_2="133" VAR="0.6818216609261385" WEIGHT="19.676301418313024"/>
<DICH_DATA CI_END="3.7256302092285765" CI_START="0.7506865143729687" EFFECT_SIZE="1.6723577235772358" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5711997464106322" LOG_CI_START="-0.12454138589998007" LOG_EFFECT_SIZE="0.22332918025532608" MODIFIED="2012-05-28 14:15:28 +0100" MODIFIED_BY="[Empty name]" ORDER="938" O_E="0.0" SE="0.4086817850934023" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.1670208014671299" WEIGHT="80.32369858168697"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9886050459713056" CI_END="1.6571589871648604" CI_START="0.541533873030518" DF="3" EFFECT_SIZE="0.9473160637014013" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="0.2193641764556094" LOG_CI_START="-0.2663743729996099" LOG_EFFECT_SIZE="-0.02350509827200023" MODIFIED="2012-11-20 15:04:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5747751674247054" P_Z="0.8495544021605114" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="297" WEIGHT="100.00000000000001" Z="0.18968700803287722">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="25.775322065244573" CI_START="0.17519179735444962" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4112041005427385" LOG_CI_START="-0.7564862317700777" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2012-05-28 14:10:01 +0100" MODIFIED_BY="[Empty name]" ORDER="1064" O_E="0.0" SE="1.2733120314407482" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="1.6213235294117647" WEIGHT="5.021236322152428"/>
<DICH_DATA CI_END="1.4631319891832764" CI_START="0.21612525357695844" EFFECT_SIZE="0.5623342175066313" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.16528350561155317" LOG_CI_START="-0.6652944841656362" LOG_EFFECT_SIZE="-0.25000548927704147" MODIFIED="2012-05-28 14:10:01 +0100" MODIFIED_BY="[Empty name]" ORDER="4994" O_E="0.0" SE="0.48788562262247864" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="0.23803238076172364" WEIGHT="34.201433308320006"/>
<DICH_DATA CI_END="2.915318092782721" CI_START="0.41018202289108285" EFFECT_SIZE="1.0935314685314685" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.46468594791266093" LOG_CI_START="-0.3870233774398318" LOG_EFFECT_SIZE="0.03883128523641456" MODIFIED="2012-05-28 14:10:01 +0100" MODIFIED_BY="[Empty name]" ORDER="968" O_E="0.0" SE="0.5002982737412099" STUDY_ID="STD-Versiani-2005" TOTAL_1="152" TOTAL_2="147" VAR="0.25029836270843464" WEIGHT="32.52537694513806"/>
<DICH_DATA CI_END="3.745390288244061" CI_START="0.45670934176296624" EFFECT_SIZE="1.3078817733990147" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5734970800325664" LOG_CI_START="-0.34036010502401653" LOG_EFFECT_SIZE="0.11656848750427493" MODIFIED="2012-05-28 14:10:01 +0100" MODIFIED_BY="[Empty name]" ORDER="4995" O_E="0.0" SE="0.5368042341682596" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.2881587858209717" WEIGHT="28.25195342438951"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.392947771339534" CI_END="2.010030047021826" CI_START="0.5362094896329139" DF="4" EFFECT_SIZE="1.038170114027752" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="31" I2="25.829061033045107" ID="CMP-005.05.03" LOG_CI_END="0.3032025495390175" LOG_CI_START="-0.27066550430550584" LOG_EFFECT_SIZE="0.016268522616755852" MODIFIED="2012-11-20 15:04:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24930111768804886" P_Z="0.9115167416806602" STUDIES="7" TAU2="0.14645409296614256" TOTAL_1="359" TOTAL_2="362" WEIGHT="100.0" Z="0.11112560874195482">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="4996" O_E="0.0" SE="0.0" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="4997" O_E="0.0" SE="0.0" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.020963513646312" CI_START="0.02815970602099903" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4801454800174838" LOG_CI_START="-1.5503718834121822" LOG_EFFECT_SIZE="-0.5351132016973492" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="4998" O_E="0.0" SE="1.1927359505016388" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="1.4226190476190477" WEIGHT="7.2419598703827495"/>
<DICH_DATA CI_END="4.0202033007439075" CI_START="0.40292358111443355" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6042480158105261" LOG_CI_START="-0.39477731477050026" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="4999" O_E="0.0" SE="0.5868324244384374" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="0.3443722943722944" WEIGHT="23.15108765735163"/>
<DICH_DATA CI_END="3.7527255472779584" CI_START="0.6972460001957009" EFFECT_SIZE="1.6175824175824176" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5743468037786098" LOG_CI_START="-0.15661396841783687" LOG_EFFECT_SIZE="0.20886641768038647" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="5000" O_E="0.0" SE="0.4293699759023706" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.18435857620640228" WEIGHT="34.349242869796484"/>
<DICH_DATA CI_END="1.3285157213086223" CI_START="0.05163213593048269" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12336669810435753" LOG_CI_START="-1.2870799085837084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="5001" O_E="0.0" SE="0.8285033185918744" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="0.686417748917749" WEIGHT="13.643353210394027"/>
<DICH_DATA CI_END="5.034286248248591" CI_START="0.45031471397479583" EFFECT_SIZE="1.5056603773584907" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7019379057893128" LOG_CI_START="-0.346483862289432" LOG_EFFECT_SIZE="0.1777270217499404" MODIFIED="2012-05-28 13:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="5002" O_E="0.0" SE="0.6158481363409063" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.37926892703456755" WEIGHT="21.614356392075106"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.260466128217253" CI_START="0.012170668584238322" DF="0" EFFECT_SIZE="0.3170731707317074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.05.04" LOG_CI_END="0.9170045547296883" LOG_CI_START="-1.9146855635554856" LOG_EFFECT_SIZE="-0.4988405044128986" MODIFIED="2012-11-20 15:04:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4898494409043541" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.690548316968497">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="8.260466128217253" CI_START="0.012170668584238322" EFFECT_SIZE="0.3170731707317073" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9170045547296883" LOG_CI_START="-1.9146855635554856" LOG_EFFECT_SIZE="-0.49884050441289873" MODIFIED="2012-05-28 13:37:15 +0100" MODIFIED_BY="[Empty name]" ORDER="5006" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.7667292057535957" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2401563331170777" CI_END="1.6088947371470619" CI_START="0.10015539874284513" DF="1" EFFECT_SIZE="0.40142184038020273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="19.365004774313856" ID="CMP-005.05.05" LOG_CI_END="0.20652763106508595" LOG_CI_START="-0.9993256356761138" LOG_EFFECT_SIZE="-0.39639900230551395" MODIFIED="2012-11-20 15:04:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.26544100973406803" P_Z="0.19753919783790547" STUDIES="2" TAU2="0.3154332863826404" TOTAL_1="110" TOTAL_2="101" WEIGHT="100.00000000000001" Z="1.2885942086901714">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="1.6570477901202991" CI_START="0.19077538702851393" EFFECT_SIZE="0.5622489959839357" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.21933503387874545" LOG_CI_START="-0.7194776567137421" LOG_EFFECT_SIZE="-0.25007131141749833" MODIFIED="2012-05-28 14:12:31 +0100" MODIFIED_BY="[Empty name]" ORDER="5008" O_E="0.0" SE="0.5514632216517946" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.3041116848345764" WEIGHT="80.98252175109727"/>
<DICH_DATA CI_END="1.8957500979869666" CI_START="0.004821702724017608" EFFECT_SIZE="0.09560723514211886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2777810871062846" LOG_CI_START="-2.3167995690101177" LOG_EFFECT_SIZE="-1.0195092409519164" MODIFIED="2012-05-28 14:12:31 +0100" MODIFIED_BY="[Empty name]" ORDER="965" O_E="0.0" SE="1.524069520784158" STUDY_ID="STD-Taner-2006" TOTAL_1="21" TOTAL_2="22" VAR="2.322787904183253" WEIGHT="19.017478248902744"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-07-02 12:06:11 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Fluoxetine versus other conventional psychotropic drugs</NAME>
<DICH_OUTCOME CHI2="12.37371616183127" CI_END="1.118858636889614" CI_START="0.6364198744196505" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8438387720309073" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="313" I2="43.428474449796795" I2_Q="33.03093932773335" ID="CMP-006.01" LOG_CI_END="0.04877521870260366" LOG_CI_START="-0.1962562664610125" LOG_EFFECT_SIZE="-0.07374052387920442" METHOD="MH" MODIFIED="2013-05-06 15:45:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08891971568224066" P_Q="0.20118083652383167" P_Z="0.23812948140748924" Q="5.9729074289621735" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10845919183274041" TOTALS="SUB" TOTAL_1="536" TOTAL_2="565" WEIGHT="500.0" Z="1.1796751010005886">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>other ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other ADs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.042102468395331" CI_START="0.12914020606049725" DF="0" EFFECT_SIZE="0.36684782608695654" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.017910424597583133" LOG_CI_START="-0.8889385249546062" LOG_EFFECT_SIZE="-0.4355140501785115" NO="1" P_CHI2="1.0" P_Z="0.059762093314523285" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.8825447248575726">
<NAME>Fluoxetine vs Amineptine</NAME>
<DICH_DATA CI_END="1.042102468395331" CI_START="0.12914020606049725" EFFECT_SIZE="0.36684782608695654" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.017910424597583133" LOG_CI_START="-0.8889385249546062" LOG_EFFECT_SIZE="-0.4355140501785115" ORDER="4837" O_E="0.0" SE="0.5326875619416536" STUDY_ID="STD-Ferreri-1989" TOTAL_1="31" TOTAL_2="32" VAR="0.283756038647343" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7635861483762625" CI_END="1.430578118979767" CI_START="0.4827152182352783" DF="1" EFFECT_SIZE="0.8310004987398818" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="108" I2="43.297354602115576" ID="CMP-006.01.02" LOG_CI_END="0.1555115781255659" LOG_CI_START="-0.316309009257913" LOG_EFFECT_SIZE="-0.08039871556617352" MODIFIED="2012-05-31 12:15:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1841779603332515" P_Z="0.5041592732916826" STUDIES="2" TAU2="0.07101711753616846" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0" Z="0.6679597759260375">
<NAME>Fluoxetine vs Bupropion</NAME>
<DICH_DATA CI_END="2.4390923069571135" CI_START="0.579888061706289" EFFECT_SIZE="1.1892857142857143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.38722823641194193" LOG_CI_START="-0.23665583208374064" LOG_EFFECT_SIZE="0.07528620216410065" MODIFIED="2012-05-31 12:15:29 +0100" MODIFIED_BY="[Empty name]" ORDER="4838" O_E="0.0" SE="0.36647259011031" STUDY_ID="STD-Feighner-1991" TOTAL_1="62" TOTAL_2="61" VAR="0.1343021593021593" WEIGHT="37.41099438884211"/>
<DICH_DATA CI_END="1.0473727997353277" CI_START="0.4295243975375973" EFFECT_SIZE="0.6707251082251082" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="84" LOG_CI_END="0.0201012910870988" LOG_CI_START="-0.36701216264759406" LOG_EFFECT_SIZE="-0.17345543578024766" MODIFIED="2012-05-31 12:15:29 +0100" MODIFIED_BY="[Empty name]" ORDER="981" O_E="0.0" SE="0.22739235896625934" STUDY_ID="STD-WELL-AK1A4006" TOTAL_1="155" TOTAL_2="158" VAR="0.05170728491624014" WEIGHT="62.58900561115788"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2623571609890276" CI_START="0.24175292618156743" DF="0" EFFECT_SIZE="0.5524296675191815" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.10118224801541262" LOG_CI_START="-0.6166282605052845" LOG_EFFECT_SIZE="-0.25772300624493594" MODIFIED="2012-08-01 16:31:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.15930504971355142" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="70" WEIGHT="100.0" Z="1.4074126924345556">
<NAME>Fluoxetine vs Pramipexole</NAME>
<DICH_DATA CI_END="1.2623571609890276" CI_START="0.24175292618156743" EFFECT_SIZE="0.5524296675191815" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" LOG_CI_END="0.10118224801541262" LOG_CI_START="-0.6166282605052845" LOG_EFFECT_SIZE="-0.25772300624493594" ORDER="4854" O_E="0.0" SE="0.4216454459243803" STUDY_ID="STD-Corrigan-2000" TOTAL_1="35" TOTAL_2="70" VAR="0.17778488206876952" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6658144519448153" CI_START="0.747724329649192" DF="0" EFFECT_SIZE="1.1160510715914274" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="102" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="0.22162662553163287" LOG_CI_START="-0.12625848793632777" LOG_EFFECT_SIZE="0.04768406879765258" MODIFIED="2012-08-01 16:31:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.59106151255005" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="191" WEIGHT="99.99999999999999" Z="0.5372984003141977">
<NAME>Fluoxetine vs Tianeptine</NAME>
<DICH_DATA CI_END="1.6658144519448153" CI_START="0.747724329649192" EFFECT_SIZE="1.1160510715914274" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="102" LOG_CI_END="0.22162662553163287" LOG_CI_START="-0.12625848793632777" LOG_EFFECT_SIZE="0.04768406879765258" ORDER="4857" O_E="0.0" SE="0.20434943771016476" STUDY_ID="STD-Loo-1999" TOTAL_1="196" TOTAL_2="191" VAR="0.041758692692460506" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.749851048258613" CI_END="1.8570906838343655" CI_START="0.12861904130465165" DF="2" EFFECT_SIZE="0.48873021532393107" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="57.89341645285407" ID="CMP-006.01.05" LOG_CI_END="0.26883311134736093" LOG_CI_START="-0.8906947318676292" LOG_EFFECT_SIZE="-0.31093081026013414" MODIFIED="2012-08-01 16:31:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.09302164653245648" P_Z="0.2931941986225468" STUDIES="3" TAU2="0.7873522551245923" TOTAL_1="57" TOTAL_2="53" WEIGHT="100.0" Z="1.0511402436081523">
<NAME>Fluoxetine vs Trazodone</NAME>
<DICH_DATA CI_END="3.6407133188726966" CI_START="0.32235746358477513" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.5611864825776013" LOG_CI_START="-0.4916622700591774" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="4858" O_E="0.0" SE="0.6184485689842224" STUDY_ID="STD-Debus-1988" TOTAL_1="22" TOTAL_2="21" VAR="0.38247863247863245" WEIGHT="39.65650927393761"/>
<DICH_DATA CI_END="0.6223035817266797" CI_START="0.006277081017534064" EFFECT_SIZE="0.0625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.20599769938567866" LOG_CI_START="-2.202242265926171" LOG_EFFECT_SIZE="-1.2041199826559248" ORDER="4859" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Falk-1989" TOTAL_1="14" TOTAL_2="13" VAR="1.375" WEIGHT="21.454140662434725"/>
<DICH_DATA CI_END="2.3516708060206337" CI_START="0.19374522949110523" EFFECT_SIZE="0.675" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.37137652780600017" LOG_CI_START="-0.7127689821439502" LOG_EFFECT_SIZE="-0.17069622716897506" ORDER="4860" O_E="0.0" SE="0.6368324391514266" STUDY_ID="STD-Perry-1989" TOTAL_1="21" TOTAL_2="19" VAR="0.4055555555555555" WEIGHT="38.88935006362767"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="93.94505673147071" CI_END="-0.08699158288208642" CI_START="-0.3433050264870278" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21514830468455712" ESTIMABLE="YES" I2="87.22657645063713" I2_Q="94.82838348768473" ID="CMP-006.02" MODIFIED="2013-05-06 15:45:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.658940314238862E-15" P_Q="1.4432899320127035E-15" P_Z="0.0010005601185527169" Q="77.3452554046636" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.24394133841195773" TOTALS="SUB" TOTAL_1="814" TOTAL_2="799" UNITS="" WEIGHT="500.0" Z="3.2903691869282246">
<NAME>End-point score on rating scales</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other ADs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2064753249981445E-30" CI_END="-1.4537079767804542" CI_START="-2.2461346583471213" DF="0" EFFECT_SIZE="-1.8499213175637876" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-006.02.01" NO="1" P_CHI2="0.0" P_Z="5.636824827625539E-20" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="69" WEIGHT="100.0" Z="9.151077925567982">
<NAME>Fluoxetine vs ABT-200</NAME>
<CONT_DATA CI_END="-1.453707976780454" CI_START="-2.246134658347121" EFFECT_SIZE="-1.8499213175637874" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="22.7" ORDER="4870" SD_1="6.3" SD_2="5.6" SE="0.20215337828073057" STUDY_ID="STD-Sramek-1995" TOTAL_1="72" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.41190282715155524" CI_START="-0.06822188642496987" DF="0" EFFECT_SIZE="0.1718404703632927" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" NO="2" P_CHI2="1.0" P_Z="0.1606247313222833" STUDIES="1" TAU2="0.0" TOTAL_1="129" TOTAL_2="139" WEIGHT="100.0" Z="1.4029735336454199">
<NAME>Fluoxetine vs Amisulpride</NAME>
<CONT_DATA CI_END="0.41190282715155524" CI_START="-0.06822188642496987" EFFECT_SIZE="0.1718404703632927" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="8.1" ORDER="4871" SD_1="9.1" SD_2="7.1" SE="0.1224830449344191" STUDY_ID="STD-Smeraldi-1998" TOTAL_1="129" TOTAL_2="139" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4249859346729516" CI_END="0.18146226940393007" CI_START="-0.2958017885243654" DF="3" EFFECT_SIZE="-0.05716975956021768" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.03" MODIFIED="2012-08-01 16:31:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6996885012313436" P_Z="0.6386735597030795" STUDIES="4" TAU2="0.0" TOTAL_1="134" TOTAL_2="137" WEIGHT="99.99999999999999" Z="0.46955419282662886">
<NAME>Fluoxetine vs Nefazodone</NAME>
<CONT_DATA CI_END="0.6674229949051124" CI_START="-0.6979703715578344" EFFECT_SIZE="-0.015273688326361012" ESTIMABLE="YES" MEAN_1="-12.1" MEAN_2="-12.0" MODIFIED="2012-05-10 10:25:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1099" SD_1="6.08" SD_2="6.7" SE="0.3483210347825254" STUDY_ID="STD-Armitage-1997" TOTAL_1="17" TOTAL_2="16" WEIGHT="12.218049544088373"/>
<CONT_DATA CI_END="0.227981945525452" CI_START="-0.6929603968783317" EFFECT_SIZE="-0.23248922567643984" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="12.8" ORDER="4882" SD_1="6.06" SD_2="6.7" SE="0.23493858807306137" STUDY_ID="STD-Berlanga-1997" TOTAL_1="37" TOTAL_2="36" WEIGHT="26.856695600590616"/>
<CONT_DATA CI_END="0.8274668681657193" CI_START="-0.3752090774009009" EFFECT_SIZE="0.22612889538240918" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="11.4" ORDER="4883" SD_1="6.03" SD_2="6.9" SE="0.3068107258738361" STUDY_ID="STD-Gillin-1997" TOTAL_1="20" TOTAL_2="23" WEIGHT="15.747811559888232"/>
<CONT_DATA CI_END="0.292003001710683" CI_START="-0.41806166886575385" EFFECT_SIZE="-0.06302933357753544" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="11.5" ORDER="4884" SD_1="6.1" SD_2="6.5" SE="0.18114227510743472" STUDY_ID="STD-Rush-1998" TOTAL_1="60" TOTAL_2="62" WEIGHT="45.177443295432774"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.340037933273903" CI_END="0.10332430076165694" CI_START="-0.40060868521875187" DF="2" EFFECT_SIZE="-0.14864219222854747" ESTIMABLE="YES" I2="62.54708253029529" ID="CMP-006.02.04" MODIFIED="2012-08-01 16:31:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.06925107031254996" P_Z="0.24758366271411103" STUDIES="3" TAU2="0.030661144140832573" TOTAL_1="373" TOTAL_2="357" WEIGHT="100.0" Z="1.1562384342999077">
<NAME>Fluoxetine vs Tianeptine</NAME>
<CONT_DATA CI_END="0.273269810764126" CI_START="-0.44598333915913163" EFFECT_SIZE="-0.08635676419750282" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.5" ORDER="4887" SD_1="7.0" SD_2="6.8" SE="0.18348631801314583" STUDY_ID="STD-Alby-1993" TOTAL_1="61" TOTAL_2="58" WEIGHT="25.69134451253842"/>
<CONT_DATA CI_END="-0.1177999472101306" CI_START="-0.6396123113323031" EFFECT_SIZE="-0.3787061292712169" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="15.2" ORDER="4888" SD_1="7.5" SD_2="8.8" SE="0.13311784508239996" STUDY_ID="STD-Guelfi-1999" TOTAL_1="118" TOTAL_2="112" WEIGHT="34.15938383507598"/>
<CONT_DATA CI_END="0.20810078999346918" CI_START="-0.1936163335818937" EFFECT_SIZE="0.007242228205787748" ESTIMABLE="YES" MEAN_1="15.77" MEAN_2="15.69" ORDER="4889" SD_1="11.19" SD_2="10.85" SE="0.10248074116260714" STUDY_ID="STD-Loo-1999" TOTAL_1="194" TOTAL_2="187" WEIGHT="40.14927165238561"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.971215205422984" CI_END="0.2623702974185894" CI_START="-0.7566747652979701" DF="3" EFFECT_SIZE="-0.24715223393969032" ESTIMABLE="YES" I2="62.36458403532955" ID="CMP-006.02.05" MODIFIED="2012-08-01 16:31:30 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04661046957890791" P_Z="0.34175031516191856" STUDIES="4" TAU2="0.16354667065568196" TOTAL_1="106" TOTAL_2="97" WEIGHT="99.99999999999999" Z="0.9507125738464939">
<NAME>Fluoxetine vs Trazodone</NAME>
<CONT_DATA CI_END="0.9807350433240322" CI_START="-0.6027683181516686" EFFECT_SIZE="0.18898336258618179" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="10.0" ORDER="4890" SD_1="8.28" SD_2="6.81" SE="0.40396236205516356" STUDY_ID="STD-Debus-1988" TOTAL_1="14" TOTAL_2="11" WEIGHT="20.68419328272313"/>
<CONT_DATA CI_END="0.0929371280142921" CI_START="-1.535652934788972" EFFECT_SIZE="-0.72135790338734" ESTIMABLE="YES" MEAN_1="10.08" MEAN_2="16.08" ORDER="4891" SD_1="7.57" SD_2="8.53" SE="0.4154642829279963" STUDY_ID="STD-Falk-1989" TOTAL_1="13" TOTAL_2="12" WEIGHT="20.10426194960911"/>
<CONT_DATA CI_END="0.8744891041323866" CI_START="-0.372058370740755" EFFECT_SIZE="0.2512153666958158" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="6.5" ORDER="4892" SD_1="9.0" SD_2="5.1" SE="0.31800264818786184" STUDY_ID="STD-Perry-1989" TOTAL_1="21" TOTAL_2="19" WEIGHT="25.534186343380124"/>
<CONT_DATA CI_END="-0.23214030627091525" CI_START="-0.9874567458851486" EFFECT_SIZE="-0.609798526078032" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="13.7" MODIFIED="2012-03-21 11:26:37 +0000" MODIFIED_BY="[Empty name]" ORDER="972" SD_1="7.0" SD_2="8.9" SE="0.1926863058637998" STUDY_ID="STD-Zhao-2006-a" TOTAL_1="58" TOTAL_2="55" WEIGHT="33.677358424287625"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="41.008435949961076" CI_END="0.9748531588570604" CI_START="0.6525015173523621" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7975544905208516" ESTIMABLE="YES" EVENTS_1="271" EVENTS_2="342" I2="60.983637562955664" I2_Q="77.84775986054474" ID="CMP-006.03" LOG_CI_END="-0.011060796712573148" LOG_CI_START="-0.18541847406325732" LOG_EFFECT_SIZE="-0.09823963538791522" METHOD="MH" MODIFIED="2013-05-06 15:33:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="5.536905839060857E-4" P_Q="4.817989747396556E-5" P_Z="0.02720010844263309" Q="31.59951298799949" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.273159305344943" TOTALS="SUB" TOTAL_1="1195" TOTAL_2="1224" WEIGHT="800.0" Z="2.2086340004104783">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other ADs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3878191799738762" CI_START="0.08256982201596368" DF="0" EFFECT_SIZE="0.17894736842105263" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="-0.4113707162711453" LOG_CI_START="-1.0831786515500024" LOG_EFFECT_SIZE="-0.7472746839105738" NO="1" P_CHI2="1.0" P_Z="1.299029877463574E-5" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="4.360268434207559">
<NAME>Fluoxetine vs ABT-200</NAME>
<DICH_DATA CI_END="0.3878191799738762" CI_START="0.08256982201596368" EFFECT_SIZE="0.17894736842105263" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" LOG_CI_END="-0.4113707162711453" LOG_CI_START="-1.0831786515500024" LOG_EFFECT_SIZE="-0.7472746839105738" ORDER="4903" O_E="0.0" SE="0.3946233066857133" STUDY_ID="STD-Sramek-1995" TOTAL_1="72" TOTAL_2="72" VAR="0.15572755417956657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9866655549040138" CI_END="2.212599036070526" CI_START="0.1659887411994169" DF="1" EFFECT_SIZE="0.6060251882359263" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="66.51784467939403" ID="CMP-006.03.02" LOG_CI_END="0.34490271885295504" LOG_CI_START="-0.7799213685912167" LOG_EFFECT_SIZE="-0.21750932486913083" NO="2" P_CHI2="0.08395306331756947" P_Z="0.44844873880801117" STUDIES="2" TAU2="0.5928476536079407" TOTAL_1="113" TOTAL_2="119" WEIGHT="100.00000000000003" Z="0.7580037586388864">
<NAME>Fluoxetine vs Amineptine</NAME>
<DICH_DATA CI_END="2.4158682714086175" CI_START="0.47703983348889667" EFFECT_SIZE="1.0735294117647058" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.383073250081537" LOG_CI_START="-0.3214453552530978" LOG_EFFECT_SIZE="0.030813947414219566" ORDER="4904" O_E="0.0" SE="0.4138377161969053" STUDY_ID="STD-Dalery-1997" TOTAL_1="82" TOTAL_2="87" VAR="0.17126165534707033" WEIGHT="57.13324998266659"/>
<DICH_DATA CI_END="1.0157976392239807" CI_START="0.07874780810546572" EFFECT_SIZE="0.2828282828282828" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.0068071991667375785" LOG_CI_START="-1.103761525677399" LOG_EFFECT_SIZE="-0.5484771632553307" ORDER="4905" O_E="0.0" SE="0.6523535663772948" STUDY_ID="STD-Ferreri-1989" TOTAL_1="31" TOTAL_2="32" VAR="0.42556517556517554" WEIGHT="42.86675001733343"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.379383322564837" CI_START="0.8107194529713897" DF="0" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="32" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="0.37646441322864477" LOG_CI_START="-0.09112940609118171" LOG_EFFECT_SIZE="0.14266750356873154" NO="3" P_CHI2="1.0" P_Z="0.23169313429347094" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="142" WEIGHT="100.0" Z="1.1960088316210005">
<NAME>Fluoxetine vs Amisulpride</NAME>
<DICH_DATA CI_END="2.379383322564837" CI_START="0.8107194529713897" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="32" LOG_CI_END="0.37646441322864477" LOG_CI_START="-0.09112940609118171" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="4906" O_E="0.0" SE="0.27466692409520155" STUDY_ID="STD-Smeraldi-1998" TOTAL_1="139" TOTAL_2="142" VAR="0.0754419191919192" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.16616578490692188" CI_END="1.4800630184696275" CI_START="0.6723957999730824" DF="1" EFFECT_SIZE="0.9975911774441775" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="78" I2="0.0" ID="CMP-006.03.04" LOG_CI_END="0.1702802072807386" LOG_CI_START="-0.17237500798421887" LOG_EFFECT_SIZE="-0.001047400351740112" MODIFIED="2012-05-31 12:15:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6835423675551136" P_Z="0.990439884802457" STUDIES="2" TAU2="0.0" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0" Z="0.011982114238172975">
<NAME>Fluoxetine vs Bupropion</NAME>
<DICH_DATA CI_END="2.538490152276137" CI_START="0.5214939044870454" EFFECT_SIZE="1.1505681818181819" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.4045754829581032" LOG_CI_START="-0.28275076348502803" LOG_EFFECT_SIZE="0.06091235973653756" MODIFIED="2012-05-31 12:15:45 +0100" MODIFIED_BY="[Empty name]" ORDER="4907" O_E="0.0" SE="0.40373883948048706" STUDY_ID="STD-Feighner-1991" TOTAL_1="62" TOTAL_2="61" VAR="0.1630050505050505" WEIGHT="24.853573183492756"/>
<DICH_DATA CI_END="1.5000286906048668" CI_START="0.603699864714381" EFFECT_SIZE="0.9516129032258065" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="0.17609956575715746" LOG_CI_START="-0.21917892146937681" LOG_EFFECT_SIZE="-0.021539677856109666" MODIFIED="2012-05-31 12:15:45 +0100" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.23218854005693462" STUDY_ID="STD-WELL-AK1A4006" TOTAL_1="155" TOTAL_2="158" VAR="0.05391151813377073" WEIGHT="75.14642681650724"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.013848084475031" CI_END="1.3122109885955355" CI_START="0.22283437042659854" DF="2" EFFECT_SIZE="0.5407455127049605" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.6876429548875701" ID="CMP-006.03.05" LOG_CI_END="0.1180036702650721" LOG_CI_START="-0.6520178218673548" LOG_EFFECT_SIZE="-0.26700707580114136" MODIFIED="2012-08-01 16:31:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.36534114521131855" P_Z="0.1740687021936737" STUDIES="3" TAU2="0.004251487367289366" TOTAL_1="79" TOTAL_2="82" WEIGHT="100.0" Z="1.3592458328360346">
<NAME>Fluoxetine vs Nefazodone</NAME>
<DICH_DATA CI_END="3.874912290729463" CI_START="0.22860211595193827" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5882618766272818" LOG_CI_START="-0.6409197540719801" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2012-05-10 10:26:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1100" O_E="0.0" SE="0.7220273744199487" STUDY_ID="STD-Armitage-1997" TOTAL_1="22" TOTAL_2="21" VAR="0.5213235294117647" WEIGHT="38.926574250100856"/>
<DICH_DATA CI_END="1.0527697577491515" CI_START="0.04075740488313881" EFFECT_SIZE="0.20714285714285716" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.02233340074622079" LOG_CI_START="-1.3897934763047846" LOG_EFFECT_SIZE="-0.6837300377792819" ORDER="4923" O_E="0.0" SE="0.8294903177205375" STUDY_ID="STD-Berlanga-1997" TOTAL_1="37" TOTAL_2="37" VAR="0.6880541871921182" WEIGHT="29.551736561552996"/>
<DICH_DATA CI_END="3.235637595267818" CI_START="0.1389798974930187" EFFECT_SIZE="0.6705882352941176" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.5099598728941104" LOG_CI_START="-0.857048012977713" LOG_EFFECT_SIZE="-0.17354407004180136" ORDER="4924" O_E="0.0" SE="0.8029871989592776" STUDY_ID="STD-Gillin-1997" TOTAL_1="20" TOTAL_2="24" VAR="0.6447884416924665" WEIGHT="31.52168918834614"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.42164182456765364" CI_START="0.03299170005348327" DF="0" EFFECT_SIZE="0.1179435483870968" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="31" I2="0.0" ID="CMP-006.03.06" LOG_CI_END="-0.37505631601653333" LOG_CI_START="-1.4815953047995005" LOG_EFFECT_SIZE="-0.928325810408017" MODIFIED="2012-08-01 16:31:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.0010068500781184836" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="70" WEIGHT="100.00000000000001" Z="3.2886055941324623">
<NAME>Fluoxetine vs Pramipexole</NAME>
<DICH_DATA CI_END="0.42164182456765364" CI_START="0.03299170005348327" EFFECT_SIZE="0.11794354838709678" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="31" LOG_CI_END="-0.37505631601653333" LOG_CI_START="-1.4815953047995005" LOG_EFFECT_SIZE="-0.928325810408017" ORDER="4926" O_E="0.0" SE="0.6499864794674487" STUDY_ID="STD-Corrigan-2000" TOTAL_1="35" TOTAL_2="70" VAR="0.42248242349048803" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5920576389589222" CI_END="1.3319437509160612" CI_START="0.6888535316839515" DF="2" EFFECT_SIZE="0.9578695928062954" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="92" I2="0.0" ID="CMP-006.03.07" LOG_CI_END="0.12448588460711946" LOG_CI_START="-0.16187311066649823" LOG_EFFECT_SIZE="-0.018693613029689395" MODIFIED="2012-08-01 16:31:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7437660232870774" P_Z="0.7980325050924512" STUDIES="3" TAU2="0.0" TOTAL_1="422" TOTAL_2="408" WEIGHT="100.0" Z="0.2558942368414952">
<NAME>Fluoxetine vs Tianeptine</NAME>
<DICH_DATA CI_END="1.4717415838692713" CI_START="0.44131982828616295" EFFECT_SIZE="0.805921052631579" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.16783156098525287" LOG_CI_START="-0.3552465594736954" LOG_EFFECT_SIZE="-0.09370749924422125" ORDER="4929" O_E="0.0" SE="0.3072586772360418" STUDY_ID="STD-Alby-1993" TOTAL_1="104" TOTAL_2="102" VAR="0.09440789473684211" WEIGHT="29.9701247609329"/>
<DICH_DATA CI_END="2.092646231603506" CI_START="0.6095717628461255" EFFECT_SIZE="1.1294326241134751" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.3206958157021025" LOG_CI_START="-0.2149751589980862" LOG_EFFECT_SIZE="0.052860328352008115" ORDER="4930" O_E="0.0" SE="0.3146557821529803" STUDY_ID="STD-Guelfi-1999" TOTAL_1="122" TOTAL_2="115" VAR="0.09900826124230379" WEIGHT="28.577578761389645"/>
<DICH_DATA CI_END="1.6165801847468837" CI_START="0.5805320214579657" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="36" LOG_CI_END="0.20859725112476915" LOG_CI_START="-0.23617382009603574" LOG_EFFECT_SIZE="-0.013788284485633297" ORDER="4931" O_E="0.0" SE="0.26126072888741114" STUDY_ID="STD-Loo-1999" TOTAL_1="196" TOTAL_2="191" VAR="0.06825716845878135" WEIGHT="41.45229647767745"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4463839528832656" CI_END="1.1325077690912149" CI_START="0.2311290762073695" DF="3" EFFECT_SIZE="0.5116204398455182" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" I2="12.952240928054987" ID="CMP-006.03.08" LOG_CI_END="0.054041189988949655" LOG_CI_START="-0.636145416519597" LOG_EFFECT_SIZE="-0.2910521132653236" MODIFIED="2012-08-02 16:34:41 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.32778291567856954" P_Z="0.0983235335691107" STUDIES="4" TAU2="0.08634376347311587" TOTAL_1="118" TOTAL_2="112" WEIGHT="99.99999999999999" Z="1.6530360173462535">
<NAME>Fluoxetine vs Trazodone</NAME>
<DICH_DATA CI_END="2.1286895191798054" CI_START="0.18560811112019815" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3281123218704283" LOG_CI_START="-0.7314030489265672" LOG_EFFECT_SIZE="-0.20164536352806942" ORDER="4932" O_E="0.0" SE="0.6223645734918258" STUDY_ID="STD-Debus-1988" TOTAL_1="22" TOTAL_2="21" VAR="0.3873376623376623" WEIGHT="34.699395043629615"/>
<DICH_DATA CI_END="0.6800591808758838" CI_START="0.021174627745563973" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.16745329198572392" LOG_CI_START="-1.6741842159190266" LOG_EFFECT_SIZE="-0.9208187539523752" ORDER="4933" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Falk-1989" TOTAL_1="14" TOTAL_2="13" VAR="0.7833333333333332" WEIGHT="18.89949612263497"/>
<DICH_DATA CI_END="4.157574955462231" CI_START="0.18725981398841926" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6188400877051932" LOG_CI_START="-0.7275554123503786" LOG_EFFECT_SIZE="-0.0543576623225927" ORDER="4934" O_E="0.0" SE="0.7908793814978561" STUDY_ID="STD-Perry-1989" TOTAL_1="21" TOTAL_2="19" VAR="0.6254901960784314" WEIGHT="23.090298936275577"/>
<DICH_DATA CI_END="3.3232290489282716" CI_START="0.15220595458680714" EFFECT_SIZE="0.7112068965517241" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5215602754518914" LOG_CI_START="-0.8175683568058782" LOG_EFFECT_SIZE="-0.1480040406769934" MODIFIED="2012-08-02 16:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2926" O_E="0.0" SE="0.7866107873818514" STUDY_ID="STD-Zhao-2006-a" TOTAL_1="61" TOTAL_2="59" VAR="0.6187565308254963" WEIGHT="23.310809897459826"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.418854154422906" CI_END="1.3574174524903495" CI_START="0.475072881359592" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.803039364142498" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.1327134286712197" LOG_CI_START="-0.32323975975555147" LOG_EFFECT_SIZE="-0.09526316554216586" METHOD="MH" MODIFIED="2013-06-21 10:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5792657535681934" P_Q="0.7815027246186226" P_Z="0.41278756535843364" Q="3.9850073171974456" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1031" TOTAL_2="1059" WEIGHT="800.0" Z="0.8189979947729191">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other ADs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1966458555460684" CI_START="0.026098833691095273" DF="0" EFFECT_SIZE="0.23943661971830987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.34176004536858784" LOG_CI_START="-1.5833789000501906" LOG_EFFECT_SIZE="-0.6208094273408014" NO="1" P_CHI2="1.0" P_Z="0.20620160038929125" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="1.2640792725599572">
<NAME>Fluoxetine vs ABT-200</NAME>
<DICH_DATA CI_END="2.1966458555460684" CI_START="0.026098833691095273" EFFECT_SIZE="0.23943661971830985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34176004536858784" LOG_CI_START="-1.5833789000501906" LOG_EFFECT_SIZE="-0.6208094273408014" ORDER="4945" O_E="0.0" SE="1.1308361461304615" STUDY_ID="STD-Sramek-1995" TOTAL_1="72" TOTAL_2="72" VAR="1.2787903893951946" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.570804164502405" CI_START="0.19255821062029185" DF="0" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.7459178915826034" LOG_CI_START="-0.7154379584691295" LOG_EFFECT_SIZE="0.015239966556736905" NO="2" P_CHI2="1.0" P_Z="0.9673919196706682" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="0.04087955110419112">
<NAME>Fluoxetine vs Amineptine</NAME>
<DICH_DATA CI_END="5.570804164502404" CI_START="0.19255821062029188" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7459178915826031" LOG_CI_START="-0.7154379584691295" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="4946" O_E="0.0" SE="0.8584076601485112" STUDY_ID="STD-Ferreri-1989" TOTAL_1="31" TOTAL_2="32" VAR="0.7368637110016419" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0973557524473176" CI_START="0.4341470427393401" DF="0" EFFECT_SIZE="1.1596153846153847" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-006.04.03" LOG_CI_END="0.49099108990689594" LOG_CI_START="-0.3623631528961916" LOG_EFFECT_SIZE="0.06431396850535219" NO="3" P_CHI2="1.0" P_Z="0.7676657055961095" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="142" WEIGHT="100.0" Z="0.2954296250037407">
<NAME>Fluoxetine vs Amisulpride</NAME>
<DICH_DATA CI_END="3.0973557524473176" CI_START="0.4341470427393401" EFFECT_SIZE="1.1596153846153847" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.49099108990689594" LOG_CI_START="-0.3623631528961916" LOG_EFFECT_SIZE="0.06431396850535219" ORDER="4947" O_E="0.0" SE="0.5012645063941621" STUDY_ID="STD-Smeraldi-1998" TOTAL_1="139" TOTAL_2="142" VAR="0.25126610537058297" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9892014447778379" CI_END="4.0984769935193" CI_START="0.3278036225290334" DF="1" EFFECT_SIZE="1.1590925784110293" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-006.04.04" LOG_CI_END="0.6126225015513055" LOG_CI_START="-0.48438625138883634" LOG_EFFECT_SIZE="0.06411812508123454" MODIFIED="2012-05-31 12:16:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3199378615513012" P_Z="0.818781468570601" STUDIES="2" TAU2="0.0" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0" Z="0.22911251269170357">
<NAME>Fluoxetine vs Bupropion</NAME>
<DICH_DATA CI_END="30.172854820461456" CI_START="0.30847827509506776" EFFECT_SIZE="3.0508474576271185" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4796164031188954" LOG_CI_START="-0.5107754161965717" LOG_EFFECT_SIZE="0.48442049346116184" MODIFIED="2012-05-31 12:16:00 +0100" MODIFIED_BY="[Empty name]" ORDER="4948" O_E="0.0" SE="1.1691660072643117" STUDY_ID="STD-Feighner-1991" TOTAL_1="62" TOTAL_2="61" VAR="1.366949152542373" WEIGHT="30.376870484506462"/>
<DICH_DATA CI_END="3.4522200953659685" CI_START="0.1672546944756167" EFFECT_SIZE="0.7598684210526315" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5380984762540154" LOG_CI_START="-0.7766216836872343" LOG_EFFECT_SIZE="-0.11926160371660946" MODIFIED="2012-05-31 12:16:00 +0100" MODIFIED_BY="[Empty name]" ORDER="983" O_E="0.0" SE="0.7722731299192409" STUDY_ID="STD-WELL-AK1A4006" TOTAL_1="155" TOTAL_2="158" VAR="0.5964057871952608" WEIGHT="69.62312951549355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4681311557022996" CI_END="10.71357825870639" CI_START="0.04749334486572885" DF="1" EFFECT_SIZE="0.7133187695460688" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="31.886194491824057" ID="CMP-006.04.05" LOG_CI_END="1.0299345463189373" LOG_CI_START="-1.323367242808514" LOG_EFFECT_SIZE="-0.14671634824478816" MODIFIED="2013-06-21 10:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.22564110160139061" P_Z="0.8069307299978383" STUDIES="3" TAU2="1.2205409485400653" TOTAL_1="79" TOTAL_2="82" WEIGHT="100.0" Z="0.2443874898082164">
<NAME>Fluoxetine vs Nefazodone</NAME>
<DICH_DATA CI_END="77.83304593428136" CI_START="0.11563211861963084" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8911640265500982" LOG_CI_START="-0.9369215171107735" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-05-10 10:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="0.0" SE="1.6612314475956143" STUDY_ID="STD-Armitage-1997" TOTAL_1="22" TOTAL_2="21" VAR="2.75968992248062" WEIGHT="48.00894807030647"/>
<DICH_DATA CI_END="4.082088766818504" CI_START="0.008781560901491521" EFFECT_SIZE="0.18933333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6108824444075618" LOG_CI_START="-2.0564282824248488" LOG_EFFECT_SIZE="-0.7227729190086436" ORDER="4962" O_E="0.0" SE="1.5667915243423975" STUDY_ID="STD-Berlanga-1997" TOTAL_1="37" TOTAL_2="37" VAR="2.4548356807511738" WEIGHT="51.991051929693526"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4963" O_E="0.0" SE="0.0" STUDY_ID="STD-Gillin-1997" TOTAL_1="20" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.521320306131403E-33" CI_END="4.5132831640315185" CI_START="0.05218160972033188" DF="0" EFFECT_SIZE="0.4852941176470588" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="100.0" ID="CMP-006.04.06" LOG_CI_END="0.6544925820728817" LOG_CI_START="-1.2824825277295795" LOG_EFFECT_SIZE="-0.3139949728283488" MODIFIED="2013-06-21 10:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.5251393995972751" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="70" WEIGHT="99.99999999999999" Z="0.6354432072521149">
<NAME>Fluoxetine vs Pramipexole</NAME>
<DICH_DATA CI_END="4.5132831640315185" CI_START="0.05218160972033188" EFFECT_SIZE="0.4852941176470588" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.6544925820728817" LOG_CI_START="-1.2824825277295795" LOG_EFFECT_SIZE="-0.3139949728283488" ORDER="4965" O_E="0.0" SE="1.1377887676793954" STUDY_ID="STD-Corrigan-2000" TOTAL_1="35" TOTAL_2="70" VAR="1.2945632798573974" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8692737260628602" CI_END="2.5251563969647464" CI_START="0.2656655697268697" DF="2" EFFECT_SIZE="0.8190525702597415" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="48.31071302791804" ID="CMP-006.04.07" LOG_CI_END="0.40228828155778057" LOG_CI_START="-0.5756647265326504" LOG_EFFECT_SIZE="-0.08668822248743495" MODIFIED="2013-06-21 10:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.14447686708845464" P_Z="0.7282365203897183" STUDIES="3" TAU2="0.47885696702583186" TOTAL_1="422" TOTAL_2="408" WEIGHT="100.0" Z="0.3474723070609066">
<NAME>Fluoxetine vs Tianeptine</NAME>
<DICH_DATA CI_END="9.477224591852558" CI_START="0.5984106561197479" EFFECT_SIZE="2.381443298969072" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.976681172684165" LOG_CI_START="-0.22300068143236604" LOG_EFFECT_SIZE="0.37684024562589946" ORDER="4968" O_E="0.0" SE="0.7046990596290034" STUDY_ID="STD-Alby-1993" TOTAL_1="104" TOTAL_2="102" VAR="0.4966007646420017" WEIGHT="33.830056445011586"/>
<DICH_DATA CI_END="2.0830648309914785" CI_START="0.025249480532092777" EFFECT_SIZE="0.22933884297520662" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31870278665619856" LOG_CI_START="-1.5977475523717086" LOG_EFFECT_SIZE="-0.639522382857755" ORDER="4969" O_E="0.0" SE="1.1257324157271684" STUDY_ID="STD-Guelfi-1999" TOTAL_1="122" TOTAL_2="115" VAR="1.2672734718189262" WEIGHT="18.898811559506676"/>
<DICH_DATA CI_END="1.5891386350195187" CI_START="0.25353975072459284" EFFECT_SIZE="0.6347517730496454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.20116178631854056" LOG_CI_START="-0.5959539409974765" LOG_EFFECT_SIZE="-0.19739607733946796" ORDER="4970" O_E="0.0" SE="0.4682297240119154" STUDY_ID="STD-Loo-1999" TOTAL_1="196" TOTAL_2="191" VAR="0.2192390744482745" WEIGHT="47.27113199548173"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08707003712959138" CI_END="1.5144662836194007" CI_START="0.0352931606970797" DF="1" EFFECT_SIZE="0.2311932133910695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-006.04.08" LOG_CI_END="0.18025960913071762" LOG_CI_START="-1.4523094464336377" LOG_EFFECT_SIZE="-0.6360249186514599" MODIFIED="2013-06-21 10:52:14 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7679355892440967" P_Z="0.1267246245881407" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="34" WEIGHT="100.0" Z="1.5271463459117849">
<NAME>Fluoxetine vs Trazodone</NAME>
<DICH_DATA CI_END="2.993191718562847" CI_START="0.02727277793632933" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4761345349649244" LOG_CI_START="-1.5642706236654758" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="4971" O_E="0.0" SE="1.1985440903479256" STUDY_ID="STD-Debus-1988" TOTAL_1="22" TOTAL_2="21" VAR="1.4365079365079365" WEIGHT="64.01920771742053"/>
<DICH_DATA CI_END="3.640802586241656" CI_START="0.006910707897693338" EFFECT_SIZE="0.15862068965517243" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5611971309992377" LOG_CI_START="-2.160477463434001" LOG_EFFECT_SIZE="-0.799640166217382" ORDER="4972" O_E="0.0" SE="1.598725129276609" STUDY_ID="STD-Falk-1989" TOTAL_1="14" TOTAL_2="13" VAR="2.5559220389805097" WEIGHT="35.98079228257948"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.33074062087631" CI_END="1.0433608161807797" CI_START="0.5636799304100524" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.766890834641644" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="143" I2="47.24823834671752" I2_Q="67.97101277092729" ID="CMP-006.05" LOG_CI_END="0.018434522595279588" LOG_CI_START="-0.24896742777930325" LOG_EFFECT_SIZE="-0.11526645259201185" METHOD="MH" MODIFIED="2013-05-06 15:45:46 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.016360943499866498" P_Q="0.0026905908561318803" P_Z="0.09108026973505852" Q="21.85520244500925" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3741551966852929" TOTALS="SUB" TOTAL_1="1195" TOTAL_2="1229" WEIGHT="800.0" Z="1.6897266111153306">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other ADs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.26901619120778103" CI_START="0.021995552523243297" DF="0" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="26" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="-0.5702215804415278" LOG_CI_START="-1.6576651241721458" LOG_EFFECT_SIZE="-1.1139433523068367" NO="1" P_CHI2="1.0" P_Z="5.9331892876604085E-5" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="4.015452321964512">
<NAME>Fluoxetine vs ABT-200</NAME>
<DICH_DATA CI_END="0.26901619120778103" CI_START="0.021995552523243297" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="26" LOG_CI_END="-0.5702215804415278" LOG_CI_START="-1.6576651241721458" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="4983" O_E="0.0" SE="0.6387697205197213" STUDY_ID="STD-Sramek-1995" TOTAL_1="72" TOTAL_2="72" VAR="0.40802675585284276" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.325572925921961" CI_END="7.819648787511792" CI_START="0.03496722944027413" DF="1" EFFECT_SIZE="0.52290673479626" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="76.88167516475616" ID="CMP-006.05.02" LOG_CI_END="0.8931872475520578" LOG_CI_START="-1.4563387767976355" LOG_EFFECT_SIZE="-0.2815757646227888" NO="2" P_CHI2="0.037543967985311566" P_Z="0.6385133074526812" STUDIES="2" TAU2="2.950474213433231" TOTAL_1="113" TOTAL_2="119" WEIGHT="100.0" Z="0.46977845902578896">
<NAME>Fluoxetine vs Amineptine</NAME>
<DICH_DATA CI_END="7.863356728966733" CI_START="0.42040380945572725" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8956079783125254" LOG_CI_START="-0.37633335730101314" LOG_EFFECT_SIZE="0.2596373105057561" ORDER="4984" O_E="0.0" SE="0.7471446367505479" STUDY_ID="STD-Dalery-1997" TOTAL_1="82" TOTAL_2="87" VAR="0.5582251082251082" WEIGHT="54.286216047852726"/>
<DICH_DATA CI_END="1.0337952007425224" CI_START="0.013709035978042619" EFFECT_SIZE="0.11904761904761904" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.014434511681664609" LOG_CI_START="-1.8629930838054278" LOG_EFFECT_SIZE="-0.9242792860618817" ORDER="4985" O_E="0.0" SE="1.102810263005598" STUDY_ID="STD-Ferreri-1989" TOTAL_1="31" TOTAL_2="32" VAR="1.2161904761904763" WEIGHT="45.71378395214727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8173933901311268" CI_START="0.32558497216096294" DF="0" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-006.05.03" LOG_CI_END="0.2594489441881633" LOG_CI_START="-0.48733564880183683" LOG_EFFECT_SIZE="-0.11394335230683675" NO="3" P_CHI2="1.0" P_Z="0.5497751177465728" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="142" WEIGHT="100.0" Z="0.5980971458047994">
<NAME>Fluoxetine vs Amisulpride</NAME>
<DICH_DATA CI_END="1.8173933901311268" CI_START="0.32558497216096294" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2594489441881633" LOG_CI_START="-0.48733564880183683" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="4986" O_E="0.0" SE="0.43866496656568005" STUDY_ID="STD-Smeraldi-1998" TOTAL_1="139" TOTAL_2="142" VAR="0.19242695289206918" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7684419625285394" CI_END="2.2525147108333767" CI_START="0.4516637163669987" DF="1" EFFECT_SIZE="1.0086521528586248" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-006.05.04" LOG_CI_END="0.3526676359720317" LOG_CI_START="-0.3451847963425601" LOG_EFFECT_SIZE="0.0037414198147358566" MODIFIED="2012-05-31 12:16:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3806995145658496" P_Z="0.9832328586651332" STUDIES="2" TAU2="0.0" TOTAL_1="217" TOTAL_2="219" WEIGHT="99.99999999999999" Z="0.021016042212835588">
<NAME>Fluoxetine vs Bupropion</NAME>
<DICH_DATA CI_END="2.361408735374529" CI_START="0.1692449458686775" EFFECT_SIZE="0.632183908045977" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3731711654582816" LOG_CI_START="-0.7714842917070309" LOG_EFFECT_SIZE="-0.19915656312437469" MODIFIED="2012-05-31 12:16:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4987" O_E="0.0" SE="0.6723762816747998" STUDY_ID="STD-Feighner-1991" TOTAL_1="62" TOTAL_2="61" VAR="0.4520898641588297" WEIGHT="37.1687218419839"/>
<DICH_DATA CI_END="3.664072992544859" CI_START="0.4825840958927178" EFFECT_SIZE="1.3297455968688845" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5639641167271713" LOG_CI_START="-0.31642699485957054" LOG_EFFECT_SIZE="0.12376856093380037" MODIFIED="2012-05-31 12:16:18 +0100" MODIFIED_BY="[Empty name]" ORDER="984" O_E="0.0" SE="0.5171460969523395" STUDY_ID="STD-WELL-AK1A4006" TOTAL_1="155" TOTAL_2="158" VAR="0.2674400855930385" WEIGHT="62.83127815801608"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6574782960044663" CI_END="1.8078076935949932" CI_START="0.3202565417582881" DF="3" EFFECT_SIZE="0.7608956828072816" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-006.05.05" LOG_CI_END="0.2571522303138553" LOG_CI_START="-0.49450199032485376" LOG_EFFECT_SIZE="-0.11867488000549926" MODIFIED="2012-08-01 16:31:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8831569194144404" P_Z="0.5359838334995073" STUDIES="4" TAU2="0.0" TOTAL_1="140" TOTAL_2="146" WEIGHT="100.0" Z="0.6188975842715109">
<NAME>Fluoxetine vs Nefazodone</NAME>
<DICH_DATA CI_END="16.27869026354514" CI_START="0.055718824043803544" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2116194598776948" LOG_CI_START="-1.2539980580175711" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2012-05-10 10:27:49 +0100" MODIFIED_BY="[Empty name]" ORDER="1102" O_E="0.0" SE="1.4483159350152326" STUDY_ID="STD-Armitage-1997" TOTAL_1="22" TOTAL_2="21" VAR="2.0976190476190473" WEIGHT="9.293617344588146"/>
<DICH_DATA CI_END="3.175380077375361" CI_START="0.031211497588284003" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5017957156524533" LOG_CI_START="-1.5056853925418425" LOG_EFFECT_SIZE="-0.5019448384446946" ORDER="5003" O_E="0.0" SE="1.1792043401450798" STUDY_ID="STD-Berlanga-1997" TOTAL_1="37" TOTAL_2="37" VAR="1.3905228758169932" WEIGHT="14.019523951978847"/>
<DICH_DATA CI_END="4.506171095028242" CI_START="0.17277344698734493" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6538076774490574" LOG_CI_START="-0.7625230020942428" LOG_EFFECT_SIZE="-0.0543576623225927" ORDER="5004" O_E="0.0" SE="0.8319596521136695" STUDY_ID="STD-Gillin-1997" TOTAL_1="20" TOTAL_2="24" VAR="0.692156862745098" WEIGHT="28.164813227417365"/>
<DICH_DATA CI_END="2.9894575660871925" CI_START="0.2491868084943904" EFFECT_SIZE="0.8630952380952381" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4755923931985601" LOG_CI_START="-0.6034749521803361" LOG_EFFECT_SIZE="-0.06394127949088795" ORDER="5005" O_E="0.0" SE="0.6338495001450694" STUDY_ID="STD-Rush-1998" TOTAL_1="61" TOTAL_2="64" VAR="0.4017651888341543" WEIGHT="48.522045476015634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.49927587341195373" CI_START="0.008247810971224501" DF="0" EFFECT_SIZE="0.06417112299465243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="22" I2="0.0" ID="CMP-006.05.06" LOG_CI_END="-0.3016594199196903" LOG_CI_START="-2.083661301058058" LOG_EFFECT_SIZE="-1.192660360488874" MODIFIED="2012-08-01 16:31:37 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.008702273287372457" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="70" WEIGHT="100.0" Z="2.6235341018310017">
<NAME>Fluoxetine vs Pramipexole</NAME>
<DICH_DATA CI_END="0.49927587341195373" CI_START="0.008247810971224501" EFFECT_SIZE="0.06417112299465241" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="22" LOG_CI_END="-0.3016594199196903" LOG_CI_START="-2.083661301058058" LOG_EFFECT_SIZE="-1.1926603604888741" ORDER="5007" O_E="0.0" SE="1.0467567260322528" STUDY_ID="STD-Corrigan-2000" TOTAL_1="35" TOTAL_2="70" VAR="1.095699643493761" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13405214562045104" CI_END="1.8030986385395649" CI_START="0.7108024228573859" DF="2" EFFECT_SIZE="1.1320984413578072" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" I2="0.0" ID="CMP-006.05.07" LOG_CI_END="0.25601948545877645" LOG_CI_START="-0.14825110051811508" LOG_EFFECT_SIZE="0.053884192470330654" MODIFIED="2012-08-01 16:31:37 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9351708291486728" P_Z="0.6013381375644735" STUDIES="3" TAU2="0.0" TOTAL_1="422" TOTAL_2="408" WEIGHT="100.0" Z="0.522477173661649">
<NAME>Fluoxetine vs Tianeptine</NAME>
<DICH_DATA CI_END="3.988181043648093" CI_START="0.44576155353057834" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6007748649035856" LOG_CI_START="-0.3508973916869858" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="5009" O_E="0.0" SE="0.5590169943749475" STUDY_ID="STD-Alby-1993" TOTAL_1="104" TOTAL_2="102" VAR="0.3125" WEIGHT="18.045522870585867"/>
<DICH_DATA CI_END="2.344849831232763" CI_START="0.555581967611954" EFFECT_SIZE="1.141383495145631" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.37011503487402414" LOG_CI_START="-0.2552518584954604" LOG_EFFECT_SIZE="0.05743158818928186" ORDER="5010" O_E="0.0" SE="0.36734360878128286" STUDY_ID="STD-Guelfi-1999" TOTAL_1="122" TOTAL_2="115" VAR="0.1349413269124562" WEIGHT="41.79020635180619"/>
<DICH_DATA CI_END="2.173795030419206" CI_START="0.5004021662073223" EFFECT_SIZE="1.0429629629629629" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.3372185915651198" LOG_CI_START="-0.3006808189429453" LOG_EFFECT_SIZE="0.01826888631108725" ORDER="5011" O_E="0.0" SE="0.3747052713854455" STUDY_ID="STD-Loo-1999" TOTAL_1="196" TOTAL_2="191" VAR="0.1404040404040404" WEIGHT="40.16427077760793"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5843563261401659" CI_END="2.19456225054513" CI_START="0.19595831499607522" DF="2" EFFECT_SIZE="0.6557764259035379" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-006.05.08" LOG_CI_END="0.34134790447231395" LOG_CI_START="-0.7078363036056475" LOG_EFFECT_SIZE="-0.1832441995666668" MODIFIED="2012-08-01 16:31:37 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4528574895416968" P_Z="0.4935767868928268" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="53" WEIGHT="100.0" Z="0.6846310281098889">
<NAME>Fluoxetine vs Trazodone</NAME>
<DICH_DATA CI_END="16.27869026354514" CI_START="0.055718824043803544" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2116194598776948" LOG_CI_START="-1.2539980580175711" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="5012" O_E="0.0" SE="1.4483159350152326" STUDY_ID="STD-Debus-1988" TOTAL_1="22" TOTAL_2="21" VAR="2.0976190476190473" WEIGHT="18.107232426504176"/>
<DICH_DATA CI_END="1.7267096937502275" CI_START="0.0411830149378877" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.23721932714457158" LOG_CI_START="-1.3852818626000092" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="5013" O_E="0.0" SE="0.9530652303663866" STUDY_ID="STD-Falk-1989" TOTAL_1="14" TOTAL_2="13" VAR="0.9083333333333334" WEIGHT="41.81512914220229"/>
<DICH_DATA CI_END="9.548097015043625" CI_START="0.210193134954785" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.979916823079172" LOG_CI_START="-0.6773814724178738" LOG_EFFECT_SIZE="0.15126767533064914" ORDER="5014" O_E="0.0" SE="0.973505222533836" STUDY_ID="STD-Perry-1989" TOTAL_1="21" TOTAL_2="19" VAR="0.9477124183006536" WEIGHT="40.07763843129354"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-07-02 12:06:29 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Fluoxetine versus other non-conventional AD agents</NAME>
<DICH_OUTCOME CHI2="16.37110272072458" CI_END="1.5593963453267552" CI_START="0.5336346780529742" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9122214460839142" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="182" I2="63.35005587372894" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.19295651205325742" LOG_CI_START="-0.2727559557075323" LOG_EFFECT_SIZE="-0.039899721827137434" METHOD="MH" MODIFIED="2013-05-06 15:45:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.011894826747399945" P_Q="0.47645473282806106" P_Z="0.7369928848141871" Q="0.5069672274994883" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3062974252891267" TOTALS="SUB" TOTAL_1="376" TOTAL_2="381" WEIGHT="200.0" Z="0.33583819711918916">
<NAME>Failure to respond - HDRS (-50%)</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other non-conventional AD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5983424489781575" CI_START="0.1078675432944646" DF="0" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.4146963884231461" LOG_CI_START="-0.9671092123010442" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2012-08-01 16:32:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.43330613912770355" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.7835467151322238">
<NAME>Fluoxetine vs Crocus Sativus</NAME>
<DICH_DATA CI_END="2.5983424489781575" CI_START="0.1078675432944646" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4146963884231461" LOG_CI_START="-0.9671092123010442" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2012-05-28 14:38:25 +0100" MODIFIED_BY="[Empty name]" ORDER="919" O_E="0.0" SE="0.8116794499134278" STUDY_ID="STD-Akhondzadeh-Basti-2007" TOTAL_1="20" TOTAL_2="20" VAR="0.6588235294117647" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.398261984469931" CI_END="1.7286564946077858" CI_START="0.5534210786849648" DF="5" EFFECT_SIZE="0.9780976136979432" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="177" I2="67.52880289319147" ID="CMP-007.01.02" LOG_CI_END="0.2377087021706472" LOG_CI_START="-0.25694430348522157" LOG_EFFECT_SIZE="-0.009617800657287156" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.008789540330457757" P_Z="0.9392462687393949" STUDIES="6" TAU2="0.32421999165981685" TOTAL_1="356" TOTAL_2="361" WEIGHT="100.0" Z="0.07621723787475719">
<NAME>Fluoxetine vs Hypericum</NAME>
<DICH_DATA CI_END="1.4494029099736787" CI_START="0.21745085337738002" EFFECT_SIZE="0.5614035087719298" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.16118912891840026" LOG_CI_START="-0.662638883623571" LOG_EFFECT_SIZE="-0.2507248773525855" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1112" O_E="0.0" SE="0.4839206525815854" STUDY_ID="STD-Behnke-2002" TOTAL_1="35" TOTAL_2="35" VAR="0.23417919799498746" WEIGHT="15.119301560664331"/>
<DICH_DATA CI_END="2.347043744031247" CI_START="0.5155421593982406" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.3705211840231115" LOG_CI_START="-0.2877358137066613" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1110" O_E="0.0" SE="0.3866634188911585" STUDY_ID="STD-Bjerkenstedt-2005" TOTAL_1="57" TOTAL_2="59" VAR="0.14950859950859952" WEIGHT="17.821609033135452"/>
<DICH_DATA CI_END="3.410190909228806" CI_START="0.6005855737960759" EFFECT_SIZE="1.4311224489795917" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.5327786923367251" LOG_CI_START="-0.22142510386531689" LOG_EFFECT_SIZE="0.15567679423570413" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1111" O_E="0.0" SE="0.44302304325808173" STUDY_ID="STD-Fava-2005" TOTAL_1="47" TOTAL_2="45" VAR="0.19626941685765215" WEIGHT="16.22051400367396"/>
<DICH_DATA CI_END="1.6884001125365147" CI_START="0.45573766713052" EFFECT_SIZE="0.8771929824561403" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" LOG_CI_END="0.22747537242929408" LOG_CI_START="-0.3412850751022392" LOG_EFFECT_SIZE="-0.05690485133647262" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1109" O_E="0.0" SE="0.33409270228964427" STUDY_ID="STD-Harrer-1999" TOTAL_1="84" TOTAL_2="77" VAR="0.11161793372319688" WEIGHT="19.37097541982431"/>
<DICH_DATA CI_END="0.8343672344513329" CI_START="0.05014439835082835" EFFECT_SIZE="0.20454545454545456" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="-0.07864275896357563" LOG_CI_START="-1.2997775751301492" LOG_EFFECT_SIZE="-0.6892101670468626" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1108" O_E="0.0" SE="0.7173006357310734" STUDY_ID="STD-Moreno-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.514520202020202" WEIGHT="10.065817523992957"/>
<DICH_DATA CI_END="3.810786167302235" CI_START="1.3482199084959303" EFFECT_SIZE="2.2666666666666666" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="50" LOG_CI_END="0.5810145801114162" LOG_CI_START="0.12976073586173154" LOG_EFFECT_SIZE="0.35538765798657385" MODIFIED="2012-11-21 13:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1107" O_E="0.0" SE="0.2650687418548191" STUDY_ID="STD-Schrader-2000" TOTAL_1="113" TOTAL_2="125" VAR="0.07026143790849673" WEIGHT="21.401782458708993"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.5955623887449044" CI_END="0.28910060848539276" CI_START="-0.02001136684462204" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13454462082038535" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2013-05-06 15:46:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.46349745392137354" P_Q="1.0" P_Z="0.08797183025117691" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="325" TOTAL_2="323" UNITS="" WEIGHT="100.0" Z="1.7061947266198176">
<NAME>End-point score on rating scales</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Hypericum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hypericum</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.5955623887449044" CI_END="0.28910060848539276" CI_START="-0.02001136684462204" DF="4" EFFECT_SIZE="0.13454462082038535" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" MODIFIED="2012-11-21 13:21:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.46349745392137354" P_Z="0.08797183025117691" STUDIES="5" TAU2="0.0" TOTAL_1="325" TOTAL_2="323" WEIGHT="100.0" Z="1.7061947266198176">
<NAME>Fluoxetine vs Hypericum</NAME>
<CONT_DATA CI_END="0.8169161320754179" CI_START="-0.19455652156954018" EFFECT_SIZE="0.31117980525293887" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="10.0" MODIFIED="2012-11-21 13:21:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1132" SD_1="6.8" SD_2="5.8" SE="0.25803347960047357" STUDY_ID="STD-Behnke-2002" TOTAL_1="32" TOTAL_2="29" WEIGHT="9.339494477618025"/>
<CONT_DATA CI_END="0.36655971585735486" CI_START="-0.38783631160203563" EFFECT_SIZE="-0.010638297872340408" ESTIMABLE="YES" MEAN_1="14.91" MEAN_2="15.0" MODIFIED="2012-11-21 13:21:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1131" SD_1="8.4" SD_2="8.4" SE="0.19245150253014087" STUDY_ID="STD-Bjerkenstedt-2005" TOTAL_1="54" TOTAL_2="54" WEIGHT="16.7893110510844"/>
<CONT_DATA CI_END="0.8552032036603774" CI_START="0.027324145813271028" EFFECT_SIZE="0.4412636747368242" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="10.2" MODIFIED="2012-11-21 13:21:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1130" SD_1="7.3" SD_2="6.6" SE="0.21119751800984882" STUDY_ID="STD-Fava-2005" TOTAL_1="47" TOTAL_2="45" WEIGHT="13.941126480486078"/>
<CONT_DATA CI_END="0.3530744936792165" CI_START="-0.2904068013132789" EFFECT_SIZE="0.031333846182968826" ESTIMABLE="YES" MEAN_1="8.11" MEAN_2="7.91" MODIFIED="2012-11-21 13:21:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1134" SD_1="6.8" SD_2="5.8" SE="0.16415640799223702" STUDY_ID="STD-Harrer-1999" TOTAL_1="79" TOTAL_2="70" WEIGHT="23.07596154418294"/>
<CONT_DATA CI_END="0.3591121888548612" CI_START="-0.1500696292885856" EFFECT_SIZE="0.10452127978313777" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="11.54" MODIFIED="2012-11-21 13:21:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1133" SD_1="6.8" SD_2="5.8" SE="0.12989570781907422" STUDY_ID="STD-Schrader-2000" TOTAL_1="113" TOTAL_2="125" WEIGHT="36.85410644662855"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.105531229898844" CI_END="1.8266407966246878" CI_START="0.5863799833103255" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0349423171552818" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="2.066998029134275" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.261653153055197" LOG_CI_START="-0.2318208632070454" LOG_EFFECT_SIZE="0.014916144924075777" METHOD="MH" MODIFIED="2013-06-21 10:52:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4031375781183866" P_Q="0.9807264706266733" P_Z="0.9056818626223493" Q="5.836155845920137E-4" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008629003876554665" TOTALS="SUB" TOTAL_1="357" TOTAL_2="362" WEIGHT="200.0" Z="0.1184869147146031">
<NAME>Failure to complete - Total</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other non-conventional AD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other non-conventional AD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.18118077307193" CI_START="0.058203217416075405" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="1.2350530073187374" LOG_CI_START="-1.2350530073187374" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-16 14:12:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>Fluoxetine vs Crocus Sativus</NAME>
<DICH_DATA CI_END="17.18118077307193" CI_START="0.058203217416075405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2350530073187374" LOG_CI_START="-1.2350530073187374" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-28 14:38:41 +0100" MODIFIED_BY="[Empty name]" ORDER="922" O_E="0.0" SE="1.4509525002200232" STUDY_ID="STD-Noorbala-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.1052631578947367" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.105011567552521" CI_END="1.8507574552269495" CI_START="0.5803940185229923" DF="4" EFFECT_SIZE="1.0364210325685967" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" I2="21.64562318675201" ID="CMP-007.03.02" LOG_CI_END="0.2673495074841486" LOG_CI_START="-0.23627707200246842" LOG_EFFECT_SIZE="0.015536217740840104" MODIFIED="2012-11-21 13:19:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2766914618955266" P_Z="0.9037507386557081" STUDIES="5" TAU2="0.09490090623704879" TOTAL_1="337" TOTAL_2="342" WEIGHT="100.0" Z="0.12092462339481419">
<NAME>Fluoxetine vs Hypericum</NAME>
<DICH_DATA CI_END="1.9790239006226413" CI_START="0.10374926020873294" EFFECT_SIZE="0.453125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2964510392017717" LOG_CI_START="-0.9840149913716337" LOG_EFFECT_SIZE="-0.3437819760849311" MODIFIED="2012-11-21 13:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1122" O_E="0.0" SE="0.7521520847678943" STUDY_ID="STD-Behnke-2002" TOTAL_1="35" TOTAL_2="35" VAR="0.5657327586206896" WEIGHT="13.247434717982456"/>
<DICH_DATA CI_END="3.350528856497003" CI_START="0.42643177654946074" EFFECT_SIZE="1.1953125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5251133626579799" LOG_CI_START="-0.370150440318519" LOG_EFFECT_SIZE="0.07748146116973044" MODIFIED="2012-11-21 13:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1121" O_E="0.0" SE="0.5258823894956925" STUDY_ID="STD-Bjerkenstedt-2005" TOTAL_1="57" TOTAL_2="59" VAR="0.2765522875816993" WEIGHT="23.560710994922324"/>
<DICH_DATA CI_END="1.486894969562044" CI_START="0.28319072976397736" EFFECT_SIZE="0.6489028213166145" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.17228029215972754" LOG_CI_START="-0.5479209673602542" LOG_EFFECT_SIZE="-0.18782033760026334" MODIFIED="2012-11-21 13:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1120" O_E="0.0" SE="0.42304978489576833" STUDY_ID="STD-Fava-2005" TOTAL_1="47" TOTAL_2="45" VAR="0.17897112050035588" WEIGHT="31.95544083841662"/>
<DICH_DATA CI_END="5.053731437625628" CI_START="0.8149447911030319" EFFECT_SIZE="2.0294117647058822" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.7036121591794124" LOG_CI_START="-0.0888718117894122" LOG_EFFECT_SIZE="0.3073701736950002" MODIFIED="2012-11-21 13:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1119" O_E="0.0" SE="0.465509007406011" STUDY_ID="STD-Harrer-1999" TOTAL_1="84" TOTAL_2="77" VAR="0.2166986359761296" WEIGHT="28.08637421462251"/>
<DICH_DATA CI_END="82.90332788335277" CI_START="0.13485277046017605" EFFECT_SIZE="3.343612334801762" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9185719642338452" LOG_CI_START="-0.8701401268291302" LOG_EFFECT_SIZE="0.5242159187023576" MODIFIED="2012-11-21 13:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1118" O_E="0.0" SE="1.6381032866378762" STUDY_ID="STD-Schrader-2000" TOTAL_1="114" TOTAL_2="126" VAR="2.683382377693812" WEIGHT="3.150039234056084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="99.39178894612022" CI_START="0.22196526059321717" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.696969696969697" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="1.9973505075091225" LOG_CI_START="-0.6537149909243144" LOG_EFFECT_SIZE="0.671817758292404" METHOD="MH" MODIFIED="2013-06-21 10:52:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.32053184143403535" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="198" TOTAL_2="203" WEIGHT="100.0" Z="0.9933655816543441">
<NAME>Failure to complete - Inefficacy</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other non-conventional AD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.39178894612022" CI_START="0.22196526059321717" DF="0" EFFECT_SIZE="4.696969696969697" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="1.9973505075091225" LOG_CI_START="-0.6537149909243144" LOG_EFFECT_SIZE="0.671817758292404" MODIFIED="2012-11-21 13:20:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32053184143403535" STUDIES="2" TAU2="0.0" TOTAL_1="198" TOTAL_2="203" WEIGHT="100.0" Z="0.9933655816543441">
<NAME>Fluoxetine vs Hypericum</NAME>
<DICH_DATA CI_END="99.39178894612022" CI_START="0.22196526059321717" EFFECT_SIZE="4.696969696969697" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9973505075091225" LOG_CI_START="-0.6537149909243144" LOG_EFFECT_SIZE="0.671817758292404" MODIFIED="2012-11-21 13:20:53 +0000" MODIFIED_BY="[Empty name]" ORDER="1124" O_E="0.0" SE="1.5572489967656629" STUDY_ID="STD-Harrer-1999" TOTAL_1="84" TOTAL_2="77" VAR="2.4250244379276635" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-21 13:20:53 +0000" MODIFIED_BY="[Empty name]" ORDER="1123" O_E="0.0" SE="0.0" STUDY_ID="STD-Schrader-2000" TOTAL_1="114" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.46670403796449" CI_END="2.6414066378403827" CI_START="0.5550000414883058" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2107769379984485" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.42183526488579914" LOG_CI_START="-0.25570698441220374" LOG_EFFECT_SIZE="0.08306414023679771" METHOD="MH" MODIFIED="2013-06-21 10:52:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9261431090314659" P_Q="1.0" P_Z="0.6308232260519244" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="337" TOTAL_2="342" WEIGHT="100.0" Z="0.48056847654765966">
<NAME>Failure to complete - Side Effects</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Hypericum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hypericum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.46670403796449" CI_END="2.6414066378403827" CI_START="0.5550000414883058" DF="3" EFFECT_SIZE="1.2107769379984485" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-007.05.01" LOG_CI_END="0.42183526488579914" LOG_CI_START="-0.25570698441220374" LOG_EFFECT_SIZE="0.08306414023679771" MODIFIED="2012-11-21 13:21:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9261431090314659" P_Z="0.6308232260519244" STUDIES="5" TAU2="0.0" TOTAL_1="337" TOTAL_2="342" WEIGHT="100.0" Z="0.48056847654765966">
<NAME>Fluoxetine vs Hypericum</NAME>
<DICH_DATA CI_END="7.526899615309096" CI_START="0.13285682699501958" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8766161239779365" LOG_CI_START="-0.8766161239779365" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-21 13:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1125" O_E="0.0" SE="1.0298573010888745" STUDY_ID="STD-Behnke-2002" TOTAL_1="35" TOTAL_2="35" VAR="1.0606060606060606" WEIGHT="14.93460919835318"/>
<DICH_DATA CI_END="4.363938444010132" CI_START="0.2467715129885388" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6398786159732995" LOG_CI_START="-0.6077049761863901" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2012-11-21 13:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1126" O_E="0.0" SE="0.7328367776729823" STUDY_ID="STD-Bjerkenstedt-2005" TOTAL_1="57" TOTAL_2="59" VAR="0.5370497427101201" WEIGHT="29.493984949372027"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-21 13:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1127" O_E="0.0" SE="0.0" STUDY_ID="STD-Fava-2005" TOTAL_1="47" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.767682712733855" CI_START="0.41180599395050776" EFFECT_SIZE="1.2456140350877194" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.576074322488461" LOG_CI_START="-0.38530733639529313" LOG_EFFECT_SIZE="0.09538349304658392" MODIFIED="2012-11-21 13:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1128" O_E="0.0" SE="0.5647203453442795" STUDY_ID="STD-Harrer-1999" TOTAL_1="84" TOTAL_2="77" VAR="0.3189090684457623" WEIGHT="49.668506153660246"/>
<DICH_DATA CI_END="82.90332788335277" CI_START="0.13485277046017605" EFFECT_SIZE="3.343612334801762" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9185719642338452" LOG_CI_START="-0.8701401268291302" LOG_EFFECT_SIZE="0.5242159187023576" MODIFIED="2012-11-21 13:21:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1129" O_E="0.0" SE="1.6381032866378762" STUDY_ID="STD-Schrader-2000" TOTAL_1="114" TOTAL_2="126" VAR="2.683382377693812" WEIGHT="5.902899698614551"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-07-02 12:07:18 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Subgroup analysis for fluoxetine versus TCAs: failure to respond</NAME>
<DICH_OUTCOME CHI2="7.261548292358327" CI_END="1.2668915663283802" CI_START="0.351811300382175" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6676127390884613" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="75" I2="44.91532881204701" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.10273944506458127" LOG_CI_START="-0.45369021486490724" LOG_EFFECT_SIZE="-0.17547538490016298" METHOD="MH" MODIFIED="2013-06-21 10:52:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12269550157780373" P_Q="0.6286456759032024" P_Z="0.21638924757885059" Q="0.9283751014047722" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23272909921921328" TOTALS="YES" TOTAL_1="169" TOTAL_2="172" WEIGHT="100.0" Z="1.2361865635315192">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.494190572645043" CI_END="1.6474271636964433" CI_START="0.18765086258361774" DF="2" EFFECT_SIZE="0.5560046117716294" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="50" I2="69.20324438238016" ID="CMP-008.01.01" LOG_CI_END="0.21680622259595642" LOG_CI_START="-0.7266494349042729" LOG_EFFECT_SIZE="-0.25492160615415826" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0388870655299165" P_Z="0.2895250809429164" STUDIES="3" TAU2="0.6325109243712784" TOTAL_1="103" TOTAL_2="104" WEIGHT="62.70366670638985" Z="1.059164069813494">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="0.9022881496892555" CI_START="0.06657856345344113" EFFECT_SIZE="0.24509803921568626" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="-0.04465474645408598" LOG_CI_START="-1.176665579725674" LOG_EFFECT_SIZE="-0.6106601630898799" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4543" O_E="0.0" SE="0.6649487670077282" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="0.4421568627450981" WEIGHT="15.829432764274657"/>
<DICH_DATA CI_END="1.1340282950884841" CI_START="0.13266860689272184" EFFECT_SIZE="0.3878787878787879" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.054623890753967744" LOG_CI_START="-0.8772318312140062" LOG_EFFECT_SIZE="-0.41130397023001913" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1003" O_E="0.0" SE="0.5473766638442052" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.2996212121212121" WEIGHT="20.0677293332798"/>
<DICH_DATA CI_END="3.0892902579021215" CI_START="0.6261429867390408" EFFECT_SIZE="1.3908045977011494" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.4898587148676853" LOG_CI_START="-0.20332647947202218" LOG_EFFECT_SIZE="0.14326611769783154" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4547" O_E="0.0" SE="0.40718041447719583" STUDY_ID="STD-Peters-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.16579588993382097" WEIGHT="26.806504608835397"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4468788399936612" CI_START="0.2745785611260464" DF="0" EFFECT_SIZE="0.6303030303030303" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.16043216531029394" LOG_CI_START="-0.5613333751405459" LOG_EFFECT_SIZE="-0.20045060491512595" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2763071283122035" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="48" WEIGHT="25.899680909270703" Z="1.088652600586918">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="1.4468788399936612" CI_START="0.2745785611260465" EFFECT_SIZE="0.6303030303030303" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.16043216531029394" LOG_CI_START="-0.5613333751405458" LOG_EFFECT_SIZE="-0.20045060491512595" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4549" O_E="0.0" SE="0.42396865125786987" STUDY_ID="STD-Pakesch-1991" TOTAL_1="46" TOTAL_2="48" VAR="0.17974941724941726" WEIGHT="25.899680909270703"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.341739229291792" CI_START="0.2733609001579917" DF="0" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2013-06-21 10:52:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6781944478191994" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.396652384339443" Z="0.4149282252652017">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="7.341739229291792" CI_START="0.2733609001579917" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4555" O_E="0.0" SE="0.8394384210560641" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.704656862745098" WEIGHT="11.396652384339443"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.789201596013054" CI_END="1.3074494816367446" CI_START="0.796174486357734" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0202734532863338" ESTIMABLE="YES" EVENTS_1="420" EVENTS_2="425" I2="28.539005685465664" I2_Q="20.96643636117295" ID="CMP-008.02" LOG_CI_END="0.11642491721789194" LOG_CI_START="-0.09899174362153318" LOG_EFFECT_SIZE="0.008716586798179384" METHOD="MH" MODIFIED="2013-06-21 10:51:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12527671660133533" P_Q="0.2757393377334131" P_Z="0.8739719222275806" Q="6.326426102774942" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07510734751947833" TOTALS="YES" TOTAL_1="860" TOTAL_2="882" WEIGHT="100.00000000000001" Z="0.15861536545944066">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7264071063735784" CI_END="1.5029774387242463" CI_START="0.7464342853687385" DF="7" EFFECT_SIZE="1.059185484416903" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="103" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.17695246141784288" LOG_CI_START="-0.12700842070249443" LOG_EFFECT_SIZE="0.02497202035767421" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9091064596227416" P_Z="0.7474200031946896" STUDIES="8" TAU2="0.0" TOTAL_1="279" TOTAL_2="291" WEIGHT="36.1411624191926" Z="0.3220431535849117">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="3.1798817064731453" CI_START="0.4528470342367313" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.5024109642669728" LOG_CI_START="-0.34404847217172324" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5025" O_E="0.0" SE="0.4972144630058766" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="0.2472222222222222" WEIGHT="4.9674514917846375"/>
<DICH_DATA CI_END="2.2007178503122966" CI_START="0.30418324071316566" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.3425643660848531" LOG_CI_START="-0.5168647175226534" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5026" O_E="0.0" SE="0.5048328979536247" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.25485625485625485" WEIGHT="4.8525246134161675"/>
<DICH_DATA CI_END="2.3503233413368143" CI_START="0.18428165894705595" EFFECT_SIZE="0.6581196581196581" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.3711276136328123" LOG_CI_START="-0.7345178867801717" LOG_EFFECT_SIZE="-0.18169513657367978" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5027" O_E="0.0" SE="0.6494616399760819" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.4218004218004218" WEIGHT="3.2222408280135286"/>
<DICH_DATA CI_END="6.499715881043865" CI_START="0.4862510738935428" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.8128943729518269" LOG_CI_START="-0.3131394265186271" LOG_EFFECT_SIZE="0.2498774732165999" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5028" O_E="0.0" SE="0.6614378277661477" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.4375" WEIGHT="3.1235535538219517"/>
<DICH_DATA CI_END="2.854752494093967" CI_START="0.7207040347215746" EFFECT_SIZE="1.434375" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.4555684610551476" LOG_CI_START="-0.14224304662043702" LOG_EFFECT_SIZE="0.15666270721735526" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5029" O_E="0.0" SE="0.35115743882332695" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="0.1233115468409586" WEIGHT="8.06957677705399"/>
<DICH_DATA CI_END="8.145930452819718" CI_START="0.04177273299209062" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.9109406979074103" LOG_CI_START="-1.379107109974146" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1011" O_E="0.0" SE="1.3451854182690985" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="1.8095238095238095" WEIGHT="0.849586135767644"/>
<DICH_DATA CI_END="2.8771971772722402" CI_START="0.22944421578567958" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.45896962555628534" LOG_CI_START="-0.6393228862544613" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5030" O_E="0.0" SE="0.645142458073247" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.41620879120879123" WEIGHT="3.2589128991450793"/>
<DICH_DATA CI_END="1.876499468915076" CI_START="0.45600799772135603" EFFECT_SIZE="0.9250398724082934" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.27334844583554696" LOG_CI_START="-0.3410275403711053" LOG_EFFECT_SIZE="-0.033839547267779164" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5031" O_E="0.0" SE="0.3608874955079673" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="0.1302397844140131" WEIGHT="7.797316120189588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3937472208700155" CI_END="5.149406376273741" CI_START="0.5619914083861046" DF="1" EFFECT_SIZE="1.70115317997953" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="28.25097800907022" ID="CMP-008.02.02" LOG_CI_END="0.7117571664454436" LOG_CI_START="-0.250270323788638" LOG_EFFECT_SIZE="0.23074342132840286" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23777351081548048" P_Z="0.34711534249193277" STUDIES="2" TAU2="0.195232997014716" TOTAL_1="42" TOTAL_2="42" WEIGHT="6.309644653445503" Z="0.9401993187599644">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="3.28304508802456" CI_START="0.37604354132626894" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.5162768471965359" LOG_CI_START="-0.42476186607518557" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5032" O_E="0.0" SE="0.5527707983925666" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.3055555555555555" WEIGHT="4.206232047108885"/>
<DICH_DATA CI_END="18.25442960754227" CI_START="0.7099646649405716" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.2613682671862079" LOG_CI_START="-0.1487632656516334" LOG_EFFECT_SIZE="0.5563025007672873" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1097" O_E="0.0" SE="0.8283182426526118" STUDY_ID="STD-Nelson-2004" TOTAL_1="14" TOTAL_2="12" VAR="0.6861111111111111" WEIGHT="2.1034126063366174"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3572921570051042" CI_END="4.199904438147432" CI_START="1.0788954875116046" DF="1" EFFECT_SIZE="2.128675162230542" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" I2="0.0" ID="CMP-008.02.03" LOG_CI_END="0.623239408860424" LOG_CI_START="0.03297937666126803" LOG_EFFECT_SIZE="0.32810939276084594" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5500141914503672" P_Z="0.02933310609205466" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="10.068444471989075" Z="2.1789806448680125">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="8.100075556648452" CI_START="0.9336332663950007" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.9084890699505573" LOG_CI_START="-0.02982368229003217" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5033" O_E="0.0" SE="0.551169555389155" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.3037878787878788" WEIGHT="4.225855568739375"/>
<DICH_DATA CI_END="4.314525215819166" CI_START="0.750951689451384" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.6349330115240771" LOG_CI_START="-0.12438800131746502" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5034" O_E="0.0" SE="0.44602892164275504" STUDY_ID="STD-Fairweather-1999" TOTAL_1="42" TOTAL_2="42" VAR="0.19894179894179892" WEIGHT="5.842588903249701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.543628888699885" CI_START="0.2821965932123575" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-008.02.04" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.255878626912656" Z="0.0">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="3.543628888699885" CI_START="0.2821965932123575" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5035" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Sandor-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.41666666666666663" WEIGHT="3.255878626912656"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.131293579039056" CI_END="1.3370221419680244" CI_START="0.3554600814803033" DF="3" EFFECT_SIZE="0.6893895847232707" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="217" I2="75.27056796990288" ID="CMP-008.02.05" LOG_CI_END="0.1261385995244423" LOG_CI_START="-0.4492091638969171" LOG_EFFECT_SIZE="-0.16153528218623736" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.00694668825231004" P_Z="0.27108675465931464" STUDIES="4" TAU2="0.3364916092254405" TOTAL_1="357" TOTAL_2="364" WEIGHT="34.509907255112815" Z="1.1005633651370381">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="2.332666527149271" CI_START="0.5012338603070389" EFFECT_SIZE="1.08130081300813" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="41" LOG_CI_END="0.36785265745195933" LOG_CI_START="-0.29995959839658354" LOG_EFFECT_SIZE="0.03394652952768786" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5036" O_E="0.0" SE="0.3922762248094146" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.1538806365507264" WEIGHT="6.992316686664297"/>
<DICH_DATA CI_END="0.6425597904356273" CI_START="0.130408119365213" EFFECT_SIZE="0.2894736842105263" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.19208645484783926" LOG_CI_START="-0.8846953680693309" LOG_EFFECT_SIZE="-0.5383909114585851" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5037" O_E="0.0" SE="0.4068419040957183" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="0.16552033492822965" WEIGHT="6.6540827130630165"/>
<DICH_DATA CI_END="1.8207727460103473" CI_START="0.8001385062288291" EFFECT_SIZE="1.207008858780615" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="101" LOG_CI_END="0.26025574408563823" LOG_CI_START="-0.09683482890267331" LOG_EFFECT_SIZE="0.08171045759148245" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5039" O_E="0.0" SE="0.2097567702001784" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.043997902644810453" WEIGHT="13.44320674236562"/>
<DICH_DATA CI_END="1.048712258712155" CI_START="0.2410714777427824" EFFECT_SIZE="0.5028067361668003" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="43" LOG_CI_END="0.020656344632479246" LOG_CI_START="-0.6178541699281317" LOG_EFFECT_SIZE="-0.29859891264782623" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5040" O_E="0.0" SE="0.3750642369309246" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="0.14067318182457675" WEIGHT="7.42030111301988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.777598902327279" CI_START="0.54947433871781" DF="0" EFFECT_SIZE="0.9883040935672515" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" I2="0.0" ID="CMP-008.02.06" LOG_CI_END="0.24983377341871357" LOG_CI_START="-0.2600525849756742" LOG_EFFECT_SIZE="-0.005109405778480298" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9686668917160041" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="9.714962573347359" Z="0.03928032646237765">
<NAME>Fluoxetine vs Lofepramine</NAME>
<DICH_DATA CI_END="1.777598902327279" CI_START="0.54947433871781" EFFECT_SIZE="0.9883040935672515" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" LOG_CI_END="0.24983377341871357" LOG_CI_START="-0.2600525849756742" LOG_EFFECT_SIZE="-0.005109405778480298" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5041" O_E="0.0" SE="0.2995097708990436" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" VAR="0.0897061028639976" WEIGHT="9.714962573347359"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-07-02 12:07:44 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Subgroup analysis for fluoxetine versus TCAs: endpoint score</NAME>
<CONT_OUTCOME CHI2="30.59551863544283" CI_END="0.504169425295016" CI_START="-0.15242532865139463" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1758720483218107" ESTIMABLE="YES" I2="67.31547479500584" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2013-06-21 10:52:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.840822034581695E-4" P_Q="0.7509755990023839" P_Z="0.2937312437750753" Q="1.9172496586586392" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1982995167972044" TOTALS="YES" TOTAL_1="269" TOTAL_2="272" UNITS="" WEIGHT="99.99999999999999" Z="1.0499714733516456">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="21.49722439227661" CI_END="1.0183566342155572" CI_START="-0.2469242131858077" DF="4" EFFECT_SIZE="0.3857162105148748" ESTIMABLE="YES" I2="81.39294670321674" ID="CMP-009.01.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.523047805983447E-4" P_Z="0.23209657825794916" STUDIES="6" TAU2="0.4104161528362119" TOTAL_1="141" TOTAL_2="149" WEIGHT="46.19549866018296" Z="1.1949756173344077">
<NAME>Fluoxetine vs Amiptriptyline</NAME>
<CONT_DATA CI_END="2.851370316464487" CI_START="0.7992590836286297" EFFECT_SIZE="1.8253147000465582" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="10.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4561" SD_1="2.0" SD_2="1.0" SE="0.5235073830495479" STUDY_ID="STD-Altamura-1989" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.939720266977027"/>
<CONT_DATA CI_END="1.4493101310713077" CI_START="0.20823583060213002" EFFECT_SIZE="0.8287729808367189" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="10.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4562" SD_1="6.21" SD_2="5.45" SE="0.3166064045713629" STUDY_ID="STD-Chouinard-1985" TOTAL_1="20" TOTAL_2="24" WEIGHT="9.398041912519767"/>
<CONT_DATA CI_END="-0.06334027783245466" CI_START="-1.2813684540758503" EFFECT_SIZE="-0.6723543659541525" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="19.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4566" SD_1="6.21" SD_2="5.45" SE="0.31072718321638726" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" WEIGHT="9.515600206075016"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="11.7" MEAN_2="11.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1004" SD_1="0.0" SD_2="5.43" SE="0.0" STUDY_ID="STD-Hosak-2000" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.7848842847162738" CI_START="-0.3356699529425175" EFFECT_SIZE="0.22460716588687818" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="7.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4570" SD_1="8.0" SD_2="5.2" SE="0.28586092563373106" STUDY_ID="STD-Laakman-1988" TOTAL_1="22" TOTAL_2="28" WEIGHT="10.019725377598089"/>
<CONT_DATA CI_END="0.5658779404354558" CI_START="-0.3062473405771292" EFFECT_SIZE="0.12981529992916327" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4573" SD_1="9.0" SD_2="6.0" SE="0.2224850272484081" STUDY_ID="STD-Peters-1990" TOTAL_1="40" TOTAL_2="41" WEIGHT="11.322410897013064"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0079377819375108" CI_END="0.35223182628624145" CI_START="-0.35841042910976" DF="1" EFFECT_SIZE="-0.003089301411759266" ESTIMABLE="YES" I2="0.7875269763429646" ID="CMP-009.01.02" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3153976581130893" P_Z="0.9864041493487017" STUDIES="2" TAU2="7.063776999572876E-4" TOTAL_1="61" TOTAL_2="63" WEIGHT="20.05442011155643" Z="0.01704069652053785">
<NAME>Fluoxetine vs Clomipramine</NAME>
<CONT_DATA CI_END="0.3967492994278131" CI_START="-1.0453979480764617" EFFECT_SIZE="-0.32432432432432434" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="10.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4579" SD_1="4.5" SD_2="4.5" SE="0.3679014662717653" STUDY_ID="STD-Manna-1989" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.409035876655915"/>
<CONT_DATA CI_END="0.5038826170584483" CI_START="-0.30543890727577566" EFFECT_SIZE="0.09922185489133634" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="7.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4581" SD_1="5.19" SD_2="6.68" SE="0.2064633663470474" STUDY_ID="STD-Pakesch-1991" TOTAL_1="46" TOTAL_2="48" WEIGHT="11.645384234900513"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8175985442394041" CI_START="-0.7247362969010612" DF="0" EFFECT_SIZE="0.046431123669171466" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.03" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9060619302627648" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="7.945628879379257" Z="0.11800722868454394">
<NAME>Fluoxetine vs Desipramine</NAME>
<CONT_DATA CI_END="0.8175985442394041" CI_START="-0.7247362969010612" EFFECT_SIZE="0.046431123669171466" ESTIMABLE="YES" MEAN_1="17.1" MEAN_2="16.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1129" SD_1="8.7" SD_2="7.9" SE="0.3934599955168069" STUDY_ID="STD-Nelson-2004" TOTAL_1="14" TOTAL_2="12" WEIGHT="7.945628879379257"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.799743838670208" CI_END="1.2232568029785098" CI_START="-1.3112879762832577" DF="1" EFFECT_SIZE="-0.04401558665237385" ESTIMABLE="YES" I2="82.75785917763422" ID="CMP-009.01.04" MODIFIED="2013-06-21 10:52:43 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.016028542289063585" P_Z="0.9457263102694253" STUDIES="2" TAU2="0.6919661372923046" TOTAL_1="33" TOTAL_2="27" WEIGHT="16.385551865290864" Z="0.06807452391682114">
<NAME>Fluoxetine vs Imipramine</NAME>
<CONT_DATA CI_END="1.3525029460270193" CI_START="-0.14471444075013407" EFFECT_SIZE="0.6038942526384427" ESTIMABLE="YES" MEAN_1="15.3" MEAN_2="10.3" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4591" SD_1="7.61" SD_2="8.7" SE="0.381950229337634" STUDY_ID="STD-Bressa-1989" TOTAL_1="18" TOTAL_2="12" WEIGHT="8.151660433089056"/>
<CONT_DATA CI_END="0.050469485619338394" CI_START="-1.4290041511727176" EFFECT_SIZE="-0.6892673327766896" ESTIMABLE="YES" MEAN_1="7.44" MEAN_2="13.23" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4597" SD_1="7.61" SD_2="8.7" SE="0.37742367932828236" STUDY_ID="STD-Loeb-1989" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.233891432201808"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.999582752263249" CI_START="-0.23739203887868027" DF="0" EFFECT_SIZE="0.3810953566922844" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.05" MODIFIED="2013-06-21 10:52:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.22717144387157706" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="9.41890048359048" Z="1.2076772770814221">
<NAME>Fluoxetine vs Trimipramine</NAME>
<CONT_DATA CI_END="0.999582752263249" CI_START="-0.23739203887868027" EFFECT_SIZE="0.3810953566922844" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="12.1" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="970" SD_1="11.1" SD_2="10.0" SE="0.3155605921585877" STUDY_ID="STD-Wehmeier-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="9.41890048359048"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="55.530863107981375" CI_END="0.14168096172310538" CI_START="-0.062209847166459976" CI_STUDY="95" CI_TOTAL="95" DF="35" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.039735557278322696" ESTIMABLE="YES" I2="36.97198631337409" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01507287827169801" P_Q="0.585902738523236" P_Z="0.4449024855990512" Q="5.610403992691591" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="36" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.03213138718223921" TOTALS="YES" TOTAL_1="1368" TOTAL_2="1359" UNITS="" WEIGHT="100.0" Z="0.7639408720313987">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.48011779235335" CI_END="0.21733514624089972" CI_START="-0.07369816004736753" DF="12" EFFECT_SIZE="0.07181849309676609" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5739172189957241" P_Z="0.3333824146746698" STUDIES="13" TAU2="0.0" TOTAL_1="361" TOTAL_2="372" WEIGHT="30.445628904447446" Z="0.9673233740070715">
<NAME>Fluoxetine vs Amiptriptyline</NAME>
<CONT_DATA CI_END="0.5174494719170113" CI_START="-0.4551428590349775" EFFECT_SIZE="0.031153306441016927" ESTIMABLE="YES" MEAN_1="14.22" MEAN_2="13.94" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5042" SD_1="8.31" SD_2="9.4" SE="0.24811484767671063" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" WEIGHT="2.8875859732039917"/>
<CONT_DATA CI_END="0.973324060503538" CI_START="-0.008266688219621676" EFFECT_SIZE="0.48252868614195815" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="7.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5043" SD_1="6.3" SD_2="4.5" SE="0.2504104045956513" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" WEIGHT="2.8527415361587596"/>
<CONT_DATA CI_END="0.3949155956580206" CI_START="-0.8821288916277359" EFFECT_SIZE="-0.24360664798485765" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="14.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5044" SD_1="6.5" SD_2="7.9" SE="0.32578264125231904" STUDY_ID="STD-Fawcett-1989" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.956701670179061"/>
<CONT_DATA CI_END="0.2598438471108258" CI_START="-0.904253749090205" EFFECT_SIZE="-0.32220495098968954" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="11.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5045" SD_1="6.2" SD_2="6.0" SE="0.29696912937770387" STUDY_ID="STD-Judd-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="2.248505209428205"/>
<CONT_DATA CI_END="0.8237093964189098" CI_START="-0.46846611945657035" EFFECT_SIZE="0.17762163848116977" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5046" SD_1="2.5" SD_2="3.0" SE="0.3296426684541134" STUDY_ID="STD-Keegan-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.9215416697765668"/>
<CONT_DATA CI_END="0.6645788119773868" CI_START="-1.144645207830558" EFFECT_SIZE="-0.24003319792658562" ESTIMABLE="YES" MEAN_1="8.44" MEAN_2="9.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5047" SD_1="6.2" SD_2="4.6" SE="0.461545220748665" STUDY_ID="STD-Kerkhofs-1990" TOTAL_1="9" TOTAL_2="10" WEIGHT="1.1035644442369688"/>
<CONT_DATA CI_END="0.44895143046490743" CI_START="-0.21060069066351855" EFFECT_SIZE="0.11917536990069444" ESTIMABLE="YES" MEAN_1="8.96" MEAN_2="8.15" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5048" SD_1="6.6" SD_2="6.9" SE="0.16825618387146113" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" WEIGHT="4.476140094316331"/>
<CONT_DATA CI_END="0.585426686970647" CI_START="-1.417763338062632" EFFECT_SIZE="-0.41616832554599253" ESTIMABLE="YES" MEAN_1="7.28" MEAN_2="10.77" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1013" SD_1="5.6" SD_2="9.3" SE="0.5110272537746067" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.9224786411350601"/>
<CONT_DATA CI_END="0.9454136072487161" CI_START="-0.27367806721812926" EFFECT_SIZE="0.33586777001529344" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="5.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5049" SD_1="6.21" SD_2="5.45" SE="0.310998488768897" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.099664104143291"/>
<CONT_DATA CI_END="0.23982829060373528" CI_START="-0.7777384753457015" EFFECT_SIZE="-0.2689550923709831" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="15.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5050" SD_1="7.8" SD_2="6.1" SE="0.2595881286533512" STUDY_ID="STD-Preskorn-1991" TOTAL_1="29" TOTAL_2="31" WEIGHT="2.7185678354589604"/>
<CONT_DATA CI_END="0.7922742845926187" CI_START="-0.6396804040217989" EFFECT_SIZE="0.0762969402854099" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="7.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5051" SD_1="2.5" SD_2="2.6" SE="0.3653012759187142" STUDY_ID="STD-Suleman-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.633957152951011"/>
<CONT_DATA CI_END="0.5302530622141995" CI_START="-0.09935464144599115" EFFECT_SIZE="0.2154492103841042" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="8.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5052" SD_1="8.9" SD_2="7.7" SE="0.16061716149542948" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="79" WEIGHT="4.6702609289676875"/>
<CONT_DATA CI_END="0.7937922300659574" CI_START="-1.1719740482477756" EFFECT_SIZE="-0.1890909090909091" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="11.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5053" SD_1="10.0" SD_2="10.0" SE="0.5014802041821805" STUDY_ID="STD-Yu-1997" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.9539196444915442"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.791428534873803" CI_END="0.09581407073808937" CI_START="-0.403848748278297" DF="2" EFFECT_SIZE="-0.1540173387701038" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.02" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6731992367876308" P_Z="0.2269363049851938" STUDIES="3" TAU2="0.0" TOTAL_1="130" TOTAL_2="118" WEIGHT="9.876986311398035" Z="1.2082885717946859">
<NAME>Fluoxetine vs Clomipramine</NAME>
<CONT_DATA CI_END="0.523753942257844" CI_START="-0.5438550682244169" EFFECT_SIZE="-0.010050562983286392" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="10.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5054" SD_1="7.2" SD_2="12.0" SE="0.2723542419410317" STUDY_ID="STD-Ginestet-1989" TOTAL_1="28" TOTAL_2="26" WEIGHT="2.5449091116715277"/>
<CONT_DATA CI_END="0.3173916975896487" CI_START="-0.5053693695561126" EFFECT_SIZE="-0.09398883598323195" ESTIMABLE="YES" MEAN_1="6.21" MEAN_2="6.66" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5055" SD_1="4.57" SD_2="4.93" SE="0.20989188414572807" STUDY_ID="STD-Noguera-1991" TOTAL_1="47" TOTAL_2="44" WEIGHT="3.551109038494302"/>
<CONT_DATA CI_END="0.10490589919086529" CI_START="-0.673404394163899" EFFECT_SIZE="-0.2842492474865168" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="9.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5056" SD_1="4.5" SD_2="5.3" SE="0.19855219266628787" STUDY_ID="STD-Ropert-1989" TOTAL_1="55" TOTAL_2="48" WEIGHT="3.7809681612322064"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.234237872693827" CI_END="1.1183939585226916" CI_START="-0.46699492757293615" DF="2" EFFECT_SIZE="0.32569951547487774" ESTIMABLE="YES" I2="75.71117046991866" ID="CMP-009.02.03" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.01629146337442866" P_Z="0.4206447804709761" STUDIES="3" TAU2="0.3641967592768327" TOTAL_1="62" TOTAL_2="59" WEIGHT="5.689060755127857" Z="0.8053031350371177">
<NAME>Fluoxetine vs Desipramine</NAME>
<CONT_DATA CI_END="0.5150180436046915" CI_START="-0.5150180436046915" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="13.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5057" SD_1="5.0" SD_2="6.2" SE="0.2627691364061218" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" WEIGHT="2.673921878967299"/>
<CONT_DATA CI_END="0.7601360463994616" CI_START="-1.1504798731999841" EFFECT_SIZE="-0.1951719134002613" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="10.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5058" SD_1="1.3" SD_2="4.5" SE="0.48741097659705496" STUDY_ID="STD-Levkovitz-2002" TOTAL_1="8" TOTAL_2="9" WEIGHT="1.0031290638095276"/>
<CONT_DATA CI_END="1.7072223948661351" CI_START="0.4532525539722374" EFFECT_SIZE="1.0802374744191863" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="6.9" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5059" SD_1="5.0" SD_2="6.2" SE="0.3198961437008669" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" WEIGHT="2.01200981235103"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.165934344972058" CI_END="0.5861846678389241" CI_START="-0.2705982821825479" DF="3" EFFECT_SIZE="0.15779319282818813" ESTIMABLE="YES" I2="67.27011249381641" ID="CMP-009.02.04" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.027164187453107003" P_Z="0.4703370655323855" STUDIES="4" TAU2="0.12814081291872098" TOTAL_1="128" TOTAL_2="138" WEIGHT="11.452222967356171" Z="0.7219307408978717">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<CONT_DATA CI_END="0.7646441439861308" CI_START="-0.136135897709597" EFFECT_SIZE="0.3142541231382669" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="9.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5060" SD_1="6.9" SD_2="5.8" SE="0.22979504950115556" STUDY_ID="STD-Corne-1989" TOTAL_1="34" TOTAL_2="44" WEIGHT="3.185234637789951"/>
<CONT_DATA CI_END="1.2178207536294277" CI_START="0.1734511405714465" EFFECT_SIZE="0.6956359471004371" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="8.9" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5061" SD_1="7.26" SD_2="5.7" SE="0.2664257152926879" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.623742944839109"/>
<CONT_DATA CI_END="0.499342319872143" CI_START="-0.5888020940924469" EFFECT_SIZE="-0.044729887110151946" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="10.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5062" SD_1="7.8" SD_2="5.0" SE="0.27759296154106256" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="27" TOTAL_2="25" WEIGHT="2.477760260444761"/>
<CONT_DATA CI_END="0.14245119467638595" CI_START="-0.7628373851357335" EFFECT_SIZE="-0.3101930952296738" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="11.3" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5063" SD_1="7.1" SD_2="6.3" SE="0.23094520791017598" STUDY_ID="STD-Stephenson-2000" TOTAL_1="37" TOTAL_2="39" WEIGHT="3.165485124282351"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.349908640879608" CI_END="0.18853487700545826" CI_START="-0.20735550513305753" DF="9" EFFECT_SIZE="-0.009410314063799627" ESTIMABLE="YES" I2="50.953434286043496" ID="CMP-009.02.05" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.03132430619842275" P_Z="0.9257631967465296" STUDIES="10" TAU2="0.04681469129500806" TOTAL_1="501" TOTAL_2="502" WEIGHT="31.826855469632456" Z="0.09317668466017345">
<NAME>Fluoxetine vs Imipramine</NAME>
<CONT_DATA CI_END="0.5909513763026629" CI_START="-0.5909513763026629" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="10.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5064" SD_1="7.61" SD_2="8.7" SE="0.30151134457776363" STUDY_ID="STD-Beasley-1993a" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.198827269261482"/>
<CONT_DATA CI_END="0.4854091799337703" CI_START="-0.7023582999897018" EFFECT_SIZE="-0.10847456002796577" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="13.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5065" SD_1="7.7" SD_2="8.5" SE="0.30300747597721955" STUDY_ID="STD-Byerley-1988" TOTAL_1="20" TOTAL_2="24" WEIGHT="2.182782186744991"/>
<CONT_DATA CI_END="-0.29312899102416495" CI_START="-1.0699158253166123" EFFECT_SIZE="-0.6815224081703887" ESTIMABLE="YES" MEAN_1="11.49" MEAN_2="17.1" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5066" SD_1="7.61" SD_2="8.7" SE="0.19816354800895394" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" WEIGHT="3.7891327789382134"/>
<CONT_DATA CI_END="0.570455451825097" CI_START="-0.22914706515307948" EFFECT_SIZE="0.17065419333600879" ESTIMABLE="YES" MEAN_1="17.69" MEAN_2="16.04" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5068" SD_1="9.91" SD_2="9.21" SE="0.20398398217654484" STUDY_ID="STD-Feighner-1989" TOTAL_1="52" TOTAL_2="45" WEIGHT="3.6688585838155707"/>
<CONT_DATA CI_END="0.9706176539575503" CI_START="-0.1584239943214426" EFFECT_SIZE="0.40609682981805384" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="6.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5069" SD_1="7.61" SD_2="8.7" SE="0.2880261211901671" STUDY_ID="STD-Levine-1989" TOTAL_1="22" TOTAL_2="28" WEIGHT="2.3507145626517154"/>
<CONT_DATA CI_END="0.7544122436813692" CI_START="-0.029051671838872417" EFFECT_SIZE="0.36268028592124835" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="5.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5070" SD_1="5.6" SD_2="4.8" SE="0.1998669163566537" STUDY_ID="STD-McGrath-2000" TOTAL_1="49" TOTAL_2="53" WEIGHT="3.753490870531051"/>
<CONT_DATA CI_END="0.47863105893962266" CI_START="-0.7184409636446375" EFFECT_SIZE="-0.11990495235250741" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="8.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5071" SD_1="7.61" SD_2="8.7" SE="0.30538112741525136" STUDY_ID="STD-Nielsen-1993" TOTAL_1="21" TOTAL_2="22" WEIGHT="2.1576431341204363"/>
<CONT_DATA CI_END="0.2334410560198807" CI_START="-0.17415626962145825" EFFECT_SIZE="0.029642393199211223" ESTIMABLE="YES" MEAN_1="16.5" MEAN_2="16.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5072" SD_1="10.1" SD_2="10.1" SE="0.1039808202743557" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="185" WEIGHT="6.300031436660619"/>
<CONT_DATA CI_END="0.8019814600379018" CI_START="-0.8729460558924156" EFFECT_SIZE="-0.035482297927256864" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="7.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4601" SD_1="4.8" SD_2="11.7" SE="0.4272852790005153" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="9" WEIGHT="1.2600819567075527"/>
<CONT_DATA CI_END="0.2781320779671402" CI_START="-0.4320218443334945" EFFECT_SIZE="-0.07694488318317715" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="12.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5073" SD_1="7.6" SD_2="7.9" SE="0.18116504382280443" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="60" WEIGHT="4.165292690200827"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4181579425649102" CI_START="-0.16206532016794667" DF="0" EFFECT_SIZE="0.12804631119848175" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.06" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.38700172281990697" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="5.00628986544264" Z="0.8650675504466304">
<NAME>Fluoxetine vs Lofepramine</NAME>
<CONT_DATA CI_END="0.4181579425649102" CI_START="-0.16206532016794667" EFFECT_SIZE="0.12804631119848175" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="13.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5074" SD_1="7.2" SD_2="6.8" SE="0.1480188583335163" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" WEIGHT="5.00628986544264"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.198040684150591" CI_START="-0.43865525196172056" DF="0" EFFECT_SIZE="-0.12030728390556479" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.07" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.45887993040661057" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="68" WEIGHT="4.623637370254472" Z="0.7406924723676833">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<CONT_DATA CI_END="0.198040684150591" CI_START="-0.43865525196172056" EFFECT_SIZE="-0.12030728390556479" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="13.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5075" SD_1="10.3" SD_2="11.3" SE="0.16242541728687054" STUDY_ID="STD-Joyce-2002" TOTAL_1="86" TOTAL_2="68" WEIGHT="4.623637370254472"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3889820403438482" CI_START="-0.44347936598721305" DF="0" EFFECT_SIZE="0.4727513371783175" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.08" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.31187732691737113" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.0793183563409388" Z="1.0112907058357488">
<NAME>Fluoxetine vs Trimipramine</NAME>
<CONT_DATA CI_END="1.388982040343848" CI_START="-0.44347936598721294" EFFECT_SIZE="0.4727513371783175" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="9.3" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5076" SD_1="8.7" SD_2="9.1" SE="0.46747323440259175" STUDY_ID="STD-Wolf-2001" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.0793183563409388"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.7285992873033984E-31" CI_END="-0.4388625439225049" CI_START="-1.272003406942508" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8554329754325064" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2013-06-21 10:52:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="5.702076195922078E-5" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="4.024812363561612">
<NAME>follow-up &gt;16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.7285992873033984E-31" CI_END="-0.4388625439225049" CI_START="-1.272003406942508" DF="0" EFFECT_SIZE="-0.8554329754325064" ESTIMABLE="YES" I2="100.0" ID="CMP-009.03.01" MODIFIED="2013-06-21 10:52:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="5.702076195922078E-5" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="4.024812363561612">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<CONT_DATA CI_END="-0.438862543922505" CI_START="-1.272003406942508" EFFECT_SIZE="-0.8554329754325065" ESTIMABLE="YES" MEAN_1="16.16" MEAN_2="19.71" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2927" SD_1="4.02" SD_2="4.21" SE="0.21253983991331263" STUDY_ID="STD-Hashemi-2012" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-07-02 12:08:16 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Subgroup analysis for fluoxetine versus TCAs: failure to complete - total</NAME>
<DICH_OUTCOME CHI2="10.72781290260485" CI_END="1.0457162700483544" CI_START="0.46985989212711904" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7009565848470882" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="102" I2="6.784354921291808" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.019413865155013515" LOG_CI_START="-0.32803162535647074" LOG_EFFECT_SIZE="-0.15430888010072857" METHOD="MH" MODIFIED="2013-06-21 10:52:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3791134464588689" P_Q="0.7693860897570175" P_Z="0.08169513428682681" Q="1.1318724420635806" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03295919541980542" TOTALS="YES" TOTAL_1="331" TOTAL_2="332" WEIGHT="100.0" Z="1.7409340788790053">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.7550344302470355" CI_END="1.1283580140178624" CI_START="0.28955077984119665" DF="5" EFFECT_SIZE="0.5715915874983954" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="44" I2="25.981132270599737" ID="CMP-010.01.01" LOG_CI_END="0.0524469177708132" LOG_CI_START="-0.5382752610525814" LOG_EFFECT_SIZE="-0.24291417164088416" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23950567725011296" P_Z="0.10697597434545608" STUDIES="6" TAU2="0.18567571877463493" TOTAL_1="150" TOTAL_2="159" WEIGHT="46.945177756937305" Z="1.6119355081565412">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="3.316202688540135" CI_START="0.07538743058858548" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.520641067060489" LOG_CI_START="-1.1227010583884514" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4607" O_E="0.0" SE="0.9653072991634228" STUDY_ID="STD-Altamura-1989" TOTAL_1="13" TOTAL_2="15" VAR="0.9318181818181819" WEIGHT="4.317391691821241"/>
<DICH_DATA CI_END="1.9275942292628039" CI_START="0.06326283430131652" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2850156174615675" LOG_CI_START="-1.1988513547243185" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4608" O_E="0.0" SE="0.8716308047219646" STUDY_ID="STD-Chouinard-1985" TOTAL_1="23" TOTAL_2="28" VAR="0.7597402597402597" WEIGHT="5.254604132537589"/>
<DICH_DATA CI_END="0.7547906056049147" CI_START="0.05493055588904852" EFFECT_SIZE="0.20361990950226244" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.12217351385863832" LOG_CI_START="-1.2601860059608958" LOG_EFFECT_SIZE="-0.691179759909767" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4612" O_E="0.0" SE="0.6684741711135538" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="0.44685771744595276" WEIGHT="8.681065050555514"/>
<DICH_DATA CI_END="1.6638491289033994" CI_START="0.11758042918440263" EFFECT_SIZE="0.4423076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.22111394367628012" LOG_CI_START="-0.9296649589106928" LOG_EFFECT_SIZE="-0.3542755076172063" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1005" O_E="0.0" SE="0.6759732238270267" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.4569397993311036" WEIGHT="8.502409430462798"/>
<DICH_DATA CI_END="3.409541412887333" CI_START="0.5552534500861718" EFFECT_SIZE="1.375921375921376" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.532695969829551" LOG_CI_START="-0.2555087342675903" LOG_EFFECT_SIZE="0.1385936177809804" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4618" O_E="0.0" SE="0.4629953448628715" STUDY_ID="STD-Peters-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.21436468936468936" WEIGHT="16.8415672290358"/>
<DICH_DATA CI_END="9.605256995687844" CI_START="0.1285304392988976" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9825089892201968" LOG_CI_START="-0.8909940080988465" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4620" O_E="0.0" SE="1.1005049346146119" STUDY_ID="STD-Upward-1988" TOTAL_1="11" TOTAL_2="12" VAR="1.2111111111111112" WEIGHT="3.348140222524361"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.314216826324215" CI_START="0.2940226285574358" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="0.7254392701636566" LOG_CI_START="-0.5316192441475438" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-06-21 10:52:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.762501310170804" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="7.203980198877912" Z="0.30219776259369374">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="5.314216826324215" CI_START="0.2940226285574358" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7254392701636566" LOG_CI_START="-0.5316192441475438" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4635" O_E="0.0" SE="0.7384023938464008" STUDY_ID="STD-Tamminen-1989" TOTAL_1="26" TOTAL_2="25" VAR="0.5452380952380953" WEIGHT="7.203980198877912"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.190846539727891" CI_END="3.134571668933981" CI_START="0.10177635736933577" DF="2" EFFECT_SIZE="0.5648232346294015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="37.320708623907805" ID="CMP-010.01.03" LOG_CI_END="0.49617820400963164" LOG_CI_START="-0.9923530968180652" LOG_EFFECT_SIZE="-0.24808744640421682" MODIFIED="2013-06-21 10:52:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2028227927013816" P_Z="0.5135510227787483" STUDIES="3" TAU2="0.8744448842859284" TOTAL_1="52" TOTAL_2="46" WEIGHT="9.310143536486292" Z="0.6533184215856276">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="5.67331316667771" CI_START="0.17626384629593778" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.753836757265777" LOG_CI_START="-0.753836757265777" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4637" O_E="0.0" SE="0.8856148855400953" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.7843137254901961" WEIGHT="5.096610601396716"/>
<DICH_DATA CI_END="17.093060428104796" CI_START="0.1106077526579963" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2328198279661584" LOG_CI_START="-0.9562144316335955" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4638" O_E="0.0" SE="1.2858495599832396" STUDY_ID="STD-Bressa-1989" TOTAL_1="18" TOTAL_2="12" VAR="1.6534090909090908" WEIGHT="2.469995354343376"/>
<DICH_DATA CI_END="1.2064460145415323" CI_START="0.002940478055883613" EFFECT_SIZE="0.05956112852664577" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.08150789308171011" LOG_CI_START="-2.5315820572904144" LOG_EFFECT_SIZE="-1.2250370821043521" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4647" O_E="0.0" SE="1.5349419718524533" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="14" VAR="2.356046856954298" WEIGHT="1.7435375807462"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3485007434802019" CI_START="0.4418173430793864" DF="0" EFFECT_SIZE="0.771875" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" I2="0.0" ID="CMP-010.01.04" LOG_CI_END="0.12985119023218777" LOG_CI_START="-0.35475724035266826" LOG_EFFECT_SIZE="-0.11245302506024026" MODIFIED="2013-06-21 10:52:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3630248763719105" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="36.54069850769849" Z="0.909616363069267">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<DICH_DATA CI_END="1.3485007434802019" CI_START="0.4418173430793864" EFFECT_SIZE="0.771875" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" LOG_CI_END="0.12985119023218777" LOG_CI_START="-0.35475724035266826" LOG_EFFECT_SIZE="-0.11245302506024026" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4652" O_E="0.0" SE="0.28466139097596405" STUDY_ID="STD-Fabre-1991" TOTAL_1="103" TOTAL_2="102" VAR="0.08103210751237067" WEIGHT="36.54069850769849"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="60.41940125507238" CI_END="0.982674982764162" CI_START="0.6349337895585874" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="OR" EFFECT_SIZE="0.789894645323583" ESTIMABLE="YES" EVENTS_1="510" EVENTS_2="600" I2="43.726684982424246" I2_Q="34.31450579217719" ID="CMP-010.02" LOG_CI_END="-0.007590100207033553" LOG_CI_START="-0.19727156026481849" LOG_EFFECT_SIZE="-0.10243083023592599" METHOD="MH" MODIFIED="2013-06-21 10:53:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0034881793677488115" P_Q="0.15430366348326896" P_Z="0.03427514158323861" Q="10.656843012937756" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="36" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17003340992772148" TOTALS="YES" TOTAL_1="1714" TOTAL_2="1736" WEIGHT="100.0" Z="2.116819831603903">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.848413291967073" CI_END="0.9010299670679597" CI_START="0.44045525387636764" DF="10" EFFECT_SIZE="0.6299709381353502" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="105" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-0.045260764719240884" LOG_CI_START="-0.356098205257953" LOG_EFFECT_SIZE="-0.200679484988597" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45389184345694134" P_Z="0.01138217873486992" STUDIES="12" TAU2="0.0" TOTAL_1="384" TOTAL_2="396" WEIGHT="24.282249192975808" Z="2.5307412281610993">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="2.2525959194364544" CI_START="0.27189802006905167" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.3526832930562181" LOG_CI_START="-0.5655939548847917" LOG_EFFECT_SIZE="-0.10645533091428679" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5077" O_E="0.0" SE="0.5394006009862361" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="0.2909530083443127" WEIGHT="2.6930030274013683"/>
<DICH_DATA CI_END="0.7764070207128679" CI_START="0.08129406164801084" EFFECT_SIZE="0.2512315270935961" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.10991054612876511" LOG_CI_START="-1.0899411775017878" LOG_EFFECT_SIZE="-0.5999258618152765" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5078" O_E="0.0" SE="0.5756748440983785" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.33140152612769247" WEIGHT="2.475770495297737"/>
<DICH_DATA CI_END="1.9143812170476135" CI_START="0.15541348740135755" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.28202842454573146" LOG_CI_START="-0.8085112940948942" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5079" O_E="0.0" SE="0.6405884289881728" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.4103535353535353" WEIGHT="2.1389830182963503"/>
<DICH_DATA CI_END="10.989588690168986" CI_START="0.5853241964793986" EFFECT_SIZE="2.536231884057971" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0409814382894846" LOG_CI_START="-0.23260352239140616" LOG_EFFECT_SIZE="0.40418895794903914" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5080" O_E="0.0" SE="0.7481101102511858" STUDY_ID="STD-Judd-1993" TOTAL_1="30" TOTAL_2="28" VAR="0.5596687370600414" WEIGHT="1.701293911662727"/>
<DICH_DATA CI_END="4.713326527047947" CI_START="0.10506356811151449" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6733275275981517" LOG_CI_START="-0.9785478540104684" LOG_EFFECT_SIZE="-0.15261016320615833" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5081" O_E="0.0" SE="0.9703197760719181" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="0.9415204678362572" WEIGHT="1.116848984859645"/>
<DICH_DATA CI_END="2.1191401204849263" CI_START="0.27136924023355763" EFFECT_SIZE="0.7583333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.32615967381390926" LOG_CI_START="-0.5664393812669719" LOG_EFFECT_SIZE="-0.12013985372653124" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5082" O_E="0.0" SE="0.5243171033910918" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="0.2749084249084249" WEIGHT="2.790112600795723"/>
<DICH_DATA CI_END="1.594216800562836" CI_START="0.017792844084640585" EFFECT_SIZE="0.16842105263157894" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20254738160566757" LOG_CI_START="-1.7497546268715134" LOG_EFFECT_SIZE="-0.773603622632923" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5083" O_E="0.0" SE="1.1467918638302979" STUDY_ID="STD-Masco-1985" TOTAL_1="20" TOTAL_2="21" VAR="1.3151315789473683" WEIGHT="0.835892193323117"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1015" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9151125318571494" CI_START="0.15795416455588412" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.28219429816297775" LOG_CI_START="-0.80146891917449" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5084" O_E="0.0" SE="0.6365491380834674" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.4051948051948052" WEIGHT="2.1581657285935956"/>
<DICH_DATA CI_END="0.996704556230113" CI_START="0.11660326777680632" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0014335564465193368" LOG_CI_START="-0.9332892784144932" LOG_EFFECT_SIZE="-0.46736141743050624" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5085" O_E="0.0" SE="0.5473766638442052" STUDY_ID="STD-Preskorn-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.2996212121212121" WEIGHT="2.6432994837388297"/>
<DICH_DATA CI_END="1.840751015282016" CI_START="0.34768417601657425" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.264995048687653" LOG_CI_START="-0.4588150747037657" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5086" O_E="0.0" SE="0.4251696493980147" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="0.18076923076923077" WEIGHT="3.538849700592596"/>
<DICH_DATA CI_END="3.437213993211045" CI_START="0.2909332971339966" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5362065711764066" LOG_CI_START="-0.5362065711764066" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5087" O_E="0.0" SE="0.629940788348712" STUDY_ID="STD-Young-1987" TOTAL_1="25" TOTAL_2="25" VAR="0.39682539682539686" WEIGHT="2.1900300484141186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.21990975969753984" CI_END="1.1407428905220256" CI_START="0.375349532013147" DF="1" EFFECT_SIZE="0.6543525885214843" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="40" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="0.057187770789712745" LOG_CI_START="-0.42556412127684046" LOG_EFFECT_SIZE="-0.18418817524356387" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6391087024208089" P_Z="0.13475757211077416" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="132" WEIGHT="7.47577020214096" Z="1.4956013463154638">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="1.7608969943800044" CI_START="0.3285658514022512" EFFECT_SIZE="0.7606382978723404" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.2457339521735525" LOG_CI_START="-0.4833775757707886" LOG_EFFECT_SIZE="-0.11882181179861807" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5088" O_E="0.0" SE="0.4282837206747771" STUDY_ID="STD-Noguera-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.18342694539503052" WEIGHT="3.512240626997386"/>
<DICH_DATA CI_END="1.2214526031994524" CI_START="0.27713919951336724" EFFECT_SIZE="0.5818181818181818" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.08687661943200746" LOG_CI_START="-0.5573020417806833" LOG_EFFECT_SIZE="-0.2352127111743379" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5089" O_E="0.0" SE="0.37839373433213475" STUDY_ID="STD-Ropert-1989" TOTAL_1="71" TOTAL_2="72" VAR="0.1431818181818182" WEIGHT="3.963529575143574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6221955042220303" CI_END="1.2408085211039226" CI_START="0.15958346910056256" DF="1" EFFECT_SIZE="0.44498598661901995" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-010.02.03" LOG_CI_END="0.0937047672811339" LOG_CI_START="-0.7970120982624607" LOG_EFFECT_SIZE="-0.35165366549066335" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.43023279761470323" P_Z="0.12172306240345908" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="50" WEIGHT="3.3947606710094664" Z="1.5475816077032907">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="2.1096848858011246" CI_START="0.16940730468855322" EFFECT_SIZE="0.5978260869565217" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.3242175915167711" LOG_CI_START="-0.7710678672193939" LOG_EFFECT_SIZE="-0.22342513785131143" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5090" O_E="0.0" SE="0.6433761002120849" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.4139328063241107" WEIGHT="2.125872671137774"/>
<DICH_DATA CI_END="1.4562396179587855" CI_START="0.042918760916288205" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.16323284214397715" LOG_CI_START="-1.367352824799902" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5091" O_E="0.0" SE="0.8990735972840785" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" VAR="0.8083333333333333" WEIGHT="1.2688879998716924"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.929996733663086" CI_END="2.6853475613172595" CI_START="0.915498626725855" DF="4" EFFECT_SIZE="1.5679387758033074" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="68" I2="42.27991507456795" ID="CMP-010.02.04" LOG_CI_END="0.4290005038879168" LOG_CI_START="-0.03834230281595006" LOG_EFFECT_SIZE="0.19532910053598332" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.13963430863448145" P_Z="0.10134650950365401" STUDIES="5" TAU2="0.15709930323590537" TOTAL_1="237" TOTAL_2="241" WEIGHT="15.900079228889734" Z="1.638360521191106">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="6.903675130153286" CI_START="0.9156909231505022" EFFECT_SIZE="2.5142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.8390803463657038" LOG_CI_START="-0.03825109076591778" LOG_EFFECT_SIZE="0.400414627799893" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5092" O_E="0.0" SE="0.515348829031769" STUDY_ID="STD-Corne-1989" TOTAL_1="49" TOTAL_2="51" VAR="0.26558441558441553" WEIGHT="2.849832461603234"/>
<DICH_DATA CI_END="8.100075556648452" CI_START="0.9336332663950007" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.9084890699505573" LOG_CI_START="-0.02982368229003217" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5093" O_E="0.0" SE="0.551169555389155" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.3037878787878788" WEIGHT="2.620054964948281"/>
<DICH_DATA CI_END="8.517969128422692" CI_START="0.9286434513604249" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.9303360617320986" LOG_CI_START="-0.03215099949326086" LOG_EFFECT_SIZE="0.4490925311194189" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5094" O_E="0.0" SE="0.5653696641515683" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="31" TOTAL_2="28" VAR="0.3196428571428571" WEIGHT="2.5352215401906926"/>
<DICH_DATA CI_END="2.2025526356465464" CI_START="0.40626213338547673" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.34292629578905837" LOG_CI_START="-0.39119365522249705" LOG_EFFECT_SIZE="-0.024133679716719363" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5095" O_E="0.0" SE="0.4312256931765528" STUDY_ID="STD-Stephenson-2000" TOTAL_1="51" TOTAL_2="56" VAR="0.18595559845559845" WEIGHT="3.4872925589341586"/>
<DICH_DATA CI_END="1.7216161674821535" CI_START="0.46469757853608457" EFFECT_SIZE="0.8944444444444445" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="30" LOG_CI_END="0.23593633241061943" LOG_CI_START="-0.3328295905535321" LOG_EFFECT_SIZE="-0.04844662907145634" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5096" O_E="0.0" SE="0.33409591858586807" STUDY_ID="STD-Thompson-2000" TOTAL_1="76" TOTAL_2="76" VAR="0.11162008281573498" WEIGHT="4.407677703213369"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1933323812263636" CI_END="1.3976246897663012" CI_START="0.4372681564880078" DF="2" EFFECT_SIZE="0.7817523722741329" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="59" I2="8.814550082840851" ID="CMP-010.02.05" LOG_CI_END="0.14539056408030748" LOG_CI_START="-0.35925214846142495" LOG_EFFECT_SIZE="-0.10693079219055872" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.33398292128433005" P_Z="0.406194305716701" STUDIES="3" TAU2="0.03065138777396992" TOTAL_1="136" TOTAL_2="136" WEIGHT="7.995428920929129" Z="0.8306094443581223">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="1.0982799642183618" CI_START="0.3092883678229756" EFFECT_SIZE="0.5828252032520326" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="48" LOG_CI_END="0.04071306089448757" LOG_CI_START="-0.5096364132825975" LOG_EFFECT_SIZE="-0.234461676194055" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5097" O_E="0.0" SE="0.3232780054054535" STUDY_ID="STD-Feighner-1985a" TOTAL_1="78" TOTAL_2="79" VAR="0.10450866877892842" WEIGHT="4.521848985211429"/>
<DICH_DATA CI_END="3.769862326152959" CI_START="0.5228880604803338" EFFECT_SIZE="1.404" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.5763254902366071" LOG_CI_START="-0.2815912746490341" LOG_EFFECT_SIZE="0.14736710779378645" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5098" O_E="0.0" SE="0.5039445544503026" STUDY_ID="STD-Remick-1989" TOTAL_1="38" TOTAL_2="37" VAR="0.253960113960114" WEIGHT="2.9279641080695256"/>
<DICH_DATA CI_END="17.18118077307193" CI_START="0.058203217416075405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2350530073187374" LOG_CI_START="-1.2350530073187374" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5099" O_E="0.0" SE="1.4509525002200232" STUDY_ID="STD-Sandor-1998" TOTAL_1="20" TOTAL_2="20" VAR="2.1052631578947367" WEIGHT="0.5456158276481745"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.217717334403236" CI_END="1.2725863210624446" CI_START="0.5123548288673428" DF="8" EFFECT_SIZE="0.8074749201968259" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="259" I2="63.99270060199964" ID="CMP-010.02.06" LOG_CI_END="0.10468725072558148" LOG_CI_START="-0.29042916627787535" LOG_EFFECT_SIZE="-0.09287095777614691" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.004528125676391048" P_Z="0.35685854920973337" STUDIES="9" TAU2="0.28437987042733687" TOTAL_1="558" TOTAL_2="569" WEIGHT="31.017660265247848" Z="0.921367600118704">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="1.8954141847193027" CI_START="0.4332348369130427" EFFECT_SIZE="0.9061784897025171" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" LOG_CI_END="0.27770412643244" LOG_CI_START="-0.3632766285222591" LOG_EFFECT_SIZE="-0.04278625104490955" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5100" O_E="0.0" SE="0.3765152683662993" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.1417637473129464" WEIGHT="3.9815559288094113"/>
<DICH_DATA CI_END="4.024726258020917" CI_START="0.5152151642282508" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.6047363471451639" LOG_CI_START="-0.2880113629546646" LOG_EFFECT_SIZE="0.15836249209524964" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5101" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Byerley-1988" TOTAL_1="32" TOTAL_2="34" VAR="0.275" WEIGHT="2.789538475772246"/>
<DICH_DATA CI_END="1.4720761005994296" CI_START="0.3162917570243721" EFFECT_SIZE="0.6823529411764706" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.1679302619145963" LOG_CI_START="-0.4999121262173072" LOG_EFFECT_SIZE="-0.16599093215135544" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5102" O_E="0.0" SE="0.39229392466181784" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="0.153894523326572" WEIGHT="3.8324506550749797"/>
<DICH_DATA CI_END="2.2726714660670098" CI_START="0.5393499783951208" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.3565366593120562" LOG_CI_START="-0.26812933432794916" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5104" O_E="0.0" SE="0.3669318968106771" STUDY_ID="STD-Feighner-1989" TOTAL_1="61" TOTAL_2="58" VAR="0.1346390168970814" WEIGHT="4.074664166151703"/>
<DICH_DATA CI_END="26.429733766912282" CI_START="0.9806135620006545" EFFECT_SIZE="5.090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.4220927884006" LOG_CI_START="-0.008502104704649216" LOG_EFFECT_SIZE="0.7067953418479753" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5105" O_E="0.0" SE="0.8403385217689542" STUDY_ID="STD-Levine-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.7061688311688311" WEIGHT="1.4168393571373001"/>
<DICH_DATA CI_END="0.8648087636462993" CI_START="0.1214418839191164" EFFECT_SIZE="0.32407407407407407" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="18" LOG_CI_END="-0.06307991805573498" LOG_CI_START="-0.9156315042176132" LOG_EFFECT_SIZE="-0.4893557111366741" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5106" O_E="0.0" SE="0.5007930219099012" STUDY_ID="STD-McGrath-2000" TOTAL_1="49" TOTAL_2="53" VAR="0.2507936507936508" WEIGHT="2.9499952257572426"/>
<DICH_DATA CI_END="3.3019711721904006" CI_START="0.3323789372171282" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5187732773418912" LOG_CI_START="-0.4783665051653172" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5107" O_E="0.0" SE="0.585724844166263" STUDY_ID="STD-Nielsen-1993" TOTAL_1="29" TOTAL_2="30" VAR="0.3430735930735931" WEIGHT="2.419452107915044"/>
<DICH_DATA CI_END="1.5188664552390403" CI_START="0.6718907268161788" EFFECT_SIZE="1.010204081632653" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" LOG_CI_END="0.18151959064857084" LOG_CI_START="-0.17270135283846075" LOG_EFFECT_SIZE="0.004409118905055016" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5108" O_E="0.0" SE="0.20807113562623145" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.0432935974807896" WEIGHT="5.819412342949184"/>
<DICH_DATA CI_END="0.4814061160735749" CI_START="0.09916106206725049" EFFECT_SIZE="0.2184873949579832" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="34" LOG_CI_END="-0.3174883964869722" LOG_CI_START="-1.0036588303564533" LOG_EFFECT_SIZE="-0.6605736134217128" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5109" O_E="0.0" SE="0.40305990945336045" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="0.16245729060855113" WEIGHT="3.733752005680737"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0412807804728923" CI_START="0.2411009060382097" DF="0" EFFECT_SIZE="0.5010526315789474" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" I2="0.0" ID="CMP-010.02.07" LOG_CI_END="0.01756785243832372" LOG_CI_START="-0.6178011575750328" LOG_EFFECT_SIZE="-0.30011665256835457" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.06408635874762932" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="4.013367093105883" Z="1.8515785973959604">
<NAME>Fluoxetine vs Lofepramine</NAME>
<DICH_DATA CI_END="1.0412807804728923" CI_START="0.2411009060382097" EFFECT_SIZE="0.5010526315789474" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.01756785243832372" LOG_CI_START="-0.6178011575750328" LOG_EFFECT_SIZE="-0.30011665256835457" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5110" O_E="0.0" SE="0.37321890160916915" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" VAR="0.1392923485183547" WEIGHT="4.013367093105883"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.093468299830004" CI_END="3.926281790086594" CI_START="0.17128640710683968" DF="1" EFFECT_SIZE="0.8200723755333693" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="31" I2="75.57083805824199" ID="CMP-010.02.08" LOG_CI_END="0.5939814657907175" LOG_CI_START="-0.766277100272804" LOG_EFFECT_SIZE="-0.08614781724104328" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.04304932219231772" P_Z="0.8039358357344303" STUDIES="2" TAU2="0.9844654601085935" TOTAL_1="124" TOTAL_2="119" WEIGHT="5.920684425701172" Z="0.24825665259776614">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<DICH_DATA CI_END="8.251259355410493" CI_START="0.5137099856738948" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.9165202381699855" LOG_CI_START="-0.2892819922259821" LOG_EFFECT_SIZE="0.3136191229720017" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5111" O_E="0.0" SE="0.7082941989518957" STUDY_ID="STD-Akhondzadeh-2003" TOTAL_1="24" TOTAL_2="24" VAR="0.5016806722689076" WEIGHT="1.8481640520886067"/>
<DICH_DATA CI_END="0.8419643412164277" CI_START="0.19964377227010083" EFFECT_SIZE="0.4099913867355728" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" LOG_CI_END="-0.07470630130423607" LOG_CI_START="-0.6997442327319254" LOG_EFFECT_SIZE="-0.3872252670180807" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5112" O_E="0.0" SE="0.36715037490828445" STUDY_ID="STD-Joyce-2002" TOTAL_1="100" TOTAL_2="95" VAR="0.13479939779529382" WEIGHT="4.072520373612565"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2013-07-02 12:08:42 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Subgroup analysis for fluoxetine versus TCAs: failure to complete - inefficacy</NAME>
<DICH_OUTCOME CHI2="1.5037085334324651" CI_END="1.5002346695767137" CI_START="0.16102216855097848" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4914987689003941" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.176159197542946" LOG_CI_START="-0.7931143288340434" LOG_EFFECT_SIZE="-0.30847756564554873" METHOD="MH" MODIFIED="2013-06-21 10:53:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6814146974496758" P_Q="0.49294025736096947" P_Z="0.2121987016590896" Q="1.4147348510639677" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="200" WEIGHT="100.00000000000001" Z="1.2475424165638682">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08521165758984806" CI_END="2.0939535171321655" CI_START="0.07039088810611341" DF="1" EFFECT_SIZE="0.38392088732426743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="0.32096703671385196" LOG_CI_START="-1.1524835553657071" LOG_EFFECT_SIZE="-0.4157582593259276" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.770355175626279" P_Z="0.2686953785808701" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="43.27345258834399" Z="1.1060719903798215">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="3.151931737693131" CI_START="0.028856875100118452" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4985768032768393" LOG_CI_START="-1.5397507002783448" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4657" O_E="0.0" SE="1.1973236654721853" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="1.4335839598997493" WEIGHT="22.612301792187985"/>
<DICH_DATA CI_END="5.823325204961337" CI_START="0.04293079833271303" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7651710440624268" LOG_CI_START="-1.3672310353903891" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1006" O_E="0.0" SE="1.2525835370311154" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="1.5689655172413794" WEIGHT="20.661150796156008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4673" O_E="0.0" SE="0.0" STUDY_ID="STD-Tamminen-1989" TOTAL_1="26" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="82.16475480197155" CI_START="0.12105854372842961" DF="0" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="1.9146855635554856" LOG_CI_START="-0.9170045547296883" LOG_EFFECT_SIZE="0.49884050441289873" MODIFIED="2013-06-21 10:53:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4898494409043541" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.716590506320792" Z="0.690548316968497">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="82.16475480197155" CI_START="0.12105854372842961" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9146855635554856" LOG_CI_START="-0.9170045547296883" LOG_EFFECT_SIZE="0.49884050441289873" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4675" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="2.766729205753596" WEIGHT="11.716590506320792"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.027142456519722" CI_START="0.07280084731454084" DF="0" EFFECT_SIZE="0.38415841584158417" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-011.01.04" LOG_CI_END="0.30688426961382753" LOG_CI_START="-1.1378635659906982" LOG_EFFECT_SIZE="-0.4154896481884353" MODIFIED="2013-06-21 10:53:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2596082919046119" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="45.00995690533523" Z="1.1273174824419165">
<NAME>Fluoxetine vs Nortriptyiline</NAME>
<DICH_DATA CI_END="2.027142456519722" CI_START="0.07280084731454084" EFFECT_SIZE="0.38415841584158417" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30688426961382753" LOG_CI_START="-1.1378635659906982" LOG_EFFECT_SIZE="-0.4154896481884353" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4685" O_E="0.0" SE="0.8486520302512245" STUDY_ID="STD-Fabre-1991" TOTAL_1="103" TOTAL_2="102" VAR="0.7202102684495253" WEIGHT="45.00995690533523"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.184290014003334" CI_END="1.8656388062326597" CI_START="1.0202812354508128" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3796652732195724" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.2708275667181929" LOG_CI_START="0.008719899378929303" LOG_EFFECT_SIZE="0.13977373304856108" METHOD="MH" MODIFIED="2013-06-21 10:53:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9741616711759404" P_Q="0.8766268708360113" P_Z="0.036584246542478285" Q="1.7957197534036442" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1249" TOTAL_2="1261" WEIGHT="100.0" Z="2.0903736662178742">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.165873116889733" CI_END="2.4660048765184857" CI_START="0.49753373797973244" DF="8" EFFECT_SIZE="1.107664490759946" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="0.3919939310768155" LOG_CI_START="-0.3031774642215111" LOG_EFFECT_SIZE="0.04440823342765218" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.841856213102696" P_Z="0.8022711791541833" STUDIES="11" TAU2="0.0" TOTAL_1="359" TOTAL_2="371" WEIGHT="14.215942677122893" Z="0.2504088595241876">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="5.803074751685154" CI_START="0.043080609969293006" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7636581649183615" LOG_CI_START="-1.3657181562463239" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5113" O_E="0.0" SE="1.2508061916349222" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="1.564516129032258" WEIGHT="1.515146441040973"/>
<DICH_DATA CI_END="5.857126622998092" CI_START="0.24761989508624313" EFFECT_SIZE="1.2043010752688172" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7676846129770684" LOG_CI_START="-0.6062144647445754" LOG_EFFECT_SIZE="0.0807350741162465" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5114" O_E="0.0" SE="0.8070351191638119" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.651305683563748" WEIGHT="3.6395675712269604"/>
<DICH_DATA CI_END="123.07864795221792" CI_START="0.24941441908990408" EFFECT_SIZE="5.54054054054054" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0901827167749967" LOG_CI_START="-0.6030784427974784" LOG_EFFECT_SIZE="0.7435521369887593" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5115" O_E="0.0" SE="1.5820349369906253" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="2.502834541858932" WEIGHT="0.9471145635914884"/>
<DICH_DATA CI_END="15.634392732993957" CI_START="0.055443484303442904" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1940810171535208" LOG_CI_START="-1.2561494846334584" LOG_EFFECT_SIZE="-0.03103423373996879" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5116" O_E="0.0" SE="1.4392775255862666" STUDY_ID="STD-Judd-1993" TOTAL_1="30" TOTAL_2="28" VAR="2.0715197956577267" WEIGHT="1.1443149371892818"/>
<DICH_DATA CI_END="89.9506535045962" CI_START="0.13320913249504976" EFFECT_SIZE="3.4615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9540043229056843" LOG_CI_START="-0.87546599996867" LOG_EFFECT_SIZE="0.5392691614685069" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5117" O_E="0.0" SE="1.6620448737603815" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.7623931623931623" WEIGHT="0.8581222532424745"/>
<DICH_DATA CI_END="6.240672274566779" CI_START="0.049007943794167605" EFFECT_SIZE="0.553030303030303" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7952313764465558" LOG_CI_START="-1.3097335186173438" LOG_EFFECT_SIZE="-0.257251071085394" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5118" O_E="0.0" SE="1.2364667991048128" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="1.5288501452885015" WEIGHT="1.5504927360994598"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5119" O_E="0.0" SE="0.0" STUDY_ID="STD-Masco-1985" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1016" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.120175997580382" CI_START="0.058410614478573784" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2335082249664329" LOG_CI_START="-1.2335082249664326" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5120" O_E="0.0" SE="1.4491376746189437" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.0999999999999996" WEIGHT="1.1287957356449647"/>
<DICH_DATA CI_END="33.9911086347409" CI_START="0.3268828690028341" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5313653295168224" LOG_CI_START="-0.4856078389561472" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5121" O_E="0.0" SE="1.184780023339229" STUDY_ID="STD-Preskorn-1991" TOTAL_1="30" TOTAL_2="31" VAR="1.4037037037037037" WEIGHT="1.6887260741706989"/>
<DICH_DATA CI_END="3.3191623413844646" CI_START="0.034362382033997316" EFFECT_SIZE="0.33771929824561403" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5210284944222353" LOG_CI_START="-1.4639167380781792" LOG_EFFECT_SIZE="-0.4714441218279719" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5122" O_E="0.0" SE="1.1659666552081103" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="1.3594782410571882" WEIGHT="1.7436623649165917"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="145.74545024217892" CI_START="0.37219979855997615" DF="0" EFFECT_SIZE="7.365217391304348" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="2.1635950062059615" LOG_CI_START="-0.42922386625177106" LOG_EFFECT_SIZE="0.8671855699770953" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.18984220228619145" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="1.0219157495841684" Z="1.3110460611981316">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="145.74545024217892" CI_START="0.37219979855997615" EFFECT_SIZE="7.3652173913043475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1635950062059615" LOG_CI_START="-0.42922386625177106" LOG_EFFECT_SIZE="0.8671855699770952" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5123" O_E="0.0" SE="1.5230346403420856" STUDY_ID="STD-Noguera-1991" TOTAL_1="60" TOTAL_2="60" VAR="2.3196345156819462" WEIGHT="1.0219157495841684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0163801780758825" CI_END="5.345326399717987" CI_START="0.20012041131976557" DF="1" EFFECT_SIZE="1.0342673337923638" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="1.6116191981323358" ID="CMP-011.02.03" LOG_CI_END="0.7279742295201764" LOG_CI_START="-0.6987086131556037" LOG_EFFECT_SIZE="0.014632808182286312" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3133794669413672" P_Z="0.9679298197477364" STUDIES="2" TAU2="0.03001448290398275" TOTAL_1="54" TOTAL_2="50" WEIGHT="3.4678536376914813" Z="0.04020483904632173">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="10.886262075961533" CI_START="0.2592625439573307" EFFECT_SIZE="1.68" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.036878785315787" LOG_CI_START="-0.5862602218640613" LOG_EFFECT_SIZE="0.22530928172586284" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5124" O_E="0.0" SE="0.9534398874851099" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.909047619047619" WEIGHT="2.6076423227838097"/>
<DICH_DATA CI_END="6.348684220381443" CI_START="0.009476571405428616" EFFECT_SIZE="0.24528301886792453" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8026837260731798" LOG_CI_START="-2.0233487606610843" LOG_EFFECT_SIZE="-0.6103325172939523" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5125" O_E="0.0" SE="1.6600254717941292" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" VAR="2.7556845670053214" WEIGHT="0.8602113149076716"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.396437076218286" CI_END="3.660573716646513" CI_START="0.49397953273514955" DF="2" EFFECT_SIZE="1.3447113051103625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-011.02.04" LOG_CI_END="0.5635491571013317" LOG_CI_START="-0.30629104501224136" LOG_EFFECT_SIZE="0.12862905604454522" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4974707981326564" P_Z="0.5621399997763366" STUDIES="3" TAU2="0.0" TOTAL_1="137" TOTAL_2="134" WEIGHT="9.079888153802795" Z="0.5796658204578491">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="15.734420680350373" CI_START="0.49827064874341565" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1968507574202762" LOG_CI_START="-0.30253469473583805" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5126" O_E="0.0" SE="0.8807464366741915" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.7757142857142857" WEIGHT="3.0558558589283566"/>
<DICH_DATA CI_END="4.807363139264934" CI_START="0.2769420383227244" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6819069291646853" LOG_CI_START="-0.5576111156669964" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5127" O_E="0.0" SE="0.7280990352474073" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="31" TOTAL_2="28" VAR="0.5301282051282051" WEIGHT="4.471505235759254"/>
<DICH_DATA CI_END="5.558186722457528" CI_START="0.04378726191303077" EFFECT_SIZE="0.49333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7449331324325046" LOG_CI_START="-1.3586522110819146" LOG_EFFECT_SIZE="-0.30685953932470506" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5128" O_E="0.0" SE="1.2356564436957576" STUDY_ID="STD-Thompson-2000" TOTAL_1="76" TOTAL_2="76" VAR="1.526846846846847" WEIGHT="1.5525270591151827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.060797849928977826" CI_END="4.919327682674528" CI_START="0.6035191341560805" DF="1" EFFECT_SIZE="1.7230520548369306" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-011.02.05" LOG_CI_END="0.6919057524307496" LOG_CI_START="-0.21930895634265338" LOG_EFFECT_SIZE="0.23629839804404812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8052393241176158" P_Z="0.3093793751402085" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="116" WEIGHT="8.274047462458064" Z="1.0165251840464202">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="5.766774153314231" CI_START="0.42335735457871115" EFFECT_SIZE="1.5625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7609329432801512" LOG_CI_START="-0.3732928912479256" LOG_EFFECT_SIZE="0.19382002601611284" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5129" O_E="0.0" SE="0.6662498697102228" STUDY_ID="STD-Feighner-1985a" TOTAL_1="78" TOTAL_2="79" VAR="0.4438888888888889" WEIGHT="5.340235144853524"/>
<DICH_DATA CI_END="11.98798498278542" CI_START="0.35358355314477835" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0787461902381124" LOG_CI_START="-0.45150794429410923" LOG_EFFECT_SIZE="0.3136191229720017" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5130" O_E="0.0" SE="0.898878853504359" STUDY_ID="STD-Remick-1989" TOTAL_1="38" TOTAL_2="37" VAR="0.8079831932773109" WEIGHT="2.933812317604541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.809215224764465" CI_END="2.0367586579391945" CI_START="0.957529589163269" DF="8" EFFECT_SIZE="1.3965159078797664" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="60" I2="0.0" ID="CMP-011.02.06" LOG_CI_END="0.30893957110381703" LOG_CI_START="-0.018847796772623274" LOG_EFFECT_SIZE="0.1450458871655969" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7777593438242532" P_Z="0.08281737818153623" STUDIES="9" TAU2="0.0" TOTAL_1="523" TOTAL_2="530" WEIGHT="63.94035231934059" Z="1.7345678498348462">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="4.673555277366459" CI_START="0.774415627231515" EFFECT_SIZE="1.9024390243902438" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.6696473837569364" LOG_CI_START="-0.11102589181544657" LOG_EFFECT_SIZE="0.2793107459707449" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5131" O_E="0.0" SE="0.45857134646625597" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.21028767979987495" WEIGHT="11.272515095084685"/>
<DICH_DATA CI_END="4.410468947564418" CI_START="0.3871193285967105" EFFECT_SIZE="1.3066666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6444847687222367" LOG_CI_START="-0.41215514412064713" LOG_EFFECT_SIZE="0.1161648123007948" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5132" O_E="0.0" SE="0.6206755152558342" STUDY_ID="STD-Byerley-1988" TOTAL_1="32" TOTAL_2="34" VAR="0.3852380952380952" WEIGHT="6.1532622919583355"/>
<DICH_DATA CI_END="1.960624471059898" CI_START="0.005406426634017478" EFFECT_SIZE="0.10295616717635066" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2923944188772434" LOG_CI_START="-2.2670896860718552" LOG_EFFECT_SIZE="-0.9873476335973059" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5133" O_E="0.0" SE="1.5034536328977535" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="2.260372826273453" WEIGHT="1.04870799069129"/>
<DICH_DATA CI_END="4.446024257991747" CI_START="0.6444547612590713" EFFECT_SIZE="1.6927083333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.6479718279273481" LOG_CI_START="-0.19080756337669866" LOG_EFFECT_SIZE="0.22858213227532476" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5135" O_E="0.0" SE="0.49270316647694706" STUDY_ID="STD-Feighner-1989" TOTAL_1="61" TOTAL_2="58" VAR="0.24275641025641023" WEIGHT="9.764813387834442"/>
<DICH_DATA CI_END="24.14845588814672" CI_START="0.17768491477903403" EFFECT_SIZE="2.0714285714285716" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3828893661145807" LOG_CI_START="-0.7503494416731445" LOG_EFFECT_SIZE="0.3162699622207181" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5136" O_E="0.0" SE="1.2530750353969131" STUDY_ID="STD-Levine-1989" TOTAL_1="30" TOTAL_2="30" VAR="1.5701970443349753" WEIGHT="1.5096646968014065"/>
<DICH_DATA CI_END="25.068757237020414" CI_START="0.18407535813453782" EFFECT_SIZE="2.1481481481481484" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3991328047008436" LOG_CI_START="-0.7350043458929435" LOG_EFFECT_SIZE="0.33206422940395003" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5137" O_E="0.0" SE="1.2536027264080623" STUDY_ID="STD-Nielsen-1993" TOTAL_1="29" TOTAL_2="30" VAR="1.5715197956577267" WEIGHT="1.5083940090378016"/>
<DICH_DATA CI_END="2.270419115947087" CI_START="0.7635643564373132" EFFECT_SIZE="1.3166666666666667" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="28" LOG_CI_END="0.35610603470051416" LOG_CI_START="-0.11715435288691854" LOG_EFFECT_SIZE="0.11947584090679779" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5138" O_E="0.0" SE="0.27799549434555876" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.07728149487643159" WEIGHT="30.673203832879583"/>
<DICH_DATA CI_END="8.2917027849037" CI_START="0.011615697584441467" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9186437264669701" LOG_CI_START="-1.9349547033862324" LOG_EFFECT_SIZE="-0.5081554884596312" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4683" O_E="0.0" SE="1.6762178432358128" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="14" VAR="2.80970625798212" WEIGHT="0.8436721946004615"/>
<DICH_DATA CI_END="16.35338689370616" CI_START="0.06114941244280502" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.213607711547949" LOG_CI_START="-1.213607711547949" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5139" O_E="0.0" SE="1.425758354436649" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="2.0327868852459012" WEIGHT="1.1661188204525805"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2013-07-02 12:09:08 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Subgroup analysis for fluoxetine versus TCAs: failure to complete - side effects</NAME>
<DICH_OUTCOME CHI2="6.741913009024434" CI_END="1.4308292621280094" CI_START="0.4630897902827707" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8140039452787139" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="43" I2="11.004488014475136" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.15558781339667738" LOG_CI_START="-0.33433479376907893" LOG_EFFECT_SIZE="-0.08937349018620078" METHOD="MH" MODIFIED="2013-06-21 10:53:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34537591271876256" P_Q="0.6540764282359693" P_Z="0.474554841973321" Q="1.6234858203993738" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06797662067526233" TOTALS="YES" TOTAL_1="275" TOTAL_2="279" WEIGHT="100.00000000000001" Z="0.71508772763504">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.248170826408738" CI_END="1.8155036606534571" CI_START="0.20996814877332542" DF="3" EFFECT_SIZE="0.6174122955680442" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" I2="42.83722654559884" ID="CMP-012.01.01" LOG_CI_END="0.2589971289305381" LOG_CI_START="-0.67784658079523" LOG_EFFECT_SIZE="-0.20942472593234593" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1545011358547249" P_Z="0.380882233268221" STUDIES="4" TAU2="0.5137101450396289" TOTAL_1="126" TOTAL_2="132" WEIGHT="45.49854891084597" Z="0.876271924630247">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="2.6303079649357346" CI_START="0.02827812038772938" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.420006600064705" LOG_CI_START="-1.5485494609418304" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4686" O_E="0.0" SE="1.1563395747448983" STUDY_ID="STD-Chouinard-1985" TOTAL_1="23" TOTAL_2="28" VAR="1.3371212121212122" WEIGHT="5.894182795237739"/>
<DICH_DATA CI_END="1.5042772627918581" CI_START="0.04727260915925346" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17732789117766895" LOG_CI_START="-1.3253904266331067" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4690" O_E="0.0" SE="0.8827041784576907" STUDY_ID="STD-Feighner-1985b" TOTAL_1="22" TOTAL_2="22" VAR="0.7791666666666667" WEIGHT="9.776272320684779"/>
<DICH_DATA CI_END="2.051842801672525" CI_START="0.10445961303699022" EFFECT_SIZE="0.46296296296296297" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3121440850063834" LOG_CI_START="-0.9810515873082452" LOG_EFFECT_SIZE="-0.3344537511509309" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1007" O_E="0.0" SE="0.7596295393394316" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.577037037037037" WEIGHT="12.839888539831287"/>
<DICH_DATA CI_END="7.780255992088858" CI_START="0.6142213515673176" EFFECT_SIZE="2.186046511627907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8909938867226687" LOG_CI_START="-0.21167509068244453" LOG_EFFECT_SIZE="0.33965939802011214" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4696" O_E="0.0" SE="0.647713215627232" STUDY_ID="STD-Peters-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.4195324096981692" WEIGHT="16.98820525509216"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="32.31355348821109" CI_START="0.3032666132414541" DF="0" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="1.5093847195609154" LOG_CI_START="-0.5181753987335642" LOG_EFFECT_SIZE="0.4956046604136756" MODIFIED="2013-06-21 10:53:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.337980214249443" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="5.571580795703453" Z="0.9581637320802028">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="32.31355348821109" CI_START="0.3032666132414541" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5093847195609154" LOG_CI_START="-0.5181753987335642" LOG_EFFECT_SIZE="0.4956046604136756" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4711" O_E="0.0" SE="1.190998850070631" STUDY_ID="STD-Tamminen-1989" TOTAL_1="26" TOTAL_2="25" VAR="1.4184782608695652" WEIGHT="5.571580795703453"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.2435986733527225" CI_START="0.09341917109101555" DF="0" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-012.01.03" LOG_CI_END="0.6277343049678096" LOG_CI_START="-1.0295639905292362" LOG_EFFECT_SIZE="-0.20091484278071337" MODIFIED="2013-06-21 10:53:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6346342964231444" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.153975433312906" Z="0.4752142168729183">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="4.2435986733527225" CI_START="0.09341917109101555" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6277343049678096" LOG_CI_START="-1.0295639905292362" LOG_EFFECT_SIZE="-0.20091484278071337" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4713" O_E="0.0" SE="0.973505222533836" STUDY_ID="STD-Bremner-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.9477124183006536" WEIGHT="8.153975433312906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.774918129496993" CI_START="0.420118298289202" DF="0" EFFECT_SIZE="0.8635250917992656" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" ID="CMP-012.01.04" LOG_CI_END="0.2491783254318418" LOG_CI_START="-0.37662840231593947" LOG_EFFECT_SIZE="-0.06372503844204884" MODIFIED="2013-06-21 10:53:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6897746713697015" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="40.77589486013768" Z="0.3991608741866518">
<NAME>Fluoxetine vs Nortriptyline</NAME>
<DICH_DATA CI_END="1.774918129496993" CI_START="0.420118298289202" EFFECT_SIZE="0.8635250917992656" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.2491783254318418" LOG_CI_START="-0.37662840231593947" LOG_EFFECT_SIZE="-0.06372503844204884" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4724" O_E="0.0" SE="0.3676019696723096" STUDY_ID="STD-Fabre-1991" TOTAL_1="103" TOTAL_2="102" VAR="0.13513120810696166" WEIGHT="40.77589486013768"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="62.52268422478161" CI_END="0.7228231798330279" CI_START="0.35503490695546325" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5065841098941726" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="312" I2="50.41799566930176" I2_Q="45.661820551113095" ID="CMP-012.02" LOG_CI_END="-0.14096792872848385" LOG_CI_START="-0.4497289451058796" LOG_EFFECT_SIZE="-0.2953484369171817" METHOD="MH" MODIFIED="2013-06-21 10:53:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.736451477639127E-4" P_Q="0.08708833323681442" P_Z="1.770841715634672E-4" Q="11.041959927354371" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="33" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4267519652569459" TOTALS="YES" TOTAL_1="1535" TOTAL_2="1558" WEIGHT="100.0" Z="3.749646286565699">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>TCAs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.215942855041595" CI_END="0.6086283429980716" CI_START="0.1754067620891293" DF="10" EFFECT_SIZE="0.32673770361096033" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="61" I2="18.139761141130926" ID="CMP-012.02.01" LOG_CI_END="-0.215647827000778" LOG_CI_START="-0.7559536682026617" LOG_EFFECT_SIZE="-0.4858007476017198" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2708643680506382" P_Z="4.242946690524945E-4" STUDIES="12" TAU2="0.1965231566850158" TOTAL_1="384" TOTAL_2="396" WEIGHT="26.139828746015578" Z="3.5244925979108017">
<NAME>Fluoxetine vs Amitriptyline</NAME>
<DICH_DATA CI_END="2.08238500019606" CI_START="0.06693180068270524" EFFECT_SIZE="0.37333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31856102680904397" LOG_CI_START="-1.1743674909080055" LOG_EFFECT_SIZE="-0.42790323204948083" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5140" O_E="0.0" SE="0.8769536014223438" STUDY_ID="STD-De-Ronchi-1998" TOTAL_1="32" TOTAL_2="33" VAR="0.7690476190476191" WEIGHT="2.7508171903085374"/>
<DICH_DATA CI_END="0.5489361347962343" CI_START="0.022119989301159163" EFFECT_SIZE="0.11019283746556474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.2604781799925115" LOG_CI_START="-1.6552150874237888" LOG_EFFECT_SIZE="-0.9578466337081502" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5141" O_E="0.0" SE="0.8192753634841714" STUDY_ID="STD-Demyttenaere-1998" TOTAL_1="35" TOTAL_2="31" VAR="0.6712121212121213" WEIGHT="2.995932283402125"/>
<DICH_DATA CI_END="1.0169686798002837" CI_START="0.06145715324514617" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.007307577898787688" LOG_CI_START="-1.2114275605547122" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5142" O_E="0.0" SE="0.7158910531638176" STUDY_ID="STD-Fawcett-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.5125" WEIGHT="3.5021763854057317"/>
<DICH_DATA CI_END="74.1336120044427" CI_START="0.11331125163252181" EFFECT_SIZE="2.8983050847457625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8700151607231488" LOG_CI_START="-0.9457269632231292" LOG_EFFECT_SIZE="0.4621440987500096" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5143" O_E="0.0" SE="1.6539808617543488" STUDY_ID="STD-Judd-1993" TOTAL_1="30" TOTAL_2="28" VAR="2.7356526910496584" WEIGHT="1.0401660793500556"/>
<DICH_DATA CI_END="2.8050797634266047" CI_START="0.00658294468003717" EFFECT_SIZE="0.13588850174216027" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4479452150836296" LOG_CI_START="-2.181579794498616" LOG_EFFECT_SIZE="-0.8668172897074932" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5144" O_E="0.0" SE="1.5445960069873335" STUDY_ID="STD-Keegan-1991" TOTAL_1="20" TOTAL_2="22" VAR="2.385776824801215" WEIGHT="1.1695617354376586"/>
<DICH_DATA CI_END="10.563903405339099" CI_START="0.2771046853217874" EFFECT_SIZE="1.7109375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0238244214330305" LOG_CI_START="-0.5573561310485308" LOG_EFFECT_SIZE="0.23323414519224997" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5145" O_E="0.0" SE="0.9287932834976358" STUDY_ID="STD-Marchesi-1998" TOTAL_1="67" TOTAL_2="75" VAR="0.8626569634703196" WEIGHT="2.5511115825106687"/>
<DICH_DATA CI_END="2.6659126353172984" CI_START="0.0062343867701999" EFFECT_SIZE="0.1289198606271777" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4258459130368416" LOG_CI_START="-2.2052062583708363" LOG_EFFECT_SIZE="-0.8896801726669974" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5146" O_E="0.0" SE="1.5454930694031654" STUDY_ID="STD-Masco-1985" TOTAL_1="20" TOTAL_2="21" VAR="2.3885488275732176" WEIGHT="1.168410161019423"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1017" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Keane-1992" TOTAL_1="7" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.171483155193931" CI_START="0.037833518513163855" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.06873604823906786" LOG_CI_START="-1.422123267488801" LOG_EFFECT_SIZE="-0.6766936096248666" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5147" O_E="0.0" SE="0.875738141931184" STUDY_ID="STD-OntiverosSanchez-1998" TOTAL_1="21" TOTAL_2="21" VAR="0.7669172932330826" WEIGHT="2.755726537541789"/>
<DICH_DATA CI_END="0.6175745325954108" CI_START="0.03832515397580421" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.20931062164468192" LOG_CI_START="-1.4165160916410293" LOG_EFFECT_SIZE="-0.8129133566428556" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5148" O_E="0.0" SE="0.7091184688393067" STUDY_ID="STD-Preskorn-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.5028490028490028" WEIGHT="3.538535528175028"/>
<DICH_DATA CI_END="1.698436326888109" CI_START="0.10523966090226755" EFFECT_SIZE="0.42277992277992277" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.23004927013482138" LOG_CI_START="-0.9778205599450508" LOG_EFFECT_SIZE="-0.3738856449051147" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5149" O_E="0.0" SE="0.7095087172410047" STUDY_ID="STD-Versiani-1999" TOTAL_1="77" TOTAL_2="80" VAR="0.503402619840976" WEIGHT="3.5364294337403144"/>
<DICH_DATA CI_END="118.95804526560195" CI_START="0.24745191881562512" EFFECT_SIZE="5.425531914893617" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.075393819187927" LOG_CI_START="-0.6065091741914517" LOG_EFFECT_SIZE="0.7344423224982377" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5150" O_E="0.0" SE="1.575363093944971" STUDY_ID="STD-Young-1987" TOTAL_1="25" TOTAL_2="25" VAR="2.4817688777638716" WEIGHT="1.1309618291242403"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0014169768468637548" CI_END="0.7904399528904086" CI_START="0.11576848421918749" DF="1" EFFECT_SIZE="0.30250295074992006" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" ID="CMP-012.02.02" LOG_CI_END="-0.10213111639446576" LOG_CI_START="-0.9364096529795829" LOG_EFFECT_SIZE="-0.5192703846870244" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9699725241842567" P_Z="0.01469394572379105" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="132" WEIGHT="7.068122716120121" Z="2.4398356366464933">
<NAME>Fluoxetine vs Clomipramine</NAME>
<DICH_DATA CI_END="1.604146835915282" CI_START="0.06004058347598737" EFFECT_SIZE="0.3103448275862069" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.20524411900366946" LOG_CI_START="-1.2215550959229318" LOG_EFFECT_SIZE="-0.5081554884596312" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5151" O_E="0.0" SE="0.8381089216179064" STUDY_ID="STD-Noguera-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.70242656449553" WEIGHT="2.913114238356858"/>
<DICH_DATA CI_END="0.9753443839784554" CI_START="0.09135922320699043" EFFECT_SIZE="0.29850746268656714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.01084201234902022" LOG_CI_START="-1.0392476017246703" LOG_EFFECT_SIZE="-0.5250448070368453" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5152" O_E="0.0" SE="0.6040905338890259" STUDY_ID="STD-Ropert-1989" TOTAL_1="71" TOTAL_2="72" VAR="0.3649253731343283" WEIGHT="4.155008477763263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2927621393119262" CI_END="1.6815625163744157" CI_START="0.04251743012135387" DF="1" EFFECT_SIZE="0.26738682986384577" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="22.646249484669244" ID="CMP-012.02.03" LOG_CI_END="0.22571301795558227" LOG_CI_START="-1.3714329933924896" LOG_EFFECT_SIZE="-0.5728599877184537" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2555396623024382" P_Z="0.15972736053724584" STUDIES="2" TAU2="0.4607325443537712" TOTAL_1="54" TOTAL_2="50" WEIGHT="3.8211501767483753" Z="1.4059891032311316">
<NAME>Fluoxetine vs Desipramine</NAME>
<DICH_DATA CI_END="2.971753439838066" CI_START="0.0841254178925499" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4730127740791998" LOG_CI_START="-1.0750727654071621" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5153" O_E="0.0" SE="0.9093531090412992" STUDY_ID="STD-Bowden-1993" TOTAL_1="28" TOTAL_2="30" VAR="0.8269230769230769" WEIGHT="2.623826703089501"/>
<DICH_DATA CI_END="1.3698239193313095" CI_START="0.003494027962182422" EFFECT_SIZE="0.06918238993710692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.13666474542104062" LOG_CI_START="-2.4566736237454934" LOG_EFFECT_SIZE="-1.1600044391622264" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5154" O_E="0.0" SE="1.5233397952803855" STUDY_ID="STD-Remick-1993" TOTAL_1="26" TOTAL_2="20" VAR="2.3205641318848866" WEIGHT="1.1973234736588745"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.830219249644456" CI_END="7.159464138949874" CI_START="0.5863014879159935" DF="4" EFFECT_SIZE="2.04880562214855" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="63.06630634341668" ID="CMP-012.02.04" LOG_CI_END="0.854880518089124" LOG_CI_START="-0.23187900366121064" LOG_EFFECT_SIZE="0.3115007572139567" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.028539932067401796" P_Z="0.26119154919000853" STUDIES="5" TAU2="1.196784987775247" TOTAL_1="237" TOTAL_2="241" WEIGHT="14.160931084929555" Z="1.1235793256506106">
<NAME>Fluoxetine vs Dothiepin/dosulepin</NAME>
<DICH_DATA CI_END="17.83409334303401" CI_START="0.6553098907894159" EFFECT_SIZE="3.4186046511627906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.2512510353942434" LOG_CI_START="-0.1835532770570643" LOG_EFFECT_SIZE="0.5338488791685896" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5155" O_E="0.0" SE="0.8428111555297908" STUDY_ID="STD-Corne-1989" TOTAL_1="49" TOTAL_2="51" VAR="0.7103306438854612" WEIGHT="2.8928646223423478"/>
<DICH_DATA CI_END="64.45722913614652" CI_START="0.8154632258389126" EFFECT_SIZE="7.25" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.809271632284812" LOG_CI_START="-0.08859561914282459" LOG_EFFECT_SIZE="0.8603380065709937" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5156" O_E="0.0" SE="1.1148166180830024" STUDY_ID="STD-Dowling-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.242816091954023" WEIGHT="1.9702257949063915"/>
<DICH_DATA CI_END="376.1915566102111" CI_START="1.1299072476526284" EFFECT_SIZE="20.617021276595743" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.5754090438492767" LOG_CI_START="0.053042794380819144" LOG_EFFECT_SIZE="1.3142259191150478" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5157" O_E="0.0" SE="1.4816504208520769" STUDY_ID="STD-SouthWalesGroup-1988" TOTAL_1="31" TOTAL_2="28" VAR="2.1952879696111367" WEIGHT="1.2545293490483373"/>
<DICH_DATA CI_END="3.0280903952619536" CI_START="0.09297917752924137" EFFECT_SIZE="0.5306122448979592" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4811688356818921" LOG_CI_START="-1.0316142997972835" LOG_EFFECT_SIZE="-0.27522273205769565" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5158" O_E="0.0" SE="0.8886163021777597" STUDY_ID="STD-Stephenson-2000" TOTAL_1="51" TOTAL_2="56" VAR="0.7896389324960754" WEIGHT="2.704250795320151"/>
<DICH_DATA CI_END="1.6147919902402612" CI_START="0.2933048351431117" EFFECT_SIZE="0.6882051282051282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.20811658653770504" LOG_CI_START="-0.5326807775967944" LOG_EFFECT_SIZE="-0.16228209552954473" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5159" O_E="0.0" SE="0.4351480386986982" STUDY_ID="STD-Thompson-2000" TOTAL_1="76" TOTAL_2="76" VAR="0.1893538155833238" WEIGHT="5.339060523312328"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.83450399081027" CI_END="1.2759616255860196" CI_START="0.4177993251673118" DF="1" EFFECT_SIZE="0.7301341699367487" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="42" I2="0.0" ID="CMP-012.02.05" LOG_CI_END="0.1058376132199033" LOG_CI_START="-0.37903226583093613" LOG_EFFECT_SIZE="-0.13659732630551644" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3609734482255952" P_Z="0.2694542110098571" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="116" WEIGHT="10.617469964704535" Z="1.1043203610311556">
<NAME>Fluoxetine vs Doxepine</NAME>
<DICH_DATA CI_END="1.1977127890014279" CI_START="0.32541890897590214" EFFECT_SIZE="0.6243063263041065" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="34" LOG_CI_END="0.07835268691287205" LOG_CI_START="-0.4875572153041978" LOG_EFFECT_SIZE="-0.20460226419566288" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5160" O_E="0.0" SE="0.3324182778615016" STUDY_ID="STD-Feighner-1985a" TOTAL_1="78" TOTAL_2="79" VAR="0.11050191145640648" WEIGHT="6.122666015537844"/>
<DICH_DATA CI_END="3.3212608707415727" CI_START="0.3810676274030262" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5213029888998102" LOG_CI_START="-0.4189979440050476" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5161" O_E="0.0" SE="0.5523374225529992" STUDY_ID="STD-Remick-1989" TOTAL_1="38" TOTAL_2="37" VAR="0.30507662835249044" WEIGHT="4.494803949166691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.638987147003835" CI_END="0.8727330957960596" CI_START="0.24828282898598383" DF="8" EFFECT_SIZE="0.4654939763025311" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="155" I2="66.15760247996086" ID="CMP-012.02.06" LOG_CI_END="-0.05911855439987996" LOG_CI_START="-0.6050533148171602" LOG_EFFECT_SIZE="-0.33208593460852" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0026337973451088237" P_Z="0.017104774059055316" STUDIES="9" TAU2="0.5159280174597779" TOTAL_1="523" TOTAL_2="530" WEIGHT="36.157148851269916" Z="2.38444780877309">
<NAME>Fluoxetine vs Imipramine</NAME>
<DICH_DATA CI_END="2.238261849740891" CI_START="0.39063634707851924" EFFECT_SIZE="0.935064935064935" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.34991089240026985" LOG_CI_START="-0.40822734988269666" LOG_EFFECT_SIZE="-0.029158228741213422" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5162" O_E="0.0" SE="0.44533415636183893" STUDY_ID="STD-Beasley-1993a" TOTAL_1="56" TOTAL_2="62" VAR="0.19832251082251082" WEIGHT="5.262454601090868"/>
<DICH_DATA CI_END="4.699689794797371" CI_START="0.24426275643645198" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6720691930732062" LOG_CI_START="-0.6121427463183198" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5163" O_E="0.0" SE="0.754352450150206" STUDY_ID="STD-Byerley-1988" TOTAL_1="32" TOTAL_2="34" VAR="0.569047619047619" WEIGHT="3.3033012912593573"/>
<DICH_DATA CI_END="0.5470991425779476" CI_START="0.08638101493517869" EFFECT_SIZE="0.21739130434782608" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.26193396585487916" LOG_CI_START="-1.063581697508269" LOG_EFFECT_SIZE="-0.6627578316815741" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5164" O_E="0.0" SE="0.47089184579347154" STUDY_ID="STD-Cohn-1985" TOTAL_1="54" TOTAL_2="54" VAR="0.22173913043478258" WEIGHT="5.072430561533086"/>
<DICH_DATA CI_END="1.3769763774124133" CI_START="0.26305872600239566" EFFECT_SIZE="0.6018518518518519" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.13892648982305533" LOG_CI_START="-0.5799472875112437" LOG_EFFECT_SIZE="-0.22051039884409412" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5166" O_E="0.0" SE="0.4222700152887555" STUDY_ID="STD-Feighner-1989" TOTAL_1="61" TOTAL_2="58" VAR="0.17831196581196582" WEIGHT="5.436493374935884"/>
<DICH_DATA CI_END="116.31012674614621" CI_START="0.24616847677305534" EFFECT_SIZE="5.350877192982456" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.065617528989033" LOG_CI_START="-0.6087675616404442" LOG_EFFECT_SIZE="0.7284249836742944" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5167" O_E="0.0" SE="1.57094704065546" STUDY_ID="STD-Levine-1989" TOTAL_1="30" TOTAL_2="30" VAR="2.4678746045441473" WEIGHT="1.1363904715677493"/>
<DICH_DATA CI_END="4.61773275154273" CI_START="0.23422750041969193" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6644287947810695" LOG_CI_START="-0.6303621161835088" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5168" O_E="0.0" SE="0.7605665904189708" STUDY_ID="STD-Nielsen-1993" TOTAL_1="29" TOTAL_2="30" VAR="0.5784615384615385" WEIGHT="3.272365562639738"/>
<DICH_DATA CI_END="0.9170546240748768" CI_START="0.34130952489779337" EFFECT_SIZE="0.5594635627530364" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="52" LOG_CI_END="-0.03760479494310931" LOG_CI_START="-0.46685159173064394" LOG_EFFECT_SIZE="-0.2522281933368766" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5169" O_E="0.0" SE="0.25214169323891034" STUDY_ID="STD-Stark-1985" TOTAL_1="185" TOTAL_2="186" VAR="0.06357543346938477" WEIGHT="6.708631949210628"/>
<DICH_DATA CI_END="0.15762174073350835" CI_START="3.0175041502760597E-4" EFFECT_SIZE="0.006896551724137931" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.8023838805685005" LOG_CI_START="-3.5203521239014495" LOG_EFFECT_SIZE="-2.161368002234975" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4721" O_E="0.0" SE="1.5965480002935644" STUDY_ID="STD-Stratta-1991" TOTAL_1="14" TOTAL_2="14" VAR="2.5489655172413794" WEIGHT="1.1054228339940035"/>
<DICH_DATA CI_END="0.37015264160433503" CI_START="0.05211396945104013" EFFECT_SIZE="0.1388888888888889" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="27" LOG_CI_END="-0.43161914691640735" LOG_CI_START="-1.2830458459461296" LOG_EFFECT_SIZE="-0.8573324964312684" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5170" O_E="0.0" SE="0.5001322576401918" STUDY_ID="STD-Tollefson-1994" TOTAL_1="62" TOTAL_2="62" VAR="0.2501322751322751" WEIGHT="4.8596582050386035"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3813187803234241" CI_START="0.019215959498092478" DF="0" EFFECT_SIZE="0.16292134831460675" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-012.02.07" LOG_CI_END="0.14029391649251957" LOG_CI_START="-1.7163379253123952" LOG_EFFECT_SIZE="-0.7880220044099379" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.0961604325785357" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="93" WEIGHT="2.035348460211915" Z="1.6637598396104953">
<NAME>Fluoxetine vs Lofepramine</NAME>
<DICH_DATA CI_END="1.3813187803234241" CI_START="0.019215959498092478" EFFECT_SIZE="0.16292134831460675" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14029391649251957" LOG_CI_START="-1.7163379253123952" LOG_EFFECT_SIZE="-0.7880220044099379" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5171" O_E="0.0" SE="1.0905947343520461" STUDY_ID="STD-Robertson-1994" TOTAL_1="90" TOTAL_2="93" VAR="1.1893968745964099" WEIGHT="2.035348460211915"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2013-07-02 12:17:43 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Subgroup analysis for fluoxetine versus heterocyclics: endpoint score</NAME>
<CONT_OUTCOME CHI2="1.49695339262473" CI_END="0.46481499603657017" CI_START="-0.3432223482505057" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.060796323893032245" ESTIMABLE="YES" I2="33.197652984598356" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22114109452302955" P_Q="1.0" P_Z="0.7680447484099299" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.03313246464727447" TOTALS="SUB" TOTAL_1="94" TOTAL_2="87" UNITS="" WEIGHT="100.0" Z="0.294933411346001">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.49695339262473" CI_END="0.46481499603657017" CI_START="-0.3432223482505057" DF="1" EFFECT_SIZE="0.060796323893032245" ESTIMABLE="YES" I2="33.197652984598356" ID="CMP-013.01.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22114109452302955" P_Z="0.7680447484099299" STUDIES="2" TAU2="0.03313246464727447" TOTAL_1="94" TOTAL_2="87" WEIGHT="100.0" Z="0.294933411346001">
<NAME>Fluoxetine vs Maprotiline</NAME>
<CONT_DATA CI_END="1.005757267026473" CI_START="-0.26522917902406035" EFFECT_SIZE="0.3702640440012063" ESTIMABLE="YES" MEAN_1="12.56" MEAN_2="10.15" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4730" SD_1="6.57" SD_2="6.14" SE="0.3242371941719114" STUDY_ID="STD-Kuha-1991" TOTAL_1="21" TOTAL_2="18" WEIGHT="30.732872727815572"/>
<CONT_DATA CI_END="0.25269709891239955" CI_START="-0.40571760255902123" EFFECT_SIZE="-0.07651025182331087" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4732" SD_1="6.5" SD_2="6.5" SE="0.1679660204638738" STUDY_ID="STD-Poelinger-1989" TOTAL_1="73" TOTAL_2="69" WEIGHT="69.26712727218442"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.024904138597272" CI_END="0.32357758548134374" CI_START="-0.151526055224826" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08602576512825885" ESTIMABLE="YES" I2="64.34913243906075" I2_Q="0.0" ID="CMP-013.02" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01545200823741999" P_Q="0.3839594517493107" P_Z="0.47784613877007653" Q="0.7579863765759514" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.12269626256058484" TOTALS="SUB" TOTAL_1="193" TOTAL_2="187" UNITS="" WEIGHT="200.0" Z="0.7097710349820923">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.53528912928314" CI_END="0.30206631852425975" CI_START="-0.19515235549413742" DF="2" EFFECT_SIZE="0.053456981515061154" ESTIMABLE="YES" I2="0.0" ID="CMP-013.02.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.46410507923807487" P_Z="0.6734342880697559" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="125" WEIGHT="99.99999999999999" Z="0.42143935441920527">
<NAME>Fluoxetine vs Maprotiline</NAME>
<CONT_DATA CI_END="0.8294461431675726" CI_START="-0.17790658249712266" EFFECT_SIZE="0.32576978033522497" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="16.38" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5175" SD_1="8.34" SD_2="7.6" SE="0.25698245825192834" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="28" TOTAL_2="34" WEIGHT="24.363054142893162"/>
<CONT_DATA CI_END="0.42794310057450474" CI_START="-0.42388392340191366" EFFECT_SIZE="0.0020295885862955643" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="6.49" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5176" SD_1="4.77" SD_2="4.98" SE="0.21730680530242424" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="40" TOTAL_2="45" WEIGHT="34.07156124153637"/>
<CONT_DATA CI_END="0.3216125142494729" CI_START="-0.4496132495409232" EFFECT_SIZE="-0.06400036764572511" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5177" SD_1="6.7" SD_2="5.5" SE="0.19674488150642727" STUDY_ID="STD-Martenyi-2001" TOTAL_1="59" TOTAL_2="46" WEIGHT="41.56538461557045"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.160162821037343" CI_END="1.2333949548146834" CI_START="-0.37757286093570536" DF="2" EFFECT_SIZE="0.42791104693948906" ESTIMABLE="YES" I2="78.16632696302324" ID="CMP-013.02.02" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.010254080573455115" P_Z="0.2977710015001649" STUDIES="3" TAU2="0.393640437833901" TOTAL_1="66" TOTAL_2="62" WEIGHT="100.0" Z="1.0412253210627491">
<NAME>Fluoxetine vs Mianserin</NAME>
<CONT_DATA CI_END="1.013770712652853" CI_START="0.023977882171884846" EFFECT_SIZE="0.5188742974123689" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="10.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5178" SD_1="5.0" SD_2="4.5" SE="0.25250281083946635" STUDY_ID="STD-Besancon-1993" TOTAL_1="33" TOTAL_2="32" WEIGHT="36.92522850987228"/>
<CONT_DATA CI_END="1.8944422288239111" CI_START="0.44291356574843854" EFFECT_SIZE="1.1686778972861749" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="6.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5179" SD_1="6.25" SD_2="7.35" SE="0.3702947285064791" STUDY_ID="STD-La-Pia-1992" TOTAL_1="19" TOTAL_2="16" WEIGHT="31.821488856646127"/>
<CONT_DATA CI_END="0.31707265229669956" CI_START="-1.1846626683853607" EFFECT_SIZE="-0.4337950080443306" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="14.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5180" SD_1="7.5" SD_2="10.2" SE="0.38310278467552383" STUDY_ID="STD-Muijen-1988" TOTAL_1="14" TOTAL_2="14" WEIGHT="31.2532826334816"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2013-07-02 12:17:56 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Subgroup analysis for fluoxetine versus heterocyclics: failure to complete - total</NAME>
<DICH_OUTCOME CHI2="0.007589157554004152" CI_END="3.7521152395094344" CI_START="0.6308328982112099" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.538492031491286" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.5742761684902015" LOG_CI_START="-0.20008566610560066" LOG_EFFECT_SIZE="0.18709525119230036" METHOD="MH" MODIFIED="2013-06-21 10:53:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9305794899013098" P_Q="1.0" P_Z="0.3435866423915064" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="97" TOTAL_2="91" WEIGHT="100.0" Z="0.9471023432005574">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.007589157554004152" CI_END="3.7521152395094344" CI_START="0.6308328982112099" DF="1" EFFECT_SIZE="1.538492031491286" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="0.5742761684902015" LOG_CI_START="-0.20008566610560066" LOG_EFFECT_SIZE="0.18709525119230036" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9305794899013098" P_Z="0.3435866423915064" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="91" WEIGHT="100.0" Z="0.9471023432005574">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="9.466538495432681" CI_START="0.2155821082347306" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9761912052812676" LOG_CI_START="-0.6663872853097813" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4738" O_E="0.0" SE="0.964858736267844" STUDY_ID="STD-Kuha-1991" TOTAL_1="24" TOTAL_2="22" VAR="0.930952380952381" WEIGHT="22.224685150293702"/>
<DICH_DATA CI_END="4.31840619753233" CI_START="0.5718285038848651" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6353234904877658" LOG_CI_START="-0.24273420019982933" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4739" O_E="0.0" SE="0.515775433965561" STUDY_ID="STD-Poelinger-1989" TOTAL_1="73" TOTAL_2="69" VAR="0.2660242982823628" WEIGHT="77.77531484970629"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.52056974609293" CI_END="2.877075735794962" CI_START="0.5924305985405395" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3055526416822387" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" I2="33.63668368145716" I2_Q="51.068133425697795" ID="CMP-014.02" LOG_CI_END="0.4589512943564063" LOG_CI_START="-0.22736251862799386" LOG_EFFECT_SIZE="0.11579438786420619" METHOD="MH" MODIFIED="2013-06-21 10:53:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21046288483807996" P_Q="0.15284214766990822" P_Z="0.5083766588519856" Q="2.0436579881568937" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2796735855382151" TOTALS="SUB" TOTAL_1="126" TOTAL_2="130" WEIGHT="200.0" Z="0.6613675130296837">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9746920781418054" CI_END="5.634204129449725" CI_START="0.7519778275672835" DF="1" EFFECT_SIZE="2.0583480224039428" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-014.02.01" LOG_CI_END="0.7508325775960869" LOG_CI_START="-0.123794964604024" LOG_EFFECT_SIZE="0.3135188064960314" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32351298090760594" P_Z="0.15998067352262366" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="83" WEIGHT="100.0" Z="1.4051365628447416">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="5.24127499084663" CI_START="0.2712312625494321" EFFECT_SIZE="1.1923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.719436946169729" LOG_CI_START="-0.5666602544428196" LOG_EFFECT_SIZE="0.0763883458634547" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5181" O_E="0.0" SE="0.7554598619236282" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="0.5707196029776674" WEIGHT="46.24861299001353"/>
<DICH_DATA CI_END="13.002691200938191" CI_START="0.8338089930068234" EFFECT_SIZE="3.292682926829268" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.1140332486727391" LOG_CI_START="-0.07893342512219785" LOG_EFFECT_SIZE="0.5175499117752705" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5182" O_E="0.0" SE="0.7007545294674203" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="0.49105691056910566" WEIGHT="53.75138700998647"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3209443906854637" CI_END="2.2518423007625605" CI_START="0.17594416622334175" DF="1" EFFECT_SIZE="0.629443020514264" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="24.296586059835523" ID="CMP-014.02.02" LOG_CI_END="0.35253797307686197" LOG_CI_START="-0.7546251284821782" LOG_EFFECT_SIZE="-0.20104357770265815" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2504227693043296" P_Z="0.4765899538098024" STUDIES="2" TAU2="0.26770695871164146" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="0.7117978752460756">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="2.0789327713338395" CI_START="0.021319270277053118" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3178404453147198" LOG_CI_START="-1.671227664564453" LOG_EFFECT_SIZE="-0.6766936096248666" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5183" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-La-Pia-1992" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="25.903304413575352"/>
<DICH_DATA CI_END="2.7156467809759937" CI_START="0.31376356155233437" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.43387328142256937" LOG_CI_START="-0.5033974939409932" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5184" O_E="0.0" SE="0.5505574930137207" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.30311355311355315" WEIGHT="74.09669558642464"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2013-07-02 12:18:12 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Subgroup analysis for fluoxetine versus heterocyclics: failure to complete - inefficacy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-21 10:53:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="24" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-015.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4744" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuha-1991" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3483682882617922" CI_END="9.120401185340345" CI_START="0.6234523972392813" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3845620106812953" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="0.9600139423577398" LOG_CI_START="-0.20519670081500507" LOG_EFFECT_SIZE="0.37740862077136744" METHOD="MH" MODIFIED="2013-06-21 10:53:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5095720316675421" P_Q="0.9367996126964098" P_Z="0.2042078525581832" Q="0.006287372155966286" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="110" WEIGHT="200.0" Z="1.2696542183182795">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3750980727071762" CI_END="19.190616434719097" CI_START="0.3349573170993223" DF="1" EFFECT_SIZE="2.535357449050463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="27.27791421950836" ID="CMP-015.02.01" LOG_CI_END="1.283088925225164" LOG_CI_START="-0.4750105306624019" LOG_EFFECT_SIZE="0.40403919728138105" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24093807986851934" P_Z="0.3676618414216217" STUDIES="2" TAU2="0.6246064597466279" TOTAL_1="80" TOTAL_2="83" WEIGHT="100.0" Z="0.9008617485911156">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="8.916726646681083" CI_START="0.15577808620632244" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9502054530097351" LOG_CI_START="-0.8074936359383985" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5185" O_E="0.0" SE="1.032481145598948" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="1.0660173160173159" WEIGHT="63.08340266649061"/>
<DICH_DATA CI_END="179.22460503285396" CI_START="0.49166009227316687" EFFECT_SIZE="9.387096774193548" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.253397631980428" LOG_CI_START="-0.30833504167715897" LOG_EFFECT_SIZE="0.9725312951516346" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5186" O_E="0.0" SE="1.5047744532877143" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="2.264346155267339" WEIGHT="36.916597333509394"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.63241489112055" CI_START="0.378897597927624" DF="0" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-015.02.02" LOG_CI_END="1.134572795012291" LOG_CI_START="-0.4214781479846658" LOG_EFFECT_SIZE="0.35654732351381263" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.36908070111313473" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.8981967023846862">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="13.63241489112055" CI_START="0.378897597927624" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.134572795012291" LOG_CI_START="-0.4214781479846658" LOG_EFFECT_SIZE="0.35654732351381263" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5187" O_E="0.0" SE="0.9140320264928059" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.8354545454545454" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2013-07-02 12:18:24 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Subgroup analysis for fluoxetine versus heterocyclics: failure to complete - side effects</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.494910833982898" CI_START="0.06707869861371313" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.39705502891685174" LOG_CI_START="-1.1734153716826143" LOG_EFFECT_SIZE="-0.38818017138288136" METHOD="MH" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.33259206671452524" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="22" WEIGHT="100.0" Z="0.9689060744253696">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.494910833982898" CI_START="0.06707869861371313" DF="0" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-016.01.01" LOG_CI_END="0.39705502891685174" LOG_CI_START="-1.1734153716826143" LOG_EFFECT_SIZE="-0.38818017138288136" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.33259206671452524" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="22" WEIGHT="100.0" Z="0.9689060744253696">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="2.4949108339828974" CI_START="0.06707869861371313" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3970550289168517" LOG_CI_START="-1.1734153716826143" LOG_EFFECT_SIZE="-0.38818017138288136" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4748" O_E="0.0" SE="0.922502087265986" STUDY_ID="STD-Kuha-1991" TOTAL_1="24" TOTAL_2="22" VAR="0.851010101010101" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3465261607665382" CI_END="2.844895690754928" CI_START="0.2768619487593808" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8874927407926073" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.45406634744109897" LOG_CI_START="-0.5577367285425696" LOG_EFFECT_SIZE="-0.051835190550735356" METHOD="MH" MODIFIED="2013-06-21 10:53:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.840916389541233" P_Q="0.735808749445571" P_Z="0.8408393860885633" Q="0.1138447412915212" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="110" WEIGHT="200.0" Z="0.2008199204424084">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Heterocyclics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heterocyclics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23252413151188228" CI_END="4.37763950428994" CI_START="0.11011652564932999" DF="1" EFFECT_SIZE="0.6942985328788067" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-016.02.01" LOG_CI_END="0.6412399948418235" LOG_CI_START="-0.9581474997408204" LOG_EFFECT_SIZE="-0.15845375244949841" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.629658529264303" P_Z="0.6977546529239145" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="83" WEIGHT="99.99999999999999" Z="0.388353227805227">
<NAME>Fluoxetine vs Maprotiline</NAME>
<DICH_DATA CI_END="19.585707496377132" CI_START="0.07018148833854859" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.291939264228172" LOG_CI_START="-1.1537774259415738" LOG_EFFECT_SIZE="0.069080919143299" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5188" O_E="0.0" SE="1.436626090298576" STUDY_ID="STD-De-Jonghe-1991" TOTAL_1="30" TOTAL_2="35" VAR="2.0638945233265718" WEIGHT="42.76565197936769"/>
<DICH_DATA CI_END="5.352803104047256" CI_START="0.04116065178507048" EFFECT_SIZE="0.46938775510204084" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7285812687153074" LOG_CI_START="-1.3855177567371488" LOG_EFFECT_SIZE="-0.3284682440109208" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5189" O_E="0.0" SE="1.2418322325097255" STUDY_ID="STD-Jakovijevic-1996" TOTAL_1="50" TOTAL_2="48" VAR="1.5421472937000889" WEIGHT="57.2343480206323"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.704721097811667" CI_START="0.23231455890551125" DF="0" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-016.02.02" LOG_CI_END="0.6725338829659199" LOG_CI_START="-0.6339235725751466" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9538094244028412" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.057923675567749466">
<NAME>Fluoxetine vs Mianserin</NAME>
<DICH_DATA CI_END="4.704721097811667" CI_START="0.23231455890551125" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6725338829659199" LOG_CI_START="-0.6339235725751466" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5190" O_E="0.0" SE="0.7674195764535269" STUDY_ID="STD-Muijen-1988" TOTAL_1="26" TOTAL_2="27" VAR="0.5889328063241106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2013-07-02 12:11:49 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Subgroup analysis for fluoxetine versus other SSRIs: failure to respond</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7936427274467222" CI_START="0.1974050739554374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5950413223140496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.2537359409652797" LOG_CI_START="-0.7046416887356429" LOG_EFFECT_SIZE="-0.22545287388518162" METHOD="MH" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3564551962881749" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.9221407080712068">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7936427274467222" CI_START="0.1974050739554374" DF="0" EFFECT_SIZE="0.5950413223140496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-017.01.01" LOG_CI_END="0.2537359409652797" LOG_CI_START="-0.7046416887356429" LOG_EFFECT_SIZE="-0.22545287388518162" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3564551962881749" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.9221407080712068">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="1.7936427274467222" CI_START="0.1974050739554374" EFFECT_SIZE="0.5950413223140496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2537359409652797" LOG_CI_START="-0.7046416887356429" LOG_EFFECT_SIZE="-0.22545287388518162" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="998" O_E="0.0" SE="0.5629557637321" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="0.31691919191919193" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.1828060037217" CI_END="1.4547618253397254" CI_START="1.0205485794591544" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2184642441622417" ESTIMABLE="YES" EVENTS_1="641" EVENTS_2="595" I2="7.30902912294494" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="0.16279189613450915" LOG_CI_START="0.008833682534593285" LOG_EFFECT_SIZE="0.08581278933455118" METHOD="MH" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3700074815610419" P_Q="0.7368864580808898" P_Z="0.02889777430905828" Q="1.2674087115458004" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.00793857518906904" TOTALS="SUB" TOTAL_1="1465" TOTAL_2="1476" WEIGHT="400.0" Z="2.184878254637466">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7414139286949246" CI_START="0.5229175340490649" DF="0" EFFECT_SIZE="0.9542619542619543" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" I2="0.0" ID="CMP-017.02.01" LOG_CI_END="0.24090201384070334" LOG_CI_START="-0.28156679551384434" LOG_EFFECT_SIZE="-0.020332390836570527" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.878754832150396" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="86" WEIGHT="100.0" Z="0.15254787671823564">
<NAME>Fluoxetine vs Fluvoxamine</NAME>
<DICH_DATA CI_END="1.7414139286949246" CI_START="0.5229175340490649" EFFECT_SIZE="0.9542619542619543" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" LOG_CI_END="0.24090201384070334" LOG_CI_START="-0.28156679551384434" LOG_EFFECT_SIZE="-0.020332390836570527" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5191" O_E="0.0" SE="0.3069007648771784" STUDY_ID="STD-Dalery-2003" TOTAL_1="91" TOTAL_2="86" VAR="0.09418807948219712" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.65453232825268" CI_END="1.6463638378864085" CI_START="0.9263257626879222" DF="8" EFFECT_SIZE="1.2349369367671947" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="335" I2="36.781543620232476" ID="CMP-017.02.02" LOG_CI_END="0.2165258183155489" LOG_CI_START="-0.03323625731576521" LOG_EFFECT_SIZE="0.09164478049989187" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12430189097972777" P_Z="0.15033970329300161" STUDIES="9" TAU2="0.06638942988340743" TOTAL_1="787" TOTAL_2="787" WEIGHT="100.0" Z="1.4383326107203978">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="1.736519630467192" CI_START="0.5434280458631325" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.2396796971517571" LOG_CI_START="-0.2648579517677981" LOG_EFFECT_SIZE="-0.012589127308020516" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5192" O_E="0.0" SE="0.29636791247698807" STUDY_ID="STD-Chouinard-1999" TOTAL_1="101" TOTAL_2="102" VAR="0.08783393954596765" WEIGHT="13.956547776569286"/>
<DICH_DATA CI_END="3.067121720912139" CI_START="0.4710015494300689" EFFECT_SIZE="1.2019230769230769" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.486731011610628" LOG_CI_START="-0.3269776641920758" LOG_EFFECT_SIZE="0.07987667370927604" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5193" O_E="0.0" SE="0.4779765040894149" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" VAR="0.22846153846153847" WEIGHT="7.300046649961981"/>
<DICH_DATA CI_END="2.2078388042654606" CI_START="0.4826243246110041" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.3439673620944976" LOG_CI_START="-0.31639079312323104" LOG_EFFECT_SIZE="0.013788284485633285" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5194" O_E="0.0" SE="0.38789764920048103" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" VAR="0.15046458625525946" WEIGHT="9.925690388543249"/>
<DICH_DATA CI_END="2.232498692745576" CI_START="0.6755463556160122" EFFECT_SIZE="1.2280701754385965" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.34879121325664275" LOG_CI_START="-0.17034484457311183" LOG_EFFECT_SIZE="0.08922318434176545" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5196" O_E="0.0" SE="0.30494309013412874" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.09299028822055137" WEIGHT="13.50501713336325"/>
<DICH_DATA CI_END="3.1513141911627143" CI_START="0.5641385371104002" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.49849170520058983" LOG_CI_START="-0.24861423198398994" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5197" O_E="0.0" SE="0.43885372573625553" STUDY_ID="STD-Gagiano-1993" TOTAL_1="45" TOTAL_2="45" VAR="0.1925925925925926" WEIGHT="8.311101300106786"/>
<DICH_DATA CI_END="7.626402951753082" CI_START="1.1688983459586533" EFFECT_SIZE="2.9857142857142858" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.8823197481051809" LOG_CI_START="0.06777674408841351" LOG_EFFECT_SIZE="0.4750482460967972" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1019" O_E="0.0" SE="0.4784665926123471" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="0.22893028024606973" WEIGHT="7.288459760308174"/>
<DICH_DATA CI_END="1.1700570869341544" CI_START="0.6048100248843087" EFFECT_SIZE="0.8412266376338232" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="132" LOG_CI_END="0.0682070514347683" LOG_CI_START="-0.21838101890259312" LOG_EFFECT_SIZE="-0.0750869837339124" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1018" O_E="0.0" SE="0.16834325114999368" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.028339450207749847" WEIGHT="22.721959993966955"/>
<DICH_DATA CI_END="2.678976916662604" CI_START="0.5682800038800113" EFFECT_SIZE="1.2338593974175036" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.42796897153682223" LOG_CI_START="-0.24543762524570553" LOG_EFFECT_SIZE="0.09126567314555831" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5198" O_E="0.0" SE="0.3955623683664715" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="61" TOTAL_2="60" VAR="0.1564695872676921" WEIGHT="9.658239775172358"/>
<DICH_DATA CI_END="8.23358195928647" CI_START="1.2712727072420802" EFFECT_SIZE="3.235294117647059" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="34" LOG_CI_END="0.915588812942743" LOG_CI_START="0.10423872328919694" LOG_EFFECT_SIZE="0.5099137681159699" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5199" O_E="0.0" SE="0.47659105891020986" STUDY_ID="STD-Schone-1993" TOTAL_1="52" TOTAL_2="54" VAR="0.2271390374331551" WEIGHT="7.33293722200796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.006282092492056" CI_END="1.7080560229589365" CI_START="1.0035616061700623" DF="4" EFFECT_SIZE="1.3092514830349131" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="179" I2="0.0" ID="CMP-017.02.03" LOG_CI_END="0.23250211112049868" LOG_CI_START="0.0015440379081819724" LOG_EFFECT_SIZE="0.11702307451434035" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7346034725524212" P_Z="0.047014438006497246" STUDIES="5" TAU2="0.0" TOTAL_1="470" TOTAL_2="480" WEIGHT="99.99999999999997" Z="1.9861701149316877">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="2.166633561485716" CI_START="0.8539865120776342" EFFECT_SIZE="1.360248447204969" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="69" LOG_CI_END="0.33578546615061683" LOG_CI_START="-0.06854898853407955" LOG_EFFECT_SIZE="0.13361823880826865" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5200" O_E="0.0" SE="0.2375080601696209" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.05641007864553626" WEIGHT="32.627574825468194"/>
<DICH_DATA CI_END="3.0616546084618483" CI_START="0.892646622256381" EFFECT_SIZE="1.6531713900134952" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="26" LOG_CI_END="0.4859561954740014" LOG_CI_START="-0.04932043403155522" LOG_EFFECT_SIZE="0.2183178807212231" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5202" O_E="0.0" SE="0.3144241418336132" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.09886254096780413" WEIGHT="18.61700138293199"/>
<DICH_DATA CI_END="4.549620045146434" CI_START="0.7197032685678197" EFFECT_SIZE="1.8095238095238095" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.6579751287040433" LOG_CI_START="-0.14284652493826153" LOG_EFFECT_SIZE="0.25756430188289087" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5203" O_E="0.0" SE="0.4704066034806081" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="42" VAR="0.22128237259816205" WEIGHT="8.317535826769545"/>
<DICH_DATA CI_END="1.9498922584891152" CI_START="0.6282099291303991" EFFECT_SIZE="1.1067708333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.29001061503617886" LOG_CI_START="-0.2018952036706175" LOG_EFFECT_SIZE="0.0440577056827807" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5204" O_E="0.0" SE="0.2889479128814455" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.08349089635854341" WEIGHT="22.04460776195085"/>
<DICH_DATA CI_END="1.8976490933092347" CI_START="0.5491535279724274" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.2782159072857199" LOG_CI_START="-0.260306221979867" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5205" O_E="0.0" SE="0.3163305644581379" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="83" VAR="0.10006502601040415" WEIGHT="18.39328020287941"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.848332559705193" CI_START="0.5626206223683673" DF="0" EFFECT_SIZE="1.0197597830298335" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" ID="CMP-017.02.04" LOG_CI_END="0.2667801139895907" LOG_CI_START="-0.2497843531934926" LOG_EFFECT_SIZE="0.008497880398049051" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9485834040827176" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="123" WEIGHT="100.0" Z="0.06448581187138412">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="1.848332559705193" CI_START="0.5626206223683673" EFFECT_SIZE="1.0197597830298335" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.2667801139895907" LOG_CI_START="-0.2497843531934926" LOG_EFFECT_SIZE="0.008497880398049051" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1032" O_E="0.0" SE="0.303432525058695" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="0.09207129726349557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6335460740365501E-31" CI_END="2.8530641619800026" CI_START="0.9720231736889672" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6653061224489796" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" I2="100.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.4553115385272248" LOG_CI_START="-0.012323381076529838" LOG_EFFECT_SIZE="0.2214940787253475" METHOD="MH" MODIFIED="2013-06-21 10:53:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.06335899856909644" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.8566638156894173">
<NAME>follow-up &gt;16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6335460740365501E-31" CI_END="2.8530641619800026" CI_START="0.9720231736889672" DF="0" EFFECT_SIZE="1.6653061224489796" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" I2="100.0" ID="CMP-017.03.01" LOG_CI_END="0.4553115385272248" LOG_CI_START="-0.012323381076529838" LOG_EFFECT_SIZE="0.2214940787253475" MODIFIED="2013-06-21 10:53:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.06335899856909644" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.8566638156894173">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="2.8530641619800026" CI_START="0.9720231736889672" EFFECT_SIZE="1.6653061224489796" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" LOG_CI_END="0.4553115385272248" LOG_CI_START="-0.012323381076529838" LOG_EFFECT_SIZE="0.2214940787253475" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4764" O_E="0.0" SE="0.27469106660543063" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.07545518207282913" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2013-07-02 12:12:19 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Subgroup analysis for fluoxetine versus other SSRIs: endpoint score</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6149533258195222" CI_START="-0.4833788868954179" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06578721946205217" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-018.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8143690858340271" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="0.2347934063955563">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other SSRIs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6149533258195222" CI_START="-0.4833788868954179" DF="0" EFFECT_SIZE="0.06578721946205217" ESTIMABLE="YES" I2="0.0" ID="CMP-018.01.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8143690858340271" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.2347934063955563">
<NAME>Fluoxetine vs Citalopram</NAME>
<CONT_DATA CI_END="0.6149533258195222" CI_START="-0.4833788868954179" EFFECT_SIZE="0.06578721946205217" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="11.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="999" SD_1="4.49" SD_2="4.49" SE="0.280191937550497" STUDY_ID="STD-Hosak-2000" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.009074633585460548" CI_END="0.4278156101038104" CI_START="0.038977444384244" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2333965272440272" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-018.02" MODIFIED="2013-06-21 10:53:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9241076220512257" P_Q="0.9241076220512257" P_Z="0.018627610028148913" Q="0.009074633585460548" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="198" TOTAL_2="212" UNITS="" WEIGHT="200.0" Z="2.352900655564408">
<NAME>follow-up &gt;16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other SSRIs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.49420814323773815" CI_START="-0.011685789513713074" DF="0" EFFECT_SIZE="0.24126117686201254" ESTIMABLE="YES" I2="0.0" ID="CMP-018.02.01" MODIFIED="2013-06-21 10:53:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06156489902553145" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="123" WEIGHT="100.0" Z="1.869416440499647">
<NAME>Fluoxetine vs Paroxetine</NAME>
<CONT_DATA CI_END="0.49420814323773815" CI_START="-0.011685789513713074" EFFECT_SIZE="0.24126117686201254" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="7.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4768" SD_1="7.2" SD_2="6.85" SE="0.12905694613316315" STUDY_ID="STD-Cassano-2002" TOTAL_1="119" TOTAL_2="123" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.203950295809705E-32" CI_END="0.5259603021564327" CI_START="-0.0818743288715999" DF="0" EFFECT_SIZE="0.2220429866424164" ESTIMABLE="YES" I2="100.0" ID="CMP-018.02.02" MODIFIED="2013-06-21 10:53:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.1521563825850806" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="89" WEIGHT="100.0" Z="1.4319561098478242">
<NAME>Fluoxetine vs Sertraline</NAME>
<CONT_DATA CI_END="0.5259603021564327" CI_START="-0.0818743288715999" EFFECT_SIZE="0.2220429866424164" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="8.9" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4783" SD_1="6.25" SD_2="6.3" SE="0.155062704167667" STUDY_ID="STD-Sechter-1999" TOTAL_1="79" TOTAL_2="89" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="77.51297828676941" CI_END="0.1389221439149696" CI_START="-0.035034452711083006" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0519438456019433" ESTIMABLE="YES" I2="76.7780823317011" I2_Q="0.0" ID="CMP-018.03" MODIFIED="2013-06-21 10:53:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.3255232184382635E-9" P_Q="0.9325971176995194" P_Z="0.241799980609139" Q="0.43652976167965696" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0719973323194314" TOTALS="SUB" TOTAL_1="1824" TOTAL_2="1828" UNITS="" WEIGHT="400.0" Z="1.1704996369545078">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other SSRIs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8192571212156212" CI_END="0.21363268399030977" CI_START="-0.1040186859657049" DF="1" EFFECT_SIZE="0.05480699901230243" ESTIMABLE="YES" I2="0.0" ID="CMP-018.03.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36539751721306934" P_Z="0.4988264835369488" STUDIES="2" TAU2="0.0" TOTAL_1="310" TOTAL_2="300" WEIGHT="100.0" Z="0.6763373580268806">
<NAME>Fluoxetine vs Citalopram</NAME>
<CONT_DATA CI_END="0.3476206029589819" CI_START="-0.0953967266408394" EFFECT_SIZE="0.12611193815907124" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="9.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5206" SD_1="8.75" SD_2="8.65" SE="0.1130167016063268" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="161" TOTAL_2="153" WEIGHT="51.41147162538573"/>
<CONT_DATA CI_END="0.20721185137868134" CI_START="-0.2484932180965598" EFFECT_SIZE="-0.020640683358939232" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="11.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5207" SD_1="9.64" SD_2="9.69" SE="0.11625342941752619" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="149" TOTAL_2="147" WEIGHT="48.58852837461427"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="66.60784015146662" CI_END="0.24014583416512475" CI_START="-0.30911052002879685" DF="9" EFFECT_SIZE="-0.03448234293183604" ESTIMABLE="YES" I2="86.48807710994089" ID="CMP-018.03.02" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.014788749870604E-11" P_Z="0.8056100213031117" STUDIES="10" TAU2="0.16341484237650203" TOTAL_1="916" TOTAL_2="903" WEIGHT="100.0" Z="0.2460932849767143">
<NAME>Fluoxetine vs Paroxetine</NAME>
<CONT_DATA CI_END="-0.8924886239704934" CI_START="-1.4983159737306562" EFFECT_SIZE="-1.1954022988505748" ESTIMABLE="YES" MEAN_1="10.67" MEAN_2="11.99" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5208" SD_1="1.1" SD_2="1.1" SE="0.15455063321031703" STUDY_ID="STD-Chouinard-1999" TOTAL_1="98" TOTAL_2="100" WEIGHT="10.482249960909195"/>
<CONT_DATA CI_END="0.7969786299527299" CI_START="-0.09895971970798961" EFFECT_SIZE="0.34900945512237014" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="9.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5209" SD_1="10.3" SD_2="9.5" SE="0.2285599012858825" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" WEIGHT="9.104068990994117"/>
<CONT_DATA CI_END="0.4735425527850616" CI_START="-0.27787694634022225" EFFECT_SIZE="0.09783280322241965" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="12.1" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5210" SD_1="10.3" SD_2="10.0" SE="0.1916921701246515" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" WEIGHT="9.808783053041646"/>
<CONT_DATA CI_END="0.3531815792547939" CI_START="-0.2299141523381427" EFFECT_SIZE="0.0616337134583256" ESTIMABLE="YES" MEAN_1="8.73" MEAN_2="8.3" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5212" SD_1="7.1" SD_2="6.8" SE="0.14875164446702116" STUDY_ID="STD-Fava-2002" TOTAL_1="88" TOTAL_2="93" WEIGHT="10.581616568554862"/>
<CONT_DATA CI_END="0.3888589498719161" CI_START="-0.5298033686924962" EFFECT_SIZE="-0.07047220941029005" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.3" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5213" SD_1="7.2" SD_2="6.85" SE="0.2343569386505832" STUDY_ID="STD-Gagiano-1993" TOTAL_1="35" TOTAL_2="38" WEIGHT="8.992172811685709"/>
<CONT_DATA CI_END="0.43414561161450693" CI_START="-0.33138954244531793" EFFECT_SIZE="0.0513780345845945" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="22.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1021" SD_1="9.6" SD_2="13.2" SE="0.19529316867510538" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="51" TOTAL_2="54" WEIGHT="9.740965737182504"/>
<CONT_DATA CI_END="0.4053652832320161" CI_START="-0.27749968482971793" EFFECT_SIZE="0.06393279920114908" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="12.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1020" SD_1="9.07" SD_2="9.6" SE="0.17420344798376033" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="68" TOTAL_2="64" WEIGHT="10.132721514955508"/>
<CONT_DATA CI_END="0.008630923263865359" CI_START="-0.2826765910950967" EFFECT_SIZE="-0.13702283391561568" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-11.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1022" SD_1="8.71" SD_2="8.79" SE="0.07431450696460715" STUDY_ID="STD-MY_x002d_1045_x002f_BRL_x002d_029060_x002f_1" TOTAL_1="377" TOTAL_2="350" WEIGHT="11.62165485208855"/>
<CONT_DATA CI_END="0.5020588345120145" CI_START="-0.24734093534106597" EFFECT_SIZE="0.12735894958547425" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="9.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5214" SD_1="7.2" SD_2="6.85" SE="0.1911769235976401" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="52" TOTAL_2="58" WEIGHT="9.818459810880327"/>
<CONT_DATA CI_END="0.8092529501979902" CI_START="0.0388085603218728" EFFECT_SIZE="0.4240307552599315" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="20.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5215" SD_1="7.2" SD_2="6.85" SE="0.19654554776344985" STUDY_ID="STD-Schone-1993" TOTAL_1="52" TOTAL_2="54" WEIGHT="9.717306699707578"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.923825103465073" CI_END="0.18814327348170015" CI_START="-0.06133873688712965" DF="5" EFFECT_SIZE="0.06340226829728525" ESTIMABLE="YES" I2="0.0" ID="CMP-018.03.03" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5604347341398093" P_Z="0.31915621314419895" STUDIES="6" TAU2="0.0" TOTAL_1="485" TOTAL_2="507" WEIGHT="99.99999999999999" Z="0.9961933705529458">
<NAME>Fluoxetine vs Sertraline</NAME>
<CONT_DATA CI_END="0.675768011881347" CI_START="-0.1669555265288981" EFFECT_SIZE="0.25440624267622447" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5216" SD_1="5.4" SD_2="5.5" SE="0.21498444488203378" STUDY_ID="STD-Aguglia-1993" TOTAL_1="40" TOTAL_2="48" WEIGHT="8.764118095100278"/>
<CONT_DATA CI_END="0.3555409373006632" CI_START="-0.1426485267893371" EFFECT_SIZE="0.10644620525566305" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="11.93" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5217" SD_1="6.25" SD_2="6.3" SE="0.1270914843383999" STUDY_ID="STD-Bennie-1995" TOTAL_1="124" TOTAL_2="124" WEIGHT="25.077797587248185"/>
<CONT_DATA CI_END="0.3763574627818866" CI_START="-0.20243026825295202" EFFECT_SIZE="0.08696359726446728" ESTIMABLE="YES" MEAN_1="8.73" MEAN_2="8.11" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5219" SD_1="7.1" SD_2="7.1" SE="0.14765264453843088" STUDY_ID="STD-Fava-2002" TOTAL_1="88" TOTAL_2="96" WEIGHT="18.579748758294365"/>
<CONT_DATA CI_END="0.7765827974616382" CI_START="-0.14607988777500086" EFFECT_SIZE="0.3152514548433186" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="9.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5220" SD_1="6.25" SD_2="6.3" SE="0.2353774591049847" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="41" WEIGHT="7.311265515102555"/>
<CONT_DATA CI_END="0.24038207768430597" CI_START="-0.2721522793932233" EFFECT_SIZE="-0.01588510085445866" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="13.8" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5221" SD_1="6.25" SD_2="6.3" SE="0.13075096305859057" STUDY_ID="STD-Newhouse-2000" TOTAL_1="118" TOTAL_2="116" WEIGHT="23.69367919128828"/>
<CONT_DATA CI_END="0.1795125473947724" CI_START="-0.4333083250136631" EFFECT_SIZE="-0.12689788880944536" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="13.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5222" SD_1="6.25" SD_2="6.3" SE="0.15633472789354508" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="82" WEIGHT="16.573390852966327"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.32971462008807373" CI_START="-0.18639925376746166" DF="0" EFFECT_SIZE="0.07165768316030605" ESTIMABLE="YES" I2="0.0" ID="CMP-018.03.04" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5862721434784897" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="118" WEIGHT="100.0" Z="0.5442460872466076">
<NAME>Fluoxetine vs Escitalopram</NAME>
<CONT_DATA CI_END="0.32971462008807373" CI_START="-0.18639925376746166" EFFECT_SIZE="0.07165768316030605" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="8.9" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1033" SD_1="7.4" SD_2="6.5" SE="0.13166412187330373" STUDY_ID="STD-Mao-2008" TOTAL_1="113" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2013-07-02 12:12:45 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Subgroup analysis for fluoxetine versus other SSRIs: failure to complete - total</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.269353505494388" CI_START="0.21655649077264413" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.6303621161835088" LOG_CI_START="-0.6644287947810695" LOG_EFFECT_SIZE="-0.017033339298780342" METHOD="MH" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9588731112888639" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.051567757047645074">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.269353505494388" CI_START="0.21655649077264413" DF="0" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-019.01.01" LOG_CI_END="0.6303621161835088" LOG_CI_START="-0.6644287947810695" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9588731112888639" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.051567757047645074">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="4.269353505494388" CI_START="0.21655649077264413" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6303621161835088" LOG_CI_START="-0.6644287947810695" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1000" O_E="0.0" SE="0.7605665904189708" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="0.5784615384615385" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.081635661888471" CI_END="1.2054485050900605" CI_START="0.9050436786294428" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0445015794363697" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="524" I2="0.0" I2_Q="29.226954400488268" ID="CMP-019.02" LOG_CI_END="0.08114866271604158" LOG_CI_START="-0.04333046065115844" LOG_EFFECT_SIZE="0.01890910103244155" METHOD="MH" MODIFIED="2013-06-21 10:53:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8188334394702783" P_Q="0.22669912231679912" P_Z="0.5515361653942252" Q="5.651869247842001" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2115" TOTAL_2="2137" WEIGHT="500.0" Z="0.5954598008260096">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1066327187603305" CI_END="1.2741170822364818" CI_START="0.5922797862110236" DF="1" EFFECT_SIZE="0.8686966058842619" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="72" I2="0.0" ID="CMP-019.02.01" LOG_CI_END="0.1052093383861998" LOG_CI_START="-0.22747308904876254" LOG_EFFECT_SIZE="-0.06113187533128138" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7440108295811625" P_Z="0.47133772811144814" STUDIES="2" TAU2="0.0" TOTAL_1="342" TOTAL_2="331" WEIGHT="100.0" Z="0.720304194486663">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="1.4963550737335654" CI_START="0.4275419891846881" EFFECT_SIZE="0.7998466257668712" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.17503466055095843" LOG_CI_START="-0.36902122648969954" LOG_EFFECT_SIZE="-0.09699328296937053" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5223" O_E="0.0" SE="0.3195811211677574" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="184" TOTAL_2="173" VAR="0.10213209300684081" WEIGHT="37.39148343802839"/>
<DICH_DATA CI_END="1.4808461351364763" CI_START="0.5624204453158014" EFFECT_SIZE="0.9126106194690266" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="48" LOG_CI_END="0.1705099362169439" LOG_CI_START="-0.24993890006782032" LOG_EFFECT_SIZE="-0.03971448192543822" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5224" O_E="0.0" SE="0.24697372768897616" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="158" TOTAL_2="158" VAR="0.06099602216858854" WEIGHT="62.608516561971605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8551917908217699" CI_END="1.374154026695488" CI_START="0.3632793174912131" DF="1" EFFECT_SIZE="0.7065420984950147" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" ID="CMP-019.02.02" LOG_CI_END="0.1380354148158281" LOG_CI_START="-0.4397593270344142" LOG_EFFECT_SIZE="-0.1508619561092931" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3550878258458121" P_Z="0.30607553579186175" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="141" WEIGHT="100.0" Z="1.0234914899523773">
<NAME>Fluoxetine vs Fluvoxamine</NAME>
<DICH_DATA CI_END="1.2877288268001506" CI_START="0.2354184436225254" EFFECT_SIZE="0.5505952380952381" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.10982441781920156" LOG_CI_START="-0.6281595157928619" LOG_EFFECT_SIZE="-0.2591675489868302" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5225" O_E="0.0" SE="0.43349541568311356" STUDY_ID="STD-Dalery-2003" TOTAL_1="94" TOTAL_2="90" VAR="0.1879182754182754" WEIGHT="61.29899530488041"/>
<DICH_DATA CI_END="3.0554429730669526" CI_START="0.3599937951046601" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4850741824386101" LOG_CI_START="-0.443704984718908" LOG_EFFECT_SIZE="0.02068459885985105" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5226" O_E="0.0" SE="0.5455694803193516" STUDY_ID="STD-Rapaport-1996" TOTAL_1="49" TOTAL_2="51" VAR="0.2976460578559274" WEIGHT="38.7010046951196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9453398794415495" CI_END="1.2461700135747278" CI_START="0.8075038312714343" DF="8" EFFECT_SIZE="1.0031386047686373" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="243" I2="0.0" ID="CMP-019.02.03" LOG_CI_END="0.09557729667342811" LOG_CI_START="-0.09285540844441946" LOG_EFFECT_SIZE="0.0013609441145043708" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9377407545894744" P_Z="0.9774137493709062" STUDIES="9" TAU2="0.0" TOTAL_1="805" TOTAL_2="801" WEIGHT="99.99999999999997" Z="0.028311448882846875">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="1.3370822867469812" CI_START="0.42317043240693003" EFFECT_SIZE="0.7522058823529412" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.12615813544483503" LOG_CI_START="-0.3734846847609497" LOG_EFFECT_SIZE="-0.12366327465805736" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5227" O_E="0.0" SE="0.2934926658607264" STUDY_ID="STD-Chouinard-1999" TOTAL_1="101" TOTAL_2="102" VAR="0.086137944914036" WEIGHT="14.223067253983352"/>
<DICH_DATA CI_END="4.566381052582725" CI_START="0.46241700841647987" EFFECT_SIZE="1.453125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6595721494076081" LOG_CI_START="-0.3349662002675122" LOG_EFFECT_SIZE="0.16230297457004794" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5228" O_E="0.0" SE="0.5841967496433944" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" VAR="0.3412858422939068" WEIGHT="3.5897937500061383"/>
<DICH_DATA CI_END="2.34071993753399" CI_START="0.450000054612555" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.3693494543375237" LOG_CI_START="-0.34678743351814556" LOG_EFFECT_SIZE="0.011281010409689084" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5229" O_E="0.0" SE="0.420662352861187" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" VAR="0.17695681511470984" WEIGHT="6.92341678300473"/>
<DICH_DATA CI_END="1.7170957865486596" CI_START="0.4737844346325153" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.2347945225396036" LOG_CI_START="-0.32441921137232815" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5231" O_E="0.0" SE="0.32848491545249575" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.10790233967983327" WEIGHT="11.354209623882925"/>
<DICH_DATA CI_END="3.7319713351904125" CI_START="0.467895734600722" EFFECT_SIZE="1.3214285714285714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5719382993251488" LOG_CI_START="-0.32985091387559723" LOG_EFFECT_SIZE="0.12104369272477576" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5232" O_E="0.0" SE="0.5297154477627168" STUDY_ID="STD-Gagiano-1993" TOTAL_1="45" TOTAL_2="45" VAR="0.2805984555984556" WEIGHT="4.366188620030988"/>
<DICH_DATA CI_END="2.885052223429204" CI_START="0.37960719686479727" EFFECT_SIZE="1.0465116279069768" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.46015367889273995" LOG_CI_START="-0.4206655625012255" LOG_EFFECT_SIZE="0.019744058195757187" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1024" O_E="0.0" SE="0.5173975825203794" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="0.26770025839793277" WEIGHT="4.576558091367565"/>
<DICH_DATA CI_END="2.842624851708605" CI_START="0.6947494234077165" EFFECT_SIZE="1.4053156146179402" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.4537195485461672" LOG_CI_START="-0.15817180498376926" LOG_EFFECT_SIZE="0.14777387178119897" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1023" O_E="0.0" SE="0.3594280099745342" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="70" TOTAL_2="68" VAR="0.12918849435425386" WEIGHT="9.483397029713165"/>
<DICH_DATA CI_END="1.3427116598183348" CI_START="0.6834876984812581" EFFECT_SIZE="0.9579806376400223" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="109" LOG_CI_END="0.12798276025285643" LOG_CI_START="-0.16526929752598446" LOG_EFFECT_SIZE="-0.01864326863656401" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1025" O_E="0.0" SE="0.17225771036038856" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.029672718778603516" WEIGHT="41.28862585101837"/>
<DICH_DATA CI_END="3.7794943997725357" CI_START="0.45436020269493693" EFFECT_SIZE="1.3104395604395604" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5774337061665241" LOG_CI_START="-0.34259971538440825" LOG_EFFECT_SIZE="0.11741699539105793" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5233" O_E="0.0" SE="0.5404321860579041" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="61" TOTAL_2="60" VAR="0.29206694772732505" WEIGHT="4.19474299699276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.989730993877707" CI_END="1.4813616969753252" CI_START="0.8510169814229547" DF="6" EFFECT_SIZE="1.122792928262165" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="141" I2="0.0" ID="CMP-019.02.04" LOG_CI_END="0.17066111106803" LOG_CI_START="-0.07006177379942759" LOG_EFFECT_SIZE="0.050299668634301235" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5451309381279067" P_Z="0.41274130719087876" STUDIES="7" TAU2="0.0" TOTAL_1="544" TOTAL_2="567" WEIGHT="99.99999999999999" Z="0.8190790751931275">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="5.094993185570374" CI_START="1.0767443131835042" EFFECT_SIZE="2.3422222222222224" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="18" LOG_CI_END="0.7071436074845133" LOG_CI_START="0.03211258671785505" LOG_EFFECT_SIZE="0.36962809710118416" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5234" O_E="0.0" SE="0.3965165630557782" STUDY_ID="STD-Aguglia-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.15722538477756695" WEIGHT="12.717076875639576"/>
<DICH_DATA CI_END="1.7470709106978453" CI_START="0.499937748450796" EFFECT_SIZE="0.9345730027548209" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.24231053263020738" LOG_CI_START="-0.3010840700388831" LOG_EFFECT_SIZE="-0.02938676870433785" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5235" O_E="0.0" SE="0.31919267945448826" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.10188396661733568" WEIGHT="19.62474932417995"/>
<DICH_DATA CI_END="1.8155443638066315" CI_START="0.4973328845276651" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.25900686559868535" LOG_CI_START="-0.3033528235010683" LOG_EFFECT_SIZE="-0.02217297895119145" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5237" O_E="0.0" SE="0.33033286510255166" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.10911980176686059" WEIGHT="18.323414015086293"/>
<DICH_DATA CI_END="2.998911379912667" CI_START="0.4564656392213444" EFFECT_SIZE="1.17" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.47696363222049015" LOG_CI_START="-0.34059190872816697" LOG_EFFECT_SIZE="0.06818586174616162" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5238" O_E="0.0" SE="0.4802361717184375" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="42" VAR="0.2306267806267806" WEIGHT="8.669623274384612"/>
<DICH_DATA CI_END="1.8200534581833416" CI_START="0.6104380856904852" EFFECT_SIZE="1.054054054054054" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" LOG_CI_END="0.26008414416808484" LOG_CI_START="-0.2143583782490765" LOG_EFFECT_SIZE="0.022862882959504165" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5239" O_E="0.0" SE="0.27868988619620316" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.07766805266805267" WEIGHT="25.74349731109928"/>
<DICH_DATA CI_END="2.7022850405251164" CI_START="0.0925142966973681" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.43173115704652326" LOG_CI_START="-1.0337911483744857" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5240" O_E="0.0" SE="0.8608550566567107" STUDY_ID="STD-Suri-2000" TOTAL_1="18" TOTAL_2="35" VAR="0.7410714285714285" WEIGHT="2.698049375446423"/>
<DICH_DATA CI_END="2.6397222912698473" CI_START="0.5407991053660222" EFFECT_SIZE="1.1948051948051948" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.42155823985731816" LOG_CI_START="-0.26696403551117137" LOG_EFFECT_SIZE="0.07729710217307338" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5241" O_E="0.0" SE="0.40444139279168123" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="83" VAR="0.163572840203275" WEIGHT="12.223589824163847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5329544217834215" CI_END="2.365269689508595" CI_START="0.9958745827589547" DF="1" EFFECT_SIZE="1.5347677235177233" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" I2="0.0" ID="CMP-019.02.05" LOG_CI_END="0.37388066642175555" LOG_CI_START="-0.0017953517824668055" LOG_EFFECT_SIZE="0.18604265731964437" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.46536747929746036" P_Z="0.052230302207998756" STUDIES="2" TAU2="0.0" TOTAL_1="281" TOTAL_2="297" WEIGHT="100.0" Z="1.941230689558729">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="2.9271703077190034" CI_START="1.0122107304670072" EFFECT_SIZE="1.721311475409836" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" LOG_CI_END="0.4664479911563339" LOG_CI_START="0.005270936962008148" LOG_EFFECT_SIZE="0.23585946405917102" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1035" O_E="0.0" SE="0.27089768449698276" STUDY_ID="STD-Kasper-2005" TOTAL_1="164" TOTAL_2="174" VAR="0.0733855554658268" WEIGHT="66.3577363415871"/>
<DICH_DATA CI_END="2.5800561544662477" CI_START="0.5806757335132254" EFFECT_SIZE="1.224" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.4116291584087449" LOG_CI_START="-0.2360663227896601" LOG_EFFECT_SIZE="0.08778141780954238" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1034" O_E="0.0" SE="0.3804595318002831" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="0.14474945533769062" WEIGHT="33.6422636584129"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.026100968821286" CI_END="1.566804543606352" CI_START="0.791797547424271" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.113818654414045" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="94" I2="1.2882363328847575" I2_Q="23.9191133233069" ID="CMP-019.03" LOG_CI_END="0.19501482229649808" LOG_CI_START="-0.1013858477994686" LOG_EFFECT_SIZE="0.04681448724851471" METHOD="MH" MODIFIED="2013-06-21 10:53:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.36310975350960417" P_Q="0.25160138638642227" P_Z="0.5358332339239789" Q="1.3143905699331757" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0012419862869177747" TOTALS="SUB" TOTAL_1="359" TOTAL_2="363" WEIGHT="200.0" Z="0.6191261911256191">
<NAME>follow-up &gt;16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.488088203631381" CI_START="0.5297105536976814" DF="0" EFFECT_SIZE="0.8878378378378379" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" I2="0.0" ID="CMP-019.03.01" LOG_CI_END="0.17262867396194437" LOG_CI_START="-0.2759613743043352" LOG_EFFECT_SIZE="-0.0516663501711954" MODIFIED="2013-06-21 10:53:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6516453467685428" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="123" WEIGHT="100.0" Z="0.45147762835821187">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="1.488088203631381" CI_START="0.5297105536976814" EFFECT_SIZE="0.8878378378378379" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" LOG_CI_END="0.17262867396194437" LOG_CI_START="-0.2759613743043352" LOG_EFFECT_SIZE="-0.0516663501711954" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4789" O_E="0.0" SE="0.2635040149081642" STUDY_ID="STD-Cassano-2002" TOTAL_1="119" TOTAL_2="123" VAR="0.06943436587272205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7116896953341287" CI_END="2.0919993727163715" CI_START="0.8427235261287793" DF="1" EFFECT_SIZE="1.3277714743263371" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" I2="0.0" ID="CMP-019.03.02" LOG_CI_END="0.32056154997255054" LOG_CI_START="-0.07431488180524404" LOG_EFFECT_SIZE="0.12312333408365324" MODIFIED="2013-06-21 10:53:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.39888391996260153" P_Z="0.22161610884268146" STUDIES="2" TAU2="0.0" TOTAL_1="240" TOTAL_2="240" WEIGHT="100.0" Z="1.2222421043160543">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="2.189149369465039" CI_START="0.47436600917752286" EFFECT_SIZE="1.019047619047619" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.3402753952459916" LOG_CI_START="-0.32388643801544853" LOG_EFFECT_SIZE="0.008194478615271538" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4799" O_E="0.0" SE="0.3901319485118672" STUDY_ID="STD-Boyer-1998" TOTAL_1="120" TOTAL_2="122" VAR="0.15220293724966621" WEIGHT="35.34879368543643"/>
<DICH_DATA CI_END="2.7009322371339817" CI_START="0.8717868979203711" EFFECT_SIZE="1.5344827586206897" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.4315136884421881" LOG_CI_START="-0.05958966227823707" LOG_EFFECT_SIZE="0.18596201308197552" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4804" O_E="0.0" SE="0.2884765392139705" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.08321871367686944" WEIGHT="64.65120631456357"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2013-07-02 12:13:23 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Subgroup analysis for fluoxetine versus other SSRIs: failure to complete - inefficacy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.432557677106979" CI_START="0.03989029015460108" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.46551724137931033" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.7350043458929435" LOG_CI_START="-1.3991328047008436" LOG_EFFECT_SIZE="-0.33206422940395" METHOD="MH" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5419101722459219" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.6099269955585611">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.432557677106979" CI_START="0.03989029015460108" DF="0" EFFECT_SIZE="0.46551724137931033" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-020.01.01" LOG_CI_END="0.7350043458929435" LOG_CI_START="-1.3991328047008436" LOG_EFFECT_SIZE="-0.33206422940395" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5419101722459219" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.6099269955585611">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="5.432557677106979" CI_START="0.03989029015460108" EFFECT_SIZE="0.46551724137931033" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7350043458929435" LOG_CI_START="-1.3991328047008436" LOG_EFFECT_SIZE="-0.33206422940395" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1001" O_E="0.0" SE="1.2536027264080623" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="1.5715197956577267" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0655943696186707" CI_START="0.46568111250286115" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.3150450411273824" LOG_CI_START="-0.33191137620110794" LOG_EFFECT_SIZE="-0.008433167536862813" METHOD="MH" MODIFIED="2013-06-21 10:53:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9592483777248806" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="0.051096810249124">
<NAME>follow-up &gt;16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0655943696186707" CI_START="0.46568111250286115" DF="0" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-020.02.01" LOG_CI_END="0.3150450411273824" LOG_CI_START="-0.33191137620110794" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2013-06-21 10:53:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9592483777248806" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="0.051096810249124">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="2.0655943696186707" CI_START="0.46568111250286115" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.3150450411273824" LOG_CI_START="-0.33191137620110794" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4816" O_E="0.0" SE="0.38002540202467" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.14441930618401205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.292281057265595" CI_END="1.358919069217408" CI_START="0.6778684274380236" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9597751468265612" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.13319359298054947" LOG_CI_START="-0.1688545934231475" LOG_EFFECT_SIZE="-0.017830500221299013" METHOD="MH" MODIFIED="2013-06-21 10:53:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.774944155238224" P_Q="0.6128567375874938" P_Z="0.8170032264628546" Q="1.8095609161586335" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1537" TOTAL_2="1537" WEIGHT="400.0" Z="0.23140107991492193">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.27339185957446965" CI_END="1.6536921401252962" CI_START="0.491322885814554" DF="1" EFFECT_SIZE="0.9013860407922936" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" I2="0.0" ID="CMP-020.03.01" LOG_CI_END="0.21845466223628346" LOG_CI_START="-0.3086330059618858" LOG_EFFECT_SIZE="-0.04508917186280119" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6010655608550111" P_Z="0.7373790310143892" STUDIES="2" TAU2="0.0" TOTAL_1="342" TOTAL_2="331" WEIGHT="100.0" Z="0.33532620198050783">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="8.584800951925201" CI_START="0.2339307747425228" EFFECT_SIZE="1.4171270718232045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.933730230017299" LOG_CI_START="-0.6309126408599979" LOG_EFFECT_SIZE="0.15140879457865059" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5242" O_E="0.0" SE="0.9190789674604466" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="184" TOTAL_2="173" VAR="0.8447061484281606" WEIGHT="11.348416323392112"/>
<DICH_DATA CI_END="1.6205452708033294" CI_START="0.4465319263157458" EFFECT_SIZE="0.8506616257088847" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.2096611677875169" LOG_CI_START="-0.35014748430720105" LOG_EFFECT_SIZE="-0.07024315825984206" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5243" O_E="0.0" SE="0.3288343733379569" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="158" TOTAL_2="158" VAR="0.10813204508856682" WEIGHT="88.65158367660788"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8423369727125827" CI_END="1.3867185526678938" CI_START="0.41001686662841313" DF="3" EFFECT_SIZE="0.7540411101925265" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" I2="0.0" ID="CMP-020.03.02" LOG_CI_END="0.1419883259425002" LOG_CI_START="-0.38719827759006403" LOG_EFFECT_SIZE="-0.12260497582378192" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.839316130971269" P_Z="0.3637771656275064" STUDIES="4" TAU2="0.0" TOTAL_1="503" TOTAL_2="502" WEIGHT="100.0" Z="0.9081913084567695">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="3.7393161423988075" CI_START="0.2925850254192717" EFFECT_SIZE="1.0459770114942528" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.572792184355913" LOG_CI_START="-0.5337479049509629" LOG_EFFECT_SIZE="0.01952213970247505" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5245" O_E="0.0" SE="0.6499871259206402" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.42248326386257423" WEIGHT="22.870906436759164"/>
<DICH_DATA CI_END="17.061232349926986" CI_START="0.06329960347815218" EFFECT_SIZE="1.0392156862745099" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2320103974905594" LOG_CI_START="-1.1985990104848538" LOG_EFFECT_SIZE="0.016705693502852715" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1027" O_E="0.0" SE="1.427751997955372" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="2.038475767665557" WEIGHT="4.740098142036321"/>
<DICH_DATA CI_END="2.338517229206193" CI_START="0.30596730798741106" EFFECT_SIZE="0.8458781362007168" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.36894057395442803" LOG_CI_START="-0.51432497456141" LOG_EFFECT_SIZE="-0.07269220030349098" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1026" O_E="0.0" SE="0.5188345554331829" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="70" TOTAL_2="68" VAR="0.2691892959115485" WEIGHT="35.895094439685835"/>
<DICH_DATA CI_END="1.4425448385077853" CI_START="0.19192883727288684" EFFECT_SIZE="0.5261805332476711" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.15912932117880135" LOG_CI_START="-0.7168597676950325" LOG_EFFECT_SIZE="-0.2788652232581156" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1028" O_E="0.0" SE="0.5145603270204135" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.2647723301433549" WEIGHT="36.493900981518685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.30602200789049" CI_END="2.292764727533766" CI_START="0.6110168095674908" DF="3" EFFECT_SIZE="1.18360372967753" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" I2="9.256502441910751" ID="CMP-020.03.03" LOG_CI_END="0.360359491809689" LOG_CI_START="-0.21394684180002366" LOG_EFFECT_SIZE="0.0732063250048327" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34680544060799967" P_Z="0.6173076146504597" STUDIES="4" TAU2="0.04262543631473451" TOTAL_1="411" TOTAL_2="407" WEIGHT="100.00000000000001" Z="0.49966978266868095">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="7.137415244873104" CI_START="0.7397331575799682" EFFECT_SIZE="2.2977777777777777" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.853540964139723" LOG_CI_START="-0.13092491417456292" LOG_EFFECT_SIZE="0.36130802498258" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5246" O_E="0.0" SE="0.5782801301065029" STUDY_ID="STD-Aguglia-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.334407908875994" WEIGHT="30.18440743064187"/>
<DICH_DATA CI_END="4.0201360029514355" CI_START="0.2416914881356969" EFFECT_SIZE="0.9857142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6042407457044245" LOG_CI_START="-0.6167386442584274" LOG_EFFECT_SIZE="-0.006248949277001492" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5247" O_E="0.0" SE="0.717209337609635" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.5143892339544514" WEIGHT="20.43128971930842"/>
<DICH_DATA CI_END="1.7247791197729314" CI_START="0.17894579762148038" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.23673348595661783" LOG_CI_START="-0.7472784961632298" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5249" O_E="0.0" SE="0.5780135092350676" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.3340996168582375" WEIGHT="30.20910876598763"/>
<DICH_DATA CI_END="7.138712835737957" CI_START="0.38911465437741316" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8536199122341563" LOG_CI_START="-0.40992241300144355" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5250" O_E="0.0" SE="0.7422110164787749" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.5508771929824562" WEIGHT="19.17519408406209"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.02420759124142" CI_END="6.529476617247789" CI_START="0.4642999207391033" DF="1" EFFECT_SIZE="1.741159233343113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="2.3635434308857652" ID="CMP-020.03.04" LOG_CI_END="0.814878370961002" LOG_CI_START="-0.3332013904724712" LOG_EFFECT_SIZE="0.24083849024426543" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.31152333176920755" P_Z="0.410904427048147" STUDIES="2" TAU2="0.023551227566773747" TOTAL_1="281" TOTAL_2="297" WEIGHT="100.0" Z="0.8223030887338119">
<NAME>Fluoxetine vs Escitalopram</NAME>
<DICH_DATA CI_END="5.338645263845943" CI_START="0.21130482034038733" EFFECT_SIZE="1.062111801242236" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7274310643168853" LOG_CI_START="-0.6750905955962773" LOG_EFFECT_SIZE="0.026170234360304082" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="0.0" SE="0.823848165627177" STUDY_ID="STD-Kasper-2005" TOTAL_1="164" TOTAL_2="174" VAR="0.6787258000072645" WEIGHT="64.7606000477371"/>
<DICH_DATA CI_END="39.21756728338028" CI_START="0.4755564831896274" EFFECT_SIZE="4.31858407079646" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5934806503166756" LOG_CI_START="-0.3227978932780941" LOG_EFFECT_SIZE="0.6353413785192908" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="0.0" SE="1.1256315022393426" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="1.2670462788335992" WEIGHT="35.2393999522629"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2013-07-02 12:13:51 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Subgroup analysis for fluoxetine versus other SSRIs: failure to complete - side effects</NAME>
<DICH_OUTCOME CHI2="3.056332907664315E-32" CI_END="9.703496801820677" CI_START="0.23187517303842778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="100.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.9869282670569043" LOG_CI_START="-0.6347457489455418" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.6703631236989763" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.4256496957288947">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.056332907664315E-32" CI_END="9.703496801820677" CI_START="0.23187517303842778" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="100.0" ID="CMP-021.01.01" LOG_CI_END="0.9869282670569043" LOG_CI_START="-0.6347457489455418" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6703631236989763" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.4256496957288947">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="9.703496801820677" CI_START="0.23187517303842783" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9869282670569043" LOG_CI_START="-0.6347457489455417" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1002" O_E="0.0" SE="0.9525793444156804" STUDY_ID="STD-Hosak-2000" TOTAL_1="30" TOTAL_2="29" VAR="0.9074074074074074" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.55065181796894" CI_END="1.1785313044212014" CI_START="0.7823515477582528" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9602217400660534" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="223" I2="0.0" I2_Q="19.78434703412595" ID="CMP-021.02" LOG_CI_END="0.0713411228440711" LOG_CI_START="-0.10659805391678905" LOG_EFFECT_SIZE="-0.017628465536358967" METHOD="MH" MODIFIED="2013-06-21 10:54:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8525290943354826" P_Q="0.2886795859601763" P_Z="0.6977585556854624" Q="4.98655792492484" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1972" TOTAL_2="1999" WEIGHT="500.0" Z="0.38834795330545896">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8632644021273517" CI_END="1.1193056791632945" CI_START="0.294060350953518" DF="1" EFFECT_SIZE="0.5737102237532674" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="0.0" ID="CMP-021.02.01" LOG_CI_END="0.048948707301118256" LOG_CI_START="-0.531563528784046" LOG_EFFECT_SIZE="-0.2413074107414639" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3528268707869988" P_Z="0.10322070466994022" STUDIES="2" TAU2="0.0" TOTAL_1="342" TOTAL_2="331" WEIGHT="100.0" Z="1.6294362284087949">
<NAME>Fluoxetine vs Citalopram</NAME>
<DICH_DATA CI_END="1.1773179347046523" CI_START="0.11144393065286957" EFFECT_SIZE="0.3622222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07089375990568784" LOG_CI_START="-0.9529435786484597" LOG_EFFECT_SIZE="-0.4410249093713859" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5251" O_E="0.0" SE="0.601407120743269" STUDY_ID="STD-Bougerol-1997a" TOTAL_1="184" TOTAL_2="173" VAR="0.3616905248807089" WEIGHT="32.14850847920494"/>
<DICH_DATA CI_END="1.6058033719893634" CI_START="0.316918719199639" EFFECT_SIZE="0.7133786848072562" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.20569236554540182" LOG_CI_START="-0.4990521079065429" LOG_EFFECT_SIZE="-0.14667987118057052" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5252" O_E="0.0" SE="0.4139703922470784" STUDY_ID="STD-Bougerol-1997b" TOTAL_1="158" TOTAL_2="158" VAR="0.17137148565719995" WEIGHT="67.85149152079507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.70654473495209" CI_START="0.14103819473791854" DF="0" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-021.02.02" LOG_CI_END="0.8868597037455603" LOG_CI_START="-0.8506632595599679" LOG_EFFECT_SIZE="0.018098222092796223" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9674311179157203" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="51" WEIGHT="100.0" Z="0.040830382372161265">
<NAME>Fluoxetine vs Fluvoxamine</NAME>
<DICH_DATA CI_END="7.70654473495209" CI_START="0.14103819473791854" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8868597037455603" LOG_CI_START="-0.8506632595599679" LOG_EFFECT_SIZE="0.018098222092796223" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5253" O_E="0.0" SE="1.0206295895230488" STUDY_ID="STD-Rapaport-1996" TOTAL_1="49" TOTAL_2="51" VAR="1.0416847590099871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8718296376901686" CI_END="1.1558257049080278" CI_START="0.6203537581754524" DF="8" EFFECT_SIZE="0.8467708189560422" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="100" I2="0.0" ID="CMP-021.02.03" LOG_CI_END="0.0628923487006865" LOG_CI_START="-0.20736058242146224" LOG_EFFECT_SIZE="-0.07223411686038787" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.868498267429265" P_Z="0.29476230095803324" STUDIES="9" TAU2="0.0" TOTAL_1="756" TOTAL_2="753" WEIGHT="100.0" Z="1.0477315965718663">
<NAME>Fluoxetine vs Paroxetine</NAME>
<DICH_DATA CI_END="10.987361768334925" CI_START="0.32576108861014585" EFFECT_SIZE="1.8918918918918919" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.040893424270497" LOG_CI_START="-0.48710079237597326" LOG_EFFECT_SIZE="0.27689631594726183" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5254" O_E="0.0" SE="0.8975513665514947" STUDY_ID="STD-De-Wilde-1993" TOTAL_1="41" TOTAL_2="37" VAR="0.8055984555984556" WEIGHT="3.128220840068188"/>
<DICH_DATA CI_END="1.9373187362654363" CI_START="0.210692750090532" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.28720107865068367" LOG_CI_START="-0.6763504081500726" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5255" O_E="0.0" SE="0.5659949130035479" STUDY_ID="STD-Fava-1998" TOTAL_1="54" TOTAL_2="55" VAR="0.3203502415458937" WEIGHT="7.86667075813272"/>
<DICH_DATA CI_END="1.9207575176636413" CI_START="0.281968985208677" EFFECT_SIZE="0.7359307359307359" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2834725416510692" LOG_CI_START="-0.5497986586788101" LOG_EFFECT_SIZE="-0.13316305851387042" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5257" O_E="0.0" SE="0.489467627832736" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.23957855869620576" WEIGHT="10.518845639794504"/>
<DICH_DATA CI_END="5.240788167404054" CI_START="0.19081099408284896" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7193966058795148" LOG_CI_START="-0.7193966058795148" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5258" O_E="0.0" SE="0.8451542547285166" STUDY_ID="STD-Gagiano-1993" TOTAL_1="45" TOTAL_2="45" VAR="0.7142857142857143" WEIGHT="3.5281258285417696"/>
<DICH_DATA CI_END="3.9847888878150517" CI_START="0.3886383994003248" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6004053176303363" LOG_CI_START="-0.4104542911686228" LOG_EFFECT_SIZE="0.09497551323085675" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1030" O_E="0.0" SE="0.593783938044273" STUDY_ID="STD-Geretsegger-1994" TOTAL_1="52" TOTAL_2="54" VAR="0.35257936507936505" WEIGHT="7.14758186986515"/>
<DICH_DATA CI_END="4.068130414488871" CI_START="0.4370011766206225" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6093948669117255" LOG_CI_START="-0.35951739369512575" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1029" O_E="0.0" SE="0.5691438580735064" STUDY_ID="STD-GSK-29060_x002f_356" TOTAL_1="70" TOTAL_2="68" VAR="0.32392473118279563" WEIGHT="7.779862526482149"/>
<DICH_DATA CI_END="1.066896323438988" CI_START="0.4333104857802805" EFFECT_SIZE="0.6799245283018868" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="53" LOG_CI_END="0.028122218537865395" LOG_CI_START="-0.3632008012462318" LOG_EFFECT_SIZE="-0.16753929135418316" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1031" O_E="0.0" SE="0.2298650789013674" STUDY_ID="STD-MY_x002d_1043_x002f_BRL_x002d_029060_x002f_115" TOTAL_1="289" TOTAL_2="284" VAR="0.052837954498331854" WEIGHT="47.69469033115953"/>
<DICH_DATA CI_END="4.899363377725196" CI_START="0.3189189859041397" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6901396515584721" LOG_CI_START="-0.4963196255423593" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5259" O_E="0.0" SE="0.6969320524371696" STUDY_ID="STD-Ontiveros-1997" TOTAL_1="61" TOTAL_2="60" VAR="0.4857142857142857" WEIGHT="5.1884203360908385"/>
<DICH_DATA CI_END="3.9847888878150517" CI_START="0.3886383994003248" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6004053176303363" LOG_CI_START="-0.4104542911686228" LOG_EFFECT_SIZE="0.09497551323085675" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5260" O_E="0.0" SE="0.593783938044273" STUDY_ID="STD-Schone-1993" TOTAL_1="52" TOTAL_2="54" VAR="0.35257936507936505" WEIGHT="7.14758186986515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.533041448746489" CI_END="1.7124790069680782" CI_START="0.8517465888185006" DF="6" EFFECT_SIZE="1.207724369468611" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="73" I2="0.0" ID="CMP-021.02.04" LOG_CI_END="0.23362525624399325" LOG_CI_START="-0.06968959707357897" LOG_EFFECT_SIZE="0.08196782958520715" MODIFIED="2013-05-27 11:07:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7395686632974825" P_Z="0.28945333869486556" STUDIES="7" TAU2="0.0" TOTAL_1="544" TOTAL_2="567" WEIGHT="100.0" Z="1.059321639680581">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.2484182378588838" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5261" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Aguglia-1993" TOTAL_1="56" TOTAL_2="52" VAR="0.4166666666666667" WEIGHT="7.618575963410876"/>
<DICH_DATA CI_END="1.8221964710504777" CI_START="0.47179316481959366" EFFECT_SIZE="0.9272" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.2605952012280484" LOG_CI_START="-0.3262483553169693" LOG_EFFECT_SIZE="-0.03282657704446041" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5262" O_E="0.0" SE="0.3447148100369983" STUDY_ID="STD-Bennie-1995" TOTAL_1="144" TOTAL_2="142" VAR="0.11882830025884382" WEIGHT="26.714230907169295"/>
<DICH_DATA CI_END="4.289402959033075" CI_START="0.47578097605235414" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.6323968470467438" LOG_CI_START="-0.32259292707525744" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5264" O_E="0.0" SE="0.560965720594886" STUDY_ID="STD-Fava-2002" TOTAL_1="92" TOTAL_2="96" VAR="0.31468253968253973" WEIGHT="10.087647870846682"/>
<DICH_DATA CI_END="5.38568512540602" CI_START="0.6339882796953598" EFFECT_SIZE="1.8478260869565217" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.7312409587494463" LOG_CI_START="-0.197918770684009" LOG_EFFECT_SIZE="0.26666109403271865" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5265" O_E="0.0" SE="0.5457930244840508" STUDY_ID="STD-Finkel-1999" TOTAL_1="33" TOTAL_2="42" VAR="0.2978900255754476" WEIGHT="10.656303933940233"/>
<DICH_DATA CI_END="2.5986098273749496" CI_START="0.7450265494004478" EFFECT_SIZE="1.3914141414141414" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.41474107652349207" LOG_CI_START="-0.1278282506709467" LOG_EFFECT_SIZE="0.14345641292627276" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5266" O_E="0.0" SE="0.31870790855549835" STUDY_ID="STD-Newhouse-2000" TOTAL_1="119" TOTAL_2="117" VAR="0.10157473097581991" WEIGHT="31.251932650226493"/>
<DICH_DATA CI_END="4.411511204754002" CI_START="0.04711055012151384" EFFECT_SIZE="0.45588235294117646" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.6445873866244426" LOG_CI_START="-1.32688182436837" LOG_EFFECT_SIZE="-0.34114721887196364" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5267" O_E="0.0" SE="1.1580507734671626" STUDY_ID="STD-Suri-2000" TOTAL_1="18" TOTAL_2="35" VAR="1.3410815939278937" WEIGHT="2.3670496007060087"/>
<DICH_DATA CI_END="2.168176454713898" CI_START="0.2716172512912326" EFFECT_SIZE="0.7674074074074074" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3360946238949966" LOG_CI_START="-0.5660426500665804" LOG_EFFECT_SIZE="-0.11497401308579189" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5268" O_E="0.0" SE="0.5299199003765576" STUDY_ID="STD-Van-Moffaert-1995" TOTAL_1="82" TOTAL_2="83" VAR="0.28081510081510075" WEIGHT="11.304259073700413"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29673881922475936" CI_END="2.121451071312649" CI_START="0.6432579133296676" DF="1" EFFECT_SIZE="1.1681781496687749" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="0.0" ID="CMP-021.02.05" LOG_CI_END="0.3266330197444127" LOG_CI_START="-0.1916148624137388" LOG_EFFECT_SIZE="0.06750907866533698" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5859342331850869" P_Z="0.6096131270936562" STUDIES="2" TAU2="0.0" TOTAL_1="281" TOTAL_2="297" WEIGHT="100.00000000000001" Z="0.5106257733752351">
<NAME>Fluoxetina vs Escitalopram</NAME>
<DICH_DATA CI_END="2.5444711220362453" CI_START="0.646604827804479" EFFECT_SIZE="1.2826797385620916" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.405597526299321" LOG_CI_START="-0.18936105709993817" LOG_EFFECT_SIZE="0.10811823459969139" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1038" O_E="0.0" SE="0.3494816169812105" STUDY_ID="STD-Kasper-2005" TOTAL_1="164" TOTAL_2="174" VAR="0.12213740060780151" WEIGHT="75.87550649700943"/>
<DICH_DATA CI_END="2.9332871832045333" CI_START="0.2583560294355592" EFFECT_SIZE="0.8705357142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.46735458462234314" LOG_CI_START="-0.5877813985656327" LOG_EFFECT_SIZE="-0.06021340697164479" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1039" O_E="0.0" SE="0.6197920995319695" STUDY_ID="STD-Mao-2008" TOTAL_1="117" TOTAL_2="123" VAR="0.38414224664224667" WEIGHT="24.124493502990585"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3981056830069794" CI_END="2.7628364311284717" CI_START="0.7176881596465225" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.408138840335341" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-021.03" LOG_CI_END="0.4413551740366393" LOG_CI_START="-0.14406421865913804" LOG_EFFECT_SIZE="0.1486454776887506" METHOD="MH" MODIFIED="2013-06-21 10:54:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.528069595425172" P_Q="1.0" P_Z="0.3195807203357278" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="240" TOTAL_2="240" WEIGHT="100.0" Z="0.9953198898762919">
<NAME>follow-up &gt;16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other SSRIs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Other SSRIs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3981056830069794" CI_END="2.7628364311284717" CI_START="0.7176881596465225" DF="1" EFFECT_SIZE="1.408138840335341" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="0.0" ID="CMP-021.03.01" LOG_CI_END="0.4413551740366393" LOG_CI_START="-0.14406421865913804" LOG_EFFECT_SIZE="0.1486454776887506" MODIFIED="2013-06-21 10:54:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.528069595425172" P_Z="0.3195807203357278" STUDIES="2" TAU2="0.0" TOTAL_1="240" TOTAL_2="240" WEIGHT="100.0" Z="0.9953198898762919">
<NAME>Fluoxetine vs Sertraline</NAME>
<DICH_DATA CI_END="2.916235765169951" CI_START="0.44674928473907405" EFFECT_SIZE="1.1414141414141414" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4648226319138607" LOG_CI_START="-0.349936134142121" LOG_EFFECT_SIZE="0.05744324888586982" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4829" O_E="0.0" SE="0.47859333230222095" STUDY_ID="STD-Boyer-1998" TOTAL_1="120" TOTAL_2="122" VAR="0.22905157772414408" WEIGHT="51.62690927872207"/>
<DICH_DATA CI_END="4.643442214870202" CI_START="0.6685360227120756" EFFECT_SIZE="1.7619047619047619" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6668400453574753" LOG_CI_START="-0.1748751866913239" LOG_EFFECT_SIZE="0.2459824293330757" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4834" O_E="0.0" SE="0.4944276938630607" STUDY_ID="STD-Sechter-1999" TOTAL_1="120" TOTAL_2="118" VAR="0.24445874445874444" WEIGHT="48.373090721277926"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2013-07-02 12:14:18 +0100" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Subgroup analysis for fluoxetine versus MAOIs or newer ADs: failure to respond</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.603556305658109" CI_START="0.39440070576268416" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="0.4155669743574751" LOG_CI_START="-0.40406231657929237" LOG_EFFECT_SIZE="0.0057523288890913415" METHOD="MH" MODIFIED="2013-06-21 10:54:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9780522700936938" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="0.027510870034824372">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.603556305658109" CI_START="0.39440070576268416" DF="0" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-022.01.01" LOG_CI_END="0.4155669743574751" LOG_CI_START="-0.40406231657929237" LOG_EFFECT_SIZE="0.0057523288890913415" MODIFIED="2013-06-21 10:54:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9780522700936938" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="0.027510870034824372">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="2.603556305658109" CI_START="0.39440070576268416" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.4155669743574751" LOG_CI_START="-0.40406231657929237" LOG_EFFECT_SIZE="0.0057523288890913415" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4847" O_E="0.0" SE="0.4814543027266815" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.2317982456140351" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.58724046872446" CI_END="1.4383973551068334" CI_START="1.0092598046780379" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2048720403696522" ESTIMABLE="YES" EVENTS_1="572" EVENTS_2="518" I2="38.018103542195995" I2_Q="52.90194054958426" ID="CMP-022.02" LOG_CI_END="0.15787887581882296" LOG_CI_START="0.004002977152835428" LOG_EFFECT_SIZE="0.08094092648582916" METHOD="MH" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06732643372766123" P_Q="0.07510228456592216" P_Z="0.039213615090020824" Q="8.492918915717008" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06591095731973576" TOTALS="SUB" TOTAL_1="1277" TOTAL_2="1250" WEIGHT="500.0" Z="2.0619382523560223">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0918768209519865" CI_START="0.9934202116055545" DF="0" EFFECT_SIZE="1.4415660630449363" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="71" I2="0.0" ID="CMP-022.02.01" LOG_CI_END="0.32053610774980235" LOG_CI_START="-0.0028670083236140877" LOG_EFFECT_SIZE="0.15883454971309413" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.054202673639201046" STUDIES="1" TAU2="0.0" TOTAL_1="263" TOTAL_2="252" WEIGHT="100.0" Z="1.9252133419000836">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="2.0918768209519865" CI_START="0.9934202116055545" EFFECT_SIZE="1.4415660630449363" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="71" LOG_CI_END="0.32053610774980235" LOG_CI_START="-0.0028670083236140877" LOG_EFFECT_SIZE="0.15883454971309413" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="0.18996859125276788" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.036088065662561196" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.117087380282814" CI_END="2.041954549664885" CI_START="1.0417711031208654" DF="3" EFFECT_SIZE="1.4585092539051843" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="105" I2="0.0" ID="CMP-022.02.02" LOG_CI_END="0.310046071223264" LOG_CI_START="0.01777230670657977" LOG_EFFECT_SIZE="0.16390918896492185" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5484636708841168" P_Z="0.027926078145720533" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="297" WEIGHT="100.0" Z="2.198323257906225">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="9.651397153685426" CI_START="0.6475746361358066" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.9845901871484379" LOG_CI_START="-0.18871016980436273" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1059" O_E="0.0" SE="0.689202437604511" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.475" WEIGHT="6.205278260332484"/>
<DICH_DATA CI_END="2.686130646529386" CI_START="0.6833576511299049" EFFECT_SIZE="1.3548387096774193" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" LOG_CI_END="0.42912713182001905" LOG_CI_START="-0.1653519386927636" LOG_EFFECT_SIZE="0.13188759656362775" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5276" O_E="0.0" SE="0.34919994873806715" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="0.12194060419866871" WEIGHT="24.171662860188693"/>
<DICH_DATA CI_END="1.961224987441794" CI_START="0.7259929367062165" EFFECT_SIZE="1.1932457786116322" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.29252741783895664" LOG_CI_START="-0.1390676045952734" LOG_EFFECT_SIZE="0.07672990662184158" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1060" O_E="0.0" SE="0.25352105260768365" STUDY_ID="STD-Versiani-2005" TOTAL_1="152" TOTAL_2="147" VAR="0.06427292411530791" WEIGHT="45.859235661504954"/>
<DICH_DATA CI_END="4.012238548647704" CI_START="1.008853467184628" EFFECT_SIZE="2.011904761904762" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="27" LOG_CI_END="0.6033867462031934" LOG_CI_START="0.0038280909003902534" LOG_EFFECT_SIZE="0.30360741855179185" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5277" O_E="0.0" SE="0.35218372198807546" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.12403337403337403" WEIGHT="23.76382321797386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.444681693085454" CI_END="1.8931501560206758" CI_START="0.9005053516324864" DF="5" EFFECT_SIZE="1.3056767773612639" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="138" I2="22.416649291391128" ID="CMP-022.02.03" LOG_CI_END="0.2771850615839655" LOG_CI_START="-0.04551370185882681" LOG_EFFECT_SIZE="0.11583567986256939" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2653207190959176" P_Z="0.1593994918191791" STUDIES="6" TAU2="0.04806184395532235" TOTAL_1="325" TOTAL_2="326" WEIGHT="100.0" Z="1.4070940851038982">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="14.803512852064111" CI_START="1.1148641822335295" EFFECT_SIZE="4.0625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="1.1703647850733412" LOG_CI_START="0.04722196290052035" LOG_EFFECT_SIZE="0.6087933739869308" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5278" O_E="0.0" SE="0.6597396533909495" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" VAR="0.43525641025641026" WEIGHT="7.434240531213251"/>
<DICH_DATA CI_END="3.3489025601908144" CI_START="0.3427866780358222" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.5249025114732565" LOG_CI_START="-0.4649760647183701" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5279" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="0.3380952380952381" WEIGHT="9.304773424990918"/>
<DICH_DATA CI_END="1.759140719638204" CI_START="0.43900304693266895" EFFECT_SIZE="0.8787878787878788" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" LOG_CI_END="0.24530058153702555" LOG_CI_START="-0.3575324654948884" LOG_EFFECT_SIZE="-0.05611594197893139" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5280" O_E="0.0" SE="0.3541071158982555" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="0.12539184952978055" WEIGHT="20.715062808649197"/>
<DICH_DATA CI_END="2.645919515276093" CI_START="0.8596850119748752" EFFECT_SIZE="1.5081967213114753" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" LOG_CI_END="0.42257662949506153" LOG_CI_START="-0.0656606448254851" LOG_EFFECT_SIZE="0.1784579923347882" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5281" O_E="0.0" SE="0.28679299174937484" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.08225022011655697" WEIGHT="27.573073763563123"/>
<DICH_DATA CI_END="1.832205108698046" CI_START="0.3653638364096653" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.26297408974100756" LOG_CI_START="-0.4372744411788078" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5282" O_E="0.0" SE="0.41132945334843113" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="0.1691919191919192" WEIGHT="16.538743002121908"/>
<DICH_DATA CI_END="3.7003764921985014" CI_START="0.8238693723674019" EFFECT_SIZE="1.746031746031746" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.5682459133010433" LOG_CI_START="-0.0841416418917567" LOG_EFFECT_SIZE="0.24205213570464335" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5283" O_E="0.0" SE="0.3832156792907316" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.14685425685425685" WEIGHT="18.434106469461597"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.341739229291792" CI_START="0.2733609001579917" DF="0" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-022.02.04" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6781944478191994" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.4149282252652017">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="7.341739229291792" CI_START="0.2733609001579917" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.865798954767413" LOG_CI_START="-0.5632636041061148" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5284" O_E="0.0" SE="0.8394384210560641" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.704656862745098" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7311268074899138" CI_END="1.0984274137731926" CI_START="0.546401332749874" DF="2" EFFECT_SIZE="0.7747142717251759" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="201" I2="26.770152359269897" ID="CMP-022.02.05" LOG_CI_END="0.04077136317795041" LOG_CI_START="-0.2624882500197703" LOG_EFFECT_SIZE="-0.11085844342090996" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2552370559818148" P_Z="0.15187094853730868" STUDIES="3" TAU2="0.025703482416435965" TOTAL_1="366" TOTAL_2="355" WEIGHT="100.00000000000001" Z="1.4329541226809683">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="1.3755176153121687" CI_START="0.5045267147338989" EFFECT_SIZE="0.8330578512396695" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="77" LOG_CI_END="0.13846615647334753" LOG_CI_START="-0.29711583288723464" LOG_EFFECT_SIZE="-0.07932483820694357" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5286" O_E="0.0" SE="0.2558630167160275" STUDY_ID="STD-Andreoli-2002" TOTAL_1="127" TOTAL_2="126" VAR="0.06546588332302618" WEIGHT="34.80610483936877"/>
<DICH_DATA CI_END="0.9214810229154664" CI_START="0.3684659474023264" EFFECT_SIZE="0.5826957852274308" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="91" LOG_CI_END="-0.03551360426255213" LOG_CI_START="-0.43360264223807893" LOG_EFFECT_SIZE="-0.23455812325031553" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="3217" O_E="0.0" SE="0.23383947147934342" STUDY_ID="STD-Clayton-2003" TOTAL_1="150" TOTAL_2="150" VAR="0.05468089842173866" WEIGHT="39.47595874943277"/>
<DICH_DATA CI_END="2.0062066215410352" CI_START="0.5892523585447124" EFFECT_SIZE="1.0872727272727272" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.30237565947902567" LOG_CI_START="-0.22969867049069173" LOG_EFFECT_SIZE="0.036338494494166956" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5287" O_E="0.0" SE="0.31254309523462287" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.09768318637883855" WEIGHT="25.717936411198462"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2013-07-02 12:14:39 +0100" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Subgroup analysis for fluoxetine versus MAOIs or newer ADs: endpoint score</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.41717144791185307" CI_START="-0.6609871801669961" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1219078661275715" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-023.01" MODIFIED="2013-06-21 10:54:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6576008551225345" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.443227964456259">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.41717144791185307" CI_START="-0.6609871801669961" DF="0" EFFECT_SIZE="-0.1219078661275715" ESTIMABLE="YES" I2="0.0" ID="CMP-023.01.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6576008551225345" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.443227964456259">
<NAME>Fluoxetine vs Moclobemide</NAME>
<CONT_DATA CI_END="0.41717144791185307" CI_START="-0.6609871801669961" EFFECT_SIZE="-0.1219078661275715" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="13.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4877" SD_1="7.0" SD_2="9.0" SE="0.2750455203726259" STUDY_ID="STD-Gattaz-1995" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.89900729118789" CI_END="0.220054619538063" CI_START="-0.02243976553107764" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09880742700349268" ESTIMABLE="YES" I2="7.555313390333606" I2_Q="0.0" ID="CMP-023.02" MODIFIED="2013-06-21 10:54:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3712824181769153" P_Q="0.5730590193517293" P_Z="0.11021565153380822" Q="2.909640309617177" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0022302672662250617" TOTALS="SUB" TOTAL_1="925" TOTAL_2="1051" UNITS="" WEIGHT="500.0" Z="1.597224597812436">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.066010657902545" CI_END="0.2252595495957109" CI_START="-0.18398565801737268" DF="2" EFFECT_SIZE="0.020636945789169116" ESTIMABLE="YES" I2="67.02940181296115" ID="CMP-023.02.01" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04817079506463695" P_Z="0.8433035675573599" STUDIES="3" TAU2="0.021818817357774547" TOTAL_1="536" TOTAL_2="677" WEIGHT="100.0" Z="0.1976696110069922">
<NAME>Fluoxetine vs Agomelatine</NAME>
<CONT_DATA CI_END="0.09111488908222917" CI_START="-0.39399374039444135" EFFECT_SIZE="-0.15143942565610607" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="14.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1094" SD_1="7.6" SD_2="8.2" SE="0.12375447541463655" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="133" TOTAL_2="129" WEIGHT="29.352117955911886"/>
<CONT_DATA CI_END="0.17255698725838758" CI_START="-0.22279813975293428" EFFECT_SIZE="-0.025120576247273357" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="12.7" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1098" SD_1="7.4" SD_2="8.2" SE="0.10085775303266607" STUDY_ID="STD-CL3_x002d_024" TOTAL_1="146" TOTAL_2="301" WEIGHT="34.070758939696724"/>
<CONT_DATA CI_END="0.3764326028861018" CI_START="0.026258420171062585" EFFECT_SIZE="0.20134551152858218" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="11.1" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1095" SD_1="8.5" SD_2="7.3" SE="0.08933179014440276" STUDY_ID="STD-Hale-2010" TOTAL_1="257" TOTAL_2="247" WEIGHT="36.5771231043914"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2896075290361066" CI_START="-0.15146810416203038" DF="0" EFFECT_SIZE="0.5690697124370382" ESTIMABLE="YES" I2="0.0" ID="CMP-023.02.02" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12163445946522651" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.5479494835311078">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<CONT_DATA CI_END="1.2896075290361066" CI_START="-0.15146810416203038" EFFECT_SIZE="0.5690697124370382" ESTIMABLE="YES" MEAN_1="10.13" MEAN_2="7.16" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1061" SD_1="5.01" SD_2="5.15" SE="0.36762809025195303" STUDY_ID="STD-Amini-2005" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5491479038421112" CI_END="0.3339322968189959" CI_START="-0.022420130689423334" DF="4" EFFECT_SIZE="0.15575608306478628" ESTIMABLE="YES" I2="0.0" ID="CMP-023.02.03" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8179014584646955" P_Z="0.08665013233689989" STUDIES="5" TAU2="0.0" TOTAL_1="245" TOTAL_2="242" WEIGHT="100.0" Z="1.7133393214940156">
<NAME>Fluoxetine vs Moclobemide</NAME>
<CONT_DATA CI_END="1.1152522460768686" CI_START="-0.11514974440434744" EFFECT_SIZE="0.5000512508362606" ESTIMABLE="YES" MEAN_1="13.44" MEAN_2="9.84" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5307" SD_1="6.84" SD_2="7.28" SE="0.31388382648519814" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" WEIGHT="8.3881346459955"/>
<CONT_DATA CI_END="0.8429597506752106" CI_START="-0.6434965928766357" EFFECT_SIZE="0.09973157889928737" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="9.1" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5308" SD_1="6.2" SD_2="7.3" SE="0.3792050148055842" STUDY_ID="STD-Geerts-1994" TOTAL_1="13" TOTAL_2="15" WEIGHT="5.747184319726977"/>
<CONT_DATA CI_END="0.42282906137380577" CI_START="-0.2707197515391227" EFFECT_SIZE="0.07605465491734152" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.5" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5309" SD_1="6.0" SD_2="7.0" SE="0.17692896869114763" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" WEIGHT="26.400088196804212"/>
<CONT_DATA CI_END="0.4446780737162884" CI_START="-0.09880321436078687" EFFECT_SIZE="0.17293742967775078" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.6" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5310" SD_1="6.0" SD_2="5.5" SE="0.13864573338183414" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" WEIGHT="42.99225758485864"/>
<CONT_DATA CI_END="0.5218809058652704" CI_START="-0.3561344981052954" EFFECT_SIZE="0.08287320387998745" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="12.2" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5311" SD_1="9.0" SD_2="7.6" SE="0.22398763724645943" STUDY_ID="STD-Reynaert-1995" TOTAL_1="42" TOTAL_2="38" WEIGHT="16.472335252614663"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5673132739545028" CI_START="-0.6725145473345209" DF="0" EFFECT_SIZE="-0.052600636690009" ESTIMABLE="YES" I2="0.0" ID="CMP-023.02.04" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8679162071891943" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.1663059203964429">
<NAME>Fluoxetine vs Phenelzine</NAME>
<CONT_DATA CI_END="0.5673132739545028" CI_START="-0.6725145473345209" EFFECT_SIZE="-0.052600636690009" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.9" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5315" SD_1="4.18" SD_2="3.21" SE="0.3162884193456174" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.280729211890643" CI_END="0.3958292885432224" CI_START="-0.30636489892625607" DF="1" EFFECT_SIZE="0.044732194808483144" ESTIMABLE="YES" I2="21.919482220306655" ID="CMP-023.02.05" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2577636018645222" P_Z="0.8028093435232704" STUDIES="2" TAU2="0.01878851431044828" TOTAL_1="109" TOTAL_2="96" WEIGHT="100.0" Z="0.24971294931964202">
<NAME>Fluoxetine vs Reboxetine</NAME>
<CONT_DATA CI_END="0.45136984356919996" CI_START="-0.1554081847913773" EFFECT_SIZE="0.14798082938891133" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.4" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5316" SD_1="8.7" SD_2="7.3" SE="0.1547931577178879" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" WEIGHT="75.06334224846012"/>
<CONT_DATA CI_END="0.3836709089458695" CI_START="-0.9157964430000726" EFFECT_SIZE="-0.2660627670271015" ESTIMABLE="YES" MEAN_1="6.65" MEAN_2="8.07" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1070" SD_1="3.11" SD_2="6.94" SE="0.3315028648985325" STUDY_ID="STD-Taner-2006" TOTAL_1="20" TOTAL_2="17" WEIGHT="24.936657751539883"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2013-07-02 12:15:15 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Subgroup analysis for fluoxetine versus MAOIs or newer ADs: failure to complete - total</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7567393745204902" CI_START="0.3090865294675779" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="0.440395709320173" LOG_CI_START="-0.5099199218385969" LOG_EFFECT_SIZE="-0.03476210625921192" METHOD="MH" MODIFIED="2013-06-21 10:54:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.885982849845507" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="0.1433891521109302">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7567393745204902" CI_START="0.3090865294675779" DF="0" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-024.01.01" LOG_CI_END="0.440395709320173" LOG_CI_START="-0.5099199218385969" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2013-06-21 10:54:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.885982849845507" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="0.1433891521109302">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="2.7567393745204902" CI_START="0.3090865294675779" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.440395709320173" LOG_CI_START="-0.5099199218385969" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4917" O_E="0.0" SE="0.5582201058809031" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.31160968660968663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.209004168676696" CI_END="0.9916076762852124" CI_START="0.64040754012987" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7968895988427188" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="303" I2="41.465182764317554" I2_Q="49.77521124859803" ID="CMP-024.02" LOG_CI_END="-0.0036601199080428647" LOG_CI_START="-0.1935435633587379" LOG_EFFECT_SIZE="-0.09860184163339038" METHOD="MH" MODIFIED="2013-06-21 10:54:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05220686222099091" P_Q="0.11292411024488214" P_Z="0.041798276508674057" Q="5.973146079019115" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09942030945387029" TOTALS="SUB" TOTAL_1="1263" TOTAL_2="1238" WEIGHT="400.0" Z="2.0355230018877126">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0274475380910295" CI_END="2.490658491297182" CI_START="0.5937140189795458" DF="1" EFFECT_SIZE="1.2160340713868103" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="52" I2="66.96887435973359" ID="CMP-024.02.01" LOG_CI_END="0.39631418297091764" LOG_CI_START="-0.2264226962422455" LOG_EFFECT_SIZE="0.0849457433643361" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0818669261688465" P_Z="0.5928531191446198" STUDIES="2" TAU2="0.18093814441470865" TOTAL_1="400" TOTAL_2="385" WEIGHT="100.0" Z="0.5347060795385822">
<NAME>Fluoxetina vs Agomelatine</NAME>
<DICH_DATA CI_END="1.5817669514700943" CI_START="0.4172547466019974" EFFECT_SIZE="0.8124036979969184" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.19914249740049184" LOG_CI_START="-0.37959871417818225" LOG_EFFECT_SIZE="-0.09022810838884521" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1096" O_E="0.0" SE="0.3399554524965136" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="137" TOTAL_2="133" VAR="0.11556970968210932" WEIGHT="45.128216905517675"/>
<DICH_DATA CI_END="2.770297148759592" CI_START="1.0363386557716212" EFFECT_SIZE="1.694392523364486" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="30" LOG_CI_END="0.44252635503745824" LOG_CI_START="0.015501697783139824" LOG_EFFECT_SIZE="0.22901402641029905" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1097" O_E="0.0" SE="0.2508363974773311" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.06291889829940564" WEIGHT="54.87178309448232"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5865027310117" CI_END="1.6800133273163476" CI_START="0.5058990064516279" DF="2" EFFECT_SIZE="0.9219094712144104" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="49" I2="22.6755117626453" ID="CMP-024.02.02" LOG_CI_END="0.22531272693835727" LOG_CI_START="-0.2959361735129571" LOG_EFFECT_SIZE="-0.035311723287299916" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2743773608250242" P_Z="0.790583187812871" STUDIES="3" TAU2="0.0677754380389755" TOTAL_1="151" TOTAL_2="150" WEIGHT="100.0" Z="0.2655533884684577">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="10.944829454668549" CI_START="0.23390040115316965" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0392089986610609" LOG_CI_START="-0.6309690333492113" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1065" O_E="0.0" SE="0.9810708435174291" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.9624999999999999" WEIGHT="9.099387531140644"/>
<DICH_DATA CI_END="1.2140052480871342" CI_START="0.29653908050829225" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="0.08422056417775314" LOG_CI_START="-0.5279180634104659" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5344" O_E="0.0" SE="0.3595732599803958" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="0.1292929292929293" WEIGHT="47.57169098956935"/>
<DICH_DATA CI_END="2.8010722863556294" CI_START="0.618148652325078" EFFECT_SIZE="1.315856777493606" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.44732431666372585" LOG_CI_START="-0.2089070732585561" LOG_EFFECT_SIZE="0.11920862170258491" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5345" O_E="0.0" SE="0.385473566838118" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.14858987073090105" WEIGHT="43.32892147929001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.131423463830354" CI_END="1.5272849122721892" CI_START="0.6837810783828214" DF="4" EFFECT_SIZE="1.021923932742203" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="66" I2="3.1810697930370995" ID="CMP-024.02.03" LOG_CI_END="0.18392006147395343" LOG_CI_START="-0.16508292118731321" LOG_EFFECT_SIZE="0.009418570143320145" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.38851200377629613" P_Z="0.915751037669307" STUDIES="6" TAU2="0.006867214167701065" TOTAL_1="325" TOTAL_2="326" WEIGHT="100.0" Z="0.10578739543145126">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5346" O_E="0.0" SE="0.0" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.808185824114187" CI_START="0.49225716141315984" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.6819812436926667" LOG_CI_START="-0.30780795697837776" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5347" O_E="0.0" SE="0.5814070760097335" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="0.338034188034188" WEIGHT="12.185364399180095"/>
<DICH_DATA CI_END="1.5755433064214213" CI_START="0.23154059444845657" EFFECT_SIZE="0.603988603988604" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.19743034497835923" LOG_CI_START="-0.6353728560525046" LOG_EFFECT_SIZE="-0.21897125553707264" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5348" O_E="0.0" SE="0.4891927227278604" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="0.23930951996989733" WEIGHT="17.072081496008078"/>
<DICH_DATA CI_END="2.413069060470331" CI_START="0.604576581794726" EFFECT_SIZE="1.2078431372549019" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.38256975131284476" LOG_CI_START="-0.21854867917986667" LOG_EFFECT_SIZE="0.08201053606648906" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5349" O_E="0.0" SE="0.35309994165563924" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.12467956879721585" WEIGHT="31.948704277618504"/>
<DICH_DATA CI_END="1.489435663170907" CI_START="0.20813261145902012" EFFECT_SIZE="0.5567765567765568" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.17302174841489976" LOG_CI_START="-0.6816598666068667" LOG_EFFECT_SIZE="-0.25431905909598346" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5350" O_E="0.0" SE="0.5020442114060125" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="0.25204839020628494" WEIGHT="16.232120415375228"/>
<DICH_DATA CI_END="3.418028386786818" CI_START="0.6496668722344996" EFFECT_SIZE="1.4901610017889089" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.5337756652231267" LOG_CI_START="-0.18730927818239804" LOG_EFFECT_SIZE="0.17323319352036431" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5351" O_E="0.0" SE="0.42356886518444214" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.17941058355363612" WEIGHT="22.561729411818092"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.618193371521924" CI_END="0.8290612955812889" CI_START="0.44058351160099024" DF="3" EFFECT_SIZE="0.60437632063117" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="136" I2="0.0" ID="CMP-024.02.04" LOG_CI_END="-0.081413359258382" LOG_CI_START="-0.3559717599194704" LOG_EFFECT_SIZE="-0.21869255958892622" MODIFIED="2013-06-21 10:54:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.45430898634221584" P_Z="0.0017943202280884614" STUDIES="4" TAU2="0.0" TOTAL_1="387" TOTAL_2="377" WEIGHT="100.0" Z="3.1223196190618134">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="0.8666744353500004" CI_START="0.2914404208333217" EFFECT_SIZE="0.5025773195876289" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="48" LOG_CI_END="-0.06214401380901906" LOG_CI_START="-0.5354502146543595" LOG_EFFECT_SIZE="-0.29879711423168925" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5356" O_E="0.0" SE="0.278022405280033" STUDY_ID="STD-Andreoli-2002" TOTAL_1="127" TOTAL_2="126" VAR="0.07729645783769494" WEIGHT="33.650001211857905"/>
<DICH_DATA CI_END="1.011714542760396" CI_START="0.3924828459827537" EFFECT_SIZE="0.6301433194637078" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="63" LOG_CI_END="0.00505799274896105" LOG_CI_START="-0.4061793199577969" LOG_EFFECT_SIZE="-0.2005606636044179" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="3218" O_E="0.0" SE="0.24156283314147814" STUDY_ID="STD-Clayton-2003" TOTAL_1="150" TOTAL_2="150" VAR="0.05835260235533761" WEIGHT="44.57429137559001"/>
<DICH_DATA CI_END="1.7402247472895396" CI_START="0.4201462595180684" EFFECT_SIZE="0.855072463768116" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.2406053403541715" LOG_CI_START="-0.3765994985443938" LOG_EFFECT_SIZE="-0.06799707909511112" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5357" O_E="0.0" SE="0.3625491775822437" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.13144190616556128" WEIGHT="19.78840672497981"/>
<DICH_DATA CI_END="1.6005013681269036" CI_START="0.01805684179690657" EFFECT_SIZE="0.17" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2042560497202079" LOG_CI_START="-1.7433582069636597" LOG_EFFECT_SIZE="-0.769551078621726" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1071" O_E="0.0" SE="1.1440382552221602" STUDY_ID="STD-Taner-2006" TOTAL_1="21" TOTAL_2="22" VAR="1.3088235294117647" WEIGHT="1.9873006875722647"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2013-07-02 12:15:44 +0100" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Subgroup analysis for fluoxetine versus MAOIs or newer ADs: failure to complete - inefficacy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.6758954602083325" CI_START="0.19965036299809322" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="0.754034387935408" LOG_CI_START="-0.6997298958481786" LOG_EFFECT_SIZE="0.027152246043614776" METHOD="MH" MODIFIED="2013-06-21 10:54:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9416364004105215" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="36" WEIGHT="99.99999999999999" Z="0.07321327802379454">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.6758954602083325" CI_START="0.19965036299809322" DF="0" EFFECT_SIZE="1.064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-025.01.01" LOG_CI_END="0.754034387935408" LOG_CI_START="-0.6997298958481786" LOG_EFFECT_SIZE="0.027152246043614776" MODIFIED="2013-06-21 10:54:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9416364004105215" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="99.99999999999999" Z="0.07321327802379454">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="5.6758954602083325" CI_START="0.19965036299809322" EFFECT_SIZE="1.064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.754034387935408" LOG_CI_START="-0.6997298958481786" LOG_EFFECT_SIZE="0.027152246043614776" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4956" O_E="0.0" SE="0.8539483365437431" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.729227761485826" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.854199048672498" CI_END="1.5157508901493997" CI_START="0.6851689572032619" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0190905047068097" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.18062783195358748" LOG_CI_START="-0.16420232174378357" LOG_EFFECT_SIZE="0.008212755104901954" METHOD="MH" MODIFIED="2013-06-21 10:54:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5396344963660487" P_Q="0.5564369530457389" P_Z="0.9256174166484772" Q="2.077702252314607" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1264" TOTAL_2="1234" WEIGHT="400.0" Z="0.09336018933878945">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4089013643439214" CI_END="2.8814659955341555" CI_START="0.40611180924584733" DF="1" EFFECT_SIZE="1.081756612518159" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="58.48729986201174" ID="CMP-025.02.01" LOG_CI_END="0.4596134987953846" LOG_CI_START="-0.3913543815620731" LOG_EFFECT_SIZE="0.034129558616655745" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12064720893556702" P_Z="0.8750749476430556" STUDIES="2" TAU2="0.292747020871044" TOTAL_1="400" TOTAL_2="385" WEIGHT="100.0" Z="0.15721558296370725">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="1.564583163770976" CI_START="0.286306861964522" EFFECT_SIZE="0.6692913385826772" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.19439865256173688" LOG_CI_START="-0.5431682430450651" LOG_EFFECT_SIZE="-0.17438479524166411" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1098" O_E="0.0" SE="0.4332504454944515" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="137" TOTAL_2="133" VAR="0.18770594852114073" WEIGHT="52.0056654943502"/>
<DICH_DATA CI_END="4.638647826204977" CI_START="0.7140874073878505" EFFECT_SIZE="1.82" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6663914014168623" LOG_CI_START="-0.14624862544671258" LOG_EFFECT_SIZE="0.2600713879850748" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1099" O_E="0.0" SE="0.47734877441267304" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.227861852433281" WEIGHT="47.994334505649796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1584125919587105" CI_END="2.9571939967914993" CI_START="0.7132009246727556" DF="3" EFFECT_SIZE="1.4522649527370752" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-025.02.02" LOG_CI_END="0.470879815893202" LOG_CI_START="-0.1467881024287988" LOG_EFFECT_SIZE="0.1620458567322016" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7629950237030916" P_Z="0.3037629418524066" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="297" WEIGHT="100.0" Z="1.0283974077911562">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="83.16605151283552" CI_START="0.12093827951085495" EFFECT_SIZE="3.1714285714285713" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9199460829082542" LOG_CI_START="-0.9174362140354908" LOG_EFFECT_SIZE="0.5012549344363818" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1066" O_E="0.0" SE="1.666692406493645" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="2.777863577863578" WEIGHT="4.738865469905533"/>
<DICH_DATA CI_END="109.46408440569732" CI_START="0.24276843640709503" EFFECT_SIZE="5.155038759689923" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.039271648828983" LOG_CI_START="-0.6148077788212715" LOG_EFFECT_SIZE="0.7122319350038556" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5383" O_E="0.0" SE="1.5590193937068118" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="2.4305414699539547" WEIGHT="5.416044923313048"/>
<DICH_DATA CI_END="2.8074997608381795" CI_START="0.49116546972165215" EFFECT_SIZE="1.1742857142857144" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4483197279373553" LOG_CI_START="-0.3087721728857681" LOG_EFFECT_SIZE="0.0697737775257936" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1069" O_E="0.0" SE="0.4447195302088533" STUDY_ID="STD-Versiani-2005" TOTAL_1="152" TOTAL_2="147" VAR="0.19777546054918316" WEIGHT="66.55993495195185"/>
<DICH_DATA CI_END="7.392745096167514" CI_START="0.38796226599574557" EFFECT_SIZE="1.6935483870967742" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8688057318655299" LOG_CI_START="-0.41121051272216164" LOG_EFFECT_SIZE="0.2287976095716842" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5384" O_E="0.0" SE="0.7518878782534094" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.5653353814644138" WEIGHT="23.28515465482958"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.3778240305313165" CI_END="1.6464091316540466" CI_START="0.22924674405041787" DF="4" EFFECT_SIZE="0.6143565193001259" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="25.62047442811532" ID="CMP-025.02.03" LOG_CI_END="0.21653776619870574" LOG_CI_START="-0.6396968238192434" LOG_EFFECT_SIZE="-0.2115795288102688" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2506795729982796" P_Z="0.3327286750503151" STUDIES="5" TAU2="0.32267542236846775" TOTAL_1="304" TOTAL_2="305" WEIGHT="100.0" Z="0.968632337839537">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="12.101088580677217" CI_START="0.612382413181689" EFFECT_SIZE="2.7222222222222223" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0828244400120106" LOG_CI_START="-0.21297729016159547" LOG_EFFECT_SIZE="0.4349235749252076" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5385" O_E="0.0" SE="0.7611603506259895" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="0.5793650793650793" WEIGHT="28.04366063800643"/>
<DICH_DATA CI_END="8.737186854248607" CI_START="0.01396717041921071" EFFECT_SIZE="0.34933333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9413716236711689" LOG_CI_START="-1.854891567815078" LOG_EFFECT_SIZE="-0.4567599720719546" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5386" O_E="0.0" SE="1.6425388404050558" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="2.6979338422391854" WEIGHT="8.374640841088201"/>
<DICH_DATA CI_END="1.5462555349544165" CI_START="0.06006757388703051" EFFECT_SIZE="0.3047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1892812672343369" LOG_CI_START="-1.2213599087344011" LOG_EFFECT_SIZE="-0.516039320750032" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5387" O_E="0.0" SE="0.8286176095504746" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.6866071428571427" WEIGHT="25.063860789766018"/>
<DICH_DATA CI_END="2.224600364340955" CI_START="0.025848275217141982" EFFECT_SIZE="0.23979591836734693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34725200401357464" LOG_CI_START="-1.5875684308550917" LOG_EFFECT_SIZE="-0.6201582134207586" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5388" O_E="0.0" SE="1.1365231009574714" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="1.291684759009987" WEIGHT="15.669686358810393"/>
<DICH_DATA CI_END="2.837187185483553" CI_START="0.08811544098292953" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4528879896347094" LOG_CI_START="-1.0549479809626718" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5389" O_E="0.0" SE="0.8857103130373326" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.7844827586206897" WEIGHT="22.848151372328953"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-025.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5392" O_E="0.0" SE="0.0" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7595966989110978" CI_END="1.7744656357983815" CI_START="0.474117932769375" DF="2" EFFECT_SIZE="0.9172273322437701" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-025.02.05" LOG_CI_END="0.24906759324255923" LOG_CI_START="-0.3241136178607596" LOG_EFFECT_SIZE="-0.03752301230910015" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6839994865115352" P_Z="0.7974751743968365" STUDIES="3" TAU2="0.0" TOTAL_1="237" TOTAL_2="227" WEIGHT="100.0" Z="0.25661606239927093">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="1.8544116054771973" CI_START="0.3840027237288681" EFFECT_SIZE="0.843859649122807" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.26820613657623726" LOG_CI_START="-0.4156656951735565" LOG_EFFECT_SIZE="-0.07372977929865965" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5394" O_E="0.0" SE="0.40170969918999216" STUDY_ID="STD-Andreoli-2002" TOTAL_1="127" TOTAL_2="126" VAR="0.161370682423314" WEIGHT="70.24808020157812"/>
<DICH_DATA CI_END="4.988963058617443" CI_START="0.36824645268333" EFFECT_SIZE="1.355421686746988" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6980102881648791" LOG_CI_START="-0.4338614280222643" LOG_EFFECT_SIZE="0.13207443007130737" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5395" O_E="0.0" SE="0.6648670489436849" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.4420481927710843" WEIGHT="25.64421894815147"/>
<DICH_DATA CI_END="8.648116214920153" CI_START="0.012848013179958985" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9369215171107735" LOG_CI_START="-1.8911640265500982" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1072" O_E="0.0" SE="1.6612314475956143" STUDY_ID="STD-Taner-2006" TOTAL_1="21" TOTAL_2="22" VAR="2.75968992248062" WEIGHT="4.107700850270421"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2013-07-02 12:16:11 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Subgroup analysis for fluoxetine versus MAOIs or newer ADs: failure to complete - side effects</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-21 10:54:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>follow-up &lt;6 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-026.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-21 10:54:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4997" O_E="0.0" SE="0.0" STUDY_ID="STD-Gattaz-1995" TOTAL_1="34" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.144843992204407" CI_END="1.4443825156868895" CI_START="0.7134919617247413" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="1.015162703510307" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" I2="1.1019072747482401" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.15968222263303433" LOG_CI_START="-0.14661091532894696" LOG_EFFECT_SIZE="0.006535653652043657" METHOD="MH" MODIFIED="2013-06-21 10:54:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4366868896510724" P_Q="0.49108362837193587" P_Z="0.9333402397276915" Q="3.4139441668402375" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0043782836242027435" TOTALS="SUB" TOTAL_1="1158" TOTAL_2="1129" WEIGHT="500.0" Z="0.08364304769389434">
<NAME>follow-up 6-16 weeks</NAME>
<GROUP_LABEL_1>Fluoxetine</GROUP_LABEL_1>
<GROUP_LABEL_2>MAIOs or newer ADs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoxetine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAOIs or newer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34935773156808214" CI_END="3.0801389729304924" CI_START="0.7328630601476664" DF="1" EFFECT_SIZE="1.5024380431092428" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-026.02.01" LOG_CI_END="0.48857031189500344" LOG_CI_START="-0.1349771683032725" LOG_EFFECT_SIZE="0.17679657179586547" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5544771317030361" P_Z="0.26638301199355086" STUDIES="2" TAU2="0.0" TOTAL_1="400" TOTAL_2="385" WEIGHT="100.0" Z="1.1114307228051383">
<NAME>Fluoxetine vs Agomelatine</NAME>
<DICH_DATA CI_END="4.894371030613178" CI_START="0.19230041380773044" EFFECT_SIZE="0.9701492537313433" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6896968890942495" LOG_CI_START="-0.7160197812101913" LOG_EFFECT_SIZE="-0.013161446057970849" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1100" O_E="0.0" SE="0.8257249305465704" STUDY_ID="STD-CL3_x002d_022" TOTAL_1="137" TOTAL_2="133" VAR="0.6818216609261385" WEIGHT="19.676301418313024"/>
<DICH_DATA CI_END="3.7256302092285765" CI_START="0.7506865143729687" EFFECT_SIZE="1.6723577235772358" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5711997464106322" LOG_CI_START="-0.12454138589998007" LOG_EFFECT_SIZE="0.22332918025532608" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="0.0" SE="0.4086817850934023" STUDY_ID="STD-Hale-2010" TOTAL_1="263" TOTAL_2="252" VAR="0.1670208014671299" WEIGHT="80.32369858168697"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9886050459713054" CI_END="1.6571589871648604" CI_START="0.541533873030518" DF="3" EFFECT_SIZE="0.9473160637014012" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" I2="0.0" ID="CMP-026.02.02" LOG_CI_END="0.2193641764556094" LOG_CI_START="-0.2663743729996099" LOG_EFFECT_SIZE="-0.023505098272000282" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5747751674247055" P_Z="0.8495544021605113" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="297" WEIGHT="100.00000000000001" Z="0.1896870080328773">
<NAME>Fluoxetine vs Mirtazapine</NAME>
<DICH_DATA CI_END="25.775322065244573" CI_START="0.17519179735444962" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4112041005427385" LOG_CI_START="-0.7564862317700777" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1067" O_E="0.0" SE="1.2733120314407482" STUDY_ID="STD-Amini-2005" TOTAL_1="18" TOTAL_2="18" VAR="1.6213235294117647" WEIGHT="5.021236322152428"/>
<DICH_DATA CI_END="1.4631319891832764" CI_START="0.21612525357695844" EFFECT_SIZE="0.5623342175066313" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.16528350561155317" LOG_CI_START="-0.6652944841656362" LOG_EFFECT_SIZE="-0.25000548927704147" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5422" O_E="0.0" SE="0.48788562262247864" STUDY_ID="STD-Hong-2003" TOTAL_1="66" TOTAL_2="66" VAR="0.23803238076172364" WEIGHT="34.201433308320006"/>
<DICH_DATA CI_END="2.915318092782721" CI_START="0.41018202289108285" EFFECT_SIZE="1.0935314685314685" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.46468594791266093" LOG_CI_START="-0.3870233774398318" LOG_EFFECT_SIZE="0.03883128523641456" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1068" O_E="0.0" SE="0.5002982737412099" STUDY_ID="STD-Versiani-2005" TOTAL_1="152" TOTAL_2="147" VAR="0.25029836270843464" WEIGHT="32.52537694513806"/>
<DICH_DATA CI_END="3.745390288244061" CI_START="0.45670934176296624" EFFECT_SIZE="1.3078817733990147" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5734970800325664" LOG_CI_START="-0.34036010502401653" LOG_EFFECT_SIZE="0.11656848750427493" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5423" O_E="0.0" SE="0.5368042341682596" STUDY_ID="STD-Wheatley-1998" TOTAL_1="67" TOTAL_2="66" VAR="0.2881587858209717" WEIGHT="28.25195342438951"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.392947771339534" CI_END="2.010030047021826" CI_START="0.536209489632914" DF="4" EFFECT_SIZE="1.038170114027752" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="31" I2="25.829061033045107" ID="CMP-026.02.03" LOG_CI_END="0.3032025495390175" LOG_CI_START="-0.27066550430550573" LOG_EFFECT_SIZE="0.016268522616755852" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24930111768804886" P_Z="0.9115167416806602" STUDIES="6" TAU2="0.14645409296614256" TOTAL_1="325" TOTAL_2="326" WEIGHT="100.0" Z="0.1111256087419549">
<NAME>Fluoxetine vs Moclobemide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5424" O_E="0.0" SE="0.0" STUDY_ID="STD-Duarte-1996" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.020963513646312" CI_START="0.02815970602099903" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4801454800174838" LOG_CI_START="-1.5503718834121822" LOG_EFFECT_SIZE="-0.5351132016973492" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5425" O_E="0.0" SE="1.1927359505016388" STUDY_ID="STD-Geerts-1994" TOTAL_1="25" TOTAL_2="24" VAR="1.4226190476190477" WEIGHT="7.2419598703827495"/>
<DICH_DATA CI_END="4.0202033007439075" CI_START="0.40292358111443355" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.6042480158105261" LOG_CI_START="-0.39477731477050026" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5426" O_E="0.0" SE="0.5868324244384374" STUDY_ID="STD-Lapierre-1997" TOTAL_1="62" TOTAL_2="66" VAR="0.3443722943722944" WEIGHT="23.15108765735163"/>
<DICH_DATA CI_END="3.7527255472779584" CI_START="0.6972460001957009" EFFECT_SIZE="1.6175824175824176" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5743468037786098" LOG_CI_START="-0.15661396841783687" LOG_EFFECT_SIZE="0.20886641768038647" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5427" O_E="0.0" SE="0.4293699759023706" STUDY_ID="STD-Lonnqvist-1994" TOTAL_1="107" TOTAL_2="102" VAR="0.18435857620640228" WEIGHT="34.349242869796484"/>
<DICH_DATA CI_END="1.3285157213086223" CI_START="0.05163213593048269" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12336669810435753" LOG_CI_START="-1.2870799085837084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5428" O_E="0.0" SE="0.8285033185918744" STUDY_ID="STD-Reynaert-1995" TOTAL_1="50" TOTAL_2="51" VAR="0.686417748917749" WEIGHT="13.643353210394027"/>
<DICH_DATA CI_END="5.034286248248591" CI_START="0.45031471397479583" EFFECT_SIZE="1.5056603773584907" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7019379057893128" LOG_CI_START="-0.346483862289432" LOG_EFFECT_SIZE="0.1777270217499404" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5429" O_E="0.0" SE="0.6158481363409063" STUDY_ID="STD-Williams-1993" TOTAL_1="60" TOTAL_2="62" VAR="0.37926892703456755" WEIGHT="21.614356392075106"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.260466128217253" CI_START="0.012170668584238322" DF="0" EFFECT_SIZE="0.3170731707317074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-026.02.04" LOG_CI_END="0.9170045547296883" LOG_CI_START="-1.9146855635554856" LOG_EFFECT_SIZE="-0.4988405044128986" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4898494409043541" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.690548316968497">
<NAME>Fluoxetine vs Phenelzine</NAME>
<DICH_DATA CI_END="8.260466128217253" CI_START="0.012170668584238322" EFFECT_SIZE="0.3170731707317073" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9170045547296883" LOG_CI_START="-1.9146855635554856" LOG_EFFECT_SIZE="-0.49884050441289873" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5433" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Pande-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.7667292057535957" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2401563331170777" CI_END="1.6088947371470619" CI_START="0.10015539874284513" DF="1" EFFECT_SIZE="0.40142184038020273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="19.365004774313856" ID="CMP-026.02.05" LOG_CI_END="0.20652763106508595" LOG_CI_START="-0.9993256356761138" LOG_EFFECT_SIZE="-0.39639900230551395" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.26544100973406803" P_Z="0.19753919783790547" STUDIES="2" TAU2="0.3154332863826404" TOTAL_1="110" TOTAL_2="101" WEIGHT="100.00000000000001" Z="1.2885942086901714">
<NAME>Fluoxetine vs Reboxetine</NAME>
<DICH_DATA CI_END="1.6570477901202991" CI_START="0.19077538702851393" EFFECT_SIZE="0.5622489959839357" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.21933503387874545" LOG_CI_START="-0.7194776567137421" LOG_EFFECT_SIZE="-0.25007131141749833" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="5435" O_E="0.0" SE="0.5514632216517946" STUDY_ID="STD-Massana-1999" TOTAL_1="89" TOTAL_2="79" VAR="0.3041116848345764" WEIGHT="80.98252175109727"/>
<DICH_DATA CI_END="1.8957500979869666" CI_START="0.004821702724017608" EFFECT_SIZE="0.09560723514211886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2777810871062846" LOG_CI_START="-2.3167995690101177" LOG_EFFECT_SIZE="-1.0195092409519164" MODIFIED="2013-05-16 11:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1073" O_E="0.0" SE="1.524069520784158" STUDY_ID="STD-Taner-2006" TOTAL_1="21" TOTAL_2="22" VAR="2.322787904183253" WEIGHT="19.017478248902744"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-07-04 15:49:16 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-02 12:16:21 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram, 2005 version.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeEAAAE4CAYAAABse0vpAAAmeElEQVR42u2df4RWTf/HlyTJSiTJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-05-27 10:40:42 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram, 2012 version.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAgkAAALaCAYAAAC7yMB5AABgTElEQVR42u29f2Reyfv/v9Sqilqh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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-07-04 15:49:16 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAhLklEQVR42u19DXBb15Xe4cPvI37fI2lL1k9Myl7XzUzj2LOKXVaN
lCjuOiPvejKJt5N0O3UmVWebdtpOt5NOZ9rd7Uw7lbfe3cY/sqWk2ok9s47TdZPIrmNH6UpWZG+5
jWOnu/HEEUlZf6RI8F0CIIEHPALo/Xt/AEiBIACB1PkkEnj33nPPeQ8H9553eb93ABCIrmEANLwI
iC6BKHgNEN0DuhcC3QuB7oVAoHsh0L0Q6F4IBLoX4oYhiJegsyB4CTwr9eheXZ0PbsrJYQUnRwTG
Xgh0LwQC3QuB7oVA99o0MHouiKhDp7YT8uWebRe2N6u6URsWQ1Zz3elScW0Lw+WmgrKsvmowvOht
hAsTK1rzi7ERaJpWC93eV6c5B02/O8Zy7jqC12CtL1191aVlHO16MTnqF2cBToSIkqZ++ztBQl+s
MDsAK0I+bdHCZEA5oW8jJ8THRJQQHUasKK+bCG9LEzEK0p+JiBKRAvTTtEIB1hctm+CSE5FAkjay
Pk2irFFtN9GdfkgyKG0g/B/THRXlUu9oOFSnG3hfTOFIMKC5glyftIE3CnGjAIphsi1FT5iQ4AkY
Co+iH/Ui9hrdBvCPc1qKjQ5H534yDZCKZdjHl45q/5e5WWU+/U9Wfr7nEd56arR67CCtm9Z+Qus+
Gf952e1p/1I1luICqSxAcvDyEv1Ny/bz2gOR+Srr9QfaK+yDT7y7Z9LpB5Q5aYMmxpl0RIuw8uqc
1PubGa47R3VrUoa2+pn2Km2ej51esgWTalX9pGMDQ+paTLROxTSTWjQ5qiW/ApAx0Y+67V6EopSk
E68KZIFNGfpB9hFN6iwwKU7D9D30dVE3rl3Q5VzyxZL+G+do3XZYpANJ+byedXtLhsAo815YZ+Xp
7Sv0M6Vlw7zWvKCzUa4YgoMsirrIe5T9wJTu2MBxzwWYvuy0ovhmkesuUt0FKnOP6HKe92VN77Ns
wdQUTLk2MGR1Q0RtZQKL1Em3myfOV6jmFfSjbof29Cu/vByiH1BQrcxpPP4lq7zI4Hhhx8zQmX3i
pqChZUMh2GUA3kZD1SYirg2NusXvhR33ve3T7ekL1hJUeBtDG7z/ZQ2s+Ozw6X3+YB9D+66E9rQv
9dfp7zioabds2AA2GgwZMDFU337IrCXoZDdEbwqoPXeLlnJZQBa6vbDfThltOysbVd3uXBGfDVS3
4dNNC6juk4kveGVkX0OGz3a/IIzYSxbb4OQRdmtaqsW+BPaYimhEANSO9GPSbkqXUkXIBGf/IKfy
Y/qjPllK0aPB/d96KWDZhfwHIJj+vdgVFWIfPpGuVaD2tMlaxtJXd9GXaDGgVap248jT0/+tCmqB
l1HUvl56lvWaLpz6dsVuJPthR9KGWDlgct3PenQDhJ8tMt2Ls7Tuoi0j+4o8Hbeo2uIRWhR9xnwO
VjyCZqhyXCnzg6u7PkYVsDN4X4XjVc/saA74J4ebEFXHpcyOjt5LOQPG1BFPn6fNADtaPETMxYbl
pxyZ3EMHvVGyfIpGOEWFtUxlB+gMC2fiSt4dgBL5jydoX3Eiyy6VAgodVxbz5LMJd/AU/TCM7ec2
hCPQTLdKI/E/zxGT6l4cJQUhI/vKL5EYjam4V5wpkOIZn8XJ4CfEdq7XPzIcANaLws7AjOAw1eXY
q1MBXKtIP3qsXS3GrRe3d9Jqa/CajrFX89irr9xLqbbWLkZntx/vbVtN+oHXOmm1GsFV+03hXlsB
uBna83cNgpuhu3VpEYAbchDoXgh0LwQC3QvRS2Boj3eOXby9QffCL2yngTRaBMZeCHQvBALdC4Hu
hUD36jaMG981Ess6hd7vmNCmxohnB30DVuGwtoq1ZIPilln70lNry9B266DRqlHvWhduEujSXvsW
Yd5WXLP+Wvd2HcyLsSn3D6/fbh002jP5CRym+mVyNMq5sjP5GIeVCD0YCY/Tz0wPk0DKw2E9LHm0
YreyaGNzYmtBxpyVZVFedjZIAmKvNBUa17Sg5Na67YlYUr9d3QunFBKmokaE6wf+7jB9NxNStHr+
rdDFMBw+LGi0wyGF6dJoLzrsjR5EP1oFnaJytIxj1VrkGZPxIej/r/+imHh8BWqRbLYKlTiklmqq
qbGaRLQ4FVgBMzlz8MEakxNtkuGBWNgCM7rwwqQqy1KxajxShuePv56e5r2aiZnYy4ErrEUqG2N1
oj3rmuJTs0V4ITGQTGThyTePJf+A0zyezCvT9N3PZ+NZ2wRb18hV1hMbdwevbv8Ob10+/t30Ry9B
mfaSr0Lc9FI58GapW1SOlubGKEQdVnN5CqZKAPdemKcfEB3UGDdVoDQFk4zDelE/KDisoo05DdNs
biWcEyvKivOcP7vymPP3vkX9McnWLYYEt5bobrj++nka4FlvTl6kWvYCEdzwUggMatbr05mK3a4o
dTn8W9rvvpKILqiuVwBCZX2SGnD+Phym+iS0N0aoBw3P6w1MVYCJT+374fya5FdoQst16LVWUL3l
Pa2OrduUjkt/T+yzQM/U0WhBuz6NVhRIXRP7ZuHOjJ8jgKH9jQzt9wQ1GhbdIY8YU3XYJq+OK2+7
Qb+scSHaHKLFh+rLBBc2llAb7xkO+ei4soxK7S1l2ENQXGaufHfI8LXz6GI4a9skde0t1UYJrmP0
0ejFaTXpUlGMAqpqsIdtRSNhsgIB7YOdV2jxL/eymijRSgXP0BENR2ibWJikVpbtYiEXG5xPmSUg
8fyuy/WjV1wVdXLciTMO5UN/QSAcI+lcFdQze9PL/Clgg9mQtlyGh94KGxXWjhb5dbHv4rbS2V9b
Fh1xXaHYokaDP61o4ujVH6OXNUV/TVnyC59bVh69AjC9bCQBEtmH2ad/25285gukcNkrOF1kbRYL
xLzolnG5i3lSSADj7wYa1H0o6iS+tsR+n6PRVnaZTKcAruxTlsTd5uWvkqWzAP+98Cspu91i0auL
4ULo4CX+RurKLZPsGzRoDOMw1TfLqjccxsN/tLej35j93v5w9LrZeY6+yawD8z2u2q/qXjfjxejw
fuWi/44CH/blAX7XOj004iXwANeYEeheCHQvBALdC4GhPd6WbonbG3Qv/MJ2ABXvQQ0nRwTGXgh0
LwQC3QuB7oVA99p6MK5zjGgXHWIKEdM0U0shICr7762oL5BIHzjfWKhfHbbaUa56X1pr7Hv3p1l/
G3rcrLNV9Khx7/6em5MpVPNfkY5fDE2rqUnxrqGq2Xix/P0mpZN7ljdiQtuS7zUer4NGm8NstD2Y
HPXsnPhyu/lhI3yPOuG5aRkb1jq8LSVWtcfCdKTTlMMTtPAhJ6csTHq4q0BSAUUXbFg9whi2dr8j
Id67kGMYCUYFvVW200WuWeB8V5ZK1tYfkURblu2WZSMVfTDSrOTbWsHAKZtGOyGz0VLZ9Fp6QpiN
thexV+ojztvEu3vuphPgqzU7wezRudP30Rbf/vlX5KjJCI3lzEsHaKvvi5yy2rssC2z6VS3KPswT
1FdX5tNLlbmxSZYkVns97/S7pN6Zc+UolueIcADZbnK0mhDM6WyuylPJSv3qvHTIA0czbNsf6yPN
s8+mp7nefxU7/Wt2Ntr9alXdL2Sn19SD2Wi77l6EkAvu0UXdeIX60L36JVlwSf+79HdyWv8v4rjM
BpdFfarI0tiJnLJTnGlfvBdYITyi27lr2XBnGcDZtKLfqxeYb9hyFKd1yUGT7b5Y0s+fEwVOblyu
f0qX6X/MR/g71ofwDZbLlr57Znqfs9u0NAVTpiO7hh7MRrsqOrTXns2CxcSKn4DK2KVrM1Kb5JR1
Mr56f4zdFWu+CXt2qGp3JrPEinZWYoZnieV5aavX1mDEOrpbpdE21ePLRot/c6x1hYimzte7rgH+
Z8fQ+0I5OfH8svTobn5X4M0pazRbFrhViXo2tMuUsa7csC0j24XMWnw/L4iDvOGwtUr9du5bpw+Z
l3a4LhutP8/sKnqMIRymuh97JbfVFfzL2+FtX8EfDoEMkkN38MFihAYwOy045ebbjL4DY41rApXw
5DPuUeQdlqzTI/c5uEP1tjug6QHxtIrZWyY9gdEfjtpjdV682zki+jBAnYE0fffbYzNBe+ErcgeM
+ROBrqLnjhD6UXfXvUwKNVmQD76R+YHf/OTFtxa9Bf/xOESCfIkkVrbA1KzalSNQiGe+JyTZT2H2
nWgu4EuLTH/S+SOyJ370v+ZSRVuOKX8vWhEyst3v/tkC2cOHu9uyj0eyXv3RRX6+546PVOi7Asyz
Pj73ebXws3fCPzoB07nnAyY7Zqb8o59W3zzuTXa8ip6BSAnXvZqve/Wa56gV+Edh3FIMkS1CqpnZ
Nadj7NU89uqpe8UuDweWxUySLhVbzT3b7xiMII22L9zrZgBuhsZstL24tAjAHRMIdC8EuhcCge6F
6CUwtMc7xy7e3qB7dWc+uMlmBaTRIjD2QqB7IRDoXgh0LwS6V3swOtQGsXnh3U64bi6swKkX1Kbk
1yeqrtRq4k+svSmHtL/XUYpqzR4ErpXVDtJ11YSPRjvAXwZuLjdqiUa7Ti6sxIOpQtNyb07X1cTn
u3zaRj7fpDSbLGygz8ZstDgGtzg56lmRv4RRX5OcwboQ4dw+XjBOeAbXQFIsTVuHScQAsjDFJTQl
sgBwNsRzwrK2gozK87tycS3A8r0WwyRwih4dtfPDakQJCp6GR5YnnuVMV9b1KZ4zdkFmlk0GbZkF
X75Yxz6eV1ZgNEoHY308Yjnl7LQWpsHgtjMZIKnxQLoYYLJnw8p4WuTAfZNzatO+/mbCXMZpd4qQ
8JuwN3I7+lGLsVfqAedtde67kwC71Zo9kVROjlFP2hWZlzNa6iVN3WGTTqGUie4GOHBMeybHJoeT
svzLqp4TzUvzL+0EuCuuJf4ePXp/bs8kl50arR4XWaVsWaEnrTqZO38jo1LJ3QlNZZ6uzNkyu6Na
hJX8C861te1bqj6wyz6HEssmVTzJGLJ2uTLHtO7gtjM7qRudTBVG5pnsgXj1K8yC6nxqP0AidnrJ
198ds4s7hKWi3YOjWuwfAETG0Y9WH+sd8MOP0Ffxv8ZfhmtazVcwUtPiQohVDfMyJhzXakOyH6ct
/T9Us4tM3rqhwfbb9tQ8NngVx92uqSTLzXhIVEsZ2jfTafcl5WjFiG3VoZoQP+SWu6c1LI9qTmmD
BZojJ+zQhr3ttu34CWtin7coVjiCNxcGvHBdykej5VzYeGW9XFjfgZsT1iPllbM0O+esndk1MTO0
zIPBljmvnL+6pNZxbhsT0IJtPW/lljeejG3ckLUy1zzZre98ZTsrznPa+mm0+DfHNWi06v11BQ/U
81qHDVhw3nl4piJ3a0NOWDe/q8VbD+b/wt+AcVHF5Pjw19WUWz7i6KGvPGety5uVMixf7AP1Zzrs
S0BrCMsG6ssbObIMsax60Xem/v7cbLSiXaiUSd4F9TlrES7qR6/kr/7IP1jFA9mYL8lrLJCLX+JC
6jOPsVyy8ku+czlVWQLy139T5oQFUtpGXx56K3TXOS6+czltLYOii5yzTn7YYIKceER04ZGleoJZ
qYfsWmKSsfPb04Uyr5Yy/nyx8mUwG3run5ftHLYq4ZbRVp5yNw9u3ehFfuUXuy85PUWjwcUVW47Z
sd0sDi972u3OE56N9v7XcPRqPnp51704F3axjgu7HPjEgo8Le2323UiIr3MU36j91o8DNsd0aGYw
G4Dbjjm8Ve3xGn3J5j/2fpGLa1btzHFILZ1ZcBmx2kDtzLGFFyXn9ZiX83pt9r2I4LxSySrj2x6d
j3z4BK/Wc1ymoMx7OLe2XO7UmXRBWhWzLDD1WZW28pTTn+KAY7vnZ4ePdavliq9/y5ZjdmxfUakd
brtZJaOkTAhcLuG6V/N1r7aIaOlHjzWuOV6vn/ZZsxvg2/aCrjvxt300Why9NsRzjBUhuNz4VIXx
c11zko3wbbUvPdVt96rLRovuhTTa7gE3QyONtheXFgG4IQeB7oVA90Ig0L0QvQSG9njn2MXbG3Sv
zs8HN+OM4F34QhotAmMvBLoXAoHuhUD3QqB7dQHGDdaD2Wi7hfZ3TBCAoUAq425Kdyq0tTbf6JO7
lurLwuXenKzUw7apgneHUL3+cLnpGciy+qq659rjwkRnUlZpWmZQ5K9bD+n27rEG74JrPboGQo+x
nLuO/mvrykZ7aQlHu65Mjnq2ag9k5HeCnMJzWHFIt0FyghZ8OiAT0FoR8mkLyCtT4kBkeuVt2b/h
3QqnzgpebEpRTujbhLydc7YYJtto3ycICdLytEJCutOPRshulrRW1FHxQPpEQHJxuZ5kQNEErRdg
NByy7bSi3CaWjVboGWHM2bpstFxWnEIoIrLRSluEviHMRrsq2k9ZxTakpwsD9s78D2Z+/Rs1iH9w
5YmcKBhYeOGoCsmZq/81z1UkwwNG2FJN/lHFo8XEN1bkpnZWVltJ/I1LkAwpsbAFZnz22MvKL7n8
X8V+8D0+d8ViEMzX4E9GB9LfqUE5MZDKVyGeV1LfsKB864CyVIWroo6KP1f8HwvcHlFvJmaey9ak
bjBCtp3JqadJpMzKpZ6q+sY3quyYWvaCtJHL8jMemXk2ZLEqakuI2iL15YKeqcEcuNn22YsJ0XvQ
kVTthJDpf+NOETrLz5qa1O1AhOhszjAv6KfFcXEapi/brVNTMOULeErT8+cA7rkg2og8tEy+6OSc
LRNYzABsN0+cp59mqKxNrtB+QpwbFrK0Scupo7aQWSLsEfWsxGa1wUrRsZPloBWPm5B6rOl9lsfG
+bJPNqsbji3EtaVo4TDV+dCePZNhf6Upx7aBhQvNSbdN2LZ15FY356yhDd7/MqOuzjIGrfFvjwzp
GZvjamy3HvhFhted3lcvDlpT3f5qD0e3lWy0ri0N2WgxtO9YNtp9tboCN9+rjQn7Nn/IgIkhTzuZ
w3XCuxgwZNSndnW5s9vg5BFg1NVa7C4a9hyrJYjDcdVLmb8mou4Lfnt83FnHENvOIada6hkyfO3q
jBmxz2UbRGxbqL4mfFxER2KvSsXPilSfLKVy3oLY86Xb/idXMbj/Wy8FLMk/jD5jPgcrEPvhH3+M
NS8e0Z9KfvwSa/OsbCN/BtOFU98WX42ru1jbYPr3Yu+rEEr9/qt/TPUVAulKFcKvf1Q1a7zuA9Ur
LuttJmSROUX42aJtZ+zDJ9LVCiuXeiJPx60qO6atpY2edKGhynGlzA+u/mvbFqrveHUFY68uxF7K
oz+uKzttBgL+RqXx/yDeLR4ipUW7+ExBKZ6h4f6Dw2xH0PYBiBcW3udtzEWf/GKefFY8IiDxEZbi
GP48p0zuAcgtkQfHqL64skRv4eKfJdmkU+e1R9RLbOcfvGo6dpIvk8KHvFzqyS+R1+x20kYPksFP
ENuWoGuLGcFhquOxV8tIF0t9dcrGLdc6mlvdUutotBh7ORej2+41WMp8/mfz/XUp0g+81snu1Ih3
wEX3QhptF4GboZFG24tLiwDckINA90KgeyEQ6F6IXgJDe7xz7OLtDbpX9+eDGztDVHquEWm0CIy9
EOheCAS6FwLdC4Hu1WsYbVWtV8TwViGxrFPo8Y6Jlp8x7zYMrU6UCFnr7s3PmNXMolsue6Nt6bt1
0GibPte+f77CN2BholN77XuBubaqVoOPMWvkz3jKZW8af7cOGi1mo+2nyVHmjh0Jj3t4s8mAomsi
p6zIHQuc4xqVHNeozaW124NNv7WCLLetcZjnq5V5ZRVfTlpax/KsFSMkmOIiepgEROa126N73XLe
Xy0o+yW2fttehuHwYaF8OKiwRLWaQsI67I3ejn7UP7FXguWhhaXoB3mAtMwnW51P5yu8XOaOpUjn
tVc0nrA2LfPQuu3lMKJBMnb6ywA7Xqry3LLWyWRhZD41BbDTySG78zsZxrRIDmrxJS4Sj2sJ8SCC
cshTzrPn6nOyX6YrInQJexmKs78l/PKu49XkNMBUQovleveIDHSvVnCR82PvvTC/Iri1RVE2J3iz
kNOn7+HtTIdBe888EFFmt3dQnt53kf6WrNzLOrl2kRNkSyF4zOQtSpM6y71oCRYu02XY7+6b9JYz
THp2zXtskyWL+j5BGzj3GB9Avya4vOfvQz/qm9B+DTqt/VZwVRs4rrBO+q0vh+zErw5aIgvuxKd4
PlwQubDc8vp+18i+K3PuTuybhTsz/pxaGNr3RWgvCKuHjIZcriJ3LKur57j62ssRRWaMbcgt6/Jn
JWP276ROymFvXHn7LXcFwi2vR6NtbjZakXN3b6k2SnAdYw20T6NtCy6/NvpUslwF42nz2as+3qz5
TetZhZeQFGe2mv/v+GC6wNiuzB9k+xdP7GIs2HIg8vQPf5SF6NGil/Eq+LOaEFGfMhljtvbDjx0V
jN2B+Pm/JZ6qEnna9JTT3mzuL39XZxv9/XLl0Iu8IFOdfZwKhZK/z9i7x2p+Gm3jDHEjUeu9yo7Q
aDeGqWUjSaOZ4rh50V8RJCVR8mGePJQAuO1OxnFlbFdw2u95ZITtJApHIP/x/fQO4cqy8ugVXy+X
v0qWRBh+uRj4Ln1541Oc+Xrbw5DIPizTUYYtb/k/ddiwYf7uYoHU2XYh9JlL/M3Y4Ahj4eaWSfYN
GvmFcZjqj9hrPSug3QfLVbvxXqzovI6xV/PY66Z2L8+q/UamAly1X9W9+m63am9vZDvRSdHvoo2Z
matw0wI3Q2/mr0ffAzfkINC9EOheCAS6FwJD+00LpNEijbY388HWnBmuv46GNFoExl4IdC8EAt0L
ge6FQPe6YTB6ILExOUQ9erxbdU2MPPBOTD133D4kdZb9UaWh6Dr402xzied+tNKOnCyrr1LjpufI
s1t1ayZ/aWH3ax/sVm2C3F/WMsqBVauvrXs7wnvNJYyvXmlLTqK+KreMo91mmBxnL+j6kgle1uxD
do5YTZJbgxZMhOxy4ARch++qKeEJLs1zxtZ2Szqs5MFaUTsv7mhEb0uO2iE5vHqEM3E1ooSKEMJs
tJvCvbY/nx5mi8Lpac1m0n6fMWkhHzudl+TWyBB8pmyX8xlo3mlfzgzuB0hFtFfZLnvtXUmHhcTc
2CTtKzwvH0lReq09OVieI8KufEx7fQlgarSaOAiQ+U30o03gXvl/V/hlcFjkiBXhjOnkiLWDpfA4
lE0Pwxamdaf9oD5VojLTkGRHU84GeEGsdfPizkTbk4PTuiq0WgYczAB8saSfP0ft/Sb60Sros732
xujyypo5Yo3h6vi5el6t097Pw71OXty25GQ22t0Vxr21EjPNstFu7UWfFv7m2J9PyFEM0LNVb45Y
EPzZYTd21iO1d51yCbu9Bcbdgv260Hy5wc2L25YcDNsM31uVKBvGQmYtvh+z0W6SyVF93jCSX6Gv
M5AWnMOdFpyi70JjwyF7OSq8GHLKbTnZXoOxPMBP98A7O5osYKm3w/Nygv2r9uTgc6BGxTc4MvkM
fTmg6YH7Ae7AbSebYd2r8NZ/+pr61HEo/OydcLLA2NCFeOb/KAUo1ooJEz73eZUWnX2SHLHLQfCn
7faaVbtC6wYyJ3MBXiEkJM26EKi9tSjSLr9QbkvOfC86KFqkc0c++r9V+N0/WyCPfw8GIiVc92q+
7rWF8jlenyGZNvkdgzFihtqRWwUzu+Z0jL2ax15byL2UtfmEg6XMtuR8E3dpXW6VBuG6bLToXlvR
vfpkDMVLgNloe3BpEYAbchDoXgh0LwQC3QvRS2Boj3eOXby9Qffq3nzQyZmhsomuANJoERh7IdC9
EAh0LwS6FwLd6+YAcss6Atwx4YeerygsI0y43Hwf2CoZaT0NcGFiU2Wj7SmGs7nq8fhwXdbaRuB3
EifHNrCUUOGxxN8XPFptnLh5bUlSrEDPhHneW4CzIWU8DXCKkPCbeOFWQT/tte+Hcf3KEYD8uzXV
1MCM/eXzUyo8mVf+2WcsMPXLtArMP7n674/y3GvPJwtLuRq8cOtA8tWs20OX9trXNtNV3JJ77TsB
D6MSSE1nLwEa9gRX+BGriodYiRuCRQLfv1fH2GuV2Avdyz+Ys+RmxkjFm41WxFqemF5mpB2yVubo
S9wCPYPuhaF9CwiP0V9jv+0t8pB6GdyMtFmVZXsMlTLJu/DCYWjfCmL5s1DMv0jfTTiBhAXPefKB
fsam0q7ccv5O+rJb0wfexguHoX0rKBReBDVvAej/WZU02mu5n/4gXZD5jsHcvqLS8J8eadnHI1kV
ZpWMkjIxtMfQvjc3Bxh7YeyF6A1wt2qnUW3yDt0L0RlgrIF3jgh0LwS6FwKB7oVA90KgeyEQ6F4I
dC8EuhdiXSA3WL6/OkD3QuDohUD3QiDqgPu9+iz22grAB4/34Nq26Z4b/br3QQc4OSIw9kKgeyEQ
GNojbsR9Dob23bh31PiL1nqY7Mjw13WJuuG01p5uNxzXWrZAPizBsXo1peheHfcuTzLulr3L/mDc
R1ys9/5Na1e3K06gVQtI3ZmuqhRjrz5azGh/SYBoHftedFQbjl5dHsjamVfbECX1C27r1621bIHW
8gmje3VrQCLsP2n5zsmeG+nrekXBkWxTd0M/bVnQTAbdq5sTHtHWNYpobYtqG9a9UQuay2Ds1R9z
I9ng1LbxeVnbeDTXKIPu1Uee2P6fwzv1h/RO/0Eel1U77yreVYLWLq9n1Wm9on6lG+hAW4/xzda9
msjgwy8R3fym4eSI6CLQvRDoXgh0LwQC3QuB7oXYEvD8UQg5LogOQWviXrgChugMCE6OCIy9EOhe
CAS6FwLdC7G1EFw78t9895Roe9+7V/2YVt3EZ7SymWyvS9FX2+zehZMjAt0LseXdi7RY29COELf0
Bv3hiTRVTjbF+Ti2r2ZSP1/6ThHRrvc4gs0Wq/bh+Wib8NKvf3IkRH6TnG8G4f9kjfcbJ1qSum+S
bOa27ukwZiv3no39Qvr6fIQu8Nnf75d+3aNXsycREM1f4z22n2rhECz9D77ouX9p7v9GY1xb+/N8
mB6f8n6/9G1OjhqR/+rGXa1hTG4Ym7UbOl5rTXVr/tf+Oh9Sd+UbDezfS9/BhwBonodUXf9yaaQv
IrE14t5+OZ8WGLZ9e+mDnb0O7NtznUcTEM9Dym68f2k+mzbt+fSrqe2ue2n8OSpaOysXnpuCnl19
0jBxkOusWvTr+ZCNLBr1/NIH13li2uojq1sj/M7fUiNOpajp6eRYp81rDHsnber782lqZz9fes9D
ANxvdz13u7qZ/ixc/zfHzWR7/d8ctestZvXpeWirfBiI/v7cYJPtokD32kzYdBt0mrtXdRN/BCub
2PbaVvs+BLfElwRt71PghhwEuhcC3QuBQPdCoHsh0L0QiLXhXZjAJzAhuude+PwlBE6OCHQvBALd
C4HuhUD3QiDQvRDoXggEAnF9/H9IjQyv7gYHpAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-07-04 15:49:16 +0100" MODIFIED_BY="Chris Champion" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZoAABVfCAIAAABr0CXuAACAAElEQVR42uy9sW7qSPy3bwkJUVCk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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;132 RCTs meeting the inclusion criteria were included in the analysis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;145 full-text articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;364 papers were considered potentially relevant for this review&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;833 records identified by CCDAN&lt;/p&gt;">
<OUT TEXT="&lt;p&gt;469 excluded after reading abstract&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;219 excluded: not RCT or other reasons&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;33 RCTs additionally included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;39 RCTs additionally included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;39 RCTs meeting the inclusion criteria were included in the analysis&lt;/p&gt;" WIDTH="118">
<FLOWCHARTBOX TEXT="&lt;p&gt;99 full-text articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;536 records were considered potentially relevant for this review&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;524 new records, published between 2005 and 2012, identified by CCDAN&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;12 unpublished studies and 10 studies awaiting assessment in 2005 and 5 on going &lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;437 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;55 full-text articles excluded or awaiting assessment: not RCT or other reasons&lt;/p&gt;&lt;p&gt;5 ongoing studies&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>